Sentence: DrugDDI.d201.s5
Drugs	NNS	drug	B-e0	T	drug
that	WDT	that	O	O	NONE
Inhibit	VBP	inhibit	O	O	NONE
or	CC	or	O	O	NONE
Induce	VBP	induce	O	O	NONE
Cytochrome	NN	cytochrome	B-e1	T	drug
P450	NN	p450	I-e1	T	drug
3A4	NN	3a4	I-e1	T	drug
Enzymes	NNS	enzyme	O	O	NONE
Lapatinib	NN	lapatinib	O	O	NONE
undergoes	VBZ	undergo	O	O	NONE
extensive	JJ	extensive	O	O	NONE
metabolism	NN	metabolism	O	O	NONE
by	IN	by	O	O	NONE
CYP3A4	NN	cyp3a4	B-e2	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
strong	JJ	strong	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
or	CC	or	O	O	NONE
inducers	NNS	inducer	O	O	NONE
of	IN	of	O	O	NONE
CYP3A4	NN	cyp3a4	B-e3	O	drug
alter	VB	alter	O	O	NONE
lapatinib	NN	lapatinib	B-e4	O	drug
concentrations	NNS	concentration	O	O	NONE
significantly	RB	significantly	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d201.s5
Drugs	NNS	drug	B-e0	T	drug
that	WDT	that	O	O	NONE
Inhibit	VBP	inhibit	O	O	NONE
or	CC	or	O	O	NONE
Induce	VBP	induce	O	O	NONE
Cytochrome	NN	cytochrome	B-e1	O	drug
P450	NN	p450	I-e1	O	drug
3A4	NN	3a4	I-e1	O	drug
Enzymes	NNS	enzyme	O	O	NONE
Lapatinib	NN	lapatinib	O	O	NONE
undergoes	VBZ	undergo	O	O	NONE
extensive	JJ	extensive	O	O	NONE
metabolism	NN	metabolism	O	O	NONE
by	IN	by	O	O	NONE
CYP3A4	NN	cyp3a4	B-e2	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
strong	JJ	strong	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
or	CC	or	O	O	NONE
inducers	NNS	inducer	O	O	NONE
of	IN	of	O	O	NONE
CYP3A4	NN	cyp3a4	B-e3	O	drug
alter	VB	alter	O	O	NONE
lapatinib	NN	lapatinib	B-e4	O	drug
concentrations	NNS	concentration	O	O	NONE
significantly	RB	significantly	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d201.s5
Drugs	NNS	drug	B-e0	T	drug
that	WDT	that	O	O	NONE
Inhibit	VBP	inhibit	O	O	NONE
or	CC	or	O	O	NONE
Induce	VBP	induce	O	O	NONE
Cytochrome	NN	cytochrome	B-e1	O	drug
P450	NN	p450	I-e1	O	drug
3A4	NN	3a4	I-e1	O	drug
Enzymes	NNS	enzyme	O	O	NONE
Lapatinib	NN	lapatinib	O	O	NONE
undergoes	VBZ	undergo	O	O	NONE
extensive	JJ	extensive	O	O	NONE
metabolism	NN	metabolism	O	O	NONE
by	IN	by	O	O	NONE
CYP3A4	NN	cyp3a4	B-e2	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
strong	JJ	strong	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
or	CC	or	O	O	NONE
inducers	NNS	inducer	O	O	NONE
of	IN	of	O	O	NONE
CYP3A4	NN	cyp3a4	B-e3	T	drug
alter	VB	alter	O	O	NONE
lapatinib	NN	lapatinib	B-e4	O	drug
concentrations	NNS	concentration	O	O	NONE
significantly	RB	significantly	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d201.s5
Drugs	NNS	drug	B-e0	T	drug
that	WDT	that	O	O	NONE
Inhibit	VBP	inhibit	O	O	NONE
or	CC	or	O	O	NONE
Induce	VBP	induce	O	O	NONE
Cytochrome	NN	cytochrome	B-e1	O	drug
P450	NN	p450	I-e1	O	drug
3A4	NN	3a4	I-e1	O	drug
Enzymes	NNS	enzyme	O	O	NONE
Lapatinib	NN	lapatinib	O	O	NONE
undergoes	VBZ	undergo	O	O	NONE
extensive	JJ	extensive	O	O	NONE
metabolism	NN	metabolism	O	O	NONE
by	IN	by	O	O	NONE
CYP3A4	NN	cyp3a4	B-e2	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
strong	JJ	strong	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
or	CC	or	O	O	NONE
inducers	NNS	inducer	O	O	NONE
of	IN	of	O	O	NONE
CYP3A4	NN	cyp3a4	B-e3	O	drug
alter	VB	alter	O	O	NONE
lapatinib	NN	lapatinib	B-e4	T	drug
concentrations	NNS	concentration	O	O	NONE
significantly	RB	significantly	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d201.s5
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
Inhibit	VBP	inhibit	O	O	NONE
or	CC	or	O	O	NONE
Induce	VBP	induce	O	O	NONE
Cytochrome	NN	cytochrome	B-e1	T	drug
P450	NN	p450	I-e1	T	drug
3A4	NN	3a4	I-e1	T	drug
Enzymes	NNS	enzyme	O	O	NONE
Lapatinib	NN	lapatinib	O	O	NONE
undergoes	VBZ	undergo	O	O	NONE
extensive	JJ	extensive	O	O	NONE
metabolism	NN	metabolism	O	O	NONE
by	IN	by	O	O	NONE
CYP3A4	NN	cyp3a4	B-e2	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
strong	JJ	strong	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
or	CC	or	O	O	NONE
inducers	NNS	inducer	O	O	NONE
of	IN	of	O	O	NONE
CYP3A4	NN	cyp3a4	B-e3	O	drug
alter	VB	alter	O	O	NONE
lapatinib	NN	lapatinib	B-e4	O	drug
concentrations	NNS	concentration	O	O	NONE
significantly	RB	significantly	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d201.s5
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
Inhibit	VBP	inhibit	O	O	NONE
or	CC	or	O	O	NONE
Induce	VBP	induce	O	O	NONE
Cytochrome	NN	cytochrome	B-e1	T	drug
P450	NN	p450	I-e1	T	drug
3A4	NN	3a4	I-e1	T	drug
Enzymes	NNS	enzyme	O	O	NONE
Lapatinib	NN	lapatinib	O	O	NONE
undergoes	VBZ	undergo	O	O	NONE
extensive	JJ	extensive	O	O	NONE
metabolism	NN	metabolism	O	O	NONE
by	IN	by	O	O	NONE
CYP3A4	NN	cyp3a4	B-e2	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
strong	JJ	strong	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
or	CC	or	O	O	NONE
inducers	NNS	inducer	O	O	NONE
of	IN	of	O	O	NONE
CYP3A4	NN	cyp3a4	B-e3	T	drug
alter	VB	alter	O	O	NONE
lapatinib	NN	lapatinib	B-e4	O	drug
concentrations	NNS	concentration	O	O	NONE
significantly	RB	significantly	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d201.s5
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
Inhibit	VBP	inhibit	O	O	NONE
or	CC	or	O	O	NONE
Induce	VBP	induce	O	O	NONE
Cytochrome	NN	cytochrome	B-e1	T	drug
P450	NN	p450	I-e1	T	drug
3A4	NN	3a4	I-e1	T	drug
Enzymes	NNS	enzyme	O	O	NONE
Lapatinib	NN	lapatinib	O	O	NONE
undergoes	VBZ	undergo	O	O	NONE
extensive	JJ	extensive	O	O	NONE
metabolism	NN	metabolism	O	O	NONE
by	IN	by	O	O	NONE
CYP3A4	NN	cyp3a4	B-e2	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
strong	JJ	strong	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
or	CC	or	O	O	NONE
inducers	NNS	inducer	O	O	NONE
of	IN	of	O	O	NONE
CYP3A4	NN	cyp3a4	B-e3	O	drug
alter	VB	alter	O	O	NONE
lapatinib	NN	lapatinib	B-e4	T	drug
concentrations	NNS	concentration	O	O	NONE
significantly	RB	significantly	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d201.s5
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
Inhibit	VBP	inhibit	O	O	NONE
or	CC	or	O	O	NONE
Induce	VBP	induce	O	O	NONE
Cytochrome	NN	cytochrome	B-e1	O	drug
P450	NN	p450	I-e1	O	drug
3A4	NN	3a4	I-e1	O	drug
Enzymes	NNS	enzyme	O	O	NONE
Lapatinib	NN	lapatinib	O	O	NONE
undergoes	VBZ	undergo	O	O	NONE
extensive	JJ	extensive	O	O	NONE
metabolism	NN	metabolism	O	O	NONE
by	IN	by	O	O	NONE
CYP3A4	NN	cyp3a4	B-e2	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
strong	JJ	strong	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
or	CC	or	O	O	NONE
inducers	NNS	inducer	O	O	NONE
of	IN	of	O	O	NONE
CYP3A4	NN	cyp3a4	B-e3	T	drug
alter	VB	alter	O	O	NONE
lapatinib	NN	lapatinib	B-e4	O	drug
concentrations	NNS	concentration	O	O	NONE
significantly	RB	significantly	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d201.s5
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
Inhibit	VBP	inhibit	O	O	NONE
or	CC	or	O	O	NONE
Induce	VBP	induce	O	O	NONE
Cytochrome	NN	cytochrome	B-e1	O	drug
P450	NN	p450	I-e1	O	drug
3A4	NN	3a4	I-e1	O	drug
Enzymes	NNS	enzyme	O	O	NONE
Lapatinib	NN	lapatinib	O	O	NONE
undergoes	VBZ	undergo	O	O	NONE
extensive	JJ	extensive	O	O	NONE
metabolism	NN	metabolism	O	O	NONE
by	IN	by	O	O	NONE
CYP3A4	NN	cyp3a4	B-e2	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
strong	JJ	strong	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
or	CC	or	O	O	NONE
inducers	NNS	inducer	O	O	NONE
of	IN	of	O	O	NONE
CYP3A4	NN	cyp3a4	B-e3	O	drug
alter	VB	alter	O	O	NONE
lapatinib	NN	lapatinib	B-e4	T	drug
concentrations	NNS	concentration	O	O	NONE
significantly	RB	significantly	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d201.s5
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
Inhibit	VBP	inhibit	O	O	NONE
or	CC	or	O	O	NONE
Induce	VBP	induce	O	O	NONE
Cytochrome	NN	cytochrome	B-e1	O	drug
P450	NN	p450	I-e1	O	drug
3A4	NN	3a4	I-e1	O	drug
Enzymes	NNS	enzyme	O	O	NONE
Lapatinib	NN	lapatinib	O	O	NONE
undergoes	VBZ	undergo	O	O	NONE
extensive	JJ	extensive	O	O	NONE
metabolism	NN	metabolism	O	O	NONE
by	IN	by	O	O	NONE
CYP3A4	NN	cyp3a4	B-e2	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
strong	JJ	strong	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
or	CC	or	O	O	NONE
inducers	NNS	inducer	O	O	NONE
of	IN	of	O	O	NONE
CYP3A4	NN	cyp3a4	B-e3	T	drug
alter	VB	alter	O	O	NONE
lapatinib	NN	lapatinib	B-e4	T	drug
concentrations	NNS	concentration	O	O	NONE
significantly	RB	significantly	O	O	NONE
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d201.s6
Dose	NN	dose	O	O	NONE
adjustment	NN	adjustment	O	O	NONE
of	IN	of	O	O	NONE
lapatinib	NN	lapatinib	B-e0	T	drug
should	MD	should	O	O	NONE
be	VB	be	O	O	NONE
considered	VBN	consider	O	O	NONE
for	IN	for	O	O	NONE
patients	NNS	patient	O	O	NONE
who	WP	who	O	O	NONE
must	MD	must	O	O	NONE
receive	VBP	receive	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
strong	JJ	strong	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
or	CC	or	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
strong	JJ	strong	O	O	NONE
inducers	NNS	inducer	O	O	NONE
of	IN	of	O	O	NONE
CYP3A4	JJ	cyp3a4	B-e1	T	drug
enzymes	NNS	enzyme	O	O	NONE
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d201.s7
Ketoconazole	NN	ketoconazole	B-e0	T	drug
:	:	:	O	O	NONE
In	IN	in	O	O	NONE
healthy	JJ	healthy	O	O	NONE
subjects	NNS	subject	O	O	NONE
receiving	VBG	receive	O	O	NONE
ketoconazole	NN	ketoconazole	B-e1	T	drug
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
CYP3A4	NN	cyp3a4	B-e2	O	drug
inhibitor	NN	inhibitor	O	O	NONE
,	,	,	O	O	NONE
at	IN	at	O	O	NONE
200	CD	200	O	O	NONE
mg	NN	mg	O	O	NONE
twice	RB	twice	O	O	NONE
daily	RB	daily	O	O	NONE
for	IN	for	O	O	NONE
7	CD	7	O	O	NONE
days	NNS	day	O	O	NONE
,	,	,	O	O	NONE
systemic	JJ	systemic	O	O	NONE
exposure	NN	exposure	O	O	NONE
(	(	(	O	O	NONE
AUC	NN	auc	O	O	NONE
)	)	)	O	O	NONE
to	TO	to	O	O	NONE
lapatinib	NN	lapatinib	B-e3	O	drug
was	VBD	be	O	O	NONE
increased	VBN	increase	O	O	NONE
to	TO	to	O	O	NONE
approximately	RB	approximately	O	O	NONE
3.6-fold	NN	3.6-fold	O	O	NONE
of	IN	of	O	O	NONE
control	NN	control	O	O	NONE
and	CC	and	O	O	NONE
half-life	NN	half-life	O	O	NONE
increased	VBD	increase	O	O	NONE
to	TO	to	O	O	NONE
1.7-fold	NN	1.7-fold	O	O	NONE
of	IN	of	O	O	NONE
control	NN	control	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d201.s7
Ketoconazole	NN	ketoconazole	B-e0	T	drug
:	:	:	O	O	NONE
In	IN	in	O	O	NONE
healthy	JJ	healthy	O	O	NONE
subjects	NNS	subject	O	O	NONE
receiving	VBG	receive	O	O	NONE
ketoconazole	NN	ketoconazole	B-e1	O	drug
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
CYP3A4	NN	cyp3a4	B-e2	T	drug
inhibitor	NN	inhibitor	O	O	NONE
,	,	,	O	O	NONE
at	IN	at	O	O	NONE
200	CD	200	O	O	NONE
mg	NN	mg	O	O	NONE
twice	RB	twice	O	O	NONE
daily	RB	daily	O	O	NONE
for	IN	for	O	O	NONE
7	CD	7	O	O	NONE
days	NNS	day	O	O	NONE
,	,	,	O	O	NONE
systemic	JJ	systemic	O	O	NONE
exposure	NN	exposure	O	O	NONE
(	(	(	O	O	NONE
AUC	NN	auc	O	O	NONE
)	)	)	O	O	NONE
to	TO	to	O	O	NONE
lapatinib	NN	lapatinib	B-e3	O	drug
was	VBD	be	O	O	NONE
increased	VBN	increase	O	O	NONE
to	TO	to	O	O	NONE
approximately	RB	approximately	O	O	NONE
3.6-fold	NN	3.6-fold	O	O	NONE
of	IN	of	O	O	NONE
control	NN	control	O	O	NONE
and	CC	and	O	O	NONE
half-life	NN	half-life	O	O	NONE
increased	VBD	increase	O	O	NONE
to	TO	to	O	O	NONE
1.7-fold	NN	1.7-fold	O	O	NONE
of	IN	of	O	O	NONE
control	NN	control	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d201.s7
Ketoconazole	NN	ketoconazole	B-e0	T	drug
:	:	:	O	O	NONE
In	IN	in	O	O	NONE
healthy	JJ	healthy	O	O	NONE
subjects	NNS	subject	O	O	NONE
receiving	VBG	receive	O	O	NONE
ketoconazole	NN	ketoconazole	B-e1	O	drug
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
CYP3A4	NN	cyp3a4	B-e2	O	drug
inhibitor	NN	inhibitor	O	O	NONE
,	,	,	O	O	NONE
at	IN	at	O	O	NONE
200	CD	200	O	O	NONE
mg	NN	mg	O	O	NONE
twice	RB	twice	O	O	NONE
daily	RB	daily	O	O	NONE
for	IN	for	O	O	NONE
7	CD	7	O	O	NONE
days	NNS	day	O	O	NONE
,	,	,	O	O	NONE
systemic	JJ	systemic	O	O	NONE
exposure	NN	exposure	O	O	NONE
(	(	(	O	O	NONE
AUC	NN	auc	O	O	NONE
)	)	)	O	O	NONE
to	TO	to	O	O	NONE
lapatinib	NN	lapatinib	B-e3	T	drug
was	VBD	be	O	O	NONE
increased	VBN	increase	O	O	NONE
to	TO	to	O	O	NONE
approximately	RB	approximately	O	O	NONE
3.6-fold	NN	3.6-fold	O	O	NONE
of	IN	of	O	O	NONE
control	NN	control	O	O	NONE
and	CC	and	O	O	NONE
half-life	NN	half-life	O	O	NONE
increased	VBD	increase	O	O	NONE
to	TO	to	O	O	NONE
1.7-fold	NN	1.7-fold	O	O	NONE
of	IN	of	O	O	NONE
control	NN	control	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d201.s7
Ketoconazole	NN	ketoconazole	B-e0	O	drug
:	:	:	O	O	NONE
In	IN	in	O	O	NONE
healthy	JJ	healthy	O	O	NONE
subjects	NNS	subject	O	O	NONE
receiving	VBG	receive	O	O	NONE
ketoconazole	NN	ketoconazole	B-e1	T	drug
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
CYP3A4	NN	cyp3a4	B-e2	T	drug
inhibitor	NN	inhibitor	O	O	NONE
,	,	,	O	O	NONE
at	IN	at	O	O	NONE
200	CD	200	O	O	NONE
mg	NN	mg	O	O	NONE
twice	RB	twice	O	O	NONE
daily	RB	daily	O	O	NONE
for	IN	for	O	O	NONE
7	CD	7	O	O	NONE
days	NNS	day	O	O	NONE
,	,	,	O	O	NONE
systemic	JJ	systemic	O	O	NONE
exposure	NN	exposure	O	O	NONE
(	(	(	O	O	NONE
AUC	NN	auc	O	O	NONE
)	)	)	O	O	NONE
to	TO	to	O	O	NONE
lapatinib	NN	lapatinib	B-e3	O	drug
was	VBD	be	O	O	NONE
increased	VBN	increase	O	O	NONE
to	TO	to	O	O	NONE
approximately	RB	approximately	O	O	NONE
3.6-fold	NN	3.6-fold	O	O	NONE
of	IN	of	O	O	NONE
control	NN	control	O	O	NONE
and	CC	and	O	O	NONE
half-life	NN	half-life	O	O	NONE
increased	VBD	increase	O	O	NONE
to	TO	to	O	O	NONE
1.7-fold	NN	1.7-fold	O	O	NONE
of	IN	of	O	O	NONE
control	NN	control	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d201.s7
Ketoconazole	NN	ketoconazole	B-e0	O	drug
:	:	:	O	O	NONE
In	IN	in	O	O	NONE
healthy	JJ	healthy	O	O	NONE
subjects	NNS	subject	O	O	NONE
receiving	VBG	receive	O	O	NONE
ketoconazole	NN	ketoconazole	B-e1	T	drug
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
CYP3A4	NN	cyp3a4	B-e2	O	drug
inhibitor	NN	inhibitor	O	O	NONE
,	,	,	O	O	NONE
at	IN	at	O	O	NONE
200	CD	200	O	O	NONE
mg	NN	mg	O	O	NONE
twice	RB	twice	O	O	NONE
daily	RB	daily	O	O	NONE
for	IN	for	O	O	NONE
7	CD	7	O	O	NONE
days	NNS	day	O	O	NONE
,	,	,	O	O	NONE
systemic	JJ	systemic	O	O	NONE
exposure	NN	exposure	O	O	NONE
(	(	(	O	O	NONE
AUC	NN	auc	O	O	NONE
)	)	)	O	O	NONE
to	TO	to	O	O	NONE
lapatinib	NN	lapatinib	B-e3	T	drug
was	VBD	be	O	O	NONE
increased	VBN	increase	O	O	NONE
to	TO	to	O	O	NONE
approximately	RB	approximately	O	O	NONE
3.6-fold	NN	3.6-fold	O	O	NONE
of	IN	of	O	O	NONE
control	NN	control	O	O	NONE
and	CC	and	O	O	NONE
half-life	NN	half-life	O	O	NONE
increased	VBD	increase	O	O	NONE
to	TO	to	O	O	NONE
1.7-fold	NN	1.7-fold	O	O	NONE
of	IN	of	O	O	NONE
control	NN	control	O	O	NONE
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d201.s7
Ketoconazole	NN	ketoconazole	B-e0	O	drug
:	:	:	O	O	NONE
In	IN	in	O	O	NONE
healthy	JJ	healthy	O	O	NONE
subjects	NNS	subject	O	O	NONE
receiving	VBG	receive	O	O	NONE
ketoconazole	NN	ketoconazole	B-e1	O	drug
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
CYP3A4	NN	cyp3a4	B-e2	T	drug
inhibitor	NN	inhibitor	O	O	NONE
,	,	,	O	O	NONE
at	IN	at	O	O	NONE
200	CD	200	O	O	NONE
mg	NN	mg	O	O	NONE
twice	RB	twice	O	O	NONE
daily	RB	daily	O	O	NONE
for	IN	for	O	O	NONE
7	CD	7	O	O	NONE
days	NNS	day	O	O	NONE
,	,	,	O	O	NONE
systemic	JJ	systemic	O	O	NONE
exposure	NN	exposure	O	O	NONE
(	(	(	O	O	NONE
AUC	NN	auc	O	O	NONE
)	)	)	O	O	NONE
to	TO	to	O	O	NONE
lapatinib	NN	lapatinib	B-e3	T	drug
was	VBD	be	O	O	NONE
increased	VBN	increase	O	O	NONE
to	TO	to	O	O	NONE
approximately	RB	approximately	O	O	NONE
3.6-fold	NN	3.6-fold	O	O	NONE
of	IN	of	O	O	NONE
control	NN	control	O	O	NONE
and	CC	and	O	O	NONE
half-life	NN	half-life	O	O	NONE
increased	VBD	increase	O	O	NONE
to	TO	to	O	O	NONE
1.7-fold	NN	1.7-fold	O	O	NONE
of	IN	of	O	O	NONE
control	NN	control	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d201.s8
Carbamazepine	NN	carbamazepine	B-e0	T	drug
:	:	:	O	O	NONE
In	IN	in	O	O	NONE
healthy	JJ	healthy	O	O	NONE
subjects	NNS	subject	O	O	NONE
receiving	VBG	receive	O	O	NONE
the	DT	the	O	O	NONE
CYP3A4	NN	cyp3a4	B-e1	T	drug
inducer	NN	inducer	O	O	NONE
,	,	,	O	O	NONE
carbamazepine	NN	carbamazepine	B-e2	O	drug
,	,	,	O	O	NONE
at	IN	at	O	O	NONE
100	CD	100	O	O	NONE
mg	NN	mg	O	O	NONE
twice	RB	twice	O	O	NONE
daily	JJ	daily	O	O	NONE
for	IN	for	O	O	NONE
3	CD	3	O	O	NONE
days	NNS	day	O	O	NONE
and	CC	and	O	O	NONE
200	CD	200	O	O	NONE
mg	NN	mg	O	O	NONE
twice	RB	twice	O	O	NONE
daily	JJ	daily	O	O	NONE
for	IN	for	O	O	NONE
17	CD	17	O	O	NONE
days	NNS	day	O	O	NONE
,	,	,	O	O	NONE
systemic	JJ	systemic	O	O	NONE
exposure	NN	exposure	O	O	NONE
(	(	(	O	O	NONE
AUC	NN	auc	O	O	NONE
)	)	)	O	O	NONE
to	TO	to	O	O	NONE
lapatinib	NN	lapatinib	B-e3	O	drug
was	VBD	be	O	O	NONE
decreased	VBN	decrease	O	O	NONE
approximately	RB	approximately	O	O	NONE
72	CD	72	O	O	NONE
%.	NN	%.	O	O	NONE

NO

Sentence: DrugDDI.d201.s8
Carbamazepine	NN	carbamazepine	B-e0	T	drug
:	:	:	O	O	NONE
In	IN	in	O	O	NONE
healthy	JJ	healthy	O	O	NONE
subjects	NNS	subject	O	O	NONE
receiving	VBG	receive	O	O	NONE
the	DT	the	O	O	NONE
CYP3A4	NN	cyp3a4	B-e1	O	drug
inducer	NN	inducer	O	O	NONE
,	,	,	O	O	NONE
carbamazepine	NN	carbamazepine	B-e2	T	drug
,	,	,	O	O	NONE
at	IN	at	O	O	NONE
100	CD	100	O	O	NONE
mg	NN	mg	O	O	NONE
twice	RB	twice	O	O	NONE
daily	JJ	daily	O	O	NONE
for	IN	for	O	O	NONE
3	CD	3	O	O	NONE
days	NNS	day	O	O	NONE
and	CC	and	O	O	NONE
200	CD	200	O	O	NONE
mg	NN	mg	O	O	NONE
twice	RB	twice	O	O	NONE
daily	JJ	daily	O	O	NONE
for	IN	for	O	O	NONE
17	CD	17	O	O	NONE
days	NNS	day	O	O	NONE
,	,	,	O	O	NONE
systemic	JJ	systemic	O	O	NONE
exposure	NN	exposure	O	O	NONE
(	(	(	O	O	NONE
AUC	NN	auc	O	O	NONE
)	)	)	O	O	NONE
to	TO	to	O	O	NONE
lapatinib	NN	lapatinib	B-e3	O	drug
was	VBD	be	O	O	NONE
decreased	VBN	decrease	O	O	NONE
approximately	RB	approximately	O	O	NONE
72	CD	72	O	O	NONE
%.	NN	%.	O	O	NONE

NO

Sentence: DrugDDI.d201.s8
Carbamazepine	NN	carbamazepine	B-e0	T	drug
:	:	:	O	O	NONE
In	IN	in	O	O	NONE
healthy	JJ	healthy	O	O	NONE
subjects	NNS	subject	O	O	NONE
receiving	VBG	receive	O	O	NONE
the	DT	the	O	O	NONE
CYP3A4	NN	cyp3a4	B-e1	O	drug
inducer	NN	inducer	O	O	NONE
,	,	,	O	O	NONE
carbamazepine	NN	carbamazepine	B-e2	O	drug
,	,	,	O	O	NONE
at	IN	at	O	O	NONE
100	CD	100	O	O	NONE
mg	NN	mg	O	O	NONE
twice	RB	twice	O	O	NONE
daily	JJ	daily	O	O	NONE
for	IN	for	O	O	NONE
3	CD	3	O	O	NONE
days	NNS	day	O	O	NONE
and	CC	and	O	O	NONE
200	CD	200	O	O	NONE
mg	NN	mg	O	O	NONE
twice	RB	twice	O	O	NONE
daily	JJ	daily	O	O	NONE
for	IN	for	O	O	NONE
17	CD	17	O	O	NONE
days	NNS	day	O	O	NONE
,	,	,	O	O	NONE
systemic	JJ	systemic	O	O	NONE
exposure	NN	exposure	O	O	NONE
(	(	(	O	O	NONE
AUC	NN	auc	O	O	NONE
)	)	)	O	O	NONE
to	TO	to	O	O	NONE
lapatinib	NN	lapatinib	B-e3	T	drug
was	VBD	be	O	O	NONE
decreased	VBN	decrease	O	O	NONE
approximately	RB	approximately	O	O	NONE
72	CD	72	O	O	NONE
%.	NN	%.	O	O	NONE

NO

Sentence: DrugDDI.d201.s8
Carbamazepine	NN	carbamazepine	B-e0	O	drug
:	:	:	O	O	NONE
In	IN	in	O	O	NONE
healthy	JJ	healthy	O	O	NONE
subjects	NNS	subject	O	O	NONE
receiving	VBG	receive	O	O	NONE
the	DT	the	O	O	NONE
CYP3A4	NN	cyp3a4	B-e1	T	drug
inducer	NN	inducer	O	O	NONE
,	,	,	O	O	NONE
carbamazepine	NN	carbamazepine	B-e2	T	drug
,	,	,	O	O	NONE
at	IN	at	O	O	NONE
100	CD	100	O	O	NONE
mg	NN	mg	O	O	NONE
twice	RB	twice	O	O	NONE
daily	JJ	daily	O	O	NONE
for	IN	for	O	O	NONE
3	CD	3	O	O	NONE
days	NNS	day	O	O	NONE
and	CC	and	O	O	NONE
200	CD	200	O	O	NONE
mg	NN	mg	O	O	NONE
twice	RB	twice	O	O	NONE
daily	JJ	daily	O	O	NONE
for	IN	for	O	O	NONE
17	CD	17	O	O	NONE
days	NNS	day	O	O	NONE
,	,	,	O	O	NONE
systemic	JJ	systemic	O	O	NONE
exposure	NN	exposure	O	O	NONE
(	(	(	O	O	NONE
AUC	NN	auc	O	O	NONE
)	)	)	O	O	NONE
to	TO	to	O	O	NONE
lapatinib	NN	lapatinib	B-e3	O	drug
was	VBD	be	O	O	NONE
decreased	VBN	decrease	O	O	NONE
approximately	RB	approximately	O	O	NONE
72	CD	72	O	O	NONE
%.	NN	%.	O	O	NONE

NO

Sentence: DrugDDI.d201.s8
Carbamazepine	NN	carbamazepine	B-e0	O	drug
:	:	:	O	O	NONE
In	IN	in	O	O	NONE
healthy	JJ	healthy	O	O	NONE
subjects	NNS	subject	O	O	NONE
receiving	VBG	receive	O	O	NONE
the	DT	the	O	O	NONE
CYP3A4	NN	cyp3a4	B-e1	T	drug
inducer	NN	inducer	O	O	NONE
,	,	,	O	O	NONE
carbamazepine	NN	carbamazepine	B-e2	O	drug
,	,	,	O	O	NONE
at	IN	at	O	O	NONE
100	CD	100	O	O	NONE
mg	NN	mg	O	O	NONE
twice	RB	twice	O	O	NONE
daily	JJ	daily	O	O	NONE
for	IN	for	O	O	NONE
3	CD	3	O	O	NONE
days	NNS	day	O	O	NONE
and	CC	and	O	O	NONE
200	CD	200	O	O	NONE
mg	NN	mg	O	O	NONE
twice	RB	twice	O	O	NONE
daily	JJ	daily	O	O	NONE
for	IN	for	O	O	NONE
17	CD	17	O	O	NONE
days	NNS	day	O	O	NONE
,	,	,	O	O	NONE
systemic	JJ	systemic	O	O	NONE
exposure	NN	exposure	O	O	NONE
(	(	(	O	O	NONE
AUC	NN	auc	O	O	NONE
)	)	)	O	O	NONE
to	TO	to	O	O	NONE
lapatinib	NN	lapatinib	B-e3	T	drug
was	VBD	be	O	O	NONE
decreased	VBN	decrease	O	O	NONE
approximately	RB	approximately	O	O	NONE
72	CD	72	O	O	NONE
%.	NN	%.	O	O	NONE

NO

Sentence: DrugDDI.d201.s8
Carbamazepine	NN	carbamazepine	B-e0	O	drug
:	:	:	O	O	NONE
In	IN	in	O	O	NONE
healthy	JJ	healthy	O	O	NONE
subjects	NNS	subject	O	O	NONE
receiving	VBG	receive	O	O	NONE
the	DT	the	O	O	NONE
CYP3A4	NN	cyp3a4	B-e1	O	drug
inducer	NN	inducer	O	O	NONE
,	,	,	O	O	NONE
carbamazepine	NN	carbamazepine	B-e2	T	drug
,	,	,	O	O	NONE
at	IN	at	O	O	NONE
100	CD	100	O	O	NONE
mg	NN	mg	O	O	NONE
twice	RB	twice	O	O	NONE
daily	JJ	daily	O	O	NONE
for	IN	for	O	O	NONE
3	CD	3	O	O	NONE
days	NNS	day	O	O	NONE
and	CC	and	O	O	NONE
200	CD	200	O	O	NONE
mg	NN	mg	O	O	NONE
twice	RB	twice	O	O	NONE
daily	JJ	daily	O	O	NONE
for	IN	for	O	O	NONE
17	CD	17	O	O	NONE
days	NNS	day	O	O	NONE
,	,	,	O	O	NONE
systemic	JJ	systemic	O	O	NONE
exposure	NN	exposure	O	O	NONE
(	(	(	O	O	NONE
AUC	NN	auc	O	O	NONE
)	)	)	O	O	NONE
to	TO	to	O	O	NONE
lapatinib	NN	lapatinib	B-e3	T	drug
was	VBD	be	O	O	NONE
decreased	VBN	decrease	O	O	NONE
approximately	RB	approximately	O	O	NONE
72	CD	72	O	O	NONE
%.	NN	%.	O	O	NONE

YES

Sentence: DrugDDI.d201.s9
Drugs	NNS	drug	B-e0	T	drug
that	WDT	that	O	O	NONE
Inhibit	VBP	inhibit	O	O	NONE
Drug	NN	drug	O	O	NONE
Transport	NN	transport	O	O	NONE
Systems	NNS	system	O	O	NONE
Lapatinib	NN	lapatinib	B-e1	T	drug
is	VBZ	be	O	O	NONE
a	DT	a	O	O	NONE
substrate	NN	substrate	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
efflux	NN	efflux	O	O	NONE
transporter	NN	transporter	B-e2	O	drug
P-glycoprotein	NN	p-glycoprotein	O	O	NONE
(	(	(	O	O	NONE
Pgp	NN	pgp	O	O	NONE
,	,	,	O	O	NONE
ABCB1	NN	abcb1	B-e3	O	drug
)	)	)	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d201.s9
Drugs	NNS	drug	B-e0	T	drug
that	WDT	that	O	O	NONE
Inhibit	VBP	inhibit	O	O	NONE
Drug	NN	drug	O	O	NONE
Transport	NN	transport	O	O	NONE
Systems	NNS	system	O	O	NONE
Lapatinib	NN	lapatinib	B-e1	O	drug
is	VBZ	be	O	O	NONE
a	DT	a	O	O	NONE
substrate	NN	substrate	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
efflux	NN	efflux	O	O	NONE
transporter	NN	transporter	B-e2	T	drug
P-glycoprotein	NN	p-glycoprotein	O	O	NONE
(	(	(	O	O	NONE
Pgp	NN	pgp	O	O	NONE
,	,	,	O	O	NONE
ABCB1	NN	abcb1	B-e3	O	drug
)	)	)	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d201.s9
Drugs	NNS	drug	B-e0	T	drug
that	WDT	that	O	O	NONE
Inhibit	VBP	inhibit	O	O	NONE
Drug	NN	drug	O	O	NONE
Transport	NN	transport	O	O	NONE
Systems	NNS	system	O	O	NONE
Lapatinib	NN	lapatinib	B-e1	O	drug
is	VBZ	be	O	O	NONE
a	DT	a	O	O	NONE
substrate	NN	substrate	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
efflux	NN	efflux	O	O	NONE
transporter	NN	transporter	B-e2	O	drug
P-glycoprotein	NN	p-glycoprotein	O	O	NONE
(	(	(	O	O	NONE
Pgp	NN	pgp	O	O	NONE
,	,	,	O	O	NONE
ABCB1	NN	abcb1	B-e3	T	drug
)	)	)	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d201.s9
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
Inhibit	VBP	inhibit	O	O	NONE
Drug	NN	drug	O	O	NONE
Transport	NN	transport	O	O	NONE
Systems	NNS	system	O	O	NONE
Lapatinib	NN	lapatinib	B-e1	T	drug
is	VBZ	be	O	O	NONE
a	DT	a	O	O	NONE
substrate	NN	substrate	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
efflux	NN	efflux	O	O	NONE
transporter	NN	transporter	B-e2	T	drug
P-glycoprotein	NN	p-glycoprotein	O	O	NONE
(	(	(	O	O	NONE
Pgp	NN	pgp	O	O	NONE
,	,	,	O	O	NONE
ABCB1	NN	abcb1	B-e3	O	drug
)	)	)	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d201.s9
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
Inhibit	VBP	inhibit	O	O	NONE
Drug	NN	drug	O	O	NONE
Transport	NN	transport	O	O	NONE
Systems	NNS	system	O	O	NONE
Lapatinib	NN	lapatinib	B-e1	T	drug
is	VBZ	be	O	O	NONE
a	DT	a	O	O	NONE
substrate	NN	substrate	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
efflux	NN	efflux	O	O	NONE
transporter	NN	transporter	B-e2	O	drug
P-glycoprotein	NN	p-glycoprotein	O	O	NONE
(	(	(	O	O	NONE
Pgp	NN	pgp	O	O	NONE
,	,	,	O	O	NONE
ABCB1	NN	abcb1	B-e3	T	drug
)	)	)	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d201.s9
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
Inhibit	VBP	inhibit	O	O	NONE
Drug	NN	drug	O	O	NONE
Transport	NN	transport	O	O	NONE
Systems	NNS	system	O	O	NONE
Lapatinib	NN	lapatinib	B-e1	O	drug
is	VBZ	be	O	O	NONE
a	DT	a	O	O	NONE
substrate	NN	substrate	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
efflux	NN	efflux	O	O	NONE
transporter	NN	transporter	B-e2	T	drug
P-glycoprotein	NN	p-glycoprotein	O	O	NONE
(	(	(	O	O	NONE
Pgp	NN	pgp	O	O	NONE
,	,	,	O	O	NONE
ABCB1	NN	abcb1	B-e3	T	drug
)	)	)	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d201.s10
If	IN	if	O	O	NONE
TYKERB	NN	tykerb	O	O	NONE
is	VBZ	be	O	O	NONE
administered	VBN	administer	O	O	NONE
with	IN	with	O	O	NONE
drugs	NNS	drug	B-e0	T	drug
that	WDT	that	O	O	NONE
inhibit	VBP	inhibit	O	O	NONE
Pgp	NN	pgp	O	O	NONE
,	,	,	O	O	NONE
increased	VBN	increase	O	O	NONE
concentrations	NNS	concentration	O	O	NONE
of	IN	of	O	O	NONE
lapatinib	NN	lapatinib	B-e1	T	drug
are	VBP	be	O	O	NONE
likely	JJ	likely	O	O	NONE
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
caution	NN	caution	O	O	NONE
should	MD	should	O	O	NONE
be	VB	be	O	O	NONE
exercised	VBN	exercise	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d201.s11
Other	JJ	other	O	O	NONE
Chemotherapy	NN	chemotherapy	O	O	NONE
Agents	NNS	agent	O	O	NONE
:	:	:	O	O	NONE
In	IN	in	O	O	NONE
a	DT	a	O	O	NONE
separate	JJ	separate	O	O	NONE
study	NN	study	O	O	NONE
,	,	,	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
lapatinib	NN	lapatinib	B-e0	T	drug
with	IN	with	O	O	NONE
capecitabine	NN	capecitabine	B-e1	T	drug
did	VBD	do	O	O	NONE
not	RB	not	O	O	NONE
meaningfully	RB	meaningfully	O	O	NONE
alter	VB	alter	O	O	NONE
the	DT	the	O	O	NONE
pharmacokinetics	NNS	pharmacokinetic	O	O	NONE
of	IN	of	O	O	NONE
either	DT	either	O	O	NONE
agent	NN	agent	O	O	NONE
(	(	(	O	O	NONE
or	CC	or	O	O	NONE
the	DT	the	O	O	NONE
metabolites	NNS	metabolite	B-e2	O	drug
of	IN	of	O	O	NONE
capecitabine	NN	capecitabine	B-e3	O	drug
)	)	)	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d201.s11
Other	JJ	other	O	O	NONE
Chemotherapy	NN	chemotherapy	O	O	NONE
Agents	NNS	agent	O	O	NONE
:	:	:	O	O	NONE
In	IN	in	O	O	NONE
a	DT	a	O	O	NONE
separate	JJ	separate	O	O	NONE
study	NN	study	O	O	NONE
,	,	,	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
lapatinib	NN	lapatinib	B-e0	T	drug
with	IN	with	O	O	NONE
capecitabine	NN	capecitabine	B-e1	O	drug
did	VBD	do	O	O	NONE
not	RB	not	O	O	NONE
meaningfully	RB	meaningfully	O	O	NONE
alter	VB	alter	O	O	NONE
the	DT	the	O	O	NONE
pharmacokinetics	NNS	pharmacokinetic	O	O	NONE
of	IN	of	O	O	NONE
either	DT	either	O	O	NONE
agent	NN	agent	O	O	NONE
(	(	(	O	O	NONE
or	CC	or	O	O	NONE
the	DT	the	O	O	NONE
metabolites	NNS	metabolite	B-e2	T	drug
of	IN	of	O	O	NONE
capecitabine	NN	capecitabine	B-e3	O	drug
)	)	)	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d201.s11
Other	JJ	other	O	O	NONE
Chemotherapy	NN	chemotherapy	O	O	NONE
Agents	NNS	agent	O	O	NONE
:	:	:	O	O	NONE
In	IN	in	O	O	NONE
a	DT	a	O	O	NONE
separate	JJ	separate	O	O	NONE
study	NN	study	O	O	NONE
,	,	,	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
lapatinib	NN	lapatinib	B-e0	T	drug
with	IN	with	O	O	NONE
capecitabine	NN	capecitabine	B-e1	O	drug
did	VBD	do	O	O	NONE
not	RB	not	O	O	NONE
meaningfully	RB	meaningfully	O	O	NONE
alter	VB	alter	O	O	NONE
the	DT	the	O	O	NONE
pharmacokinetics	NNS	pharmacokinetic	O	O	NONE
of	IN	of	O	O	NONE
either	DT	either	O	O	NONE
agent	NN	agent	O	O	NONE
(	(	(	O	O	NONE
or	CC	or	O	O	NONE
the	DT	the	O	O	NONE
metabolites	NNS	metabolite	B-e2	O	drug
of	IN	of	O	O	NONE
capecitabine	NN	capecitabine	B-e3	T	drug
)	)	)	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d201.s11
Other	JJ	other	O	O	NONE
Chemotherapy	NN	chemotherapy	O	O	NONE
Agents	NNS	agent	O	O	NONE
:	:	:	O	O	NONE
In	IN	in	O	O	NONE
a	DT	a	O	O	NONE
separate	JJ	separate	O	O	NONE
study	NN	study	O	O	NONE
,	,	,	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
lapatinib	NN	lapatinib	B-e0	O	drug
with	IN	with	O	O	NONE
capecitabine	NN	capecitabine	B-e1	T	drug
did	VBD	do	O	O	NONE
not	RB	not	O	O	NONE
meaningfully	RB	meaningfully	O	O	NONE
alter	VB	alter	O	O	NONE
the	DT	the	O	O	NONE
pharmacokinetics	NNS	pharmacokinetic	O	O	NONE
of	IN	of	O	O	NONE
either	DT	either	O	O	NONE
agent	NN	agent	O	O	NONE
(	(	(	O	O	NONE
or	CC	or	O	O	NONE
the	DT	the	O	O	NONE
metabolites	NNS	metabolite	B-e2	T	drug
of	IN	of	O	O	NONE
capecitabine	NN	capecitabine	B-e3	O	drug
)	)	)	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d201.s11
Other	JJ	other	O	O	NONE
Chemotherapy	NN	chemotherapy	O	O	NONE
Agents	NNS	agent	O	O	NONE
:	:	:	O	O	NONE
In	IN	in	O	O	NONE
a	DT	a	O	O	NONE
separate	JJ	separate	O	O	NONE
study	NN	study	O	O	NONE
,	,	,	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
lapatinib	NN	lapatinib	B-e0	O	drug
with	IN	with	O	O	NONE
capecitabine	NN	capecitabine	B-e1	T	drug
did	VBD	do	O	O	NONE
not	RB	not	O	O	NONE
meaningfully	RB	meaningfully	O	O	NONE
alter	VB	alter	O	O	NONE
the	DT	the	O	O	NONE
pharmacokinetics	NNS	pharmacokinetic	O	O	NONE
of	IN	of	O	O	NONE
either	DT	either	O	O	NONE
agent	NN	agent	O	O	NONE
(	(	(	O	O	NONE
or	CC	or	O	O	NONE
the	DT	the	O	O	NONE
metabolites	NNS	metabolite	B-e2	O	drug
of	IN	of	O	O	NONE
capecitabine	NN	capecitabine	B-e3	T	drug
)	)	)	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d201.s11
Other	JJ	other	O	O	NONE
Chemotherapy	NN	chemotherapy	O	O	NONE
Agents	NNS	agent	O	O	NONE
:	:	:	O	O	NONE
In	IN	in	O	O	NONE
a	DT	a	O	O	NONE
separate	JJ	separate	O	O	NONE
study	NN	study	O	O	NONE
,	,	,	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
lapatinib	NN	lapatinib	B-e0	O	drug
with	IN	with	O	O	NONE
capecitabine	NN	capecitabine	B-e1	O	drug
did	VBD	do	O	O	NONE
not	RB	not	O	O	NONE
meaningfully	RB	meaningfully	O	O	NONE
alter	VB	alter	O	O	NONE
the	DT	the	O	O	NONE
pharmacokinetics	NNS	pharmacokinetic	O	O	NONE
of	IN	of	O	O	NONE
either	DT	either	O	O	NONE
agent	NN	agent	O	O	NONE
(	(	(	O	O	NONE
or	CC	or	O	O	NONE
the	DT	the	O	O	NONE
metabolites	NNS	metabolite	B-e2	T	drug
of	IN	of	O	O	NONE
capecitabine	NN	capecitabine	B-e3	T	drug
)	)	)	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d581.s0
Cholestyramine	NN	cholestyramine	B-e0	T	drug
and	CC	and	O	O	NONE
Charcoal	NN	charcoal	B-e1	T	drug
Administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
cholestyramine	NN	cholestyramine	B-e2	O	drug
or	CC	or	O	O	NONE
activated	VBN	activate	B-e3	O	drug
charcoal	NN	charcoal	I-e3	O	drug
in	IN	in	O	O	NONE
patients	NNS	patient	O	O	NONE
(	(	(	O	O	NONE
n=13	NN	n=13	O	O	NONE
)	)	)	O	O	NONE
and	CC	and	O	O	NONE
volunteers	NNS	volunteer	O	O	NONE
(	(	(	O	O	NONE
n=96	CD	n=96	O	O	NONE
)	)	)	O	O	NONE
resulted	VBD	result	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
rapid	JJ	rapid	O	O	NONE
and	CC	and	O	O	NONE
significant	JJ	significant	O	O	NONE
decrease	NN	decrease	O	O	NONE
in	IN	in	O	O	NONE
plasma	NN	plasma	O	O	NONE
M1	NN	m1	O	O	NONE
(	(	(	O	O	NONE
the	DT	the	O	O	NONE
active	JJ	active	B-e4	O	drug
metabolite	NN	metabolite	I-e4	O	drug
of	IN	of	O	O	NONE
leflunomide	NN	leflunomide	B-e5	O	drug
)	)	)	O	O	NONE
concentration	NN	concentration	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d581.s0
Cholestyramine	NN	cholestyramine	B-e0	T	drug
and	CC	and	O	O	NONE
Charcoal	NN	charcoal	B-e1	O	drug
Administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
cholestyramine	NN	cholestyramine	B-e2	T	drug
or	CC	or	O	O	NONE
activated	VBN	activate	B-e3	O	drug
charcoal	NN	charcoal	I-e3	O	drug
in	IN	in	O	O	NONE
patients	NNS	patient	O	O	NONE
(	(	(	O	O	NONE
n=13	NN	n=13	O	O	NONE
)	)	)	O	O	NONE
and	CC	and	O	O	NONE
volunteers	NNS	volunteer	O	O	NONE
(	(	(	O	O	NONE
n=96	CD	n=96	O	O	NONE
)	)	)	O	O	NONE
resulted	VBD	result	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
rapid	JJ	rapid	O	O	NONE
and	CC	and	O	O	NONE
significant	JJ	significant	O	O	NONE
decrease	NN	decrease	O	O	NONE
in	IN	in	O	O	NONE
plasma	NN	plasma	O	O	NONE
M1	NN	m1	O	O	NONE
(	(	(	O	O	NONE
the	DT	the	O	O	NONE
active	JJ	active	B-e4	O	drug
metabolite	NN	metabolite	I-e4	O	drug
of	IN	of	O	O	NONE
leflunomide	NN	leflunomide	B-e5	O	drug
)	)	)	O	O	NONE
concentration	NN	concentration	O	O	NONE
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d581.s0
Cholestyramine	NN	cholestyramine	B-e0	T	drug
and	CC	and	O	O	NONE
Charcoal	NN	charcoal	B-e1	O	drug
Administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
cholestyramine	NN	cholestyramine	B-e2	O	drug
or	CC	or	O	O	NONE
activated	VBN	activate	B-e3	T	drug
charcoal	NN	charcoal	I-e3	T	drug
in	IN	in	O	O	NONE
patients	NNS	patient	O	O	NONE
(	(	(	O	O	NONE
n=13	NN	n=13	O	O	NONE
)	)	)	O	O	NONE
and	CC	and	O	O	NONE
volunteers	NNS	volunteer	O	O	NONE
(	(	(	O	O	NONE
n=96	CD	n=96	O	O	NONE
)	)	)	O	O	NONE
resulted	VBD	result	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
rapid	JJ	rapid	O	O	NONE
and	CC	and	O	O	NONE
significant	JJ	significant	O	O	NONE
decrease	NN	decrease	O	O	NONE
in	IN	in	O	O	NONE
plasma	NN	plasma	O	O	NONE
M1	NN	m1	O	O	NONE
(	(	(	O	O	NONE
the	DT	the	O	O	NONE
active	JJ	active	B-e4	O	drug
metabolite	NN	metabolite	I-e4	O	drug
of	IN	of	O	O	NONE
leflunomide	NN	leflunomide	B-e5	O	drug
)	)	)	O	O	NONE
concentration	NN	concentration	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d581.s0
Cholestyramine	NN	cholestyramine	B-e0	T	drug
and	CC	and	O	O	NONE
Charcoal	NN	charcoal	B-e1	O	drug
Administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
cholestyramine	NN	cholestyramine	B-e2	O	drug
or	CC	or	O	O	NONE
activated	VBN	activate	B-e3	O	drug
charcoal	NN	charcoal	I-e3	O	drug
in	IN	in	O	O	NONE
patients	NNS	patient	O	O	NONE
(	(	(	O	O	NONE
n=13	NN	n=13	O	O	NONE
)	)	)	O	O	NONE
and	CC	and	O	O	NONE
volunteers	NNS	volunteer	O	O	NONE
(	(	(	O	O	NONE
n=96	CD	n=96	O	O	NONE
)	)	)	O	O	NONE
resulted	VBD	result	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
rapid	JJ	rapid	O	O	NONE
and	CC	and	O	O	NONE
significant	JJ	significant	O	O	NONE
decrease	NN	decrease	O	O	NONE
in	IN	in	O	O	NONE
plasma	NN	plasma	O	O	NONE
M1	NN	m1	O	O	NONE
(	(	(	O	O	NONE
the	DT	the	O	O	NONE
active	JJ	active	B-e4	T	drug
metabolite	NN	metabolite	I-e4	T	drug
of	IN	of	O	O	NONE
leflunomide	NN	leflunomide	B-e5	O	drug
)	)	)	O	O	NONE
concentration	NN	concentration	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d581.s0
Cholestyramine	NN	cholestyramine	B-e0	T	drug
and	CC	and	O	O	NONE
Charcoal	NN	charcoal	B-e1	O	drug
Administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
cholestyramine	NN	cholestyramine	B-e2	O	drug
or	CC	or	O	O	NONE
activated	VBN	activate	B-e3	O	drug
charcoal	NN	charcoal	I-e3	O	drug
in	IN	in	O	O	NONE
patients	NNS	patient	O	O	NONE
(	(	(	O	O	NONE
n=13	NN	n=13	O	O	NONE
)	)	)	O	O	NONE
and	CC	and	O	O	NONE
volunteers	NNS	volunteer	O	O	NONE
(	(	(	O	O	NONE
n=96	CD	n=96	O	O	NONE
)	)	)	O	O	NONE
resulted	VBD	result	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
rapid	JJ	rapid	O	O	NONE
and	CC	and	O	O	NONE
significant	JJ	significant	O	O	NONE
decrease	NN	decrease	O	O	NONE
in	IN	in	O	O	NONE
plasma	NN	plasma	O	O	NONE
M1	NN	m1	O	O	NONE
(	(	(	O	O	NONE
the	DT	the	O	O	NONE
active	JJ	active	B-e4	O	drug
metabolite	NN	metabolite	I-e4	O	drug
of	IN	of	O	O	NONE
leflunomide	NN	leflunomide	B-e5	T	drug
)	)	)	O	O	NONE
concentration	NN	concentration	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d581.s0
Cholestyramine	NN	cholestyramine	B-e0	O	drug
and	CC	and	O	O	NONE
Charcoal	NN	charcoal	B-e1	T	drug
Administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
cholestyramine	NN	cholestyramine	B-e2	T	drug
or	CC	or	O	O	NONE
activated	VBN	activate	B-e3	O	drug
charcoal	NN	charcoal	I-e3	O	drug
in	IN	in	O	O	NONE
patients	NNS	patient	O	O	NONE
(	(	(	O	O	NONE
n=13	NN	n=13	O	O	NONE
)	)	)	O	O	NONE
and	CC	and	O	O	NONE
volunteers	NNS	volunteer	O	O	NONE
(	(	(	O	O	NONE
n=96	CD	n=96	O	O	NONE
)	)	)	O	O	NONE
resulted	VBD	result	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
rapid	JJ	rapid	O	O	NONE
and	CC	and	O	O	NONE
significant	JJ	significant	O	O	NONE
decrease	NN	decrease	O	O	NONE
in	IN	in	O	O	NONE
plasma	NN	plasma	O	O	NONE
M1	NN	m1	O	O	NONE
(	(	(	O	O	NONE
the	DT	the	O	O	NONE
active	JJ	active	B-e4	O	drug
metabolite	NN	metabolite	I-e4	O	drug
of	IN	of	O	O	NONE
leflunomide	NN	leflunomide	B-e5	O	drug
)	)	)	O	O	NONE
concentration	NN	concentration	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d581.s0
Cholestyramine	NN	cholestyramine	B-e0	O	drug
and	CC	and	O	O	NONE
Charcoal	NN	charcoal	B-e1	T	drug
Administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
cholestyramine	NN	cholestyramine	B-e2	O	drug
or	CC	or	O	O	NONE
activated	VBN	activate	B-e3	T	drug
charcoal	NN	charcoal	I-e3	T	drug
in	IN	in	O	O	NONE
patients	NNS	patient	O	O	NONE
(	(	(	O	O	NONE
n=13	NN	n=13	O	O	NONE
)	)	)	O	O	NONE
and	CC	and	O	O	NONE
volunteers	NNS	volunteer	O	O	NONE
(	(	(	O	O	NONE
n=96	CD	n=96	O	O	NONE
)	)	)	O	O	NONE
resulted	VBD	result	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
rapid	JJ	rapid	O	O	NONE
and	CC	and	O	O	NONE
significant	JJ	significant	O	O	NONE
decrease	NN	decrease	O	O	NONE
in	IN	in	O	O	NONE
plasma	NN	plasma	O	O	NONE
M1	NN	m1	O	O	NONE
(	(	(	O	O	NONE
the	DT	the	O	O	NONE
active	JJ	active	B-e4	O	drug
metabolite	NN	metabolite	I-e4	O	drug
of	IN	of	O	O	NONE
leflunomide	NN	leflunomide	B-e5	O	drug
)	)	)	O	O	NONE
concentration	NN	concentration	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d581.s0
Cholestyramine	NN	cholestyramine	B-e0	O	drug
and	CC	and	O	O	NONE
Charcoal	NN	charcoal	B-e1	T	drug
Administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
cholestyramine	NN	cholestyramine	B-e2	O	drug
or	CC	or	O	O	NONE
activated	VBN	activate	B-e3	O	drug
charcoal	NN	charcoal	I-e3	O	drug
in	IN	in	O	O	NONE
patients	NNS	patient	O	O	NONE
(	(	(	O	O	NONE
n=13	NN	n=13	O	O	NONE
)	)	)	O	O	NONE
and	CC	and	O	O	NONE
volunteers	NNS	volunteer	O	O	NONE
(	(	(	O	O	NONE
n=96	CD	n=96	O	O	NONE
)	)	)	O	O	NONE
resulted	VBD	result	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
rapid	JJ	rapid	O	O	NONE
and	CC	and	O	O	NONE
significant	JJ	significant	O	O	NONE
decrease	NN	decrease	O	O	NONE
in	IN	in	O	O	NONE
plasma	NN	plasma	O	O	NONE
M1	NN	m1	O	O	NONE
(	(	(	O	O	NONE
the	DT	the	O	O	NONE
active	JJ	active	B-e4	T	drug
metabolite	NN	metabolite	I-e4	T	drug
of	IN	of	O	O	NONE
leflunomide	NN	leflunomide	B-e5	O	drug
)	)	)	O	O	NONE
concentration	NN	concentration	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d581.s0
Cholestyramine	NN	cholestyramine	B-e0	O	drug
and	CC	and	O	O	NONE
Charcoal	NN	charcoal	B-e1	T	drug
Administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
cholestyramine	NN	cholestyramine	B-e2	O	drug
or	CC	or	O	O	NONE
activated	VBN	activate	B-e3	O	drug
charcoal	NN	charcoal	I-e3	O	drug
in	IN	in	O	O	NONE
patients	NNS	patient	O	O	NONE
(	(	(	O	O	NONE
n=13	NN	n=13	O	O	NONE
)	)	)	O	O	NONE
and	CC	and	O	O	NONE
volunteers	NNS	volunteer	O	O	NONE
(	(	(	O	O	NONE
n=96	CD	n=96	O	O	NONE
)	)	)	O	O	NONE
resulted	VBD	result	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
rapid	JJ	rapid	O	O	NONE
and	CC	and	O	O	NONE
significant	JJ	significant	O	O	NONE
decrease	NN	decrease	O	O	NONE
in	IN	in	O	O	NONE
plasma	NN	plasma	O	O	NONE
M1	NN	m1	O	O	NONE
(	(	(	O	O	NONE
the	DT	the	O	O	NONE
active	JJ	active	B-e4	O	drug
metabolite	NN	metabolite	I-e4	O	drug
of	IN	of	O	O	NONE
leflunomide	NN	leflunomide	B-e5	T	drug
)	)	)	O	O	NONE
concentration	NN	concentration	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d581.s0
Cholestyramine	NN	cholestyramine	B-e0	O	drug
and	CC	and	O	O	NONE
Charcoal	NN	charcoal	B-e1	O	drug
Administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
cholestyramine	NN	cholestyramine	B-e2	T	drug
or	CC	or	O	O	NONE
activated	VBN	activate	B-e3	T	drug
charcoal	NN	charcoal	I-e3	T	drug
in	IN	in	O	O	NONE
patients	NNS	patient	O	O	NONE
(	(	(	O	O	NONE
n=13	NN	n=13	O	O	NONE
)	)	)	O	O	NONE
and	CC	and	O	O	NONE
volunteers	NNS	volunteer	O	O	NONE
(	(	(	O	O	NONE
n=96	CD	n=96	O	O	NONE
)	)	)	O	O	NONE
resulted	VBD	result	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
rapid	JJ	rapid	O	O	NONE
and	CC	and	O	O	NONE
significant	JJ	significant	O	O	NONE
decrease	NN	decrease	O	O	NONE
in	IN	in	O	O	NONE
plasma	NN	plasma	O	O	NONE
M1	NN	m1	O	O	NONE
(	(	(	O	O	NONE
the	DT	the	O	O	NONE
active	JJ	active	B-e4	O	drug
metabolite	NN	metabolite	I-e4	O	drug
of	IN	of	O	O	NONE
leflunomide	NN	leflunomide	B-e5	O	drug
)	)	)	O	O	NONE
concentration	NN	concentration	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d581.s0
Cholestyramine	NN	cholestyramine	B-e0	O	drug
and	CC	and	O	O	NONE
Charcoal	NN	charcoal	B-e1	O	drug
Administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
cholestyramine	NN	cholestyramine	B-e2	T	drug
or	CC	or	O	O	NONE
activated	VBN	activate	B-e3	O	drug
charcoal	NN	charcoal	I-e3	O	drug
in	IN	in	O	O	NONE
patients	NNS	patient	O	O	NONE
(	(	(	O	O	NONE
n=13	NN	n=13	O	O	NONE
)	)	)	O	O	NONE
and	CC	and	O	O	NONE
volunteers	NNS	volunteer	O	O	NONE
(	(	(	O	O	NONE
n=96	CD	n=96	O	O	NONE
)	)	)	O	O	NONE
resulted	VBD	result	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
rapid	JJ	rapid	O	O	NONE
and	CC	and	O	O	NONE
significant	JJ	significant	O	O	NONE
decrease	NN	decrease	O	O	NONE
in	IN	in	O	O	NONE
plasma	NN	plasma	O	O	NONE
M1	NN	m1	O	O	NONE
(	(	(	O	O	NONE
the	DT	the	O	O	NONE
active	JJ	active	B-e4	T	drug
metabolite	NN	metabolite	I-e4	T	drug
of	IN	of	O	O	NONE
leflunomide	NN	leflunomide	B-e5	O	drug
)	)	)	O	O	NONE
concentration	NN	concentration	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d581.s0
Cholestyramine	NN	cholestyramine	B-e0	O	drug
and	CC	and	O	O	NONE
Charcoal	NN	charcoal	B-e1	O	drug
Administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
cholestyramine	NN	cholestyramine	B-e2	T	drug
or	CC	or	O	O	NONE
activated	VBN	activate	B-e3	O	drug
charcoal	NN	charcoal	I-e3	O	drug
in	IN	in	O	O	NONE
patients	NNS	patient	O	O	NONE
(	(	(	O	O	NONE
n=13	NN	n=13	O	O	NONE
)	)	)	O	O	NONE
and	CC	and	O	O	NONE
volunteers	NNS	volunteer	O	O	NONE
(	(	(	O	O	NONE
n=96	CD	n=96	O	O	NONE
)	)	)	O	O	NONE
resulted	VBD	result	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
rapid	JJ	rapid	O	O	NONE
and	CC	and	O	O	NONE
significant	JJ	significant	O	O	NONE
decrease	NN	decrease	O	O	NONE
in	IN	in	O	O	NONE
plasma	NN	plasma	O	O	NONE
M1	NN	m1	O	O	NONE
(	(	(	O	O	NONE
the	DT	the	O	O	NONE
active	JJ	active	B-e4	O	drug
metabolite	NN	metabolite	I-e4	O	drug
of	IN	of	O	O	NONE
leflunomide	NN	leflunomide	B-e5	T	drug
)	)	)	O	O	NONE
concentration	NN	concentration	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d581.s0
Cholestyramine	NN	cholestyramine	B-e0	O	drug
and	CC	and	O	O	NONE
Charcoal	NN	charcoal	B-e1	O	drug
Administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
cholestyramine	NN	cholestyramine	B-e2	O	drug
or	CC	or	O	O	NONE
activated	VBN	activate	B-e3	T	drug
charcoal	NN	charcoal	I-e3	T	drug
in	IN	in	O	O	NONE
patients	NNS	patient	O	O	NONE
(	(	(	O	O	NONE
n=13	NN	n=13	O	O	NONE
)	)	)	O	O	NONE
and	CC	and	O	O	NONE
volunteers	NNS	volunteer	O	O	NONE
(	(	(	O	O	NONE
n=96	CD	n=96	O	O	NONE
)	)	)	O	O	NONE
resulted	VBD	result	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
rapid	JJ	rapid	O	O	NONE
and	CC	and	O	O	NONE
significant	JJ	significant	O	O	NONE
decrease	NN	decrease	O	O	NONE
in	IN	in	O	O	NONE
plasma	NN	plasma	O	O	NONE
M1	NN	m1	O	O	NONE
(	(	(	O	O	NONE
the	DT	the	O	O	NONE
active	JJ	active	B-e4	T	drug
metabolite	NN	metabolite	I-e4	T	drug
of	IN	of	O	O	NONE
leflunomide	NN	leflunomide	B-e5	O	drug
)	)	)	O	O	NONE
concentration	NN	concentration	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d581.s0
Cholestyramine	NN	cholestyramine	B-e0	O	drug
and	CC	and	O	O	NONE
Charcoal	NN	charcoal	B-e1	O	drug
Administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
cholestyramine	NN	cholestyramine	B-e2	O	drug
or	CC	or	O	O	NONE
activated	VBN	activate	B-e3	T	drug
charcoal	NN	charcoal	I-e3	T	drug
in	IN	in	O	O	NONE
patients	NNS	patient	O	O	NONE
(	(	(	O	O	NONE
n=13	NN	n=13	O	O	NONE
)	)	)	O	O	NONE
and	CC	and	O	O	NONE
volunteers	NNS	volunteer	O	O	NONE
(	(	(	O	O	NONE
n=96	CD	n=96	O	O	NONE
)	)	)	O	O	NONE
resulted	VBD	result	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
rapid	JJ	rapid	O	O	NONE
and	CC	and	O	O	NONE
significant	JJ	significant	O	O	NONE
decrease	NN	decrease	O	O	NONE
in	IN	in	O	O	NONE
plasma	NN	plasma	O	O	NONE
M1	NN	m1	O	O	NONE
(	(	(	O	O	NONE
the	DT	the	O	O	NONE
active	JJ	active	B-e4	O	drug
metabolite	NN	metabolite	I-e4	O	drug
of	IN	of	O	O	NONE
leflunomide	NN	leflunomide	B-e5	T	drug
)	)	)	O	O	NONE
concentration	NN	concentration	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d581.s0
Cholestyramine	NN	cholestyramine	B-e0	O	drug
and	CC	and	O	O	NONE
Charcoal	NN	charcoal	B-e1	O	drug
Administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
cholestyramine	NN	cholestyramine	B-e2	O	drug
or	CC	or	O	O	NONE
activated	VBN	activate	B-e3	O	drug
charcoal	NN	charcoal	I-e3	O	drug
in	IN	in	O	O	NONE
patients	NNS	patient	O	O	NONE
(	(	(	O	O	NONE
n=13	NN	n=13	O	O	NONE
)	)	)	O	O	NONE
and	CC	and	O	O	NONE
volunteers	NNS	volunteer	O	O	NONE
(	(	(	O	O	NONE
n=96	CD	n=96	O	O	NONE
)	)	)	O	O	NONE
resulted	VBD	result	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
rapid	JJ	rapid	O	O	NONE
and	CC	and	O	O	NONE
significant	JJ	significant	O	O	NONE
decrease	NN	decrease	O	O	NONE
in	IN	in	O	O	NONE
plasma	NN	plasma	O	O	NONE
M1	NN	m1	O	O	NONE
(	(	(	O	O	NONE
the	DT	the	O	O	NONE
active	JJ	active	B-e4	T	drug
metabolite	NN	metabolite	I-e4	T	drug
of	IN	of	O	O	NONE
leflunomide	NN	leflunomide	B-e5	T	drug
)	)	)	O	O	NONE
concentration	NN	concentration	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d581.s1
Hepatotoxic	JJ	hepatotoxic	O	O	NONE
Drugs	NNS	drug	B-e0	T	drug
Increased	VBN	increase	O	O	NONE
side	NN	side	O	O	NONE
effects	NNS	effect	O	O	NONE
may	MD	may	O	O	NONE
occur	VB	occur	O	O	NONE
when	WRB	when	O	O	NONE
leflunomide	NN	leflunomide	B-e1	T	drug
is	VBZ	be	O	O	NONE
given	VBN	give	O	O	NONE
concomitantly	RB	concomitantly	O	O	NONE
with	IN	with	O	O	NONE
hepatotoxic	JJ	hepatotoxic	O	O	NONE
substances	NNS	substance	O	O	NONE
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d581.s2
This	DT	this	O	O	NONE
is	VBZ	be	O	O	NONE
also	RB	also	O	O	NONE
to	TO	to	O	O	NONE
be	VB	be	O	O	NONE
considered	VBN	consider	O	O	NONE
when	WRB	when	O	O	NONE
leflunomide	NN	leflunomide	B-e0	T	drug
treatment	NN	treatment	O	O	NONE
is	VBZ	be	O	O	NONE
followed	VBN	follow	O	O	NONE
by	IN	by	O	O	NONE
such	JJ	such	O	O	NONE
drugs	NNS	drug	B-e1	T	drug
without	IN	without	O	O	NONE
a	DT	a	O	O	NONE
drug	NN	drug	O	O	NONE
elimination	NN	elimination	O	O	NONE
procedure	NN	procedure	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d581.s3
In	IN	in	O	O	NONE
a	DT	a	O	O	NONE
small	JJ	small	O	O	NONE
(	(	(	O	O	NONE
n=30	NN	n=30	O	O	NONE
)	)	)	O	O	NONE
combination	NN	combination	O	O	NONE
study	NN	study	O	O	NONE
of	IN	of	O	O	NONE
ARAVA	NN	arava	B-e0	T	drug
with	IN	with	O	O	NONE
methotrexate	NN	methotrexate	B-e1	T	drug
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
2-	CD	2-	O	O	NONE
to	TO	to	O	O	NONE
3-fold	JJ	3-fold	O	O	NONE
elevation	NN	elevation	O	O	NONE
in	IN	in	O	O	NONE
liver	NN	liver	B-e2	O	drug
enzymes	NNS	enzyme	I-e2	O	drug
was	VBD	be	O	O	NONE
seen	VBN	see	O	O	NONE
in	IN	in	O	O	NONE
5	CD	5	O	O	NONE
of	IN	of	O	O	NONE
30	CD	30	O	O	NONE
patients	NNS	patient	O	O	NONE
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d581.s3
In	IN	in	O	O	NONE
a	DT	a	O	O	NONE
small	JJ	small	O	O	NONE
(	(	(	O	O	NONE
n=30	NN	n=30	O	O	NONE
)	)	)	O	O	NONE
combination	NN	combination	O	O	NONE
study	NN	study	O	O	NONE
of	IN	of	O	O	NONE
ARAVA	NN	arava	B-e0	T	drug
with	IN	with	O	O	NONE
methotrexate	NN	methotrexate	B-e1	O	drug
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
2-	CD	2-	O	O	NONE
to	TO	to	O	O	NONE
3-fold	JJ	3-fold	O	O	NONE
elevation	NN	elevation	O	O	NONE
in	IN	in	O	O	NONE
liver	NN	liver	B-e2	T	drug
enzymes	NNS	enzyme	I-e2	T	drug
was	VBD	be	O	O	NONE
seen	VBN	see	O	O	NONE
in	IN	in	O	O	NONE
5	CD	5	O	O	NONE
of	IN	of	O	O	NONE
30	CD	30	O	O	NONE
patients	NNS	patient	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d581.s3
In	IN	in	O	O	NONE
a	DT	a	O	O	NONE
small	JJ	small	O	O	NONE
(	(	(	O	O	NONE
n=30	NN	n=30	O	O	NONE
)	)	)	O	O	NONE
combination	NN	combination	O	O	NONE
study	NN	study	O	O	NONE
of	IN	of	O	O	NONE
ARAVA	NN	arava	B-e0	O	drug
with	IN	with	O	O	NONE
methotrexate	NN	methotrexate	B-e1	T	drug
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
2-	CD	2-	O	O	NONE
to	TO	to	O	O	NONE
3-fold	JJ	3-fold	O	O	NONE
elevation	NN	elevation	O	O	NONE
in	IN	in	O	O	NONE
liver	NN	liver	B-e2	T	drug
enzymes	NNS	enzyme	I-e2	T	drug
was	VBD	be	O	O	NONE
seen	VBN	see	O	O	NONE
in	IN	in	O	O	NONE
5	CD	5	O	O	NONE
of	IN	of	O	O	NONE
30	CD	30	O	O	NONE
patients	NNS	patient	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d581.s4
All	DT	all	O	O	NONE
elevations	NNS	elevation	O	O	NONE
resolved	VBN	resolve	O	O	NONE
,	,	,	O	O	NONE
2	CD	2	O	O	NONE
with	IN	with	O	O	NONE
continuation	NN	continuation	O	O	NONE
of	IN	of	O	O	NONE
both	DT	both	O	O	NONE
drugs	NNS	drug	B-e0	T	drug
and	CC	and	O	O	NONE
3	CD	3	O	O	NONE
after	IN	after	O	O	NONE
discontinuation	NN	discontinuation	O	O	NONE
of	IN	of	O	O	NONE
leflunomide	NN	leflunomide	B-e1	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d581.s6
All	DT	all	O	O	NONE
of	IN	of	O	O	NONE
these	DT	these	O	O	NONE
also	RB	also	O	O	NONE
resolved	VBN	resolve	O	O	NONE
,	,	,	O	O	NONE
2	CD	2	O	O	NONE
with	IN	with	O	O	NONE
continuation	NN	continuation	O	O	NONE
of	IN	of	O	O	NONE
both	DT	both	O	O	NONE
drugs	NNS	drug	B-e0	T	drug
and	CC	and	O	O	NONE
3	CD	3	O	O	NONE
after	IN	after	O	O	NONE
discontinuation	NN	discontinuation	O	O	NONE
of	IN	of	O	O	NONE
leflunomide	NN	leflunomide	B-e1	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d581.s9
NSAIDs	NNS	nsaid	B-e0	T	drug
:	:	:	O	O	NONE
In	IN	in	O	O	NONE
in	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
studies	NNS	study	O	O	NONE
,	,	,	O	O	NONE
M1	NN	m1	O	O	NONE
was	VBD	be	O	O	NONE
shown	VBN	show	O	O	NONE
to	TO	to	O	O	NONE
cause	VB	cause	O	O	NONE
increases	NNS	increase	O	O	NONE
ranging	VBG	range	O	O	NONE
from	IN	from	O	O	NONE
13	CD	13	O	O	NONE
-	CC	-	O	O	NONE
50	CD	50	O	O	NONE
%	NN	%	O	O	NONE
in	IN	in	O	O	NONE
the	DT	the	O	O	NONE
free	JJ	free	O	O	NONE
fraction	NN	fraction	O	O	NONE
of	IN	of	O	O	NONE
diclofenac	NN	diclofenac	B-e1	T	drug
and	CC	and	O	O	NONE
ibuprofen	NN	ibuprofen	B-e2	O	drug
at	IN	at	O	O	NONE
concentrations	NNS	concentration	O	O	NONE
in	IN	in	O	O	NONE
the	DT	the	O	O	NONE
clinical	JJ	clinical	O	O	NONE
range	NN	range	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d581.s9
NSAIDs	NNS	nsaid	B-e0	T	drug
:	:	:	O	O	NONE
In	IN	in	O	O	NONE
in	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
studies	NNS	study	O	O	NONE
,	,	,	O	O	NONE
M1	NN	m1	O	O	NONE
was	VBD	be	O	O	NONE
shown	VBN	show	O	O	NONE
to	TO	to	O	O	NONE
cause	VB	cause	O	O	NONE
increases	NNS	increase	O	O	NONE
ranging	VBG	range	O	O	NONE
from	IN	from	O	O	NONE
13	CD	13	O	O	NONE
-	CC	-	O	O	NONE
50	CD	50	O	O	NONE
%	NN	%	O	O	NONE
in	IN	in	O	O	NONE
the	DT	the	O	O	NONE
free	JJ	free	O	O	NONE
fraction	NN	fraction	O	O	NONE
of	IN	of	O	O	NONE
diclofenac	NN	diclofenac	B-e1	O	drug
and	CC	and	O	O	NONE
ibuprofen	NN	ibuprofen	B-e2	T	drug
at	IN	at	O	O	NONE
concentrations	NNS	concentration	O	O	NONE
in	IN	in	O	O	NONE
the	DT	the	O	O	NONE
clinical	JJ	clinical	O	O	NONE
range	NN	range	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d581.s9
NSAIDs	NNS	nsaid	B-e0	O	drug
:	:	:	O	O	NONE
In	IN	in	O	O	NONE
in	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
studies	NNS	study	O	O	NONE
,	,	,	O	O	NONE
M1	NN	m1	O	O	NONE
was	VBD	be	O	O	NONE
shown	VBN	show	O	O	NONE
to	TO	to	O	O	NONE
cause	VB	cause	O	O	NONE
increases	NNS	increase	O	O	NONE
ranging	VBG	range	O	O	NONE
from	IN	from	O	O	NONE
13	CD	13	O	O	NONE
-	CC	-	O	O	NONE
50	CD	50	O	O	NONE
%	NN	%	O	O	NONE
in	IN	in	O	O	NONE
the	DT	the	O	O	NONE
free	JJ	free	O	O	NONE
fraction	NN	fraction	O	O	NONE
of	IN	of	O	O	NONE
diclofenac	NN	diclofenac	B-e1	T	drug
and	CC	and	O	O	NONE
ibuprofen	NN	ibuprofen	B-e2	T	drug
at	IN	at	O	O	NONE
concentrations	NNS	concentration	O	O	NONE
in	IN	in	O	O	NONE
the	DT	the	O	O	NONE
clinical	JJ	clinical	O	O	NONE
range	NN	range	O	O	NONE
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d581.s12
Tolbutamide	NN	tolbutamide	B-e0	T	drug
:	:	:	O	O	NONE
In	IN	in	O	O	NONE
in	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
studies	NNS	study	O	O	NONE
,	,	,	O	O	NONE
M1	NN	m1	O	O	NONE
was	VBD	be	O	O	NONE
shown	VBN	show	O	O	NONE
to	TO	to	O	O	NONE
cause	VB	cause	O	O	NONE
increases	NNS	increase	O	O	NONE
ranging	VBG	range	O	O	NONE
from	IN	from	O	O	NONE
13	CD	13	O	O	NONE
-	CC	-	O	O	NONE
50	CD	50	O	O	NONE
%	NN	%	O	O	NONE
in	IN	in	O	O	NONE
the	DT	the	O	O	NONE
free	JJ	free	O	O	NONE
fraction	NN	fraction	O	O	NONE
of	IN	of	O	O	NONE
tolbutamide	NN	tolbutamide	B-e1	T	drug
at	IN	at	O	O	NONE
concentrations	NNS	concentration	O	O	NONE
in	IN	in	O	O	NONE
the	DT	the	O	O	NONE
clinical	JJ	clinical	O	O	NONE
range	NN	range	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d581.s14
Rifampin	NN	rifampin	B-e0	T	drug
Following	VBG	follow	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
a	DT	a	O	O	NONE
single	JJ	single	O	O	NONE
dose	NN	dose	O	O	NONE
of	IN	of	O	O	NONE
ARAVA	NN	arava	B-e1	T	drug
to	TO	to	O	O	NONE
subjects	NNS	subject	O	O	NONE
receiving	VBG	receive	O	O	NONE
multiple	JJ	multiple	O	O	NONE
doses	NNS	dose	O	O	NONE
of	IN	of	O	O	NONE
rifampin	NN	rifampin	B-e2	O	drug
,	,	,	O	O	NONE
M1	NN	m1	O	O	NONE
peak	NN	peak	O	O	NONE
levels	NNS	level	O	O	NONE
were	VBD	be	O	O	NONE
increased	VBN	increase	O	O	NONE
(	(	(	O	O	NONE
~40	CD	~40	O	O	NONE
%	NN	%	O	O	NONE
)	)	)	O	O	NONE
over	IN	over	O	O	NONE
those	DT	those	O	O	NONE
seen	VBN	see	O	O	NONE
when	WRB	when	O	O	NONE
ARAVA	NN	arava	B-e3	O	drug
was	VBD	be	O	O	NONE
given	VBN	give	O	O	NONE
alone	RB	alone	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d581.s14
Rifampin	NN	rifampin	B-e0	T	drug
Following	VBG	follow	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
a	DT	a	O	O	NONE
single	JJ	single	O	O	NONE
dose	NN	dose	O	O	NONE
of	IN	of	O	O	NONE
ARAVA	NN	arava	B-e1	O	drug
to	TO	to	O	O	NONE
subjects	NNS	subject	O	O	NONE
receiving	VBG	receive	O	O	NONE
multiple	JJ	multiple	O	O	NONE
doses	NNS	dose	O	O	NONE
of	IN	of	O	O	NONE
rifampin	NN	rifampin	B-e2	T	drug
,	,	,	O	O	NONE
M1	NN	m1	O	O	NONE
peak	NN	peak	O	O	NONE
levels	NNS	level	O	O	NONE
were	VBD	be	O	O	NONE
increased	VBN	increase	O	O	NONE
(	(	(	O	O	NONE
~40	CD	~40	O	O	NONE
%	NN	%	O	O	NONE
)	)	)	O	O	NONE
over	IN	over	O	O	NONE
those	DT	those	O	O	NONE
seen	VBN	see	O	O	NONE
when	WRB	when	O	O	NONE
ARAVA	NN	arava	B-e3	O	drug
was	VBD	be	O	O	NONE
given	VBN	give	O	O	NONE
alone	RB	alone	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d581.s14
Rifampin	NN	rifampin	B-e0	T	drug
Following	VBG	follow	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
a	DT	a	O	O	NONE
single	JJ	single	O	O	NONE
dose	NN	dose	O	O	NONE
of	IN	of	O	O	NONE
ARAVA	NN	arava	B-e1	O	drug
to	TO	to	O	O	NONE
subjects	NNS	subject	O	O	NONE
receiving	VBG	receive	O	O	NONE
multiple	JJ	multiple	O	O	NONE
doses	NNS	dose	O	O	NONE
of	IN	of	O	O	NONE
rifampin	NN	rifampin	B-e2	O	drug
,	,	,	O	O	NONE
M1	NN	m1	O	O	NONE
peak	NN	peak	O	O	NONE
levels	NNS	level	O	O	NONE
were	VBD	be	O	O	NONE
increased	VBN	increase	O	O	NONE
(	(	(	O	O	NONE
~40	CD	~40	O	O	NONE
%	NN	%	O	O	NONE
)	)	)	O	O	NONE
over	IN	over	O	O	NONE
those	DT	those	O	O	NONE
seen	VBN	see	O	O	NONE
when	WRB	when	O	O	NONE
ARAVA	NN	arava	B-e3	T	drug
was	VBD	be	O	O	NONE
given	VBN	give	O	O	NONE
alone	RB	alone	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d581.s14
Rifampin	NN	rifampin	B-e0	O	drug
Following	VBG	follow	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
a	DT	a	O	O	NONE
single	JJ	single	O	O	NONE
dose	NN	dose	O	O	NONE
of	IN	of	O	O	NONE
ARAVA	NN	arava	B-e1	T	drug
to	TO	to	O	O	NONE
subjects	NNS	subject	O	O	NONE
receiving	VBG	receive	O	O	NONE
multiple	JJ	multiple	O	O	NONE
doses	NNS	dose	O	O	NONE
of	IN	of	O	O	NONE
rifampin	NN	rifampin	B-e2	T	drug
,	,	,	O	O	NONE
M1	NN	m1	O	O	NONE
peak	NN	peak	O	O	NONE
levels	NNS	level	O	O	NONE
were	VBD	be	O	O	NONE
increased	VBN	increase	O	O	NONE
(	(	(	O	O	NONE
~40	CD	~40	O	O	NONE
%	NN	%	O	O	NONE
)	)	)	O	O	NONE
over	IN	over	O	O	NONE
those	DT	those	O	O	NONE
seen	VBN	see	O	O	NONE
when	WRB	when	O	O	NONE
ARAVA	NN	arava	B-e3	O	drug
was	VBD	be	O	O	NONE
given	VBN	give	O	O	NONE
alone	RB	alone	O	O	NONE
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d581.s14
Rifampin	NN	rifampin	B-e0	O	drug
Following	VBG	follow	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
a	DT	a	O	O	NONE
single	JJ	single	O	O	NONE
dose	NN	dose	O	O	NONE
of	IN	of	O	O	NONE
ARAVA	NN	arava	B-e1	T	drug
to	TO	to	O	O	NONE
subjects	NNS	subject	O	O	NONE
receiving	VBG	receive	O	O	NONE
multiple	JJ	multiple	O	O	NONE
doses	NNS	dose	O	O	NONE
of	IN	of	O	O	NONE
rifampin	NN	rifampin	B-e2	O	drug
,	,	,	O	O	NONE
M1	NN	m1	O	O	NONE
peak	NN	peak	O	O	NONE
levels	NNS	level	O	O	NONE
were	VBD	be	O	O	NONE
increased	VBN	increase	O	O	NONE
(	(	(	O	O	NONE
~40	CD	~40	O	O	NONE
%	NN	%	O	O	NONE
)	)	)	O	O	NONE
over	IN	over	O	O	NONE
those	DT	those	O	O	NONE
seen	VBN	see	O	O	NONE
when	WRB	when	O	O	NONE
ARAVA	NN	arava	B-e3	T	drug
was	VBD	be	O	O	NONE
given	VBN	give	O	O	NONE
alone	RB	alone	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d581.s14
Rifampin	NN	rifampin	B-e0	O	drug
Following	VBG	follow	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
a	DT	a	O	O	NONE
single	JJ	single	O	O	NONE
dose	NN	dose	O	O	NONE
of	IN	of	O	O	NONE
ARAVA	NN	arava	B-e1	O	drug
to	TO	to	O	O	NONE
subjects	NNS	subject	O	O	NONE
receiving	VBG	receive	O	O	NONE
multiple	JJ	multiple	O	O	NONE
doses	NNS	dose	O	O	NONE
of	IN	of	O	O	NONE
rifampin	NN	rifampin	B-e2	T	drug
,	,	,	O	O	NONE
M1	NN	m1	O	O	NONE
peak	NN	peak	O	O	NONE
levels	NNS	level	O	O	NONE
were	VBD	be	O	O	NONE
increased	VBN	increase	O	O	NONE
(	(	(	O	O	NONE
~40	CD	~40	O	O	NONE
%	NN	%	O	O	NONE
)	)	)	O	O	NONE
over	IN	over	O	O	NONE
those	DT	those	O	O	NONE
seen	VBN	see	O	O	NONE
when	WRB	when	O	O	NONE
ARAVA	NN	arava	B-e3	T	drug
was	VBD	be	O	O	NONE
given	VBN	give	O	O	NONE
alone	RB	alone	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d581.s15
Because	IN	because	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
potential	NN	potential	O	O	NONE
for	IN	for	O	O	NONE
ARAVA	NN	arava	B-e0	T	drug
levels	NNS	level	O	O	NONE
to	TO	to	O	O	NONE
continue	VBP	continue	O	O	NONE
to	TO	to	O	O	NONE
increase	VB	increase	O	O	NONE
with	IN	with	O	O	NONE
multiple	JJ	multiple	O	O	NONE
dosing	NN	dosing	O	O	NONE
,	,	,	O	O	NONE
caution	NN	caution	O	O	NONE
should	MD	should	O	O	NONE
be	VB	be	O	O	NONE
used	VBN	use	O	O	NONE
if	IN	if	O	O	NONE
patients	NNS	patient	O	O	NONE
are	VBP	be	O	O	NONE
to	TO	to	O	O	NONE
be	VB	be	O	O	NONE
receiving	VBG	receive	O	O	NONE
both	CC	both	O	O	NONE
ARAVA	NN	arava	B-e1	T	drug
and	CC	and	O	O	NONE
rifampin	NN	rifampin	B-e2	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d581.s15
Because	IN	because	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
potential	NN	potential	O	O	NONE
for	IN	for	O	O	NONE
ARAVA	NN	arava	B-e0	T	drug
levels	NNS	level	O	O	NONE
to	TO	to	O	O	NONE
continue	VBP	continue	O	O	NONE
to	TO	to	O	O	NONE
increase	VB	increase	O	O	NONE
with	IN	with	O	O	NONE
multiple	JJ	multiple	O	O	NONE
dosing	NN	dosing	O	O	NONE
,	,	,	O	O	NONE
caution	NN	caution	O	O	NONE
should	MD	should	O	O	NONE
be	VB	be	O	O	NONE
used	VBN	use	O	O	NONE
if	IN	if	O	O	NONE
patients	NNS	patient	O	O	NONE
are	VBP	be	O	O	NONE
to	TO	to	O	O	NONE
be	VB	be	O	O	NONE
receiving	VBG	receive	O	O	NONE
both	CC	both	O	O	NONE
ARAVA	NN	arava	B-e1	O	drug
and	CC	and	O	O	NONE
rifampin	NN	rifampin	B-e2	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d581.s15
Because	IN	because	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
potential	NN	potential	O	O	NONE
for	IN	for	O	O	NONE
ARAVA	NN	arava	B-e0	O	drug
levels	NNS	level	O	O	NONE
to	TO	to	O	O	NONE
continue	VBP	continue	O	O	NONE
to	TO	to	O	O	NONE
increase	VB	increase	O	O	NONE
with	IN	with	O	O	NONE
multiple	JJ	multiple	O	O	NONE
dosing	NN	dosing	O	O	NONE
,	,	,	O	O	NONE
caution	NN	caution	O	O	NONE
should	MD	should	O	O	NONE
be	VB	be	O	O	NONE
used	VBN	use	O	O	NONE
if	IN	if	O	O	NONE
patients	NNS	patient	O	O	NONE
are	VBP	be	O	O	NONE
to	TO	to	O	O	NONE
be	VB	be	O	O	NONE
receiving	VBG	receive	O	O	NONE
both	CC	both	O	O	NONE
ARAVA	NN	arava	B-e1	T	drug
and	CC	and	O	O	NONE
rifampin	NN	rifampin	B-e2	T	drug
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d581.s16
Warfarin	JJ	warfarin	B-e0	T	drug
Increased	VBN	increase	O	O	NONE
INR	NN	inr	O	O	NONE
(	(	(	O	O	NONE
International	NNP	International	O	O	NONE
Normalized	VBN	normalize	O	O	NONE
Ratio	NN	ratio	O	O	NONE
)	)	)	O	O	NONE
when	WRB	when	O	O	NONE
ARAVA	NN	arava	B-e1	T	drug
and	CC	and	O	O	NONE
warfarin	NN	warfarin	B-e2	O	drug
were	VBD	be	O	O	NONE
co-administered	VBN	co-administer	O	O	NONE
has	VBZ	have	O	O	NONE
been	VBN	be	O	O	NONE
rarely	RB	rarely	O	O	NONE
reported	VBN	report	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d581.s16
Warfarin	JJ	warfarin	B-e0	T	drug
Increased	VBN	increase	O	O	NONE
INR	NN	inr	O	O	NONE
(	(	(	O	O	NONE
International	NNP	International	O	O	NONE
Normalized	VBN	normalize	O	O	NONE
Ratio	NN	ratio	O	O	NONE
)	)	)	O	O	NONE
when	WRB	when	O	O	NONE
ARAVA	NN	arava	B-e1	O	drug
and	CC	and	O	O	NONE
warfarin	NN	warfarin	B-e2	T	drug
were	VBD	be	O	O	NONE
co-administered	VBN	co-administer	O	O	NONE
has	VBZ	have	O	O	NONE
been	VBN	be	O	O	NONE
rarely	RB	rarely	O	O	NONE
reported	VBN	report	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d581.s16
Warfarin	JJ	warfarin	B-e0	O	drug
Increased	VBN	increase	O	O	NONE
INR	NN	inr	O	O	NONE
(	(	(	O	O	NONE
International	NNP	International	O	O	NONE
Normalized	VBN	normalize	O	O	NONE
Ratio	NN	ratio	O	O	NONE
)	)	)	O	O	NONE
when	WRB	when	O	O	NONE
ARAVA	NN	arava	B-e1	T	drug
and	CC	and	O	O	NONE
warfarin	NN	warfarin	B-e2	T	drug
were	VBD	be	O	O	NONE
co-administered	VBN	co-administer	O	O	NONE
has	VBZ	have	O	O	NONE
been	VBN	be	O	O	NONE
rarely	RB	rarely	O	O	NONE
reported	VBN	report	O	O	NONE
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d379.s0
Clinical	JJ	clinical	O	O	NONE
interaction	NN	interaction	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
cimetidine	NN	cimetidine	B-e0	T	drug
and	CC	and	O	O	NONE
warfarin	NN	warfarin	B-e1	T	drug
indicated	VBD	indicate	O	O	NONE
that	IN	that	O	O	NONE
the	DT	the	O	O	NONE
coadministration	NN	coadministration	O	O	NONE
of	IN	of	O	O	NONE
Femara	NN	femara	B-e2	O	drug
with	IN	with	O	O	NONE
these	DT	these	O	O	NONE
drugs	NNS	drug	B-e3	O	drug
does	VBZ	do	O	O	NONE
not	RB	not	O	O	NONE
result	VB	result	O	O	NONE
in	IN	in	O	O	NONE
clinically-	JJ	clinically-	O	O	NONE
significant	JJ	significant	O	O	NONE
drug	NN	drug	O	O	NONE
interactions	NNS	interaction	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d379.s0
Clinical	JJ	clinical	O	O	NONE
interaction	NN	interaction	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
cimetidine	NN	cimetidine	B-e0	T	drug
and	CC	and	O	O	NONE
warfarin	NN	warfarin	B-e1	O	drug
indicated	VBD	indicate	O	O	NONE
that	IN	that	O	O	NONE
the	DT	the	O	O	NONE
coadministration	NN	coadministration	O	O	NONE
of	IN	of	O	O	NONE
Femara	NN	femara	B-e2	T	drug
with	IN	with	O	O	NONE
these	DT	these	O	O	NONE
drugs	NNS	drug	B-e3	O	drug
does	VBZ	do	O	O	NONE
not	RB	not	O	O	NONE
result	VB	result	O	O	NONE
in	IN	in	O	O	NONE
clinically-	JJ	clinically-	O	O	NONE
significant	JJ	significant	O	O	NONE
drug	NN	drug	O	O	NONE
interactions	NNS	interaction	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d379.s0
Clinical	JJ	clinical	O	O	NONE
interaction	NN	interaction	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
cimetidine	NN	cimetidine	B-e0	T	drug
and	CC	and	O	O	NONE
warfarin	NN	warfarin	B-e1	O	drug
indicated	VBD	indicate	O	O	NONE
that	IN	that	O	O	NONE
the	DT	the	O	O	NONE
coadministration	NN	coadministration	O	O	NONE
of	IN	of	O	O	NONE
Femara	NN	femara	B-e2	O	drug
with	IN	with	O	O	NONE
these	DT	these	O	O	NONE
drugs	NNS	drug	B-e3	T	drug
does	VBZ	do	O	O	NONE
not	RB	not	O	O	NONE
result	VB	result	O	O	NONE
in	IN	in	O	O	NONE
clinically-	JJ	clinically-	O	O	NONE
significant	JJ	significant	O	O	NONE
drug	NN	drug	O	O	NONE
interactions	NNS	interaction	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d379.s0
Clinical	JJ	clinical	O	O	NONE
interaction	NN	interaction	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
cimetidine	NN	cimetidine	B-e0	O	drug
and	CC	and	O	O	NONE
warfarin	NN	warfarin	B-e1	T	drug
indicated	VBD	indicate	O	O	NONE
that	IN	that	O	O	NONE
the	DT	the	O	O	NONE
coadministration	NN	coadministration	O	O	NONE
of	IN	of	O	O	NONE
Femara	NN	femara	B-e2	T	drug
with	IN	with	O	O	NONE
these	DT	these	O	O	NONE
drugs	NNS	drug	B-e3	O	drug
does	VBZ	do	O	O	NONE
not	RB	not	O	O	NONE
result	VB	result	O	O	NONE
in	IN	in	O	O	NONE
clinically-	JJ	clinically-	O	O	NONE
significant	JJ	significant	O	O	NONE
drug	NN	drug	O	O	NONE
interactions	NNS	interaction	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d379.s0
Clinical	JJ	clinical	O	O	NONE
interaction	NN	interaction	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
cimetidine	NN	cimetidine	B-e0	O	drug
and	CC	and	O	O	NONE
warfarin	NN	warfarin	B-e1	T	drug
indicated	VBD	indicate	O	O	NONE
that	IN	that	O	O	NONE
the	DT	the	O	O	NONE
coadministration	NN	coadministration	O	O	NONE
of	IN	of	O	O	NONE
Femara	NN	femara	B-e2	O	drug
with	IN	with	O	O	NONE
these	DT	these	O	O	NONE
drugs	NNS	drug	B-e3	T	drug
does	VBZ	do	O	O	NONE
not	RB	not	O	O	NONE
result	VB	result	O	O	NONE
in	IN	in	O	O	NONE
clinically-	JJ	clinically-	O	O	NONE
significant	JJ	significant	O	O	NONE
drug	NN	drug	O	O	NONE
interactions	NNS	interaction	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d379.s0
Clinical	JJ	clinical	O	O	NONE
interaction	NN	interaction	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
cimetidine	NN	cimetidine	B-e0	O	drug
and	CC	and	O	O	NONE
warfarin	NN	warfarin	B-e1	O	drug
indicated	VBD	indicate	O	O	NONE
that	IN	that	O	O	NONE
the	DT	the	O	O	NONE
coadministration	NN	coadministration	O	O	NONE
of	IN	of	O	O	NONE
Femara	NN	femara	B-e2	T	drug
with	IN	with	O	O	NONE
these	DT	these	O	O	NONE
drugs	NNS	drug	B-e3	T	drug
does	VBZ	do	O	O	NONE
not	RB	not	O	O	NONE
result	VB	result	O	O	NONE
in	IN	in	O	O	NONE
clinically-	JJ	clinically-	O	O	NONE
significant	JJ	significant	O	O	NONE
drug	NN	drug	O	O	NONE
interactions	NNS	interaction	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d379.s1
(	(	(	O	O	NONE
See	VB	see	O	O	NONE
CLINICAL	JJ	clinical	O	O	NONE
PHARMACOLOGY	NN	pharmacology	O	O	NONE
)	)	)	O	O	NONE
Coadministration	NN	coadministration	O	O	NONE
of	IN	of	O	O	NONE
Femara	NN	femara	B-e0	T	drug
and	CC	and	O	O	NONE
tamoxifen	NN	tamoxifen	B-e1	T	drug
20	CD	20	I-e1	T	drug
mg	NN	mg	I-e1	T	drug
daily	RB	daily	O	O	NONE
resulted	VBD	result	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
reduction	NN	reduction	O	O	NONE
of	IN	of	O	O	NONE
letrozole	NN	letrozole	B-e2	O	drug
plasma	NN	plasma	O	O	NONE
levels	NNS	level	O	O	NONE
by	IN	by	O	O	NONE
38	CD	38	O	O	NONE
%	NN	%	O	O	NONE
on	IN	on	O	O	NONE
average	NN	average	O	O	NONE
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d379.s1
(	(	(	O	O	NONE
See	VB	see	O	O	NONE
CLINICAL	JJ	clinical	O	O	NONE
PHARMACOLOGY	NN	pharmacology	O	O	NONE
)	)	)	O	O	NONE
Coadministration	NN	coadministration	O	O	NONE
of	IN	of	O	O	NONE
Femara	NN	femara	B-e0	T	drug
and	CC	and	O	O	NONE
tamoxifen	NN	tamoxifen	B-e1	O	drug
20	CD	20	I-e1	O	drug
mg	NN	mg	I-e1	O	drug
daily	RB	daily	O	O	NONE
resulted	VBD	result	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
reduction	NN	reduction	O	O	NONE
of	IN	of	O	O	NONE
letrozole	NN	letrozole	B-e2	T	drug
plasma	NN	plasma	O	O	NONE
levels	NNS	level	O	O	NONE
by	IN	by	O	O	NONE
38	CD	38	O	O	NONE
%	NN	%	O	O	NONE
on	IN	on	O	O	NONE
average	NN	average	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d379.s1
(	(	(	O	O	NONE
See	VB	see	O	O	NONE
CLINICAL	JJ	clinical	O	O	NONE
PHARMACOLOGY	NN	pharmacology	O	O	NONE
)	)	)	O	O	NONE
Coadministration	NN	coadministration	O	O	NONE
of	IN	of	O	O	NONE
Femara	NN	femara	B-e0	O	drug
and	CC	and	O	O	NONE
tamoxifen	NN	tamoxifen	B-e1	T	drug
20	CD	20	I-e1	T	drug
mg	NN	mg	I-e1	T	drug
daily	RB	daily	O	O	NONE
resulted	VBD	result	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
reduction	NN	reduction	O	O	NONE
of	IN	of	O	O	NONE
letrozole	NN	letrozole	B-e2	T	drug
plasma	NN	plasma	O	O	NONE
levels	NNS	level	O	O	NONE
by	IN	by	O	O	NONE
38	CD	38	O	O	NONE
%	NN	%	O	O	NONE
on	IN	on	O	O	NONE
average	NN	average	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d341.s0
Folic	JJ	folic	B-e0	T	drug
acid	NN	acid	I-e0	T	drug
in	IN	in	O	O	NONE
large	JJ	large	O	O	NONE
amounts	NNS	amount	O	O	NONE
may	MD	may	O	O	NONE
counteract	VB	counteract	O	O	NONE
the	DT	the	O	O	NONE
antiepileptic	JJ	antiepileptic	B-e1	T	drug
effect	NN	effect	O	O	NONE
of	IN	of	O	O	NONE
phenobarbital	NN	phenobarbital	B-e2	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e3	O	drug
and	CC	and	O	O	NONE
primidone	NN	primidone	B-e4	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
increase	VB	increase	O	O	NONE
the	DT	the	O	O	NONE
frequency	NN	frequency	O	O	NONE
of	IN	of	O	O	NONE
seizures	NNS	seizure	O	O	NONE
in	IN	in	O	O	NONE
susceptible	JJ	susceptible	O	O	NONE
pediatric	JJ	pediatric	B-e5	O	drug
patients	NNS	patient	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d341.s0
Folic	JJ	folic	B-e0	T	drug
acid	NN	acid	I-e0	T	drug
in	IN	in	O	O	NONE
large	JJ	large	O	O	NONE
amounts	NNS	amount	O	O	NONE
may	MD	may	O	O	NONE
counteract	VB	counteract	O	O	NONE
the	DT	the	O	O	NONE
antiepileptic	JJ	antiepileptic	B-e1	O	drug
effect	NN	effect	O	O	NONE
of	IN	of	O	O	NONE
phenobarbital	NN	phenobarbital	B-e2	T	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e3	O	drug
and	CC	and	O	O	NONE
primidone	NN	primidone	B-e4	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
increase	VB	increase	O	O	NONE
the	DT	the	O	O	NONE
frequency	NN	frequency	O	O	NONE
of	IN	of	O	O	NONE
seizures	NNS	seizure	O	O	NONE
in	IN	in	O	O	NONE
susceptible	JJ	susceptible	O	O	NONE
pediatric	JJ	pediatric	B-e5	O	drug
patients	NNS	patient	O	O	NONE
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d341.s0
Folic	JJ	folic	B-e0	T	drug
acid	NN	acid	I-e0	T	drug
in	IN	in	O	O	NONE
large	JJ	large	O	O	NONE
amounts	NNS	amount	O	O	NONE
may	MD	may	O	O	NONE
counteract	VB	counteract	O	O	NONE
the	DT	the	O	O	NONE
antiepileptic	JJ	antiepileptic	B-e1	O	drug
effect	NN	effect	O	O	NONE
of	IN	of	O	O	NONE
phenobarbital	NN	phenobarbital	B-e2	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e3	T	drug
and	CC	and	O	O	NONE
primidone	NN	primidone	B-e4	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
increase	VB	increase	O	O	NONE
the	DT	the	O	O	NONE
frequency	NN	frequency	O	O	NONE
of	IN	of	O	O	NONE
seizures	NNS	seizure	O	O	NONE
in	IN	in	O	O	NONE
susceptible	JJ	susceptible	O	O	NONE
pediatric	JJ	pediatric	B-e5	O	drug
patients	NNS	patient	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d341.s0
Folic	JJ	folic	B-e0	T	drug
acid	NN	acid	I-e0	T	drug
in	IN	in	O	O	NONE
large	JJ	large	O	O	NONE
amounts	NNS	amount	O	O	NONE
may	MD	may	O	O	NONE
counteract	VB	counteract	O	O	NONE
the	DT	the	O	O	NONE
antiepileptic	JJ	antiepileptic	B-e1	O	drug
effect	NN	effect	O	O	NONE
of	IN	of	O	O	NONE
phenobarbital	NN	phenobarbital	B-e2	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e3	O	drug
and	CC	and	O	O	NONE
primidone	NN	primidone	B-e4	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
increase	VB	increase	O	O	NONE
the	DT	the	O	O	NONE
frequency	NN	frequency	O	O	NONE
of	IN	of	O	O	NONE
seizures	NNS	seizure	O	O	NONE
in	IN	in	O	O	NONE
susceptible	JJ	susceptible	O	O	NONE
pediatric	JJ	pediatric	B-e5	O	drug
patients	NNS	patient	O	O	NONE
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d341.s0
Folic	JJ	folic	B-e0	T	drug
acid	NN	acid	I-e0	T	drug
in	IN	in	O	O	NONE
large	JJ	large	O	O	NONE
amounts	NNS	amount	O	O	NONE
may	MD	may	O	O	NONE
counteract	VB	counteract	O	O	NONE
the	DT	the	O	O	NONE
antiepileptic	JJ	antiepileptic	B-e1	O	drug
effect	NN	effect	O	O	NONE
of	IN	of	O	O	NONE
phenobarbital	NN	phenobarbital	B-e2	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e3	O	drug
and	CC	and	O	O	NONE
primidone	NN	primidone	B-e4	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
increase	VB	increase	O	O	NONE
the	DT	the	O	O	NONE
frequency	NN	frequency	O	O	NONE
of	IN	of	O	O	NONE
seizures	NNS	seizure	O	O	NONE
in	IN	in	O	O	NONE
susceptible	JJ	susceptible	O	O	NONE
pediatric	JJ	pediatric	B-e5	T	drug
patients	NNS	patient	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d341.s0
Folic	JJ	folic	B-e0	O	drug
acid	NN	acid	I-e0	O	drug
in	IN	in	O	O	NONE
large	JJ	large	O	O	NONE
amounts	NNS	amount	O	O	NONE
may	MD	may	O	O	NONE
counteract	VB	counteract	O	O	NONE
the	DT	the	O	O	NONE
antiepileptic	JJ	antiepileptic	B-e1	T	drug
effect	NN	effect	O	O	NONE
of	IN	of	O	O	NONE
phenobarbital	NN	phenobarbital	B-e2	T	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e3	O	drug
and	CC	and	O	O	NONE
primidone	NN	primidone	B-e4	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
increase	VB	increase	O	O	NONE
the	DT	the	O	O	NONE
frequency	NN	frequency	O	O	NONE
of	IN	of	O	O	NONE
seizures	NNS	seizure	O	O	NONE
in	IN	in	O	O	NONE
susceptible	JJ	susceptible	O	O	NONE
pediatric	JJ	pediatric	B-e5	O	drug
patients	NNS	patient	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d341.s0
Folic	JJ	folic	B-e0	O	drug
acid	NN	acid	I-e0	O	drug
in	IN	in	O	O	NONE
large	JJ	large	O	O	NONE
amounts	NNS	amount	O	O	NONE
may	MD	may	O	O	NONE
counteract	VB	counteract	O	O	NONE
the	DT	the	O	O	NONE
antiepileptic	JJ	antiepileptic	B-e1	T	drug
effect	NN	effect	O	O	NONE
of	IN	of	O	O	NONE
phenobarbital	NN	phenobarbital	B-e2	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e3	T	drug
and	CC	and	O	O	NONE
primidone	NN	primidone	B-e4	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
increase	VB	increase	O	O	NONE
the	DT	the	O	O	NONE
frequency	NN	frequency	O	O	NONE
of	IN	of	O	O	NONE
seizures	NNS	seizure	O	O	NONE
in	IN	in	O	O	NONE
susceptible	JJ	susceptible	O	O	NONE
pediatric	JJ	pediatric	B-e5	O	drug
patients	NNS	patient	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d341.s0
Folic	JJ	folic	B-e0	O	drug
acid	NN	acid	I-e0	O	drug
in	IN	in	O	O	NONE
large	JJ	large	O	O	NONE
amounts	NNS	amount	O	O	NONE
may	MD	may	O	O	NONE
counteract	VB	counteract	O	O	NONE
the	DT	the	O	O	NONE
antiepileptic	JJ	antiepileptic	B-e1	T	drug
effect	NN	effect	O	O	NONE
of	IN	of	O	O	NONE
phenobarbital	NN	phenobarbital	B-e2	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e3	O	drug
and	CC	and	O	O	NONE
primidone	NN	primidone	B-e4	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
increase	VB	increase	O	O	NONE
the	DT	the	O	O	NONE
frequency	NN	frequency	O	O	NONE
of	IN	of	O	O	NONE
seizures	NNS	seizure	O	O	NONE
in	IN	in	O	O	NONE
susceptible	JJ	susceptible	O	O	NONE
pediatric	JJ	pediatric	B-e5	O	drug
patients	NNS	patient	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d341.s0
Folic	JJ	folic	B-e0	O	drug
acid	NN	acid	I-e0	O	drug
in	IN	in	O	O	NONE
large	JJ	large	O	O	NONE
amounts	NNS	amount	O	O	NONE
may	MD	may	O	O	NONE
counteract	VB	counteract	O	O	NONE
the	DT	the	O	O	NONE
antiepileptic	JJ	antiepileptic	B-e1	T	drug
effect	NN	effect	O	O	NONE
of	IN	of	O	O	NONE
phenobarbital	NN	phenobarbital	B-e2	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e3	O	drug
and	CC	and	O	O	NONE
primidone	NN	primidone	B-e4	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
increase	VB	increase	O	O	NONE
the	DT	the	O	O	NONE
frequency	NN	frequency	O	O	NONE
of	IN	of	O	O	NONE
seizures	NNS	seizure	O	O	NONE
in	IN	in	O	O	NONE
susceptible	JJ	susceptible	O	O	NONE
pediatric	JJ	pediatric	B-e5	T	drug
patients	NNS	patient	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d341.s0
Folic	JJ	folic	B-e0	O	drug
acid	NN	acid	I-e0	O	drug
in	IN	in	O	O	NONE
large	JJ	large	O	O	NONE
amounts	NNS	amount	O	O	NONE
may	MD	may	O	O	NONE
counteract	VB	counteract	O	O	NONE
the	DT	the	O	O	NONE
antiepileptic	JJ	antiepileptic	B-e1	O	drug
effect	NN	effect	O	O	NONE
of	IN	of	O	O	NONE
phenobarbital	NN	phenobarbital	B-e2	T	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e3	T	drug
and	CC	and	O	O	NONE
primidone	NN	primidone	B-e4	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
increase	VB	increase	O	O	NONE
the	DT	the	O	O	NONE
frequency	NN	frequency	O	O	NONE
of	IN	of	O	O	NONE
seizures	NNS	seizure	O	O	NONE
in	IN	in	O	O	NONE
susceptible	JJ	susceptible	O	O	NONE
pediatric	JJ	pediatric	B-e5	O	drug
patients	NNS	patient	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d341.s0
Folic	JJ	folic	B-e0	O	drug
acid	NN	acid	I-e0	O	drug
in	IN	in	O	O	NONE
large	JJ	large	O	O	NONE
amounts	NNS	amount	O	O	NONE
may	MD	may	O	O	NONE
counteract	VB	counteract	O	O	NONE
the	DT	the	O	O	NONE
antiepileptic	JJ	antiepileptic	B-e1	O	drug
effect	NN	effect	O	O	NONE
of	IN	of	O	O	NONE
phenobarbital	NN	phenobarbital	B-e2	T	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e3	O	drug
and	CC	and	O	O	NONE
primidone	NN	primidone	B-e4	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
increase	VB	increase	O	O	NONE
the	DT	the	O	O	NONE
frequency	NN	frequency	O	O	NONE
of	IN	of	O	O	NONE
seizures	NNS	seizure	O	O	NONE
in	IN	in	O	O	NONE
susceptible	JJ	susceptible	O	O	NONE
pediatric	JJ	pediatric	B-e5	O	drug
patients	NNS	patient	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d341.s0
Folic	JJ	folic	B-e0	O	drug
acid	NN	acid	I-e0	O	drug
in	IN	in	O	O	NONE
large	JJ	large	O	O	NONE
amounts	NNS	amount	O	O	NONE
may	MD	may	O	O	NONE
counteract	VB	counteract	O	O	NONE
the	DT	the	O	O	NONE
antiepileptic	JJ	antiepileptic	B-e1	O	drug
effect	NN	effect	O	O	NONE
of	IN	of	O	O	NONE
phenobarbital	NN	phenobarbital	B-e2	T	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e3	O	drug
and	CC	and	O	O	NONE
primidone	NN	primidone	B-e4	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
increase	VB	increase	O	O	NONE
the	DT	the	O	O	NONE
frequency	NN	frequency	O	O	NONE
of	IN	of	O	O	NONE
seizures	NNS	seizure	O	O	NONE
in	IN	in	O	O	NONE
susceptible	JJ	susceptible	O	O	NONE
pediatric	JJ	pediatric	B-e5	T	drug
patients	NNS	patient	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d341.s0
Folic	JJ	folic	B-e0	O	drug
acid	NN	acid	I-e0	O	drug
in	IN	in	O	O	NONE
large	JJ	large	O	O	NONE
amounts	NNS	amount	O	O	NONE
may	MD	may	O	O	NONE
counteract	VB	counteract	O	O	NONE
the	DT	the	O	O	NONE
antiepileptic	JJ	antiepileptic	B-e1	O	drug
effect	NN	effect	O	O	NONE
of	IN	of	O	O	NONE
phenobarbital	NN	phenobarbital	B-e2	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e3	T	drug
and	CC	and	O	O	NONE
primidone	NN	primidone	B-e4	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
increase	VB	increase	O	O	NONE
the	DT	the	O	O	NONE
frequency	NN	frequency	O	O	NONE
of	IN	of	O	O	NONE
seizures	NNS	seizure	O	O	NONE
in	IN	in	O	O	NONE
susceptible	JJ	susceptible	O	O	NONE
pediatric	JJ	pediatric	B-e5	O	drug
patients	NNS	patient	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d341.s0
Folic	JJ	folic	B-e0	O	drug
acid	NN	acid	I-e0	O	drug
in	IN	in	O	O	NONE
large	JJ	large	O	O	NONE
amounts	NNS	amount	O	O	NONE
may	MD	may	O	O	NONE
counteract	VB	counteract	O	O	NONE
the	DT	the	O	O	NONE
antiepileptic	JJ	antiepileptic	B-e1	O	drug
effect	NN	effect	O	O	NONE
of	IN	of	O	O	NONE
phenobarbital	NN	phenobarbital	B-e2	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e3	T	drug
and	CC	and	O	O	NONE
primidone	NN	primidone	B-e4	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
increase	VB	increase	O	O	NONE
the	DT	the	O	O	NONE
frequency	NN	frequency	O	O	NONE
of	IN	of	O	O	NONE
seizures	NNS	seizure	O	O	NONE
in	IN	in	O	O	NONE
susceptible	JJ	susceptible	O	O	NONE
pediatric	JJ	pediatric	B-e5	T	drug
patients	NNS	patient	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d341.s0
Folic	JJ	folic	B-e0	O	drug
acid	NN	acid	I-e0	O	drug
in	IN	in	O	O	NONE
large	JJ	large	O	O	NONE
amounts	NNS	amount	O	O	NONE
may	MD	may	O	O	NONE
counteract	VB	counteract	O	O	NONE
the	DT	the	O	O	NONE
antiepileptic	JJ	antiepileptic	B-e1	O	drug
effect	NN	effect	O	O	NONE
of	IN	of	O	O	NONE
phenobarbital	NN	phenobarbital	B-e2	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e3	O	drug
and	CC	and	O	O	NONE
primidone	NN	primidone	B-e4	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
increase	VB	increase	O	O	NONE
the	DT	the	O	O	NONE
frequency	NN	frequency	O	O	NONE
of	IN	of	O	O	NONE
seizures	NNS	seizure	O	O	NONE
in	IN	in	O	O	NONE
susceptible	JJ	susceptible	O	O	NONE
pediatric	JJ	pediatric	B-e5	T	drug
patients	NNS	patient	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d341.s1
Preliminary	JJ	preliminary	O	O	NONE
animal	JJ	animal	O	O	NONE
and	CC	and	O	O	NONE
human	JJ	human	O	O	NONE
studies	NNS	study	O	O	NONE
have	VBP	have	O	O	NONE
shown	VBN	show	O	O	NONE
that	IN	that	O	O	NONE
small	JJ	small	O	O	NONE
quantities	NNS	quantity	O	O	NONE
of	IN	of	O	O	NONE
systemically	RB	systemically	O	O	NONE
administered	VBN	administer	O	O	NONE
leucovorin	NN	leucovorin	B-e0	T	drug
enter	VBP	enter	O	O	NONE
the	DT	the	O	O	NONE
CSF	NN	csf	O	O	NONE
primarily	RB	primarily	O	O	NONE
as	IN	as	O	O	NONE
5-methyltetrahydro-folate	NN	5-methyltetrahydro-folate	O	O	NONE
and	CC	and	O	O	NONE
,	,	,	O	O	NONE
in	IN	in	O	O	NONE
humans	NNS	human	O	O	NONE
,	,	,	O	O	NONE
remain	VBP	remain	O	O	NONE
1	CD	1	O	O	NONE
to	TO	to	O	O	NONE
3	CD	3	O	O	NONE
orders	NNS	order	O	O	NONE
of	IN	of	O	O	NONE
magnitude	NN	magnitude	O	O	NONE
lower	JJR	lower	O	O	NONE
than	IN	than	O	O	NONE
the	DT	the	O	O	NONE
usual	JJ	usual	O	O	NONE
methotrexate	NN	methotrexate	B-e1	T	drug
concentrations	NNS	concentration	O	O	NONE
following	VBG	follow	O	O	NONE
intrathecal	JJ	intrathecal	O	O	NONE
administration	NN	administration	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d341.s2
However	RB	however	O	O	NONE
,	,	,	O	O	NONE
high	JJ	high	O	O	NONE
doses	NNS	dose	O	O	NONE
of	IN	of	O	O	NONE
leucovorin	NN	leucovorin	B-e0	T	drug
may	MD	may	O	O	NONE
reduce	VB	reduce	O	O	NONE
the	DT	the	O	O	NONE
efficacy	NN	efficacy	O	O	NONE
of	IN	of	O	O	NONE
intrathecally	RB	intrathecally	O	O	NONE
administered	VBN	administer	O	O	NONE
methotrexate	NN	methotrexate	B-e1	T	drug
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d341.s3
Leucovorin	NN	leucovorin	B-e0	T	drug
may	MD	may	O	O	NONE
enhance	VB	enhance	O	O	NONE
the	DT	the	O	O	NONE
toxicity	NN	toxicity	O	O	NONE
of	IN	of	O	O	NONE
5-	CD	5-	O	O	NONE
fluorouracil	NN	fluorouracil	B-e1	T	drug
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d484.s0
Although	IN	although	O	O	NONE
BETAGAN	NN	betagan	B-e0	T	drug
used	VBN	use	O	O	NONE
alone	RB	alone	O	O	NONE
has	VBZ	have	O	O	NONE
little	JJ	little	O	O	NONE
or	CC	or	O	O	NONE
no	DT	no	O	O	NONE
effect	NN	effect	O	O	NONE
on	IN	on	O	O	NONE
pupil	NN	pupil	O	O	NONE
size	NN	size	O	O	NONE
,	,	,	O	O	NONE
mydriasis	NNS	mydriasis	O	O	NONE
resulting	VBG	result	O	O	NONE
from	IN	from	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
therapy	NN	therapy	O	O	NONE
with	IN	with	O	O	NONE
BETAGAN	NN	betagan	B-e1	T	drug
and	CC	and	O	O	NONE
epinephrine	NN	epinephrine	B-e2	O	drug
may	MD	may	O	O	NONE
occur	VB	occur	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d484.s0
Although	IN	although	O	O	NONE
BETAGAN	NN	betagan	B-e0	T	drug
used	VBN	use	O	O	NONE
alone	RB	alone	O	O	NONE
has	VBZ	have	O	O	NONE
little	JJ	little	O	O	NONE
or	CC	or	O	O	NONE
no	DT	no	O	O	NONE
effect	NN	effect	O	O	NONE
on	IN	on	O	O	NONE
pupil	NN	pupil	O	O	NONE
size	NN	size	O	O	NONE
,	,	,	O	O	NONE
mydriasis	NNS	mydriasis	O	O	NONE
resulting	VBG	result	O	O	NONE
from	IN	from	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
therapy	NN	therapy	O	O	NONE
with	IN	with	O	O	NONE
BETAGAN	NN	betagan	B-e1	O	drug
and	CC	and	O	O	NONE
epinephrine	NN	epinephrine	B-e2	T	drug
may	MD	may	O	O	NONE
occur	VB	occur	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d484.s0
Although	IN	although	O	O	NONE
BETAGAN	NN	betagan	B-e0	O	drug
used	VBN	use	O	O	NONE
alone	RB	alone	O	O	NONE
has	VBZ	have	O	O	NONE
little	JJ	little	O	O	NONE
or	CC	or	O	O	NONE
no	DT	no	O	O	NONE
effect	NN	effect	O	O	NONE
on	IN	on	O	O	NONE
pupil	NN	pupil	O	O	NONE
size	NN	size	O	O	NONE
,	,	,	O	O	NONE
mydriasis	NNS	mydriasis	O	O	NONE
resulting	VBG	result	O	O	NONE
from	IN	from	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
therapy	NN	therapy	O	O	NONE
with	IN	with	O	O	NONE
BETAGAN	NN	betagan	B-e1	T	drug
and	CC	and	O	O	NONE
epinephrine	NN	epinephrine	B-e2	T	drug
may	MD	may	O	O	NONE
occur	VB	occur	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d484.s1
Close	JJ	close	O	O	NONE
observation	NN	observation	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
patient	NN	patient	O	O	NONE
is	VBZ	be	O	O	NONE
recommended	VBN	recommend	O	O	NONE
when	WRB	when	O	O	NONE
a	DT	a	O	O	NONE
beta-blocker	NN	beta-blocker	B-e0	T	drug
is	VBZ	be	O	O	NONE
administered	VBN	administer	O	O	NONE
to	TO	to	O	O	NONE
patients	NNS	patient	O	O	NONE
receiving	VBG	receive	O	O	NONE
catecholamine-depleting	JJ	catecholamine-depleting	O	O	NONE
drugs	NNS	drug	B-e1	T	drug
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
reserpine	NN	reserpine	B-e2	O	drug
,	,	,	O	O	NONE
because	IN	because	O	O	NONE
of	IN	of	O	O	NONE
possible	JJ	possible	O	O	NONE
additive	JJ	additive	O	O	NONE
effects	NNS	effect	O	O	NONE
and	CC	and	O	O	NONE
the	DT	the	O	O	NONE
production	NN	production	O	O	NONE
of	IN	of	O	O	NONE
hypotension	NN	hypotension	O	O	NONE
and/or	CC	and/or	O	O	NONE
marked	JJ	marked	O	O	NONE
bradycardia	NN	bradycardium	O	O	NONE
,	,	,	O	O	NONE
which	WDT	which	O	O	NONE
may	MD	may	O	O	NONE
produce	VB	produce	O	O	NONE
vertigo	NN	vertigo	O	O	NONE
,	,	,	O	O	NONE
syncope	NN	syncope	O	O	NONE
or	CC	or	O	O	NONE
postural	JJ	postural	O	O	NONE
hypotension	NN	hypotension	O	O	NONE
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d484.s1
Close	JJ	close	O	O	NONE
observation	NN	observation	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
patient	NN	patient	O	O	NONE
is	VBZ	be	O	O	NONE
recommended	VBN	recommend	O	O	NONE
when	WRB	when	O	O	NONE
a	DT	a	O	O	NONE
beta-blocker	NN	beta-blocker	B-e0	T	drug
is	VBZ	be	O	O	NONE
administered	VBN	administer	O	O	NONE
to	TO	to	O	O	NONE
patients	NNS	patient	O	O	NONE
receiving	VBG	receive	O	O	NONE
catecholamine-depleting	JJ	catecholamine-depleting	O	O	NONE
drugs	NNS	drug	B-e1	O	drug
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
reserpine	NN	reserpine	B-e2	T	drug
,	,	,	O	O	NONE
because	IN	because	O	O	NONE
of	IN	of	O	O	NONE
possible	JJ	possible	O	O	NONE
additive	JJ	additive	O	O	NONE
effects	NNS	effect	O	O	NONE
and	CC	and	O	O	NONE
the	DT	the	O	O	NONE
production	NN	production	O	O	NONE
of	IN	of	O	O	NONE
hypotension	NN	hypotension	O	O	NONE
and/or	CC	and/or	O	O	NONE
marked	JJ	marked	O	O	NONE
bradycardia	NN	bradycardium	O	O	NONE
,	,	,	O	O	NONE
which	WDT	which	O	O	NONE
may	MD	may	O	O	NONE
produce	VB	produce	O	O	NONE
vertigo	NN	vertigo	O	O	NONE
,	,	,	O	O	NONE
syncope	NN	syncope	O	O	NONE
or	CC	or	O	O	NONE
postural	JJ	postural	O	O	NONE
hypotension	NN	hypotension	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d484.s1
Close	JJ	close	O	O	NONE
observation	NN	observation	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
patient	NN	patient	O	O	NONE
is	VBZ	be	O	O	NONE
recommended	VBN	recommend	O	O	NONE
when	WRB	when	O	O	NONE
a	DT	a	O	O	NONE
beta-blocker	NN	beta-blocker	B-e0	O	drug
is	VBZ	be	O	O	NONE
administered	VBN	administer	O	O	NONE
to	TO	to	O	O	NONE
patients	NNS	patient	O	O	NONE
receiving	VBG	receive	O	O	NONE
catecholamine-depleting	JJ	catecholamine-depleting	O	O	NONE
drugs	NNS	drug	B-e1	T	drug
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
reserpine	NN	reserpine	B-e2	T	drug
,	,	,	O	O	NONE
because	IN	because	O	O	NONE
of	IN	of	O	O	NONE
possible	JJ	possible	O	O	NONE
additive	JJ	additive	O	O	NONE
effects	NNS	effect	O	O	NONE
and	CC	and	O	O	NONE
the	DT	the	O	O	NONE
production	NN	production	O	O	NONE
of	IN	of	O	O	NONE
hypotension	NN	hypotension	O	O	NONE
and/or	CC	and/or	O	O	NONE
marked	JJ	marked	O	O	NONE
bradycardia	NN	bradycardium	O	O	NONE
,	,	,	O	O	NONE
which	WDT	which	O	O	NONE
may	MD	may	O	O	NONE
produce	VB	produce	O	O	NONE
vertigo	NN	vertigo	O	O	NONE
,	,	,	O	O	NONE
syncope	NN	syncope	O	O	NONE
or	CC	or	O	O	NONE
postural	JJ	postural	O	O	NONE
hypotension	NN	hypotension	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d484.s2
Patients	NNS	patient	O	O	NONE
receiving	VBG	receive	O	O	NONE
beta-adrenergic	JJ	beta-adrenergic	B-e0	T	drug
blocking	NN	blocking	I-e0	T	drug
agents	NNS	agent	I-e0	T	drug
along	IN	along	O	O	NONE
with	IN	with	O	O	NONE
either	CC	either	O	O	NONE
oral	JJ	oral	O	O	NONE
or	CC	or	O	O	NONE
intravenous	JJ	intravenous	O	O	NONE
calcium	NN	calcium	B-e1	T	drug
antagonist	NN	antagonist	I-e1	T	drug
s	NN	s	O	O	NONE
should	MD	should	O	O	NONE
be	VB	be	O	O	NONE
monitored	VBN	monitor	O	O	NONE
for	IN	for	O	O	NONE
possible	JJ	possible	O	O	NONE
atrioventricular	JJ	atrioventricular	B-e2	O	DISO
conduction	NN	conduction	I-e2	O	DISO
disturbances	NNS	disturbance	I-e2	O	DISO
,	,	,	O	O	NONE
left	JJ	left	O	O	NONE
ventricular	NN	ventricular	B-e3	O	DISO
failure	NN	failure	I-e3	O	DISO
and	CC	and	O	O	NONE
hypotension	NN	hypotension	O	O	NONE
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d484.s4
The	DT	the	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
use	NN	use	O	O	NONE
of	IN	of	O	O	NONE
beta-adrenergic	JJ	beta-adrenergic	B-e0	T	drug
blocking	NN	blocking	I-e0	T	drug
agents	NNS	agent	I-e0	T	drug
with	IN	with	O	O	NONE
digitalis	NN	digitali	B-e1	T	drug
and	CC	and	O	O	NONE
calcium	NN	calcium	B-e2	O	drug
antagonist	NN	antagonist	I-e2	O	drug
s	NN	s	O	O	NONE
may	MD	may	O	O	NONE
have	VB	have	O	O	NONE
additive	JJ	additive	O	O	NONE
effects	NNS	effect	O	O	NONE
on	IN	on	O	O	NONE
prolonging	VBG	prolong	O	O	NONE
atrioventricular	JJ	atrioventricular	O	O	NONE
conduction	NN	conduction	O	O	NONE
time	NN	time	O	O	NONE
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d484.s4
The	DT	the	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
use	NN	use	O	O	NONE
of	IN	of	O	O	NONE
beta-adrenergic	JJ	beta-adrenergic	B-e0	T	drug
blocking	NN	blocking	I-e0	T	drug
agents	NNS	agent	I-e0	T	drug
with	IN	with	O	O	NONE
digitalis	NN	digitali	B-e1	O	drug
and	CC	and	O	O	NONE
calcium	NN	calcium	B-e2	T	drug
antagonist	NN	antagonist	I-e2	T	drug
s	NN	s	O	O	NONE
may	MD	may	O	O	NONE
have	VB	have	O	O	NONE
additive	JJ	additive	O	O	NONE
effects	NNS	effect	O	O	NONE
on	IN	on	O	O	NONE
prolonging	VBG	prolong	O	O	NONE
atrioventricular	JJ	atrioventricular	O	O	NONE
conduction	NN	conduction	O	O	NONE
time	NN	time	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d484.s4
The	DT	the	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
use	NN	use	O	O	NONE
of	IN	of	O	O	NONE
beta-adrenergic	JJ	beta-adrenergic	B-e0	O	drug
blocking	NN	blocking	I-e0	O	drug
agents	NNS	agent	I-e0	O	drug
with	IN	with	O	O	NONE
digitalis	NN	digitali	B-e1	T	drug
and	CC	and	O	O	NONE
calcium	NN	calcium	B-e2	T	drug
antagonist	NN	antagonist	I-e2	T	drug
s	NN	s	O	O	NONE
may	MD	may	O	O	NONE
have	VB	have	O	O	NONE
additive	JJ	additive	O	O	NONE
effects	NNS	effect	O	O	NONE
on	IN	on	O	O	NONE
prolonging	VBG	prolong	O	O	NONE
atrioventricular	JJ	atrioventricular	O	O	NONE
conduction	NN	conduction	O	O	NONE
time	NN	time	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d484.s5
Phenothiazine	JJ	phenothiazine	B-e0	T	drug
-related	JJ	-related	O	O	NONE
compounds	NNS	compound	O	O	NONE
and	CC	and	O	O	NONE
beta-adrenergic	JJ	beta-adrenergic	B-e1	T	drug
blocking	NN	blocking	I-e1	T	drug
agents	NNS	agent	I-e1	T	drug
may	MD	may	O	O	NONE
have	VB	have	O	O	NONE
additive	JJ	additive	O	O	NONE
hypotensite	JJ	hypotensite	O	O	NONE
effects	NNS	effect	O	O	NONE
due	JJ	due	O	O	NONE
to	TO	to	O	O	NONE
the	DT	the	O	O	NONE
inhibition	NN	inhibition	O	O	NONE
of	IN	of	O	O	NONE
each	DT	each	O	O	NONE
other	JJ	other	O	O	NONE
@	NN	@	O	O	NONE
s	NN	s	O	O	NONE
metabolism	NN	metabolism	O	O	NONE
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d112.s0
No	DT	no	O	O	NONE
significant	JJ	significant	O	O	NONE
drug-drug	JJ	drug-drug	O	O	NONE
pharmacokinetic	JJ	pharmacokinetic	O	O	NONE
interactions	NNS	interaction	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
found	VBN	find	O	O	NONE
in	IN	in	O	O	NONE
interaction	NN	interaction	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
hydrochlorothiazide	NN	hydrochlorothiazide	B-e0	T	drug
,	,	,	O	O	NONE
digoxin	NN	digoxin	B-e1	T	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e2	O	drug
,	,	,	O	O	NONE
cimetidine	NN	cimetidine	B-e3	O	drug
and	CC	and	O	O	NONE
phenobarbital	NN	phenobarbital	B-e4	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d112.s0
No	DT	no	O	O	NONE
significant	JJ	significant	O	O	NONE
drug-drug	JJ	drug-drug	O	O	NONE
pharmacokinetic	JJ	pharmacokinetic	O	O	NONE
interactions	NNS	interaction	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
found	VBN	find	O	O	NONE
in	IN	in	O	O	NONE
interaction	NN	interaction	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
hydrochlorothiazide	NN	hydrochlorothiazide	B-e0	T	drug
,	,	,	O	O	NONE
digoxin	NN	digoxin	B-e1	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e2	T	drug
,	,	,	O	O	NONE
cimetidine	NN	cimetidine	B-e3	O	drug
and	CC	and	O	O	NONE
phenobarbital	NN	phenobarbital	B-e4	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d112.s0
No	DT	no	O	O	NONE
significant	JJ	significant	O	O	NONE
drug-drug	JJ	drug-drug	O	O	NONE
pharmacokinetic	JJ	pharmacokinetic	O	O	NONE
interactions	NNS	interaction	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
found	VBN	find	O	O	NONE
in	IN	in	O	O	NONE
interaction	NN	interaction	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
hydrochlorothiazide	NN	hydrochlorothiazide	B-e0	T	drug
,	,	,	O	O	NONE
digoxin	NN	digoxin	B-e1	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e2	O	drug
,	,	,	O	O	NONE
cimetidine	NN	cimetidine	B-e3	T	drug
and	CC	and	O	O	NONE
phenobarbital	NN	phenobarbital	B-e4	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d112.s0
No	DT	no	O	O	NONE
significant	JJ	significant	O	O	NONE
drug-drug	JJ	drug-drug	O	O	NONE
pharmacokinetic	JJ	pharmacokinetic	O	O	NONE
interactions	NNS	interaction	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
found	VBN	find	O	O	NONE
in	IN	in	O	O	NONE
interaction	NN	interaction	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
hydrochlorothiazide	NN	hydrochlorothiazide	B-e0	T	drug
,	,	,	O	O	NONE
digoxin	NN	digoxin	B-e1	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e2	O	drug
,	,	,	O	O	NONE
cimetidine	NN	cimetidine	B-e3	O	drug
and	CC	and	O	O	NONE
phenobarbital	NN	phenobarbital	B-e4	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d112.s0
No	DT	no	O	O	NONE
significant	JJ	significant	O	O	NONE
drug-drug	JJ	drug-drug	O	O	NONE
pharmacokinetic	JJ	pharmacokinetic	O	O	NONE
interactions	NNS	interaction	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
found	VBN	find	O	O	NONE
in	IN	in	O	O	NONE
interaction	NN	interaction	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
hydrochlorothiazide	NN	hydrochlorothiazide	B-e0	O	drug
,	,	,	O	O	NONE
digoxin	NN	digoxin	B-e1	T	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e2	T	drug
,	,	,	O	O	NONE
cimetidine	NN	cimetidine	B-e3	O	drug
and	CC	and	O	O	NONE
phenobarbital	NN	phenobarbital	B-e4	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d112.s0
No	DT	no	O	O	NONE
significant	JJ	significant	O	O	NONE
drug-drug	JJ	drug-drug	O	O	NONE
pharmacokinetic	JJ	pharmacokinetic	O	O	NONE
interactions	NNS	interaction	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
found	VBN	find	O	O	NONE
in	IN	in	O	O	NONE
interaction	NN	interaction	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
hydrochlorothiazide	NN	hydrochlorothiazide	B-e0	O	drug
,	,	,	O	O	NONE
digoxin	NN	digoxin	B-e1	T	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e2	O	drug
,	,	,	O	O	NONE
cimetidine	NN	cimetidine	B-e3	T	drug
and	CC	and	O	O	NONE
phenobarbital	NN	phenobarbital	B-e4	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d112.s0
No	DT	no	O	O	NONE
significant	JJ	significant	O	O	NONE
drug-drug	JJ	drug-drug	O	O	NONE
pharmacokinetic	JJ	pharmacokinetic	O	O	NONE
interactions	NNS	interaction	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
found	VBN	find	O	O	NONE
in	IN	in	O	O	NONE
interaction	NN	interaction	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
hydrochlorothiazide	NN	hydrochlorothiazide	B-e0	O	drug
,	,	,	O	O	NONE
digoxin	NN	digoxin	B-e1	T	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e2	O	drug
,	,	,	O	O	NONE
cimetidine	NN	cimetidine	B-e3	O	drug
and	CC	and	O	O	NONE
phenobarbital	NN	phenobarbital	B-e4	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d112.s0
No	DT	no	O	O	NONE
significant	JJ	significant	O	O	NONE
drug-drug	JJ	drug-drug	O	O	NONE
pharmacokinetic	JJ	pharmacokinetic	O	O	NONE
interactions	NNS	interaction	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
found	VBN	find	O	O	NONE
in	IN	in	O	O	NONE
interaction	NN	interaction	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
hydrochlorothiazide	NN	hydrochlorothiazide	B-e0	O	drug
,	,	,	O	O	NONE
digoxin	NN	digoxin	B-e1	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e2	T	drug
,	,	,	O	O	NONE
cimetidine	NN	cimetidine	B-e3	T	drug
and	CC	and	O	O	NONE
phenobarbital	NN	phenobarbital	B-e4	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d112.s0
No	DT	no	O	O	NONE
significant	JJ	significant	O	O	NONE
drug-drug	JJ	drug-drug	O	O	NONE
pharmacokinetic	JJ	pharmacokinetic	O	O	NONE
interactions	NNS	interaction	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
found	VBN	find	O	O	NONE
in	IN	in	O	O	NONE
interaction	NN	interaction	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
hydrochlorothiazide	NN	hydrochlorothiazide	B-e0	O	drug
,	,	,	O	O	NONE
digoxin	NN	digoxin	B-e1	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e2	T	drug
,	,	,	O	O	NONE
cimetidine	NN	cimetidine	B-e3	O	drug
and	CC	and	O	O	NONE
phenobarbital	NN	phenobarbital	B-e4	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d112.s0
No	DT	no	O	O	NONE
significant	JJ	significant	O	O	NONE
drug-drug	JJ	drug-drug	O	O	NONE
pharmacokinetic	JJ	pharmacokinetic	O	O	NONE
interactions	NNS	interaction	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
found	VBN	find	O	O	NONE
in	IN	in	O	O	NONE
interaction	NN	interaction	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
hydrochlorothiazide	NN	hydrochlorothiazide	B-e0	O	drug
,	,	,	O	O	NONE
digoxin	NN	digoxin	B-e1	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e2	O	drug
,	,	,	O	O	NONE
cimetidine	NN	cimetidine	B-e3	T	drug
and	CC	and	O	O	NONE
phenobarbital	NN	phenobarbital	B-e4	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d112.s1
Rifampin	NN	rifampin	B-e0	T	drug
,	,	,	O	O	NONE
an	DT	a	O	O	NONE
inducer	NN	inducer	O	O	NONE
of	IN	of	O	O	NONE
drug	NN	drug	O	O	NONE
metabolism	NN	metabolism	O	O	NONE
,	,	,	O	O	NONE
decreased	VBD	decrease	O	O	NONE
the	DT	the	O	O	NONE
concentrations	NNS	concentration	O	O	NONE
of	IN	of	O	O	NONE
losartan	NN	losartan	B-e1	T	drug
and	CC	and	O	O	NONE
its	PRP$	its	O	O	NONE
active	JJ	active	B-e2	O	drug
metabolite	NN	metabolite	I-e2	O	drug
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d112.s1
Rifampin	NN	rifampin	B-e0	T	drug
,	,	,	O	O	NONE
an	DT	a	O	O	NONE
inducer	NN	inducer	O	O	NONE
of	IN	of	O	O	NONE
drug	NN	drug	O	O	NONE
metabolism	NN	metabolism	O	O	NONE
,	,	,	O	O	NONE
decreased	VBD	decrease	O	O	NONE
the	DT	the	O	O	NONE
concentrations	NNS	concentration	O	O	NONE
of	IN	of	O	O	NONE
losartan	NN	losartan	B-e1	O	drug
and	CC	and	O	O	NONE
its	PRP$	its	O	O	NONE
active	JJ	active	B-e2	T	drug
metabolite	NN	metabolite	I-e2	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d112.s1
Rifampin	NN	rifampin	B-e0	O	drug
,	,	,	O	O	NONE
an	DT	a	O	O	NONE
inducer	NN	inducer	O	O	NONE
of	IN	of	O	O	NONE
drug	NN	drug	O	O	NONE
metabolism	NN	metabolism	O	O	NONE
,	,	,	O	O	NONE
decreased	VBD	decrease	O	O	NONE
the	DT	the	O	O	NONE
concentrations	NNS	concentration	O	O	NONE
of	IN	of	O	O	NONE
losartan	NN	losartan	B-e1	T	drug
and	CC	and	O	O	NONE
its	PRP$	its	O	O	NONE
active	JJ	active	B-e2	T	drug
metabolite	NN	metabolite	I-e2	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d112.s3
Ketoconazole	NN	ketoconazole	B-e0	T	drug
did	VBD	do	O	O	NONE
not	RB	not	O	O	NONE
affect	VB	affect	O	O	NONE
the	DT	the	O	O	NONE
conversion	NN	conversion	O	O	NONE
of	IN	of	O	O	NONE
losartan	NN	losartan	B-e1	T	drug
to	TO	to	O	O	NONE
the	DT	the	O	O	NONE
active	JJ	active	B-e2	O	drug
metabolite	NN	metabolite	I-e2	O	drug
after	IN	after	O	O	NONE
intravenous	JJ	intravenous	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
losartan	NN	losartan	B-e3	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
erythromycin	NN	erythromycin	B-e4	O	drug
had	VBD	have	O	O	NONE
no	DT	no	O	O	NONE
clinically	RB	clinically	O	O	NONE
significant	JJ	significant	O	O	NONE
effect	NN	effect	O	O	NONE
after	IN	after	O	O	NONE
oral	JJ	oral	O	O	NONE
administration	NN	administration	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d112.s3
Ketoconazole	NN	ketoconazole	B-e0	T	drug
did	VBD	do	O	O	NONE
not	RB	not	O	O	NONE
affect	VB	affect	O	O	NONE
the	DT	the	O	O	NONE
conversion	NN	conversion	O	O	NONE
of	IN	of	O	O	NONE
losartan	NN	losartan	B-e1	O	drug
to	TO	to	O	O	NONE
the	DT	the	O	O	NONE
active	JJ	active	B-e2	T	drug
metabolite	NN	metabolite	I-e2	T	drug
after	IN	after	O	O	NONE
intravenous	JJ	intravenous	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
losartan	NN	losartan	B-e3	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
erythromycin	NN	erythromycin	B-e4	O	drug
had	VBD	have	O	O	NONE
no	DT	no	O	O	NONE
clinically	RB	clinically	O	O	NONE
significant	JJ	significant	O	O	NONE
effect	NN	effect	O	O	NONE
after	IN	after	O	O	NONE
oral	JJ	oral	O	O	NONE
administration	NN	administration	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d112.s3
Ketoconazole	NN	ketoconazole	B-e0	T	drug
did	VBD	do	O	O	NONE
not	RB	not	O	O	NONE
affect	VB	affect	O	O	NONE
the	DT	the	O	O	NONE
conversion	NN	conversion	O	O	NONE
of	IN	of	O	O	NONE
losartan	NN	losartan	B-e1	O	drug
to	TO	to	O	O	NONE
the	DT	the	O	O	NONE
active	JJ	active	B-e2	O	drug
metabolite	NN	metabolite	I-e2	O	drug
after	IN	after	O	O	NONE
intravenous	JJ	intravenous	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
losartan	NN	losartan	B-e3	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
erythromycin	NN	erythromycin	B-e4	O	drug
had	VBD	have	O	O	NONE
no	DT	no	O	O	NONE
clinically	RB	clinically	O	O	NONE
significant	JJ	significant	O	O	NONE
effect	NN	effect	O	O	NONE
after	IN	after	O	O	NONE
oral	JJ	oral	O	O	NONE
administration	NN	administration	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d112.s3
Ketoconazole	NN	ketoconazole	B-e0	T	drug
did	VBD	do	O	O	NONE
not	RB	not	O	O	NONE
affect	VB	affect	O	O	NONE
the	DT	the	O	O	NONE
conversion	NN	conversion	O	O	NONE
of	IN	of	O	O	NONE
losartan	NN	losartan	B-e1	O	drug
to	TO	to	O	O	NONE
the	DT	the	O	O	NONE
active	JJ	active	B-e2	O	drug
metabolite	NN	metabolite	I-e2	O	drug
after	IN	after	O	O	NONE
intravenous	JJ	intravenous	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
losartan	NN	losartan	B-e3	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
erythromycin	NN	erythromycin	B-e4	T	drug
had	VBD	have	O	O	NONE
no	DT	no	O	O	NONE
clinically	RB	clinically	O	O	NONE
significant	JJ	significant	O	O	NONE
effect	NN	effect	O	O	NONE
after	IN	after	O	O	NONE
oral	JJ	oral	O	O	NONE
administration	NN	administration	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d112.s3
Ketoconazole	NN	ketoconazole	B-e0	O	drug
did	VBD	do	O	O	NONE
not	RB	not	O	O	NONE
affect	VB	affect	O	O	NONE
the	DT	the	O	O	NONE
conversion	NN	conversion	O	O	NONE
of	IN	of	O	O	NONE
losartan	NN	losartan	B-e1	T	drug
to	TO	to	O	O	NONE
the	DT	the	O	O	NONE
active	JJ	active	B-e2	T	drug
metabolite	NN	metabolite	I-e2	T	drug
after	IN	after	O	O	NONE
intravenous	JJ	intravenous	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
losartan	NN	losartan	B-e3	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
erythromycin	NN	erythromycin	B-e4	O	drug
had	VBD	have	O	O	NONE
no	DT	no	O	O	NONE
clinically	RB	clinically	O	O	NONE
significant	JJ	significant	O	O	NONE
effect	NN	effect	O	O	NONE
after	IN	after	O	O	NONE
oral	JJ	oral	O	O	NONE
administration	NN	administration	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d112.s3
Ketoconazole	NN	ketoconazole	B-e0	O	drug
did	VBD	do	O	O	NONE
not	RB	not	O	O	NONE
affect	VB	affect	O	O	NONE
the	DT	the	O	O	NONE
conversion	NN	conversion	O	O	NONE
of	IN	of	O	O	NONE
losartan	NN	losartan	B-e1	T	drug
to	TO	to	O	O	NONE
the	DT	the	O	O	NONE
active	JJ	active	B-e2	O	drug
metabolite	NN	metabolite	I-e2	O	drug
after	IN	after	O	O	NONE
intravenous	JJ	intravenous	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
losartan	NN	losartan	B-e3	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
erythromycin	NN	erythromycin	B-e4	O	drug
had	VBD	have	O	O	NONE
no	DT	no	O	O	NONE
clinically	RB	clinically	O	O	NONE
significant	JJ	significant	O	O	NONE
effect	NN	effect	O	O	NONE
after	IN	after	O	O	NONE
oral	JJ	oral	O	O	NONE
administration	NN	administration	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d112.s3
Ketoconazole	NN	ketoconazole	B-e0	O	drug
did	VBD	do	O	O	NONE
not	RB	not	O	O	NONE
affect	VB	affect	O	O	NONE
the	DT	the	O	O	NONE
conversion	NN	conversion	O	O	NONE
of	IN	of	O	O	NONE
losartan	NN	losartan	B-e1	T	drug
to	TO	to	O	O	NONE
the	DT	the	O	O	NONE
active	JJ	active	B-e2	O	drug
metabolite	NN	metabolite	I-e2	O	drug
after	IN	after	O	O	NONE
intravenous	JJ	intravenous	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
losartan	NN	losartan	B-e3	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
erythromycin	NN	erythromycin	B-e4	T	drug
had	VBD	have	O	O	NONE
no	DT	no	O	O	NONE
clinically	RB	clinically	O	O	NONE
significant	JJ	significant	O	O	NONE
effect	NN	effect	O	O	NONE
after	IN	after	O	O	NONE
oral	JJ	oral	O	O	NONE
administration	NN	administration	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d112.s3
Ketoconazole	NN	ketoconazole	B-e0	O	drug
did	VBD	do	O	O	NONE
not	RB	not	O	O	NONE
affect	VB	affect	O	O	NONE
the	DT	the	O	O	NONE
conversion	NN	conversion	O	O	NONE
of	IN	of	O	O	NONE
losartan	NN	losartan	B-e1	O	drug
to	TO	to	O	O	NONE
the	DT	the	O	O	NONE
active	JJ	active	B-e2	T	drug
metabolite	NN	metabolite	I-e2	T	drug
after	IN	after	O	O	NONE
intravenous	JJ	intravenous	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
losartan	NN	losartan	B-e3	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
erythromycin	NN	erythromycin	B-e4	O	drug
had	VBD	have	O	O	NONE
no	DT	no	O	O	NONE
clinically	RB	clinically	O	O	NONE
significant	JJ	significant	O	O	NONE
effect	NN	effect	O	O	NONE
after	IN	after	O	O	NONE
oral	JJ	oral	O	O	NONE
administration	NN	administration	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d112.s3
Ketoconazole	NN	ketoconazole	B-e0	O	drug
did	VBD	do	O	O	NONE
not	RB	not	O	O	NONE
affect	VB	affect	O	O	NONE
the	DT	the	O	O	NONE
conversion	NN	conversion	O	O	NONE
of	IN	of	O	O	NONE
losartan	NN	losartan	B-e1	O	drug
to	TO	to	O	O	NONE
the	DT	the	O	O	NONE
active	JJ	active	B-e2	T	drug
metabolite	NN	metabolite	I-e2	T	drug
after	IN	after	O	O	NONE
intravenous	JJ	intravenous	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
losartan	NN	losartan	B-e3	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
erythromycin	NN	erythromycin	B-e4	T	drug
had	VBD	have	O	O	NONE
no	DT	no	O	O	NONE
clinically	RB	clinically	O	O	NONE
significant	JJ	significant	O	O	NONE
effect	NN	effect	O	O	NONE
after	IN	after	O	O	NONE
oral	JJ	oral	O	O	NONE
administration	NN	administration	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d112.s3
Ketoconazole	NN	ketoconazole	B-e0	O	drug
did	VBD	do	O	O	NONE
not	RB	not	O	O	NONE
affect	VB	affect	O	O	NONE
the	DT	the	O	O	NONE
conversion	NN	conversion	O	O	NONE
of	IN	of	O	O	NONE
losartan	NN	losartan	B-e1	O	drug
to	TO	to	O	O	NONE
the	DT	the	O	O	NONE
active	JJ	active	B-e2	O	drug
metabolite	NN	metabolite	I-e2	O	drug
after	IN	after	O	O	NONE
intravenous	JJ	intravenous	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
losartan	NN	losartan	B-e3	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
erythromycin	NN	erythromycin	B-e4	T	drug
had	VBD	have	O	O	NONE
no	DT	no	O	O	NONE
clinically	RB	clinically	O	O	NONE
significant	JJ	significant	O	O	NONE
effect	NN	effect	O	O	NONE
after	IN	after	O	O	NONE
oral	JJ	oral	O	O	NONE
administration	NN	administration	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d112.s4
Fluconazole	NN	fluconazole	B-e0	T	drug
,	,	,	O	O	NONE
an	DT	a	O	O	NONE
inhibitor	NN	inhibitor	O	O	NONE
of	IN	of	O	O	NONE
P450	NN	p450	B-e1	T	drug
2C9	NNS	2c9	O	O	NONE
,	,	,	O	O	NONE
decreased	VBD	decrease	O	O	NONE
active	JJ	active	B-e2	O	drug
metabolite	NN	metabolite	I-e2	O	drug
concentration	NN	concentration	O	O	NONE
and	CC	and	O	O	NONE
increased	VBD	increase	O	O	NONE
losartan	NN	losartan	B-e3	O	drug
concentration	NN	concentration	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d112.s4
Fluconazole	NN	fluconazole	B-e0	T	drug
,	,	,	O	O	NONE
an	DT	a	O	O	NONE
inhibitor	NN	inhibitor	O	O	NONE
of	IN	of	O	O	NONE
P450	NN	p450	B-e1	O	drug
2C9	NNS	2c9	O	O	NONE
,	,	,	O	O	NONE
decreased	VBD	decrease	O	O	NONE
active	JJ	active	B-e2	T	drug
metabolite	NN	metabolite	I-e2	T	drug
concentration	NN	concentration	O	O	NONE
and	CC	and	O	O	NONE
increased	VBD	increase	O	O	NONE
losartan	NN	losartan	B-e3	O	drug
concentration	NN	concentration	O	O	NONE
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d112.s4
Fluconazole	NN	fluconazole	B-e0	T	drug
,	,	,	O	O	NONE
an	DT	a	O	O	NONE
inhibitor	NN	inhibitor	O	O	NONE
of	IN	of	O	O	NONE
P450	NN	p450	B-e1	O	drug
2C9	NNS	2c9	O	O	NONE
,	,	,	O	O	NONE
decreased	VBD	decrease	O	O	NONE
active	JJ	active	B-e2	O	drug
metabolite	NN	metabolite	I-e2	O	drug
concentration	NN	concentration	O	O	NONE
and	CC	and	O	O	NONE
increased	VBD	increase	O	O	NONE
losartan	NN	losartan	B-e3	T	drug
concentration	NN	concentration	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d112.s4
Fluconazole	NN	fluconazole	B-e0	O	drug
,	,	,	O	O	NONE
an	DT	a	O	O	NONE
inhibitor	NN	inhibitor	O	O	NONE
of	IN	of	O	O	NONE
P450	NN	p450	B-e1	T	drug
2C9	NNS	2c9	O	O	NONE
,	,	,	O	O	NONE
decreased	VBD	decrease	O	O	NONE
active	JJ	active	B-e2	T	drug
metabolite	NN	metabolite	I-e2	T	drug
concentration	NN	concentration	O	O	NONE
and	CC	and	O	O	NONE
increased	VBD	increase	O	O	NONE
losartan	NN	losartan	B-e3	O	drug
concentration	NN	concentration	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d112.s4
Fluconazole	NN	fluconazole	B-e0	O	drug
,	,	,	O	O	NONE
an	DT	a	O	O	NONE
inhibitor	NN	inhibitor	O	O	NONE
of	IN	of	O	O	NONE
P450	NN	p450	B-e1	T	drug
2C9	NNS	2c9	O	O	NONE
,	,	,	O	O	NONE
decreased	VBD	decrease	O	O	NONE
active	JJ	active	B-e2	O	drug
metabolite	NN	metabolite	I-e2	O	drug
concentration	NN	concentration	O	O	NONE
and	CC	and	O	O	NONE
increased	VBD	increase	O	O	NONE
losartan	NN	losartan	B-e3	T	drug
concentration	NN	concentration	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d112.s4
Fluconazole	NN	fluconazole	B-e0	O	drug
,	,	,	O	O	NONE
an	DT	a	O	O	NONE
inhibitor	NN	inhibitor	O	O	NONE
of	IN	of	O	O	NONE
P450	NN	p450	B-e1	O	drug
2C9	NNS	2c9	O	O	NONE
,	,	,	O	O	NONE
decreased	VBD	decrease	O	O	NONE
active	JJ	active	B-e2	T	drug
metabolite	NN	metabolite	I-e2	T	drug
concentration	NN	concentration	O	O	NONE
and	CC	and	O	O	NONE
increased	VBD	increase	O	O	NONE
losartan	NN	losartan	B-e3	T	drug
concentration	NN	concentration	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d112.s5
The	DT	the	O	O	NONE
pharmacodynamic	JJ	pharmacodynamic	O	O	NONE
consequences	NNS	consequence	O	O	NONE
of	IN	of	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
use	NN	use	O	O	NONE
of	IN	of	O	O	NONE
losartan	NN	losartan	B-e0	T	drug
and	CC	and	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
of	IN	of	O	O	NONE
P450	NN	p450	B-e1	T	drug
2C9	NNS	2c9	O	O	NONE
have	VBP	have	O	O	NONE
not	RB	not	O	O	NONE
been	VBN	be	O	O	NONE
examined	VBN	examine	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d112.s6
Subjects	NNS	subject	O	O	NONE
who	WP	who	O	O	NONE
do	VBP	do	O	O	NONE
not	RB	not	O	O	NONE
metabolize	VB	metabolize	O	O	NONE
losartan	NN	losartan	B-e0	T	drug
to	TO	to	O	O	NONE
active	JJ	active	B-e1	T	drug
metabolite	NN	metabolite	I-e1	T	drug
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
shown	VBN	show	O	O	NONE
to	TO	to	O	O	NONE
have	VB	have	O	O	NONE
a	DT	a	O	O	NONE
specific	JJ	specific	O	O	NONE
,	,	,	O	O	NONE
rare	JJ	rare	O	O	NONE
defect	NN	defect	O	O	NONE
in	IN	in	O	O	NONE
cytochrome	NN	cytochrome	B-e2	O	drug
P450	NN	p450	I-e2	O	drug
2C9	NN	2c9	I-e2	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d112.s6
Subjects	NNS	subject	O	O	NONE
who	WP	who	O	O	NONE
do	VBP	do	O	O	NONE
not	RB	not	O	O	NONE
metabolize	VB	metabolize	O	O	NONE
losartan	NN	losartan	B-e0	T	drug
to	TO	to	O	O	NONE
active	JJ	active	B-e1	O	drug
metabolite	NN	metabolite	I-e1	O	drug
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
shown	VBN	show	O	O	NONE
to	TO	to	O	O	NONE
have	VB	have	O	O	NONE
a	DT	a	O	O	NONE
specific	JJ	specific	O	O	NONE
,	,	,	O	O	NONE
rare	JJ	rare	O	O	NONE
defect	NN	defect	O	O	NONE
in	IN	in	O	O	NONE
cytochrome	NN	cytochrome	B-e2	T	drug
P450	NN	p450	I-e2	T	drug
2C9	NN	2c9	I-e2	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d112.s6
Subjects	NNS	subject	O	O	NONE
who	WP	who	O	O	NONE
do	VBP	do	O	O	NONE
not	RB	not	O	O	NONE
metabolize	VB	metabolize	O	O	NONE
losartan	NN	losartan	B-e0	O	drug
to	TO	to	O	O	NONE
active	JJ	active	B-e1	T	drug
metabolite	NN	metabolite	I-e1	T	drug
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
shown	VBN	show	O	O	NONE
to	TO	to	O	O	NONE
have	VB	have	O	O	NONE
a	DT	a	O	O	NONE
specific	JJ	specific	O	O	NONE
,	,	,	O	O	NONE
rare	JJ	rare	O	O	NONE
defect	NN	defect	O	O	NONE
in	IN	in	O	O	NONE
cytochrome	NN	cytochrome	B-e2	T	drug
P450	NN	p450	I-e2	T	drug
2C9	NN	2c9	I-e2	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d112.s7
These	DT	these	O	O	NONE
data	NNS	datum	O	O	NONE
suggest	VBP	suggest	O	O	NONE
that	IN	that	O	O	NONE
the	DT	the	O	O	NONE
conversion	NN	conversion	O	O	NONE
of	IN	of	O	O	NONE
losartan	NN	losartan	B-e0	T	drug
to	TO	to	O	O	NONE
its	PRP$	its	O	O	NONE
active	JJ	active	B-e1	T	drug
metabolite	NN	metabolite	I-e1	T	drug
is	VBZ	be	O	O	NONE
mediated	VBN	mediate	O	O	NONE
primarily	RB	primarily	O	O	NONE
by	IN	by	O	O	NONE
P450	NN	p450	B-e2	O	drug
2C9	NN	2c9	O	O	NONE
and	CC	and	O	O	NONE
not	RB	not	O	O	NONE
P450	NN	p450	B-e3	O	drug
3A4	NN	3a4	I-e3	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d112.s7
These	DT	these	O	O	NONE
data	NNS	datum	O	O	NONE
suggest	VBP	suggest	O	O	NONE
that	IN	that	O	O	NONE
the	DT	the	O	O	NONE
conversion	NN	conversion	O	O	NONE
of	IN	of	O	O	NONE
losartan	NN	losartan	B-e0	T	drug
to	TO	to	O	O	NONE
its	PRP$	its	O	O	NONE
active	JJ	active	B-e1	O	drug
metabolite	NN	metabolite	I-e1	O	drug
is	VBZ	be	O	O	NONE
mediated	VBN	mediate	O	O	NONE
primarily	RB	primarily	O	O	NONE
by	IN	by	O	O	NONE
P450	NN	p450	B-e2	T	drug
2C9	NN	2c9	O	O	NONE
and	CC	and	O	O	NONE
not	RB	not	O	O	NONE
P450	NN	p450	B-e3	O	drug
3A4	NN	3a4	I-e3	O	drug
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d112.s7
These	DT	these	O	O	NONE
data	NNS	datum	O	O	NONE
suggest	VBP	suggest	O	O	NONE
that	IN	that	O	O	NONE
the	DT	the	O	O	NONE
conversion	NN	conversion	O	O	NONE
of	IN	of	O	O	NONE
losartan	NN	losartan	B-e0	T	drug
to	TO	to	O	O	NONE
its	PRP$	its	O	O	NONE
active	JJ	active	B-e1	O	drug
metabolite	NN	metabolite	I-e1	O	drug
is	VBZ	be	O	O	NONE
mediated	VBN	mediate	O	O	NONE
primarily	RB	primarily	O	O	NONE
by	IN	by	O	O	NONE
P450	NN	p450	B-e2	O	drug
2C9	NN	2c9	O	O	NONE
and	CC	and	O	O	NONE
not	RB	not	O	O	NONE
P450	NN	p450	B-e3	T	drug
3A4	NN	3a4	I-e3	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d112.s7
These	DT	these	O	O	NONE
data	NNS	datum	O	O	NONE
suggest	VBP	suggest	O	O	NONE
that	IN	that	O	O	NONE
the	DT	the	O	O	NONE
conversion	NN	conversion	O	O	NONE
of	IN	of	O	O	NONE
losartan	NN	losartan	B-e0	O	drug
to	TO	to	O	O	NONE
its	PRP$	its	O	O	NONE
active	JJ	active	B-e1	T	drug
metabolite	NN	metabolite	I-e1	T	drug
is	VBZ	be	O	O	NONE
mediated	VBN	mediate	O	O	NONE
primarily	RB	primarily	O	O	NONE
by	IN	by	O	O	NONE
P450	NN	p450	B-e2	T	drug
2C9	NN	2c9	O	O	NONE
and	CC	and	O	O	NONE
not	RB	not	O	O	NONE
P450	NN	p450	B-e3	O	drug
3A4	NN	3a4	I-e3	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d112.s7
These	DT	these	O	O	NONE
data	NNS	datum	O	O	NONE
suggest	VBP	suggest	O	O	NONE
that	IN	that	O	O	NONE
the	DT	the	O	O	NONE
conversion	NN	conversion	O	O	NONE
of	IN	of	O	O	NONE
losartan	NN	losartan	B-e0	O	drug
to	TO	to	O	O	NONE
its	PRP$	its	O	O	NONE
active	JJ	active	B-e1	T	drug
metabolite	NN	metabolite	I-e1	T	drug
is	VBZ	be	O	O	NONE
mediated	VBN	mediate	O	O	NONE
primarily	RB	primarily	O	O	NONE
by	IN	by	O	O	NONE
P450	NN	p450	B-e2	O	drug
2C9	NN	2c9	O	O	NONE
and	CC	and	O	O	NONE
not	RB	not	O	O	NONE
P450	NN	p450	B-e3	T	drug
3A4	NN	3a4	I-e3	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d112.s7
These	DT	these	O	O	NONE
data	NNS	datum	O	O	NONE
suggest	VBP	suggest	O	O	NONE
that	IN	that	O	O	NONE
the	DT	the	O	O	NONE
conversion	NN	conversion	O	O	NONE
of	IN	of	O	O	NONE
losartan	NN	losartan	B-e0	O	drug
to	TO	to	O	O	NONE
its	PRP$	its	O	O	NONE
active	JJ	active	B-e1	O	drug
metabolite	NN	metabolite	I-e1	O	drug
is	VBZ	be	O	O	NONE
mediated	VBN	mediate	O	O	NONE
primarily	RB	primarily	O	O	NONE
by	IN	by	O	O	NONE
P450	NN	p450	B-e2	T	drug
2C9	NN	2c9	O	O	NONE
and	CC	and	O	O	NONE
not	RB	not	O	O	NONE
P450	NN	p450	B-e3	T	drug
3A4	NN	3a4	I-e3	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d112.s8
As	IN	as	O	O	NONE
with	IN	with	O	O	NONE
other	JJ	other	O	O	NONE
drugs	NNS	drug	B-e0	T	drug
that	WDT	that	O	O	NONE
block	VBP	block	O	O	NONE
angiotensin	NN	angiotensin	B-e1	T	drug
II	CD	ii	I-e1	T	drug
or	CC	or	O	O	NONE
its	PRP$	its	O	O	NONE
effects	NNS	effect	O	O	NONE
,	,	,	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
use	NN	use	O	O	NONE
of	IN	of	O	O	NONE
potassium-sparing	JJ	potassium-sparing	B-e2	O	drug
diuretics	NNS	diuretic	I-e2	O	drug
(	(	(	O	O	NONE
e.g.	FW	e.g.	O	O	NONE
,	,	,	O	O	NONE
spironolactone	NN	spironolactone	B-e3	O	drug
,	,	,	O	O	NONE
triamterene	NN	triamterene	B-e4	O	drug
,	,	,	O	O	NONE
amiloride	NN	amiloride	B-e5	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
potassium	NN	potassium	B-e6	O	drug
supplement	NN	supplement	I-e6	O	drug
s	NNS	s	O	O	NONE
,	,	,	O	O	NONE
or	CC	or	O	O	NONE
salt	NN	salt	B-e7	O	drug
substitutes	VBZ	substitute	O	O	NONE
containing	VBG	contain	O	O	NONE
potassium	NN	potassium	B-e8	O	drug
may	MD	may	O	O	NONE
lead	VB	lead	O	O	NONE
to	TO	to	O	O	NONE
increases	NNS	increase	O	O	NONE
in	IN	in	O	O	NONE
serum	NN	serum	O	O	NONE
potassium	NN	potassium	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d112.s8
As	IN	as	O	O	NONE
with	IN	with	O	O	NONE
other	JJ	other	O	O	NONE
drugs	NNS	drug	B-e0	T	drug
that	WDT	that	O	O	NONE
block	VBP	block	O	O	NONE
angiotensin	NN	angiotensin	B-e1	O	drug
II	CD	ii	I-e1	O	drug
or	CC	or	O	O	NONE
its	PRP$	its	O	O	NONE
effects	NNS	effect	O	O	NONE
,	,	,	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
use	NN	use	O	O	NONE
of	IN	of	O	O	NONE
potassium-sparing	JJ	potassium-sparing	B-e2	T	drug
diuretics	NNS	diuretic	I-e2	T	drug
(	(	(	O	O	NONE
e.g.	FW	e.g.	O	O	NONE
,	,	,	O	O	NONE
spironolactone	NN	spironolactone	B-e3	O	drug
,	,	,	O	O	NONE
triamterene	NN	triamterene	B-e4	O	drug
,	,	,	O	O	NONE
amiloride	NN	amiloride	B-e5	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
potassium	NN	potassium	B-e6	O	drug
supplement	NN	supplement	I-e6	O	drug
s	NNS	s	O	O	NONE
,	,	,	O	O	NONE
or	CC	or	O	O	NONE
salt	NN	salt	B-e7	O	drug
substitutes	VBZ	substitute	O	O	NONE
containing	VBG	contain	O	O	NONE
potassium	NN	potassium	B-e8	O	drug
may	MD	may	O	O	NONE
lead	VB	lead	O	O	NONE
to	TO	to	O	O	NONE
increases	NNS	increase	O	O	NONE
in	IN	in	O	O	NONE
serum	NN	serum	O	O	NONE
potassium	NN	potassium	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d112.s8
As	IN	as	O	O	NONE
with	IN	with	O	O	NONE
other	JJ	other	O	O	NONE
drugs	NNS	drug	B-e0	T	drug
that	WDT	that	O	O	NONE
block	VBP	block	O	O	NONE
angiotensin	NN	angiotensin	B-e1	O	drug
II	CD	ii	I-e1	O	drug
or	CC	or	O	O	NONE
its	PRP$	its	O	O	NONE
effects	NNS	effect	O	O	NONE
,	,	,	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
use	NN	use	O	O	NONE
of	IN	of	O	O	NONE
potassium-sparing	JJ	potassium-sparing	B-e2	O	drug
diuretics	NNS	diuretic	I-e2	O	drug
(	(	(	O	O	NONE
e.g.	FW	e.g.	O	O	NONE
,	,	,	O	O	NONE
spironolactone	NN	spironolactone	B-e3	T	drug
,	,	,	O	O	NONE
triamterene	NN	triamterene	B-e4	O	drug
,	,	,	O	O	NONE
amiloride	NN	amiloride	B-e5	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
potassium	NN	potassium	B-e6	O	drug
supplement	NN	supplement	I-e6	O	drug
s	NNS	s	O	O	NONE
,	,	,	O	O	NONE
or	CC	or	O	O	NONE
salt	NN	salt	B-e7	O	drug
substitutes	VBZ	substitute	O	O	NONE
containing	VBG	contain	O	O	NONE
potassium	NN	potassium	B-e8	O	drug
may	MD	may	O	O	NONE
lead	VB	lead	O	O	NONE
to	TO	to	O	O	NONE
increases	NNS	increase	O	O	NONE
in	IN	in	O	O	NONE
serum	NN	serum	O	O	NONE
potassium	NN	potassium	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d112.s8
As	IN	as	O	O	NONE
with	IN	with	O	O	NONE
other	JJ	other	O	O	NONE
drugs	NNS	drug	B-e0	T	drug
that	WDT	that	O	O	NONE
block	VBP	block	O	O	NONE
angiotensin	NN	angiotensin	B-e1	O	drug
II	CD	ii	I-e1	O	drug
or	CC	or	O	O	NONE
its	PRP$	its	O	O	NONE
effects	NNS	effect	O	O	NONE
,	,	,	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
use	NN	use	O	O	NONE
of	IN	of	O	O	NONE
potassium-sparing	JJ	potassium-sparing	B-e2	O	drug
diuretics	NNS	diuretic	I-e2	O	drug
(	(	(	O	O	NONE
e.g.	FW	e.g.	O	O	NONE
,	,	,	O	O	NONE
spironolactone	NN	spironolactone	B-e3	O	drug
,	,	,	O	O	NONE
triamterene	NN	triamterene	B-e4	T	drug
,	,	,	O	O	NONE
amiloride	NN	amiloride	B-e5	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
potassium	NN	potassium	B-e6	O	drug
supplement	NN	supplement	I-e6	O	drug
s	NNS	s	O	O	NONE
,	,	,	O	O	NONE
or	CC	or	O	O	NONE
salt	NN	salt	B-e7	O	drug
substitutes	VBZ	substitute	O	O	NONE
containing	VBG	contain	O	O	NONE
potassium	NN	potassium	B-e8	O	drug
may	MD	may	O	O	NONE
lead	VB	lead	O	O	NONE
to	TO	to	O	O	NONE
increases	NNS	increase	O	O	NONE
in	IN	in	O	O	NONE
serum	NN	serum	O	O	NONE
potassium	NN	potassium	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d112.s8
As	IN	as	O	O	NONE
with	IN	with	O	O	NONE
other	JJ	other	O	O	NONE
drugs	NNS	drug	B-e0	T	drug
that	WDT	that	O	O	NONE
block	VBP	block	O	O	NONE
angiotensin	NN	angiotensin	B-e1	O	drug
II	CD	ii	I-e1	O	drug
or	CC	or	O	O	NONE
its	PRP$	its	O	O	NONE
effects	NNS	effect	O	O	NONE
,	,	,	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
use	NN	use	O	O	NONE
of	IN	of	O	O	NONE
potassium-sparing	JJ	potassium-sparing	B-e2	O	drug
diuretics	NNS	diuretic	I-e2	O	drug
(	(	(	O	O	NONE
e.g.	FW	e.g.	O	O	NONE
,	,	,	O	O	NONE
spironolactone	NN	spironolactone	B-e3	O	drug
,	,	,	O	O	NONE
triamterene	NN	triamterene	B-e4	O	drug
,	,	,	O	O	NONE
amiloride	NN	amiloride	B-e5	T	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
potassium	NN	potassium	B-e6	O	drug
supplement	NN	supplement	I-e6	O	drug
s	NNS	s	O	O	NONE
,	,	,	O	O	NONE
or	CC	or	O	O	NONE
salt	NN	salt	B-e7	O	drug
substitutes	VBZ	substitute	O	O	NONE
containing	VBG	contain	O	O	NONE
potassium	NN	potassium	B-e8	O	drug
may	MD	may	O	O	NONE
lead	VB	lead	O	O	NONE
to	TO	to	O	O	NONE
increases	NNS	increase	O	O	NONE
in	IN	in	O	O	NONE
serum	NN	serum	O	O	NONE
potassium	NN	potassium	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d112.s8
As	IN	as	O	O	NONE
with	IN	with	O	O	NONE
other	JJ	other	O	O	NONE
drugs	NNS	drug	B-e0	T	drug
that	WDT	that	O	O	NONE
block	VBP	block	O	O	NONE
angiotensin	NN	angiotensin	B-e1	O	drug
II	CD	ii	I-e1	O	drug
or	CC	or	O	O	NONE
its	PRP$	its	O	O	NONE
effects	NNS	effect	O	O	NONE
,	,	,	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
use	NN	use	O	O	NONE
of	IN	of	O	O	NONE
potassium-sparing	JJ	potassium-sparing	B-e2	O	drug
diuretics	NNS	diuretic	I-e2	O	drug
(	(	(	O	O	NONE
e.g.	FW	e.g.	O	O	NONE
,	,	,	O	O	NONE
spironolactone	NN	spironolactone	B-e3	O	drug
,	,	,	O	O	NONE
triamterene	NN	triamterene	B-e4	O	drug
,	,	,	O	O	NONE
amiloride	NN	amiloride	B-e5	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
potassium	NN	potassium	B-e6	T	drug
supplement	NN	supplement	I-e6	T	drug
s	NNS	s	O	O	NONE
,	,	,	O	O	NONE
or	CC	or	O	O	NONE
salt	NN	salt	B-e7	O	drug
substitutes	VBZ	substitute	O	O	NONE
containing	VBG	contain	O	O	NONE
potassium	NN	potassium	B-e8	O	drug
may	MD	may	O	O	NONE
lead	VB	lead	O	O	NONE
to	TO	to	O	O	NONE
increases	NNS	increase	O	O	NONE
in	IN	in	O	O	NONE
serum	NN	serum	O	O	NONE
potassium	NN	potassium	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d112.s8
As	IN	as	O	O	NONE
with	IN	with	O	O	NONE
other	JJ	other	O	O	NONE
drugs	NNS	drug	B-e0	T	drug
that	WDT	that	O	O	NONE
block	VBP	block	O	O	NONE
angiotensin	NN	angiotensin	B-e1	O	drug
II	CD	ii	I-e1	O	drug
or	CC	or	O	O	NONE
its	PRP$	its	O	O	NONE
effects	NNS	effect	O	O	NONE
,	,	,	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
use	NN	use	O	O	NONE
of	IN	of	O	O	NONE
potassium-sparing	JJ	potassium-sparing	B-e2	O	drug
diuretics	NNS	diuretic	I-e2	O	drug
(	(	(	O	O	NONE
e.g.	FW	e.g.	O	O	NONE
,	,	,	O	O	NONE
spironolactone	NN	spironolactone	B-e3	O	drug
,	,	,	O	O	NONE
triamterene	NN	triamterene	B-e4	O	drug
,	,	,	O	O	NONE
amiloride	NN	amiloride	B-e5	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
potassium	NN	potassium	B-e6	O	drug
supplement	NN	supplement	I-e6	O	drug
s	NNS	s	O	O	NONE
,	,	,	O	O	NONE
or	CC	or	O	O	NONE
salt	NN	salt	B-e7	T	drug
substitutes	VBZ	substitute	O	O	NONE
containing	VBG	contain	O	O	NONE
potassium	NN	potassium	B-e8	O	drug
may	MD	may	O	O	NONE
lead	VB	lead	O	O	NONE
to	TO	to	O	O	NONE
increases	NNS	increase	O	O	NONE
in	IN	in	O	O	NONE
serum	NN	serum	O	O	NONE
potassium	NN	potassium	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d112.s8
As	IN	as	O	O	NONE
with	IN	with	O	O	NONE
other	JJ	other	O	O	NONE
drugs	NNS	drug	B-e0	T	drug
that	WDT	that	O	O	NONE
block	VBP	block	O	O	NONE
angiotensin	NN	angiotensin	B-e1	O	drug
II	CD	ii	I-e1	O	drug
or	CC	or	O	O	NONE
its	PRP$	its	O	O	NONE
effects	NNS	effect	O	O	NONE
,	,	,	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
use	NN	use	O	O	NONE
of	IN	of	O	O	NONE
potassium-sparing	JJ	potassium-sparing	B-e2	O	drug
diuretics	NNS	diuretic	I-e2	O	drug
(	(	(	O	O	NONE
e.g.	FW	e.g.	O	O	NONE
,	,	,	O	O	NONE
spironolactone	NN	spironolactone	B-e3	O	drug
,	,	,	O	O	NONE
triamterene	NN	triamterene	B-e4	O	drug
,	,	,	O	O	NONE
amiloride	NN	amiloride	B-e5	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
potassium	NN	potassium	B-e6	O	drug
supplement	NN	supplement	I-e6	O	drug
s	NNS	s	O	O	NONE
,	,	,	O	O	NONE
or	CC	or	O	O	NONE
salt	NN	salt	B-e7	O	drug
substitutes	VBZ	substitute	O	O	NONE
containing	VBG	contain	O	O	NONE
potassium	NN	potassium	B-e8	T	drug
may	MD	may	O	O	NONE
lead	VB	lead	O	O	NONE
to	TO	to	O	O	NONE
increases	NNS	increase	O	O	NONE
in	IN	in	O	O	NONE
serum	NN	serum	O	O	NONE
potassium	NN	potassium	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d112.s8
As	IN	as	O	O	NONE
with	IN	with	O	O	NONE
other	JJ	other	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
block	VBP	block	O	O	NONE
angiotensin	NN	angiotensin	B-e1	T	drug
II	CD	ii	I-e1	T	drug
or	CC	or	O	O	NONE
its	PRP$	its	O	O	NONE
effects	NNS	effect	O	O	NONE
,	,	,	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
use	NN	use	O	O	NONE
of	IN	of	O	O	NONE
potassium-sparing	JJ	potassium-sparing	B-e2	T	drug
diuretics	NNS	diuretic	I-e2	T	drug
(	(	(	O	O	NONE
e.g.	FW	e.g.	O	O	NONE
,	,	,	O	O	NONE
spironolactone	NN	spironolactone	B-e3	O	drug
,	,	,	O	O	NONE
triamterene	NN	triamterene	B-e4	O	drug
,	,	,	O	O	NONE
amiloride	NN	amiloride	B-e5	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
potassium	NN	potassium	B-e6	O	drug
supplement	NN	supplement	I-e6	O	drug
s	NNS	s	O	O	NONE
,	,	,	O	O	NONE
or	CC	or	O	O	NONE
salt	NN	salt	B-e7	O	drug
substitutes	VBZ	substitute	O	O	NONE
containing	VBG	contain	O	O	NONE
potassium	NN	potassium	B-e8	O	drug
may	MD	may	O	O	NONE
lead	VB	lead	O	O	NONE
to	TO	to	O	O	NONE
increases	NNS	increase	O	O	NONE
in	IN	in	O	O	NONE
serum	NN	serum	O	O	NONE
potassium	NN	potassium	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d112.s8
As	IN	as	O	O	NONE
with	IN	with	O	O	NONE
other	JJ	other	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
block	VBP	block	O	O	NONE
angiotensin	NN	angiotensin	B-e1	T	drug
II	CD	ii	I-e1	T	drug
or	CC	or	O	O	NONE
its	PRP$	its	O	O	NONE
effects	NNS	effect	O	O	NONE
,	,	,	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
use	NN	use	O	O	NONE
of	IN	of	O	O	NONE
potassium-sparing	JJ	potassium-sparing	B-e2	O	drug
diuretics	NNS	diuretic	I-e2	O	drug
(	(	(	O	O	NONE
e.g.	FW	e.g.	O	O	NONE
,	,	,	O	O	NONE
spironolactone	NN	spironolactone	B-e3	T	drug
,	,	,	O	O	NONE
triamterene	NN	triamterene	B-e4	O	drug
,	,	,	O	O	NONE
amiloride	NN	amiloride	B-e5	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
potassium	NN	potassium	B-e6	O	drug
supplement	NN	supplement	I-e6	O	drug
s	NNS	s	O	O	NONE
,	,	,	O	O	NONE
or	CC	or	O	O	NONE
salt	NN	salt	B-e7	O	drug
substitutes	VBZ	substitute	O	O	NONE
containing	VBG	contain	O	O	NONE
potassium	NN	potassium	B-e8	O	drug
may	MD	may	O	O	NONE
lead	VB	lead	O	O	NONE
to	TO	to	O	O	NONE
increases	NNS	increase	O	O	NONE
in	IN	in	O	O	NONE
serum	NN	serum	O	O	NONE
potassium	NN	potassium	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d112.s8
As	IN	as	O	O	NONE
with	IN	with	O	O	NONE
other	JJ	other	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
block	VBP	block	O	O	NONE
angiotensin	NN	angiotensin	B-e1	T	drug
II	CD	ii	I-e1	T	drug
or	CC	or	O	O	NONE
its	PRP$	its	O	O	NONE
effects	NNS	effect	O	O	NONE
,	,	,	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
use	NN	use	O	O	NONE
of	IN	of	O	O	NONE
potassium-sparing	JJ	potassium-sparing	B-e2	O	drug
diuretics	NNS	diuretic	I-e2	O	drug
(	(	(	O	O	NONE
e.g.	FW	e.g.	O	O	NONE
,	,	,	O	O	NONE
spironolactone	NN	spironolactone	B-e3	O	drug
,	,	,	O	O	NONE
triamterene	NN	triamterene	B-e4	T	drug
,	,	,	O	O	NONE
amiloride	NN	amiloride	B-e5	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
potassium	NN	potassium	B-e6	O	drug
supplement	NN	supplement	I-e6	O	drug
s	NNS	s	O	O	NONE
,	,	,	O	O	NONE
or	CC	or	O	O	NONE
salt	NN	salt	B-e7	O	drug
substitutes	VBZ	substitute	O	O	NONE
containing	VBG	contain	O	O	NONE
potassium	NN	potassium	B-e8	O	drug
may	MD	may	O	O	NONE
lead	VB	lead	O	O	NONE
to	TO	to	O	O	NONE
increases	NNS	increase	O	O	NONE
in	IN	in	O	O	NONE
serum	NN	serum	O	O	NONE
potassium	NN	potassium	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d112.s8
As	IN	as	O	O	NONE
with	IN	with	O	O	NONE
other	JJ	other	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
block	VBP	block	O	O	NONE
angiotensin	NN	angiotensin	B-e1	T	drug
II	CD	ii	I-e1	T	drug
or	CC	or	O	O	NONE
its	PRP$	its	O	O	NONE
effects	NNS	effect	O	O	NONE
,	,	,	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
use	NN	use	O	O	NONE
of	IN	of	O	O	NONE
potassium-sparing	JJ	potassium-sparing	B-e2	O	drug
diuretics	NNS	diuretic	I-e2	O	drug
(	(	(	O	O	NONE
e.g.	FW	e.g.	O	O	NONE
,	,	,	O	O	NONE
spironolactone	NN	spironolactone	B-e3	O	drug
,	,	,	O	O	NONE
triamterene	NN	triamterene	B-e4	O	drug
,	,	,	O	O	NONE
amiloride	NN	amiloride	B-e5	T	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
potassium	NN	potassium	B-e6	O	drug
supplement	NN	supplement	I-e6	O	drug
s	NNS	s	O	O	NONE
,	,	,	O	O	NONE
or	CC	or	O	O	NONE
salt	NN	salt	B-e7	O	drug
substitutes	VBZ	substitute	O	O	NONE
containing	VBG	contain	O	O	NONE
potassium	NN	potassium	B-e8	O	drug
may	MD	may	O	O	NONE
lead	VB	lead	O	O	NONE
to	TO	to	O	O	NONE
increases	NNS	increase	O	O	NONE
in	IN	in	O	O	NONE
serum	NN	serum	O	O	NONE
potassium	NN	potassium	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d112.s8
As	IN	as	O	O	NONE
with	IN	with	O	O	NONE
other	JJ	other	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
block	VBP	block	O	O	NONE
angiotensin	NN	angiotensin	B-e1	T	drug
II	CD	ii	I-e1	T	drug
or	CC	or	O	O	NONE
its	PRP$	its	O	O	NONE
effects	NNS	effect	O	O	NONE
,	,	,	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
use	NN	use	O	O	NONE
of	IN	of	O	O	NONE
potassium-sparing	JJ	potassium-sparing	B-e2	O	drug
diuretics	NNS	diuretic	I-e2	O	drug
(	(	(	O	O	NONE
e.g.	FW	e.g.	O	O	NONE
,	,	,	O	O	NONE
spironolactone	NN	spironolactone	B-e3	O	drug
,	,	,	O	O	NONE
triamterene	NN	triamterene	B-e4	O	drug
,	,	,	O	O	NONE
amiloride	NN	amiloride	B-e5	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
potassium	NN	potassium	B-e6	T	drug
supplement	NN	supplement	I-e6	T	drug
s	NNS	s	O	O	NONE
,	,	,	O	O	NONE
or	CC	or	O	O	NONE
salt	NN	salt	B-e7	O	drug
substitutes	VBZ	substitute	O	O	NONE
containing	VBG	contain	O	O	NONE
potassium	NN	potassium	B-e8	O	drug
may	MD	may	O	O	NONE
lead	VB	lead	O	O	NONE
to	TO	to	O	O	NONE
increases	NNS	increase	O	O	NONE
in	IN	in	O	O	NONE
serum	NN	serum	O	O	NONE
potassium	NN	potassium	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d112.s8
As	IN	as	O	O	NONE
with	IN	with	O	O	NONE
other	JJ	other	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
block	VBP	block	O	O	NONE
angiotensin	NN	angiotensin	B-e1	T	drug
II	CD	ii	I-e1	T	drug
or	CC	or	O	O	NONE
its	PRP$	its	O	O	NONE
effects	NNS	effect	O	O	NONE
,	,	,	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
use	NN	use	O	O	NONE
of	IN	of	O	O	NONE
potassium-sparing	JJ	potassium-sparing	B-e2	O	drug
diuretics	NNS	diuretic	I-e2	O	drug
(	(	(	O	O	NONE
e.g.	FW	e.g.	O	O	NONE
,	,	,	O	O	NONE
spironolactone	NN	spironolactone	B-e3	O	drug
,	,	,	O	O	NONE
triamterene	NN	triamterene	B-e4	O	drug
,	,	,	O	O	NONE
amiloride	NN	amiloride	B-e5	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
potassium	NN	potassium	B-e6	O	drug
supplement	NN	supplement	I-e6	O	drug
s	NNS	s	O	O	NONE
,	,	,	O	O	NONE
or	CC	or	O	O	NONE
salt	NN	salt	B-e7	T	drug
substitutes	VBZ	substitute	O	O	NONE
containing	VBG	contain	O	O	NONE
potassium	NN	potassium	B-e8	O	drug
may	MD	may	O	O	NONE
lead	VB	lead	O	O	NONE
to	TO	to	O	O	NONE
increases	NNS	increase	O	O	NONE
in	IN	in	O	O	NONE
serum	NN	serum	O	O	NONE
potassium	NN	potassium	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d112.s8
As	IN	as	O	O	NONE
with	IN	with	O	O	NONE
other	JJ	other	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
block	VBP	block	O	O	NONE
angiotensin	NN	angiotensin	B-e1	T	drug
II	CD	ii	I-e1	T	drug
or	CC	or	O	O	NONE
its	PRP$	its	O	O	NONE
effects	NNS	effect	O	O	NONE
,	,	,	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
use	NN	use	O	O	NONE
of	IN	of	O	O	NONE
potassium-sparing	JJ	potassium-sparing	B-e2	O	drug
diuretics	NNS	diuretic	I-e2	O	drug
(	(	(	O	O	NONE
e.g.	FW	e.g.	O	O	NONE
,	,	,	O	O	NONE
spironolactone	NN	spironolactone	B-e3	O	drug
,	,	,	O	O	NONE
triamterene	NN	triamterene	B-e4	O	drug
,	,	,	O	O	NONE
amiloride	NN	amiloride	B-e5	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
potassium	NN	potassium	B-e6	O	drug
supplement	NN	supplement	I-e6	O	drug
s	NNS	s	O	O	NONE
,	,	,	O	O	NONE
or	CC	or	O	O	NONE
salt	NN	salt	B-e7	O	drug
substitutes	VBZ	substitute	O	O	NONE
containing	VBG	contain	O	O	NONE
potassium	NN	potassium	B-e8	T	drug
may	MD	may	O	O	NONE
lead	VB	lead	O	O	NONE
to	TO	to	O	O	NONE
increases	NNS	increase	O	O	NONE
in	IN	in	O	O	NONE
serum	NN	serum	O	O	NONE
potassium	NN	potassium	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d112.s8
As	IN	as	O	O	NONE
with	IN	with	O	O	NONE
other	JJ	other	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
block	VBP	block	O	O	NONE
angiotensin	NN	angiotensin	B-e1	O	drug
II	CD	ii	I-e1	O	drug
or	CC	or	O	O	NONE
its	PRP$	its	O	O	NONE
effects	NNS	effect	O	O	NONE
,	,	,	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
use	NN	use	O	O	NONE
of	IN	of	O	O	NONE
potassium-sparing	JJ	potassium-sparing	B-e2	T	drug
diuretics	NNS	diuretic	I-e2	T	drug
(	(	(	O	O	NONE
e.g.	FW	e.g.	O	O	NONE
,	,	,	O	O	NONE
spironolactone	NN	spironolactone	B-e3	T	drug
,	,	,	O	O	NONE
triamterene	NN	triamterene	B-e4	O	drug
,	,	,	O	O	NONE
amiloride	NN	amiloride	B-e5	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
potassium	NN	potassium	B-e6	O	drug
supplement	NN	supplement	I-e6	O	drug
s	NNS	s	O	O	NONE
,	,	,	O	O	NONE
or	CC	or	O	O	NONE
salt	NN	salt	B-e7	O	drug
substitutes	VBZ	substitute	O	O	NONE
containing	VBG	contain	O	O	NONE
potassium	NN	potassium	B-e8	O	drug
may	MD	may	O	O	NONE
lead	VB	lead	O	O	NONE
to	TO	to	O	O	NONE
increases	NNS	increase	O	O	NONE
in	IN	in	O	O	NONE
serum	NN	serum	O	O	NONE
potassium	NN	potassium	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d112.s8
As	IN	as	O	O	NONE
with	IN	with	O	O	NONE
other	JJ	other	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
block	VBP	block	O	O	NONE
angiotensin	NN	angiotensin	B-e1	O	drug
II	CD	ii	I-e1	O	drug
or	CC	or	O	O	NONE
its	PRP$	its	O	O	NONE
effects	NNS	effect	O	O	NONE
,	,	,	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
use	NN	use	O	O	NONE
of	IN	of	O	O	NONE
potassium-sparing	JJ	potassium-sparing	B-e2	T	drug
diuretics	NNS	diuretic	I-e2	T	drug
(	(	(	O	O	NONE
e.g.	FW	e.g.	O	O	NONE
,	,	,	O	O	NONE
spironolactone	NN	spironolactone	B-e3	O	drug
,	,	,	O	O	NONE
triamterene	NN	triamterene	B-e4	T	drug
,	,	,	O	O	NONE
amiloride	NN	amiloride	B-e5	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
potassium	NN	potassium	B-e6	O	drug
supplement	NN	supplement	I-e6	O	drug
s	NNS	s	O	O	NONE
,	,	,	O	O	NONE
or	CC	or	O	O	NONE
salt	NN	salt	B-e7	O	drug
substitutes	VBZ	substitute	O	O	NONE
containing	VBG	contain	O	O	NONE
potassium	NN	potassium	B-e8	O	drug
may	MD	may	O	O	NONE
lead	VB	lead	O	O	NONE
to	TO	to	O	O	NONE
increases	NNS	increase	O	O	NONE
in	IN	in	O	O	NONE
serum	NN	serum	O	O	NONE
potassium	NN	potassium	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d112.s8
As	IN	as	O	O	NONE
with	IN	with	O	O	NONE
other	JJ	other	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
block	VBP	block	O	O	NONE
angiotensin	NN	angiotensin	B-e1	O	drug
II	CD	ii	I-e1	O	drug
or	CC	or	O	O	NONE
its	PRP$	its	O	O	NONE
effects	NNS	effect	O	O	NONE
,	,	,	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
use	NN	use	O	O	NONE
of	IN	of	O	O	NONE
potassium-sparing	JJ	potassium-sparing	B-e2	T	drug
diuretics	NNS	diuretic	I-e2	T	drug
(	(	(	O	O	NONE
e.g.	FW	e.g.	O	O	NONE
,	,	,	O	O	NONE
spironolactone	NN	spironolactone	B-e3	O	drug
,	,	,	O	O	NONE
triamterene	NN	triamterene	B-e4	O	drug
,	,	,	O	O	NONE
amiloride	NN	amiloride	B-e5	T	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
potassium	NN	potassium	B-e6	O	drug
supplement	NN	supplement	I-e6	O	drug
s	NNS	s	O	O	NONE
,	,	,	O	O	NONE
or	CC	or	O	O	NONE
salt	NN	salt	B-e7	O	drug
substitutes	VBZ	substitute	O	O	NONE
containing	VBG	contain	O	O	NONE
potassium	NN	potassium	B-e8	O	drug
may	MD	may	O	O	NONE
lead	VB	lead	O	O	NONE
to	TO	to	O	O	NONE
increases	NNS	increase	O	O	NONE
in	IN	in	O	O	NONE
serum	NN	serum	O	O	NONE
potassium	NN	potassium	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d112.s8
As	IN	as	O	O	NONE
with	IN	with	O	O	NONE
other	JJ	other	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
block	VBP	block	O	O	NONE
angiotensin	NN	angiotensin	B-e1	O	drug
II	CD	ii	I-e1	O	drug
or	CC	or	O	O	NONE
its	PRP$	its	O	O	NONE
effects	NNS	effect	O	O	NONE
,	,	,	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
use	NN	use	O	O	NONE
of	IN	of	O	O	NONE
potassium-sparing	JJ	potassium-sparing	B-e2	T	drug
diuretics	NNS	diuretic	I-e2	T	drug
(	(	(	O	O	NONE
e.g.	FW	e.g.	O	O	NONE
,	,	,	O	O	NONE
spironolactone	NN	spironolactone	B-e3	O	drug
,	,	,	O	O	NONE
triamterene	NN	triamterene	B-e4	O	drug
,	,	,	O	O	NONE
amiloride	NN	amiloride	B-e5	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
potassium	NN	potassium	B-e6	T	drug
supplement	NN	supplement	I-e6	T	drug
s	NNS	s	O	O	NONE
,	,	,	O	O	NONE
or	CC	or	O	O	NONE
salt	NN	salt	B-e7	O	drug
substitutes	VBZ	substitute	O	O	NONE
containing	VBG	contain	O	O	NONE
potassium	NN	potassium	B-e8	O	drug
may	MD	may	O	O	NONE
lead	VB	lead	O	O	NONE
to	TO	to	O	O	NONE
increases	NNS	increase	O	O	NONE
in	IN	in	O	O	NONE
serum	NN	serum	O	O	NONE
potassium	NN	potassium	O	O	NONE
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d112.s8
As	IN	as	O	O	NONE
with	IN	with	O	O	NONE
other	JJ	other	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
block	VBP	block	O	O	NONE
angiotensin	NN	angiotensin	B-e1	O	drug
II	CD	ii	I-e1	O	drug
or	CC	or	O	O	NONE
its	PRP$	its	O	O	NONE
effects	NNS	effect	O	O	NONE
,	,	,	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
use	NN	use	O	O	NONE
of	IN	of	O	O	NONE
potassium-sparing	JJ	potassium-sparing	B-e2	T	drug
diuretics	NNS	diuretic	I-e2	T	drug
(	(	(	O	O	NONE
e.g.	FW	e.g.	O	O	NONE
,	,	,	O	O	NONE
spironolactone	NN	spironolactone	B-e3	O	drug
,	,	,	O	O	NONE
triamterene	NN	triamterene	B-e4	O	drug
,	,	,	O	O	NONE
amiloride	NN	amiloride	B-e5	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
potassium	NN	potassium	B-e6	O	drug
supplement	NN	supplement	I-e6	O	drug
s	NNS	s	O	O	NONE
,	,	,	O	O	NONE
or	CC	or	O	O	NONE
salt	NN	salt	B-e7	T	drug
substitutes	VBZ	substitute	O	O	NONE
containing	VBG	contain	O	O	NONE
potassium	NN	potassium	B-e8	O	drug
may	MD	may	O	O	NONE
lead	VB	lead	O	O	NONE
to	TO	to	O	O	NONE
increases	NNS	increase	O	O	NONE
in	IN	in	O	O	NONE
serum	NN	serum	O	O	NONE
potassium	NN	potassium	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d112.s8
As	IN	as	O	O	NONE
with	IN	with	O	O	NONE
other	JJ	other	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
block	VBP	block	O	O	NONE
angiotensin	NN	angiotensin	B-e1	O	drug
II	CD	ii	I-e1	O	drug
or	CC	or	O	O	NONE
its	PRP$	its	O	O	NONE
effects	NNS	effect	O	O	NONE
,	,	,	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
use	NN	use	O	O	NONE
of	IN	of	O	O	NONE
potassium-sparing	JJ	potassium-sparing	B-e2	T	drug
diuretics	NNS	diuretic	I-e2	T	drug
(	(	(	O	O	NONE
e.g.	FW	e.g.	O	O	NONE
,	,	,	O	O	NONE
spironolactone	NN	spironolactone	B-e3	O	drug
,	,	,	O	O	NONE
triamterene	NN	triamterene	B-e4	O	drug
,	,	,	O	O	NONE
amiloride	NN	amiloride	B-e5	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
potassium	NN	potassium	B-e6	O	drug
supplement	NN	supplement	I-e6	O	drug
s	NNS	s	O	O	NONE
,	,	,	O	O	NONE
or	CC	or	O	O	NONE
salt	NN	salt	B-e7	O	drug
substitutes	VBZ	substitute	O	O	NONE
containing	VBG	contain	O	O	NONE
potassium	NN	potassium	B-e8	T	drug
may	MD	may	O	O	NONE
lead	VB	lead	O	O	NONE
to	TO	to	O	O	NONE
increases	NNS	increase	O	O	NONE
in	IN	in	O	O	NONE
serum	NN	serum	O	O	NONE
potassium	NN	potassium	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d112.s8
As	IN	as	O	O	NONE
with	IN	with	O	O	NONE
other	JJ	other	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
block	VBP	block	O	O	NONE
angiotensin	NN	angiotensin	B-e1	O	drug
II	CD	ii	I-e1	O	drug
or	CC	or	O	O	NONE
its	PRP$	its	O	O	NONE
effects	NNS	effect	O	O	NONE
,	,	,	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
use	NN	use	O	O	NONE
of	IN	of	O	O	NONE
potassium-sparing	JJ	potassium-sparing	B-e2	O	drug
diuretics	NNS	diuretic	I-e2	O	drug
(	(	(	O	O	NONE
e.g.	FW	e.g.	O	O	NONE
,	,	,	O	O	NONE
spironolactone	NN	spironolactone	B-e3	T	drug
,	,	,	O	O	NONE
triamterene	NN	triamterene	B-e4	T	drug
,	,	,	O	O	NONE
amiloride	NN	amiloride	B-e5	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
potassium	NN	potassium	B-e6	O	drug
supplement	NN	supplement	I-e6	O	drug
s	NNS	s	O	O	NONE
,	,	,	O	O	NONE
or	CC	or	O	O	NONE
salt	NN	salt	B-e7	O	drug
substitutes	VBZ	substitute	O	O	NONE
containing	VBG	contain	O	O	NONE
potassium	NN	potassium	B-e8	O	drug
may	MD	may	O	O	NONE
lead	VB	lead	O	O	NONE
to	TO	to	O	O	NONE
increases	NNS	increase	O	O	NONE
in	IN	in	O	O	NONE
serum	NN	serum	O	O	NONE
potassium	NN	potassium	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d112.s8
As	IN	as	O	O	NONE
with	IN	with	O	O	NONE
other	JJ	other	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
block	VBP	block	O	O	NONE
angiotensin	NN	angiotensin	B-e1	O	drug
II	CD	ii	I-e1	O	drug
or	CC	or	O	O	NONE
its	PRP$	its	O	O	NONE
effects	NNS	effect	O	O	NONE
,	,	,	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
use	NN	use	O	O	NONE
of	IN	of	O	O	NONE
potassium-sparing	JJ	potassium-sparing	B-e2	O	drug
diuretics	NNS	diuretic	I-e2	O	drug
(	(	(	O	O	NONE
e.g.	FW	e.g.	O	O	NONE
,	,	,	O	O	NONE
spironolactone	NN	spironolactone	B-e3	T	drug
,	,	,	O	O	NONE
triamterene	NN	triamterene	B-e4	O	drug
,	,	,	O	O	NONE
amiloride	NN	amiloride	B-e5	T	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
potassium	NN	potassium	B-e6	O	drug
supplement	NN	supplement	I-e6	O	drug
s	NNS	s	O	O	NONE
,	,	,	O	O	NONE
or	CC	or	O	O	NONE
salt	NN	salt	B-e7	O	drug
substitutes	VBZ	substitute	O	O	NONE
containing	VBG	contain	O	O	NONE
potassium	NN	potassium	B-e8	O	drug
may	MD	may	O	O	NONE
lead	VB	lead	O	O	NONE
to	TO	to	O	O	NONE
increases	NNS	increase	O	O	NONE
in	IN	in	O	O	NONE
serum	NN	serum	O	O	NONE
potassium	NN	potassium	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d112.s8
As	IN	as	O	O	NONE
with	IN	with	O	O	NONE
other	JJ	other	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
block	VBP	block	O	O	NONE
angiotensin	NN	angiotensin	B-e1	O	drug
II	CD	ii	I-e1	O	drug
or	CC	or	O	O	NONE
its	PRP$	its	O	O	NONE
effects	NNS	effect	O	O	NONE
,	,	,	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
use	NN	use	O	O	NONE
of	IN	of	O	O	NONE
potassium-sparing	JJ	potassium-sparing	B-e2	O	drug
diuretics	NNS	diuretic	I-e2	O	drug
(	(	(	O	O	NONE
e.g.	FW	e.g.	O	O	NONE
,	,	,	O	O	NONE
spironolactone	NN	spironolactone	B-e3	T	drug
,	,	,	O	O	NONE
triamterene	NN	triamterene	B-e4	O	drug
,	,	,	O	O	NONE
amiloride	NN	amiloride	B-e5	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
potassium	NN	potassium	B-e6	T	drug
supplement	NN	supplement	I-e6	T	drug
s	NNS	s	O	O	NONE
,	,	,	O	O	NONE
or	CC	or	O	O	NONE
salt	NN	salt	B-e7	O	drug
substitutes	VBZ	substitute	O	O	NONE
containing	VBG	contain	O	O	NONE
potassium	NN	potassium	B-e8	O	drug
may	MD	may	O	O	NONE
lead	VB	lead	O	O	NONE
to	TO	to	O	O	NONE
increases	NNS	increase	O	O	NONE
in	IN	in	O	O	NONE
serum	NN	serum	O	O	NONE
potassium	NN	potassium	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d112.s8
As	IN	as	O	O	NONE
with	IN	with	O	O	NONE
other	JJ	other	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
block	VBP	block	O	O	NONE
angiotensin	NN	angiotensin	B-e1	O	drug
II	CD	ii	I-e1	O	drug
or	CC	or	O	O	NONE
its	PRP$	its	O	O	NONE
effects	NNS	effect	O	O	NONE
,	,	,	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
use	NN	use	O	O	NONE
of	IN	of	O	O	NONE
potassium-sparing	JJ	potassium-sparing	B-e2	O	drug
diuretics	NNS	diuretic	I-e2	O	drug
(	(	(	O	O	NONE
e.g.	FW	e.g.	O	O	NONE
,	,	,	O	O	NONE
spironolactone	NN	spironolactone	B-e3	T	drug
,	,	,	O	O	NONE
triamterene	NN	triamterene	B-e4	O	drug
,	,	,	O	O	NONE
amiloride	NN	amiloride	B-e5	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
potassium	NN	potassium	B-e6	O	drug
supplement	NN	supplement	I-e6	O	drug
s	NNS	s	O	O	NONE
,	,	,	O	O	NONE
or	CC	or	O	O	NONE
salt	NN	salt	B-e7	T	drug
substitutes	VBZ	substitute	O	O	NONE
containing	VBG	contain	O	O	NONE
potassium	NN	potassium	B-e8	O	drug
may	MD	may	O	O	NONE
lead	VB	lead	O	O	NONE
to	TO	to	O	O	NONE
increases	NNS	increase	O	O	NONE
in	IN	in	O	O	NONE
serum	NN	serum	O	O	NONE
potassium	NN	potassium	O	O	NONE
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d112.s8
As	IN	as	O	O	NONE
with	IN	with	O	O	NONE
other	JJ	other	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
block	VBP	block	O	O	NONE
angiotensin	NN	angiotensin	B-e1	O	drug
II	CD	ii	I-e1	O	drug
or	CC	or	O	O	NONE
its	PRP$	its	O	O	NONE
effects	NNS	effect	O	O	NONE
,	,	,	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
use	NN	use	O	O	NONE
of	IN	of	O	O	NONE
potassium-sparing	JJ	potassium-sparing	B-e2	O	drug
diuretics	NNS	diuretic	I-e2	O	drug
(	(	(	O	O	NONE
e.g.	FW	e.g.	O	O	NONE
,	,	,	O	O	NONE
spironolactone	NN	spironolactone	B-e3	T	drug
,	,	,	O	O	NONE
triamterene	NN	triamterene	B-e4	O	drug
,	,	,	O	O	NONE
amiloride	NN	amiloride	B-e5	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
potassium	NN	potassium	B-e6	O	drug
supplement	NN	supplement	I-e6	O	drug
s	NNS	s	O	O	NONE
,	,	,	O	O	NONE
or	CC	or	O	O	NONE
salt	NN	salt	B-e7	O	drug
substitutes	VBZ	substitute	O	O	NONE
containing	VBG	contain	O	O	NONE
potassium	NN	potassium	B-e8	T	drug
may	MD	may	O	O	NONE
lead	VB	lead	O	O	NONE
to	TO	to	O	O	NONE
increases	NNS	increase	O	O	NONE
in	IN	in	O	O	NONE
serum	NN	serum	O	O	NONE
potassium	NN	potassium	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d112.s8
As	IN	as	O	O	NONE
with	IN	with	O	O	NONE
other	JJ	other	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
block	VBP	block	O	O	NONE
angiotensin	NN	angiotensin	B-e1	O	drug
II	CD	ii	I-e1	O	drug
or	CC	or	O	O	NONE
its	PRP$	its	O	O	NONE
effects	NNS	effect	O	O	NONE
,	,	,	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
use	NN	use	O	O	NONE
of	IN	of	O	O	NONE
potassium-sparing	JJ	potassium-sparing	B-e2	O	drug
diuretics	NNS	diuretic	I-e2	O	drug
(	(	(	O	O	NONE
e.g.	FW	e.g.	O	O	NONE
,	,	,	O	O	NONE
spironolactone	NN	spironolactone	B-e3	O	drug
,	,	,	O	O	NONE
triamterene	NN	triamterene	B-e4	T	drug
,	,	,	O	O	NONE
amiloride	NN	amiloride	B-e5	T	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
potassium	NN	potassium	B-e6	O	drug
supplement	NN	supplement	I-e6	O	drug
s	NNS	s	O	O	NONE
,	,	,	O	O	NONE
or	CC	or	O	O	NONE
salt	NN	salt	B-e7	O	drug
substitutes	VBZ	substitute	O	O	NONE
containing	VBG	contain	O	O	NONE
potassium	NN	potassium	B-e8	O	drug
may	MD	may	O	O	NONE
lead	VB	lead	O	O	NONE
to	TO	to	O	O	NONE
increases	NNS	increase	O	O	NONE
in	IN	in	O	O	NONE
serum	NN	serum	O	O	NONE
potassium	NN	potassium	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d112.s8
As	IN	as	O	O	NONE
with	IN	with	O	O	NONE
other	JJ	other	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
block	VBP	block	O	O	NONE
angiotensin	NN	angiotensin	B-e1	O	drug
II	CD	ii	I-e1	O	drug
or	CC	or	O	O	NONE
its	PRP$	its	O	O	NONE
effects	NNS	effect	O	O	NONE
,	,	,	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
use	NN	use	O	O	NONE
of	IN	of	O	O	NONE
potassium-sparing	JJ	potassium-sparing	B-e2	O	drug
diuretics	NNS	diuretic	I-e2	O	drug
(	(	(	O	O	NONE
e.g.	FW	e.g.	O	O	NONE
,	,	,	O	O	NONE
spironolactone	NN	spironolactone	B-e3	O	drug
,	,	,	O	O	NONE
triamterene	NN	triamterene	B-e4	T	drug
,	,	,	O	O	NONE
amiloride	NN	amiloride	B-e5	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
potassium	NN	potassium	B-e6	T	drug
supplement	NN	supplement	I-e6	T	drug
s	NNS	s	O	O	NONE
,	,	,	O	O	NONE
or	CC	or	O	O	NONE
salt	NN	salt	B-e7	O	drug
substitutes	VBZ	substitute	O	O	NONE
containing	VBG	contain	O	O	NONE
potassium	NN	potassium	B-e8	O	drug
may	MD	may	O	O	NONE
lead	VB	lead	O	O	NONE
to	TO	to	O	O	NONE
increases	NNS	increase	O	O	NONE
in	IN	in	O	O	NONE
serum	NN	serum	O	O	NONE
potassium	NN	potassium	O	O	NONE
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d112.s8
As	IN	as	O	O	NONE
with	IN	with	O	O	NONE
other	JJ	other	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
block	VBP	block	O	O	NONE
angiotensin	NN	angiotensin	B-e1	O	drug
II	CD	ii	I-e1	O	drug
or	CC	or	O	O	NONE
its	PRP$	its	O	O	NONE
effects	NNS	effect	O	O	NONE
,	,	,	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
use	NN	use	O	O	NONE
of	IN	of	O	O	NONE
potassium-sparing	JJ	potassium-sparing	B-e2	O	drug
diuretics	NNS	diuretic	I-e2	O	drug
(	(	(	O	O	NONE
e.g.	FW	e.g.	O	O	NONE
,	,	,	O	O	NONE
spironolactone	NN	spironolactone	B-e3	O	drug
,	,	,	O	O	NONE
triamterene	NN	triamterene	B-e4	T	drug
,	,	,	O	O	NONE
amiloride	NN	amiloride	B-e5	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
potassium	NN	potassium	B-e6	O	drug
supplement	NN	supplement	I-e6	O	drug
s	NNS	s	O	O	NONE
,	,	,	O	O	NONE
or	CC	or	O	O	NONE
salt	NN	salt	B-e7	T	drug
substitutes	VBZ	substitute	O	O	NONE
containing	VBG	contain	O	O	NONE
potassium	NN	potassium	B-e8	O	drug
may	MD	may	O	O	NONE
lead	VB	lead	O	O	NONE
to	TO	to	O	O	NONE
increases	NNS	increase	O	O	NONE
in	IN	in	O	O	NONE
serum	NN	serum	O	O	NONE
potassium	NN	potassium	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d112.s8
As	IN	as	O	O	NONE
with	IN	with	O	O	NONE
other	JJ	other	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
block	VBP	block	O	O	NONE
angiotensin	NN	angiotensin	B-e1	O	drug
II	CD	ii	I-e1	O	drug
or	CC	or	O	O	NONE
its	PRP$	its	O	O	NONE
effects	NNS	effect	O	O	NONE
,	,	,	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
use	NN	use	O	O	NONE
of	IN	of	O	O	NONE
potassium-sparing	JJ	potassium-sparing	B-e2	O	drug
diuretics	NNS	diuretic	I-e2	O	drug
(	(	(	O	O	NONE
e.g.	FW	e.g.	O	O	NONE
,	,	,	O	O	NONE
spironolactone	NN	spironolactone	B-e3	O	drug
,	,	,	O	O	NONE
triamterene	NN	triamterene	B-e4	T	drug
,	,	,	O	O	NONE
amiloride	NN	amiloride	B-e5	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
potassium	NN	potassium	B-e6	O	drug
supplement	NN	supplement	I-e6	O	drug
s	NNS	s	O	O	NONE
,	,	,	O	O	NONE
or	CC	or	O	O	NONE
salt	NN	salt	B-e7	O	drug
substitutes	VBZ	substitute	O	O	NONE
containing	VBG	contain	O	O	NONE
potassium	NN	potassium	B-e8	T	drug
may	MD	may	O	O	NONE
lead	VB	lead	O	O	NONE
to	TO	to	O	O	NONE
increases	NNS	increase	O	O	NONE
in	IN	in	O	O	NONE
serum	NN	serum	O	O	NONE
potassium	NN	potassium	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d112.s8
As	IN	as	O	O	NONE
with	IN	with	O	O	NONE
other	JJ	other	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
block	VBP	block	O	O	NONE
angiotensin	NN	angiotensin	B-e1	O	drug
II	CD	ii	I-e1	O	drug
or	CC	or	O	O	NONE
its	PRP$	its	O	O	NONE
effects	NNS	effect	O	O	NONE
,	,	,	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
use	NN	use	O	O	NONE
of	IN	of	O	O	NONE
potassium-sparing	JJ	potassium-sparing	B-e2	O	drug
diuretics	NNS	diuretic	I-e2	O	drug
(	(	(	O	O	NONE
e.g.	FW	e.g.	O	O	NONE
,	,	,	O	O	NONE
spironolactone	NN	spironolactone	B-e3	O	drug
,	,	,	O	O	NONE
triamterene	NN	triamterene	B-e4	O	drug
,	,	,	O	O	NONE
amiloride	NN	amiloride	B-e5	T	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
potassium	NN	potassium	B-e6	T	drug
supplement	NN	supplement	I-e6	T	drug
s	NNS	s	O	O	NONE
,	,	,	O	O	NONE
or	CC	or	O	O	NONE
salt	NN	salt	B-e7	O	drug
substitutes	VBZ	substitute	O	O	NONE
containing	VBG	contain	O	O	NONE
potassium	NN	potassium	B-e8	O	drug
may	MD	may	O	O	NONE
lead	VB	lead	O	O	NONE
to	TO	to	O	O	NONE
increases	NNS	increase	O	O	NONE
in	IN	in	O	O	NONE
serum	NN	serum	O	O	NONE
potassium	NN	potassium	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d112.s8
As	IN	as	O	O	NONE
with	IN	with	O	O	NONE
other	JJ	other	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
block	VBP	block	O	O	NONE
angiotensin	NN	angiotensin	B-e1	O	drug
II	CD	ii	I-e1	O	drug
or	CC	or	O	O	NONE
its	PRP$	its	O	O	NONE
effects	NNS	effect	O	O	NONE
,	,	,	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
use	NN	use	O	O	NONE
of	IN	of	O	O	NONE
potassium-sparing	JJ	potassium-sparing	B-e2	O	drug
diuretics	NNS	diuretic	I-e2	O	drug
(	(	(	O	O	NONE
e.g.	FW	e.g.	O	O	NONE
,	,	,	O	O	NONE
spironolactone	NN	spironolactone	B-e3	O	drug
,	,	,	O	O	NONE
triamterene	NN	triamterene	B-e4	O	drug
,	,	,	O	O	NONE
amiloride	NN	amiloride	B-e5	T	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
potassium	NN	potassium	B-e6	O	drug
supplement	NN	supplement	I-e6	O	drug
s	NNS	s	O	O	NONE
,	,	,	O	O	NONE
or	CC	or	O	O	NONE
salt	NN	salt	B-e7	T	drug
substitutes	VBZ	substitute	O	O	NONE
containing	VBG	contain	O	O	NONE
potassium	NN	potassium	B-e8	O	drug
may	MD	may	O	O	NONE
lead	VB	lead	O	O	NONE
to	TO	to	O	O	NONE
increases	NNS	increase	O	O	NONE
in	IN	in	O	O	NONE
serum	NN	serum	O	O	NONE
potassium	NN	potassium	O	O	NONE
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d112.s8
As	IN	as	O	O	NONE
with	IN	with	O	O	NONE
other	JJ	other	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
block	VBP	block	O	O	NONE
angiotensin	NN	angiotensin	B-e1	O	drug
II	CD	ii	I-e1	O	drug
or	CC	or	O	O	NONE
its	PRP$	its	O	O	NONE
effects	NNS	effect	O	O	NONE
,	,	,	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
use	NN	use	O	O	NONE
of	IN	of	O	O	NONE
potassium-sparing	JJ	potassium-sparing	B-e2	O	drug
diuretics	NNS	diuretic	I-e2	O	drug
(	(	(	O	O	NONE
e.g.	FW	e.g.	O	O	NONE
,	,	,	O	O	NONE
spironolactone	NN	spironolactone	B-e3	O	drug
,	,	,	O	O	NONE
triamterene	NN	triamterene	B-e4	O	drug
,	,	,	O	O	NONE
amiloride	NN	amiloride	B-e5	T	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
potassium	NN	potassium	B-e6	O	drug
supplement	NN	supplement	I-e6	O	drug
s	NNS	s	O	O	NONE
,	,	,	O	O	NONE
or	CC	or	O	O	NONE
salt	NN	salt	B-e7	O	drug
substitutes	VBZ	substitute	O	O	NONE
containing	VBG	contain	O	O	NONE
potassium	NN	potassium	B-e8	T	drug
may	MD	may	O	O	NONE
lead	VB	lead	O	O	NONE
to	TO	to	O	O	NONE
increases	NNS	increase	O	O	NONE
in	IN	in	O	O	NONE
serum	NN	serum	O	O	NONE
potassium	NN	potassium	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d112.s8
As	IN	as	O	O	NONE
with	IN	with	O	O	NONE
other	JJ	other	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
block	VBP	block	O	O	NONE
angiotensin	NN	angiotensin	B-e1	O	drug
II	CD	ii	I-e1	O	drug
or	CC	or	O	O	NONE
its	PRP$	its	O	O	NONE
effects	NNS	effect	O	O	NONE
,	,	,	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
use	NN	use	O	O	NONE
of	IN	of	O	O	NONE
potassium-sparing	JJ	potassium-sparing	B-e2	O	drug
diuretics	NNS	diuretic	I-e2	O	drug
(	(	(	O	O	NONE
e.g.	FW	e.g.	O	O	NONE
,	,	,	O	O	NONE
spironolactone	NN	spironolactone	B-e3	O	drug
,	,	,	O	O	NONE
triamterene	NN	triamterene	B-e4	O	drug
,	,	,	O	O	NONE
amiloride	NN	amiloride	B-e5	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
potassium	NN	potassium	B-e6	T	drug
supplement	NN	supplement	I-e6	T	drug
s	NNS	s	O	O	NONE
,	,	,	O	O	NONE
or	CC	or	O	O	NONE
salt	NN	salt	B-e7	T	drug
substitutes	VBZ	substitute	O	O	NONE
containing	VBG	contain	O	O	NONE
potassium	NN	potassium	B-e8	O	drug
may	MD	may	O	O	NONE
lead	VB	lead	O	O	NONE
to	TO	to	O	O	NONE
increases	NNS	increase	O	O	NONE
in	IN	in	O	O	NONE
serum	NN	serum	O	O	NONE
potassium	NN	potassium	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d112.s8
As	IN	as	O	O	NONE
with	IN	with	O	O	NONE
other	JJ	other	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
block	VBP	block	O	O	NONE
angiotensin	NN	angiotensin	B-e1	O	drug
II	CD	ii	I-e1	O	drug
or	CC	or	O	O	NONE
its	PRP$	its	O	O	NONE
effects	NNS	effect	O	O	NONE
,	,	,	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
use	NN	use	O	O	NONE
of	IN	of	O	O	NONE
potassium-sparing	JJ	potassium-sparing	B-e2	O	drug
diuretics	NNS	diuretic	I-e2	O	drug
(	(	(	O	O	NONE
e.g.	FW	e.g.	O	O	NONE
,	,	,	O	O	NONE
spironolactone	NN	spironolactone	B-e3	O	drug
,	,	,	O	O	NONE
triamterene	NN	triamterene	B-e4	O	drug
,	,	,	O	O	NONE
amiloride	NN	amiloride	B-e5	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
potassium	NN	potassium	B-e6	T	drug
supplement	NN	supplement	I-e6	T	drug
s	NNS	s	O	O	NONE
,	,	,	O	O	NONE
or	CC	or	O	O	NONE
salt	NN	salt	B-e7	O	drug
substitutes	VBZ	substitute	O	O	NONE
containing	VBG	contain	O	O	NONE
potassium	NN	potassium	B-e8	T	drug
may	MD	may	O	O	NONE
lead	VB	lead	O	O	NONE
to	TO	to	O	O	NONE
increases	NNS	increase	O	O	NONE
in	IN	in	O	O	NONE
serum	NN	serum	O	O	NONE
potassium	NN	potassium	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d112.s8
As	IN	as	O	O	NONE
with	IN	with	O	O	NONE
other	JJ	other	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
block	VBP	block	O	O	NONE
angiotensin	NN	angiotensin	B-e1	O	drug
II	CD	ii	I-e1	O	drug
or	CC	or	O	O	NONE
its	PRP$	its	O	O	NONE
effects	NNS	effect	O	O	NONE
,	,	,	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
use	NN	use	O	O	NONE
of	IN	of	O	O	NONE
potassium-sparing	JJ	potassium-sparing	B-e2	O	drug
diuretics	NNS	diuretic	I-e2	O	drug
(	(	(	O	O	NONE
e.g.	FW	e.g.	O	O	NONE
,	,	,	O	O	NONE
spironolactone	NN	spironolactone	B-e3	O	drug
,	,	,	O	O	NONE
triamterene	NN	triamterene	B-e4	O	drug
,	,	,	O	O	NONE
amiloride	NN	amiloride	B-e5	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
potassium	NN	potassium	B-e6	O	drug
supplement	NN	supplement	I-e6	O	drug
s	NNS	s	O	O	NONE
,	,	,	O	O	NONE
or	CC	or	O	O	NONE
salt	NN	salt	B-e7	T	drug
substitutes	VBZ	substitute	O	O	NONE
containing	VBG	contain	O	O	NONE
potassium	NN	potassium	B-e8	T	drug
may	MD	may	O	O	NONE
lead	VB	lead	O	O	NONE
to	TO	to	O	O	NONE
increases	NNS	increase	O	O	NONE
in	IN	in	O	O	NONE
serum	NN	serum	O	O	NONE
potassium	NN	potassium	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d112.s9
As	IN	as	O	O	NONE
with	IN	with	O	O	NONE
other	JJ	other	O	O	NONE
antihypertensive	JJ	antihypertensive	B-e0	T	drug
agents	NNS	agent	I-e0	T	drug
,	,	,	O	O	NONE
the	DT	the	O	O	NONE
antihypertensive	JJ	antihypertensive	B-e1	T	drug
effect	NN	effect	O	O	NONE
of	IN	of	O	O	NONE
losartan	NN	losartan	B-e2	O	drug
may	MD	may	O	O	NONE
be	VB	be	O	O	NONE
blunted	VBN	blunt	O	O	NONE
by	IN	by	O	O	NONE
the	DT	the	O	O	NONE
non-steroidal	JJ	non-steroidal	B-e3	O	drug
anti-inflammatory	JJ	anti-inflammatory	I-e3	O	drug
drug	NN	drug	I-e3	O	drug
indomethacin	NN	indomethacin	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d112.s9
As	IN	as	O	O	NONE
with	IN	with	O	O	NONE
other	JJ	other	O	O	NONE
antihypertensive	JJ	antihypertensive	B-e0	T	drug
agents	NNS	agent	I-e0	T	drug
,	,	,	O	O	NONE
the	DT	the	O	O	NONE
antihypertensive	JJ	antihypertensive	B-e1	O	drug
effect	NN	effect	O	O	NONE
of	IN	of	O	O	NONE
losartan	NN	losartan	B-e2	T	drug
may	MD	may	O	O	NONE
be	VB	be	O	O	NONE
blunted	VBN	blunt	O	O	NONE
by	IN	by	O	O	NONE
the	DT	the	O	O	NONE
non-steroidal	JJ	non-steroidal	B-e3	O	drug
anti-inflammatory	JJ	anti-inflammatory	I-e3	O	drug
drug	NN	drug	I-e3	O	drug
indomethacin	NN	indomethacin	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d112.s9
As	IN	as	O	O	NONE
with	IN	with	O	O	NONE
other	JJ	other	O	O	NONE
antihypertensive	JJ	antihypertensive	B-e0	T	drug
agents	NNS	agent	I-e0	T	drug
,	,	,	O	O	NONE
the	DT	the	O	O	NONE
antihypertensive	JJ	antihypertensive	B-e1	O	drug
effect	NN	effect	O	O	NONE
of	IN	of	O	O	NONE
losartan	NN	losartan	B-e2	O	drug
may	MD	may	O	O	NONE
be	VB	be	O	O	NONE
blunted	VBN	blunt	O	O	NONE
by	IN	by	O	O	NONE
the	DT	the	O	O	NONE
non-steroidal	JJ	non-steroidal	B-e3	T	drug
anti-inflammatory	JJ	anti-inflammatory	I-e3	T	drug
drug	NN	drug	I-e3	T	drug
indomethacin	NN	indomethacin	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d112.s9
As	IN	as	O	O	NONE
with	IN	with	O	O	NONE
other	JJ	other	O	O	NONE
antihypertensive	JJ	antihypertensive	B-e0	O	drug
agents	NNS	agent	I-e0	O	drug
,	,	,	O	O	NONE
the	DT	the	O	O	NONE
antihypertensive	JJ	antihypertensive	B-e1	T	drug
effect	NN	effect	O	O	NONE
of	IN	of	O	O	NONE
losartan	NN	losartan	B-e2	T	drug
may	MD	may	O	O	NONE
be	VB	be	O	O	NONE
blunted	VBN	blunt	O	O	NONE
by	IN	by	O	O	NONE
the	DT	the	O	O	NONE
non-steroidal	JJ	non-steroidal	B-e3	O	drug
anti-inflammatory	JJ	anti-inflammatory	I-e3	O	drug
drug	NN	drug	I-e3	O	drug
indomethacin	NN	indomethacin	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d112.s9
As	IN	as	O	O	NONE
with	IN	with	O	O	NONE
other	JJ	other	O	O	NONE
antihypertensive	JJ	antihypertensive	B-e0	O	drug
agents	NNS	agent	I-e0	O	drug
,	,	,	O	O	NONE
the	DT	the	O	O	NONE
antihypertensive	JJ	antihypertensive	B-e1	T	drug
effect	NN	effect	O	O	NONE
of	IN	of	O	O	NONE
losartan	NN	losartan	B-e2	O	drug
may	MD	may	O	O	NONE
be	VB	be	O	O	NONE
blunted	VBN	blunt	O	O	NONE
by	IN	by	O	O	NONE
the	DT	the	O	O	NONE
non-steroidal	JJ	non-steroidal	B-e3	T	drug
anti-inflammatory	JJ	anti-inflammatory	I-e3	T	drug
drug	NN	drug	I-e3	T	drug
indomethacin	NN	indomethacin	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d112.s9
As	IN	as	O	O	NONE
with	IN	with	O	O	NONE
other	JJ	other	O	O	NONE
antihypertensive	JJ	antihypertensive	B-e0	O	drug
agents	NNS	agent	I-e0	O	drug
,	,	,	O	O	NONE
the	DT	the	O	O	NONE
antihypertensive	JJ	antihypertensive	B-e1	O	drug
effect	NN	effect	O	O	NONE
of	IN	of	O	O	NONE
losartan	NN	losartan	B-e2	T	drug
may	MD	may	O	O	NONE
be	VB	be	O	O	NONE
blunted	VBN	blunt	O	O	NONE
by	IN	by	O	O	NONE
the	DT	the	O	O	NONE
non-steroidal	JJ	non-steroidal	B-e3	T	drug
anti-inflammatory	JJ	anti-inflammatory	I-e3	T	drug
drug	NN	drug	I-e3	T	drug
indomethacin	NN	indomethacin	O	O	NONE
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d464.s0
When	WRB	when	O	O	NONE
administered	VBN	administer	O	O	NONE
concurrently	RB	concurrently	O	O	NONE
,	,	,	O	O	NONE
the	DT	the	O	O	NONE
following	VBG	follow	O	O	NONE
drugs	NNS	drug	B-e0	T	drug
may	MD	may	O	O	NONE
interact	VB	interact	O	O	NONE
with	IN	with	O	O	NONE
beta-adrenergic	JJ	beta-adrenergic	B-e1	T	drug
receptor	NN	receptor	I-e1	T	drug
blocking	NN	blocking	I-e1	T	drug
agents	NNS	agent	I-e1	T	drug
:	:	:	O	O	NONE
Anesthetics	NN	anesthetic	B-e2	O	drug
,	,	,	O	O	NONE
general	JJ	general	O	O	NONE
:	:	:	O	O	NONE
exaggeration	NN	exaggeration	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
hypotension	NN	hypotension	O	O	NONE
induced	VBN	induce	O	O	NONE
by	IN	by	O	O	NONE
general	JJ	general	B-e3	O	drug
anesthetics	NNS	anesthetic	I-e3	O	drug
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d464.s0
When	WRB	when	O	O	NONE
administered	VBN	administer	O	O	NONE
concurrently	RB	concurrently	O	O	NONE
,	,	,	O	O	NONE
the	DT	the	O	O	NONE
following	VBG	follow	O	O	NONE
drugs	NNS	drug	B-e0	T	drug
may	MD	may	O	O	NONE
interact	VB	interact	O	O	NONE
with	IN	with	O	O	NONE
beta-adrenergic	JJ	beta-adrenergic	B-e1	O	drug
receptor	NN	receptor	I-e1	O	drug
blocking	NN	blocking	I-e1	O	drug
agents	NNS	agent	I-e1	O	drug
:	:	:	O	O	NONE
Anesthetics	NN	anesthetic	B-e2	T	drug
,	,	,	O	O	NONE
general	JJ	general	O	O	NONE
:	:	:	O	O	NONE
exaggeration	NN	exaggeration	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
hypotension	NN	hypotension	O	O	NONE
induced	VBN	induce	O	O	NONE
by	IN	by	O	O	NONE
general	JJ	general	B-e3	O	drug
anesthetics	NNS	anesthetic	I-e3	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d464.s0
When	WRB	when	O	O	NONE
administered	VBN	administer	O	O	NONE
concurrently	RB	concurrently	O	O	NONE
,	,	,	O	O	NONE
the	DT	the	O	O	NONE
following	VBG	follow	O	O	NONE
drugs	NNS	drug	B-e0	T	drug
may	MD	may	O	O	NONE
interact	VB	interact	O	O	NONE
with	IN	with	O	O	NONE
beta-adrenergic	JJ	beta-adrenergic	B-e1	O	drug
receptor	NN	receptor	I-e1	O	drug
blocking	NN	blocking	I-e1	O	drug
agents	NNS	agent	I-e1	O	drug
:	:	:	O	O	NONE
Anesthetics	NN	anesthetic	B-e2	O	drug
,	,	,	O	O	NONE
general	JJ	general	O	O	NONE
:	:	:	O	O	NONE
exaggeration	NN	exaggeration	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
hypotension	NN	hypotension	O	O	NONE
induced	VBN	induce	O	O	NONE
by	IN	by	O	O	NONE
general	JJ	general	B-e3	T	drug
anesthetics	NNS	anesthetic	I-e3	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d464.s0
When	WRB	when	O	O	NONE
administered	VBN	administer	O	O	NONE
concurrently	RB	concurrently	O	O	NONE
,	,	,	O	O	NONE
the	DT	the	O	O	NONE
following	VBG	follow	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
may	MD	may	O	O	NONE
interact	VB	interact	O	O	NONE
with	IN	with	O	O	NONE
beta-adrenergic	JJ	beta-adrenergic	B-e1	T	drug
receptor	NN	receptor	I-e1	T	drug
blocking	NN	blocking	I-e1	T	drug
agents	NNS	agent	I-e1	T	drug
:	:	:	O	O	NONE
Anesthetics	NN	anesthetic	B-e2	T	drug
,	,	,	O	O	NONE
general	JJ	general	O	O	NONE
:	:	:	O	O	NONE
exaggeration	NN	exaggeration	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
hypotension	NN	hypotension	O	O	NONE
induced	VBN	induce	O	O	NONE
by	IN	by	O	O	NONE
general	JJ	general	B-e3	O	drug
anesthetics	NNS	anesthetic	I-e3	O	drug
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d464.s0
When	WRB	when	O	O	NONE
administered	VBN	administer	O	O	NONE
concurrently	RB	concurrently	O	O	NONE
,	,	,	O	O	NONE
the	DT	the	O	O	NONE
following	VBG	follow	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
may	MD	may	O	O	NONE
interact	VB	interact	O	O	NONE
with	IN	with	O	O	NONE
beta-adrenergic	JJ	beta-adrenergic	B-e1	T	drug
receptor	NN	receptor	I-e1	T	drug
blocking	NN	blocking	I-e1	T	drug
agents	NNS	agent	I-e1	T	drug
:	:	:	O	O	NONE
Anesthetics	NN	anesthetic	B-e2	O	drug
,	,	,	O	O	NONE
general	JJ	general	O	O	NONE
:	:	:	O	O	NONE
exaggeration	NN	exaggeration	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
hypotension	NN	hypotension	O	O	NONE
induced	VBN	induce	O	O	NONE
by	IN	by	O	O	NONE
general	JJ	general	B-e3	T	drug
anesthetics	NNS	anesthetic	I-e3	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d464.s0
When	WRB	when	O	O	NONE
administered	VBN	administer	O	O	NONE
concurrently	RB	concurrently	O	O	NONE
,	,	,	O	O	NONE
the	DT	the	O	O	NONE
following	VBG	follow	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
may	MD	may	O	O	NONE
interact	VB	interact	O	O	NONE
with	IN	with	O	O	NONE
beta-adrenergic	JJ	beta-adrenergic	B-e1	O	drug
receptor	NN	receptor	I-e1	O	drug
blocking	NN	blocking	I-e1	O	drug
agents	NNS	agent	I-e1	O	drug
:	:	:	O	O	NONE
Anesthetics	NN	anesthetic	B-e2	T	drug
,	,	,	O	O	NONE
general	JJ	general	O	O	NONE
:	:	:	O	O	NONE
exaggeration	NN	exaggeration	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
hypotension	NN	hypotension	O	O	NONE
induced	VBN	induce	O	O	NONE
by	IN	by	O	O	NONE
general	JJ	general	B-e3	T	drug
anesthetics	NNS	anesthetic	I-e3	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d464.s1
Antidiabetic	JJ	antidiabetic	B-e0	T	drug
drugs	NNS	drug	I-e0	T	drug
(	(	(	O	O	NONE
oral	JJ	oral	O	O	NONE
agents	NNS	agent	O	O	NONE
and	CC	and	O	O	NONE
insulin	NN	insulin	B-e1	T	drug
)	)	)	O	O	NONE
:	:	:	O	O	NONE
hypoglycemia	NN	hypoglycemia	B-e2	O	DISO
or	CC	or	O	O	NONE
hyperglycemia	NN	hyperglycemia	B-e3	O	DISO
;	:	;	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d464.s3
Catecholamine-depleting	JJ	catecholamine-depleting	O	O	NONE
drugs	NNS	drug	B-e0	T	drug
(	(	(	O	O	NONE
e.g.	FW	e.g.	O	O	NONE
,	,	,	O	O	NONE
reserpine	NN	reserpine	B-e1	T	drug
)	)	)	O	O	NONE
:	:	:	O	O	NONE
additive	JJ	additive	O	O	NONE
effect	NN	effect	O	O	NONE
;	:	;	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d485.s0
Elevated	JJ	elevated	O	O	NONE
plasma	NN	plasma	O	O	NONE
levels	NNS	level	O	O	NONE
of	IN	of	O	O	NONE
theophylline	NN	theophylline	B-e0	T	drug
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
reported	VBN	report	O	O	NONE
with	IN	with	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
quinolone	NN	quinolone	B-e1	T	drug
use	NN	use	O	O	NONE
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d485.s1
There	EX	there	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
reports	NNS	report	O	O	NONE
of	IN	of	O	O	NONE
theophylline	NN	theophylline	B-e0	T	drug
-related	JJ	-related	O	O	NONE
side	JJ	side	O	O	NONE
effects	NNS	effect	O	O	NONE
in	IN	in	O	O	NONE
patients	NNS	patient	O	O	NONE
on	IN	on	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
therapy	NN	therapy	O	O	NONE
with	IN	with	O	O	NONE
quinolones	NNS	quinolone	B-e1	T	drug
and	CC	and	O	O	NONE
theophylline	NN	theophylline	B-e2	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d485.s1
There	EX	there	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
reports	NNS	report	O	O	NONE
of	IN	of	O	O	NONE
theophylline	NN	theophylline	B-e0	T	drug
-related	JJ	-related	O	O	NONE
side	JJ	side	O	O	NONE
effects	NNS	effect	O	O	NONE
in	IN	in	O	O	NONE
patients	NNS	patient	O	O	NONE
on	IN	on	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
therapy	NN	therapy	O	O	NONE
with	IN	with	O	O	NONE
quinolones	NNS	quinolone	B-e1	O	drug
and	CC	and	O	O	NONE
theophylline	NN	theophylline	B-e2	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d485.s1
There	EX	there	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
reports	NNS	report	O	O	NONE
of	IN	of	O	O	NONE
theophylline	NN	theophylline	B-e0	O	drug
-related	JJ	-related	O	O	NONE
side	JJ	side	O	O	NONE
effects	NNS	effect	O	O	NONE
in	IN	in	O	O	NONE
patients	NNS	patient	O	O	NONE
on	IN	on	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
therapy	NN	therapy	O	O	NONE
with	IN	with	O	O	NONE
quinolones	NNS	quinolone	B-e1	T	drug
and	CC	and	O	O	NONE
theophylline	NN	theophylline	B-e2	T	drug
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d485.s3
Quinolones	NNS	quinolone	B-e0	T	drug
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
shown	VBN	show	O	O	NONE
to	TO	to	O	O	NONE
interfere	VB	interfere	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
metabolism	NN	metabolism	O	O	NONE
of	IN	of	O	O	NONE
caffeine	NN	caffeine	B-e1	T	drug
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d485.s5
Quinolones	NNS	quinolone	B-e0	T	drug
,	,	,	O	O	NONE
including	VBG	include	O	O	NONE
nalidixic	JJ	nalidixic	B-e1	T	drug
acid	NN	acid	I-e1	T	drug
,	,	,	O	O	NONE
may	MD	may	O	O	NONE
enhance	VB	enhance	O	O	NONE
the	DT	the	O	O	NONE
effects	NNS	effect	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
oral	JJ	oral	B-e2	O	drug
anticoagulant	NN	anticoagulant	I-e2	O	drug
warfarin	NN	warfarin	I-e2	O	drug
or	CC	or	O	O	NONE
its	PRP$	its	O	O	NONE
derivatives	NNS	derivative	B-e3	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d485.s5
Quinolones	NNS	quinolone	B-e0	T	drug
,	,	,	O	O	NONE
including	VBG	include	O	O	NONE
nalidixic	JJ	nalidixic	B-e1	O	drug
acid	NN	acid	I-e1	O	drug
,	,	,	O	O	NONE
may	MD	may	O	O	NONE
enhance	VB	enhance	O	O	NONE
the	DT	the	O	O	NONE
effects	NNS	effect	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
oral	JJ	oral	B-e2	T	drug
anticoagulant	NN	anticoagulant	I-e2	T	drug
warfarin	NN	warfarin	I-e2	T	drug
or	CC	or	O	O	NONE
its	PRP$	its	O	O	NONE
derivatives	NNS	derivative	B-e3	O	drug
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d485.s5
Quinolones	NNS	quinolone	B-e0	T	drug
,	,	,	O	O	NONE
including	VBG	include	O	O	NONE
nalidixic	JJ	nalidixic	B-e1	O	drug
acid	NN	acid	I-e1	O	drug
,	,	,	O	O	NONE
may	MD	may	O	O	NONE
enhance	VB	enhance	O	O	NONE
the	DT	the	O	O	NONE
effects	NNS	effect	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
oral	JJ	oral	B-e2	O	drug
anticoagulant	NN	anticoagulant	I-e2	O	drug
warfarin	NN	warfarin	I-e2	O	drug
or	CC	or	O	O	NONE
its	PRP$	its	O	O	NONE
derivatives	NNS	derivative	B-e3	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d485.s5
Quinolones	NNS	quinolone	B-e0	O	drug
,	,	,	O	O	NONE
including	VBG	include	O	O	NONE
nalidixic	JJ	nalidixic	B-e1	T	drug
acid	NN	acid	I-e1	T	drug
,	,	,	O	O	NONE
may	MD	may	O	O	NONE
enhance	VB	enhance	O	O	NONE
the	DT	the	O	O	NONE
effects	NNS	effect	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
oral	JJ	oral	B-e2	T	drug
anticoagulant	NN	anticoagulant	I-e2	T	drug
warfarin	NN	warfarin	I-e2	T	drug
or	CC	or	O	O	NONE
its	PRP$	its	O	O	NONE
derivatives	NNS	derivative	B-e3	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d485.s5
Quinolones	NNS	quinolone	B-e0	O	drug
,	,	,	O	O	NONE
including	VBG	include	O	O	NONE
nalidixic	JJ	nalidixic	B-e1	T	drug
acid	NN	acid	I-e1	T	drug
,	,	,	O	O	NONE
may	MD	may	O	O	NONE
enhance	VB	enhance	O	O	NONE
the	DT	the	O	O	NONE
effects	NNS	effect	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
oral	JJ	oral	B-e2	O	drug
anticoagulant	NN	anticoagulant	I-e2	O	drug
warfarin	NN	warfarin	I-e2	O	drug
or	CC	or	O	O	NONE
its	PRP$	its	O	O	NONE
derivatives	NNS	derivative	B-e3	T	drug
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d485.s5
Quinolones	NNS	quinolone	B-e0	O	drug
,	,	,	O	O	NONE
including	VBG	include	O	O	NONE
nalidixic	JJ	nalidixic	B-e1	O	drug
acid	NN	acid	I-e1	O	drug
,	,	,	O	O	NONE
may	MD	may	O	O	NONE
enhance	VB	enhance	O	O	NONE
the	DT	the	O	O	NONE
effects	NNS	effect	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
oral	JJ	oral	B-e2	T	drug
anticoagulant	NN	anticoagulant	I-e2	T	drug
warfarin	NN	warfarin	I-e2	T	drug
or	CC	or	O	O	NONE
its	PRP$	its	O	O	NONE
derivatives	NNS	derivative	B-e3	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d485.s7
Nitrofurantoin	NN	nitrofurantoin	B-e0	T	drug
interferes	VBZ	interfere	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
therapeutic	JJ	therapeutic	O	O	NONE
action	NN	action	O	O	NONE
of	IN	of	O	O	NONE
nalidixic	JJ	nalidixic	B-e1	T	drug
acid	NN	acid	I-e1	T	drug
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d485.s8
Antacids	NNS	antacid	B-e0	T	drug
containing	VBG	contain	O	O	NONE
magnesium	NN	magnesium	B-e1	T	drug
,	,	,	O	O	NONE
aluminum	NN	aluminum	O	O	NONE
,	,	,	O	O	NONE
or	CC	or	O	O	NONE
calcium	NN	calcium	B-e2	O	drug
;	:	;	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d485.s8
Antacids	NNS	antacid	B-e0	T	drug
containing	VBG	contain	O	O	NONE
magnesium	NN	magnesium	B-e1	O	drug
,	,	,	O	O	NONE
aluminum	NN	aluminum	O	O	NONE
,	,	,	O	O	NONE
or	CC	or	O	O	NONE
calcium	NN	calcium	B-e2	T	drug
;	:	;	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d485.s8
Antacids	NNS	antacid	B-e0	O	drug
containing	VBG	contain	O	O	NONE
magnesium	NN	magnesium	B-e1	T	drug
,	,	,	O	O	NONE
aluminum	NN	aluminum	O	O	NONE
,	,	,	O	O	NONE
or	CC	or	O	O	NONE
calcium	NN	calcium	B-e2	T	drug
;	:	;	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d485.s9
sucralfate	VBP	sucralfate	B-e0	T	drug
or	CC	or	O	O	NONE
divalent	JJ	divalent	O	O	NONE
or	CC	or	O	O	NONE
trivalent	JJ	trivalent	O	O	NONE
cations	NNS	cation	B-e1	T	drug
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
iron	NN	iron	B-e2	O	drug
;	:	;	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d485.s9
sucralfate	VBP	sucralfate	B-e0	T	drug
or	CC	or	O	O	NONE
divalent	JJ	divalent	O	O	NONE
or	CC	or	O	O	NONE
trivalent	JJ	trivalent	O	O	NONE
cations	NNS	cation	B-e1	O	drug
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
iron	NN	iron	B-e2	T	drug
;	:	;	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d485.s9
sucralfate	VBP	sucralfate	B-e0	O	drug
or	CC	or	O	O	NONE
divalent	JJ	divalent	O	O	NONE
or	CC	or	O	O	NONE
trivalent	JJ	trivalent	O	O	NONE
cations	NNS	cation	B-e1	T	drug
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
iron	NN	iron	B-e2	T	drug
;	:	;	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d485.s10
multivitamins	NNS	multivitamin	B-e0	T	drug
containing	VBG	contain	O	O	NONE
zinc	NN	zinc	B-e1	T	drug
;	:	;	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d485.s11
and	CC	and	O	O	NONE
Videx	NN	videx	O	O	NONE
@	NN	@	O	O	NONE
,	,	,	O	O	NONE
(	(	(	O	O	NONE
Didanosine	NN	didanosine	B-e0	T	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
chewable/	NN	chewable/	O	O	NONE
buffer	NN	buffer	B-e1	T	drug
ed	NN	ed	O	O	NONE
tablets	NNS	tablet	O	O	NONE
or	CC	or	O	O	NONE
the	DT	the	O	O	NONE
pediatric	JJ	pediatric	B-e2	O	drug
powder	NN	powder	O	O	NONE
for	IN	for	O	O	NONE
oral	JJ	oral	O	O	NONE
solution	NN	solution	O	O	NONE
may	MD	may	O	O	NONE
substantially	RB	substantially	O	O	NONE
interfere	VB	interfere	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
absorption	NN	absorption	O	O	NONE
of	IN	of	O	O	NONE
quinolones	NNS	quinolone	B-e3	O	drug
,	,	,	O	O	NONE
resulting	VBG	result	O	O	NONE
in	IN	in	O	O	NONE
systemic	JJ	systemic	O	O	NONE
levels	NNS	level	O	O	NONE
considerably	RB	considerably	O	O	NONE
lower	JJR	lower	O	O	NONE
than	IN	than	O	O	NONE
desired	VBN	desire	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d485.s11
and	CC	and	O	O	NONE
Videx	NN	videx	O	O	NONE
@	NN	@	O	O	NONE
,	,	,	O	O	NONE
(	(	(	O	O	NONE
Didanosine	NN	didanosine	B-e0	T	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
chewable/	NN	chewable/	O	O	NONE
buffer	NN	buffer	B-e1	O	drug
ed	NN	ed	O	O	NONE
tablets	NNS	tablet	O	O	NONE
or	CC	or	O	O	NONE
the	DT	the	O	O	NONE
pediatric	JJ	pediatric	B-e2	T	drug
powder	NN	powder	O	O	NONE
for	IN	for	O	O	NONE
oral	JJ	oral	O	O	NONE
solution	NN	solution	O	O	NONE
may	MD	may	O	O	NONE
substantially	RB	substantially	O	O	NONE
interfere	VB	interfere	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
absorption	NN	absorption	O	O	NONE
of	IN	of	O	O	NONE
quinolones	NNS	quinolone	B-e3	O	drug
,	,	,	O	O	NONE
resulting	VBG	result	O	O	NONE
in	IN	in	O	O	NONE
systemic	JJ	systemic	O	O	NONE
levels	NNS	level	O	O	NONE
considerably	RB	considerably	O	O	NONE
lower	JJR	lower	O	O	NONE
than	IN	than	O	O	NONE
desired	VBN	desire	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d485.s11
and	CC	and	O	O	NONE
Videx	NN	videx	O	O	NONE
@	NN	@	O	O	NONE
,	,	,	O	O	NONE
(	(	(	O	O	NONE
Didanosine	NN	didanosine	B-e0	T	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
chewable/	NN	chewable/	O	O	NONE
buffer	NN	buffer	B-e1	O	drug
ed	NN	ed	O	O	NONE
tablets	NNS	tablet	O	O	NONE
or	CC	or	O	O	NONE
the	DT	the	O	O	NONE
pediatric	JJ	pediatric	B-e2	O	drug
powder	NN	powder	O	O	NONE
for	IN	for	O	O	NONE
oral	JJ	oral	O	O	NONE
solution	NN	solution	O	O	NONE
may	MD	may	O	O	NONE
substantially	RB	substantially	O	O	NONE
interfere	VB	interfere	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
absorption	NN	absorption	O	O	NONE
of	IN	of	O	O	NONE
quinolones	NNS	quinolone	B-e3	T	drug
,	,	,	O	O	NONE
resulting	VBG	result	O	O	NONE
in	IN	in	O	O	NONE
systemic	JJ	systemic	O	O	NONE
levels	NNS	level	O	O	NONE
considerably	RB	considerably	O	O	NONE
lower	JJR	lower	O	O	NONE
than	IN	than	O	O	NONE
desired	VBN	desire	O	O	NONE
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d485.s11
and	CC	and	O	O	NONE
Videx	NN	videx	O	O	NONE
@	NN	@	O	O	NONE
,	,	,	O	O	NONE
(	(	(	O	O	NONE
Didanosine	NN	didanosine	B-e0	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
chewable/	NN	chewable/	O	O	NONE
buffer	NN	buffer	B-e1	T	drug
ed	NN	ed	O	O	NONE
tablets	NNS	tablet	O	O	NONE
or	CC	or	O	O	NONE
the	DT	the	O	O	NONE
pediatric	JJ	pediatric	B-e2	T	drug
powder	NN	powder	O	O	NONE
for	IN	for	O	O	NONE
oral	JJ	oral	O	O	NONE
solution	NN	solution	O	O	NONE
may	MD	may	O	O	NONE
substantially	RB	substantially	O	O	NONE
interfere	VB	interfere	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
absorption	NN	absorption	O	O	NONE
of	IN	of	O	O	NONE
quinolones	NNS	quinolone	B-e3	O	drug
,	,	,	O	O	NONE
resulting	VBG	result	O	O	NONE
in	IN	in	O	O	NONE
systemic	JJ	systemic	O	O	NONE
levels	NNS	level	O	O	NONE
considerably	RB	considerably	O	O	NONE
lower	JJR	lower	O	O	NONE
than	IN	than	O	O	NONE
desired	VBN	desire	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d485.s11
and	CC	and	O	O	NONE
Videx	NN	videx	O	O	NONE
@	NN	@	O	O	NONE
,	,	,	O	O	NONE
(	(	(	O	O	NONE
Didanosine	NN	didanosine	B-e0	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
chewable/	NN	chewable/	O	O	NONE
buffer	NN	buffer	B-e1	T	drug
ed	NN	ed	O	O	NONE
tablets	NNS	tablet	O	O	NONE
or	CC	or	O	O	NONE
the	DT	the	O	O	NONE
pediatric	JJ	pediatric	B-e2	O	drug
powder	NN	powder	O	O	NONE
for	IN	for	O	O	NONE
oral	JJ	oral	O	O	NONE
solution	NN	solution	O	O	NONE
may	MD	may	O	O	NONE
substantially	RB	substantially	O	O	NONE
interfere	VB	interfere	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
absorption	NN	absorption	O	O	NONE
of	IN	of	O	O	NONE
quinolones	NNS	quinolone	B-e3	T	drug
,	,	,	O	O	NONE
resulting	VBG	result	O	O	NONE
in	IN	in	O	O	NONE
systemic	JJ	systemic	O	O	NONE
levels	NNS	level	O	O	NONE
considerably	RB	considerably	O	O	NONE
lower	JJR	lower	O	O	NONE
than	IN	than	O	O	NONE
desired	VBN	desire	O	O	NONE
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d485.s11
and	CC	and	O	O	NONE
Videx	NN	videx	O	O	NONE
@	NN	@	O	O	NONE
,	,	,	O	O	NONE
(	(	(	O	O	NONE
Didanosine	NN	didanosine	B-e0	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
chewable/	NN	chewable/	O	O	NONE
buffer	NN	buffer	B-e1	O	drug
ed	NN	ed	O	O	NONE
tablets	NNS	tablet	O	O	NONE
or	CC	or	O	O	NONE
the	DT	the	O	O	NONE
pediatric	JJ	pediatric	B-e2	T	drug
powder	NN	powder	O	O	NONE
for	IN	for	O	O	NONE
oral	JJ	oral	O	O	NONE
solution	NN	solution	O	O	NONE
may	MD	may	O	O	NONE
substantially	RB	substantially	O	O	NONE
interfere	VB	interfere	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
absorption	NN	absorption	O	O	NONE
of	IN	of	O	O	NONE
quinolones	NNS	quinolone	B-e3	T	drug
,	,	,	O	O	NONE
resulting	VBG	result	O	O	NONE
in	IN	in	O	O	NONE
systemic	JJ	systemic	O	O	NONE
levels	NNS	level	O	O	NONE
considerably	RB	considerably	O	O	NONE
lower	JJR	lower	O	O	NONE
than	IN	than	O	O	NONE
desired	VBN	desire	O	O	NONE
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d485.s13
Elevated	JJ	elevated	O	O	NONE
serum	NN	serum	O	O	NONE
levels	NNS	level	O	O	NONE
of	IN	of	O	O	NONE
cyclosporine	NN	cyclosporine	B-e0	T	drug
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
reported	VBN	report	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
use	NN	use	O	O	NONE
of	IN	of	O	O	NONE
some	DT	some	O	O	NONE
quinolones	NN	quinolone	B-e1	T	drug
and	CC	and	O	O	NONE
cyclosporine	NN	cyclosporine	B-e2	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d485.s13
Elevated	JJ	elevated	O	O	NONE
serum	NN	serum	O	O	NONE
levels	NNS	level	O	O	NONE
of	IN	of	O	O	NONE
cyclosporine	NN	cyclosporine	B-e0	T	drug
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
reported	VBN	report	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
use	NN	use	O	O	NONE
of	IN	of	O	O	NONE
some	DT	some	O	O	NONE
quinolones	NN	quinolone	B-e1	O	drug
and	CC	and	O	O	NONE
cyclosporine	NN	cyclosporine	B-e2	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d485.s13
Elevated	JJ	elevated	O	O	NONE
serum	NN	serum	O	O	NONE
levels	NNS	level	O	O	NONE
of	IN	of	O	O	NONE
cyclosporine	NN	cyclosporine	B-e0	O	drug
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
reported	VBN	report	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
use	NN	use	O	O	NONE
of	IN	of	O	O	NONE
some	DT	some	O	O	NONE
quinolones	NN	quinolone	B-e1	T	drug
and	CC	and	O	O	NONE
cyclosporine	NN	cyclosporine	B-e2	T	drug
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d485.s14
Therefore	RB	therefore	O	O	NONE
,	,	,	O	O	NONE
cyclosporine	NN	cyclosporine	B-e0	T	drug
serum	NN	serum	O	O	NONE
levels	NNS	level	O	O	NONE
should	MD	should	O	O	NONE
be	VB	be	O	O	NONE
monitored	VBN	monitor	O	O	NONE
and	CC	and	O	O	NONE
appropriate	JJ	appropriate	O	O	NONE
cyclosporine	NN	cyclosporine	B-e1	T	drug
dosage	NN	dosage	O	O	NONE
adjustments	NNS	adjustment	O	O	NONE
made	VBD	make	O	O	NONE
when	WRB	when	O	O	NONE
these	DT	these	O	O	NONE
drugs	NNS	drug	B-e2	O	drug
are	VBP	be	O	O	NONE
used	VBN	use	O	O	NONE
concomitantly	RB	concomitantly	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d485.s14
Therefore	RB	therefore	O	O	NONE
,	,	,	O	O	NONE
cyclosporine	NN	cyclosporine	B-e0	T	drug
serum	NN	serum	O	O	NONE
levels	NNS	level	O	O	NONE
should	MD	should	O	O	NONE
be	VB	be	O	O	NONE
monitored	VBN	monitor	O	O	NONE
and	CC	and	O	O	NONE
appropriate	JJ	appropriate	O	O	NONE
cyclosporine	NN	cyclosporine	B-e1	O	drug
dosage	NN	dosage	O	O	NONE
adjustments	NNS	adjustment	O	O	NONE
made	VBD	make	O	O	NONE
when	WRB	when	O	O	NONE
these	DT	these	O	O	NONE
drugs	NNS	drug	B-e2	T	drug
are	VBP	be	O	O	NONE
used	VBN	use	O	O	NONE
concomitantly	RB	concomitantly	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d485.s14
Therefore	RB	therefore	O	O	NONE
,	,	,	O	O	NONE
cyclosporine	NN	cyclosporine	B-e0	O	drug
serum	NN	serum	O	O	NONE
levels	NNS	level	O	O	NONE
should	MD	should	O	O	NONE
be	VB	be	O	O	NONE
monitored	VBN	monitor	O	O	NONE
and	CC	and	O	O	NONE
appropriate	JJ	appropriate	O	O	NONE
cyclosporine	NN	cyclosporine	B-e1	T	drug
dosage	NN	dosage	O	O	NONE
adjustments	NNS	adjustment	O	O	NONE
made	VBD	make	O	O	NONE
when	WRB	when	O	O	NONE
these	DT	these	O	O	NONE
drugs	NNS	drug	B-e2	T	drug
are	VBP	be	O	O	NONE
used	VBN	use	O	O	NONE
concomitantly	RB	concomitantly	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s0
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
drug	NN	drug	O	O	NONE
metabolism	NN	metabolism	O	O	NONE
studies	NNS	study	O	O	NONE
indicate	VBP	indicate	O	O	NONE
that	IN	that	O	O	NONE
Starlix	NN	starlix	B-e0	T	drug
is	VBZ	be	O	O	NONE
predominantly	RB	predominantly	O	O	NONE
metabolized	VBN	metabolize	O	O	NONE
by	IN	by	O	O	NONE
the	DT	the	O	O	NONE
cytochrome	NN	cytochrome	B-e1	T	drug
P450	NN	p450	I-e1	T	drug
isozyme	NN	isozyme	O	O	NONE
CYP2C9	NN	cyp2c9	O	O	NONE
(	(	(	O	O	NONE
70	CD	70	O	O	NONE
%	NN	%	O	O	NONE
)	)	)	O	O	NONE
and	CC	and	O	O	NONE
to	TO	to	O	O	NONE
a	DT	a	O	O	NONE
lesser	JJR	lesser	O	O	NONE
extent	NN	extent	O	O	NONE
CYP3A4	NN	cyp3a4	B-e2	O	drug
(	(	(	O	O	NONE
30%).	NN	30%).	O	O	NONE

YES

Sentence: DrugDDI.d249.s0
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
drug	NN	drug	O	O	NONE
metabolism	NN	metabolism	O	O	NONE
studies	NNS	study	O	O	NONE
indicate	VBP	indicate	O	O	NONE
that	IN	that	O	O	NONE
Starlix	NN	starlix	B-e0	T	drug
is	VBZ	be	O	O	NONE
predominantly	RB	predominantly	O	O	NONE
metabolized	VBN	metabolize	O	O	NONE
by	IN	by	O	O	NONE
the	DT	the	O	O	NONE
cytochrome	NN	cytochrome	B-e1	O	drug
P450	NN	p450	I-e1	O	drug
isozyme	NN	isozyme	O	O	NONE
CYP2C9	NN	cyp2c9	O	O	NONE
(	(	(	O	O	NONE
70	CD	70	O	O	NONE
%	NN	%	O	O	NONE
)	)	)	O	O	NONE
and	CC	and	O	O	NONE
to	TO	to	O	O	NONE
a	DT	a	O	O	NONE
lesser	JJR	lesser	O	O	NONE
extent	NN	extent	O	O	NONE
CYP3A4	NN	cyp3a4	B-e2	T	drug
(	(	(	O	O	NONE
30%).	NN	30%).	O	O	NONE

NO

Sentence: DrugDDI.d249.s0
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
drug	NN	drug	O	O	NONE
metabolism	NN	metabolism	O	O	NONE
studies	NNS	study	O	O	NONE
indicate	VBP	indicate	O	O	NONE
that	IN	that	O	O	NONE
Starlix	NN	starlix	B-e0	O	drug
is	VBZ	be	O	O	NONE
predominantly	RB	predominantly	O	O	NONE
metabolized	VBN	metabolize	O	O	NONE
by	IN	by	O	O	NONE
the	DT	the	O	O	NONE
cytochrome	NN	cytochrome	B-e1	T	drug
P450	NN	p450	I-e1	T	drug
isozyme	NN	isozyme	O	O	NONE
CYP2C9	NN	cyp2c9	O	O	NONE
(	(	(	O	O	NONE
70	CD	70	O	O	NONE
%	NN	%	O	O	NONE
)	)	)	O	O	NONE
and	CC	and	O	O	NONE
to	TO	to	O	O	NONE
a	DT	a	O	O	NONE
lesser	JJR	lesser	O	O	NONE
extent	NN	extent	O	O	NONE
CYP3A4	NN	cyp3a4	B-e2	T	drug
(	(	(	O	O	NONE
30%).	NN	30%).	O	O	NONE

NO

Sentence: DrugDDI.d249.s1
Starlix	NN	starlix	B-e0	T	drug
is	VBZ	be	O	O	NONE
a	DT	a	O	O	NONE
potential	JJ	potential	O	O	NONE
inhibitor	NN	inhibitor	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
CYP2C9	NN	cyp2c9	B-e1	T	drug
isoenzyme	NN	isoenzyme	I-e1	T	drug
in	FW	in	O	O	NONE
vivo	FW	vivo	O	O	NONE
as	IN	as	O	O	NONE
indicated	VBN	indicate	O	O	NONE
by	IN	by	O	O	NONE
its	PRP$	its	O	O	NONE
ability	NN	ability	O	O	NONE
to	TO	to	O	O	NONE
inhibit	VB	inhibit	O	O	NONE
the	DT	the	O	O	NONE
in	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
metabolism	NN	metabolism	O	O	NONE
of	IN	of	O	O	NONE
tolbutamide	NN	tolbutamide	B-e2	O	drug
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d249.s1
Starlix	NN	starlix	B-e0	T	drug
is	VBZ	be	O	O	NONE
a	DT	a	O	O	NONE
potential	JJ	potential	O	O	NONE
inhibitor	NN	inhibitor	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
CYP2C9	NN	cyp2c9	B-e1	O	drug
isoenzyme	NN	isoenzyme	I-e1	O	drug
in	FW	in	O	O	NONE
vivo	FW	vivo	O	O	NONE
as	IN	as	O	O	NONE
indicated	VBN	indicate	O	O	NONE
by	IN	by	O	O	NONE
its	PRP$	its	O	O	NONE
ability	NN	ability	O	O	NONE
to	TO	to	O	O	NONE
inhibit	VB	inhibit	O	O	NONE
the	DT	the	O	O	NONE
in	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
metabolism	NN	metabolism	O	O	NONE
of	IN	of	O	O	NONE
tolbutamide	NN	tolbutamide	B-e2	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s1
Starlix	NN	starlix	B-e0	O	drug
is	VBZ	be	O	O	NONE
a	DT	a	O	O	NONE
potential	JJ	potential	O	O	NONE
inhibitor	NN	inhibitor	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
CYP2C9	NN	cyp2c9	B-e1	T	drug
isoenzyme	NN	isoenzyme	I-e1	T	drug
in	FW	in	O	O	NONE
vivo	FW	vivo	O	O	NONE
as	IN	as	O	O	NONE
indicated	VBN	indicate	O	O	NONE
by	IN	by	O	O	NONE
its	PRP$	its	O	O	NONE
ability	NN	ability	O	O	NONE
to	TO	to	O	O	NONE
inhibit	VB	inhibit	O	O	NONE
the	DT	the	O	O	NONE
in	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
metabolism	NN	metabolism	O	O	NONE
of	IN	of	O	O	NONE
tolbutamide	NN	tolbutamide	B-e2	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s3
Glyburide	NN	glyburide	B-e0	T	drug
:	:	:	O	O	NONE
In	IN	in	O	O	NONE
a	DT	a	O	O	NONE
randomized	JJ	randomized	O	O	NONE
,	,	,	O	O	NONE
multiple-dose	JJ	multiple-dose	O	O	NONE
crossover	NN	crossover	O	O	NONE
study	NN	study	O	O	NONE
,	,	,	O	O	NONE
patients	NNS	patient	O	O	NONE
with	IN	with	O	O	NONE
Type	NN	type	O	O	NONE
2	CD	2	O	O	NONE
diabetes	NNS	diabetes	O	O	NONE
were	VBD	be	O	O	NONE
administered	VBN	administer	O	O	NONE
120	CD	120	O	O	NONE
mg	NN	mg	O	O	NONE
Starlix	NN	starlix	B-e1	T	drug
three	CD	three	O	O	NONE
times	NNS	time	O	O	NONE
a	DT	a	O	O	NONE
day	NN	day	O	O	NONE
before	IN	before	O	O	NONE
meals	NN	meal	O	O	NONE
for	IN	for	O	O	NONE
1	CD	1	O	O	NONE
day	NN	day	O	O	NONE
in	IN	in	O	O	NONE
combination	NN	combination	O	O	NONE
with	IN	with	O	O	NONE
glyburide	NN	glyburide	B-e2	O	drug
10	CD	10	O	O	NONE
mg	NN	mg	O	O	NONE
daily	RB	daily	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s3
Glyburide	NN	glyburide	B-e0	T	drug
:	:	:	O	O	NONE
In	IN	in	O	O	NONE
a	DT	a	O	O	NONE
randomized	JJ	randomized	O	O	NONE
,	,	,	O	O	NONE
multiple-dose	JJ	multiple-dose	O	O	NONE
crossover	NN	crossover	O	O	NONE
study	NN	study	O	O	NONE
,	,	,	O	O	NONE
patients	NNS	patient	O	O	NONE
with	IN	with	O	O	NONE
Type	NN	type	O	O	NONE
2	CD	2	O	O	NONE
diabetes	NNS	diabetes	O	O	NONE
were	VBD	be	O	O	NONE
administered	VBN	administer	O	O	NONE
120	CD	120	O	O	NONE
mg	NN	mg	O	O	NONE
Starlix	NN	starlix	B-e1	O	drug
three	CD	three	O	O	NONE
times	NNS	time	O	O	NONE
a	DT	a	O	O	NONE
day	NN	day	O	O	NONE
before	IN	before	O	O	NONE
meals	NN	meal	O	O	NONE
for	IN	for	O	O	NONE
1	CD	1	O	O	NONE
day	NN	day	O	O	NONE
in	IN	in	O	O	NONE
combination	NN	combination	O	O	NONE
with	IN	with	O	O	NONE
glyburide	NN	glyburide	B-e2	T	drug
10	CD	10	O	O	NONE
mg	NN	mg	O	O	NONE
daily	RB	daily	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s3
Glyburide	NN	glyburide	B-e0	O	drug
:	:	:	O	O	NONE
In	IN	in	O	O	NONE
a	DT	a	O	O	NONE
randomized	JJ	randomized	O	O	NONE
,	,	,	O	O	NONE
multiple-dose	JJ	multiple-dose	O	O	NONE
crossover	NN	crossover	O	O	NONE
study	NN	study	O	O	NONE
,	,	,	O	O	NONE
patients	NNS	patient	O	O	NONE
with	IN	with	O	O	NONE
Type	NN	type	O	O	NONE
2	CD	2	O	O	NONE
diabetes	NNS	diabetes	O	O	NONE
were	VBD	be	O	O	NONE
administered	VBN	administer	O	O	NONE
120	CD	120	O	O	NONE
mg	NN	mg	O	O	NONE
Starlix	NN	starlix	B-e1	T	drug
three	CD	three	O	O	NONE
times	NNS	time	O	O	NONE
a	DT	a	O	O	NONE
day	NN	day	O	O	NONE
before	IN	before	O	O	NONE
meals	NN	meal	O	O	NONE
for	IN	for	O	O	NONE
1	CD	1	O	O	NONE
day	NN	day	O	O	NONE
in	IN	in	O	O	NONE
combination	NN	combination	O	O	NONE
with	IN	with	O	O	NONE
glyburide	NN	glyburide	B-e2	T	drug
10	CD	10	O	O	NONE
mg	NN	mg	O	O	NONE
daily	RB	daily	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s5
Metformin	NN	metformin	B-e0	T	drug
:	:	:	O	O	NONE
When	WRB	when	O	O	NONE
Starlix	NN	starlix	B-e1	T	drug
120	CD	120	O	O	NONE
mg	NN	mg	O	O	NONE
three	CD	three	O	O	NONE
times	NNS	time	O	O	NONE
daily	RB	daily	O	O	NONE
before	IN	before	O	O	NONE
meals	NN	meal	O	O	NONE
was	VBD	be	O	O	NONE
administered	VBN	administer	O	O	NONE
in	IN	in	O	O	NONE
combination	NN	combination	O	O	NONE
with	IN	with	O	O	NONE
metformin	NN	metformin	B-e2	O	drug
500	CD	500	I-e2	O	drug
mg	NN	mg	I-e2	O	drug
three	CD	three	O	O	NONE
times	NNS	time	O	O	NONE
daily	JJ	daily	O	O	NONE
to	TO	to	O	O	NONE
patients	NNS	patient	O	O	NONE
with	IN	with	O	O	NONE
Type	NN	type	B-e3	O	DISO
2	CD	2	I-e3	O	DISO
diabetes	NNS	diabetes	I-e3	O	DISO
,	,	,	O	O	NONE
there	EX	there	O	O	NONE
were	VBD	be	O	O	NONE
no	DT	no	O	O	NONE
clinically	RB	clinically	O	O	NONE
relevant	JJ	relevant	O	O	NONE
changes	NNS	change	O	O	NONE
in	IN	in	O	O	NONE
the	DT	the	O	O	NONE
pharmacokinetics	NNS	pharmacokinetic	O	O	NONE
of	IN	of	O	O	NONE
either	DT	either	O	O	NONE
agent	NN	agent	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s5
Metformin	NN	metformin	B-e0	T	drug
:	:	:	O	O	NONE
When	WRB	when	O	O	NONE
Starlix	NN	starlix	B-e1	O	drug
120	CD	120	O	O	NONE
mg	NN	mg	O	O	NONE
three	CD	three	O	O	NONE
times	NNS	time	O	O	NONE
daily	RB	daily	O	O	NONE
before	IN	before	O	O	NONE
meals	NN	meal	O	O	NONE
was	VBD	be	O	O	NONE
administered	VBN	administer	O	O	NONE
in	IN	in	O	O	NONE
combination	NN	combination	O	O	NONE
with	IN	with	O	O	NONE
metformin	NN	metformin	B-e2	T	drug
500	CD	500	I-e2	T	drug
mg	NN	mg	I-e2	T	drug
three	CD	three	O	O	NONE
times	NNS	time	O	O	NONE
daily	JJ	daily	O	O	NONE
to	TO	to	O	O	NONE
patients	NNS	patient	O	O	NONE
with	IN	with	O	O	NONE
Type	NN	type	B-e3	O	DISO
2	CD	2	I-e3	O	DISO
diabetes	NNS	diabetes	I-e3	O	DISO
,	,	,	O	O	NONE
there	EX	there	O	O	NONE
were	VBD	be	O	O	NONE
no	DT	no	O	O	NONE
clinically	RB	clinically	O	O	NONE
relevant	JJ	relevant	O	O	NONE
changes	NNS	change	O	O	NONE
in	IN	in	O	O	NONE
the	DT	the	O	O	NONE
pharmacokinetics	NNS	pharmacokinetic	O	O	NONE
of	IN	of	O	O	NONE
either	DT	either	O	O	NONE
agent	NN	agent	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s5
Metformin	NN	metformin	B-e0	O	drug
:	:	:	O	O	NONE
When	WRB	when	O	O	NONE
Starlix	NN	starlix	B-e1	T	drug
120	CD	120	O	O	NONE
mg	NN	mg	O	O	NONE
three	CD	three	O	O	NONE
times	NNS	time	O	O	NONE
daily	RB	daily	O	O	NONE
before	IN	before	O	O	NONE
meals	NN	meal	O	O	NONE
was	VBD	be	O	O	NONE
administered	VBN	administer	O	O	NONE
in	IN	in	O	O	NONE
combination	NN	combination	O	O	NONE
with	IN	with	O	O	NONE
metformin	NN	metformin	B-e2	T	drug
500	CD	500	I-e2	T	drug
mg	NN	mg	I-e2	T	drug
three	CD	three	O	O	NONE
times	NNS	time	O	O	NONE
daily	JJ	daily	O	O	NONE
to	TO	to	O	O	NONE
patients	NNS	patient	O	O	NONE
with	IN	with	O	O	NONE
Type	NN	type	B-e3	O	DISO
2	CD	2	I-e3	O	DISO
diabetes	NNS	diabetes	I-e3	O	DISO
,	,	,	O	O	NONE
there	EX	there	O	O	NONE
were	VBD	be	O	O	NONE
no	DT	no	O	O	NONE
clinically	RB	clinically	O	O	NONE
relevant	JJ	relevant	O	O	NONE
changes	NNS	change	O	O	NONE
in	IN	in	O	O	NONE
the	DT	the	O	O	NONE
pharmacokinetics	NNS	pharmacokinetic	O	O	NONE
of	IN	of	O	O	NONE
either	DT	either	O	O	NONE
agent	NN	agent	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s6
Digoxin	NN	digoxin	B-e0	T	drug
:	:	:	O	O	NONE
When	WRB	when	O	O	NONE
Starlix	NN	starlix	B-e1	T	drug
120	CD	120	O	O	NONE
mg	NN	mg	O	O	NONE
before	IN	before	O	O	NONE
meals	NN	meal	O	O	NONE
was	VBD	be	O	O	NONE
administered	VBN	administer	O	O	NONE
in	IN	in	O	O	NONE
combination	NN	combination	O	O	NONE
with	IN	with	O	O	NONE
a	DT	a	O	O	NONE
single	JJ	single	O	O	NONE
1-mg	JJ	1-mg	O	O	NONE
dose	NN	dose	O	O	NONE
of	IN	of	O	O	NONE
digoxin	NN	digoxin	B-e2	O	drug
to	TO	to	O	O	NONE
healthy	JJ	healthy	O	O	NONE
volunteers	NNS	volunteer	O	O	NONE
,	,	,	O	O	NONE
there	EX	there	O	O	NONE
were	VBD	be	O	O	NONE
no	DT	no	O	O	NONE
clinically	RB	clinically	O	O	NONE
relevant	JJ	relevant	O	O	NONE
changes	NNS	change	O	O	NONE
in	IN	in	O	O	NONE
the	DT	the	O	O	NONE
pharmacokinetics	NNS	pharmacokinetic	O	O	NONE
of	IN	of	O	O	NONE
either	DT	either	O	O	NONE
agent	NN	agent	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s6
Digoxin	NN	digoxin	B-e0	T	drug
:	:	:	O	O	NONE
When	WRB	when	O	O	NONE
Starlix	NN	starlix	B-e1	O	drug
120	CD	120	O	O	NONE
mg	NN	mg	O	O	NONE
before	IN	before	O	O	NONE
meals	NN	meal	O	O	NONE
was	VBD	be	O	O	NONE
administered	VBN	administer	O	O	NONE
in	IN	in	O	O	NONE
combination	NN	combination	O	O	NONE
with	IN	with	O	O	NONE
a	DT	a	O	O	NONE
single	JJ	single	O	O	NONE
1-mg	JJ	1-mg	O	O	NONE
dose	NN	dose	O	O	NONE
of	IN	of	O	O	NONE
digoxin	NN	digoxin	B-e2	T	drug
to	TO	to	O	O	NONE
healthy	JJ	healthy	O	O	NONE
volunteers	NNS	volunteer	O	O	NONE
,	,	,	O	O	NONE
there	EX	there	O	O	NONE
were	VBD	be	O	O	NONE
no	DT	no	O	O	NONE
clinically	RB	clinically	O	O	NONE
relevant	JJ	relevant	O	O	NONE
changes	NNS	change	O	O	NONE
in	IN	in	O	O	NONE
the	DT	the	O	O	NONE
pharmacokinetics	NNS	pharmacokinetic	O	O	NONE
of	IN	of	O	O	NONE
either	DT	either	O	O	NONE
agent	NN	agent	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s6
Digoxin	NN	digoxin	B-e0	O	drug
:	:	:	O	O	NONE
When	WRB	when	O	O	NONE
Starlix	NN	starlix	B-e1	T	drug
120	CD	120	O	O	NONE
mg	NN	mg	O	O	NONE
before	IN	before	O	O	NONE
meals	NN	meal	O	O	NONE
was	VBD	be	O	O	NONE
administered	VBN	administer	O	O	NONE
in	IN	in	O	O	NONE
combination	NN	combination	O	O	NONE
with	IN	with	O	O	NONE
a	DT	a	O	O	NONE
single	JJ	single	O	O	NONE
1-mg	JJ	1-mg	O	O	NONE
dose	NN	dose	O	O	NONE
of	IN	of	O	O	NONE
digoxin	NN	digoxin	B-e2	T	drug
to	TO	to	O	O	NONE
healthy	JJ	healthy	O	O	NONE
volunteers	NNS	volunteer	O	O	NONE
,	,	,	O	O	NONE
there	EX	there	O	O	NONE
were	VBD	be	O	O	NONE
no	DT	no	O	O	NONE
clinically	RB	clinically	O	O	NONE
relevant	JJ	relevant	O	O	NONE
changes	NNS	change	O	O	NONE
in	IN	in	O	O	NONE
the	DT	the	O	O	NONE
pharmacokinetics	NNS	pharmacokinetic	O	O	NONE
of	IN	of	O	O	NONE
either	DT	either	O	O	NONE
agent	NN	agent	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s7
Warfarin	NN	warfarin	B-e0	T	drug
:	:	:	O	O	NONE
When	WRB	when	O	O	NONE
healthy	JJ	healthy	O	O	NONE
subjects	NNS	subject	O	O	NONE
were	VBD	be	O	O	NONE
administered	VBN	administer	O	O	NONE
Starlix	NN	starlix	B-e1	T	drug
120	CD	120	O	O	NONE
mg	NN	mg	O	O	NONE
three	CD	three	O	O	NONE
times	NNS	time	O	O	NONE
daily	RB	daily	O	O	NONE
before	IN	before	O	O	NONE
meals	NN	meal	O	O	NONE
for	IN	for	O	O	NONE
four	CD	four	O	O	NONE
days	NNS	day	O	O	NONE
in	IN	in	O	O	NONE
combination	NN	combination	O	O	NONE
with	IN	with	O	O	NONE
a	DT	a	O	O	NONE
single	JJ	single	O	O	NONE
dose	NN	dose	O	O	NONE
of	IN	of	O	O	NONE
warfarin	NN	warfarin	B-e2	O	drug
30	CD	30	O	O	NONE
mg	NN	mg	O	O	NONE
on	IN	on	O	O	NONE
day	NN	day	O	O	NONE
2	CD	2	O	O	NONE
,	,	,	O	O	NONE
there	EX	there	O	O	NONE
were	VBD	be	O	O	NONE
no	DT	no	O	O	NONE
alterations	NNS	alteration	O	O	NONE
in	IN	in	O	O	NONE
the	DT	the	O	O	NONE
pharmacokinetics	NNS	pharmacokinetic	O	O	NONE
of	IN	of	O	O	NONE
either	DT	either	O	O	NONE
agent	NN	agent	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s7
Warfarin	NN	warfarin	B-e0	T	drug
:	:	:	O	O	NONE
When	WRB	when	O	O	NONE
healthy	JJ	healthy	O	O	NONE
subjects	NNS	subject	O	O	NONE
were	VBD	be	O	O	NONE
administered	VBN	administer	O	O	NONE
Starlix	NN	starlix	B-e1	O	drug
120	CD	120	O	O	NONE
mg	NN	mg	O	O	NONE
three	CD	three	O	O	NONE
times	NNS	time	O	O	NONE
daily	RB	daily	O	O	NONE
before	IN	before	O	O	NONE
meals	NN	meal	O	O	NONE
for	IN	for	O	O	NONE
four	CD	four	O	O	NONE
days	NNS	day	O	O	NONE
in	IN	in	O	O	NONE
combination	NN	combination	O	O	NONE
with	IN	with	O	O	NONE
a	DT	a	O	O	NONE
single	JJ	single	O	O	NONE
dose	NN	dose	O	O	NONE
of	IN	of	O	O	NONE
warfarin	NN	warfarin	B-e2	T	drug
30	CD	30	O	O	NONE
mg	NN	mg	O	O	NONE
on	IN	on	O	O	NONE
day	NN	day	O	O	NONE
2	CD	2	O	O	NONE
,	,	,	O	O	NONE
there	EX	there	O	O	NONE
were	VBD	be	O	O	NONE
no	DT	no	O	O	NONE
alterations	NNS	alteration	O	O	NONE
in	IN	in	O	O	NONE
the	DT	the	O	O	NONE
pharmacokinetics	NNS	pharmacokinetic	O	O	NONE
of	IN	of	O	O	NONE
either	DT	either	O	O	NONE
agent	NN	agent	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s7
Warfarin	NN	warfarin	B-e0	O	drug
:	:	:	O	O	NONE
When	WRB	when	O	O	NONE
healthy	JJ	healthy	O	O	NONE
subjects	NNS	subject	O	O	NONE
were	VBD	be	O	O	NONE
administered	VBN	administer	O	O	NONE
Starlix	NN	starlix	B-e1	T	drug
120	CD	120	O	O	NONE
mg	NN	mg	O	O	NONE
three	CD	three	O	O	NONE
times	NNS	time	O	O	NONE
daily	RB	daily	O	O	NONE
before	IN	before	O	O	NONE
meals	NN	meal	O	O	NONE
for	IN	for	O	O	NONE
four	CD	four	O	O	NONE
days	NNS	day	O	O	NONE
in	IN	in	O	O	NONE
combination	NN	combination	O	O	NONE
with	IN	with	O	O	NONE
a	DT	a	O	O	NONE
single	JJ	single	O	O	NONE
dose	NN	dose	O	O	NONE
of	IN	of	O	O	NONE
warfarin	NN	warfarin	B-e2	T	drug
30	CD	30	O	O	NONE
mg	NN	mg	O	O	NONE
on	IN	on	O	O	NONE
day	NN	day	O	O	NONE
2	CD	2	O	O	NONE
,	,	,	O	O	NONE
there	EX	there	O	O	NONE
were	VBD	be	O	O	NONE
no	DT	no	O	O	NONE
alterations	NNS	alteration	O	O	NONE
in	IN	in	O	O	NONE
the	DT	the	O	O	NONE
pharmacokinetics	NNS	pharmacokinetic	O	O	NONE
of	IN	of	O	O	NONE
either	DT	either	O	O	NONE
agent	NN	agent	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s9
Diclofenac	NN	diclofenac	B-e0	T	drug
:	:	:	O	O	NONE
Administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
morning	NN	morning	O	O	NONE
and	CC	and	O	O	NONE
lunch	NN	lunch	O	O	NONE
doses	NNS	dose	O	O	NONE
of	IN	of	O	O	NONE
Starlix	NN	starlix	B-e1	T	drug
120	CD	120	O	O	NONE
mg	NN	mg	O	O	NONE
in	IN	in	O	O	NONE
combination	NN	combination	O	O	NONE
with	IN	with	O	O	NONE
a	DT	a	O	O	NONE
single	JJ	single	O	O	NONE
75-mg	NN	75-mg	O	O	NONE
dose	NN	dose	O	O	NONE
of	IN	of	O	O	NONE
diclofenac	NN	diclofenac	B-e2	O	drug
in	IN	in	O	O	NONE
healthy	JJ	healthy	O	O	NONE
volunteers	NNS	volunteer	O	O	NONE
resulted	VBD	result	O	O	NONE
in	IN	in	O	O	NONE
no	DT	no	O	O	NONE
significant	JJ	significant	O	O	NONE
changes	NNS	change	O	O	NONE
to	TO	to	O	O	NONE
the	DT	the	O	O	NONE
pharmacokinetics	NNS	pharmacokinetic	O	O	NONE
of	IN	of	O	O	NONE
either	DT	either	O	O	NONE
agent	NN	agent	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s9
Diclofenac	NN	diclofenac	B-e0	T	drug
:	:	:	O	O	NONE
Administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
morning	NN	morning	O	O	NONE
and	CC	and	O	O	NONE
lunch	NN	lunch	O	O	NONE
doses	NNS	dose	O	O	NONE
of	IN	of	O	O	NONE
Starlix	NN	starlix	B-e1	O	drug
120	CD	120	O	O	NONE
mg	NN	mg	O	O	NONE
in	IN	in	O	O	NONE
combination	NN	combination	O	O	NONE
with	IN	with	O	O	NONE
a	DT	a	O	O	NONE
single	JJ	single	O	O	NONE
75-mg	NN	75-mg	O	O	NONE
dose	NN	dose	O	O	NONE
of	IN	of	O	O	NONE
diclofenac	NN	diclofenac	B-e2	T	drug
in	IN	in	O	O	NONE
healthy	JJ	healthy	O	O	NONE
volunteers	NNS	volunteer	O	O	NONE
resulted	VBD	result	O	O	NONE
in	IN	in	O	O	NONE
no	DT	no	O	O	NONE
significant	JJ	significant	O	O	NONE
changes	NNS	change	O	O	NONE
to	TO	to	O	O	NONE
the	DT	the	O	O	NONE
pharmacokinetics	NNS	pharmacokinetic	O	O	NONE
of	IN	of	O	O	NONE
either	DT	either	O	O	NONE
agent	NN	agent	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s9
Diclofenac	NN	diclofenac	B-e0	O	drug
:	:	:	O	O	NONE
Administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
morning	NN	morning	O	O	NONE
and	CC	and	O	O	NONE
lunch	NN	lunch	O	O	NONE
doses	NNS	dose	O	O	NONE
of	IN	of	O	O	NONE
Starlix	NN	starlix	B-e1	T	drug
120	CD	120	O	O	NONE
mg	NN	mg	O	O	NONE
in	IN	in	O	O	NONE
combination	NN	combination	O	O	NONE
with	IN	with	O	O	NONE
a	DT	a	O	O	NONE
single	JJ	single	O	O	NONE
75-mg	NN	75-mg	O	O	NONE
dose	NN	dose	O	O	NONE
of	IN	of	O	O	NONE
diclofenac	NN	diclofenac	B-e2	T	drug
in	IN	in	O	O	NONE
healthy	JJ	healthy	O	O	NONE
volunteers	NNS	volunteer	O	O	NONE
resulted	VBD	result	O	O	NONE
in	IN	in	O	O	NONE
no	DT	no	O	O	NONE
significant	JJ	significant	O	O	NONE
changes	NNS	change	O	O	NONE
to	TO	to	O	O	NONE
the	DT	the	O	O	NONE
pharmacokinetics	NNS	pharmacokinetic	O	O	NONE
of	IN	of	O	O	NONE
either	DT	either	O	O	NONE
agent	NN	agent	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s10
Nateglinide	NN	nateglinide	B-e0	T	drug
is	VBZ	be	O	O	NONE
highly	RB	highly	O	O	NONE
bound	VBN	bind	O	O	NONE
to	TO	to	O	O	NONE
plasma	NN	plasma	B-e1	T	drug
proteins	NNS	protein	I-e1	T	drug
(	(	(	O	O	NONE
98	CD	98	O	O	NONE
%	NN	%	O	O	NONE
)	)	)	O	O	NONE
,	,	,	O	O	NONE
mainly	RB	mainly	O	O	NONE
albumin	NN	albumin	B-e2	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s10
Nateglinide	NN	nateglinide	B-e0	T	drug
is	VBZ	be	O	O	NONE
highly	RB	highly	O	O	NONE
bound	VBN	bind	O	O	NONE
to	TO	to	O	O	NONE
plasma	NN	plasma	B-e1	O	drug
proteins	NNS	protein	I-e1	O	drug
(	(	(	O	O	NONE
98	CD	98	O	O	NONE
%	NN	%	O	O	NONE
)	)	)	O	O	NONE
,	,	,	O	O	NONE
mainly	RB	mainly	O	O	NONE
albumin	NN	albumin	B-e2	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s10
Nateglinide	NN	nateglinide	B-e0	O	drug
is	VBZ	be	O	O	NONE
highly	RB	highly	O	O	NONE
bound	VBN	bind	O	O	NONE
to	TO	to	O	O	NONE
plasma	NN	plasma	B-e1	T	drug
proteins	NNS	protein	I-e1	T	drug
(	(	(	O	O	NONE
98	CD	98	O	O	NONE
%	NN	%	O	O	NONE
)	)	)	O	O	NONE
,	,	,	O	O	NONE
mainly	RB	mainly	O	O	NONE
albumin	NN	albumin	B-e2	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s11
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
displacement	NN	displacement	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
highly	RB	highly	O	O	NONE
protein	NN	protein	B-e0	T	drug
-bound	JJ	-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
furosemide	NN	furosemide	B-e1	T	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
captopril	NN	captopril	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
pravastatin	NN	pravastatin	B-e5	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e6	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e7	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e8	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e9	O	drug
acid	NN	acid	I-e9	O	drug
,	,	,	O	O	NONE
tolbutamide	NN	tolbutamide	B-e10	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
metformin	NN	metformin	B-e11	O	drug
showed	VBD	show	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
extent	NN	extent	O	O	NONE
of	IN	of	O	O	NONE
nateglinide	JJ	nateglinide	B-e12	O	drug
protein	NN	protein	O	O	NONE
binding	NN	binding	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s11
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
displacement	NN	displacement	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
highly	RB	highly	O	O	NONE
protein	NN	protein	B-e0	T	drug
-bound	JJ	-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
furosemide	NN	furosemide	B-e1	O	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e2	T	drug
,	,	,	O	O	NONE
captopril	NN	captopril	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
pravastatin	NN	pravastatin	B-e5	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e6	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e7	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e8	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e9	O	drug
acid	NN	acid	I-e9	O	drug
,	,	,	O	O	NONE
tolbutamide	NN	tolbutamide	B-e10	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
metformin	NN	metformin	B-e11	O	drug
showed	VBD	show	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
extent	NN	extent	O	O	NONE
of	IN	of	O	O	NONE
nateglinide	JJ	nateglinide	B-e12	O	drug
protein	NN	protein	O	O	NONE
binding	NN	binding	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s11
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
displacement	NN	displacement	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
highly	RB	highly	O	O	NONE
protein	NN	protein	B-e0	T	drug
-bound	JJ	-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
furosemide	NN	furosemide	B-e1	O	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
captopril	NN	captopril	B-e3	T	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
pravastatin	NN	pravastatin	B-e5	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e6	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e7	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e8	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e9	O	drug
acid	NN	acid	I-e9	O	drug
,	,	,	O	O	NONE
tolbutamide	NN	tolbutamide	B-e10	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
metformin	NN	metformin	B-e11	O	drug
showed	VBD	show	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
extent	NN	extent	O	O	NONE
of	IN	of	O	O	NONE
nateglinide	JJ	nateglinide	B-e12	O	drug
protein	NN	protein	O	O	NONE
binding	NN	binding	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s11
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
displacement	NN	displacement	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
highly	RB	highly	O	O	NONE
protein	NN	protein	B-e0	T	drug
-bound	JJ	-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
furosemide	NN	furosemide	B-e1	O	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
captopril	NN	captopril	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	T	drug
,	,	,	O	O	NONE
pravastatin	NN	pravastatin	B-e5	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e6	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e7	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e8	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e9	O	drug
acid	NN	acid	I-e9	O	drug
,	,	,	O	O	NONE
tolbutamide	NN	tolbutamide	B-e10	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
metformin	NN	metformin	B-e11	O	drug
showed	VBD	show	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
extent	NN	extent	O	O	NONE
of	IN	of	O	O	NONE
nateglinide	JJ	nateglinide	B-e12	O	drug
protein	NN	protein	O	O	NONE
binding	NN	binding	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s11
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
displacement	NN	displacement	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
highly	RB	highly	O	O	NONE
protein	NN	protein	B-e0	T	drug
-bound	JJ	-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
furosemide	NN	furosemide	B-e1	O	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
captopril	NN	captopril	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
pravastatin	NN	pravastatin	B-e5	T	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e6	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e7	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e8	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e9	O	drug
acid	NN	acid	I-e9	O	drug
,	,	,	O	O	NONE
tolbutamide	NN	tolbutamide	B-e10	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
metformin	NN	metformin	B-e11	O	drug
showed	VBD	show	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
extent	NN	extent	O	O	NONE
of	IN	of	O	O	NONE
nateglinide	JJ	nateglinide	B-e12	O	drug
protein	NN	protein	O	O	NONE
binding	NN	binding	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s11
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
displacement	NN	displacement	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
highly	RB	highly	O	O	NONE
protein	NN	protein	B-e0	T	drug
-bound	JJ	-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
furosemide	NN	furosemide	B-e1	O	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
captopril	NN	captopril	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
pravastatin	NN	pravastatin	B-e5	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e6	T	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e7	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e8	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e9	O	drug
acid	NN	acid	I-e9	O	drug
,	,	,	O	O	NONE
tolbutamide	NN	tolbutamide	B-e10	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
metformin	NN	metformin	B-e11	O	drug
showed	VBD	show	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
extent	NN	extent	O	O	NONE
of	IN	of	O	O	NONE
nateglinide	JJ	nateglinide	B-e12	O	drug
protein	NN	protein	O	O	NONE
binding	NN	binding	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s11
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
displacement	NN	displacement	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
highly	RB	highly	O	O	NONE
protein	NN	protein	B-e0	T	drug
-bound	JJ	-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
furosemide	NN	furosemide	B-e1	O	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
captopril	NN	captopril	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
pravastatin	NN	pravastatin	B-e5	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e6	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e7	T	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e8	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e9	O	drug
acid	NN	acid	I-e9	O	drug
,	,	,	O	O	NONE
tolbutamide	NN	tolbutamide	B-e10	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
metformin	NN	metformin	B-e11	O	drug
showed	VBD	show	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
extent	NN	extent	O	O	NONE
of	IN	of	O	O	NONE
nateglinide	JJ	nateglinide	B-e12	O	drug
protein	NN	protein	O	O	NONE
binding	NN	binding	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s11
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
displacement	NN	displacement	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
highly	RB	highly	O	O	NONE
protein	NN	protein	B-e0	T	drug
-bound	JJ	-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
furosemide	NN	furosemide	B-e1	O	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
captopril	NN	captopril	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
pravastatin	NN	pravastatin	B-e5	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e6	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e7	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e8	T	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e9	O	drug
acid	NN	acid	I-e9	O	drug
,	,	,	O	O	NONE
tolbutamide	NN	tolbutamide	B-e10	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
metformin	NN	metformin	B-e11	O	drug
showed	VBD	show	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
extent	NN	extent	O	O	NONE
of	IN	of	O	O	NONE
nateglinide	JJ	nateglinide	B-e12	O	drug
protein	NN	protein	O	O	NONE
binding	NN	binding	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s11
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
displacement	NN	displacement	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
highly	RB	highly	O	O	NONE
protein	NN	protein	B-e0	T	drug
-bound	JJ	-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
furosemide	NN	furosemide	B-e1	O	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
captopril	NN	captopril	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
pravastatin	NN	pravastatin	B-e5	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e6	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e7	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e8	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e9	T	drug
acid	NN	acid	I-e9	T	drug
,	,	,	O	O	NONE
tolbutamide	NN	tolbutamide	B-e10	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
metformin	NN	metformin	B-e11	O	drug
showed	VBD	show	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
extent	NN	extent	O	O	NONE
of	IN	of	O	O	NONE
nateglinide	JJ	nateglinide	B-e12	O	drug
protein	NN	protein	O	O	NONE
binding	NN	binding	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s11
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
displacement	NN	displacement	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
highly	RB	highly	O	O	NONE
protein	NN	protein	B-e0	T	drug
-bound	JJ	-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
furosemide	NN	furosemide	B-e1	O	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
captopril	NN	captopril	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
pravastatin	NN	pravastatin	B-e5	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e6	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e7	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e8	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e9	O	drug
acid	NN	acid	I-e9	O	drug
,	,	,	O	O	NONE
tolbutamide	NN	tolbutamide	B-e10	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
metformin	NN	metformin	B-e11	O	drug
showed	VBD	show	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
extent	NN	extent	O	O	NONE
of	IN	of	O	O	NONE
nateglinide	JJ	nateglinide	B-e12	O	drug
protein	NN	protein	O	O	NONE
binding	NN	binding	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s11
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
displacement	NN	displacement	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
highly	RB	highly	O	O	NONE
protein	NN	protein	B-e0	T	drug
-bound	JJ	-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
furosemide	NN	furosemide	B-e1	O	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
captopril	NN	captopril	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
pravastatin	NN	pravastatin	B-e5	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e6	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e7	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e8	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e9	O	drug
acid	NN	acid	I-e9	O	drug
,	,	,	O	O	NONE
tolbutamide	NN	tolbutamide	B-e10	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
metformin	NN	metformin	B-e11	T	drug
showed	VBD	show	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
extent	NN	extent	O	O	NONE
of	IN	of	O	O	NONE
nateglinide	JJ	nateglinide	B-e12	O	drug
protein	NN	protein	O	O	NONE
binding	NN	binding	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s11
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
displacement	NN	displacement	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
highly	RB	highly	O	O	NONE
protein	NN	protein	B-e0	T	drug
-bound	JJ	-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
furosemide	NN	furosemide	B-e1	O	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
captopril	NN	captopril	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
pravastatin	NN	pravastatin	B-e5	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e6	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e7	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e8	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e9	O	drug
acid	NN	acid	I-e9	O	drug
,	,	,	O	O	NONE
tolbutamide	NN	tolbutamide	B-e10	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
metformin	NN	metformin	B-e11	O	drug
showed	VBD	show	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
extent	NN	extent	O	O	NONE
of	IN	of	O	O	NONE
nateglinide	JJ	nateglinide	B-e12	T	drug
protein	NN	protein	O	O	NONE
binding	NN	binding	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s11
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
displacement	NN	displacement	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
highly	RB	highly	O	O	NONE
protein	NN	protein	B-e0	O	drug
-bound	JJ	-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
furosemide	NN	furosemide	B-e1	T	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e2	T	drug
,	,	,	O	O	NONE
captopril	NN	captopril	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
pravastatin	NN	pravastatin	B-e5	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e6	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e7	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e8	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e9	O	drug
acid	NN	acid	I-e9	O	drug
,	,	,	O	O	NONE
tolbutamide	NN	tolbutamide	B-e10	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
metformin	NN	metformin	B-e11	O	drug
showed	VBD	show	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
extent	NN	extent	O	O	NONE
of	IN	of	O	O	NONE
nateglinide	JJ	nateglinide	B-e12	O	drug
protein	NN	protein	O	O	NONE
binding	NN	binding	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s11
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
displacement	NN	displacement	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
highly	RB	highly	O	O	NONE
protein	NN	protein	B-e0	O	drug
-bound	JJ	-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
furosemide	NN	furosemide	B-e1	T	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
captopril	NN	captopril	B-e3	T	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
pravastatin	NN	pravastatin	B-e5	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e6	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e7	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e8	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e9	O	drug
acid	NN	acid	I-e9	O	drug
,	,	,	O	O	NONE
tolbutamide	NN	tolbutamide	B-e10	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
metformin	NN	metformin	B-e11	O	drug
showed	VBD	show	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
extent	NN	extent	O	O	NONE
of	IN	of	O	O	NONE
nateglinide	JJ	nateglinide	B-e12	O	drug
protein	NN	protein	O	O	NONE
binding	NN	binding	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s11
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
displacement	NN	displacement	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
highly	RB	highly	O	O	NONE
protein	NN	protein	B-e0	O	drug
-bound	JJ	-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
furosemide	NN	furosemide	B-e1	T	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
captopril	NN	captopril	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	T	drug
,	,	,	O	O	NONE
pravastatin	NN	pravastatin	B-e5	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e6	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e7	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e8	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e9	O	drug
acid	NN	acid	I-e9	O	drug
,	,	,	O	O	NONE
tolbutamide	NN	tolbutamide	B-e10	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
metformin	NN	metformin	B-e11	O	drug
showed	VBD	show	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
extent	NN	extent	O	O	NONE
of	IN	of	O	O	NONE
nateglinide	JJ	nateglinide	B-e12	O	drug
protein	NN	protein	O	O	NONE
binding	NN	binding	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s11
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
displacement	NN	displacement	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
highly	RB	highly	O	O	NONE
protein	NN	protein	B-e0	O	drug
-bound	JJ	-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
furosemide	NN	furosemide	B-e1	T	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
captopril	NN	captopril	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
pravastatin	NN	pravastatin	B-e5	T	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e6	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e7	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e8	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e9	O	drug
acid	NN	acid	I-e9	O	drug
,	,	,	O	O	NONE
tolbutamide	NN	tolbutamide	B-e10	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
metformin	NN	metformin	B-e11	O	drug
showed	VBD	show	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
extent	NN	extent	O	O	NONE
of	IN	of	O	O	NONE
nateglinide	JJ	nateglinide	B-e12	O	drug
protein	NN	protein	O	O	NONE
binding	NN	binding	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s11
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
displacement	NN	displacement	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
highly	RB	highly	O	O	NONE
protein	NN	protein	B-e0	O	drug
-bound	JJ	-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
furosemide	NN	furosemide	B-e1	T	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
captopril	NN	captopril	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
pravastatin	NN	pravastatin	B-e5	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e6	T	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e7	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e8	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e9	O	drug
acid	NN	acid	I-e9	O	drug
,	,	,	O	O	NONE
tolbutamide	NN	tolbutamide	B-e10	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
metformin	NN	metformin	B-e11	O	drug
showed	VBD	show	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
extent	NN	extent	O	O	NONE
of	IN	of	O	O	NONE
nateglinide	JJ	nateglinide	B-e12	O	drug
protein	NN	protein	O	O	NONE
binding	NN	binding	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s11
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
displacement	NN	displacement	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
highly	RB	highly	O	O	NONE
protein	NN	protein	B-e0	O	drug
-bound	JJ	-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
furosemide	NN	furosemide	B-e1	T	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
captopril	NN	captopril	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
pravastatin	NN	pravastatin	B-e5	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e6	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e7	T	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e8	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e9	O	drug
acid	NN	acid	I-e9	O	drug
,	,	,	O	O	NONE
tolbutamide	NN	tolbutamide	B-e10	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
metformin	NN	metformin	B-e11	O	drug
showed	VBD	show	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
extent	NN	extent	O	O	NONE
of	IN	of	O	O	NONE
nateglinide	JJ	nateglinide	B-e12	O	drug
protein	NN	protein	O	O	NONE
binding	NN	binding	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s11
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
displacement	NN	displacement	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
highly	RB	highly	O	O	NONE
protein	NN	protein	B-e0	O	drug
-bound	JJ	-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
furosemide	NN	furosemide	B-e1	T	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
captopril	NN	captopril	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
pravastatin	NN	pravastatin	B-e5	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e6	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e7	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e8	T	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e9	O	drug
acid	NN	acid	I-e9	O	drug
,	,	,	O	O	NONE
tolbutamide	NN	tolbutamide	B-e10	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
metformin	NN	metformin	B-e11	O	drug
showed	VBD	show	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
extent	NN	extent	O	O	NONE
of	IN	of	O	O	NONE
nateglinide	JJ	nateglinide	B-e12	O	drug
protein	NN	protein	O	O	NONE
binding	NN	binding	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s11
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
displacement	NN	displacement	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
highly	RB	highly	O	O	NONE
protein	NN	protein	B-e0	O	drug
-bound	JJ	-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
furosemide	NN	furosemide	B-e1	T	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
captopril	NN	captopril	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
pravastatin	NN	pravastatin	B-e5	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e6	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e7	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e8	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e9	T	drug
acid	NN	acid	I-e9	T	drug
,	,	,	O	O	NONE
tolbutamide	NN	tolbutamide	B-e10	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
metformin	NN	metformin	B-e11	O	drug
showed	VBD	show	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
extent	NN	extent	O	O	NONE
of	IN	of	O	O	NONE
nateglinide	JJ	nateglinide	B-e12	O	drug
protein	NN	protein	O	O	NONE
binding	NN	binding	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s11
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
displacement	NN	displacement	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
highly	RB	highly	O	O	NONE
protein	NN	protein	B-e0	O	drug
-bound	JJ	-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
furosemide	NN	furosemide	B-e1	T	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
captopril	NN	captopril	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
pravastatin	NN	pravastatin	B-e5	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e6	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e7	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e8	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e9	O	drug
acid	NN	acid	I-e9	O	drug
,	,	,	O	O	NONE
tolbutamide	NN	tolbutamide	B-e10	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
metformin	NN	metformin	B-e11	O	drug
showed	VBD	show	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
extent	NN	extent	O	O	NONE
of	IN	of	O	O	NONE
nateglinide	JJ	nateglinide	B-e12	O	drug
protein	NN	protein	O	O	NONE
binding	NN	binding	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s11
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
displacement	NN	displacement	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
highly	RB	highly	O	O	NONE
protein	NN	protein	B-e0	O	drug
-bound	JJ	-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
furosemide	NN	furosemide	B-e1	T	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
captopril	NN	captopril	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
pravastatin	NN	pravastatin	B-e5	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e6	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e7	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e8	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e9	O	drug
acid	NN	acid	I-e9	O	drug
,	,	,	O	O	NONE
tolbutamide	NN	tolbutamide	B-e10	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
metformin	NN	metformin	B-e11	T	drug
showed	VBD	show	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
extent	NN	extent	O	O	NONE
of	IN	of	O	O	NONE
nateglinide	JJ	nateglinide	B-e12	O	drug
protein	NN	protein	O	O	NONE
binding	NN	binding	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s11
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
displacement	NN	displacement	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
highly	RB	highly	O	O	NONE
protein	NN	protein	B-e0	O	drug
-bound	JJ	-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
furosemide	NN	furosemide	B-e1	T	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
captopril	NN	captopril	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
pravastatin	NN	pravastatin	B-e5	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e6	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e7	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e8	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e9	O	drug
acid	NN	acid	I-e9	O	drug
,	,	,	O	O	NONE
tolbutamide	NN	tolbutamide	B-e10	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
metformin	NN	metformin	B-e11	O	drug
showed	VBD	show	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
extent	NN	extent	O	O	NONE
of	IN	of	O	O	NONE
nateglinide	JJ	nateglinide	B-e12	T	drug
protein	NN	protein	O	O	NONE
binding	NN	binding	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s11
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
displacement	NN	displacement	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
highly	RB	highly	O	O	NONE
protein	NN	protein	B-e0	O	drug
-bound	JJ	-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
furosemide	NN	furosemide	B-e1	O	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e2	T	drug
,	,	,	O	O	NONE
captopril	NN	captopril	B-e3	T	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
pravastatin	NN	pravastatin	B-e5	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e6	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e7	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e8	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e9	O	drug
acid	NN	acid	I-e9	O	drug
,	,	,	O	O	NONE
tolbutamide	NN	tolbutamide	B-e10	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
metformin	NN	metformin	B-e11	O	drug
showed	VBD	show	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
extent	NN	extent	O	O	NONE
of	IN	of	O	O	NONE
nateglinide	JJ	nateglinide	B-e12	O	drug
protein	NN	protein	O	O	NONE
binding	NN	binding	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s11
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
displacement	NN	displacement	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
highly	RB	highly	O	O	NONE
protein	NN	protein	B-e0	O	drug
-bound	JJ	-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
furosemide	NN	furosemide	B-e1	O	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e2	T	drug
,	,	,	O	O	NONE
captopril	NN	captopril	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	T	drug
,	,	,	O	O	NONE
pravastatin	NN	pravastatin	B-e5	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e6	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e7	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e8	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e9	O	drug
acid	NN	acid	I-e9	O	drug
,	,	,	O	O	NONE
tolbutamide	NN	tolbutamide	B-e10	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
metformin	NN	metformin	B-e11	O	drug
showed	VBD	show	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
extent	NN	extent	O	O	NONE
of	IN	of	O	O	NONE
nateglinide	JJ	nateglinide	B-e12	O	drug
protein	NN	protein	O	O	NONE
binding	NN	binding	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s11
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
displacement	NN	displacement	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
highly	RB	highly	O	O	NONE
protein	NN	protein	B-e0	O	drug
-bound	JJ	-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
furosemide	NN	furosemide	B-e1	O	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e2	T	drug
,	,	,	O	O	NONE
captopril	NN	captopril	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
pravastatin	NN	pravastatin	B-e5	T	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e6	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e7	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e8	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e9	O	drug
acid	NN	acid	I-e9	O	drug
,	,	,	O	O	NONE
tolbutamide	NN	tolbutamide	B-e10	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
metformin	NN	metformin	B-e11	O	drug
showed	VBD	show	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
extent	NN	extent	O	O	NONE
of	IN	of	O	O	NONE
nateglinide	JJ	nateglinide	B-e12	O	drug
protein	NN	protein	O	O	NONE
binding	NN	binding	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s11
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
displacement	NN	displacement	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
highly	RB	highly	O	O	NONE
protein	NN	protein	B-e0	O	drug
-bound	JJ	-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
furosemide	NN	furosemide	B-e1	O	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e2	T	drug
,	,	,	O	O	NONE
captopril	NN	captopril	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
pravastatin	NN	pravastatin	B-e5	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e6	T	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e7	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e8	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e9	O	drug
acid	NN	acid	I-e9	O	drug
,	,	,	O	O	NONE
tolbutamide	NN	tolbutamide	B-e10	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
metformin	NN	metformin	B-e11	O	drug
showed	VBD	show	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
extent	NN	extent	O	O	NONE
of	IN	of	O	O	NONE
nateglinide	JJ	nateglinide	B-e12	O	drug
protein	NN	protein	O	O	NONE
binding	NN	binding	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s11
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
displacement	NN	displacement	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
highly	RB	highly	O	O	NONE
protein	NN	protein	B-e0	O	drug
-bound	JJ	-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
furosemide	NN	furosemide	B-e1	O	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e2	T	drug
,	,	,	O	O	NONE
captopril	NN	captopril	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
pravastatin	NN	pravastatin	B-e5	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e6	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e7	T	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e8	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e9	O	drug
acid	NN	acid	I-e9	O	drug
,	,	,	O	O	NONE
tolbutamide	NN	tolbutamide	B-e10	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
metformin	NN	metformin	B-e11	O	drug
showed	VBD	show	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
extent	NN	extent	O	O	NONE
of	IN	of	O	O	NONE
nateglinide	JJ	nateglinide	B-e12	O	drug
protein	NN	protein	O	O	NONE
binding	NN	binding	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s11
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
displacement	NN	displacement	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
highly	RB	highly	O	O	NONE
protein	NN	protein	B-e0	O	drug
-bound	JJ	-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
furosemide	NN	furosemide	B-e1	O	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e2	T	drug
,	,	,	O	O	NONE
captopril	NN	captopril	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
pravastatin	NN	pravastatin	B-e5	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e6	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e7	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e8	T	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e9	O	drug
acid	NN	acid	I-e9	O	drug
,	,	,	O	O	NONE
tolbutamide	NN	tolbutamide	B-e10	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
metformin	NN	metformin	B-e11	O	drug
showed	VBD	show	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
extent	NN	extent	O	O	NONE
of	IN	of	O	O	NONE
nateglinide	JJ	nateglinide	B-e12	O	drug
protein	NN	protein	O	O	NONE
binding	NN	binding	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s11
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
displacement	NN	displacement	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
highly	RB	highly	O	O	NONE
protein	NN	protein	B-e0	O	drug
-bound	JJ	-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
furosemide	NN	furosemide	B-e1	O	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e2	T	drug
,	,	,	O	O	NONE
captopril	NN	captopril	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
pravastatin	NN	pravastatin	B-e5	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e6	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e7	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e8	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e9	T	drug
acid	NN	acid	I-e9	T	drug
,	,	,	O	O	NONE
tolbutamide	NN	tolbutamide	B-e10	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
metformin	NN	metformin	B-e11	O	drug
showed	VBD	show	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
extent	NN	extent	O	O	NONE
of	IN	of	O	O	NONE
nateglinide	JJ	nateglinide	B-e12	O	drug
protein	NN	protein	O	O	NONE
binding	NN	binding	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s11
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
displacement	NN	displacement	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
highly	RB	highly	O	O	NONE
protein	NN	protein	B-e0	O	drug
-bound	JJ	-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
furosemide	NN	furosemide	B-e1	O	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e2	T	drug
,	,	,	O	O	NONE
captopril	NN	captopril	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
pravastatin	NN	pravastatin	B-e5	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e6	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e7	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e8	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e9	O	drug
acid	NN	acid	I-e9	O	drug
,	,	,	O	O	NONE
tolbutamide	NN	tolbutamide	B-e10	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
metformin	NN	metformin	B-e11	O	drug
showed	VBD	show	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
extent	NN	extent	O	O	NONE
of	IN	of	O	O	NONE
nateglinide	JJ	nateglinide	B-e12	O	drug
protein	NN	protein	O	O	NONE
binding	NN	binding	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s11
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
displacement	NN	displacement	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
highly	RB	highly	O	O	NONE
protein	NN	protein	B-e0	O	drug
-bound	JJ	-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
furosemide	NN	furosemide	B-e1	O	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e2	T	drug
,	,	,	O	O	NONE
captopril	NN	captopril	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
pravastatin	NN	pravastatin	B-e5	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e6	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e7	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e8	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e9	O	drug
acid	NN	acid	I-e9	O	drug
,	,	,	O	O	NONE
tolbutamide	NN	tolbutamide	B-e10	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
metformin	NN	metformin	B-e11	T	drug
showed	VBD	show	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
extent	NN	extent	O	O	NONE
of	IN	of	O	O	NONE
nateglinide	JJ	nateglinide	B-e12	O	drug
protein	NN	protein	O	O	NONE
binding	NN	binding	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s11
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
displacement	NN	displacement	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
highly	RB	highly	O	O	NONE
protein	NN	protein	B-e0	O	drug
-bound	JJ	-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
furosemide	NN	furosemide	B-e1	O	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e2	T	drug
,	,	,	O	O	NONE
captopril	NN	captopril	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
pravastatin	NN	pravastatin	B-e5	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e6	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e7	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e8	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e9	O	drug
acid	NN	acid	I-e9	O	drug
,	,	,	O	O	NONE
tolbutamide	NN	tolbutamide	B-e10	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
metformin	NN	metformin	B-e11	O	drug
showed	VBD	show	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
extent	NN	extent	O	O	NONE
of	IN	of	O	O	NONE
nateglinide	JJ	nateglinide	B-e12	T	drug
protein	NN	protein	O	O	NONE
binding	NN	binding	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s11
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
displacement	NN	displacement	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
highly	RB	highly	O	O	NONE
protein	NN	protein	B-e0	O	drug
-bound	JJ	-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
furosemide	NN	furosemide	B-e1	O	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
captopril	NN	captopril	B-e3	T	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	T	drug
,	,	,	O	O	NONE
pravastatin	NN	pravastatin	B-e5	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e6	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e7	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e8	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e9	O	drug
acid	NN	acid	I-e9	O	drug
,	,	,	O	O	NONE
tolbutamide	NN	tolbutamide	B-e10	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
metformin	NN	metformin	B-e11	O	drug
showed	VBD	show	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
extent	NN	extent	O	O	NONE
of	IN	of	O	O	NONE
nateglinide	JJ	nateglinide	B-e12	O	drug
protein	NN	protein	O	O	NONE
binding	NN	binding	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s11
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
displacement	NN	displacement	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
highly	RB	highly	O	O	NONE
protein	NN	protein	B-e0	O	drug
-bound	JJ	-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
furosemide	NN	furosemide	B-e1	O	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
captopril	NN	captopril	B-e3	T	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
pravastatin	NN	pravastatin	B-e5	T	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e6	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e7	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e8	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e9	O	drug
acid	NN	acid	I-e9	O	drug
,	,	,	O	O	NONE
tolbutamide	NN	tolbutamide	B-e10	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
metformin	NN	metformin	B-e11	O	drug
showed	VBD	show	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
extent	NN	extent	O	O	NONE
of	IN	of	O	O	NONE
nateglinide	JJ	nateglinide	B-e12	O	drug
protein	NN	protein	O	O	NONE
binding	NN	binding	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s11
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
displacement	NN	displacement	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
highly	RB	highly	O	O	NONE
protein	NN	protein	B-e0	O	drug
-bound	JJ	-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
furosemide	NN	furosemide	B-e1	O	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
captopril	NN	captopril	B-e3	T	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
pravastatin	NN	pravastatin	B-e5	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e6	T	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e7	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e8	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e9	O	drug
acid	NN	acid	I-e9	O	drug
,	,	,	O	O	NONE
tolbutamide	NN	tolbutamide	B-e10	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
metformin	NN	metformin	B-e11	O	drug
showed	VBD	show	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
extent	NN	extent	O	O	NONE
of	IN	of	O	O	NONE
nateglinide	JJ	nateglinide	B-e12	O	drug
protein	NN	protein	O	O	NONE
binding	NN	binding	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s11
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
displacement	NN	displacement	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
highly	RB	highly	O	O	NONE
protein	NN	protein	B-e0	O	drug
-bound	JJ	-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
furosemide	NN	furosemide	B-e1	O	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
captopril	NN	captopril	B-e3	T	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
pravastatin	NN	pravastatin	B-e5	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e6	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e7	T	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e8	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e9	O	drug
acid	NN	acid	I-e9	O	drug
,	,	,	O	O	NONE
tolbutamide	NN	tolbutamide	B-e10	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
metformin	NN	metformin	B-e11	O	drug
showed	VBD	show	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
extent	NN	extent	O	O	NONE
of	IN	of	O	O	NONE
nateglinide	JJ	nateglinide	B-e12	O	drug
protein	NN	protein	O	O	NONE
binding	NN	binding	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s11
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
displacement	NN	displacement	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
highly	RB	highly	O	O	NONE
protein	NN	protein	B-e0	O	drug
-bound	JJ	-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
furosemide	NN	furosemide	B-e1	O	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
captopril	NN	captopril	B-e3	T	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
pravastatin	NN	pravastatin	B-e5	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e6	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e7	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e8	T	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e9	O	drug
acid	NN	acid	I-e9	O	drug
,	,	,	O	O	NONE
tolbutamide	NN	tolbutamide	B-e10	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
metformin	NN	metformin	B-e11	O	drug
showed	VBD	show	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
extent	NN	extent	O	O	NONE
of	IN	of	O	O	NONE
nateglinide	JJ	nateglinide	B-e12	O	drug
protein	NN	protein	O	O	NONE
binding	NN	binding	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s11
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
displacement	NN	displacement	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
highly	RB	highly	O	O	NONE
protein	NN	protein	B-e0	O	drug
-bound	JJ	-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
furosemide	NN	furosemide	B-e1	O	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
captopril	NN	captopril	B-e3	T	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
pravastatin	NN	pravastatin	B-e5	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e6	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e7	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e8	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e9	T	drug
acid	NN	acid	I-e9	T	drug
,	,	,	O	O	NONE
tolbutamide	NN	tolbutamide	B-e10	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
metformin	NN	metformin	B-e11	O	drug
showed	VBD	show	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
extent	NN	extent	O	O	NONE
of	IN	of	O	O	NONE
nateglinide	JJ	nateglinide	B-e12	O	drug
protein	NN	protein	O	O	NONE
binding	NN	binding	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s11
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
displacement	NN	displacement	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
highly	RB	highly	O	O	NONE
protein	NN	protein	B-e0	O	drug
-bound	JJ	-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
furosemide	NN	furosemide	B-e1	O	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
captopril	NN	captopril	B-e3	T	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
pravastatin	NN	pravastatin	B-e5	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e6	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e7	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e8	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e9	O	drug
acid	NN	acid	I-e9	O	drug
,	,	,	O	O	NONE
tolbutamide	NN	tolbutamide	B-e10	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
metformin	NN	metformin	B-e11	O	drug
showed	VBD	show	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
extent	NN	extent	O	O	NONE
of	IN	of	O	O	NONE
nateglinide	JJ	nateglinide	B-e12	O	drug
protein	NN	protein	O	O	NONE
binding	NN	binding	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s11
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
displacement	NN	displacement	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
highly	RB	highly	O	O	NONE
protein	NN	protein	B-e0	O	drug
-bound	JJ	-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
furosemide	NN	furosemide	B-e1	O	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
captopril	NN	captopril	B-e3	T	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
pravastatin	NN	pravastatin	B-e5	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e6	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e7	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e8	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e9	O	drug
acid	NN	acid	I-e9	O	drug
,	,	,	O	O	NONE
tolbutamide	NN	tolbutamide	B-e10	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
metformin	NN	metformin	B-e11	T	drug
showed	VBD	show	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
extent	NN	extent	O	O	NONE
of	IN	of	O	O	NONE
nateglinide	JJ	nateglinide	B-e12	O	drug
protein	NN	protein	O	O	NONE
binding	NN	binding	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s11
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
displacement	NN	displacement	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
highly	RB	highly	O	O	NONE
protein	NN	protein	B-e0	O	drug
-bound	JJ	-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
furosemide	NN	furosemide	B-e1	O	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
captopril	NN	captopril	B-e3	T	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
pravastatin	NN	pravastatin	B-e5	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e6	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e7	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e8	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e9	O	drug
acid	NN	acid	I-e9	O	drug
,	,	,	O	O	NONE
tolbutamide	NN	tolbutamide	B-e10	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
metformin	NN	metformin	B-e11	O	drug
showed	VBD	show	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
extent	NN	extent	O	O	NONE
of	IN	of	O	O	NONE
nateglinide	JJ	nateglinide	B-e12	T	drug
protein	NN	protein	O	O	NONE
binding	NN	binding	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s11
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
displacement	NN	displacement	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
highly	RB	highly	O	O	NONE
protein	NN	protein	B-e0	O	drug
-bound	JJ	-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
furosemide	NN	furosemide	B-e1	O	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
captopril	NN	captopril	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	T	drug
,	,	,	O	O	NONE
pravastatin	NN	pravastatin	B-e5	T	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e6	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e7	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e8	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e9	O	drug
acid	NN	acid	I-e9	O	drug
,	,	,	O	O	NONE
tolbutamide	NN	tolbutamide	B-e10	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
metformin	NN	metformin	B-e11	O	drug
showed	VBD	show	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
extent	NN	extent	O	O	NONE
of	IN	of	O	O	NONE
nateglinide	JJ	nateglinide	B-e12	O	drug
protein	NN	protein	O	O	NONE
binding	NN	binding	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s11
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
displacement	NN	displacement	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
highly	RB	highly	O	O	NONE
protein	NN	protein	B-e0	O	drug
-bound	JJ	-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
furosemide	NN	furosemide	B-e1	O	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
captopril	NN	captopril	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	T	drug
,	,	,	O	O	NONE
pravastatin	NN	pravastatin	B-e5	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e6	T	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e7	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e8	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e9	O	drug
acid	NN	acid	I-e9	O	drug
,	,	,	O	O	NONE
tolbutamide	NN	tolbutamide	B-e10	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
metformin	NN	metformin	B-e11	O	drug
showed	VBD	show	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
extent	NN	extent	O	O	NONE
of	IN	of	O	O	NONE
nateglinide	JJ	nateglinide	B-e12	O	drug
protein	NN	protein	O	O	NONE
binding	NN	binding	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s11
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
displacement	NN	displacement	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
highly	RB	highly	O	O	NONE
protein	NN	protein	B-e0	O	drug
-bound	JJ	-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
furosemide	NN	furosemide	B-e1	O	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
captopril	NN	captopril	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	T	drug
,	,	,	O	O	NONE
pravastatin	NN	pravastatin	B-e5	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e6	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e7	T	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e8	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e9	O	drug
acid	NN	acid	I-e9	O	drug
,	,	,	O	O	NONE
tolbutamide	NN	tolbutamide	B-e10	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
metformin	NN	metformin	B-e11	O	drug
showed	VBD	show	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
extent	NN	extent	O	O	NONE
of	IN	of	O	O	NONE
nateglinide	JJ	nateglinide	B-e12	O	drug
protein	NN	protein	O	O	NONE
binding	NN	binding	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s11
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
displacement	NN	displacement	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
highly	RB	highly	O	O	NONE
protein	NN	protein	B-e0	O	drug
-bound	JJ	-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
furosemide	NN	furosemide	B-e1	O	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
captopril	NN	captopril	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	T	drug
,	,	,	O	O	NONE
pravastatin	NN	pravastatin	B-e5	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e6	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e7	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e8	T	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e9	O	drug
acid	NN	acid	I-e9	O	drug
,	,	,	O	O	NONE
tolbutamide	NN	tolbutamide	B-e10	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
metformin	NN	metformin	B-e11	O	drug
showed	VBD	show	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
extent	NN	extent	O	O	NONE
of	IN	of	O	O	NONE
nateglinide	JJ	nateglinide	B-e12	O	drug
protein	NN	protein	O	O	NONE
binding	NN	binding	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s11
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
displacement	NN	displacement	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
highly	RB	highly	O	O	NONE
protein	NN	protein	B-e0	O	drug
-bound	JJ	-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
furosemide	NN	furosemide	B-e1	O	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
captopril	NN	captopril	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	T	drug
,	,	,	O	O	NONE
pravastatin	NN	pravastatin	B-e5	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e6	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e7	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e8	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e9	T	drug
acid	NN	acid	I-e9	T	drug
,	,	,	O	O	NONE
tolbutamide	NN	tolbutamide	B-e10	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
metformin	NN	metformin	B-e11	O	drug
showed	VBD	show	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
extent	NN	extent	O	O	NONE
of	IN	of	O	O	NONE
nateglinide	JJ	nateglinide	B-e12	O	drug
protein	NN	protein	O	O	NONE
binding	NN	binding	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s11
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
displacement	NN	displacement	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
highly	RB	highly	O	O	NONE
protein	NN	protein	B-e0	O	drug
-bound	JJ	-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
furosemide	NN	furosemide	B-e1	O	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
captopril	NN	captopril	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	T	drug
,	,	,	O	O	NONE
pravastatin	NN	pravastatin	B-e5	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e6	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e7	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e8	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e9	O	drug
acid	NN	acid	I-e9	O	drug
,	,	,	O	O	NONE
tolbutamide	NN	tolbutamide	B-e10	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
metformin	NN	metformin	B-e11	O	drug
showed	VBD	show	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
extent	NN	extent	O	O	NONE
of	IN	of	O	O	NONE
nateglinide	JJ	nateglinide	B-e12	O	drug
protein	NN	protein	O	O	NONE
binding	NN	binding	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s11
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
displacement	NN	displacement	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
highly	RB	highly	O	O	NONE
protein	NN	protein	B-e0	O	drug
-bound	JJ	-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
furosemide	NN	furosemide	B-e1	O	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
captopril	NN	captopril	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	T	drug
,	,	,	O	O	NONE
pravastatin	NN	pravastatin	B-e5	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e6	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e7	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e8	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e9	O	drug
acid	NN	acid	I-e9	O	drug
,	,	,	O	O	NONE
tolbutamide	NN	tolbutamide	B-e10	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
metformin	NN	metformin	B-e11	T	drug
showed	VBD	show	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
extent	NN	extent	O	O	NONE
of	IN	of	O	O	NONE
nateglinide	JJ	nateglinide	B-e12	O	drug
protein	NN	protein	O	O	NONE
binding	NN	binding	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s11
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
displacement	NN	displacement	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
highly	RB	highly	O	O	NONE
protein	NN	protein	B-e0	O	drug
-bound	JJ	-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
furosemide	NN	furosemide	B-e1	O	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
captopril	NN	captopril	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	T	drug
,	,	,	O	O	NONE
pravastatin	NN	pravastatin	B-e5	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e6	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e7	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e8	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e9	O	drug
acid	NN	acid	I-e9	O	drug
,	,	,	O	O	NONE
tolbutamide	NN	tolbutamide	B-e10	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
metformin	NN	metformin	B-e11	O	drug
showed	VBD	show	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
extent	NN	extent	O	O	NONE
of	IN	of	O	O	NONE
nateglinide	JJ	nateglinide	B-e12	T	drug
protein	NN	protein	O	O	NONE
binding	NN	binding	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s11
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
displacement	NN	displacement	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
highly	RB	highly	O	O	NONE
protein	NN	protein	B-e0	O	drug
-bound	JJ	-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
furosemide	NN	furosemide	B-e1	O	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
captopril	NN	captopril	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
pravastatin	NN	pravastatin	B-e5	T	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e6	T	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e7	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e8	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e9	O	drug
acid	NN	acid	I-e9	O	drug
,	,	,	O	O	NONE
tolbutamide	NN	tolbutamide	B-e10	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
metformin	NN	metformin	B-e11	O	drug
showed	VBD	show	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
extent	NN	extent	O	O	NONE
of	IN	of	O	O	NONE
nateglinide	JJ	nateglinide	B-e12	O	drug
protein	NN	protein	O	O	NONE
binding	NN	binding	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s11
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
displacement	NN	displacement	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
highly	RB	highly	O	O	NONE
protein	NN	protein	B-e0	O	drug
-bound	JJ	-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
furosemide	NN	furosemide	B-e1	O	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
captopril	NN	captopril	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
pravastatin	NN	pravastatin	B-e5	T	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e6	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e7	T	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e8	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e9	O	drug
acid	NN	acid	I-e9	O	drug
,	,	,	O	O	NONE
tolbutamide	NN	tolbutamide	B-e10	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
metformin	NN	metformin	B-e11	O	drug
showed	VBD	show	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
extent	NN	extent	O	O	NONE
of	IN	of	O	O	NONE
nateglinide	JJ	nateglinide	B-e12	O	drug
protein	NN	protein	O	O	NONE
binding	NN	binding	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s11
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
displacement	NN	displacement	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
highly	RB	highly	O	O	NONE
protein	NN	protein	B-e0	O	drug
-bound	JJ	-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
furosemide	NN	furosemide	B-e1	O	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
captopril	NN	captopril	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
pravastatin	NN	pravastatin	B-e5	T	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e6	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e7	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e8	T	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e9	O	drug
acid	NN	acid	I-e9	O	drug
,	,	,	O	O	NONE
tolbutamide	NN	tolbutamide	B-e10	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
metformin	NN	metformin	B-e11	O	drug
showed	VBD	show	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
extent	NN	extent	O	O	NONE
of	IN	of	O	O	NONE
nateglinide	JJ	nateglinide	B-e12	O	drug
protein	NN	protein	O	O	NONE
binding	NN	binding	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s11
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
displacement	NN	displacement	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
highly	RB	highly	O	O	NONE
protein	NN	protein	B-e0	O	drug
-bound	JJ	-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
furosemide	NN	furosemide	B-e1	O	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
captopril	NN	captopril	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
pravastatin	NN	pravastatin	B-e5	T	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e6	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e7	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e8	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e9	T	drug
acid	NN	acid	I-e9	T	drug
,	,	,	O	O	NONE
tolbutamide	NN	tolbutamide	B-e10	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
metformin	NN	metformin	B-e11	O	drug
showed	VBD	show	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
extent	NN	extent	O	O	NONE
of	IN	of	O	O	NONE
nateglinide	JJ	nateglinide	B-e12	O	drug
protein	NN	protein	O	O	NONE
binding	NN	binding	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s11
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
displacement	NN	displacement	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
highly	RB	highly	O	O	NONE
protein	NN	protein	B-e0	O	drug
-bound	JJ	-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
furosemide	NN	furosemide	B-e1	O	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
captopril	NN	captopril	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
pravastatin	NN	pravastatin	B-e5	T	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e6	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e7	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e8	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e9	O	drug
acid	NN	acid	I-e9	O	drug
,	,	,	O	O	NONE
tolbutamide	NN	tolbutamide	B-e10	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
metformin	NN	metformin	B-e11	O	drug
showed	VBD	show	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
extent	NN	extent	O	O	NONE
of	IN	of	O	O	NONE
nateglinide	JJ	nateglinide	B-e12	O	drug
protein	NN	protein	O	O	NONE
binding	NN	binding	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s11
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
displacement	NN	displacement	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
highly	RB	highly	O	O	NONE
protein	NN	protein	B-e0	O	drug
-bound	JJ	-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
furosemide	NN	furosemide	B-e1	O	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
captopril	NN	captopril	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
pravastatin	NN	pravastatin	B-e5	T	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e6	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e7	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e8	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e9	O	drug
acid	NN	acid	I-e9	O	drug
,	,	,	O	O	NONE
tolbutamide	NN	tolbutamide	B-e10	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
metformin	NN	metformin	B-e11	T	drug
showed	VBD	show	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
extent	NN	extent	O	O	NONE
of	IN	of	O	O	NONE
nateglinide	JJ	nateglinide	B-e12	O	drug
protein	NN	protein	O	O	NONE
binding	NN	binding	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s11
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
displacement	NN	displacement	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
highly	RB	highly	O	O	NONE
protein	NN	protein	B-e0	O	drug
-bound	JJ	-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
furosemide	NN	furosemide	B-e1	O	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
captopril	NN	captopril	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
pravastatin	NN	pravastatin	B-e5	T	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e6	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e7	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e8	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e9	O	drug
acid	NN	acid	I-e9	O	drug
,	,	,	O	O	NONE
tolbutamide	NN	tolbutamide	B-e10	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
metformin	NN	metformin	B-e11	O	drug
showed	VBD	show	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
extent	NN	extent	O	O	NONE
of	IN	of	O	O	NONE
nateglinide	JJ	nateglinide	B-e12	T	drug
protein	NN	protein	O	O	NONE
binding	NN	binding	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s11
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
displacement	NN	displacement	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
highly	RB	highly	O	O	NONE
protein	NN	protein	B-e0	O	drug
-bound	JJ	-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
furosemide	NN	furosemide	B-e1	O	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
captopril	NN	captopril	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
pravastatin	NN	pravastatin	B-e5	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e6	T	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e7	T	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e8	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e9	O	drug
acid	NN	acid	I-e9	O	drug
,	,	,	O	O	NONE
tolbutamide	NN	tolbutamide	B-e10	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
metformin	NN	metformin	B-e11	O	drug
showed	VBD	show	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
extent	NN	extent	O	O	NONE
of	IN	of	O	O	NONE
nateglinide	JJ	nateglinide	B-e12	O	drug
protein	NN	protein	O	O	NONE
binding	NN	binding	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s11
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
displacement	NN	displacement	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
highly	RB	highly	O	O	NONE
protein	NN	protein	B-e0	O	drug
-bound	JJ	-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
furosemide	NN	furosemide	B-e1	O	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
captopril	NN	captopril	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
pravastatin	NN	pravastatin	B-e5	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e6	T	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e7	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e8	T	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e9	O	drug
acid	NN	acid	I-e9	O	drug
,	,	,	O	O	NONE
tolbutamide	NN	tolbutamide	B-e10	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
metformin	NN	metformin	B-e11	O	drug
showed	VBD	show	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
extent	NN	extent	O	O	NONE
of	IN	of	O	O	NONE
nateglinide	JJ	nateglinide	B-e12	O	drug
protein	NN	protein	O	O	NONE
binding	NN	binding	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s11
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
displacement	NN	displacement	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
highly	RB	highly	O	O	NONE
protein	NN	protein	B-e0	O	drug
-bound	JJ	-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
furosemide	NN	furosemide	B-e1	O	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
captopril	NN	captopril	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
pravastatin	NN	pravastatin	B-e5	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e6	T	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e7	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e8	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e9	T	drug
acid	NN	acid	I-e9	T	drug
,	,	,	O	O	NONE
tolbutamide	NN	tolbutamide	B-e10	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
metformin	NN	metformin	B-e11	O	drug
showed	VBD	show	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
extent	NN	extent	O	O	NONE
of	IN	of	O	O	NONE
nateglinide	JJ	nateglinide	B-e12	O	drug
protein	NN	protein	O	O	NONE
binding	NN	binding	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s11
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
displacement	NN	displacement	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
highly	RB	highly	O	O	NONE
protein	NN	protein	B-e0	O	drug
-bound	JJ	-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
furosemide	NN	furosemide	B-e1	O	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
captopril	NN	captopril	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
pravastatin	NN	pravastatin	B-e5	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e6	T	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e7	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e8	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e9	O	drug
acid	NN	acid	I-e9	O	drug
,	,	,	O	O	NONE
tolbutamide	NN	tolbutamide	B-e10	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
metformin	NN	metformin	B-e11	O	drug
showed	VBD	show	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
extent	NN	extent	O	O	NONE
of	IN	of	O	O	NONE
nateglinide	JJ	nateglinide	B-e12	O	drug
protein	NN	protein	O	O	NONE
binding	NN	binding	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s11
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
displacement	NN	displacement	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
highly	RB	highly	O	O	NONE
protein	NN	protein	B-e0	O	drug
-bound	JJ	-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
furosemide	NN	furosemide	B-e1	O	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
captopril	NN	captopril	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
pravastatin	NN	pravastatin	B-e5	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e6	T	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e7	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e8	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e9	O	drug
acid	NN	acid	I-e9	O	drug
,	,	,	O	O	NONE
tolbutamide	NN	tolbutamide	B-e10	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
metformin	NN	metformin	B-e11	T	drug
showed	VBD	show	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
extent	NN	extent	O	O	NONE
of	IN	of	O	O	NONE
nateglinide	JJ	nateglinide	B-e12	O	drug
protein	NN	protein	O	O	NONE
binding	NN	binding	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s11
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
displacement	NN	displacement	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
highly	RB	highly	O	O	NONE
protein	NN	protein	B-e0	O	drug
-bound	JJ	-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
furosemide	NN	furosemide	B-e1	O	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
captopril	NN	captopril	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
pravastatin	NN	pravastatin	B-e5	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e6	T	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e7	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e8	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e9	O	drug
acid	NN	acid	I-e9	O	drug
,	,	,	O	O	NONE
tolbutamide	NN	tolbutamide	B-e10	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
metformin	NN	metformin	B-e11	O	drug
showed	VBD	show	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
extent	NN	extent	O	O	NONE
of	IN	of	O	O	NONE
nateglinide	JJ	nateglinide	B-e12	T	drug
protein	NN	protein	O	O	NONE
binding	NN	binding	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s11
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
displacement	NN	displacement	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
highly	RB	highly	O	O	NONE
protein	NN	protein	B-e0	O	drug
-bound	JJ	-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
furosemide	NN	furosemide	B-e1	O	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
captopril	NN	captopril	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
pravastatin	NN	pravastatin	B-e5	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e6	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e7	T	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e8	T	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e9	O	drug
acid	NN	acid	I-e9	O	drug
,	,	,	O	O	NONE
tolbutamide	NN	tolbutamide	B-e10	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
metformin	NN	metformin	B-e11	O	drug
showed	VBD	show	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
extent	NN	extent	O	O	NONE
of	IN	of	O	O	NONE
nateglinide	JJ	nateglinide	B-e12	O	drug
protein	NN	protein	O	O	NONE
binding	NN	binding	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s11
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
displacement	NN	displacement	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
highly	RB	highly	O	O	NONE
protein	NN	protein	B-e0	O	drug
-bound	JJ	-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
furosemide	NN	furosemide	B-e1	O	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
captopril	NN	captopril	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
pravastatin	NN	pravastatin	B-e5	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e6	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e7	T	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e8	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e9	T	drug
acid	NN	acid	I-e9	T	drug
,	,	,	O	O	NONE
tolbutamide	NN	tolbutamide	B-e10	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
metformin	NN	metformin	B-e11	O	drug
showed	VBD	show	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
extent	NN	extent	O	O	NONE
of	IN	of	O	O	NONE
nateglinide	JJ	nateglinide	B-e12	O	drug
protein	NN	protein	O	O	NONE
binding	NN	binding	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s11
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
displacement	NN	displacement	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
highly	RB	highly	O	O	NONE
protein	NN	protein	B-e0	O	drug
-bound	JJ	-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
furosemide	NN	furosemide	B-e1	O	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
captopril	NN	captopril	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
pravastatin	NN	pravastatin	B-e5	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e6	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e7	T	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e8	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e9	O	drug
acid	NN	acid	I-e9	O	drug
,	,	,	O	O	NONE
tolbutamide	NN	tolbutamide	B-e10	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
metformin	NN	metformin	B-e11	O	drug
showed	VBD	show	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
extent	NN	extent	O	O	NONE
of	IN	of	O	O	NONE
nateglinide	JJ	nateglinide	B-e12	O	drug
protein	NN	protein	O	O	NONE
binding	NN	binding	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s11
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
displacement	NN	displacement	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
highly	RB	highly	O	O	NONE
protein	NN	protein	B-e0	O	drug
-bound	JJ	-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
furosemide	NN	furosemide	B-e1	O	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
captopril	NN	captopril	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
pravastatin	NN	pravastatin	B-e5	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e6	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e7	T	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e8	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e9	O	drug
acid	NN	acid	I-e9	O	drug
,	,	,	O	O	NONE
tolbutamide	NN	tolbutamide	B-e10	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
metformin	NN	metformin	B-e11	T	drug
showed	VBD	show	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
extent	NN	extent	O	O	NONE
of	IN	of	O	O	NONE
nateglinide	JJ	nateglinide	B-e12	O	drug
protein	NN	protein	O	O	NONE
binding	NN	binding	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s11
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
displacement	NN	displacement	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
highly	RB	highly	O	O	NONE
protein	NN	protein	B-e0	O	drug
-bound	JJ	-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
furosemide	NN	furosemide	B-e1	O	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
captopril	NN	captopril	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
pravastatin	NN	pravastatin	B-e5	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e6	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e7	T	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e8	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e9	O	drug
acid	NN	acid	I-e9	O	drug
,	,	,	O	O	NONE
tolbutamide	NN	tolbutamide	B-e10	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
metformin	NN	metformin	B-e11	O	drug
showed	VBD	show	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
extent	NN	extent	O	O	NONE
of	IN	of	O	O	NONE
nateglinide	JJ	nateglinide	B-e12	T	drug
protein	NN	protein	O	O	NONE
binding	NN	binding	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s11
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
displacement	NN	displacement	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
highly	RB	highly	O	O	NONE
protein	NN	protein	B-e0	O	drug
-bound	JJ	-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
furosemide	NN	furosemide	B-e1	O	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
captopril	NN	captopril	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
pravastatin	NN	pravastatin	B-e5	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e6	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e7	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e8	T	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e9	T	drug
acid	NN	acid	I-e9	T	drug
,	,	,	O	O	NONE
tolbutamide	NN	tolbutamide	B-e10	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
metformin	NN	metformin	B-e11	O	drug
showed	VBD	show	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
extent	NN	extent	O	O	NONE
of	IN	of	O	O	NONE
nateglinide	JJ	nateglinide	B-e12	O	drug
protein	NN	protein	O	O	NONE
binding	NN	binding	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s11
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
displacement	NN	displacement	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
highly	RB	highly	O	O	NONE
protein	NN	protein	B-e0	O	drug
-bound	JJ	-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
furosemide	NN	furosemide	B-e1	O	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
captopril	NN	captopril	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
pravastatin	NN	pravastatin	B-e5	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e6	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e7	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e8	T	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e9	O	drug
acid	NN	acid	I-e9	O	drug
,	,	,	O	O	NONE
tolbutamide	NN	tolbutamide	B-e10	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
metformin	NN	metformin	B-e11	O	drug
showed	VBD	show	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
extent	NN	extent	O	O	NONE
of	IN	of	O	O	NONE
nateglinide	JJ	nateglinide	B-e12	O	drug
protein	NN	protein	O	O	NONE
binding	NN	binding	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s11
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
displacement	NN	displacement	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
highly	RB	highly	O	O	NONE
protein	NN	protein	B-e0	O	drug
-bound	JJ	-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
furosemide	NN	furosemide	B-e1	O	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
captopril	NN	captopril	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
pravastatin	NN	pravastatin	B-e5	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e6	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e7	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e8	T	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e9	O	drug
acid	NN	acid	I-e9	O	drug
,	,	,	O	O	NONE
tolbutamide	NN	tolbutamide	B-e10	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
metformin	NN	metformin	B-e11	T	drug
showed	VBD	show	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
extent	NN	extent	O	O	NONE
of	IN	of	O	O	NONE
nateglinide	JJ	nateglinide	B-e12	O	drug
protein	NN	protein	O	O	NONE
binding	NN	binding	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s11
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
displacement	NN	displacement	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
highly	RB	highly	O	O	NONE
protein	NN	protein	B-e0	O	drug
-bound	JJ	-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
furosemide	NN	furosemide	B-e1	O	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
captopril	NN	captopril	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
pravastatin	NN	pravastatin	B-e5	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e6	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e7	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e8	T	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e9	O	drug
acid	NN	acid	I-e9	O	drug
,	,	,	O	O	NONE
tolbutamide	NN	tolbutamide	B-e10	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
metformin	NN	metformin	B-e11	O	drug
showed	VBD	show	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
extent	NN	extent	O	O	NONE
of	IN	of	O	O	NONE
nateglinide	JJ	nateglinide	B-e12	T	drug
protein	NN	protein	O	O	NONE
binding	NN	binding	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s11
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
displacement	NN	displacement	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
highly	RB	highly	O	O	NONE
protein	NN	protein	B-e0	O	drug
-bound	JJ	-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
furosemide	NN	furosemide	B-e1	O	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
captopril	NN	captopril	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
pravastatin	NN	pravastatin	B-e5	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e6	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e7	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e8	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e9	T	drug
acid	NN	acid	I-e9	T	drug
,	,	,	O	O	NONE
tolbutamide	NN	tolbutamide	B-e10	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
metformin	NN	metformin	B-e11	O	drug
showed	VBD	show	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
extent	NN	extent	O	O	NONE
of	IN	of	O	O	NONE
nateglinide	JJ	nateglinide	B-e12	O	drug
protein	NN	protein	O	O	NONE
binding	NN	binding	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s11
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
displacement	NN	displacement	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
highly	RB	highly	O	O	NONE
protein	NN	protein	B-e0	O	drug
-bound	JJ	-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
furosemide	NN	furosemide	B-e1	O	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
captopril	NN	captopril	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
pravastatin	NN	pravastatin	B-e5	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e6	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e7	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e8	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e9	T	drug
acid	NN	acid	I-e9	T	drug
,	,	,	O	O	NONE
tolbutamide	NN	tolbutamide	B-e10	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
metformin	NN	metformin	B-e11	T	drug
showed	VBD	show	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
extent	NN	extent	O	O	NONE
of	IN	of	O	O	NONE
nateglinide	JJ	nateglinide	B-e12	O	drug
protein	NN	protein	O	O	NONE
binding	NN	binding	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s11
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
displacement	NN	displacement	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
highly	RB	highly	O	O	NONE
protein	NN	protein	B-e0	O	drug
-bound	JJ	-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
furosemide	NN	furosemide	B-e1	O	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
captopril	NN	captopril	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
pravastatin	NN	pravastatin	B-e5	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e6	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e7	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e8	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e9	T	drug
acid	NN	acid	I-e9	T	drug
,	,	,	O	O	NONE
tolbutamide	NN	tolbutamide	B-e10	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
metformin	NN	metformin	B-e11	O	drug
showed	VBD	show	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
extent	NN	extent	O	O	NONE
of	IN	of	O	O	NONE
nateglinide	JJ	nateglinide	B-e12	T	drug
protein	NN	protein	O	O	NONE
binding	NN	binding	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s11
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
displacement	NN	displacement	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
highly	RB	highly	O	O	NONE
protein	NN	protein	B-e0	O	drug
-bound	JJ	-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
furosemide	NN	furosemide	B-e1	O	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
captopril	NN	captopril	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
pravastatin	NN	pravastatin	B-e5	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e6	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e7	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e8	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e9	O	drug
acid	NN	acid	I-e9	O	drug
,	,	,	O	O	NONE
tolbutamide	NN	tolbutamide	B-e10	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
metformin	NN	metformin	B-e11	T	drug
showed	VBD	show	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
extent	NN	extent	O	O	NONE
of	IN	of	O	O	NONE
nateglinide	JJ	nateglinide	B-e12	O	drug
protein	NN	protein	O	O	NONE
binding	NN	binding	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s11
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
displacement	NN	displacement	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
highly	RB	highly	O	O	NONE
protein	NN	protein	B-e0	O	drug
-bound	JJ	-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
furosemide	NN	furosemide	B-e1	O	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
captopril	NN	captopril	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
pravastatin	NN	pravastatin	B-e5	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e6	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e7	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e8	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e9	O	drug
acid	NN	acid	I-e9	O	drug
,	,	,	O	O	NONE
tolbutamide	NN	tolbutamide	B-e10	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
metformin	NN	metformin	B-e11	O	drug
showed	VBD	show	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
extent	NN	extent	O	O	NONE
of	IN	of	O	O	NONE
nateglinide	JJ	nateglinide	B-e12	T	drug
protein	NN	protein	O	O	NONE
binding	NN	binding	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s11
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
displacement	NN	displacement	O	O	NONE
studies	NNS	study	O	O	NONE
with	IN	with	O	O	NONE
highly	RB	highly	O	O	NONE
protein	NN	protein	B-e0	O	drug
-bound	JJ	-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
furosemide	NN	furosemide	B-e1	O	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
captopril	NN	captopril	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
pravastatin	NN	pravastatin	B-e5	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e6	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e7	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e8	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e9	O	drug
acid	NN	acid	I-e9	O	drug
,	,	,	O	O	NONE
tolbutamide	NN	tolbutamide	B-e10	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
metformin	NN	metformin	B-e11	T	drug
showed	VBD	show	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
extent	NN	extent	O	O	NONE
of	IN	of	O	O	NONE
nateglinide	JJ	nateglinide	B-e12	T	drug
protein	NN	protein	O	O	NONE
binding	NN	binding	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s12
Similarly	RB	similarly	O	O	NONE
,	,	,	O	O	NONE
nateglinide	NN	nateglinide	B-e0	T	drug
had	VBD	have	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
serum	NN	serum	O	O	NONE
protein	NN	protein	B-e1	T	drug
binding	NN	binding	I-e1	T	drug
of	IN	of	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e5	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e6	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e7	O	drug
acid	NN	acid	I-e7	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
tolbutamide	NN	tolbutamide	B-e8	O	drug
in	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s12
Similarly	RB	similarly	O	O	NONE
,	,	,	O	O	NONE
nateglinide	NN	nateglinide	B-e0	T	drug
had	VBD	have	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
serum	NN	serum	O	O	NONE
protein	NN	protein	B-e1	O	drug
binding	NN	binding	I-e1	O	drug
of	IN	of	O	O	NONE
propranolol	NN	propranolol	B-e2	T	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e5	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e6	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e7	O	drug
acid	NN	acid	I-e7	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
tolbutamide	NN	tolbutamide	B-e8	O	drug
in	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s12
Similarly	RB	similarly	O	O	NONE
,	,	,	O	O	NONE
nateglinide	NN	nateglinide	B-e0	T	drug
had	VBD	have	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
serum	NN	serum	O	O	NONE
protein	NN	protein	B-e1	O	drug
binding	NN	binding	I-e1	O	drug
of	IN	of	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e3	T	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e5	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e6	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e7	O	drug
acid	NN	acid	I-e7	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
tolbutamide	NN	tolbutamide	B-e8	O	drug
in	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s12
Similarly	RB	similarly	O	O	NONE
,	,	,	O	O	NONE
nateglinide	NN	nateglinide	B-e0	T	drug
had	VBD	have	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
serum	NN	serum	O	O	NONE
protein	NN	protein	B-e1	O	drug
binding	NN	binding	I-e1	O	drug
of	IN	of	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	T	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e5	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e6	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e7	O	drug
acid	NN	acid	I-e7	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
tolbutamide	NN	tolbutamide	B-e8	O	drug
in	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s12
Similarly	RB	similarly	O	O	NONE
,	,	,	O	O	NONE
nateglinide	NN	nateglinide	B-e0	T	drug
had	VBD	have	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
serum	NN	serum	O	O	NONE
protein	NN	protein	B-e1	O	drug
binding	NN	binding	I-e1	O	drug
of	IN	of	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e5	T	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e6	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e7	O	drug
acid	NN	acid	I-e7	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
tolbutamide	NN	tolbutamide	B-e8	O	drug
in	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s12
Similarly	RB	similarly	O	O	NONE
,	,	,	O	O	NONE
nateglinide	NN	nateglinide	B-e0	T	drug
had	VBD	have	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
serum	NN	serum	O	O	NONE
protein	NN	protein	B-e1	O	drug
binding	NN	binding	I-e1	O	drug
of	IN	of	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e5	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e6	T	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e7	O	drug
acid	NN	acid	I-e7	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
tolbutamide	NN	tolbutamide	B-e8	O	drug
in	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s12
Similarly	RB	similarly	O	O	NONE
,	,	,	O	O	NONE
nateglinide	NN	nateglinide	B-e0	T	drug
had	VBD	have	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
serum	NN	serum	O	O	NONE
protein	NN	protein	B-e1	O	drug
binding	NN	binding	I-e1	O	drug
of	IN	of	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e5	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e6	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e7	T	drug
acid	NN	acid	I-e7	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
tolbutamide	NN	tolbutamide	B-e8	O	drug
in	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s12
Similarly	RB	similarly	O	O	NONE
,	,	,	O	O	NONE
nateglinide	NN	nateglinide	B-e0	T	drug
had	VBD	have	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
serum	NN	serum	O	O	NONE
protein	NN	protein	B-e1	O	drug
binding	NN	binding	I-e1	O	drug
of	IN	of	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e5	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e6	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e7	O	drug
acid	NN	acid	I-e7	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
tolbutamide	NN	tolbutamide	B-e8	T	drug
in	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s12
Similarly	RB	similarly	O	O	NONE
,	,	,	O	O	NONE
nateglinide	NN	nateglinide	B-e0	O	drug
had	VBD	have	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
serum	NN	serum	O	O	NONE
protein	NN	protein	B-e1	T	drug
binding	NN	binding	I-e1	T	drug
of	IN	of	O	O	NONE
propranolol	NN	propranolol	B-e2	T	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e5	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e6	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e7	O	drug
acid	NN	acid	I-e7	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
tolbutamide	NN	tolbutamide	B-e8	O	drug
in	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s12
Similarly	RB	similarly	O	O	NONE
,	,	,	O	O	NONE
nateglinide	NN	nateglinide	B-e0	O	drug
had	VBD	have	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
serum	NN	serum	O	O	NONE
protein	NN	protein	B-e1	T	drug
binding	NN	binding	I-e1	T	drug
of	IN	of	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e3	T	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e5	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e6	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e7	O	drug
acid	NN	acid	I-e7	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
tolbutamide	NN	tolbutamide	B-e8	O	drug
in	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s12
Similarly	RB	similarly	O	O	NONE
,	,	,	O	O	NONE
nateglinide	NN	nateglinide	B-e0	O	drug
had	VBD	have	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
serum	NN	serum	O	O	NONE
protein	NN	protein	B-e1	T	drug
binding	NN	binding	I-e1	T	drug
of	IN	of	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	T	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e5	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e6	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e7	O	drug
acid	NN	acid	I-e7	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
tolbutamide	NN	tolbutamide	B-e8	O	drug
in	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s12
Similarly	RB	similarly	O	O	NONE
,	,	,	O	O	NONE
nateglinide	NN	nateglinide	B-e0	O	drug
had	VBD	have	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
serum	NN	serum	O	O	NONE
protein	NN	protein	B-e1	T	drug
binding	NN	binding	I-e1	T	drug
of	IN	of	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e5	T	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e6	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e7	O	drug
acid	NN	acid	I-e7	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
tolbutamide	NN	tolbutamide	B-e8	O	drug
in	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s12
Similarly	RB	similarly	O	O	NONE
,	,	,	O	O	NONE
nateglinide	NN	nateglinide	B-e0	O	drug
had	VBD	have	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
serum	NN	serum	O	O	NONE
protein	NN	protein	B-e1	T	drug
binding	NN	binding	I-e1	T	drug
of	IN	of	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e5	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e6	T	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e7	O	drug
acid	NN	acid	I-e7	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
tolbutamide	NN	tolbutamide	B-e8	O	drug
in	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s12
Similarly	RB	similarly	O	O	NONE
,	,	,	O	O	NONE
nateglinide	NN	nateglinide	B-e0	O	drug
had	VBD	have	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
serum	NN	serum	O	O	NONE
protein	NN	protein	B-e1	T	drug
binding	NN	binding	I-e1	T	drug
of	IN	of	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e5	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e6	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e7	T	drug
acid	NN	acid	I-e7	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
tolbutamide	NN	tolbutamide	B-e8	O	drug
in	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s12
Similarly	RB	similarly	O	O	NONE
,	,	,	O	O	NONE
nateglinide	NN	nateglinide	B-e0	O	drug
had	VBD	have	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
serum	NN	serum	O	O	NONE
protein	NN	protein	B-e1	T	drug
binding	NN	binding	I-e1	T	drug
of	IN	of	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e5	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e6	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e7	O	drug
acid	NN	acid	I-e7	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
tolbutamide	NN	tolbutamide	B-e8	T	drug
in	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s12
Similarly	RB	similarly	O	O	NONE
,	,	,	O	O	NONE
nateglinide	NN	nateglinide	B-e0	O	drug
had	VBD	have	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
serum	NN	serum	O	O	NONE
protein	NN	protein	B-e1	O	drug
binding	NN	binding	I-e1	O	drug
of	IN	of	O	O	NONE
propranolol	NN	propranolol	B-e2	T	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e3	T	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e5	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e6	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e7	O	drug
acid	NN	acid	I-e7	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
tolbutamide	NN	tolbutamide	B-e8	O	drug
in	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s12
Similarly	RB	similarly	O	O	NONE
,	,	,	O	O	NONE
nateglinide	NN	nateglinide	B-e0	O	drug
had	VBD	have	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
serum	NN	serum	O	O	NONE
protein	NN	protein	B-e1	O	drug
binding	NN	binding	I-e1	O	drug
of	IN	of	O	O	NONE
propranolol	NN	propranolol	B-e2	T	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	T	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e5	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e6	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e7	O	drug
acid	NN	acid	I-e7	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
tolbutamide	NN	tolbutamide	B-e8	O	drug
in	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s12
Similarly	RB	similarly	O	O	NONE
,	,	,	O	O	NONE
nateglinide	NN	nateglinide	B-e0	O	drug
had	VBD	have	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
serum	NN	serum	O	O	NONE
protein	NN	protein	B-e1	O	drug
binding	NN	binding	I-e1	O	drug
of	IN	of	O	O	NONE
propranolol	NN	propranolol	B-e2	T	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e5	T	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e6	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e7	O	drug
acid	NN	acid	I-e7	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
tolbutamide	NN	tolbutamide	B-e8	O	drug
in	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s12
Similarly	RB	similarly	O	O	NONE
,	,	,	O	O	NONE
nateglinide	NN	nateglinide	B-e0	O	drug
had	VBD	have	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
serum	NN	serum	O	O	NONE
protein	NN	protein	B-e1	O	drug
binding	NN	binding	I-e1	O	drug
of	IN	of	O	O	NONE
propranolol	NN	propranolol	B-e2	T	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e5	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e6	T	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e7	O	drug
acid	NN	acid	I-e7	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
tolbutamide	NN	tolbutamide	B-e8	O	drug
in	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s12
Similarly	RB	similarly	O	O	NONE
,	,	,	O	O	NONE
nateglinide	NN	nateglinide	B-e0	O	drug
had	VBD	have	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
serum	NN	serum	O	O	NONE
protein	NN	protein	B-e1	O	drug
binding	NN	binding	I-e1	O	drug
of	IN	of	O	O	NONE
propranolol	NN	propranolol	B-e2	T	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e5	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e6	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e7	T	drug
acid	NN	acid	I-e7	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
tolbutamide	NN	tolbutamide	B-e8	O	drug
in	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s12
Similarly	RB	similarly	O	O	NONE
,	,	,	O	O	NONE
nateglinide	NN	nateglinide	B-e0	O	drug
had	VBD	have	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
serum	NN	serum	O	O	NONE
protein	NN	protein	B-e1	O	drug
binding	NN	binding	I-e1	O	drug
of	IN	of	O	O	NONE
propranolol	NN	propranolol	B-e2	T	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e5	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e6	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e7	O	drug
acid	NN	acid	I-e7	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
tolbutamide	NN	tolbutamide	B-e8	T	drug
in	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s12
Similarly	RB	similarly	O	O	NONE
,	,	,	O	O	NONE
nateglinide	NN	nateglinide	B-e0	O	drug
had	VBD	have	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
serum	NN	serum	O	O	NONE
protein	NN	protein	B-e1	O	drug
binding	NN	binding	I-e1	O	drug
of	IN	of	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e3	T	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	T	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e5	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e6	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e7	O	drug
acid	NN	acid	I-e7	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
tolbutamide	NN	tolbutamide	B-e8	O	drug
in	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s12
Similarly	RB	similarly	O	O	NONE
,	,	,	O	O	NONE
nateglinide	NN	nateglinide	B-e0	O	drug
had	VBD	have	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
serum	NN	serum	O	O	NONE
protein	NN	protein	B-e1	O	drug
binding	NN	binding	I-e1	O	drug
of	IN	of	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e3	T	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e5	T	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e6	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e7	O	drug
acid	NN	acid	I-e7	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
tolbutamide	NN	tolbutamide	B-e8	O	drug
in	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s12
Similarly	RB	similarly	O	O	NONE
,	,	,	O	O	NONE
nateglinide	NN	nateglinide	B-e0	O	drug
had	VBD	have	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
serum	NN	serum	O	O	NONE
protein	NN	protein	B-e1	O	drug
binding	NN	binding	I-e1	O	drug
of	IN	of	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e3	T	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e5	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e6	T	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e7	O	drug
acid	NN	acid	I-e7	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
tolbutamide	NN	tolbutamide	B-e8	O	drug
in	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s12
Similarly	RB	similarly	O	O	NONE
,	,	,	O	O	NONE
nateglinide	NN	nateglinide	B-e0	O	drug
had	VBD	have	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
serum	NN	serum	O	O	NONE
protein	NN	protein	B-e1	O	drug
binding	NN	binding	I-e1	O	drug
of	IN	of	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e3	T	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e5	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e6	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e7	T	drug
acid	NN	acid	I-e7	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
tolbutamide	NN	tolbutamide	B-e8	O	drug
in	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s12
Similarly	RB	similarly	O	O	NONE
,	,	,	O	O	NONE
nateglinide	NN	nateglinide	B-e0	O	drug
had	VBD	have	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
serum	NN	serum	O	O	NONE
protein	NN	protein	B-e1	O	drug
binding	NN	binding	I-e1	O	drug
of	IN	of	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e3	T	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e5	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e6	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e7	O	drug
acid	NN	acid	I-e7	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
tolbutamide	NN	tolbutamide	B-e8	T	drug
in	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s12
Similarly	RB	similarly	O	O	NONE
,	,	,	O	O	NONE
nateglinide	NN	nateglinide	B-e0	O	drug
had	VBD	have	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
serum	NN	serum	O	O	NONE
protein	NN	protein	B-e1	O	drug
binding	NN	binding	I-e1	O	drug
of	IN	of	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	T	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e5	T	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e6	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e7	O	drug
acid	NN	acid	I-e7	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
tolbutamide	NN	tolbutamide	B-e8	O	drug
in	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s12
Similarly	RB	similarly	O	O	NONE
,	,	,	O	O	NONE
nateglinide	NN	nateglinide	B-e0	O	drug
had	VBD	have	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
serum	NN	serum	O	O	NONE
protein	NN	protein	B-e1	O	drug
binding	NN	binding	I-e1	O	drug
of	IN	of	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	T	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e5	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e6	T	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e7	O	drug
acid	NN	acid	I-e7	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
tolbutamide	NN	tolbutamide	B-e8	O	drug
in	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s12
Similarly	RB	similarly	O	O	NONE
,	,	,	O	O	NONE
nateglinide	NN	nateglinide	B-e0	O	drug
had	VBD	have	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
serum	NN	serum	O	O	NONE
protein	NN	protein	B-e1	O	drug
binding	NN	binding	I-e1	O	drug
of	IN	of	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	T	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e5	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e6	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e7	T	drug
acid	NN	acid	I-e7	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
tolbutamide	NN	tolbutamide	B-e8	O	drug
in	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s12
Similarly	RB	similarly	O	O	NONE
,	,	,	O	O	NONE
nateglinide	NN	nateglinide	B-e0	O	drug
had	VBD	have	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
serum	NN	serum	O	O	NONE
protein	NN	protein	B-e1	O	drug
binding	NN	binding	I-e1	O	drug
of	IN	of	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	T	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e5	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e6	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e7	O	drug
acid	NN	acid	I-e7	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
tolbutamide	NN	tolbutamide	B-e8	T	drug
in	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s12
Similarly	RB	similarly	O	O	NONE
,	,	,	O	O	NONE
nateglinide	NN	nateglinide	B-e0	O	drug
had	VBD	have	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
serum	NN	serum	O	O	NONE
protein	NN	protein	B-e1	O	drug
binding	NN	binding	I-e1	O	drug
of	IN	of	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e5	T	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e6	T	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e7	O	drug
acid	NN	acid	I-e7	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
tolbutamide	NN	tolbutamide	B-e8	O	drug
in	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s12
Similarly	RB	similarly	O	O	NONE
,	,	,	O	O	NONE
nateglinide	NN	nateglinide	B-e0	O	drug
had	VBD	have	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
serum	NN	serum	O	O	NONE
protein	NN	protein	B-e1	O	drug
binding	NN	binding	I-e1	O	drug
of	IN	of	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e5	T	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e6	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e7	T	drug
acid	NN	acid	I-e7	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
tolbutamide	NN	tolbutamide	B-e8	O	drug
in	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s12
Similarly	RB	similarly	O	O	NONE
,	,	,	O	O	NONE
nateglinide	NN	nateglinide	B-e0	O	drug
had	VBD	have	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
serum	NN	serum	O	O	NONE
protein	NN	protein	B-e1	O	drug
binding	NN	binding	I-e1	O	drug
of	IN	of	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e5	T	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e6	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e7	O	drug
acid	NN	acid	I-e7	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
tolbutamide	NN	tolbutamide	B-e8	T	drug
in	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s12
Similarly	RB	similarly	O	O	NONE
,	,	,	O	O	NONE
nateglinide	NN	nateglinide	B-e0	O	drug
had	VBD	have	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
serum	NN	serum	O	O	NONE
protein	NN	protein	B-e1	O	drug
binding	NN	binding	I-e1	O	drug
of	IN	of	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e5	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e6	T	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e7	T	drug
acid	NN	acid	I-e7	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
tolbutamide	NN	tolbutamide	B-e8	O	drug
in	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s12
Similarly	RB	similarly	O	O	NONE
,	,	,	O	O	NONE
nateglinide	NN	nateglinide	B-e0	O	drug
had	VBD	have	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
serum	NN	serum	O	O	NONE
protein	NN	protein	B-e1	O	drug
binding	NN	binding	I-e1	O	drug
of	IN	of	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e5	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e6	T	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e7	O	drug
acid	NN	acid	I-e7	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
tolbutamide	NN	tolbutamide	B-e8	T	drug
in	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s12
Similarly	RB	similarly	O	O	NONE
,	,	,	O	O	NONE
nateglinide	NN	nateglinide	B-e0	O	drug
had	VBD	have	O	O	NONE
no	DT	no	O	O	NONE
influence	NN	influence	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
serum	NN	serum	O	O	NONE
protein	NN	protein	B-e1	O	drug
binding	NN	binding	I-e1	O	drug
of	IN	of	O	O	NONE
propranolol	NN	propranolol	B-e2	O	drug
,	,	,	O	O	NONE
glyburide	NN	glyburide	B-e3	O	drug
,	,	,	O	O	NONE
nicardipine	NN	nicardipine	B-e4	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e5	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e6	O	drug
,	,	,	O	O	NONE
acetylsalicylic	JJ	acetylsalicylic	B-e7	T	drug
acid	NN	acid	I-e7	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
tolbutamide	NN	tolbutamide	B-e8	T	drug
in	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s14
Certain	JJ	certain	O	O	NONE
drugs	NNS	drug	B-e0	T	drug
,	,	,	O	O	NONE
including	VBG	include	O	O	NONE
nonsteroidal	JJ	nonsteroidal	B-e1	T	drug
anti-inflammatory	JJ	anti-inflammatory	I-e1	T	drug
agents	NNS	agent	I-e1	T	drug
(	(	(	O	O	NONE
NSAIDs	NNS	nsaid	B-e2	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
salicylates	NNS	salicylate	B-e3	O	drug
,	,	,	O	O	NONE
monoamine	NN	monoamine	B-e4	O	drug
oxidase	NN	oxidase	I-e4	O	drug
inhibitors	NNS	inhibitor	I-e4	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
non-selective	JJ	non-selective	B-e5	O	drug
beta-adrenergic-blocking	JJ	beta-adrenergic-blocking	I-e5	O	drug
agents	NNS	agent	I-e5	O	drug
may	MD	may	O	O	NONE
potentiate	VB	potentiate	O	O	NONE
the	DT	the	O	O	NONE
hypoglycemic	JJ	hypoglycemic	B-e6	O	drug
action	NN	action	I-e6	O	drug
of	IN	of	O	O	NONE
Starlix	NN	starlix	B-e7	O	drug
and	CC	and	O	O	NONE
other	JJ	other	O	O	NONE
oral	JJ	oral	O	O	NONE
antidiabetic	JJ	antidiabetic	B-e8	O	drug
drugs	NNS	drug	I-e8	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s14
Certain	JJ	certain	O	O	NONE
drugs	NNS	drug	B-e0	T	drug
,	,	,	O	O	NONE
including	VBG	include	O	O	NONE
nonsteroidal	JJ	nonsteroidal	B-e1	O	drug
anti-inflammatory	JJ	anti-inflammatory	I-e1	O	drug
agents	NNS	agent	I-e1	O	drug
(	(	(	O	O	NONE
NSAIDs	NNS	nsaid	B-e2	T	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
salicylates	NNS	salicylate	B-e3	O	drug
,	,	,	O	O	NONE
monoamine	NN	monoamine	B-e4	O	drug
oxidase	NN	oxidase	I-e4	O	drug
inhibitors	NNS	inhibitor	I-e4	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
non-selective	JJ	non-selective	B-e5	O	drug
beta-adrenergic-blocking	JJ	beta-adrenergic-blocking	I-e5	O	drug
agents	NNS	agent	I-e5	O	drug
may	MD	may	O	O	NONE
potentiate	VB	potentiate	O	O	NONE
the	DT	the	O	O	NONE
hypoglycemic	JJ	hypoglycemic	B-e6	O	drug
action	NN	action	I-e6	O	drug
of	IN	of	O	O	NONE
Starlix	NN	starlix	B-e7	O	drug
and	CC	and	O	O	NONE
other	JJ	other	O	O	NONE
oral	JJ	oral	O	O	NONE
antidiabetic	JJ	antidiabetic	B-e8	O	drug
drugs	NNS	drug	I-e8	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s14
Certain	JJ	certain	O	O	NONE
drugs	NNS	drug	B-e0	T	drug
,	,	,	O	O	NONE
including	VBG	include	O	O	NONE
nonsteroidal	JJ	nonsteroidal	B-e1	O	drug
anti-inflammatory	JJ	anti-inflammatory	I-e1	O	drug
agents	NNS	agent	I-e1	O	drug
(	(	(	O	O	NONE
NSAIDs	NNS	nsaid	B-e2	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
salicylates	NNS	salicylate	B-e3	T	drug
,	,	,	O	O	NONE
monoamine	NN	monoamine	B-e4	O	drug
oxidase	NN	oxidase	I-e4	O	drug
inhibitors	NNS	inhibitor	I-e4	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
non-selective	JJ	non-selective	B-e5	O	drug
beta-adrenergic-blocking	JJ	beta-adrenergic-blocking	I-e5	O	drug
agents	NNS	agent	I-e5	O	drug
may	MD	may	O	O	NONE
potentiate	VB	potentiate	O	O	NONE
the	DT	the	O	O	NONE
hypoglycemic	JJ	hypoglycemic	B-e6	O	drug
action	NN	action	I-e6	O	drug
of	IN	of	O	O	NONE
Starlix	NN	starlix	B-e7	O	drug
and	CC	and	O	O	NONE
other	JJ	other	O	O	NONE
oral	JJ	oral	O	O	NONE
antidiabetic	JJ	antidiabetic	B-e8	O	drug
drugs	NNS	drug	I-e8	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s14
Certain	JJ	certain	O	O	NONE
drugs	NNS	drug	B-e0	T	drug
,	,	,	O	O	NONE
including	VBG	include	O	O	NONE
nonsteroidal	JJ	nonsteroidal	B-e1	O	drug
anti-inflammatory	JJ	anti-inflammatory	I-e1	O	drug
agents	NNS	agent	I-e1	O	drug
(	(	(	O	O	NONE
NSAIDs	NNS	nsaid	B-e2	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
salicylates	NNS	salicylate	B-e3	O	drug
,	,	,	O	O	NONE
monoamine	NN	monoamine	B-e4	T	drug
oxidase	NN	oxidase	I-e4	T	drug
inhibitors	NNS	inhibitor	I-e4	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
non-selective	JJ	non-selective	B-e5	O	drug
beta-adrenergic-blocking	JJ	beta-adrenergic-blocking	I-e5	O	drug
agents	NNS	agent	I-e5	O	drug
may	MD	may	O	O	NONE
potentiate	VB	potentiate	O	O	NONE
the	DT	the	O	O	NONE
hypoglycemic	JJ	hypoglycemic	B-e6	O	drug
action	NN	action	I-e6	O	drug
of	IN	of	O	O	NONE
Starlix	NN	starlix	B-e7	O	drug
and	CC	and	O	O	NONE
other	JJ	other	O	O	NONE
oral	JJ	oral	O	O	NONE
antidiabetic	JJ	antidiabetic	B-e8	O	drug
drugs	NNS	drug	I-e8	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s14
Certain	JJ	certain	O	O	NONE
drugs	NNS	drug	B-e0	T	drug
,	,	,	O	O	NONE
including	VBG	include	O	O	NONE
nonsteroidal	JJ	nonsteroidal	B-e1	O	drug
anti-inflammatory	JJ	anti-inflammatory	I-e1	O	drug
agents	NNS	agent	I-e1	O	drug
(	(	(	O	O	NONE
NSAIDs	NNS	nsaid	B-e2	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
salicylates	NNS	salicylate	B-e3	O	drug
,	,	,	O	O	NONE
monoamine	NN	monoamine	B-e4	O	drug
oxidase	NN	oxidase	I-e4	O	drug
inhibitors	NNS	inhibitor	I-e4	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
non-selective	JJ	non-selective	B-e5	T	drug
beta-adrenergic-blocking	JJ	beta-adrenergic-blocking	I-e5	T	drug
agents	NNS	agent	I-e5	T	drug
may	MD	may	O	O	NONE
potentiate	VB	potentiate	O	O	NONE
the	DT	the	O	O	NONE
hypoglycemic	JJ	hypoglycemic	B-e6	O	drug
action	NN	action	I-e6	O	drug
of	IN	of	O	O	NONE
Starlix	NN	starlix	B-e7	O	drug
and	CC	and	O	O	NONE
other	JJ	other	O	O	NONE
oral	JJ	oral	O	O	NONE
antidiabetic	JJ	antidiabetic	B-e8	O	drug
drugs	NNS	drug	I-e8	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s14
Certain	JJ	certain	O	O	NONE
drugs	NNS	drug	B-e0	T	drug
,	,	,	O	O	NONE
including	VBG	include	O	O	NONE
nonsteroidal	JJ	nonsteroidal	B-e1	O	drug
anti-inflammatory	JJ	anti-inflammatory	I-e1	O	drug
agents	NNS	agent	I-e1	O	drug
(	(	(	O	O	NONE
NSAIDs	NNS	nsaid	B-e2	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
salicylates	NNS	salicylate	B-e3	O	drug
,	,	,	O	O	NONE
monoamine	NN	monoamine	B-e4	O	drug
oxidase	NN	oxidase	I-e4	O	drug
inhibitors	NNS	inhibitor	I-e4	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
non-selective	JJ	non-selective	B-e5	O	drug
beta-adrenergic-blocking	JJ	beta-adrenergic-blocking	I-e5	O	drug
agents	NNS	agent	I-e5	O	drug
may	MD	may	O	O	NONE
potentiate	VB	potentiate	O	O	NONE
the	DT	the	O	O	NONE
hypoglycemic	JJ	hypoglycemic	B-e6	T	drug
action	NN	action	I-e6	T	drug
of	IN	of	O	O	NONE
Starlix	NN	starlix	B-e7	O	drug
and	CC	and	O	O	NONE
other	JJ	other	O	O	NONE
oral	JJ	oral	O	O	NONE
antidiabetic	JJ	antidiabetic	B-e8	O	drug
drugs	NNS	drug	I-e8	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s14
Certain	JJ	certain	O	O	NONE
drugs	NNS	drug	B-e0	T	drug
,	,	,	O	O	NONE
including	VBG	include	O	O	NONE
nonsteroidal	JJ	nonsteroidal	B-e1	O	drug
anti-inflammatory	JJ	anti-inflammatory	I-e1	O	drug
agents	NNS	agent	I-e1	O	drug
(	(	(	O	O	NONE
NSAIDs	NNS	nsaid	B-e2	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
salicylates	NNS	salicylate	B-e3	O	drug
,	,	,	O	O	NONE
monoamine	NN	monoamine	B-e4	O	drug
oxidase	NN	oxidase	I-e4	O	drug
inhibitors	NNS	inhibitor	I-e4	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
non-selective	JJ	non-selective	B-e5	O	drug
beta-adrenergic-blocking	JJ	beta-adrenergic-blocking	I-e5	O	drug
agents	NNS	agent	I-e5	O	drug
may	MD	may	O	O	NONE
potentiate	VB	potentiate	O	O	NONE
the	DT	the	O	O	NONE
hypoglycemic	JJ	hypoglycemic	B-e6	O	drug
action	NN	action	I-e6	O	drug
of	IN	of	O	O	NONE
Starlix	NN	starlix	B-e7	T	drug
and	CC	and	O	O	NONE
other	JJ	other	O	O	NONE
oral	JJ	oral	O	O	NONE
antidiabetic	JJ	antidiabetic	B-e8	O	drug
drugs	NNS	drug	I-e8	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s14
Certain	JJ	certain	O	O	NONE
drugs	NNS	drug	B-e0	T	drug
,	,	,	O	O	NONE
including	VBG	include	O	O	NONE
nonsteroidal	JJ	nonsteroidal	B-e1	O	drug
anti-inflammatory	JJ	anti-inflammatory	I-e1	O	drug
agents	NNS	agent	I-e1	O	drug
(	(	(	O	O	NONE
NSAIDs	NNS	nsaid	B-e2	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
salicylates	NNS	salicylate	B-e3	O	drug
,	,	,	O	O	NONE
monoamine	NN	monoamine	B-e4	O	drug
oxidase	NN	oxidase	I-e4	O	drug
inhibitors	NNS	inhibitor	I-e4	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
non-selective	JJ	non-selective	B-e5	O	drug
beta-adrenergic-blocking	JJ	beta-adrenergic-blocking	I-e5	O	drug
agents	NNS	agent	I-e5	O	drug
may	MD	may	O	O	NONE
potentiate	VB	potentiate	O	O	NONE
the	DT	the	O	O	NONE
hypoglycemic	JJ	hypoglycemic	B-e6	O	drug
action	NN	action	I-e6	O	drug
of	IN	of	O	O	NONE
Starlix	NN	starlix	B-e7	O	drug
and	CC	and	O	O	NONE
other	JJ	other	O	O	NONE
oral	JJ	oral	O	O	NONE
antidiabetic	JJ	antidiabetic	B-e8	T	drug
drugs	NNS	drug	I-e8	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s14
Certain	JJ	certain	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
,	,	,	O	O	NONE
including	VBG	include	O	O	NONE
nonsteroidal	JJ	nonsteroidal	B-e1	T	drug
anti-inflammatory	JJ	anti-inflammatory	I-e1	T	drug
agents	NNS	agent	I-e1	T	drug
(	(	(	O	O	NONE
NSAIDs	NNS	nsaid	B-e2	T	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
salicylates	NNS	salicylate	B-e3	O	drug
,	,	,	O	O	NONE
monoamine	NN	monoamine	B-e4	O	drug
oxidase	NN	oxidase	I-e4	O	drug
inhibitors	NNS	inhibitor	I-e4	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
non-selective	JJ	non-selective	B-e5	O	drug
beta-adrenergic-blocking	JJ	beta-adrenergic-blocking	I-e5	O	drug
agents	NNS	agent	I-e5	O	drug
may	MD	may	O	O	NONE
potentiate	VB	potentiate	O	O	NONE
the	DT	the	O	O	NONE
hypoglycemic	JJ	hypoglycemic	B-e6	O	drug
action	NN	action	I-e6	O	drug
of	IN	of	O	O	NONE
Starlix	NN	starlix	B-e7	O	drug
and	CC	and	O	O	NONE
other	JJ	other	O	O	NONE
oral	JJ	oral	O	O	NONE
antidiabetic	JJ	antidiabetic	B-e8	O	drug
drugs	NNS	drug	I-e8	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s14
Certain	JJ	certain	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
,	,	,	O	O	NONE
including	VBG	include	O	O	NONE
nonsteroidal	JJ	nonsteroidal	B-e1	T	drug
anti-inflammatory	JJ	anti-inflammatory	I-e1	T	drug
agents	NNS	agent	I-e1	T	drug
(	(	(	O	O	NONE
NSAIDs	NNS	nsaid	B-e2	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
salicylates	NNS	salicylate	B-e3	T	drug
,	,	,	O	O	NONE
monoamine	NN	monoamine	B-e4	O	drug
oxidase	NN	oxidase	I-e4	O	drug
inhibitors	NNS	inhibitor	I-e4	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
non-selective	JJ	non-selective	B-e5	O	drug
beta-adrenergic-blocking	JJ	beta-adrenergic-blocking	I-e5	O	drug
agents	NNS	agent	I-e5	O	drug
may	MD	may	O	O	NONE
potentiate	VB	potentiate	O	O	NONE
the	DT	the	O	O	NONE
hypoglycemic	JJ	hypoglycemic	B-e6	O	drug
action	NN	action	I-e6	O	drug
of	IN	of	O	O	NONE
Starlix	NN	starlix	B-e7	O	drug
and	CC	and	O	O	NONE
other	JJ	other	O	O	NONE
oral	JJ	oral	O	O	NONE
antidiabetic	JJ	antidiabetic	B-e8	O	drug
drugs	NNS	drug	I-e8	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s14
Certain	JJ	certain	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
,	,	,	O	O	NONE
including	VBG	include	O	O	NONE
nonsteroidal	JJ	nonsteroidal	B-e1	T	drug
anti-inflammatory	JJ	anti-inflammatory	I-e1	T	drug
agents	NNS	agent	I-e1	T	drug
(	(	(	O	O	NONE
NSAIDs	NNS	nsaid	B-e2	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
salicylates	NNS	salicylate	B-e3	O	drug
,	,	,	O	O	NONE
monoamine	NN	monoamine	B-e4	T	drug
oxidase	NN	oxidase	I-e4	T	drug
inhibitors	NNS	inhibitor	I-e4	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
non-selective	JJ	non-selective	B-e5	O	drug
beta-adrenergic-blocking	JJ	beta-adrenergic-blocking	I-e5	O	drug
agents	NNS	agent	I-e5	O	drug
may	MD	may	O	O	NONE
potentiate	VB	potentiate	O	O	NONE
the	DT	the	O	O	NONE
hypoglycemic	JJ	hypoglycemic	B-e6	O	drug
action	NN	action	I-e6	O	drug
of	IN	of	O	O	NONE
Starlix	NN	starlix	B-e7	O	drug
and	CC	and	O	O	NONE
other	JJ	other	O	O	NONE
oral	JJ	oral	O	O	NONE
antidiabetic	JJ	antidiabetic	B-e8	O	drug
drugs	NNS	drug	I-e8	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s14
Certain	JJ	certain	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
,	,	,	O	O	NONE
including	VBG	include	O	O	NONE
nonsteroidal	JJ	nonsteroidal	B-e1	T	drug
anti-inflammatory	JJ	anti-inflammatory	I-e1	T	drug
agents	NNS	agent	I-e1	T	drug
(	(	(	O	O	NONE
NSAIDs	NNS	nsaid	B-e2	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
salicylates	NNS	salicylate	B-e3	O	drug
,	,	,	O	O	NONE
monoamine	NN	monoamine	B-e4	O	drug
oxidase	NN	oxidase	I-e4	O	drug
inhibitors	NNS	inhibitor	I-e4	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
non-selective	JJ	non-selective	B-e5	T	drug
beta-adrenergic-blocking	JJ	beta-adrenergic-blocking	I-e5	T	drug
agents	NNS	agent	I-e5	T	drug
may	MD	may	O	O	NONE
potentiate	VB	potentiate	O	O	NONE
the	DT	the	O	O	NONE
hypoglycemic	JJ	hypoglycemic	B-e6	O	drug
action	NN	action	I-e6	O	drug
of	IN	of	O	O	NONE
Starlix	NN	starlix	B-e7	O	drug
and	CC	and	O	O	NONE
other	JJ	other	O	O	NONE
oral	JJ	oral	O	O	NONE
antidiabetic	JJ	antidiabetic	B-e8	O	drug
drugs	NNS	drug	I-e8	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s14
Certain	JJ	certain	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
,	,	,	O	O	NONE
including	VBG	include	O	O	NONE
nonsteroidal	JJ	nonsteroidal	B-e1	T	drug
anti-inflammatory	JJ	anti-inflammatory	I-e1	T	drug
agents	NNS	agent	I-e1	T	drug
(	(	(	O	O	NONE
NSAIDs	NNS	nsaid	B-e2	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
salicylates	NNS	salicylate	B-e3	O	drug
,	,	,	O	O	NONE
monoamine	NN	monoamine	B-e4	O	drug
oxidase	NN	oxidase	I-e4	O	drug
inhibitors	NNS	inhibitor	I-e4	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
non-selective	JJ	non-selective	B-e5	O	drug
beta-adrenergic-blocking	JJ	beta-adrenergic-blocking	I-e5	O	drug
agents	NNS	agent	I-e5	O	drug
may	MD	may	O	O	NONE
potentiate	VB	potentiate	O	O	NONE
the	DT	the	O	O	NONE
hypoglycemic	JJ	hypoglycemic	B-e6	T	drug
action	NN	action	I-e6	T	drug
of	IN	of	O	O	NONE
Starlix	NN	starlix	B-e7	O	drug
and	CC	and	O	O	NONE
other	JJ	other	O	O	NONE
oral	JJ	oral	O	O	NONE
antidiabetic	JJ	antidiabetic	B-e8	O	drug
drugs	NNS	drug	I-e8	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s14
Certain	JJ	certain	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
,	,	,	O	O	NONE
including	VBG	include	O	O	NONE
nonsteroidal	JJ	nonsteroidal	B-e1	T	drug
anti-inflammatory	JJ	anti-inflammatory	I-e1	T	drug
agents	NNS	agent	I-e1	T	drug
(	(	(	O	O	NONE
NSAIDs	NNS	nsaid	B-e2	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
salicylates	NNS	salicylate	B-e3	O	drug
,	,	,	O	O	NONE
monoamine	NN	monoamine	B-e4	O	drug
oxidase	NN	oxidase	I-e4	O	drug
inhibitors	NNS	inhibitor	I-e4	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
non-selective	JJ	non-selective	B-e5	O	drug
beta-adrenergic-blocking	JJ	beta-adrenergic-blocking	I-e5	O	drug
agents	NNS	agent	I-e5	O	drug
may	MD	may	O	O	NONE
potentiate	VB	potentiate	O	O	NONE
the	DT	the	O	O	NONE
hypoglycemic	JJ	hypoglycemic	B-e6	O	drug
action	NN	action	I-e6	O	drug
of	IN	of	O	O	NONE
Starlix	NN	starlix	B-e7	T	drug
and	CC	and	O	O	NONE
other	JJ	other	O	O	NONE
oral	JJ	oral	O	O	NONE
antidiabetic	JJ	antidiabetic	B-e8	O	drug
drugs	NNS	drug	I-e8	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s14
Certain	JJ	certain	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
,	,	,	O	O	NONE
including	VBG	include	O	O	NONE
nonsteroidal	JJ	nonsteroidal	B-e1	T	drug
anti-inflammatory	JJ	anti-inflammatory	I-e1	T	drug
agents	NNS	agent	I-e1	T	drug
(	(	(	O	O	NONE
NSAIDs	NNS	nsaid	B-e2	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
salicylates	NNS	salicylate	B-e3	O	drug
,	,	,	O	O	NONE
monoamine	NN	monoamine	B-e4	O	drug
oxidase	NN	oxidase	I-e4	O	drug
inhibitors	NNS	inhibitor	I-e4	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
non-selective	JJ	non-selective	B-e5	O	drug
beta-adrenergic-blocking	JJ	beta-adrenergic-blocking	I-e5	O	drug
agents	NNS	agent	I-e5	O	drug
may	MD	may	O	O	NONE
potentiate	VB	potentiate	O	O	NONE
the	DT	the	O	O	NONE
hypoglycemic	JJ	hypoglycemic	B-e6	O	drug
action	NN	action	I-e6	O	drug
of	IN	of	O	O	NONE
Starlix	NN	starlix	B-e7	O	drug
and	CC	and	O	O	NONE
other	JJ	other	O	O	NONE
oral	JJ	oral	O	O	NONE
antidiabetic	JJ	antidiabetic	B-e8	T	drug
drugs	NNS	drug	I-e8	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s14
Certain	JJ	certain	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
,	,	,	O	O	NONE
including	VBG	include	O	O	NONE
nonsteroidal	JJ	nonsteroidal	B-e1	O	drug
anti-inflammatory	JJ	anti-inflammatory	I-e1	O	drug
agents	NNS	agent	I-e1	O	drug
(	(	(	O	O	NONE
NSAIDs	NNS	nsaid	B-e2	T	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
salicylates	NNS	salicylate	B-e3	T	drug
,	,	,	O	O	NONE
monoamine	NN	monoamine	B-e4	O	drug
oxidase	NN	oxidase	I-e4	O	drug
inhibitors	NNS	inhibitor	I-e4	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
non-selective	JJ	non-selective	B-e5	O	drug
beta-adrenergic-blocking	JJ	beta-adrenergic-blocking	I-e5	O	drug
agents	NNS	agent	I-e5	O	drug
may	MD	may	O	O	NONE
potentiate	VB	potentiate	O	O	NONE
the	DT	the	O	O	NONE
hypoglycemic	JJ	hypoglycemic	B-e6	O	drug
action	NN	action	I-e6	O	drug
of	IN	of	O	O	NONE
Starlix	NN	starlix	B-e7	O	drug
and	CC	and	O	O	NONE
other	JJ	other	O	O	NONE
oral	JJ	oral	O	O	NONE
antidiabetic	JJ	antidiabetic	B-e8	O	drug
drugs	NNS	drug	I-e8	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s14
Certain	JJ	certain	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
,	,	,	O	O	NONE
including	VBG	include	O	O	NONE
nonsteroidal	JJ	nonsteroidal	B-e1	O	drug
anti-inflammatory	JJ	anti-inflammatory	I-e1	O	drug
agents	NNS	agent	I-e1	O	drug
(	(	(	O	O	NONE
NSAIDs	NNS	nsaid	B-e2	T	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
salicylates	NNS	salicylate	B-e3	O	drug
,	,	,	O	O	NONE
monoamine	NN	monoamine	B-e4	T	drug
oxidase	NN	oxidase	I-e4	T	drug
inhibitors	NNS	inhibitor	I-e4	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
non-selective	JJ	non-selective	B-e5	O	drug
beta-adrenergic-blocking	JJ	beta-adrenergic-blocking	I-e5	O	drug
agents	NNS	agent	I-e5	O	drug
may	MD	may	O	O	NONE
potentiate	VB	potentiate	O	O	NONE
the	DT	the	O	O	NONE
hypoglycemic	JJ	hypoglycemic	B-e6	O	drug
action	NN	action	I-e6	O	drug
of	IN	of	O	O	NONE
Starlix	NN	starlix	B-e7	O	drug
and	CC	and	O	O	NONE
other	JJ	other	O	O	NONE
oral	JJ	oral	O	O	NONE
antidiabetic	JJ	antidiabetic	B-e8	O	drug
drugs	NNS	drug	I-e8	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s14
Certain	JJ	certain	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
,	,	,	O	O	NONE
including	VBG	include	O	O	NONE
nonsteroidal	JJ	nonsteroidal	B-e1	O	drug
anti-inflammatory	JJ	anti-inflammatory	I-e1	O	drug
agents	NNS	agent	I-e1	O	drug
(	(	(	O	O	NONE
NSAIDs	NNS	nsaid	B-e2	T	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
salicylates	NNS	salicylate	B-e3	O	drug
,	,	,	O	O	NONE
monoamine	NN	monoamine	B-e4	O	drug
oxidase	NN	oxidase	I-e4	O	drug
inhibitors	NNS	inhibitor	I-e4	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
non-selective	JJ	non-selective	B-e5	T	drug
beta-adrenergic-blocking	JJ	beta-adrenergic-blocking	I-e5	T	drug
agents	NNS	agent	I-e5	T	drug
may	MD	may	O	O	NONE
potentiate	VB	potentiate	O	O	NONE
the	DT	the	O	O	NONE
hypoglycemic	JJ	hypoglycemic	B-e6	O	drug
action	NN	action	I-e6	O	drug
of	IN	of	O	O	NONE
Starlix	NN	starlix	B-e7	O	drug
and	CC	and	O	O	NONE
other	JJ	other	O	O	NONE
oral	JJ	oral	O	O	NONE
antidiabetic	JJ	antidiabetic	B-e8	O	drug
drugs	NNS	drug	I-e8	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s14
Certain	JJ	certain	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
,	,	,	O	O	NONE
including	VBG	include	O	O	NONE
nonsteroidal	JJ	nonsteroidal	B-e1	O	drug
anti-inflammatory	JJ	anti-inflammatory	I-e1	O	drug
agents	NNS	agent	I-e1	O	drug
(	(	(	O	O	NONE
NSAIDs	NNS	nsaid	B-e2	T	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
salicylates	NNS	salicylate	B-e3	O	drug
,	,	,	O	O	NONE
monoamine	NN	monoamine	B-e4	O	drug
oxidase	NN	oxidase	I-e4	O	drug
inhibitors	NNS	inhibitor	I-e4	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
non-selective	JJ	non-selective	B-e5	O	drug
beta-adrenergic-blocking	JJ	beta-adrenergic-blocking	I-e5	O	drug
agents	NNS	agent	I-e5	O	drug
may	MD	may	O	O	NONE
potentiate	VB	potentiate	O	O	NONE
the	DT	the	O	O	NONE
hypoglycemic	JJ	hypoglycemic	B-e6	T	drug
action	NN	action	I-e6	T	drug
of	IN	of	O	O	NONE
Starlix	NN	starlix	B-e7	O	drug
and	CC	and	O	O	NONE
other	JJ	other	O	O	NONE
oral	JJ	oral	O	O	NONE
antidiabetic	JJ	antidiabetic	B-e8	O	drug
drugs	NNS	drug	I-e8	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s14
Certain	JJ	certain	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
,	,	,	O	O	NONE
including	VBG	include	O	O	NONE
nonsteroidal	JJ	nonsteroidal	B-e1	O	drug
anti-inflammatory	JJ	anti-inflammatory	I-e1	O	drug
agents	NNS	agent	I-e1	O	drug
(	(	(	O	O	NONE
NSAIDs	NNS	nsaid	B-e2	T	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
salicylates	NNS	salicylate	B-e3	O	drug
,	,	,	O	O	NONE
monoamine	NN	monoamine	B-e4	O	drug
oxidase	NN	oxidase	I-e4	O	drug
inhibitors	NNS	inhibitor	I-e4	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
non-selective	JJ	non-selective	B-e5	O	drug
beta-adrenergic-blocking	JJ	beta-adrenergic-blocking	I-e5	O	drug
agents	NNS	agent	I-e5	O	drug
may	MD	may	O	O	NONE
potentiate	VB	potentiate	O	O	NONE
the	DT	the	O	O	NONE
hypoglycemic	JJ	hypoglycemic	B-e6	O	drug
action	NN	action	I-e6	O	drug
of	IN	of	O	O	NONE
Starlix	NN	starlix	B-e7	T	drug
and	CC	and	O	O	NONE
other	JJ	other	O	O	NONE
oral	JJ	oral	O	O	NONE
antidiabetic	JJ	antidiabetic	B-e8	O	drug
drugs	NNS	drug	I-e8	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s14
Certain	JJ	certain	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
,	,	,	O	O	NONE
including	VBG	include	O	O	NONE
nonsteroidal	JJ	nonsteroidal	B-e1	O	drug
anti-inflammatory	JJ	anti-inflammatory	I-e1	O	drug
agents	NNS	agent	I-e1	O	drug
(	(	(	O	O	NONE
NSAIDs	NNS	nsaid	B-e2	T	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
salicylates	NNS	salicylate	B-e3	O	drug
,	,	,	O	O	NONE
monoamine	NN	monoamine	B-e4	O	drug
oxidase	NN	oxidase	I-e4	O	drug
inhibitors	NNS	inhibitor	I-e4	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
non-selective	JJ	non-selective	B-e5	O	drug
beta-adrenergic-blocking	JJ	beta-adrenergic-blocking	I-e5	O	drug
agents	NNS	agent	I-e5	O	drug
may	MD	may	O	O	NONE
potentiate	VB	potentiate	O	O	NONE
the	DT	the	O	O	NONE
hypoglycemic	JJ	hypoglycemic	B-e6	O	drug
action	NN	action	I-e6	O	drug
of	IN	of	O	O	NONE
Starlix	NN	starlix	B-e7	O	drug
and	CC	and	O	O	NONE
other	JJ	other	O	O	NONE
oral	JJ	oral	O	O	NONE
antidiabetic	JJ	antidiabetic	B-e8	T	drug
drugs	NNS	drug	I-e8	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s14
Certain	JJ	certain	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
,	,	,	O	O	NONE
including	VBG	include	O	O	NONE
nonsteroidal	JJ	nonsteroidal	B-e1	O	drug
anti-inflammatory	JJ	anti-inflammatory	I-e1	O	drug
agents	NNS	agent	I-e1	O	drug
(	(	(	O	O	NONE
NSAIDs	NNS	nsaid	B-e2	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
salicylates	NNS	salicylate	B-e3	T	drug
,	,	,	O	O	NONE
monoamine	NN	monoamine	B-e4	T	drug
oxidase	NN	oxidase	I-e4	T	drug
inhibitors	NNS	inhibitor	I-e4	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
non-selective	JJ	non-selective	B-e5	O	drug
beta-adrenergic-blocking	JJ	beta-adrenergic-blocking	I-e5	O	drug
agents	NNS	agent	I-e5	O	drug
may	MD	may	O	O	NONE
potentiate	VB	potentiate	O	O	NONE
the	DT	the	O	O	NONE
hypoglycemic	JJ	hypoglycemic	B-e6	O	drug
action	NN	action	I-e6	O	drug
of	IN	of	O	O	NONE
Starlix	NN	starlix	B-e7	O	drug
and	CC	and	O	O	NONE
other	JJ	other	O	O	NONE
oral	JJ	oral	O	O	NONE
antidiabetic	JJ	antidiabetic	B-e8	O	drug
drugs	NNS	drug	I-e8	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s14
Certain	JJ	certain	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
,	,	,	O	O	NONE
including	VBG	include	O	O	NONE
nonsteroidal	JJ	nonsteroidal	B-e1	O	drug
anti-inflammatory	JJ	anti-inflammatory	I-e1	O	drug
agents	NNS	agent	I-e1	O	drug
(	(	(	O	O	NONE
NSAIDs	NNS	nsaid	B-e2	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
salicylates	NNS	salicylate	B-e3	T	drug
,	,	,	O	O	NONE
monoamine	NN	monoamine	B-e4	O	drug
oxidase	NN	oxidase	I-e4	O	drug
inhibitors	NNS	inhibitor	I-e4	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
non-selective	JJ	non-selective	B-e5	T	drug
beta-adrenergic-blocking	JJ	beta-adrenergic-blocking	I-e5	T	drug
agents	NNS	agent	I-e5	T	drug
may	MD	may	O	O	NONE
potentiate	VB	potentiate	O	O	NONE
the	DT	the	O	O	NONE
hypoglycemic	JJ	hypoglycemic	B-e6	O	drug
action	NN	action	I-e6	O	drug
of	IN	of	O	O	NONE
Starlix	NN	starlix	B-e7	O	drug
and	CC	and	O	O	NONE
other	JJ	other	O	O	NONE
oral	JJ	oral	O	O	NONE
antidiabetic	JJ	antidiabetic	B-e8	O	drug
drugs	NNS	drug	I-e8	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s14
Certain	JJ	certain	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
,	,	,	O	O	NONE
including	VBG	include	O	O	NONE
nonsteroidal	JJ	nonsteroidal	B-e1	O	drug
anti-inflammatory	JJ	anti-inflammatory	I-e1	O	drug
agents	NNS	agent	I-e1	O	drug
(	(	(	O	O	NONE
NSAIDs	NNS	nsaid	B-e2	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
salicylates	NNS	salicylate	B-e3	T	drug
,	,	,	O	O	NONE
monoamine	NN	monoamine	B-e4	O	drug
oxidase	NN	oxidase	I-e4	O	drug
inhibitors	NNS	inhibitor	I-e4	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
non-selective	JJ	non-selective	B-e5	O	drug
beta-adrenergic-blocking	JJ	beta-adrenergic-blocking	I-e5	O	drug
agents	NNS	agent	I-e5	O	drug
may	MD	may	O	O	NONE
potentiate	VB	potentiate	O	O	NONE
the	DT	the	O	O	NONE
hypoglycemic	JJ	hypoglycemic	B-e6	T	drug
action	NN	action	I-e6	T	drug
of	IN	of	O	O	NONE
Starlix	NN	starlix	B-e7	O	drug
and	CC	and	O	O	NONE
other	JJ	other	O	O	NONE
oral	JJ	oral	O	O	NONE
antidiabetic	JJ	antidiabetic	B-e8	O	drug
drugs	NNS	drug	I-e8	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s14
Certain	JJ	certain	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
,	,	,	O	O	NONE
including	VBG	include	O	O	NONE
nonsteroidal	JJ	nonsteroidal	B-e1	O	drug
anti-inflammatory	JJ	anti-inflammatory	I-e1	O	drug
agents	NNS	agent	I-e1	O	drug
(	(	(	O	O	NONE
NSAIDs	NNS	nsaid	B-e2	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
salicylates	NNS	salicylate	B-e3	T	drug
,	,	,	O	O	NONE
monoamine	NN	monoamine	B-e4	O	drug
oxidase	NN	oxidase	I-e4	O	drug
inhibitors	NNS	inhibitor	I-e4	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
non-selective	JJ	non-selective	B-e5	O	drug
beta-adrenergic-blocking	JJ	beta-adrenergic-blocking	I-e5	O	drug
agents	NNS	agent	I-e5	O	drug
may	MD	may	O	O	NONE
potentiate	VB	potentiate	O	O	NONE
the	DT	the	O	O	NONE
hypoglycemic	JJ	hypoglycemic	B-e6	O	drug
action	NN	action	I-e6	O	drug
of	IN	of	O	O	NONE
Starlix	NN	starlix	B-e7	T	drug
and	CC	and	O	O	NONE
other	JJ	other	O	O	NONE
oral	JJ	oral	O	O	NONE
antidiabetic	JJ	antidiabetic	B-e8	O	drug
drugs	NNS	drug	I-e8	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s14
Certain	JJ	certain	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
,	,	,	O	O	NONE
including	VBG	include	O	O	NONE
nonsteroidal	JJ	nonsteroidal	B-e1	O	drug
anti-inflammatory	JJ	anti-inflammatory	I-e1	O	drug
agents	NNS	agent	I-e1	O	drug
(	(	(	O	O	NONE
NSAIDs	NNS	nsaid	B-e2	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
salicylates	NNS	salicylate	B-e3	T	drug
,	,	,	O	O	NONE
monoamine	NN	monoamine	B-e4	O	drug
oxidase	NN	oxidase	I-e4	O	drug
inhibitors	NNS	inhibitor	I-e4	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
non-selective	JJ	non-selective	B-e5	O	drug
beta-adrenergic-blocking	JJ	beta-adrenergic-blocking	I-e5	O	drug
agents	NNS	agent	I-e5	O	drug
may	MD	may	O	O	NONE
potentiate	VB	potentiate	O	O	NONE
the	DT	the	O	O	NONE
hypoglycemic	JJ	hypoglycemic	B-e6	O	drug
action	NN	action	I-e6	O	drug
of	IN	of	O	O	NONE
Starlix	NN	starlix	B-e7	O	drug
and	CC	and	O	O	NONE
other	JJ	other	O	O	NONE
oral	JJ	oral	O	O	NONE
antidiabetic	JJ	antidiabetic	B-e8	T	drug
drugs	NNS	drug	I-e8	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s14
Certain	JJ	certain	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
,	,	,	O	O	NONE
including	VBG	include	O	O	NONE
nonsteroidal	JJ	nonsteroidal	B-e1	O	drug
anti-inflammatory	JJ	anti-inflammatory	I-e1	O	drug
agents	NNS	agent	I-e1	O	drug
(	(	(	O	O	NONE
NSAIDs	NNS	nsaid	B-e2	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
salicylates	NNS	salicylate	B-e3	O	drug
,	,	,	O	O	NONE
monoamine	NN	monoamine	B-e4	T	drug
oxidase	NN	oxidase	I-e4	T	drug
inhibitors	NNS	inhibitor	I-e4	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
non-selective	JJ	non-selective	B-e5	T	drug
beta-adrenergic-blocking	JJ	beta-adrenergic-blocking	I-e5	T	drug
agents	NNS	agent	I-e5	T	drug
may	MD	may	O	O	NONE
potentiate	VB	potentiate	O	O	NONE
the	DT	the	O	O	NONE
hypoglycemic	JJ	hypoglycemic	B-e6	O	drug
action	NN	action	I-e6	O	drug
of	IN	of	O	O	NONE
Starlix	NN	starlix	B-e7	O	drug
and	CC	and	O	O	NONE
other	JJ	other	O	O	NONE
oral	JJ	oral	O	O	NONE
antidiabetic	JJ	antidiabetic	B-e8	O	drug
drugs	NNS	drug	I-e8	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s14
Certain	JJ	certain	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
,	,	,	O	O	NONE
including	VBG	include	O	O	NONE
nonsteroidal	JJ	nonsteroidal	B-e1	O	drug
anti-inflammatory	JJ	anti-inflammatory	I-e1	O	drug
agents	NNS	agent	I-e1	O	drug
(	(	(	O	O	NONE
NSAIDs	NNS	nsaid	B-e2	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
salicylates	NNS	salicylate	B-e3	O	drug
,	,	,	O	O	NONE
monoamine	NN	monoamine	B-e4	T	drug
oxidase	NN	oxidase	I-e4	T	drug
inhibitors	NNS	inhibitor	I-e4	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
non-selective	JJ	non-selective	B-e5	O	drug
beta-adrenergic-blocking	JJ	beta-adrenergic-blocking	I-e5	O	drug
agents	NNS	agent	I-e5	O	drug
may	MD	may	O	O	NONE
potentiate	VB	potentiate	O	O	NONE
the	DT	the	O	O	NONE
hypoglycemic	JJ	hypoglycemic	B-e6	T	drug
action	NN	action	I-e6	T	drug
of	IN	of	O	O	NONE
Starlix	NN	starlix	B-e7	O	drug
and	CC	and	O	O	NONE
other	JJ	other	O	O	NONE
oral	JJ	oral	O	O	NONE
antidiabetic	JJ	antidiabetic	B-e8	O	drug
drugs	NNS	drug	I-e8	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s14
Certain	JJ	certain	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
,	,	,	O	O	NONE
including	VBG	include	O	O	NONE
nonsteroidal	JJ	nonsteroidal	B-e1	O	drug
anti-inflammatory	JJ	anti-inflammatory	I-e1	O	drug
agents	NNS	agent	I-e1	O	drug
(	(	(	O	O	NONE
NSAIDs	NNS	nsaid	B-e2	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
salicylates	NNS	salicylate	B-e3	O	drug
,	,	,	O	O	NONE
monoamine	NN	monoamine	B-e4	T	drug
oxidase	NN	oxidase	I-e4	T	drug
inhibitors	NNS	inhibitor	I-e4	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
non-selective	JJ	non-selective	B-e5	O	drug
beta-adrenergic-blocking	JJ	beta-adrenergic-blocking	I-e5	O	drug
agents	NNS	agent	I-e5	O	drug
may	MD	may	O	O	NONE
potentiate	VB	potentiate	O	O	NONE
the	DT	the	O	O	NONE
hypoglycemic	JJ	hypoglycemic	B-e6	O	drug
action	NN	action	I-e6	O	drug
of	IN	of	O	O	NONE
Starlix	NN	starlix	B-e7	T	drug
and	CC	and	O	O	NONE
other	JJ	other	O	O	NONE
oral	JJ	oral	O	O	NONE
antidiabetic	JJ	antidiabetic	B-e8	O	drug
drugs	NNS	drug	I-e8	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s14
Certain	JJ	certain	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
,	,	,	O	O	NONE
including	VBG	include	O	O	NONE
nonsteroidal	JJ	nonsteroidal	B-e1	O	drug
anti-inflammatory	JJ	anti-inflammatory	I-e1	O	drug
agents	NNS	agent	I-e1	O	drug
(	(	(	O	O	NONE
NSAIDs	NNS	nsaid	B-e2	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
salicylates	NNS	salicylate	B-e3	O	drug
,	,	,	O	O	NONE
monoamine	NN	monoamine	B-e4	T	drug
oxidase	NN	oxidase	I-e4	T	drug
inhibitors	NNS	inhibitor	I-e4	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
non-selective	JJ	non-selective	B-e5	O	drug
beta-adrenergic-blocking	JJ	beta-adrenergic-blocking	I-e5	O	drug
agents	NNS	agent	I-e5	O	drug
may	MD	may	O	O	NONE
potentiate	VB	potentiate	O	O	NONE
the	DT	the	O	O	NONE
hypoglycemic	JJ	hypoglycemic	B-e6	O	drug
action	NN	action	I-e6	O	drug
of	IN	of	O	O	NONE
Starlix	NN	starlix	B-e7	O	drug
and	CC	and	O	O	NONE
other	JJ	other	O	O	NONE
oral	JJ	oral	O	O	NONE
antidiabetic	JJ	antidiabetic	B-e8	T	drug
drugs	NNS	drug	I-e8	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s14
Certain	JJ	certain	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
,	,	,	O	O	NONE
including	VBG	include	O	O	NONE
nonsteroidal	JJ	nonsteroidal	B-e1	O	drug
anti-inflammatory	JJ	anti-inflammatory	I-e1	O	drug
agents	NNS	agent	I-e1	O	drug
(	(	(	O	O	NONE
NSAIDs	NNS	nsaid	B-e2	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
salicylates	NNS	salicylate	B-e3	O	drug
,	,	,	O	O	NONE
monoamine	NN	monoamine	B-e4	O	drug
oxidase	NN	oxidase	I-e4	O	drug
inhibitors	NNS	inhibitor	I-e4	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
non-selective	JJ	non-selective	B-e5	T	drug
beta-adrenergic-blocking	JJ	beta-adrenergic-blocking	I-e5	T	drug
agents	NNS	agent	I-e5	T	drug
may	MD	may	O	O	NONE
potentiate	VB	potentiate	O	O	NONE
the	DT	the	O	O	NONE
hypoglycemic	JJ	hypoglycemic	B-e6	T	drug
action	NN	action	I-e6	T	drug
of	IN	of	O	O	NONE
Starlix	NN	starlix	B-e7	O	drug
and	CC	and	O	O	NONE
other	JJ	other	O	O	NONE
oral	JJ	oral	O	O	NONE
antidiabetic	JJ	antidiabetic	B-e8	O	drug
drugs	NNS	drug	I-e8	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s14
Certain	JJ	certain	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
,	,	,	O	O	NONE
including	VBG	include	O	O	NONE
nonsteroidal	JJ	nonsteroidal	B-e1	O	drug
anti-inflammatory	JJ	anti-inflammatory	I-e1	O	drug
agents	NNS	agent	I-e1	O	drug
(	(	(	O	O	NONE
NSAIDs	NNS	nsaid	B-e2	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
salicylates	NNS	salicylate	B-e3	O	drug
,	,	,	O	O	NONE
monoamine	NN	monoamine	B-e4	O	drug
oxidase	NN	oxidase	I-e4	O	drug
inhibitors	NNS	inhibitor	I-e4	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
non-selective	JJ	non-selective	B-e5	T	drug
beta-adrenergic-blocking	JJ	beta-adrenergic-blocking	I-e5	T	drug
agents	NNS	agent	I-e5	T	drug
may	MD	may	O	O	NONE
potentiate	VB	potentiate	O	O	NONE
the	DT	the	O	O	NONE
hypoglycemic	JJ	hypoglycemic	B-e6	O	drug
action	NN	action	I-e6	O	drug
of	IN	of	O	O	NONE
Starlix	NN	starlix	B-e7	T	drug
and	CC	and	O	O	NONE
other	JJ	other	O	O	NONE
oral	JJ	oral	O	O	NONE
antidiabetic	JJ	antidiabetic	B-e8	O	drug
drugs	NNS	drug	I-e8	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s14
Certain	JJ	certain	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
,	,	,	O	O	NONE
including	VBG	include	O	O	NONE
nonsteroidal	JJ	nonsteroidal	B-e1	O	drug
anti-inflammatory	JJ	anti-inflammatory	I-e1	O	drug
agents	NNS	agent	I-e1	O	drug
(	(	(	O	O	NONE
NSAIDs	NNS	nsaid	B-e2	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
salicylates	NNS	salicylate	B-e3	O	drug
,	,	,	O	O	NONE
monoamine	NN	monoamine	B-e4	O	drug
oxidase	NN	oxidase	I-e4	O	drug
inhibitors	NNS	inhibitor	I-e4	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
non-selective	JJ	non-selective	B-e5	T	drug
beta-adrenergic-blocking	JJ	beta-adrenergic-blocking	I-e5	T	drug
agents	NNS	agent	I-e5	T	drug
may	MD	may	O	O	NONE
potentiate	VB	potentiate	O	O	NONE
the	DT	the	O	O	NONE
hypoglycemic	JJ	hypoglycemic	B-e6	O	drug
action	NN	action	I-e6	O	drug
of	IN	of	O	O	NONE
Starlix	NN	starlix	B-e7	O	drug
and	CC	and	O	O	NONE
other	JJ	other	O	O	NONE
oral	JJ	oral	O	O	NONE
antidiabetic	JJ	antidiabetic	B-e8	T	drug
drugs	NNS	drug	I-e8	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s14
Certain	JJ	certain	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
,	,	,	O	O	NONE
including	VBG	include	O	O	NONE
nonsteroidal	JJ	nonsteroidal	B-e1	O	drug
anti-inflammatory	JJ	anti-inflammatory	I-e1	O	drug
agents	NNS	agent	I-e1	O	drug
(	(	(	O	O	NONE
NSAIDs	NNS	nsaid	B-e2	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
salicylates	NNS	salicylate	B-e3	O	drug
,	,	,	O	O	NONE
monoamine	NN	monoamine	B-e4	O	drug
oxidase	NN	oxidase	I-e4	O	drug
inhibitors	NNS	inhibitor	I-e4	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
non-selective	JJ	non-selective	B-e5	O	drug
beta-adrenergic-blocking	JJ	beta-adrenergic-blocking	I-e5	O	drug
agents	NNS	agent	I-e5	O	drug
may	MD	may	O	O	NONE
potentiate	VB	potentiate	O	O	NONE
the	DT	the	O	O	NONE
hypoglycemic	JJ	hypoglycemic	B-e6	T	drug
action	NN	action	I-e6	T	drug
of	IN	of	O	O	NONE
Starlix	NN	starlix	B-e7	T	drug
and	CC	and	O	O	NONE
other	JJ	other	O	O	NONE
oral	JJ	oral	O	O	NONE
antidiabetic	JJ	antidiabetic	B-e8	O	drug
drugs	NNS	drug	I-e8	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s14
Certain	JJ	certain	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
,	,	,	O	O	NONE
including	VBG	include	O	O	NONE
nonsteroidal	JJ	nonsteroidal	B-e1	O	drug
anti-inflammatory	JJ	anti-inflammatory	I-e1	O	drug
agents	NNS	agent	I-e1	O	drug
(	(	(	O	O	NONE
NSAIDs	NNS	nsaid	B-e2	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
salicylates	NNS	salicylate	B-e3	O	drug
,	,	,	O	O	NONE
monoamine	NN	monoamine	B-e4	O	drug
oxidase	NN	oxidase	I-e4	O	drug
inhibitors	NNS	inhibitor	I-e4	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
non-selective	JJ	non-selective	B-e5	O	drug
beta-adrenergic-blocking	JJ	beta-adrenergic-blocking	I-e5	O	drug
agents	NNS	agent	I-e5	O	drug
may	MD	may	O	O	NONE
potentiate	VB	potentiate	O	O	NONE
the	DT	the	O	O	NONE
hypoglycemic	JJ	hypoglycemic	B-e6	T	drug
action	NN	action	I-e6	T	drug
of	IN	of	O	O	NONE
Starlix	NN	starlix	B-e7	O	drug
and	CC	and	O	O	NONE
other	JJ	other	O	O	NONE
oral	JJ	oral	O	O	NONE
antidiabetic	JJ	antidiabetic	B-e8	T	drug
drugs	NNS	drug	I-e8	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s14
Certain	JJ	certain	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
,	,	,	O	O	NONE
including	VBG	include	O	O	NONE
nonsteroidal	JJ	nonsteroidal	B-e1	O	drug
anti-inflammatory	JJ	anti-inflammatory	I-e1	O	drug
agents	NNS	agent	I-e1	O	drug
(	(	(	O	O	NONE
NSAIDs	NNS	nsaid	B-e2	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
salicylates	NNS	salicylate	B-e3	O	drug
,	,	,	O	O	NONE
monoamine	NN	monoamine	B-e4	O	drug
oxidase	NN	oxidase	I-e4	O	drug
inhibitors	NNS	inhibitor	I-e4	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
non-selective	JJ	non-selective	B-e5	O	drug
beta-adrenergic-blocking	JJ	beta-adrenergic-blocking	I-e5	O	drug
agents	NNS	agent	I-e5	O	drug
may	MD	may	O	O	NONE
potentiate	VB	potentiate	O	O	NONE
the	DT	the	O	O	NONE
hypoglycemic	JJ	hypoglycemic	B-e6	O	drug
action	NN	action	I-e6	O	drug
of	IN	of	O	O	NONE
Starlix	NN	starlix	B-e7	T	drug
and	CC	and	O	O	NONE
other	JJ	other	O	O	NONE
oral	JJ	oral	O	O	NONE
antidiabetic	JJ	antidiabetic	B-e8	T	drug
drugs	NNS	drug	I-e8	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s15
Certain	JJ	certain	O	O	NONE
drugs	NNS	drug	B-e0	T	drug
including	VBG	include	O	O	NONE
thiazides	NNS	thiazide	B-e1	T	drug
,	,	,	O	O	NONE
corticosteroids	NNS	corticosteroid	B-e2	O	drug
,	,	,	O	O	NONE
thyroid	NN	thyroid	B-e3	O	drug
products	NNS	product	O	O	NONE
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
sympathomimetics	NNS	sympathomimetic	B-e4	O	drug
may	MD	may	O	O	NONE
reduce	VB	reduce	O	O	NONE
the	DT	the	O	O	NONE
hypoglycemic	JJ	hypoglycemic	B-e5	O	drug
action	NN	action	I-e5	O	drug
of	IN	of	O	O	NONE
Starlix	NN	starlix	B-e6	O	drug
and	CC	and	O	O	NONE
other	JJ	other	O	O	NONE
oral	JJ	oral	O	O	NONE
antidiabetic	JJ	antidiabetic	B-e7	O	drug
drugs	NNS	drug	I-e7	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s15
Certain	JJ	certain	O	O	NONE
drugs	NNS	drug	B-e0	T	drug
including	VBG	include	O	O	NONE
thiazides	NNS	thiazide	B-e1	O	drug
,	,	,	O	O	NONE
corticosteroids	NNS	corticosteroid	B-e2	T	drug
,	,	,	O	O	NONE
thyroid	NN	thyroid	B-e3	O	drug
products	NNS	product	O	O	NONE
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
sympathomimetics	NNS	sympathomimetic	B-e4	O	drug
may	MD	may	O	O	NONE
reduce	VB	reduce	O	O	NONE
the	DT	the	O	O	NONE
hypoglycemic	JJ	hypoglycemic	B-e5	O	drug
action	NN	action	I-e5	O	drug
of	IN	of	O	O	NONE
Starlix	NN	starlix	B-e6	O	drug
and	CC	and	O	O	NONE
other	JJ	other	O	O	NONE
oral	JJ	oral	O	O	NONE
antidiabetic	JJ	antidiabetic	B-e7	O	drug
drugs	NNS	drug	I-e7	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s15
Certain	JJ	certain	O	O	NONE
drugs	NNS	drug	B-e0	T	drug
including	VBG	include	O	O	NONE
thiazides	NNS	thiazide	B-e1	O	drug
,	,	,	O	O	NONE
corticosteroids	NNS	corticosteroid	B-e2	O	drug
,	,	,	O	O	NONE
thyroid	NN	thyroid	B-e3	T	drug
products	NNS	product	O	O	NONE
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
sympathomimetics	NNS	sympathomimetic	B-e4	O	drug
may	MD	may	O	O	NONE
reduce	VB	reduce	O	O	NONE
the	DT	the	O	O	NONE
hypoglycemic	JJ	hypoglycemic	B-e5	O	drug
action	NN	action	I-e5	O	drug
of	IN	of	O	O	NONE
Starlix	NN	starlix	B-e6	O	drug
and	CC	and	O	O	NONE
other	JJ	other	O	O	NONE
oral	JJ	oral	O	O	NONE
antidiabetic	JJ	antidiabetic	B-e7	O	drug
drugs	NNS	drug	I-e7	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s15
Certain	JJ	certain	O	O	NONE
drugs	NNS	drug	B-e0	T	drug
including	VBG	include	O	O	NONE
thiazides	NNS	thiazide	B-e1	O	drug
,	,	,	O	O	NONE
corticosteroids	NNS	corticosteroid	B-e2	O	drug
,	,	,	O	O	NONE
thyroid	NN	thyroid	B-e3	O	drug
products	NNS	product	O	O	NONE
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
sympathomimetics	NNS	sympathomimetic	B-e4	T	drug
may	MD	may	O	O	NONE
reduce	VB	reduce	O	O	NONE
the	DT	the	O	O	NONE
hypoglycemic	JJ	hypoglycemic	B-e5	O	drug
action	NN	action	I-e5	O	drug
of	IN	of	O	O	NONE
Starlix	NN	starlix	B-e6	O	drug
and	CC	and	O	O	NONE
other	JJ	other	O	O	NONE
oral	JJ	oral	O	O	NONE
antidiabetic	JJ	antidiabetic	B-e7	O	drug
drugs	NNS	drug	I-e7	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s15
Certain	JJ	certain	O	O	NONE
drugs	NNS	drug	B-e0	T	drug
including	VBG	include	O	O	NONE
thiazides	NNS	thiazide	B-e1	O	drug
,	,	,	O	O	NONE
corticosteroids	NNS	corticosteroid	B-e2	O	drug
,	,	,	O	O	NONE
thyroid	NN	thyroid	B-e3	O	drug
products	NNS	product	O	O	NONE
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
sympathomimetics	NNS	sympathomimetic	B-e4	O	drug
may	MD	may	O	O	NONE
reduce	VB	reduce	O	O	NONE
the	DT	the	O	O	NONE
hypoglycemic	JJ	hypoglycemic	B-e5	T	drug
action	NN	action	I-e5	T	drug
of	IN	of	O	O	NONE
Starlix	NN	starlix	B-e6	O	drug
and	CC	and	O	O	NONE
other	JJ	other	O	O	NONE
oral	JJ	oral	O	O	NONE
antidiabetic	JJ	antidiabetic	B-e7	O	drug
drugs	NNS	drug	I-e7	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s15
Certain	JJ	certain	O	O	NONE
drugs	NNS	drug	B-e0	T	drug
including	VBG	include	O	O	NONE
thiazides	NNS	thiazide	B-e1	O	drug
,	,	,	O	O	NONE
corticosteroids	NNS	corticosteroid	B-e2	O	drug
,	,	,	O	O	NONE
thyroid	NN	thyroid	B-e3	O	drug
products	NNS	product	O	O	NONE
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
sympathomimetics	NNS	sympathomimetic	B-e4	O	drug
may	MD	may	O	O	NONE
reduce	VB	reduce	O	O	NONE
the	DT	the	O	O	NONE
hypoglycemic	JJ	hypoglycemic	B-e5	O	drug
action	NN	action	I-e5	O	drug
of	IN	of	O	O	NONE
Starlix	NN	starlix	B-e6	T	drug
and	CC	and	O	O	NONE
other	JJ	other	O	O	NONE
oral	JJ	oral	O	O	NONE
antidiabetic	JJ	antidiabetic	B-e7	O	drug
drugs	NNS	drug	I-e7	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s15
Certain	JJ	certain	O	O	NONE
drugs	NNS	drug	B-e0	T	drug
including	VBG	include	O	O	NONE
thiazides	NNS	thiazide	B-e1	O	drug
,	,	,	O	O	NONE
corticosteroids	NNS	corticosteroid	B-e2	O	drug
,	,	,	O	O	NONE
thyroid	NN	thyroid	B-e3	O	drug
products	NNS	product	O	O	NONE
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
sympathomimetics	NNS	sympathomimetic	B-e4	O	drug
may	MD	may	O	O	NONE
reduce	VB	reduce	O	O	NONE
the	DT	the	O	O	NONE
hypoglycemic	JJ	hypoglycemic	B-e5	O	drug
action	NN	action	I-e5	O	drug
of	IN	of	O	O	NONE
Starlix	NN	starlix	B-e6	O	drug
and	CC	and	O	O	NONE
other	JJ	other	O	O	NONE
oral	JJ	oral	O	O	NONE
antidiabetic	JJ	antidiabetic	B-e7	T	drug
drugs	NNS	drug	I-e7	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s15
Certain	JJ	certain	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
including	VBG	include	O	O	NONE
thiazides	NNS	thiazide	B-e1	T	drug
,	,	,	O	O	NONE
corticosteroids	NNS	corticosteroid	B-e2	T	drug
,	,	,	O	O	NONE
thyroid	NN	thyroid	B-e3	O	drug
products	NNS	product	O	O	NONE
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
sympathomimetics	NNS	sympathomimetic	B-e4	O	drug
may	MD	may	O	O	NONE
reduce	VB	reduce	O	O	NONE
the	DT	the	O	O	NONE
hypoglycemic	JJ	hypoglycemic	B-e5	O	drug
action	NN	action	I-e5	O	drug
of	IN	of	O	O	NONE
Starlix	NN	starlix	B-e6	O	drug
and	CC	and	O	O	NONE
other	JJ	other	O	O	NONE
oral	JJ	oral	O	O	NONE
antidiabetic	JJ	antidiabetic	B-e7	O	drug
drugs	NNS	drug	I-e7	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s15
Certain	JJ	certain	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
including	VBG	include	O	O	NONE
thiazides	NNS	thiazide	B-e1	T	drug
,	,	,	O	O	NONE
corticosteroids	NNS	corticosteroid	B-e2	O	drug
,	,	,	O	O	NONE
thyroid	NN	thyroid	B-e3	T	drug
products	NNS	product	O	O	NONE
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
sympathomimetics	NNS	sympathomimetic	B-e4	O	drug
may	MD	may	O	O	NONE
reduce	VB	reduce	O	O	NONE
the	DT	the	O	O	NONE
hypoglycemic	JJ	hypoglycemic	B-e5	O	drug
action	NN	action	I-e5	O	drug
of	IN	of	O	O	NONE
Starlix	NN	starlix	B-e6	O	drug
and	CC	and	O	O	NONE
other	JJ	other	O	O	NONE
oral	JJ	oral	O	O	NONE
antidiabetic	JJ	antidiabetic	B-e7	O	drug
drugs	NNS	drug	I-e7	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s15
Certain	JJ	certain	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
including	VBG	include	O	O	NONE
thiazides	NNS	thiazide	B-e1	T	drug
,	,	,	O	O	NONE
corticosteroids	NNS	corticosteroid	B-e2	O	drug
,	,	,	O	O	NONE
thyroid	NN	thyroid	B-e3	O	drug
products	NNS	product	O	O	NONE
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
sympathomimetics	NNS	sympathomimetic	B-e4	T	drug
may	MD	may	O	O	NONE
reduce	VB	reduce	O	O	NONE
the	DT	the	O	O	NONE
hypoglycemic	JJ	hypoglycemic	B-e5	O	drug
action	NN	action	I-e5	O	drug
of	IN	of	O	O	NONE
Starlix	NN	starlix	B-e6	O	drug
and	CC	and	O	O	NONE
other	JJ	other	O	O	NONE
oral	JJ	oral	O	O	NONE
antidiabetic	JJ	antidiabetic	B-e7	O	drug
drugs	NNS	drug	I-e7	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s15
Certain	JJ	certain	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
including	VBG	include	O	O	NONE
thiazides	NNS	thiazide	B-e1	T	drug
,	,	,	O	O	NONE
corticosteroids	NNS	corticosteroid	B-e2	O	drug
,	,	,	O	O	NONE
thyroid	NN	thyroid	B-e3	O	drug
products	NNS	product	O	O	NONE
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
sympathomimetics	NNS	sympathomimetic	B-e4	O	drug
may	MD	may	O	O	NONE
reduce	VB	reduce	O	O	NONE
the	DT	the	O	O	NONE
hypoglycemic	JJ	hypoglycemic	B-e5	T	drug
action	NN	action	I-e5	T	drug
of	IN	of	O	O	NONE
Starlix	NN	starlix	B-e6	O	drug
and	CC	and	O	O	NONE
other	JJ	other	O	O	NONE
oral	JJ	oral	O	O	NONE
antidiabetic	JJ	antidiabetic	B-e7	O	drug
drugs	NNS	drug	I-e7	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s15
Certain	JJ	certain	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
including	VBG	include	O	O	NONE
thiazides	NNS	thiazide	B-e1	T	drug
,	,	,	O	O	NONE
corticosteroids	NNS	corticosteroid	B-e2	O	drug
,	,	,	O	O	NONE
thyroid	NN	thyroid	B-e3	O	drug
products	NNS	product	O	O	NONE
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
sympathomimetics	NNS	sympathomimetic	B-e4	O	drug
may	MD	may	O	O	NONE
reduce	VB	reduce	O	O	NONE
the	DT	the	O	O	NONE
hypoglycemic	JJ	hypoglycemic	B-e5	O	drug
action	NN	action	I-e5	O	drug
of	IN	of	O	O	NONE
Starlix	NN	starlix	B-e6	T	drug
and	CC	and	O	O	NONE
other	JJ	other	O	O	NONE
oral	JJ	oral	O	O	NONE
antidiabetic	JJ	antidiabetic	B-e7	O	drug
drugs	NNS	drug	I-e7	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s15
Certain	JJ	certain	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
including	VBG	include	O	O	NONE
thiazides	NNS	thiazide	B-e1	T	drug
,	,	,	O	O	NONE
corticosteroids	NNS	corticosteroid	B-e2	O	drug
,	,	,	O	O	NONE
thyroid	NN	thyroid	B-e3	O	drug
products	NNS	product	O	O	NONE
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
sympathomimetics	NNS	sympathomimetic	B-e4	O	drug
may	MD	may	O	O	NONE
reduce	VB	reduce	O	O	NONE
the	DT	the	O	O	NONE
hypoglycemic	JJ	hypoglycemic	B-e5	O	drug
action	NN	action	I-e5	O	drug
of	IN	of	O	O	NONE
Starlix	NN	starlix	B-e6	O	drug
and	CC	and	O	O	NONE
other	JJ	other	O	O	NONE
oral	JJ	oral	O	O	NONE
antidiabetic	JJ	antidiabetic	B-e7	T	drug
drugs	NNS	drug	I-e7	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s15
Certain	JJ	certain	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
including	VBG	include	O	O	NONE
thiazides	NNS	thiazide	B-e1	O	drug
,	,	,	O	O	NONE
corticosteroids	NNS	corticosteroid	B-e2	T	drug
,	,	,	O	O	NONE
thyroid	NN	thyroid	B-e3	T	drug
products	NNS	product	O	O	NONE
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
sympathomimetics	NNS	sympathomimetic	B-e4	O	drug
may	MD	may	O	O	NONE
reduce	VB	reduce	O	O	NONE
the	DT	the	O	O	NONE
hypoglycemic	JJ	hypoglycemic	B-e5	O	drug
action	NN	action	I-e5	O	drug
of	IN	of	O	O	NONE
Starlix	NN	starlix	B-e6	O	drug
and	CC	and	O	O	NONE
other	JJ	other	O	O	NONE
oral	JJ	oral	O	O	NONE
antidiabetic	JJ	antidiabetic	B-e7	O	drug
drugs	NNS	drug	I-e7	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s15
Certain	JJ	certain	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
including	VBG	include	O	O	NONE
thiazides	NNS	thiazide	B-e1	O	drug
,	,	,	O	O	NONE
corticosteroids	NNS	corticosteroid	B-e2	T	drug
,	,	,	O	O	NONE
thyroid	NN	thyroid	B-e3	O	drug
products	NNS	product	O	O	NONE
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
sympathomimetics	NNS	sympathomimetic	B-e4	T	drug
may	MD	may	O	O	NONE
reduce	VB	reduce	O	O	NONE
the	DT	the	O	O	NONE
hypoglycemic	JJ	hypoglycemic	B-e5	O	drug
action	NN	action	I-e5	O	drug
of	IN	of	O	O	NONE
Starlix	NN	starlix	B-e6	O	drug
and	CC	and	O	O	NONE
other	JJ	other	O	O	NONE
oral	JJ	oral	O	O	NONE
antidiabetic	JJ	antidiabetic	B-e7	O	drug
drugs	NNS	drug	I-e7	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s15
Certain	JJ	certain	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
including	VBG	include	O	O	NONE
thiazides	NNS	thiazide	B-e1	O	drug
,	,	,	O	O	NONE
corticosteroids	NNS	corticosteroid	B-e2	T	drug
,	,	,	O	O	NONE
thyroid	NN	thyroid	B-e3	O	drug
products	NNS	product	O	O	NONE
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
sympathomimetics	NNS	sympathomimetic	B-e4	O	drug
may	MD	may	O	O	NONE
reduce	VB	reduce	O	O	NONE
the	DT	the	O	O	NONE
hypoglycemic	JJ	hypoglycemic	B-e5	T	drug
action	NN	action	I-e5	T	drug
of	IN	of	O	O	NONE
Starlix	NN	starlix	B-e6	O	drug
and	CC	and	O	O	NONE
other	JJ	other	O	O	NONE
oral	JJ	oral	O	O	NONE
antidiabetic	JJ	antidiabetic	B-e7	O	drug
drugs	NNS	drug	I-e7	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s15
Certain	JJ	certain	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
including	VBG	include	O	O	NONE
thiazides	NNS	thiazide	B-e1	O	drug
,	,	,	O	O	NONE
corticosteroids	NNS	corticosteroid	B-e2	T	drug
,	,	,	O	O	NONE
thyroid	NN	thyroid	B-e3	O	drug
products	NNS	product	O	O	NONE
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
sympathomimetics	NNS	sympathomimetic	B-e4	O	drug
may	MD	may	O	O	NONE
reduce	VB	reduce	O	O	NONE
the	DT	the	O	O	NONE
hypoglycemic	JJ	hypoglycemic	B-e5	O	drug
action	NN	action	I-e5	O	drug
of	IN	of	O	O	NONE
Starlix	NN	starlix	B-e6	T	drug
and	CC	and	O	O	NONE
other	JJ	other	O	O	NONE
oral	JJ	oral	O	O	NONE
antidiabetic	JJ	antidiabetic	B-e7	O	drug
drugs	NNS	drug	I-e7	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s15
Certain	JJ	certain	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
including	VBG	include	O	O	NONE
thiazides	NNS	thiazide	B-e1	O	drug
,	,	,	O	O	NONE
corticosteroids	NNS	corticosteroid	B-e2	T	drug
,	,	,	O	O	NONE
thyroid	NN	thyroid	B-e3	O	drug
products	NNS	product	O	O	NONE
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
sympathomimetics	NNS	sympathomimetic	B-e4	O	drug
may	MD	may	O	O	NONE
reduce	VB	reduce	O	O	NONE
the	DT	the	O	O	NONE
hypoglycemic	JJ	hypoglycemic	B-e5	O	drug
action	NN	action	I-e5	O	drug
of	IN	of	O	O	NONE
Starlix	NN	starlix	B-e6	O	drug
and	CC	and	O	O	NONE
other	JJ	other	O	O	NONE
oral	JJ	oral	O	O	NONE
antidiabetic	JJ	antidiabetic	B-e7	T	drug
drugs	NNS	drug	I-e7	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s15
Certain	JJ	certain	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
including	VBG	include	O	O	NONE
thiazides	NNS	thiazide	B-e1	O	drug
,	,	,	O	O	NONE
corticosteroids	NNS	corticosteroid	B-e2	O	drug
,	,	,	O	O	NONE
thyroid	NN	thyroid	B-e3	T	drug
products	NNS	product	O	O	NONE
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
sympathomimetics	NNS	sympathomimetic	B-e4	T	drug
may	MD	may	O	O	NONE
reduce	VB	reduce	O	O	NONE
the	DT	the	O	O	NONE
hypoglycemic	JJ	hypoglycemic	B-e5	O	drug
action	NN	action	I-e5	O	drug
of	IN	of	O	O	NONE
Starlix	NN	starlix	B-e6	O	drug
and	CC	and	O	O	NONE
other	JJ	other	O	O	NONE
oral	JJ	oral	O	O	NONE
antidiabetic	JJ	antidiabetic	B-e7	O	drug
drugs	NNS	drug	I-e7	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s15
Certain	JJ	certain	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
including	VBG	include	O	O	NONE
thiazides	NNS	thiazide	B-e1	O	drug
,	,	,	O	O	NONE
corticosteroids	NNS	corticosteroid	B-e2	O	drug
,	,	,	O	O	NONE
thyroid	NN	thyroid	B-e3	T	drug
products	NNS	product	O	O	NONE
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
sympathomimetics	NNS	sympathomimetic	B-e4	O	drug
may	MD	may	O	O	NONE
reduce	VB	reduce	O	O	NONE
the	DT	the	O	O	NONE
hypoglycemic	JJ	hypoglycemic	B-e5	T	drug
action	NN	action	I-e5	T	drug
of	IN	of	O	O	NONE
Starlix	NN	starlix	B-e6	O	drug
and	CC	and	O	O	NONE
other	JJ	other	O	O	NONE
oral	JJ	oral	O	O	NONE
antidiabetic	JJ	antidiabetic	B-e7	O	drug
drugs	NNS	drug	I-e7	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s15
Certain	JJ	certain	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
including	VBG	include	O	O	NONE
thiazides	NNS	thiazide	B-e1	O	drug
,	,	,	O	O	NONE
corticosteroids	NNS	corticosteroid	B-e2	O	drug
,	,	,	O	O	NONE
thyroid	NN	thyroid	B-e3	T	drug
products	NNS	product	O	O	NONE
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
sympathomimetics	NNS	sympathomimetic	B-e4	O	drug
may	MD	may	O	O	NONE
reduce	VB	reduce	O	O	NONE
the	DT	the	O	O	NONE
hypoglycemic	JJ	hypoglycemic	B-e5	O	drug
action	NN	action	I-e5	O	drug
of	IN	of	O	O	NONE
Starlix	NN	starlix	B-e6	T	drug
and	CC	and	O	O	NONE
other	JJ	other	O	O	NONE
oral	JJ	oral	O	O	NONE
antidiabetic	JJ	antidiabetic	B-e7	O	drug
drugs	NNS	drug	I-e7	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s15
Certain	JJ	certain	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
including	VBG	include	O	O	NONE
thiazides	NNS	thiazide	B-e1	O	drug
,	,	,	O	O	NONE
corticosteroids	NNS	corticosteroid	B-e2	O	drug
,	,	,	O	O	NONE
thyroid	NN	thyroid	B-e3	T	drug
products	NNS	product	O	O	NONE
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
sympathomimetics	NNS	sympathomimetic	B-e4	O	drug
may	MD	may	O	O	NONE
reduce	VB	reduce	O	O	NONE
the	DT	the	O	O	NONE
hypoglycemic	JJ	hypoglycemic	B-e5	O	drug
action	NN	action	I-e5	O	drug
of	IN	of	O	O	NONE
Starlix	NN	starlix	B-e6	O	drug
and	CC	and	O	O	NONE
other	JJ	other	O	O	NONE
oral	JJ	oral	O	O	NONE
antidiabetic	JJ	antidiabetic	B-e7	T	drug
drugs	NNS	drug	I-e7	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s15
Certain	JJ	certain	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
including	VBG	include	O	O	NONE
thiazides	NNS	thiazide	B-e1	O	drug
,	,	,	O	O	NONE
corticosteroids	NNS	corticosteroid	B-e2	O	drug
,	,	,	O	O	NONE
thyroid	NN	thyroid	B-e3	O	drug
products	NNS	product	O	O	NONE
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
sympathomimetics	NNS	sympathomimetic	B-e4	T	drug
may	MD	may	O	O	NONE
reduce	VB	reduce	O	O	NONE
the	DT	the	O	O	NONE
hypoglycemic	JJ	hypoglycemic	B-e5	T	drug
action	NN	action	I-e5	T	drug
of	IN	of	O	O	NONE
Starlix	NN	starlix	B-e6	O	drug
and	CC	and	O	O	NONE
other	JJ	other	O	O	NONE
oral	JJ	oral	O	O	NONE
antidiabetic	JJ	antidiabetic	B-e7	O	drug
drugs	NNS	drug	I-e7	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s15
Certain	JJ	certain	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
including	VBG	include	O	O	NONE
thiazides	NNS	thiazide	B-e1	O	drug
,	,	,	O	O	NONE
corticosteroids	NNS	corticosteroid	B-e2	O	drug
,	,	,	O	O	NONE
thyroid	NN	thyroid	B-e3	O	drug
products	NNS	product	O	O	NONE
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
sympathomimetics	NNS	sympathomimetic	B-e4	T	drug
may	MD	may	O	O	NONE
reduce	VB	reduce	O	O	NONE
the	DT	the	O	O	NONE
hypoglycemic	JJ	hypoglycemic	B-e5	O	drug
action	NN	action	I-e5	O	drug
of	IN	of	O	O	NONE
Starlix	NN	starlix	B-e6	T	drug
and	CC	and	O	O	NONE
other	JJ	other	O	O	NONE
oral	JJ	oral	O	O	NONE
antidiabetic	JJ	antidiabetic	B-e7	O	drug
drugs	NNS	drug	I-e7	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s15
Certain	JJ	certain	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
including	VBG	include	O	O	NONE
thiazides	NNS	thiazide	B-e1	O	drug
,	,	,	O	O	NONE
corticosteroids	NNS	corticosteroid	B-e2	O	drug
,	,	,	O	O	NONE
thyroid	NN	thyroid	B-e3	O	drug
products	NNS	product	O	O	NONE
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
sympathomimetics	NNS	sympathomimetic	B-e4	T	drug
may	MD	may	O	O	NONE
reduce	VB	reduce	O	O	NONE
the	DT	the	O	O	NONE
hypoglycemic	JJ	hypoglycemic	B-e5	O	drug
action	NN	action	I-e5	O	drug
of	IN	of	O	O	NONE
Starlix	NN	starlix	B-e6	O	drug
and	CC	and	O	O	NONE
other	JJ	other	O	O	NONE
oral	JJ	oral	O	O	NONE
antidiabetic	JJ	antidiabetic	B-e7	T	drug
drugs	NNS	drug	I-e7	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s15
Certain	JJ	certain	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
including	VBG	include	O	O	NONE
thiazides	NNS	thiazide	B-e1	O	drug
,	,	,	O	O	NONE
corticosteroids	NNS	corticosteroid	B-e2	O	drug
,	,	,	O	O	NONE
thyroid	NN	thyroid	B-e3	O	drug
products	NNS	product	O	O	NONE
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
sympathomimetics	NNS	sympathomimetic	B-e4	O	drug
may	MD	may	O	O	NONE
reduce	VB	reduce	O	O	NONE
the	DT	the	O	O	NONE
hypoglycemic	JJ	hypoglycemic	B-e5	T	drug
action	NN	action	I-e5	T	drug
of	IN	of	O	O	NONE
Starlix	NN	starlix	B-e6	T	drug
and	CC	and	O	O	NONE
other	JJ	other	O	O	NONE
oral	JJ	oral	O	O	NONE
antidiabetic	JJ	antidiabetic	B-e7	O	drug
drugs	NNS	drug	I-e7	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s15
Certain	JJ	certain	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
including	VBG	include	O	O	NONE
thiazides	NNS	thiazide	B-e1	O	drug
,	,	,	O	O	NONE
corticosteroids	NNS	corticosteroid	B-e2	O	drug
,	,	,	O	O	NONE
thyroid	NN	thyroid	B-e3	O	drug
products	NNS	product	O	O	NONE
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
sympathomimetics	NNS	sympathomimetic	B-e4	O	drug
may	MD	may	O	O	NONE
reduce	VB	reduce	O	O	NONE
the	DT	the	O	O	NONE
hypoglycemic	JJ	hypoglycemic	B-e5	T	drug
action	NN	action	I-e5	T	drug
of	IN	of	O	O	NONE
Starlix	NN	starlix	B-e6	O	drug
and	CC	and	O	O	NONE
other	JJ	other	O	O	NONE
oral	JJ	oral	O	O	NONE
antidiabetic	JJ	antidiabetic	B-e7	T	drug
drugs	NNS	drug	I-e7	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s15
Certain	JJ	certain	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
including	VBG	include	O	O	NONE
thiazides	NNS	thiazide	B-e1	O	drug
,	,	,	O	O	NONE
corticosteroids	NNS	corticosteroid	B-e2	O	drug
,	,	,	O	O	NONE
thyroid	NN	thyroid	B-e3	O	drug
products	NNS	product	O	O	NONE
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
sympathomimetics	NNS	sympathomimetic	B-e4	O	drug
may	MD	may	O	O	NONE
reduce	VB	reduce	O	O	NONE
the	DT	the	O	O	NONE
hypoglycemic	JJ	hypoglycemic	B-e5	O	drug
action	NN	action	I-e5	O	drug
of	IN	of	O	O	NONE
Starlix	NN	starlix	B-e6	T	drug
and	CC	and	O	O	NONE
other	JJ	other	O	O	NONE
oral	JJ	oral	O	O	NONE
antidiabetic	JJ	antidiabetic	B-e7	T	drug
drugs	NNS	drug	I-e7	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d249.s16
When	WRB	when	O	O	NONE
these	DT	these	O	O	NONE
drugs	NNS	drug	B-e0	T	drug
are	VBP	be	O	O	NONE
administered	VBN	administer	O	O	NONE
to	TO	to	O	O	NONE
or	CC	or	O	O	NONE
withdrawn	VBN	withdraw	O	O	NONE
from	IN	from	O	O	NONE
patients	NNS	patient	O	O	NONE
receiving	VBG	receive	O	O	NONE
Starlix	NN	starlix	B-e1	T	drug
,	,	,	O	O	NONE
the	DT	the	O	O	NONE
patient	NN	patient	O	O	NONE
should	MD	should	O	O	NONE
be	VB	be	O	O	NONE
observed	VBN	observe	O	O	NONE
closely	RB	closely	O	O	NONE
for	IN	for	O	O	NONE
changes	NNS	change	O	O	NONE
in	IN	in	O	O	NONE
glycemic	JJ	glycemic	O	O	NONE
control	NN	control	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d312.s0
In	IN	in	O	O	NONE
clinical	JJ	clinical	O	O	NONE
studies	NNS	study	O	O	NONE
,	,	,	O	O	NONE
Tilade	NN	tilade	B-e0	T	drug
has	VBZ	have	O	O	NONE
been	VBN	be	O	O	NONE
co-administered	VBN	co-administer	O	O	NONE
with	IN	with	O	O	NONE
other	JJ	other	O	O	NONE
anti-asthma	NN	anti-asthma	B-e1	T	drug
medications	NNS	medication	I-e1	T	drug
,	,	,	O	O	NONE
including	VBG	include	O	O	NONE
inhaled	JJ	inhaled	O	O	NONE
and	CC	and	O	O	NONE
oral	JJ	oral	O	O	NONE
bronchodilators	NNS	bronchodilator	B-e2	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
inhaled	JJ	inhaled	O	O	NONE
corticosteroids	NNS	corticosteroid	B-e3	O	drug
,	,	,	O	O	NONE
with	IN	with	O	O	NONE
no	DT	no	O	O	NONE
evidence	NN	evidence	O	O	NONE
of	IN	of	O	O	NONE
increased	VBN	increase	O	O	NONE
frequency	NN	frequency	O	O	NONE
of	IN	of	O	O	NONE
adverse	JJ	adverse	O	O	NONE
events	NNS	event	O	O	NONE
or	CC	or	O	O	NONE
laboratory	NN	laboratory	O	O	NONE
abnormalities	NNS	abnormality	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d312.s0
In	IN	in	O	O	NONE
clinical	JJ	clinical	O	O	NONE
studies	NNS	study	O	O	NONE
,	,	,	O	O	NONE
Tilade	NN	tilade	B-e0	T	drug
has	VBZ	have	O	O	NONE
been	VBN	be	O	O	NONE
co-administered	VBN	co-administer	O	O	NONE
with	IN	with	O	O	NONE
other	JJ	other	O	O	NONE
anti-asthma	NN	anti-asthma	B-e1	O	drug
medications	NNS	medication	I-e1	O	drug
,	,	,	O	O	NONE
including	VBG	include	O	O	NONE
inhaled	JJ	inhaled	O	O	NONE
and	CC	and	O	O	NONE
oral	JJ	oral	O	O	NONE
bronchodilators	NNS	bronchodilator	B-e2	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
inhaled	JJ	inhaled	O	O	NONE
corticosteroids	NNS	corticosteroid	B-e3	O	drug
,	,	,	O	O	NONE
with	IN	with	O	O	NONE
no	DT	no	O	O	NONE
evidence	NN	evidence	O	O	NONE
of	IN	of	O	O	NONE
increased	VBN	increase	O	O	NONE
frequency	NN	frequency	O	O	NONE
of	IN	of	O	O	NONE
adverse	JJ	adverse	O	O	NONE
events	NNS	event	O	O	NONE
or	CC	or	O	O	NONE
laboratory	NN	laboratory	O	O	NONE
abnormalities	NNS	abnormality	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d312.s0
In	IN	in	O	O	NONE
clinical	JJ	clinical	O	O	NONE
studies	NNS	study	O	O	NONE
,	,	,	O	O	NONE
Tilade	NN	tilade	B-e0	T	drug
has	VBZ	have	O	O	NONE
been	VBN	be	O	O	NONE
co-administered	VBN	co-administer	O	O	NONE
with	IN	with	O	O	NONE
other	JJ	other	O	O	NONE
anti-asthma	NN	anti-asthma	B-e1	O	drug
medications	NNS	medication	I-e1	O	drug
,	,	,	O	O	NONE
including	VBG	include	O	O	NONE
inhaled	JJ	inhaled	O	O	NONE
and	CC	and	O	O	NONE
oral	JJ	oral	O	O	NONE
bronchodilators	NNS	bronchodilator	B-e2	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
inhaled	JJ	inhaled	O	O	NONE
corticosteroids	NNS	corticosteroid	B-e3	T	drug
,	,	,	O	O	NONE
with	IN	with	O	O	NONE
no	DT	no	O	O	NONE
evidence	NN	evidence	O	O	NONE
of	IN	of	O	O	NONE
increased	VBN	increase	O	O	NONE
frequency	NN	frequency	O	O	NONE
of	IN	of	O	O	NONE
adverse	JJ	adverse	O	O	NONE
events	NNS	event	O	O	NONE
or	CC	or	O	O	NONE
laboratory	NN	laboratory	O	O	NONE
abnormalities	NNS	abnormality	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d312.s0
In	IN	in	O	O	NONE
clinical	JJ	clinical	O	O	NONE
studies	NNS	study	O	O	NONE
,	,	,	O	O	NONE
Tilade	NN	tilade	B-e0	O	drug
has	VBZ	have	O	O	NONE
been	VBN	be	O	O	NONE
co-administered	VBN	co-administer	O	O	NONE
with	IN	with	O	O	NONE
other	JJ	other	O	O	NONE
anti-asthma	NN	anti-asthma	B-e1	T	drug
medications	NNS	medication	I-e1	T	drug
,	,	,	O	O	NONE
including	VBG	include	O	O	NONE
inhaled	JJ	inhaled	O	O	NONE
and	CC	and	O	O	NONE
oral	JJ	oral	O	O	NONE
bronchodilators	NNS	bronchodilator	B-e2	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
inhaled	JJ	inhaled	O	O	NONE
corticosteroids	NNS	corticosteroid	B-e3	O	drug
,	,	,	O	O	NONE
with	IN	with	O	O	NONE
no	DT	no	O	O	NONE
evidence	NN	evidence	O	O	NONE
of	IN	of	O	O	NONE
increased	VBN	increase	O	O	NONE
frequency	NN	frequency	O	O	NONE
of	IN	of	O	O	NONE
adverse	JJ	adverse	O	O	NONE
events	NNS	event	O	O	NONE
or	CC	or	O	O	NONE
laboratory	NN	laboratory	O	O	NONE
abnormalities	NNS	abnormality	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d312.s0
In	IN	in	O	O	NONE
clinical	JJ	clinical	O	O	NONE
studies	NNS	study	O	O	NONE
,	,	,	O	O	NONE
Tilade	NN	tilade	B-e0	O	drug
has	VBZ	have	O	O	NONE
been	VBN	be	O	O	NONE
co-administered	VBN	co-administer	O	O	NONE
with	IN	with	O	O	NONE
other	JJ	other	O	O	NONE
anti-asthma	NN	anti-asthma	B-e1	T	drug
medications	NNS	medication	I-e1	T	drug
,	,	,	O	O	NONE
including	VBG	include	O	O	NONE
inhaled	JJ	inhaled	O	O	NONE
and	CC	and	O	O	NONE
oral	JJ	oral	O	O	NONE
bronchodilators	NNS	bronchodilator	B-e2	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
inhaled	JJ	inhaled	O	O	NONE
corticosteroids	NNS	corticosteroid	B-e3	T	drug
,	,	,	O	O	NONE
with	IN	with	O	O	NONE
no	DT	no	O	O	NONE
evidence	NN	evidence	O	O	NONE
of	IN	of	O	O	NONE
increased	VBN	increase	O	O	NONE
frequency	NN	frequency	O	O	NONE
of	IN	of	O	O	NONE
adverse	JJ	adverse	O	O	NONE
events	NNS	event	O	O	NONE
or	CC	or	O	O	NONE
laboratory	NN	laboratory	O	O	NONE
abnormalities	NNS	abnormality	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d312.s0
In	IN	in	O	O	NONE
clinical	JJ	clinical	O	O	NONE
studies	NNS	study	O	O	NONE
,	,	,	O	O	NONE
Tilade	NN	tilade	B-e0	O	drug
has	VBZ	have	O	O	NONE
been	VBN	be	O	O	NONE
co-administered	VBN	co-administer	O	O	NONE
with	IN	with	O	O	NONE
other	JJ	other	O	O	NONE
anti-asthma	NN	anti-asthma	B-e1	O	drug
medications	NNS	medication	I-e1	O	drug
,	,	,	O	O	NONE
including	VBG	include	O	O	NONE
inhaled	JJ	inhaled	O	O	NONE
and	CC	and	O	O	NONE
oral	JJ	oral	O	O	NONE
bronchodilators	NNS	bronchodilator	B-e2	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
inhaled	JJ	inhaled	O	O	NONE
corticosteroids	NNS	corticosteroid	B-e3	T	drug
,	,	,	O	O	NONE
with	IN	with	O	O	NONE
no	DT	no	O	O	NONE
evidence	NN	evidence	O	O	NONE
of	IN	of	O	O	NONE
increased	VBN	increase	O	O	NONE
frequency	NN	frequency	O	O	NONE
of	IN	of	O	O	NONE
adverse	JJ	adverse	O	O	NONE
events	NNS	event	O	O	NONE
or	CC	or	O	O	NONE
laboratory	NN	laboratory	O	O	NONE
abnormalities	NNS	abnormality	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d336.s0
Caution	NN	caution	O	O	NONE
should	MD	should	O	O	NONE
be	VB	be	O	O	NONE
taken	VBN	take	O	O	NONE
in	IN	in	O	O	NONE
concurrent	JJ	concurrent	O	O	NONE
or	CC	or	O	O	NONE
serial	JJ	serial	O	O	NONE
use	NN	use	O	O	NONE
of	IN	of	O	O	NONE
other	JJ	other	O	O	NONE
neurotoxic	JJ	neurotoxic	O	O	NONE
and/	NN	and/	O	O	NONE
or	CC	or	O	O	NONE
nephrotoxic	JJ	nephrotoxic	O	O	NONE
drugs	NNS	drug	B-e0	T	drug
because	IN	because	O	O	NONE
of	IN	of	O	O	NONE
possible	JJ	possible	O	O	NONE
enhancement	NN	enhancement	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
nephrotoxicity	NN	nephrotoxicity	B-e1	O	DISO
and/or	CC	and/or	O	O	NONE
ototoxicity	NN	ototoxicity	O	O	NONE
of	IN	of	O	O	NONE
neomycin	NN	neomycin	B-e2	T	drug
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d336.s1
Caution	NN	caution	O	O	NONE
should	MD	should	O	O	NONE
also	RB	also	O	O	NONE
be	VB	be	O	O	NONE
taken	VBN	take	O	O	NONE
in	IN	in	O	O	NONE
concurrent	JJ	concurrent	O	O	NONE
or	CC	or	O	O	NONE
serial	JJ	serial	O	O	NONE
use	NN	use	O	O	NONE
of	IN	of	O	O	NONE
other	JJ	other	O	O	NONE
aminoglycosides	NNS	aminoglycoside	B-e0	T	drug
and	CC	and	O	O	NONE
polymyxins	NNS	polymyxin	B-e1	T	drug
because	IN	because	O	O	NONE
they	PRP	they	O	O	NONE
may	MD	may	O	O	NONE
enhance	VB	enhance	O	O	NONE
neomycin	NN	neomycin	O	O	NONE
@	NN	@	O	O	NONE
s	NN	s	O	O	NONE
nephrotoxicity	NN	nephrotoxicity	B-e2	O	DISO
and/or	CC	and/or	O	O	NONE
ototoxicity	NN	ototoxicity	O	O	NONE
and	CC	and	O	O	NONE
potentiate	VB	potentiate	O	O	NONE
neomycin	NN	neomycin	B-e3	O	drug
sulfate	NN	sulfate	O	O	NONE
@	NN	@	O	O	NONE
s	NN	s	O	O	NONE
neuromuscular	JJ	neuromuscular	O	O	NONE
blocking	VBG	block	O	O	NONE
effects	NNS	effect	O	O	NONE
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d336.s1
Caution	NN	caution	O	O	NONE
should	MD	should	O	O	NONE
also	RB	also	O	O	NONE
be	VB	be	O	O	NONE
taken	VBN	take	O	O	NONE
in	IN	in	O	O	NONE
concurrent	JJ	concurrent	O	O	NONE
or	CC	or	O	O	NONE
serial	JJ	serial	O	O	NONE
use	NN	use	O	O	NONE
of	IN	of	O	O	NONE
other	JJ	other	O	O	NONE
aminoglycosides	NNS	aminoglycoside	B-e0	T	drug
and	CC	and	O	O	NONE
polymyxins	NNS	polymyxin	B-e1	O	drug
because	IN	because	O	O	NONE
they	PRP	they	O	O	NONE
may	MD	may	O	O	NONE
enhance	VB	enhance	O	O	NONE
neomycin	NN	neomycin	O	O	NONE
@	NN	@	O	O	NONE
s	NN	s	O	O	NONE
nephrotoxicity	NN	nephrotoxicity	B-e2	O	DISO
and/or	CC	and/or	O	O	NONE
ototoxicity	NN	ototoxicity	O	O	NONE
and	CC	and	O	O	NONE
potentiate	VB	potentiate	O	O	NONE
neomycin	NN	neomycin	B-e3	T	drug
sulfate	NN	sulfate	O	O	NONE
@	NN	@	O	O	NONE
s	NN	s	O	O	NONE
neuromuscular	JJ	neuromuscular	O	O	NONE
blocking	VBG	block	O	O	NONE
effects	NNS	effect	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d336.s1
Caution	NN	caution	O	O	NONE
should	MD	should	O	O	NONE
also	RB	also	O	O	NONE
be	VB	be	O	O	NONE
taken	VBN	take	O	O	NONE
in	IN	in	O	O	NONE
concurrent	JJ	concurrent	O	O	NONE
or	CC	or	O	O	NONE
serial	JJ	serial	O	O	NONE
use	NN	use	O	O	NONE
of	IN	of	O	O	NONE
other	JJ	other	O	O	NONE
aminoglycosides	NNS	aminoglycoside	B-e0	O	drug
and	CC	and	O	O	NONE
polymyxins	NNS	polymyxin	B-e1	T	drug
because	IN	because	O	O	NONE
they	PRP	they	O	O	NONE
may	MD	may	O	O	NONE
enhance	VB	enhance	O	O	NONE
neomycin	NN	neomycin	O	O	NONE
@	NN	@	O	O	NONE
s	NN	s	O	O	NONE
nephrotoxicity	NN	nephrotoxicity	B-e2	O	DISO
and/or	CC	and/or	O	O	NONE
ototoxicity	NN	ototoxicity	O	O	NONE
and	CC	and	O	O	NONE
potentiate	VB	potentiate	O	O	NONE
neomycin	NN	neomycin	B-e3	T	drug
sulfate	NN	sulfate	O	O	NONE
@	NN	@	O	O	NONE
s	NN	s	O	O	NONE
neuromuscular	JJ	neuromuscular	O	O	NONE
blocking	VBG	block	O	O	NONE
effects	NNS	effect	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d336.s2
Oral	JJ	oral	B-e0	T	drug
neomycin	NN	neomycin	I-e0	T	drug
inhibits	VBZ	inhibit	O	O	NONE
the	DT	the	O	O	NONE
gastrointestinal	JJ	gastrointestinal	O	O	NONE
absorption	NN	absorption	O	O	NONE
of	IN	of	O	O	NONE
penicillin	NN	penicillin	B-e1	T	drug
V	NN	v	I-e1	T	drug
,	,	,	O	O	NONE
oral	JJ	oral	B-e2	O	drug
vitamin	NN	vitamin	I-e2	O	drug
B-12	NN	b-12	I-e2	O	drug
,	,	,	O	O	NONE
methotrexate	NN	methotrexate	B-e3	O	drug
and	CC	and	O	O	NONE
5-fluorouracil	NN	5-fluorouracil	B-e4	O	drug
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d336.s2
Oral	JJ	oral	B-e0	T	drug
neomycin	NN	neomycin	I-e0	T	drug
inhibits	VBZ	inhibit	O	O	NONE
the	DT	the	O	O	NONE
gastrointestinal	JJ	gastrointestinal	O	O	NONE
absorption	NN	absorption	O	O	NONE
of	IN	of	O	O	NONE
penicillin	NN	penicillin	B-e1	O	drug
V	NN	v	I-e1	O	drug
,	,	,	O	O	NONE
oral	JJ	oral	B-e2	T	drug
vitamin	NN	vitamin	I-e2	T	drug
B-12	NN	b-12	I-e2	T	drug
,	,	,	O	O	NONE
methotrexate	NN	methotrexate	B-e3	O	drug
and	CC	and	O	O	NONE
5-fluorouracil	NN	5-fluorouracil	B-e4	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d336.s2
Oral	JJ	oral	B-e0	T	drug
neomycin	NN	neomycin	I-e0	T	drug
inhibits	VBZ	inhibit	O	O	NONE
the	DT	the	O	O	NONE
gastrointestinal	JJ	gastrointestinal	O	O	NONE
absorption	NN	absorption	O	O	NONE
of	IN	of	O	O	NONE
penicillin	NN	penicillin	B-e1	O	drug
V	NN	v	I-e1	O	drug
,	,	,	O	O	NONE
oral	JJ	oral	B-e2	O	drug
vitamin	NN	vitamin	I-e2	O	drug
B-12	NN	b-12	I-e2	O	drug
,	,	,	O	O	NONE
methotrexate	NN	methotrexate	B-e3	T	drug
and	CC	and	O	O	NONE
5-fluorouracil	NN	5-fluorouracil	B-e4	O	drug
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d336.s2
Oral	JJ	oral	B-e0	T	drug
neomycin	NN	neomycin	I-e0	T	drug
inhibits	VBZ	inhibit	O	O	NONE
the	DT	the	O	O	NONE
gastrointestinal	JJ	gastrointestinal	O	O	NONE
absorption	NN	absorption	O	O	NONE
of	IN	of	O	O	NONE
penicillin	NN	penicillin	B-e1	O	drug
V	NN	v	I-e1	O	drug
,	,	,	O	O	NONE
oral	JJ	oral	B-e2	O	drug
vitamin	NN	vitamin	I-e2	O	drug
B-12	NN	b-12	I-e2	O	drug
,	,	,	O	O	NONE
methotrexate	NN	methotrexate	B-e3	O	drug
and	CC	and	O	O	NONE
5-fluorouracil	NN	5-fluorouracil	B-e4	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d336.s2
Oral	JJ	oral	B-e0	O	drug
neomycin	NN	neomycin	I-e0	O	drug
inhibits	VBZ	inhibit	O	O	NONE
the	DT	the	O	O	NONE
gastrointestinal	JJ	gastrointestinal	O	O	NONE
absorption	NN	absorption	O	O	NONE
of	IN	of	O	O	NONE
penicillin	NN	penicillin	B-e1	T	drug
V	NN	v	I-e1	T	drug
,	,	,	O	O	NONE
oral	JJ	oral	B-e2	T	drug
vitamin	NN	vitamin	I-e2	T	drug
B-12	NN	b-12	I-e2	T	drug
,	,	,	O	O	NONE
methotrexate	NN	methotrexate	B-e3	O	drug
and	CC	and	O	O	NONE
5-fluorouracil	NN	5-fluorouracil	B-e4	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d336.s2
Oral	JJ	oral	B-e0	O	drug
neomycin	NN	neomycin	I-e0	O	drug
inhibits	VBZ	inhibit	O	O	NONE
the	DT	the	O	O	NONE
gastrointestinal	JJ	gastrointestinal	O	O	NONE
absorption	NN	absorption	O	O	NONE
of	IN	of	O	O	NONE
penicillin	NN	penicillin	B-e1	T	drug
V	NN	v	I-e1	T	drug
,	,	,	O	O	NONE
oral	JJ	oral	B-e2	O	drug
vitamin	NN	vitamin	I-e2	O	drug
B-12	NN	b-12	I-e2	O	drug
,	,	,	O	O	NONE
methotrexate	NN	methotrexate	B-e3	T	drug
and	CC	and	O	O	NONE
5-fluorouracil	NN	5-fluorouracil	B-e4	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d336.s2
Oral	JJ	oral	B-e0	O	drug
neomycin	NN	neomycin	I-e0	O	drug
inhibits	VBZ	inhibit	O	O	NONE
the	DT	the	O	O	NONE
gastrointestinal	JJ	gastrointestinal	O	O	NONE
absorption	NN	absorption	O	O	NONE
of	IN	of	O	O	NONE
penicillin	NN	penicillin	B-e1	T	drug
V	NN	v	I-e1	T	drug
,	,	,	O	O	NONE
oral	JJ	oral	B-e2	O	drug
vitamin	NN	vitamin	I-e2	O	drug
B-12	NN	b-12	I-e2	O	drug
,	,	,	O	O	NONE
methotrexate	NN	methotrexate	B-e3	O	drug
and	CC	and	O	O	NONE
5-fluorouracil	NN	5-fluorouracil	B-e4	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d336.s2
Oral	JJ	oral	B-e0	O	drug
neomycin	NN	neomycin	I-e0	O	drug
inhibits	VBZ	inhibit	O	O	NONE
the	DT	the	O	O	NONE
gastrointestinal	JJ	gastrointestinal	O	O	NONE
absorption	NN	absorption	O	O	NONE
of	IN	of	O	O	NONE
penicillin	NN	penicillin	B-e1	O	drug
V	NN	v	I-e1	O	drug
,	,	,	O	O	NONE
oral	JJ	oral	B-e2	T	drug
vitamin	NN	vitamin	I-e2	T	drug
B-12	NN	b-12	I-e2	T	drug
,	,	,	O	O	NONE
methotrexate	NN	methotrexate	B-e3	T	drug
and	CC	and	O	O	NONE
5-fluorouracil	NN	5-fluorouracil	B-e4	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d336.s2
Oral	JJ	oral	B-e0	O	drug
neomycin	NN	neomycin	I-e0	O	drug
inhibits	VBZ	inhibit	O	O	NONE
the	DT	the	O	O	NONE
gastrointestinal	JJ	gastrointestinal	O	O	NONE
absorption	NN	absorption	O	O	NONE
of	IN	of	O	O	NONE
penicillin	NN	penicillin	B-e1	O	drug
V	NN	v	I-e1	O	drug
,	,	,	O	O	NONE
oral	JJ	oral	B-e2	T	drug
vitamin	NN	vitamin	I-e2	T	drug
B-12	NN	b-12	I-e2	T	drug
,	,	,	O	O	NONE
methotrexate	NN	methotrexate	B-e3	O	drug
and	CC	and	O	O	NONE
5-fluorouracil	NN	5-fluorouracil	B-e4	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d336.s2
Oral	JJ	oral	B-e0	O	drug
neomycin	NN	neomycin	I-e0	O	drug
inhibits	VBZ	inhibit	O	O	NONE
the	DT	the	O	O	NONE
gastrointestinal	JJ	gastrointestinal	O	O	NONE
absorption	NN	absorption	O	O	NONE
of	IN	of	O	O	NONE
penicillin	NN	penicillin	B-e1	O	drug
V	NN	v	I-e1	O	drug
,	,	,	O	O	NONE
oral	JJ	oral	B-e2	O	drug
vitamin	NN	vitamin	I-e2	O	drug
B-12	NN	b-12	I-e2	O	drug
,	,	,	O	O	NONE
methotrexate	NN	methotrexate	B-e3	T	drug
and	CC	and	O	O	NONE
5-fluorouracil	NN	5-fluorouracil	B-e4	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d336.s5
Oral	JJ	oral	B-e0	T	drug
neomycin	NN	neomycin	I-e0	T	drug
sulfate	NN	sulfate	O	O	NONE
may	MD	may	O	O	NONE
enhance	VB	enhance	O	O	NONE
the	DT	the	O	O	NONE
effect	NN	effect	O	O	NONE
of	IN	of	O	O	NONE
coumarin	NN	coumarin	B-e1	T	drug
in	IN	in	O	O	NONE
anticoagulants	NNS	anticoagulant	B-e2	O	drug
by	IN	by	O	O	NONE
decreasing	VBG	decrease	O	O	NONE
vitamin	NN	vitamin	O	O	NONE
K	NN	k	O	O	NONE
availability	NN	availability	O	O	NONE
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d336.s5
Oral	JJ	oral	B-e0	T	drug
neomycin	NN	neomycin	I-e0	T	drug
sulfate	NN	sulfate	O	O	NONE
may	MD	may	O	O	NONE
enhance	VB	enhance	O	O	NONE
the	DT	the	O	O	NONE
effect	NN	effect	O	O	NONE
of	IN	of	O	O	NONE
coumarin	NN	coumarin	B-e1	O	drug
in	IN	in	O	O	NONE
anticoagulants	NNS	anticoagulant	B-e2	T	drug
by	IN	by	O	O	NONE
decreasing	VBG	decrease	O	O	NONE
vitamin	NN	vitamin	O	O	NONE
K	NN	k	O	O	NONE
availability	NN	availability	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d336.s5
Oral	JJ	oral	B-e0	O	drug
neomycin	NN	neomycin	I-e0	O	drug
sulfate	NN	sulfate	O	O	NONE
may	MD	may	O	O	NONE
enhance	VB	enhance	O	O	NONE
the	DT	the	O	O	NONE
effect	NN	effect	O	O	NONE
of	IN	of	O	O	NONE
coumarin	NN	coumarin	B-e1	T	drug
in	IN	in	O	O	NONE
anticoagulants	NNS	anticoagulant	B-e2	T	drug
by	IN	by	O	O	NONE
decreasing	VBG	decrease	O	O	NONE
vitamin	NN	vitamin	O	O	NONE
K	NN	k	O	O	NONE
availability	NN	availability	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d266.s0
Beta-adrenergic	JJ	beta-adrenergic	B-e0	T	drug
Blocking	NN	blocking	I-e0	T	drug
Agents	NNS	agent	I-e0	T	drug
:	:	:	O	O	NONE
Experience	VBP	experience	O	O	NONE
in	IN	in	O	O	NONE
over	IN	over	O	O	NONE
1400	CD	1400	O	O	NONE
patients	NNS	patient	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
non-comparative	JJ	non-comparative	O	O	NONE
clinical	JJ	clinical	O	O	NONE
trial	NN	trial	O	O	NONE
has	VBZ	have	O	O	NONE
shown	VBN	show	O	O	NONE
that	IN	that	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
nifedipine	NN	nifedipine	B-e1	T	drug
and	CC	and	O	O	NONE
beta-blocking	JJ	beta-blocking	B-e2	O	drug
agent	NN	agent	I-e2	O	drug
s	NNS	s	O	O	NONE
is	VBZ	be	O	O	NONE
usually	RB	usually	O	O	NONE
well	RB	well	O	O	NONE
tolerated	VBN	tolerate	O	O	NONE
,	,	,	O	O	NONE
but	CC	but	O	O	NONE
there	EX	there	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
occasional	JJ	occasional	O	O	NONE
literature	NN	literature	O	O	NONE
reports	NNS	report	O	O	NONE
suggesting	VBG	suggest	O	O	NONE
that	IN	that	O	O	NONE
the	DT	the	O	O	NONE
combination	NN	combination	O	O	NONE
may	MD	may	O	O	NONE
increase	VBP	increase	O	O	NONE
the	DT	the	O	O	NONE
likelihood	NN	likelihood	O	O	NONE
of	IN	of	O	O	NONE
congestive	JJ	congestive	B-e3	O	DISO
heart	NN	heart	I-e3	O	DISO
failure	NN	failure	I-e3	O	DISO
,	,	,	O	O	NONE
severe	JJ	severe	O	O	NONE
hypotension	NN	hypotension	O	O	NONE
or	CC	or	O	O	NONE
exacerbation	NN	exacerbation	O	O	NONE
of	IN	of	O	O	NONE
angina	NN	angina	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d266.s0
Beta-adrenergic	JJ	beta-adrenergic	B-e0	T	drug
Blocking	NN	blocking	I-e0	T	drug
Agents	NNS	agent	I-e0	T	drug
:	:	:	O	O	NONE
Experience	VBP	experience	O	O	NONE
in	IN	in	O	O	NONE
over	IN	over	O	O	NONE
1400	CD	1400	O	O	NONE
patients	NNS	patient	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
non-comparative	JJ	non-comparative	O	O	NONE
clinical	JJ	clinical	O	O	NONE
trial	NN	trial	O	O	NONE
has	VBZ	have	O	O	NONE
shown	VBN	show	O	O	NONE
that	IN	that	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
nifedipine	NN	nifedipine	B-e1	O	drug
and	CC	and	O	O	NONE
beta-blocking	JJ	beta-blocking	B-e2	T	drug
agent	NN	agent	I-e2	T	drug
s	NNS	s	O	O	NONE
is	VBZ	be	O	O	NONE
usually	RB	usually	O	O	NONE
well	RB	well	O	O	NONE
tolerated	VBN	tolerate	O	O	NONE
,	,	,	O	O	NONE
but	CC	but	O	O	NONE
there	EX	there	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
occasional	JJ	occasional	O	O	NONE
literature	NN	literature	O	O	NONE
reports	NNS	report	O	O	NONE
suggesting	VBG	suggest	O	O	NONE
that	IN	that	O	O	NONE
the	DT	the	O	O	NONE
combination	NN	combination	O	O	NONE
may	MD	may	O	O	NONE
increase	VBP	increase	O	O	NONE
the	DT	the	O	O	NONE
likelihood	NN	likelihood	O	O	NONE
of	IN	of	O	O	NONE
congestive	JJ	congestive	B-e3	O	DISO
heart	NN	heart	I-e3	O	DISO
failure	NN	failure	I-e3	O	DISO
,	,	,	O	O	NONE
severe	JJ	severe	O	O	NONE
hypotension	NN	hypotension	O	O	NONE
or	CC	or	O	O	NONE
exacerbation	NN	exacerbation	O	O	NONE
of	IN	of	O	O	NONE
angina	NN	angina	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d266.s0
Beta-adrenergic	JJ	beta-adrenergic	B-e0	O	drug
Blocking	NN	blocking	I-e0	O	drug
Agents	NNS	agent	I-e0	O	drug
:	:	:	O	O	NONE
Experience	VBP	experience	O	O	NONE
in	IN	in	O	O	NONE
over	IN	over	O	O	NONE
1400	CD	1400	O	O	NONE
patients	NNS	patient	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
non-comparative	JJ	non-comparative	O	O	NONE
clinical	JJ	clinical	O	O	NONE
trial	NN	trial	O	O	NONE
has	VBZ	have	O	O	NONE
shown	VBN	show	O	O	NONE
that	IN	that	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
nifedipine	NN	nifedipine	B-e1	T	drug
and	CC	and	O	O	NONE
beta-blocking	JJ	beta-blocking	B-e2	T	drug
agent	NN	agent	I-e2	T	drug
s	NNS	s	O	O	NONE
is	VBZ	be	O	O	NONE
usually	RB	usually	O	O	NONE
well	RB	well	O	O	NONE
tolerated	VBN	tolerate	O	O	NONE
,	,	,	O	O	NONE
but	CC	but	O	O	NONE
there	EX	there	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
occasional	JJ	occasional	O	O	NONE
literature	NN	literature	O	O	NONE
reports	NNS	report	O	O	NONE
suggesting	VBG	suggest	O	O	NONE
that	IN	that	O	O	NONE
the	DT	the	O	O	NONE
combination	NN	combination	O	O	NONE
may	MD	may	O	O	NONE
increase	VBP	increase	O	O	NONE
the	DT	the	O	O	NONE
likelihood	NN	likelihood	O	O	NONE
of	IN	of	O	O	NONE
congestive	JJ	congestive	B-e3	O	DISO
heart	NN	heart	I-e3	O	DISO
failure	NN	failure	I-e3	O	DISO
,	,	,	O	O	NONE
severe	JJ	severe	O	O	NONE
hypotension	NN	hypotension	O	O	NONE
or	CC	or	O	O	NONE
exacerbation	NN	exacerbation	O	O	NONE
of	IN	of	O	O	NONE
angina	NN	angina	O	O	NONE
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d266.s1
Long	JJ	long	O	O	NONE
Acting	NN	acting	O	O	NONE
Nitrates	NNS	nitrate	B-e0	T	drug
:	:	:	O	O	NONE
Nifedipine	NN	nifedipine	B-e1	T	drug
may	MD	may	O	O	NONE
be	VB	be	O	O	NONE
safely	RB	safely	O	O	NONE
co-administered	VBN	co-administer	O	O	NONE
with	IN	with	O	O	NONE
nitrates	NNS	nitrate	B-e2	O	drug
,	,	,	O	O	NONE
but	CC	but	O	O	NONE
there	EX	there	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
no	DT	no	O	O	NONE
controlled	JJ	controlled	O	O	NONE
studies	NNS	study	O	O	NONE
to	TO	to	O	O	NONE
evaluate	VB	evaluate	O	O	NONE
the	DT	the	O	O	NONE
antianginal	JJ	antianginal	O	O	NONE
effectiveness	NN	effectiveness	O	O	NONE
of	IN	of	O	O	NONE
this	DT	this	O	O	NONE
combination	NN	combination	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d266.s1
Long	JJ	long	O	O	NONE
Acting	NN	acting	O	O	NONE
Nitrates	NNS	nitrate	B-e0	T	drug
:	:	:	O	O	NONE
Nifedipine	NN	nifedipine	B-e1	O	drug
may	MD	may	O	O	NONE
be	VB	be	O	O	NONE
safely	RB	safely	O	O	NONE
co-administered	VBN	co-administer	O	O	NONE
with	IN	with	O	O	NONE
nitrates	NNS	nitrate	B-e2	T	drug
,	,	,	O	O	NONE
but	CC	but	O	O	NONE
there	EX	there	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
no	DT	no	O	O	NONE
controlled	JJ	controlled	O	O	NONE
studies	NNS	study	O	O	NONE
to	TO	to	O	O	NONE
evaluate	VB	evaluate	O	O	NONE
the	DT	the	O	O	NONE
antianginal	JJ	antianginal	O	O	NONE
effectiveness	NN	effectiveness	O	O	NONE
of	IN	of	O	O	NONE
this	DT	this	O	O	NONE
combination	NN	combination	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d266.s1
Long	JJ	long	O	O	NONE
Acting	NN	acting	O	O	NONE
Nitrates	NNS	nitrate	B-e0	O	drug
:	:	:	O	O	NONE
Nifedipine	NN	nifedipine	B-e1	T	drug
may	MD	may	O	O	NONE
be	VB	be	O	O	NONE
safely	RB	safely	O	O	NONE
co-administered	VBN	co-administer	O	O	NONE
with	IN	with	O	O	NONE
nitrates	NNS	nitrate	B-e2	T	drug
,	,	,	O	O	NONE
but	CC	but	O	O	NONE
there	EX	there	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
no	DT	no	O	O	NONE
controlled	JJ	controlled	O	O	NONE
studies	NNS	study	O	O	NONE
to	TO	to	O	O	NONE
evaluate	VB	evaluate	O	O	NONE
the	DT	the	O	O	NONE
antianginal	JJ	antianginal	O	O	NONE
effectiveness	NN	effectiveness	O	O	NONE
of	IN	of	O	O	NONE
this	DT	this	O	O	NONE
combination	NN	combination	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d266.s2
Digitalis	NN	digitali	B-e0	T	drug
:	:	:	O	O	NONE
Immediate	JJ	immediate	O	O	NONE
Release	NN	release	O	O	NONE
Capsules	NNS	capsule	O	O	NONE
:	:	:	O	O	NONE
Since	IN	since	O	O	NONE
there	EX	there	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
isolated	VBN	isolate	O	O	NONE
reports	NNS	report	O	O	NONE
of	IN	of	O	O	NONE
patients	NNS	patient	O	O	NONE
with	IN	with	O	O	NONE
elevated	JJ	elevated	O	O	NONE
digoxin	NN	digoxin	O	O	NONE
levels	NNS	level	O	O	NONE
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
there	EX	there	O	O	NONE
is	VBZ	be	O	O	NONE
a	DT	a	O	O	NONE
possible	JJ	possible	O	O	NONE
interaction	NN	interaction	O	O	NONE
between	IN	between	O	O	NONE
digoxin	NN	digoxin	B-e1	T	drug
and	CC	and	O	O	NONE
nifedipine	NN	nifedipine	B-e2	O	drug
,	,	,	O	O	NONE
it	PRP	it	O	O	NONE
is	VBZ	be	O	O	NONE
recommended	VBN	recommend	O	O	NONE
that	IN	that	O	O	NONE
digoxin	NN	digoxin	O	O	NONE
levels	NNS	level	O	O	NONE
be	VB	be	O	O	NONE
monitored	VBN	monitor	O	O	NONE
when	WRB	when	O	O	NONE
initiating	VBG	initiate	O	O	NONE
,	,	,	O	O	NONE
adjusting	VBG	adjust	O	O	NONE
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
discontinuing	VBG	discontinue	O	O	NONE
nifedipine	NN	nifedipine	B-e3	O	drug
to	TO	to	O	O	NONE
avoid	VB	avoid	O	O	NONE
possible	JJ	possible	O	O	NONE
over-	NN	over-_NN	O	O	NONE
or	CC	or	O	O	NONE
under-digitalization	NN	under-digitalization	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d266.s2
Digitalis	NN	digitali	B-e0	T	drug
:	:	:	O	O	NONE
Immediate	JJ	immediate	O	O	NONE
Release	NN	release	O	O	NONE
Capsules	NNS	capsule	O	O	NONE
:	:	:	O	O	NONE
Since	IN	since	O	O	NONE
there	EX	there	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
isolated	VBN	isolate	O	O	NONE
reports	NNS	report	O	O	NONE
of	IN	of	O	O	NONE
patients	NNS	patient	O	O	NONE
with	IN	with	O	O	NONE
elevated	JJ	elevated	O	O	NONE
digoxin	NN	digoxin	O	O	NONE
levels	NNS	level	O	O	NONE
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
there	EX	there	O	O	NONE
is	VBZ	be	O	O	NONE
a	DT	a	O	O	NONE
possible	JJ	possible	O	O	NONE
interaction	NN	interaction	O	O	NONE
between	IN	between	O	O	NONE
digoxin	NN	digoxin	B-e1	O	drug
and	CC	and	O	O	NONE
nifedipine	NN	nifedipine	B-e2	T	drug
,	,	,	O	O	NONE
it	PRP	it	O	O	NONE
is	VBZ	be	O	O	NONE
recommended	VBN	recommend	O	O	NONE
that	IN	that	O	O	NONE
digoxin	NN	digoxin	O	O	NONE
levels	NNS	level	O	O	NONE
be	VB	be	O	O	NONE
monitored	VBN	monitor	O	O	NONE
when	WRB	when	O	O	NONE
initiating	VBG	initiate	O	O	NONE
,	,	,	O	O	NONE
adjusting	VBG	adjust	O	O	NONE
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
discontinuing	VBG	discontinue	O	O	NONE
nifedipine	NN	nifedipine	B-e3	O	drug
to	TO	to	O	O	NONE
avoid	VB	avoid	O	O	NONE
possible	JJ	possible	O	O	NONE
over-	NN	over-_NN	O	O	NONE
or	CC	or	O	O	NONE
under-digitalization	NN	under-digitalization	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d266.s2
Digitalis	NN	digitali	B-e0	T	drug
:	:	:	O	O	NONE
Immediate	JJ	immediate	O	O	NONE
Release	NN	release	O	O	NONE
Capsules	NNS	capsule	O	O	NONE
:	:	:	O	O	NONE
Since	IN	since	O	O	NONE
there	EX	there	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
isolated	VBN	isolate	O	O	NONE
reports	NNS	report	O	O	NONE
of	IN	of	O	O	NONE
patients	NNS	patient	O	O	NONE
with	IN	with	O	O	NONE
elevated	JJ	elevated	O	O	NONE
digoxin	NN	digoxin	O	O	NONE
levels	NNS	level	O	O	NONE
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
there	EX	there	O	O	NONE
is	VBZ	be	O	O	NONE
a	DT	a	O	O	NONE
possible	JJ	possible	O	O	NONE
interaction	NN	interaction	O	O	NONE
between	IN	between	O	O	NONE
digoxin	NN	digoxin	B-e1	O	drug
and	CC	and	O	O	NONE
nifedipine	NN	nifedipine	B-e2	O	drug
,	,	,	O	O	NONE
it	PRP	it	O	O	NONE
is	VBZ	be	O	O	NONE
recommended	VBN	recommend	O	O	NONE
that	IN	that	O	O	NONE
digoxin	NN	digoxin	O	O	NONE
levels	NNS	level	O	O	NONE
be	VB	be	O	O	NONE
monitored	VBN	monitor	O	O	NONE
when	WRB	when	O	O	NONE
initiating	VBG	initiate	O	O	NONE
,	,	,	O	O	NONE
adjusting	VBG	adjust	O	O	NONE
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
discontinuing	VBG	discontinue	O	O	NONE
nifedipine	NN	nifedipine	B-e3	T	drug
to	TO	to	O	O	NONE
avoid	VB	avoid	O	O	NONE
possible	JJ	possible	O	O	NONE
over-	NN	over-_NN	O	O	NONE
or	CC	or	O	O	NONE
under-digitalization	NN	under-digitalization	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d266.s2
Digitalis	NN	digitali	B-e0	O	drug
:	:	:	O	O	NONE
Immediate	JJ	immediate	O	O	NONE
Release	NN	release	O	O	NONE
Capsules	NNS	capsule	O	O	NONE
:	:	:	O	O	NONE
Since	IN	since	O	O	NONE
there	EX	there	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
isolated	VBN	isolate	O	O	NONE
reports	NNS	report	O	O	NONE
of	IN	of	O	O	NONE
patients	NNS	patient	O	O	NONE
with	IN	with	O	O	NONE
elevated	JJ	elevated	O	O	NONE
digoxin	NN	digoxin	O	O	NONE
levels	NNS	level	O	O	NONE
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
there	EX	there	O	O	NONE
is	VBZ	be	O	O	NONE
a	DT	a	O	O	NONE
possible	JJ	possible	O	O	NONE
interaction	NN	interaction	O	O	NONE
between	IN	between	O	O	NONE
digoxin	NN	digoxin	B-e1	T	drug
and	CC	and	O	O	NONE
nifedipine	NN	nifedipine	B-e2	T	drug
,	,	,	O	O	NONE
it	PRP	it	O	O	NONE
is	VBZ	be	O	O	NONE
recommended	VBN	recommend	O	O	NONE
that	IN	that	O	O	NONE
digoxin	NN	digoxin	O	O	NONE
levels	NNS	level	O	O	NONE
be	VB	be	O	O	NONE
monitored	VBN	monitor	O	O	NONE
when	WRB	when	O	O	NONE
initiating	VBG	initiate	O	O	NONE
,	,	,	O	O	NONE
adjusting	VBG	adjust	O	O	NONE
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
discontinuing	VBG	discontinue	O	O	NONE
nifedipine	NN	nifedipine	B-e3	O	drug
to	TO	to	O	O	NONE
avoid	VB	avoid	O	O	NONE
possible	JJ	possible	O	O	NONE
over-	NN	over-_NN	O	O	NONE
or	CC	or	O	O	NONE
under-digitalization	NN	under-digitalization	O	O	NONE
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d266.s2
Digitalis	NN	digitali	B-e0	O	drug
:	:	:	O	O	NONE
Immediate	JJ	immediate	O	O	NONE
Release	NN	release	O	O	NONE
Capsules	NNS	capsule	O	O	NONE
:	:	:	O	O	NONE
Since	IN	since	O	O	NONE
there	EX	there	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
isolated	VBN	isolate	O	O	NONE
reports	NNS	report	O	O	NONE
of	IN	of	O	O	NONE
patients	NNS	patient	O	O	NONE
with	IN	with	O	O	NONE
elevated	JJ	elevated	O	O	NONE
digoxin	NN	digoxin	O	O	NONE
levels	NNS	level	O	O	NONE
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
there	EX	there	O	O	NONE
is	VBZ	be	O	O	NONE
a	DT	a	O	O	NONE
possible	JJ	possible	O	O	NONE
interaction	NN	interaction	O	O	NONE
between	IN	between	O	O	NONE
digoxin	NN	digoxin	B-e1	T	drug
and	CC	and	O	O	NONE
nifedipine	NN	nifedipine	B-e2	O	drug
,	,	,	O	O	NONE
it	PRP	it	O	O	NONE
is	VBZ	be	O	O	NONE
recommended	VBN	recommend	O	O	NONE
that	IN	that	O	O	NONE
digoxin	NN	digoxin	O	O	NONE
levels	NNS	level	O	O	NONE
be	VB	be	O	O	NONE
monitored	VBN	monitor	O	O	NONE
when	WRB	when	O	O	NONE
initiating	VBG	initiate	O	O	NONE
,	,	,	O	O	NONE
adjusting	VBG	adjust	O	O	NONE
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
discontinuing	VBG	discontinue	O	O	NONE
nifedipine	NN	nifedipine	B-e3	T	drug
to	TO	to	O	O	NONE
avoid	VB	avoid	O	O	NONE
possible	JJ	possible	O	O	NONE
over-	NN	over-_NN	O	O	NONE
or	CC	or	O	O	NONE
under-digitalization	NN	under-digitalization	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d266.s2
Digitalis	NN	digitali	B-e0	O	drug
:	:	:	O	O	NONE
Immediate	JJ	immediate	O	O	NONE
Release	NN	release	O	O	NONE
Capsules	NNS	capsule	O	O	NONE
:	:	:	O	O	NONE
Since	IN	since	O	O	NONE
there	EX	there	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
isolated	VBN	isolate	O	O	NONE
reports	NNS	report	O	O	NONE
of	IN	of	O	O	NONE
patients	NNS	patient	O	O	NONE
with	IN	with	O	O	NONE
elevated	JJ	elevated	O	O	NONE
digoxin	NN	digoxin	O	O	NONE
levels	NNS	level	O	O	NONE
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
there	EX	there	O	O	NONE
is	VBZ	be	O	O	NONE
a	DT	a	O	O	NONE
possible	JJ	possible	O	O	NONE
interaction	NN	interaction	O	O	NONE
between	IN	between	O	O	NONE
digoxin	NN	digoxin	B-e1	O	drug
and	CC	and	O	O	NONE
nifedipine	NN	nifedipine	B-e2	T	drug
,	,	,	O	O	NONE
it	PRP	it	O	O	NONE
is	VBZ	be	O	O	NONE
recommended	VBN	recommend	O	O	NONE
that	IN	that	O	O	NONE
digoxin	NN	digoxin	O	O	NONE
levels	NNS	level	O	O	NONE
be	VB	be	O	O	NONE
monitored	VBN	monitor	O	O	NONE
when	WRB	when	O	O	NONE
initiating	VBG	initiate	O	O	NONE
,	,	,	O	O	NONE
adjusting	VBG	adjust	O	O	NONE
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
discontinuing	VBG	discontinue	O	O	NONE
nifedipine	NN	nifedipine	B-e3	T	drug
to	TO	to	O	O	NONE
avoid	VB	avoid	O	O	NONE
possible	JJ	possible	O	O	NONE
over-	NN	over-_NN	O	O	NONE
or	CC	or	O	O	NONE
under-digitalization	NN	under-digitalization	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d266.s3
Extended	JJ	extended	O	O	NONE
Release	NN	release	O	O	NONE
Tablets	NNS	tablet	O	O	NONE
:	:	:	O	O	NONE
Administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
nifedipine	NN	nifedipine	B-e0	T	drug
with	IN	with	O	O	NONE
digoxin	NN	digoxin	B-e1	T	drug
increased	VBD	increase	O	O	NONE
digoxin	NN	digoxin	O	O	NONE
levels	NNS	level	O	O	NONE
in	IN	in	O	O	NONE
9	CD	9	O	O	NONE
of	IN	of	O	O	NONE
12	CD	12	O	O	NONE
normal	JJ	normal	O	O	NONE
volunteers	NNS	volunteer	O	O	NONE
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d266.s8
Quinidine	NN	quinidine	B-e0	T	drug
:	:	:	O	O	NONE
Immediate	JJ	immediate	O	O	NONE
Release	NN	release	O	O	NONE
Capsules	NNS	capsule	O	O	NONE
:	:	:	O	O	NONE
There	EX	there	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
rare	JJ	rare	O	O	NONE
reports	NNS	report	O	O	NONE
of	IN	of	O	O	NONE
an	DT	a	O	O	NONE
interaction	NN	interaction	O	O	NONE
between	IN	between	O	O	NONE
quinidine	NN	quinidine	B-e1	T	drug
and	CC	and	O	O	NONE
nifedipine	NN	nifedipine	B-e2	O	drug
(	(	(	O	O	NONE
with	IN	with	O	O	NONE
a	DT	a	O	O	NONE
decreased	VBN	decrease	O	O	NONE
plasma	NN	plasma	O	O	NONE
level	NN	level	O	O	NONE
of	IN	of	O	O	NONE
quinidine	NN	quinidine	B-e3	O	drug
)	)	)	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d266.s8
Quinidine	NN	quinidine	B-e0	T	drug
:	:	:	O	O	NONE
Immediate	JJ	immediate	O	O	NONE
Release	NN	release	O	O	NONE
Capsules	NNS	capsule	O	O	NONE
:	:	:	O	O	NONE
There	EX	there	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
rare	JJ	rare	O	O	NONE
reports	NNS	report	O	O	NONE
of	IN	of	O	O	NONE
an	DT	a	O	O	NONE
interaction	NN	interaction	O	O	NONE
between	IN	between	O	O	NONE
quinidine	NN	quinidine	B-e1	O	drug
and	CC	and	O	O	NONE
nifedipine	NN	nifedipine	B-e2	T	drug
(	(	(	O	O	NONE
with	IN	with	O	O	NONE
a	DT	a	O	O	NONE
decreased	VBN	decrease	O	O	NONE
plasma	NN	plasma	O	O	NONE
level	NN	level	O	O	NONE
of	IN	of	O	O	NONE
quinidine	NN	quinidine	B-e3	O	drug
)	)	)	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d266.s8
Quinidine	NN	quinidine	B-e0	T	drug
:	:	:	O	O	NONE
Immediate	JJ	immediate	O	O	NONE
Release	NN	release	O	O	NONE
Capsules	NNS	capsule	O	O	NONE
:	:	:	O	O	NONE
There	EX	there	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
rare	JJ	rare	O	O	NONE
reports	NNS	report	O	O	NONE
of	IN	of	O	O	NONE
an	DT	a	O	O	NONE
interaction	NN	interaction	O	O	NONE
between	IN	between	O	O	NONE
quinidine	NN	quinidine	B-e1	O	drug
and	CC	and	O	O	NONE
nifedipine	NN	nifedipine	B-e2	O	drug
(	(	(	O	O	NONE
with	IN	with	O	O	NONE
a	DT	a	O	O	NONE
decreased	VBN	decrease	O	O	NONE
plasma	NN	plasma	O	O	NONE
level	NN	level	O	O	NONE
of	IN	of	O	O	NONE
quinidine	NN	quinidine	B-e3	T	drug
)	)	)	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d266.s8
Quinidine	NN	quinidine	B-e0	O	drug
:	:	:	O	O	NONE
Immediate	JJ	immediate	O	O	NONE
Release	NN	release	O	O	NONE
Capsules	NNS	capsule	O	O	NONE
:	:	:	O	O	NONE
There	EX	there	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
rare	JJ	rare	O	O	NONE
reports	NNS	report	O	O	NONE
of	IN	of	O	O	NONE
an	DT	a	O	O	NONE
interaction	NN	interaction	O	O	NONE
between	IN	between	O	O	NONE
quinidine	NN	quinidine	B-e1	T	drug
and	CC	and	O	O	NONE
nifedipine	NN	nifedipine	B-e2	T	drug
(	(	(	O	O	NONE
with	IN	with	O	O	NONE
a	DT	a	O	O	NONE
decreased	VBN	decrease	O	O	NONE
plasma	NN	plasma	O	O	NONE
level	NN	level	O	O	NONE
of	IN	of	O	O	NONE
quinidine	NN	quinidine	B-e3	O	drug
)	)	)	O	O	NONE
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d266.s8
Quinidine	NN	quinidine	B-e0	O	drug
:	:	:	O	O	NONE
Immediate	JJ	immediate	O	O	NONE
Release	NN	release	O	O	NONE
Capsules	NNS	capsule	O	O	NONE
:	:	:	O	O	NONE
There	EX	there	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
rare	JJ	rare	O	O	NONE
reports	NNS	report	O	O	NONE
of	IN	of	O	O	NONE
an	DT	a	O	O	NONE
interaction	NN	interaction	O	O	NONE
between	IN	between	O	O	NONE
quinidine	NN	quinidine	B-e1	T	drug
and	CC	and	O	O	NONE
nifedipine	NN	nifedipine	B-e2	O	drug
(	(	(	O	O	NONE
with	IN	with	O	O	NONE
a	DT	a	O	O	NONE
decreased	VBN	decrease	O	O	NONE
plasma	NN	plasma	O	O	NONE
level	NN	level	O	O	NONE
of	IN	of	O	O	NONE
quinidine	NN	quinidine	B-e3	T	drug
)	)	)	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d266.s8
Quinidine	NN	quinidine	B-e0	O	drug
:	:	:	O	O	NONE
Immediate	JJ	immediate	O	O	NONE
Release	NN	release	O	O	NONE
Capsules	NNS	capsule	O	O	NONE
:	:	:	O	O	NONE
There	EX	there	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
rare	JJ	rare	O	O	NONE
reports	NNS	report	O	O	NONE
of	IN	of	O	O	NONE
an	DT	a	O	O	NONE
interaction	NN	interaction	O	O	NONE
between	IN	between	O	O	NONE
quinidine	NN	quinidine	B-e1	O	drug
and	CC	and	O	O	NONE
nifedipine	NN	nifedipine	B-e2	T	drug
(	(	(	O	O	NONE
with	IN	with	O	O	NONE
a	DT	a	O	O	NONE
decreased	VBN	decrease	O	O	NONE
plasma	NN	plasma	O	O	NONE
level	NN	level	O	O	NONE
of	IN	of	O	O	NONE
quinidine	NN	quinidine	B-e3	T	drug
)	)	)	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d266.s9
Coumarin	NN	coumarin	B-e0	T	drug
Anticoagulant	NN	anticoagulant	I-e0	T	drug
s	NNS	s	O	O	NONE
:	:	:	O	O	NONE
There	EX	there	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
rare	JJ	rare	O	O	NONE
reports	NNS	report	O	O	NONE
of	IN	of	O	O	NONE
increased	VBN	increase	O	O	NONE
prothrombin	NN	prothrombin	O	O	NONE
time	NN	time	O	O	NONE
in	IN	in	O	O	NONE
patients	NNS	patient	O	O	NONE
taking	VBG	take	O	O	NONE
coumarin	NN	coumarin	B-e1	T	drug
anticoagulant	NN	anticoagulant	I-e1	T	drug
s	NNS	s	O	O	NONE
to	TO	to	O	O	NONE
whom	WP	whom	O	O	NONE
nifedipine	NN	nifedipine	B-e2	O	drug
was	VBD	be	O	O	NONE
administered	VBN	administer	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d266.s9
Coumarin	NN	coumarin	B-e0	T	drug
Anticoagulant	NN	anticoagulant	I-e0	T	drug
s	NNS	s	O	O	NONE
:	:	:	O	O	NONE
There	EX	there	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
rare	JJ	rare	O	O	NONE
reports	NNS	report	O	O	NONE
of	IN	of	O	O	NONE
increased	VBN	increase	O	O	NONE
prothrombin	NN	prothrombin	O	O	NONE
time	NN	time	O	O	NONE
in	IN	in	O	O	NONE
patients	NNS	patient	O	O	NONE
taking	VBG	take	O	O	NONE
coumarin	NN	coumarin	B-e1	O	drug
anticoagulant	NN	anticoagulant	I-e1	O	drug
s	NNS	s	O	O	NONE
to	TO	to	O	O	NONE
whom	WP	whom	O	O	NONE
nifedipine	NN	nifedipine	B-e2	T	drug
was	VBD	be	O	O	NONE
administered	VBN	administer	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d266.s9
Coumarin	NN	coumarin	B-e0	O	drug
Anticoagulant	NN	anticoagulant	I-e0	O	drug
s	NNS	s	O	O	NONE
:	:	:	O	O	NONE
There	EX	there	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
rare	JJ	rare	O	O	NONE
reports	NNS	report	O	O	NONE
of	IN	of	O	O	NONE
increased	VBN	increase	O	O	NONE
prothrombin	NN	prothrombin	O	O	NONE
time	NN	time	O	O	NONE
in	IN	in	O	O	NONE
patients	NNS	patient	O	O	NONE
taking	VBG	take	O	O	NONE
coumarin	NN	coumarin	B-e1	T	drug
anticoagulant	NN	anticoagulant	I-e1	T	drug
s	NNS	s	O	O	NONE
to	TO	to	O	O	NONE
whom	WP	whom	O	O	NONE
nifedipine	NN	nifedipine	B-e2	T	drug
was	VBD	be	O	O	NONE
administered	VBN	administer	O	O	NONE
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d266.s11
Cimetidine	NN	cimetidine	B-e0	T	drug
:	:	:	O	O	NONE
A	DT	a	O	O	NONE
study	NN	study	O	O	NONE
in	IN	in	O	O	NONE
6	CD	6	O	O	NONE
healthy	JJ	healthy	O	O	NONE
volunteers	NNS	volunteer	O	O	NONE
has	VBZ	have	O	O	NONE
shown	VBN	show	O	O	NONE
a	DT	a	O	O	NONE
significant	JJ	significant	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
peak	NN	peak	O	O	NONE
nifedipine	NN	nifedipine	B-e1	T	drug
plasma	NN	plasma	O	O	NONE
levels	NNS	level	O	O	NONE
(	(	(	O	O	NONE
80	CD	80	O	O	NONE
%	NN	%	O	O	NONE
)	)	)	O	O	NONE
and	CC	and	O	O	NONE
area-under-the-curve	JJ	area-under-the-curve	O	O	NONE
(	(	(	O	O	NONE
74	CD	74	O	O	NONE
%	NN	%	O	O	NONE
)	)	)	O	O	NONE
after	IN	after	O	O	NONE
a	DT	a	O	O	NONE
1	CD	1	O	O	NONE
week	NN	week	O	O	NONE
course	NN	course	O	O	NONE
of	IN	of	O	O	NONE
cimetidine	NN	cimetidine	B-e2	O	drug
at	IN	at	O	O	NONE
1000	CD	1000	O	O	NONE
mg	NN	mg	O	O	NONE
per	IN	per	O	O	NONE
day	NN	day	O	O	NONE
and	CC	and	O	O	NONE
nifedipine	NN	nifedipine	B-e3	O	drug
at	IN	at	O	O	NONE
40	CD	40	O	O	NONE
mg	NN	mg	O	O	NONE
per	IN	per	O	O	NONE
day	NN	day	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d266.s11
Cimetidine	NN	cimetidine	B-e0	T	drug
:	:	:	O	O	NONE
A	DT	a	O	O	NONE
study	NN	study	O	O	NONE
in	IN	in	O	O	NONE
6	CD	6	O	O	NONE
healthy	JJ	healthy	O	O	NONE
volunteers	NNS	volunteer	O	O	NONE
has	VBZ	have	O	O	NONE
shown	VBN	show	O	O	NONE
a	DT	a	O	O	NONE
significant	JJ	significant	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
peak	NN	peak	O	O	NONE
nifedipine	NN	nifedipine	B-e1	O	drug
plasma	NN	plasma	O	O	NONE
levels	NNS	level	O	O	NONE
(	(	(	O	O	NONE
80	CD	80	O	O	NONE
%	NN	%	O	O	NONE
)	)	)	O	O	NONE
and	CC	and	O	O	NONE
area-under-the-curve	JJ	area-under-the-curve	O	O	NONE
(	(	(	O	O	NONE
74	CD	74	O	O	NONE
%	NN	%	O	O	NONE
)	)	)	O	O	NONE
after	IN	after	O	O	NONE
a	DT	a	O	O	NONE
1	CD	1	O	O	NONE
week	NN	week	O	O	NONE
course	NN	course	O	O	NONE
of	IN	of	O	O	NONE
cimetidine	NN	cimetidine	B-e2	T	drug
at	IN	at	O	O	NONE
1000	CD	1000	O	O	NONE
mg	NN	mg	O	O	NONE
per	IN	per	O	O	NONE
day	NN	day	O	O	NONE
and	CC	and	O	O	NONE
nifedipine	NN	nifedipine	B-e3	O	drug
at	IN	at	O	O	NONE
40	CD	40	O	O	NONE
mg	NN	mg	O	O	NONE
per	IN	per	O	O	NONE
day	NN	day	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d266.s11
Cimetidine	NN	cimetidine	B-e0	T	drug
:	:	:	O	O	NONE
A	DT	a	O	O	NONE
study	NN	study	O	O	NONE
in	IN	in	O	O	NONE
6	CD	6	O	O	NONE
healthy	JJ	healthy	O	O	NONE
volunteers	NNS	volunteer	O	O	NONE
has	VBZ	have	O	O	NONE
shown	VBN	show	O	O	NONE
a	DT	a	O	O	NONE
significant	JJ	significant	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
peak	NN	peak	O	O	NONE
nifedipine	NN	nifedipine	B-e1	O	drug
plasma	NN	plasma	O	O	NONE
levels	NNS	level	O	O	NONE
(	(	(	O	O	NONE
80	CD	80	O	O	NONE
%	NN	%	O	O	NONE
)	)	)	O	O	NONE
and	CC	and	O	O	NONE
area-under-the-curve	JJ	area-under-the-curve	O	O	NONE
(	(	(	O	O	NONE
74	CD	74	O	O	NONE
%	NN	%	O	O	NONE
)	)	)	O	O	NONE
after	IN	after	O	O	NONE
a	DT	a	O	O	NONE
1	CD	1	O	O	NONE
week	NN	week	O	O	NONE
course	NN	course	O	O	NONE
of	IN	of	O	O	NONE
cimetidine	NN	cimetidine	B-e2	O	drug
at	IN	at	O	O	NONE
1000	CD	1000	O	O	NONE
mg	NN	mg	O	O	NONE
per	IN	per	O	O	NONE
day	NN	day	O	O	NONE
and	CC	and	O	O	NONE
nifedipine	NN	nifedipine	B-e3	T	drug
at	IN	at	O	O	NONE
40	CD	40	O	O	NONE
mg	NN	mg	O	O	NONE
per	IN	per	O	O	NONE
day	NN	day	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d266.s11
Cimetidine	NN	cimetidine	B-e0	O	drug
:	:	:	O	O	NONE
A	DT	a	O	O	NONE
study	NN	study	O	O	NONE
in	IN	in	O	O	NONE
6	CD	6	O	O	NONE
healthy	JJ	healthy	O	O	NONE
volunteers	NNS	volunteer	O	O	NONE
has	VBZ	have	O	O	NONE
shown	VBN	show	O	O	NONE
a	DT	a	O	O	NONE
significant	JJ	significant	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
peak	NN	peak	O	O	NONE
nifedipine	NN	nifedipine	B-e1	T	drug
plasma	NN	plasma	O	O	NONE
levels	NNS	level	O	O	NONE
(	(	(	O	O	NONE
80	CD	80	O	O	NONE
%	NN	%	O	O	NONE
)	)	)	O	O	NONE
and	CC	and	O	O	NONE
area-under-the-curve	JJ	area-under-the-curve	O	O	NONE
(	(	(	O	O	NONE
74	CD	74	O	O	NONE
%	NN	%	O	O	NONE
)	)	)	O	O	NONE
after	IN	after	O	O	NONE
a	DT	a	O	O	NONE
1	CD	1	O	O	NONE
week	NN	week	O	O	NONE
course	NN	course	O	O	NONE
of	IN	of	O	O	NONE
cimetidine	NN	cimetidine	B-e2	T	drug
at	IN	at	O	O	NONE
1000	CD	1000	O	O	NONE
mg	NN	mg	O	O	NONE
per	IN	per	O	O	NONE
day	NN	day	O	O	NONE
and	CC	and	O	O	NONE
nifedipine	NN	nifedipine	B-e3	O	drug
at	IN	at	O	O	NONE
40	CD	40	O	O	NONE
mg	NN	mg	O	O	NONE
per	IN	per	O	O	NONE
day	NN	day	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d266.s11
Cimetidine	NN	cimetidine	B-e0	O	drug
:	:	:	O	O	NONE
A	DT	a	O	O	NONE
study	NN	study	O	O	NONE
in	IN	in	O	O	NONE
6	CD	6	O	O	NONE
healthy	JJ	healthy	O	O	NONE
volunteers	NNS	volunteer	O	O	NONE
has	VBZ	have	O	O	NONE
shown	VBN	show	O	O	NONE
a	DT	a	O	O	NONE
significant	JJ	significant	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
peak	NN	peak	O	O	NONE
nifedipine	NN	nifedipine	B-e1	T	drug
plasma	NN	plasma	O	O	NONE
levels	NNS	level	O	O	NONE
(	(	(	O	O	NONE
80	CD	80	O	O	NONE
%	NN	%	O	O	NONE
)	)	)	O	O	NONE
and	CC	and	O	O	NONE
area-under-the-curve	JJ	area-under-the-curve	O	O	NONE
(	(	(	O	O	NONE
74	CD	74	O	O	NONE
%	NN	%	O	O	NONE
)	)	)	O	O	NONE
after	IN	after	O	O	NONE
a	DT	a	O	O	NONE
1	CD	1	O	O	NONE
week	NN	week	O	O	NONE
course	NN	course	O	O	NONE
of	IN	of	O	O	NONE
cimetidine	NN	cimetidine	B-e2	O	drug
at	IN	at	O	O	NONE
1000	CD	1000	O	O	NONE
mg	NN	mg	O	O	NONE
per	IN	per	O	O	NONE
day	NN	day	O	O	NONE
and	CC	and	O	O	NONE
nifedipine	NN	nifedipine	B-e3	T	drug
at	IN	at	O	O	NONE
40	CD	40	O	O	NONE
mg	NN	mg	O	O	NONE
per	IN	per	O	O	NONE
day	NN	day	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d266.s11
Cimetidine	NN	cimetidine	B-e0	O	drug
:	:	:	O	O	NONE
A	DT	a	O	O	NONE
study	NN	study	O	O	NONE
in	IN	in	O	O	NONE
6	CD	6	O	O	NONE
healthy	JJ	healthy	O	O	NONE
volunteers	NNS	volunteer	O	O	NONE
has	VBZ	have	O	O	NONE
shown	VBN	show	O	O	NONE
a	DT	a	O	O	NONE
significant	JJ	significant	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
peak	NN	peak	O	O	NONE
nifedipine	NN	nifedipine	B-e1	O	drug
plasma	NN	plasma	O	O	NONE
levels	NNS	level	O	O	NONE
(	(	(	O	O	NONE
80	CD	80	O	O	NONE
%	NN	%	O	O	NONE
)	)	)	O	O	NONE
and	CC	and	O	O	NONE
area-under-the-curve	JJ	area-under-the-curve	O	O	NONE
(	(	(	O	O	NONE
74	CD	74	O	O	NONE
%	NN	%	O	O	NONE
)	)	)	O	O	NONE
after	IN	after	O	O	NONE
a	DT	a	O	O	NONE
1	CD	1	O	O	NONE
week	NN	week	O	O	NONE
course	NN	course	O	O	NONE
of	IN	of	O	O	NONE
cimetidine	NN	cimetidine	B-e2	T	drug
at	IN	at	O	O	NONE
1000	CD	1000	O	O	NONE
mg	NN	mg	O	O	NONE
per	IN	per	O	O	NONE
day	NN	day	O	O	NONE
and	CC	and	O	O	NONE
nifedipine	NN	nifedipine	B-e3	T	drug
at	IN	at	O	O	NONE
40	CD	40	O	O	NONE
mg	NN	mg	O	O	NONE
per	IN	per	O	O	NONE
day	NN	day	O	O	NONE
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d266.s13
The	DT	the	O	O	NONE
effect	NN	effect	O	O	NONE
may	MD	may	O	O	NONE
be	VB	be	O	O	NONE
mediated	VBN	mediate	O	O	NONE
by	IN	by	O	O	NONE
the	DT	the	O	O	NONE
known	JJ	known	O	O	NONE
inhibition	NN	inhibition	O	O	NONE
of	IN	of	O	O	NONE
cimetidine	NN	cimetidine	B-e0	T	drug
on	IN	on	O	O	NONE
hepatic	JJ	hepatic	O	O	NONE
cytochrome	NN	cytochrome	B-e1	T	drug
P-450	NN	p-450	I-e1	T	drug
,	,	,	O	O	NONE
the	DT	the	O	O	NONE
enzyme	NN	enzyme	O	O	NONE
system	NN	system	O	O	NONE
probably	RB	probably	O	O	NONE
responsible	JJ	responsible	O	O	NONE
for	IN	for	O	O	NONE
the	DT	the	O	O	NONE
first-pass	NN	first-pass	O	O	NONE
metabolism	NN	metabolism	O	O	NONE
of	IN	of	O	O	NONE
nifedipine	NN	nifedipine	B-e2	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d266.s13
The	DT	the	O	O	NONE
effect	NN	effect	O	O	NONE
may	MD	may	O	O	NONE
be	VB	be	O	O	NONE
mediated	VBN	mediate	O	O	NONE
by	IN	by	O	O	NONE
the	DT	the	O	O	NONE
known	JJ	known	O	O	NONE
inhibition	NN	inhibition	O	O	NONE
of	IN	of	O	O	NONE
cimetidine	NN	cimetidine	B-e0	T	drug
on	IN	on	O	O	NONE
hepatic	JJ	hepatic	O	O	NONE
cytochrome	NN	cytochrome	B-e1	O	drug
P-450	NN	p-450	I-e1	O	drug
,	,	,	O	O	NONE
the	DT	the	O	O	NONE
enzyme	NN	enzyme	O	O	NONE
system	NN	system	O	O	NONE
probably	RB	probably	O	O	NONE
responsible	JJ	responsible	O	O	NONE
for	IN	for	O	O	NONE
the	DT	the	O	O	NONE
first-pass	NN	first-pass	O	O	NONE
metabolism	NN	metabolism	O	O	NONE
of	IN	of	O	O	NONE
nifedipine	NN	nifedipine	B-e2	T	drug
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d266.s13
The	DT	the	O	O	NONE
effect	NN	effect	O	O	NONE
may	MD	may	O	O	NONE
be	VB	be	O	O	NONE
mediated	VBN	mediate	O	O	NONE
by	IN	by	O	O	NONE
the	DT	the	O	O	NONE
known	JJ	known	O	O	NONE
inhibition	NN	inhibition	O	O	NONE
of	IN	of	O	O	NONE
cimetidine	NN	cimetidine	B-e0	O	drug
on	IN	on	O	O	NONE
hepatic	JJ	hepatic	O	O	NONE
cytochrome	NN	cytochrome	B-e1	T	drug
P-450	NN	p-450	I-e1	T	drug
,	,	,	O	O	NONE
the	DT	the	O	O	NONE
enzyme	NN	enzyme	O	O	NONE
system	NN	system	O	O	NONE
probably	RB	probably	O	O	NONE
responsible	JJ	responsible	O	O	NONE
for	IN	for	O	O	NONE
the	DT	the	O	O	NONE
first-pass	NN	first-pass	O	O	NONE
metabolism	NN	metabolism	O	O	NONE
of	IN	of	O	O	NONE
nifedipine	NN	nifedipine	B-e2	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d266.s14
If	IN	if	O	O	NONE
nifedipine	NN	nifedipine	B-e0	T	drug
therapy	NN	therapy	O	O	NONE
is	VBZ	be	O	O	NONE
initiated	VBN	initiate	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
patient	NN	patient	O	O	NONE
currently	RB	currently	O	O	NONE
receiving	VBG	receive	O	O	NONE
cimetidine	NN	cimetidine	B-e1	T	drug
,	,	,	O	O	NONE
cautious	JJ	cautious	O	O	NONE
titration	NN	titration	O	O	NONE
is	VBZ	be	O	O	NONE
advised	VBN	advise	O	O	NONE
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d234.s0
A	DT	a	O	O	NONE
30	CD	30	O	O	NONE
to	TO	to	O	O	NONE
45	CD	45	O	O	NONE
%	NN	%	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
AUC	NN	auc	O	O	NONE
and	CC	and	O	O	NONE
Cmax	NN	cmax	O	O	NONE
of	IN	of	O	O	NONE
nisoldipine	NN	nisoldipine	B-e0	T	drug
was	VBD	be	O	O	NONE
observed	VBN	observe	O	O	NONE
with	IN	with	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
cimetidine	NN	cimetidine	B-e1	T	drug
400	CD	400	I-e1	T	drug
mg	NN	mg	I-e1	T	drug
twice	RB	twice	O	O	NONE
daily	RB	daily	O	O	NONE
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d234.s1
Ranitidine	NN	ranitidine	B-e0	T	drug
150	CD	150	I-e0	T	drug
mg	NN	mg	I-e0	T	drug
twice	RB	twice	O	O	NONE
daily	RB	daily	O	O	NONE
did	VBD	do	O	O	NONE
not	RB	not	O	O	NONE
interact	VB	interact	O	O	NONE
significantly	RB	significantly	O	O	NONE
with	IN	with	O	O	NONE
nisoldipine	NN	nisoldipine	B-e1	T	drug
(	(	(	O	O	NONE
AUC	NN	auc	O	O	NONE
was	VBD	be	O	O	NONE
decreased	VBN	decrease	O	O	NONE
by	IN	by	O	O	NONE
15-20	CD	15-20	O	O	NONE
%	NN	%	O	O	NONE
).	CD	).	O	O	NONE

NO

Sentence: DrugDDI.d234.s3
Coadministration	NN	coadministration	O	O	NONE
of	IN	of	O	O	NONE
phenytoin	NN	phenytoin	B-e0	T	drug
with	IN	with	O	O	NONE
40	CD	40	O	O	NONE
mg	NN	mg	O	O	NONE
SULAR	NN	sular	B-e1	T	drug
tablets	NNS	tablet	O	O	NONE
in	IN	in	O	O	NONE
epileptic	JJ	epileptic	O	O	NONE
patients	NNS	patient	O	O	NONE
lowered	VBD	lower	O	O	NONE
the	DT	the	O	O	NONE
nisoldipine	NN	nisoldipine	B-e2	O	drug
plasma	NN	plasma	O	O	NONE
concentrations	NNS	concentration	O	O	NONE
to	TO	to	O	O	NONE
undetectable	JJ	undetectable	O	O	NONE
levels	NNS	level	O	O	NONE
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d234.s3
Coadministration	NN	coadministration	O	O	NONE
of	IN	of	O	O	NONE
phenytoin	NN	phenytoin	B-e0	T	drug
with	IN	with	O	O	NONE
40	CD	40	O	O	NONE
mg	NN	mg	O	O	NONE
SULAR	NN	sular	B-e1	O	drug
tablets	NNS	tablet	O	O	NONE
in	IN	in	O	O	NONE
epileptic	JJ	epileptic	O	O	NONE
patients	NNS	patient	O	O	NONE
lowered	VBD	lower	O	O	NONE
the	DT	the	O	O	NONE
nisoldipine	NN	nisoldipine	B-e2	T	drug
plasma	NN	plasma	O	O	NONE
concentrations	NNS	concentration	O	O	NONE
to	TO	to	O	O	NONE
undetectable	JJ	undetectable	O	O	NONE
levels	NNS	level	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d234.s3
Coadministration	NN	coadministration	O	O	NONE
of	IN	of	O	O	NONE
phenytoin	NN	phenytoin	B-e0	O	drug
with	IN	with	O	O	NONE
40	CD	40	O	O	NONE
mg	NN	mg	O	O	NONE
SULAR	NN	sular	B-e1	T	drug
tablets	NNS	tablet	O	O	NONE
in	IN	in	O	O	NONE
epileptic	JJ	epileptic	O	O	NONE
patients	NNS	patient	O	O	NONE
lowered	VBD	lower	O	O	NONE
the	DT	the	O	O	NONE
nisoldipine	NN	nisoldipine	B-e2	T	drug
plasma	NN	plasma	O	O	NONE
concentrations	NNS	concentration	O	O	NONE
to	TO	to	O	O	NONE
undetectable	JJ	undetectable	O	O	NONE
levels	NNS	level	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d234.s4
Coadministration	NN	coadministration	O	O	NONE
of	IN	of	O	O	NONE
SULAR	NN	sular	B-e0	T	drug
with	IN	with	O	O	NONE
phenytoin	NN	phenytoin	B-e1	T	drug
or	CC	or	O	O	NONE
any	DT	any	O	O	NONE
known	JJ	known	O	O	NONE
CYP3A4	NN	cyp3a4	B-e2	O	drug
inducer	NN	inducer	O	O	NONE
should	MD	should	O	O	NONE
be	VB	be	O	O	NONE
avoided	VBN	avoid	O	O	NONE
and	CC	and	O	O	NONE
alternative	JJ	alternative	O	O	NONE
antihypertensive	JJ	antihypertensive	B-e3	O	drug
therapy	NN	therapy	O	O	NONE
should	MD	should	O	O	NONE
be	VB	be	O	O	NONE
considered	VBN	consider	O	O	NONE
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d234.s4
Coadministration	NN	coadministration	O	O	NONE
of	IN	of	O	O	NONE
SULAR	NN	sular	B-e0	T	drug
with	IN	with	O	O	NONE
phenytoin	NN	phenytoin	B-e1	O	drug
or	CC	or	O	O	NONE
any	DT	any	O	O	NONE
known	JJ	known	O	O	NONE
CYP3A4	NN	cyp3a4	B-e2	T	drug
inducer	NN	inducer	O	O	NONE
should	MD	should	O	O	NONE
be	VB	be	O	O	NONE
avoided	VBN	avoid	O	O	NONE
and	CC	and	O	O	NONE
alternative	JJ	alternative	O	O	NONE
antihypertensive	JJ	antihypertensive	B-e3	O	drug
therapy	NN	therapy	O	O	NONE
should	MD	should	O	O	NONE
be	VB	be	O	O	NONE
considered	VBN	consider	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d234.s4
Coadministration	NN	coadministration	O	O	NONE
of	IN	of	O	O	NONE
SULAR	NN	sular	B-e0	T	drug
with	IN	with	O	O	NONE
phenytoin	NN	phenytoin	B-e1	O	drug
or	CC	or	O	O	NONE
any	DT	any	O	O	NONE
known	JJ	known	O	O	NONE
CYP3A4	NN	cyp3a4	B-e2	O	drug
inducer	NN	inducer	O	O	NONE
should	MD	should	O	O	NONE
be	VB	be	O	O	NONE
avoided	VBN	avoid	O	O	NONE
and	CC	and	O	O	NONE
alternative	JJ	alternative	O	O	NONE
antihypertensive	JJ	antihypertensive	B-e3	T	drug
therapy	NN	therapy	O	O	NONE
should	MD	should	O	O	NONE
be	VB	be	O	O	NONE
considered	VBN	consider	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d234.s4
Coadministration	NN	coadministration	O	O	NONE
of	IN	of	O	O	NONE
SULAR	NN	sular	B-e0	O	drug
with	IN	with	O	O	NONE
phenytoin	NN	phenytoin	B-e1	T	drug
or	CC	or	O	O	NONE
any	DT	any	O	O	NONE
known	JJ	known	O	O	NONE
CYP3A4	NN	cyp3a4	B-e2	T	drug
inducer	NN	inducer	O	O	NONE
should	MD	should	O	O	NONE
be	VB	be	O	O	NONE
avoided	VBN	avoid	O	O	NONE
and	CC	and	O	O	NONE
alternative	JJ	alternative	O	O	NONE
antihypertensive	JJ	antihypertensive	B-e3	O	drug
therapy	NN	therapy	O	O	NONE
should	MD	should	O	O	NONE
be	VB	be	O	O	NONE
considered	VBN	consider	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d234.s4
Coadministration	NN	coadministration	O	O	NONE
of	IN	of	O	O	NONE
SULAR	NN	sular	B-e0	O	drug
with	IN	with	O	O	NONE
phenytoin	NN	phenytoin	B-e1	T	drug
or	CC	or	O	O	NONE
any	DT	any	O	O	NONE
known	JJ	known	O	O	NONE
CYP3A4	NN	cyp3a4	B-e2	O	drug
inducer	NN	inducer	O	O	NONE
should	MD	should	O	O	NONE
be	VB	be	O	O	NONE
avoided	VBN	avoid	O	O	NONE
and	CC	and	O	O	NONE
alternative	JJ	alternative	O	O	NONE
antihypertensive	JJ	antihypertensive	B-e3	T	drug
therapy	NN	therapy	O	O	NONE
should	MD	should	O	O	NONE
be	VB	be	O	O	NONE
considered	VBN	consider	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d234.s4
Coadministration	NN	coadministration	O	O	NONE
of	IN	of	O	O	NONE
SULAR	NN	sular	B-e0	O	drug
with	IN	with	O	O	NONE
phenytoin	NN	phenytoin	B-e1	O	drug
or	CC	or	O	O	NONE
any	DT	any	O	O	NONE
known	JJ	known	O	O	NONE
CYP3A4	NN	cyp3a4	B-e2	T	drug
inducer	NN	inducer	O	O	NONE
should	MD	should	O	O	NONE
be	VB	be	O	O	NONE
avoided	VBN	avoid	O	O	NONE
and	CC	and	O	O	NONE
alternative	JJ	alternative	O	O	NONE
antihypertensive	JJ	antihypertensive	B-e3	T	drug
therapy	NN	therapy	O	O	NONE
should	MD	should	O	O	NONE
be	VB	be	O	O	NONE
considered	VBN	consider	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d234.s5
Pharmacokinetic	JJ	pharmacokinetic	O	O	NONE
interactions	NNS	interaction	O	O	NONE
between	IN	between	O	O	NONE
nisoldipine	NN	nisoldipine	B-e0	T	drug
and	CC	and	O	O	NONE
beta-blockers	NNS	beta-blocker	B-e1	T	drug
(	(	(	O	O	NONE
atenolol	NN	atenolol	B-e2	O	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e3	O	drug
)	)	)	O	O	NONE
were	VBD	be	O	O	NONE
variable	JJ	variable	O	O	NONE
and	CC	and	O	O	NONE
not	RB	not	O	O	NONE
significant	JJ	significant	O	O	NONE
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d234.s5
Pharmacokinetic	JJ	pharmacokinetic	O	O	NONE
interactions	NNS	interaction	O	O	NONE
between	IN	between	O	O	NONE
nisoldipine	NN	nisoldipine	B-e0	T	drug
and	CC	and	O	O	NONE
beta-blockers	NNS	beta-blocker	B-e1	O	drug
(	(	(	O	O	NONE
atenolol	NN	atenolol	B-e2	T	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e3	O	drug
)	)	)	O	O	NONE
were	VBD	be	O	O	NONE
variable	JJ	variable	O	O	NONE
and	CC	and	O	O	NONE
not	RB	not	O	O	NONE
significant	JJ	significant	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d234.s5
Pharmacokinetic	JJ	pharmacokinetic	O	O	NONE
interactions	NNS	interaction	O	O	NONE
between	IN	between	O	O	NONE
nisoldipine	NN	nisoldipine	B-e0	T	drug
and	CC	and	O	O	NONE
beta-blockers	NNS	beta-blocker	B-e1	O	drug
(	(	(	O	O	NONE
atenolol	NN	atenolol	B-e2	O	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e3	T	drug
)	)	)	O	O	NONE
were	VBD	be	O	O	NONE
variable	JJ	variable	O	O	NONE
and	CC	and	O	O	NONE
not	RB	not	O	O	NONE
significant	JJ	significant	O	O	NONE
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d234.s5
Pharmacokinetic	JJ	pharmacokinetic	O	O	NONE
interactions	NNS	interaction	O	O	NONE
between	IN	between	O	O	NONE
nisoldipine	NN	nisoldipine	B-e0	O	drug
and	CC	and	O	O	NONE
beta-blockers	NNS	beta-blocker	B-e1	T	drug
(	(	(	O	O	NONE
atenolol	NN	atenolol	B-e2	T	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e3	O	drug
)	)	)	O	O	NONE
were	VBD	be	O	O	NONE
variable	JJ	variable	O	O	NONE
and	CC	and	O	O	NONE
not	RB	not	O	O	NONE
significant	JJ	significant	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d234.s5
Pharmacokinetic	JJ	pharmacokinetic	O	O	NONE
interactions	NNS	interaction	O	O	NONE
between	IN	between	O	O	NONE
nisoldipine	NN	nisoldipine	B-e0	O	drug
and	CC	and	O	O	NONE
beta-blockers	NNS	beta-blocker	B-e1	T	drug
(	(	(	O	O	NONE
atenolol	NN	atenolol	B-e2	O	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e3	T	drug
)	)	)	O	O	NONE
were	VBD	be	O	O	NONE
variable	JJ	variable	O	O	NONE
and	CC	and	O	O	NONE
not	RB	not	O	O	NONE
significant	JJ	significant	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d234.s5
Pharmacokinetic	JJ	pharmacokinetic	O	O	NONE
interactions	NNS	interaction	O	O	NONE
between	IN	between	O	O	NONE
nisoldipine	NN	nisoldipine	B-e0	O	drug
and	CC	and	O	O	NONE
beta-blockers	NNS	beta-blocker	B-e1	O	drug
(	(	(	O	O	NONE
atenolol	NN	atenolol	B-e2	T	drug
,	,	,	O	O	NONE
propranolol	NN	propranolol	B-e3	T	drug
)	)	)	O	O	NONE
were	VBD	be	O	O	NONE
variable	JJ	variable	O	O	NONE
and	CC	and	O	O	NONE
not	RB	not	O	O	NONE
significant	JJ	significant	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d234.s6
Propranolol	NN	propranolol	B-e0	T	drug
attenuated	VBD	attenuate	O	O	NONE
the	DT	the	O	O	NONE
heart	NN	heart	O	O	NONE
rate	NN	rate	O	O	NONE
increase	NN	increase	O	O	NONE
following	VBG	follow	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
immediate	JJ	immediate	O	O	NONE
release	NN	release	O	O	NONE
nisoldipine	NN	nisoldipine	B-e1	T	drug
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d234.s7
The	DT	the	O	O	NONE
blood	NN	blood	O	O	NONE
pressure	NN	pressure	O	O	NONE
effect	NN	effect	O	O	NONE
of	IN	of	O	O	NONE
SULAR	NN	sular	B-e0	T	drug
tended	VBD	tend	O	O	NONE
to	TO	to	O	O	NONE
be	VB	be	O	O	NONE
greater	JJR	greater	O	O	NONE
in	IN	in	O	O	NONE
patients	NNS	patient	O	O	NONE
on	IN	on	O	O	NONE
atenolol	NN	atenolol	B-e1	T	drug
than	IN	than	O	O	NONE
in	IN	in	O	O	NONE
patients	NNS	patient	O	O	NONE
on	IN	on	O	O	NONE
no	DT	no	O	O	NONE
other	JJ	other	O	O	NONE
antihypertensive	JJ	antihypertensive	B-e2	O	drug
therapy	NN	therapy	O	O	NONE
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d234.s7
The	DT	the	O	O	NONE
blood	NN	blood	O	O	NONE
pressure	NN	pressure	O	O	NONE
effect	NN	effect	O	O	NONE
of	IN	of	O	O	NONE
SULAR	NN	sular	B-e0	T	drug
tended	VBD	tend	O	O	NONE
to	TO	to	O	O	NONE
be	VB	be	O	O	NONE
greater	JJR	greater	O	O	NONE
in	IN	in	O	O	NONE
patients	NNS	patient	O	O	NONE
on	IN	on	O	O	NONE
atenolol	NN	atenolol	B-e1	O	drug
than	IN	than	O	O	NONE
in	IN	in	O	O	NONE
patients	NNS	patient	O	O	NONE
on	IN	on	O	O	NONE
no	DT	no	O	O	NONE
other	JJ	other	O	O	NONE
antihypertensive	JJ	antihypertensive	B-e2	T	drug
therapy	NN	therapy	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d234.s7
The	DT	the	O	O	NONE
blood	NN	blood	O	O	NONE
pressure	NN	pressure	O	O	NONE
effect	NN	effect	O	O	NONE
of	IN	of	O	O	NONE
SULAR	NN	sular	B-e0	O	drug
tended	VBD	tend	O	O	NONE
to	TO	to	O	O	NONE
be	VB	be	O	O	NONE
greater	JJR	greater	O	O	NONE
in	IN	in	O	O	NONE
patients	NNS	patient	O	O	NONE
on	IN	on	O	O	NONE
atenolol	NN	atenolol	B-e1	T	drug
than	IN	than	O	O	NONE
in	IN	in	O	O	NONE
patients	NNS	patient	O	O	NONE
on	IN	on	O	O	NONE
no	DT	no	O	O	NONE
other	JJ	other	O	O	NONE
antihypertensive	JJ	antihypertensive	B-e2	T	drug
therapy	NN	therapy	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d234.s8
Quinidine	NN	quinidine	B-e0	T	drug
at	IN	at	O	O	NONE
648	CD	648	O	O	NONE
mg	NN	mg	O	O	NONE
bid	NN	bid	B-e1	T	drug
decreased	VBD	decrease	O	O	NONE
the	DT	the	O	O	NONE
bioavailability	NN	bioavailability	O	O	NONE
(	(	(	O	O	NONE
AUC	NN	auc	O	O	NONE
)	)	)	O	O	NONE
of	IN	of	O	O	NONE
nisoldipine	NN	nisoldipine	B-e2	O	drug
by	IN	by	O	O	NONE
26	CD	26	O	O	NONE
%	NN	%	O	O	NONE
,	,	,	O	O	NONE
but	CC	but	O	O	NONE
not	RB	not	O	O	NONE
the	DT	the	O	O	NONE
peak	JJ	peak	O	O	NONE
concentration	NN	concentration	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d234.s8
Quinidine	NN	quinidine	B-e0	T	drug
at	IN	at	O	O	NONE
648	CD	648	O	O	NONE
mg	NN	mg	O	O	NONE
bid	NN	bid	B-e1	O	drug
decreased	VBD	decrease	O	O	NONE
the	DT	the	O	O	NONE
bioavailability	NN	bioavailability	O	O	NONE
(	(	(	O	O	NONE
AUC	NN	auc	O	O	NONE
)	)	)	O	O	NONE
of	IN	of	O	O	NONE
nisoldipine	NN	nisoldipine	B-e2	T	drug
by	IN	by	O	O	NONE
26	CD	26	O	O	NONE
%	NN	%	O	O	NONE
,	,	,	O	O	NONE
but	CC	but	O	O	NONE
not	RB	not	O	O	NONE
the	DT	the	O	O	NONE
peak	JJ	peak	O	O	NONE
concentration	NN	concentration	O	O	NONE
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d234.s8
Quinidine	NN	quinidine	B-e0	O	drug
at	IN	at	O	O	NONE
648	CD	648	O	O	NONE
mg	NN	mg	O	O	NONE
bid	NN	bid	B-e1	T	drug
decreased	VBD	decrease	O	O	NONE
the	DT	the	O	O	NONE
bioavailability	NN	bioavailability	O	O	NONE
(	(	(	O	O	NONE
AUC	NN	auc	O	O	NONE
)	)	)	O	O	NONE
of	IN	of	O	O	NONE
nisoldipine	NN	nisoldipine	B-e2	T	drug
by	IN	by	O	O	NONE
26	CD	26	O	O	NONE
%	NN	%	O	O	NONE
,	,	,	O	O	NONE
but	CC	but	O	O	NONE
not	RB	not	O	O	NONE
the	DT	the	O	O	NONE
peak	JJ	peak	O	O	NONE
concentration	NN	concentration	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d234.s11
No	DT	no	O	O	NONE
significant	JJ	significant	O	O	NONE
interactions	NNS	interaction	O	O	NONE
were	VBD	be	O	O	NONE
found	VBN	find	O	O	NONE
between	IN	between	O	O	NONE
nisoldipine	NN	nisoldipine	B-e0	T	drug
and	CC	and	O	O	NONE
warfarin	NN	warfarin	B-e1	T	drug
or	CC	or	O	O	NONE
digoxin	NN	digoxin	B-e2	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d234.s11
No	DT	no	O	O	NONE
significant	JJ	significant	O	O	NONE
interactions	NNS	interaction	O	O	NONE
were	VBD	be	O	O	NONE
found	VBN	find	O	O	NONE
between	IN	between	O	O	NONE
nisoldipine	NN	nisoldipine	B-e0	T	drug
and	CC	and	O	O	NONE
warfarin	NN	warfarin	B-e1	O	drug
or	CC	or	O	O	NONE
digoxin	NN	digoxin	B-e2	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d234.s11
No	DT	no	O	O	NONE
significant	JJ	significant	O	O	NONE
interactions	NNS	interaction	O	O	NONE
were	VBD	be	O	O	NONE
found	VBN	find	O	O	NONE
between	IN	between	O	O	NONE
nisoldipine	NN	nisoldipine	B-e0	O	drug
and	CC	and	O	O	NONE
warfarin	NN	warfarin	B-e1	T	drug
or	CC	or	O	O	NONE
digoxin	NN	digoxin	B-e2	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d306.s0
Tizoxanide	NN	tizoxanide	B-e0	T	drug
is	VBZ	be	O	O	NONE
highly	RB	highly	O	O	NONE
bound	VBN	bind	O	O	NONE
to	TO	to	O	O	NONE
plasma	NN	plasma	B-e1	T	drug
protein	NN	protein	I-e1	T	drug
(	(	(	O	O	NONE
99.9	CD	99.9	O	O	NONE
%).	NN	%).	O	O	NONE

YES

Sentence: DrugDDI.d306.s1
Therefore	RB	therefore	O	O	NONE
,	,	,	O	O	NONE
caution	NN	caution	O	O	NONE
should	MD	should	O	O	NONE
be	VB	be	O	O	NONE
used	VBN	use	O	O	NONE
when	WRB	when	O	O	NONE
administering	VBG	administer	O	O	NONE
nitazoxanide	NN	nitazoxanide	B-e0	T	drug
concurrently	RB	concurrently	O	O	NONE
with	IN	with	O	O	NONE
other	JJ	other	O	O	NONE
highly	RB	highly	O	O	NONE
plasma	NN	plasma	O	O	NONE
protein-bound	JJ	protein-bound	O	O	NONE
drugs	NNS	drug	O	O	NONE
with	IN	with	O	O	NONE
narrow	JJ	narrow	O	O	NONE
therapeutic	JJ	therapeutic	O	O	NONE
indices	NNS	index	O	O	NONE
,	,	,	O	O	NONE
as	IN	as	O	O	NONE
competition	NN	competition	O	O	NONE
for	IN	for	O	O	NONE
binding	NN	binding	O	O	NONE
sites	NNS	site	O	O	NONE
may	MD	may	O	O	NONE
occur	VB	occur	O	O	NONE
(	(	(	O	O	NONE
e.g.	FW	e.g.	O	O	NONE
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e1	T	drug
)	)	)	O	O	NONE
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d306.s2
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
metabolism	NN	metabolism	O	O	NONE
studies	NNS	study	O	O	NONE
have	VBP	have	O	O	NONE
demonstrated	VBN	demonstrate	O	O	NONE
that	IN	that	O	O	NONE
tizoxanide	NN	tizoxanide	B-e0	T	drug
has	VBZ	have	O	O	NONE
no	DT	no	O	O	NONE
significant	JJ	significant	O	O	NONE
inhibitory	JJ	inhibitory	O	O	NONE
effect	NN	effect	O	O	NONE
on	IN	on	O	O	NONE
cytochrome	NN	cytochrome	B-e1	T	drug
P450	NN	p450	I-e1	T	drug
enzymes	NNS	enzyme	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d306.s3
Although	IN	although	O	O	NONE
no	DT	no	O	O	NONE
drug-drug	JJ	drug-drug	O	O	NONE
interaction	NN	interaction	O	O	NONE
studies	NNS	study	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
conducted	VBN	conduct	O	O	NONE
in	FW	in	O	O	NONE
vivo	FW	vivo	O	O	NONE
,	,	,	O	O	NONE
it	PRP	it	O	O	NONE
is	VBZ	be	O	O	NONE
expected	VBN	expect	O	O	NONE
that	IN	that	O	O	NONE
no	DT	no	O	O	NONE
significant	JJ	significant	O	O	NONE
interaction	NN	interaction	O	O	NONE
would	MD	would	O	O	NONE
occur	VB	occur	O	O	NONE
when	WRB	when	O	O	NONE
nitazoxanide	NN	nitazoxanide	B-e0	T	drug
is	VBZ	be	O	O	NONE
co-administered	VBN	co-administer	O	O	NONE
with	IN	with	O	O	NONE
drugs	NNS	drug	B-e1	T	drug
that	WDT	that	O	O	NONE
either	RB	either	O	O	NONE
are	VBP	be	O	O	NONE
metabolized	VBN	metabolize	O	O	NONE
by	IN	by	O	O	NONE
or	CC	or	O	O	NONE
inhibit	VB	inhibit	O	O	NONE
cytochrome	NN	cytochrome	B-e2	O	drug
P450	NN	p450	I-e2	O	drug
enzymes	NNS	enzyme	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d306.s3
Although	IN	although	O	O	NONE
no	DT	no	O	O	NONE
drug-drug	JJ	drug-drug	O	O	NONE
interaction	NN	interaction	O	O	NONE
studies	NNS	study	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
conducted	VBN	conduct	O	O	NONE
in	FW	in	O	O	NONE
vivo	FW	vivo	O	O	NONE
,	,	,	O	O	NONE
it	PRP	it	O	O	NONE
is	VBZ	be	O	O	NONE
expected	VBN	expect	O	O	NONE
that	IN	that	O	O	NONE
no	DT	no	O	O	NONE
significant	JJ	significant	O	O	NONE
interaction	NN	interaction	O	O	NONE
would	MD	would	O	O	NONE
occur	VB	occur	O	O	NONE
when	WRB	when	O	O	NONE
nitazoxanide	NN	nitazoxanide	B-e0	T	drug
is	VBZ	be	O	O	NONE
co-administered	VBN	co-administer	O	O	NONE
with	IN	with	O	O	NONE
drugs	NNS	drug	B-e1	O	drug
that	WDT	that	O	O	NONE
either	RB	either	O	O	NONE
are	VBP	be	O	O	NONE
metabolized	VBN	metabolize	O	O	NONE
by	IN	by	O	O	NONE
or	CC	or	O	O	NONE
inhibit	VB	inhibit	O	O	NONE
cytochrome	NN	cytochrome	B-e2	T	drug
P450	NN	p450	I-e2	T	drug
enzymes	NNS	enzyme	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d306.s3
Although	IN	although	O	O	NONE
no	DT	no	O	O	NONE
drug-drug	JJ	drug-drug	O	O	NONE
interaction	NN	interaction	O	O	NONE
studies	NNS	study	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
conducted	VBN	conduct	O	O	NONE
in	FW	in	O	O	NONE
vivo	FW	vivo	O	O	NONE
,	,	,	O	O	NONE
it	PRP	it	O	O	NONE
is	VBZ	be	O	O	NONE
expected	VBN	expect	O	O	NONE
that	IN	that	O	O	NONE
no	DT	no	O	O	NONE
significant	JJ	significant	O	O	NONE
interaction	NN	interaction	O	O	NONE
would	MD	would	O	O	NONE
occur	VB	occur	O	O	NONE
when	WRB	when	O	O	NONE
nitazoxanide	NN	nitazoxanide	B-e0	O	drug
is	VBZ	be	O	O	NONE
co-administered	VBN	co-administer	O	O	NONE
with	IN	with	O	O	NONE
drugs	NNS	drug	B-e1	T	drug
that	WDT	that	O	O	NONE
either	RB	either	O	O	NONE
are	VBP	be	O	O	NONE
metabolized	VBN	metabolize	O	O	NONE
by	IN	by	O	O	NONE
or	CC	or	O	O	NONE
inhibit	VB	inhibit	O	O	NONE
cytochrome	NN	cytochrome	B-e2	T	drug
P450	NN	p450	I-e2	T	drug
enzymes	NNS	enzyme	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s0
Oxcarbazepine	NN	oxcarbazepine	B-e0	T	drug
can	MD	can	O	O	NONE
inhibit	VB	inhibit	O	O	NONE
CYP2C19	NN	cyp2c19	B-e1	T	drug
and	CC	and	O	O	NONE
induce	VB	induce	O	O	NONE
CYP3A4	NN	cyp3a4	B-e2	O	drug
/5	NN	/5	O	O	NONE
with	IN	with	O	O	NONE
potentially	RB	potentially	O	O	NONE
important	JJ	important	O	O	NONE
effects	NNS	effect	O	O	NONE
on	IN	on	O	O	NONE
plasma	NN	plasma	O	O	NONE
concentrations	NNS	concentration	O	O	NONE
of	IN	of	O	O	NONE
other	JJ	other	O	O	NONE
drugs	NNS	drug	B-e3	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s0
Oxcarbazepine	NN	oxcarbazepine	B-e0	T	drug
can	MD	can	O	O	NONE
inhibit	VB	inhibit	O	O	NONE
CYP2C19	NN	cyp2c19	B-e1	O	drug
and	CC	and	O	O	NONE
induce	VB	induce	O	O	NONE
CYP3A4	NN	cyp3a4	B-e2	T	drug
/5	NN	/5	O	O	NONE
with	IN	with	O	O	NONE
potentially	RB	potentially	O	O	NONE
important	JJ	important	O	O	NONE
effects	NNS	effect	O	O	NONE
on	IN	on	O	O	NONE
plasma	NN	plasma	O	O	NONE
concentrations	NNS	concentration	O	O	NONE
of	IN	of	O	O	NONE
other	JJ	other	O	O	NONE
drugs	NNS	drug	B-e3	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s0
Oxcarbazepine	NN	oxcarbazepine	B-e0	T	drug
can	MD	can	O	O	NONE
inhibit	VB	inhibit	O	O	NONE
CYP2C19	NN	cyp2c19	B-e1	O	drug
and	CC	and	O	O	NONE
induce	VB	induce	O	O	NONE
CYP3A4	NN	cyp3a4	B-e2	O	drug
/5	NN	/5	O	O	NONE
with	IN	with	O	O	NONE
potentially	RB	potentially	O	O	NONE
important	JJ	important	O	O	NONE
effects	NNS	effect	O	O	NONE
on	IN	on	O	O	NONE
plasma	NN	plasma	O	O	NONE
concentrations	NNS	concentration	O	O	NONE
of	IN	of	O	O	NONE
other	JJ	other	O	O	NONE
drugs	NNS	drug	B-e3	T	drug
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d20.s0
Oxcarbazepine	NN	oxcarbazepine	B-e0	O	drug
can	MD	can	O	O	NONE
inhibit	VB	inhibit	O	O	NONE
CYP2C19	NN	cyp2c19	B-e1	T	drug
and	CC	and	O	O	NONE
induce	VB	induce	O	O	NONE
CYP3A4	NN	cyp3a4	B-e2	T	drug
/5	NN	/5	O	O	NONE
with	IN	with	O	O	NONE
potentially	RB	potentially	O	O	NONE
important	JJ	important	O	O	NONE
effects	NNS	effect	O	O	NONE
on	IN	on	O	O	NONE
plasma	NN	plasma	O	O	NONE
concentrations	NNS	concentration	O	O	NONE
of	IN	of	O	O	NONE
other	JJ	other	O	O	NONE
drugs	NNS	drug	B-e3	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s0
Oxcarbazepine	NN	oxcarbazepine	B-e0	O	drug
can	MD	can	O	O	NONE
inhibit	VB	inhibit	O	O	NONE
CYP2C19	NN	cyp2c19	B-e1	T	drug
and	CC	and	O	O	NONE
induce	VB	induce	O	O	NONE
CYP3A4	NN	cyp3a4	B-e2	O	drug
/5	NN	/5	O	O	NONE
with	IN	with	O	O	NONE
potentially	RB	potentially	O	O	NONE
important	JJ	important	O	O	NONE
effects	NNS	effect	O	O	NONE
on	IN	on	O	O	NONE
plasma	NN	plasma	O	O	NONE
concentrations	NNS	concentration	O	O	NONE
of	IN	of	O	O	NONE
other	JJ	other	O	O	NONE
drugs	NNS	drug	B-e3	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s0
Oxcarbazepine	NN	oxcarbazepine	B-e0	O	drug
can	MD	can	O	O	NONE
inhibit	VB	inhibit	O	O	NONE
CYP2C19	NN	cyp2c19	B-e1	O	drug
and	CC	and	O	O	NONE
induce	VB	induce	O	O	NONE
CYP3A4	NN	cyp3a4	B-e2	T	drug
/5	NN	/5	O	O	NONE
with	IN	with	O	O	NONE
potentially	RB	potentially	O	O	NONE
important	JJ	important	O	O	NONE
effects	NNS	effect	O	O	NONE
on	IN	on	O	O	NONE
plasma	NN	plasma	O	O	NONE
concentrations	NNS	concentration	O	O	NONE
of	IN	of	O	O	NONE
other	JJ	other	O	O	NONE
drugs	NNS	drug	B-e3	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s1
In	IN	in	O	O	NONE
addition	NN	addition	O	O	NONE
,	,	,	O	O	NONE
several	JJ	several	O	O	NONE
AED	JJ	aed	O	O	NONE
@	NN	@	O	O	NONE
s	NNS	s	O	O	NONE
that	WDT	that	O	O	NONE
are	VBP	be	O	O	NONE
cytochrome	NN	cytochrome	B-e0	T	drug
P450	NN	p450	I-e0	T	drug
inducers	NNS	inducer	O	O	NONE
can	MD	can	O	O	NONE
decrease	VB	decrease	O	O	NONE
plasma	NN	plasma	O	O	NONE
concentrations	NNS	concentration	O	O	NONE
of	IN	of	O	O	NONE
oxcarbazepine	NN	oxcarbazepine	B-e1	T	drug
and	CC	and	O	O	NONE
MHD	NN	mhd	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s2
Oxcarbazepine	NN	oxcarbazepine	B-e0	T	drug
was	VBD	be	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
in	IN	in	O	O	NONE
human	JJ	human	O	O	NONE
liver	NN	liver	O	O	NONE
microsomes	NNS	microsome	O	O	NONE
to	TO	to	O	O	NONE
determine	VB	determine	O	O	NONE
its	PRP$	its	O	O	NONE
capacity	NN	capacity	O	O	NONE
to	TO	to	O	O	NONE
inhibit	VB	inhibit	O	O	NONE
the	DT	the	O	O	NONE
major	JJ	major	O	O	NONE
cytochrome	NN	cytochrome	B-e1	T	drug
P450	NN	p450	I-e1	T	drug
enzymes	NNS	enzyme	O	O	NONE
responsible	JJ	responsible	O	O	NONE
for	IN	for	O	O	NONE
the	DT	the	O	O	NONE
metabolism	NN	metabolism	O	O	NONE
of	IN	of	O	O	NONE
other	JJ	other	O	O	NONE
drugs	NNS	drug	B-e2	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s2
Oxcarbazepine	NN	oxcarbazepine	B-e0	T	drug
was	VBD	be	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
in	IN	in	O	O	NONE
human	JJ	human	O	O	NONE
liver	NN	liver	O	O	NONE
microsomes	NNS	microsome	O	O	NONE
to	TO	to	O	O	NONE
determine	VB	determine	O	O	NONE
its	PRP$	its	O	O	NONE
capacity	NN	capacity	O	O	NONE
to	TO	to	O	O	NONE
inhibit	VB	inhibit	O	O	NONE
the	DT	the	O	O	NONE
major	JJ	major	O	O	NONE
cytochrome	NN	cytochrome	B-e1	O	drug
P450	NN	p450	I-e1	O	drug
enzymes	NNS	enzyme	O	O	NONE
responsible	JJ	responsible	O	O	NONE
for	IN	for	O	O	NONE
the	DT	the	O	O	NONE
metabolism	NN	metabolism	O	O	NONE
of	IN	of	O	O	NONE
other	JJ	other	O	O	NONE
drugs	NNS	drug	B-e2	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s2
Oxcarbazepine	NN	oxcarbazepine	B-e0	O	drug
was	VBD	be	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
in	IN	in	O	O	NONE
human	JJ	human	O	O	NONE
liver	NN	liver	O	O	NONE
microsomes	NNS	microsome	O	O	NONE
to	TO	to	O	O	NONE
determine	VB	determine	O	O	NONE
its	PRP$	its	O	O	NONE
capacity	NN	capacity	O	O	NONE
to	TO	to	O	O	NONE
inhibit	VB	inhibit	O	O	NONE
the	DT	the	O	O	NONE
major	JJ	major	O	O	NONE
cytochrome	NN	cytochrome	B-e1	T	drug
P450	NN	p450	I-e1	T	drug
enzymes	NNS	enzyme	O	O	NONE
responsible	JJ	responsible	O	O	NONE
for	IN	for	O	O	NONE
the	DT	the	O	O	NONE
metabolism	NN	metabolism	O	O	NONE
of	IN	of	O	O	NONE
other	JJ	other	O	O	NONE
drugs	NNS	drug	B-e2	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s3
Results	NNS	result	O	O	NONE
demonstrate	VBP	demonstrate	O	O	NONE
that	IN	that	O	O	NONE
oxcarbazepine	NN	oxcarbazepine	B-e0	T	drug
and	CC	and	O	O	NONE
its	PRP$	its	O	O	NONE
pharmacologically	RB	pharmacologically	O	O	NONE
active	JJ	active	B-e1	T	drug
10-monohydroxy	NN	10-monohydroxy	I-e1	T	drug
metabolite	NN	metabolite	I-e1	T	drug
(	(	(	O	O	NONE
MHD	NN	mhd	O	O	NONE
)	)	)	O	O	NONE
have	VBP	have	O	O	NONE
little	JJ	little	O	O	NONE
or	CC	or	O	O	NONE
no	DT	no	O	O	NONE
capacity	NN	capacity	O	O	NONE
to	TO	to	O	O	NONE
function	VB	function	O	O	NONE
as	IN	as	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
for	IN	for	O	O	NONE
most	JJS	most	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
human	JJ	human	O	O	NONE
cytochrome	NN	cytochrome	B-e2	O	drug
P450	NN	p450	I-e2	O	drug
enzymes	NNS	enzyme	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
(	(	(	O	O	NONE
CYP1A2	NN	cyp1a2	B-e3	O	drug
,	,	,	O	O	NONE
CYP2A6	NN	cyp2a6	B-e4	O	drug
,	,	,	O	O	NONE
CYP2C9	NN	cyp2c9	B-e5	O	drug
,	,	,	O	O	NONE
CYP2D6	NN	cyp2d6	B-e6	O	drug
,	,	,	O	O	NONE
CYP2E1	NN	cyp2e1	B-e7	O	drug
,	,	,	O	O	NONE
CYP4A9	NN	cyp4a9	O	O	NONE
and	CC	and	O	O	NONE
CYP4A11	NN	cyp4a11	B-e8	O	drug
)	)	)	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
exception	NN	exception	O	O	NONE
of	IN	of	O	O	NONE
CYP2C19	NN	cyp2c19	B-e9	O	drug
and	CC	and	O	O	NONE
CYP3A4	NN	cyp3a4	B-e10	O	drug
/5	NN	/5	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s3
Results	NNS	result	O	O	NONE
demonstrate	VBP	demonstrate	O	O	NONE
that	IN	that	O	O	NONE
oxcarbazepine	NN	oxcarbazepine	B-e0	T	drug
and	CC	and	O	O	NONE
its	PRP$	its	O	O	NONE
pharmacologically	RB	pharmacologically	O	O	NONE
active	JJ	active	B-e1	O	drug
10-monohydroxy	NN	10-monohydroxy	I-e1	O	drug
metabolite	NN	metabolite	I-e1	O	drug
(	(	(	O	O	NONE
MHD	NN	mhd	O	O	NONE
)	)	)	O	O	NONE
have	VBP	have	O	O	NONE
little	JJ	little	O	O	NONE
or	CC	or	O	O	NONE
no	DT	no	O	O	NONE
capacity	NN	capacity	O	O	NONE
to	TO	to	O	O	NONE
function	VB	function	O	O	NONE
as	IN	as	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
for	IN	for	O	O	NONE
most	JJS	most	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
human	JJ	human	O	O	NONE
cytochrome	NN	cytochrome	B-e2	T	drug
P450	NN	p450	I-e2	T	drug
enzymes	NNS	enzyme	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
(	(	(	O	O	NONE
CYP1A2	NN	cyp1a2	B-e3	O	drug
,	,	,	O	O	NONE
CYP2A6	NN	cyp2a6	B-e4	O	drug
,	,	,	O	O	NONE
CYP2C9	NN	cyp2c9	B-e5	O	drug
,	,	,	O	O	NONE
CYP2D6	NN	cyp2d6	B-e6	O	drug
,	,	,	O	O	NONE
CYP2E1	NN	cyp2e1	B-e7	O	drug
,	,	,	O	O	NONE
CYP4A9	NN	cyp4a9	O	O	NONE
and	CC	and	O	O	NONE
CYP4A11	NN	cyp4a11	B-e8	O	drug
)	)	)	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
exception	NN	exception	O	O	NONE
of	IN	of	O	O	NONE
CYP2C19	NN	cyp2c19	B-e9	O	drug
and	CC	and	O	O	NONE
CYP3A4	NN	cyp3a4	B-e10	O	drug
/5	NN	/5	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s3
Results	NNS	result	O	O	NONE
demonstrate	VBP	demonstrate	O	O	NONE
that	IN	that	O	O	NONE
oxcarbazepine	NN	oxcarbazepine	B-e0	T	drug
and	CC	and	O	O	NONE
its	PRP$	its	O	O	NONE
pharmacologically	RB	pharmacologically	O	O	NONE
active	JJ	active	B-e1	O	drug
10-monohydroxy	NN	10-monohydroxy	I-e1	O	drug
metabolite	NN	metabolite	I-e1	O	drug
(	(	(	O	O	NONE
MHD	NN	mhd	O	O	NONE
)	)	)	O	O	NONE
have	VBP	have	O	O	NONE
little	JJ	little	O	O	NONE
or	CC	or	O	O	NONE
no	DT	no	O	O	NONE
capacity	NN	capacity	O	O	NONE
to	TO	to	O	O	NONE
function	VB	function	O	O	NONE
as	IN	as	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
for	IN	for	O	O	NONE
most	JJS	most	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
human	JJ	human	O	O	NONE
cytochrome	NN	cytochrome	B-e2	O	drug
P450	NN	p450	I-e2	O	drug
enzymes	NNS	enzyme	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
(	(	(	O	O	NONE
CYP1A2	NN	cyp1a2	B-e3	T	drug
,	,	,	O	O	NONE
CYP2A6	NN	cyp2a6	B-e4	O	drug
,	,	,	O	O	NONE
CYP2C9	NN	cyp2c9	B-e5	O	drug
,	,	,	O	O	NONE
CYP2D6	NN	cyp2d6	B-e6	O	drug
,	,	,	O	O	NONE
CYP2E1	NN	cyp2e1	B-e7	O	drug
,	,	,	O	O	NONE
CYP4A9	NN	cyp4a9	O	O	NONE
and	CC	and	O	O	NONE
CYP4A11	NN	cyp4a11	B-e8	O	drug
)	)	)	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
exception	NN	exception	O	O	NONE
of	IN	of	O	O	NONE
CYP2C19	NN	cyp2c19	B-e9	O	drug
and	CC	and	O	O	NONE
CYP3A4	NN	cyp3a4	B-e10	O	drug
/5	NN	/5	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s3
Results	NNS	result	O	O	NONE
demonstrate	VBP	demonstrate	O	O	NONE
that	IN	that	O	O	NONE
oxcarbazepine	NN	oxcarbazepine	B-e0	T	drug
and	CC	and	O	O	NONE
its	PRP$	its	O	O	NONE
pharmacologically	RB	pharmacologically	O	O	NONE
active	JJ	active	B-e1	O	drug
10-monohydroxy	NN	10-monohydroxy	I-e1	O	drug
metabolite	NN	metabolite	I-e1	O	drug
(	(	(	O	O	NONE
MHD	NN	mhd	O	O	NONE
)	)	)	O	O	NONE
have	VBP	have	O	O	NONE
little	JJ	little	O	O	NONE
or	CC	or	O	O	NONE
no	DT	no	O	O	NONE
capacity	NN	capacity	O	O	NONE
to	TO	to	O	O	NONE
function	VB	function	O	O	NONE
as	IN	as	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
for	IN	for	O	O	NONE
most	JJS	most	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
human	JJ	human	O	O	NONE
cytochrome	NN	cytochrome	B-e2	O	drug
P450	NN	p450	I-e2	O	drug
enzymes	NNS	enzyme	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
(	(	(	O	O	NONE
CYP1A2	NN	cyp1a2	B-e3	O	drug
,	,	,	O	O	NONE
CYP2A6	NN	cyp2a6	B-e4	T	drug
,	,	,	O	O	NONE
CYP2C9	NN	cyp2c9	B-e5	O	drug
,	,	,	O	O	NONE
CYP2D6	NN	cyp2d6	B-e6	O	drug
,	,	,	O	O	NONE
CYP2E1	NN	cyp2e1	B-e7	O	drug
,	,	,	O	O	NONE
CYP4A9	NN	cyp4a9	O	O	NONE
and	CC	and	O	O	NONE
CYP4A11	NN	cyp4a11	B-e8	O	drug
)	)	)	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
exception	NN	exception	O	O	NONE
of	IN	of	O	O	NONE
CYP2C19	NN	cyp2c19	B-e9	O	drug
and	CC	and	O	O	NONE
CYP3A4	NN	cyp3a4	B-e10	O	drug
/5	NN	/5	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s3
Results	NNS	result	O	O	NONE
demonstrate	VBP	demonstrate	O	O	NONE
that	IN	that	O	O	NONE
oxcarbazepine	NN	oxcarbazepine	B-e0	T	drug
and	CC	and	O	O	NONE
its	PRP$	its	O	O	NONE
pharmacologically	RB	pharmacologically	O	O	NONE
active	JJ	active	B-e1	O	drug
10-monohydroxy	NN	10-monohydroxy	I-e1	O	drug
metabolite	NN	metabolite	I-e1	O	drug
(	(	(	O	O	NONE
MHD	NN	mhd	O	O	NONE
)	)	)	O	O	NONE
have	VBP	have	O	O	NONE
little	JJ	little	O	O	NONE
or	CC	or	O	O	NONE
no	DT	no	O	O	NONE
capacity	NN	capacity	O	O	NONE
to	TO	to	O	O	NONE
function	VB	function	O	O	NONE
as	IN	as	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
for	IN	for	O	O	NONE
most	JJS	most	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
human	JJ	human	O	O	NONE
cytochrome	NN	cytochrome	B-e2	O	drug
P450	NN	p450	I-e2	O	drug
enzymes	NNS	enzyme	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
(	(	(	O	O	NONE
CYP1A2	NN	cyp1a2	B-e3	O	drug
,	,	,	O	O	NONE
CYP2A6	NN	cyp2a6	B-e4	O	drug
,	,	,	O	O	NONE
CYP2C9	NN	cyp2c9	B-e5	T	drug
,	,	,	O	O	NONE
CYP2D6	NN	cyp2d6	B-e6	O	drug
,	,	,	O	O	NONE
CYP2E1	NN	cyp2e1	B-e7	O	drug
,	,	,	O	O	NONE
CYP4A9	NN	cyp4a9	O	O	NONE
and	CC	and	O	O	NONE
CYP4A11	NN	cyp4a11	B-e8	O	drug
)	)	)	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
exception	NN	exception	O	O	NONE
of	IN	of	O	O	NONE
CYP2C19	NN	cyp2c19	B-e9	O	drug
and	CC	and	O	O	NONE
CYP3A4	NN	cyp3a4	B-e10	O	drug
/5	NN	/5	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s3
Results	NNS	result	O	O	NONE
demonstrate	VBP	demonstrate	O	O	NONE
that	IN	that	O	O	NONE
oxcarbazepine	NN	oxcarbazepine	B-e0	T	drug
and	CC	and	O	O	NONE
its	PRP$	its	O	O	NONE
pharmacologically	RB	pharmacologically	O	O	NONE
active	JJ	active	B-e1	O	drug
10-monohydroxy	NN	10-monohydroxy	I-e1	O	drug
metabolite	NN	metabolite	I-e1	O	drug
(	(	(	O	O	NONE
MHD	NN	mhd	O	O	NONE
)	)	)	O	O	NONE
have	VBP	have	O	O	NONE
little	JJ	little	O	O	NONE
or	CC	or	O	O	NONE
no	DT	no	O	O	NONE
capacity	NN	capacity	O	O	NONE
to	TO	to	O	O	NONE
function	VB	function	O	O	NONE
as	IN	as	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
for	IN	for	O	O	NONE
most	JJS	most	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
human	JJ	human	O	O	NONE
cytochrome	NN	cytochrome	B-e2	O	drug
P450	NN	p450	I-e2	O	drug
enzymes	NNS	enzyme	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
(	(	(	O	O	NONE
CYP1A2	NN	cyp1a2	B-e3	O	drug
,	,	,	O	O	NONE
CYP2A6	NN	cyp2a6	B-e4	O	drug
,	,	,	O	O	NONE
CYP2C9	NN	cyp2c9	B-e5	O	drug
,	,	,	O	O	NONE
CYP2D6	NN	cyp2d6	B-e6	T	drug
,	,	,	O	O	NONE
CYP2E1	NN	cyp2e1	B-e7	O	drug
,	,	,	O	O	NONE
CYP4A9	NN	cyp4a9	O	O	NONE
and	CC	and	O	O	NONE
CYP4A11	NN	cyp4a11	B-e8	O	drug
)	)	)	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
exception	NN	exception	O	O	NONE
of	IN	of	O	O	NONE
CYP2C19	NN	cyp2c19	B-e9	O	drug
and	CC	and	O	O	NONE
CYP3A4	NN	cyp3a4	B-e10	O	drug
/5	NN	/5	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s3
Results	NNS	result	O	O	NONE
demonstrate	VBP	demonstrate	O	O	NONE
that	IN	that	O	O	NONE
oxcarbazepine	NN	oxcarbazepine	B-e0	T	drug
and	CC	and	O	O	NONE
its	PRP$	its	O	O	NONE
pharmacologically	RB	pharmacologically	O	O	NONE
active	JJ	active	B-e1	O	drug
10-monohydroxy	NN	10-monohydroxy	I-e1	O	drug
metabolite	NN	metabolite	I-e1	O	drug
(	(	(	O	O	NONE
MHD	NN	mhd	O	O	NONE
)	)	)	O	O	NONE
have	VBP	have	O	O	NONE
little	JJ	little	O	O	NONE
or	CC	or	O	O	NONE
no	DT	no	O	O	NONE
capacity	NN	capacity	O	O	NONE
to	TO	to	O	O	NONE
function	VB	function	O	O	NONE
as	IN	as	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
for	IN	for	O	O	NONE
most	JJS	most	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
human	JJ	human	O	O	NONE
cytochrome	NN	cytochrome	B-e2	O	drug
P450	NN	p450	I-e2	O	drug
enzymes	NNS	enzyme	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
(	(	(	O	O	NONE
CYP1A2	NN	cyp1a2	B-e3	O	drug
,	,	,	O	O	NONE
CYP2A6	NN	cyp2a6	B-e4	O	drug
,	,	,	O	O	NONE
CYP2C9	NN	cyp2c9	B-e5	O	drug
,	,	,	O	O	NONE
CYP2D6	NN	cyp2d6	B-e6	O	drug
,	,	,	O	O	NONE
CYP2E1	NN	cyp2e1	B-e7	T	drug
,	,	,	O	O	NONE
CYP4A9	NN	cyp4a9	O	O	NONE
and	CC	and	O	O	NONE
CYP4A11	NN	cyp4a11	B-e8	O	drug
)	)	)	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
exception	NN	exception	O	O	NONE
of	IN	of	O	O	NONE
CYP2C19	NN	cyp2c19	B-e9	O	drug
and	CC	and	O	O	NONE
CYP3A4	NN	cyp3a4	B-e10	O	drug
/5	NN	/5	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s3
Results	NNS	result	O	O	NONE
demonstrate	VBP	demonstrate	O	O	NONE
that	IN	that	O	O	NONE
oxcarbazepine	NN	oxcarbazepine	B-e0	T	drug
and	CC	and	O	O	NONE
its	PRP$	its	O	O	NONE
pharmacologically	RB	pharmacologically	O	O	NONE
active	JJ	active	B-e1	O	drug
10-monohydroxy	NN	10-monohydroxy	I-e1	O	drug
metabolite	NN	metabolite	I-e1	O	drug
(	(	(	O	O	NONE
MHD	NN	mhd	O	O	NONE
)	)	)	O	O	NONE
have	VBP	have	O	O	NONE
little	JJ	little	O	O	NONE
or	CC	or	O	O	NONE
no	DT	no	O	O	NONE
capacity	NN	capacity	O	O	NONE
to	TO	to	O	O	NONE
function	VB	function	O	O	NONE
as	IN	as	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
for	IN	for	O	O	NONE
most	JJS	most	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
human	JJ	human	O	O	NONE
cytochrome	NN	cytochrome	B-e2	O	drug
P450	NN	p450	I-e2	O	drug
enzymes	NNS	enzyme	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
(	(	(	O	O	NONE
CYP1A2	NN	cyp1a2	B-e3	O	drug
,	,	,	O	O	NONE
CYP2A6	NN	cyp2a6	B-e4	O	drug
,	,	,	O	O	NONE
CYP2C9	NN	cyp2c9	B-e5	O	drug
,	,	,	O	O	NONE
CYP2D6	NN	cyp2d6	B-e6	O	drug
,	,	,	O	O	NONE
CYP2E1	NN	cyp2e1	B-e7	O	drug
,	,	,	O	O	NONE
CYP4A9	NN	cyp4a9	O	O	NONE
and	CC	and	O	O	NONE
CYP4A11	NN	cyp4a11	B-e8	T	drug
)	)	)	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
exception	NN	exception	O	O	NONE
of	IN	of	O	O	NONE
CYP2C19	NN	cyp2c19	B-e9	O	drug
and	CC	and	O	O	NONE
CYP3A4	NN	cyp3a4	B-e10	O	drug
/5	NN	/5	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s3
Results	NNS	result	O	O	NONE
demonstrate	VBP	demonstrate	O	O	NONE
that	IN	that	O	O	NONE
oxcarbazepine	NN	oxcarbazepine	B-e0	T	drug
and	CC	and	O	O	NONE
its	PRP$	its	O	O	NONE
pharmacologically	RB	pharmacologically	O	O	NONE
active	JJ	active	B-e1	O	drug
10-monohydroxy	NN	10-monohydroxy	I-e1	O	drug
metabolite	NN	metabolite	I-e1	O	drug
(	(	(	O	O	NONE
MHD	NN	mhd	O	O	NONE
)	)	)	O	O	NONE
have	VBP	have	O	O	NONE
little	JJ	little	O	O	NONE
or	CC	or	O	O	NONE
no	DT	no	O	O	NONE
capacity	NN	capacity	O	O	NONE
to	TO	to	O	O	NONE
function	VB	function	O	O	NONE
as	IN	as	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
for	IN	for	O	O	NONE
most	JJS	most	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
human	JJ	human	O	O	NONE
cytochrome	NN	cytochrome	B-e2	O	drug
P450	NN	p450	I-e2	O	drug
enzymes	NNS	enzyme	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
(	(	(	O	O	NONE
CYP1A2	NN	cyp1a2	B-e3	O	drug
,	,	,	O	O	NONE
CYP2A6	NN	cyp2a6	B-e4	O	drug
,	,	,	O	O	NONE
CYP2C9	NN	cyp2c9	B-e5	O	drug
,	,	,	O	O	NONE
CYP2D6	NN	cyp2d6	B-e6	O	drug
,	,	,	O	O	NONE
CYP2E1	NN	cyp2e1	B-e7	O	drug
,	,	,	O	O	NONE
CYP4A9	NN	cyp4a9	O	O	NONE
and	CC	and	O	O	NONE
CYP4A11	NN	cyp4a11	B-e8	O	drug
)	)	)	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
exception	NN	exception	O	O	NONE
of	IN	of	O	O	NONE
CYP2C19	NN	cyp2c19	B-e9	T	drug
and	CC	and	O	O	NONE
CYP3A4	NN	cyp3a4	B-e10	O	drug
/5	NN	/5	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s3
Results	NNS	result	O	O	NONE
demonstrate	VBP	demonstrate	O	O	NONE
that	IN	that	O	O	NONE
oxcarbazepine	NN	oxcarbazepine	B-e0	T	drug
and	CC	and	O	O	NONE
its	PRP$	its	O	O	NONE
pharmacologically	RB	pharmacologically	O	O	NONE
active	JJ	active	B-e1	O	drug
10-monohydroxy	NN	10-monohydroxy	I-e1	O	drug
metabolite	NN	metabolite	I-e1	O	drug
(	(	(	O	O	NONE
MHD	NN	mhd	O	O	NONE
)	)	)	O	O	NONE
have	VBP	have	O	O	NONE
little	JJ	little	O	O	NONE
or	CC	or	O	O	NONE
no	DT	no	O	O	NONE
capacity	NN	capacity	O	O	NONE
to	TO	to	O	O	NONE
function	VB	function	O	O	NONE
as	IN	as	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
for	IN	for	O	O	NONE
most	JJS	most	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
human	JJ	human	O	O	NONE
cytochrome	NN	cytochrome	B-e2	O	drug
P450	NN	p450	I-e2	O	drug
enzymes	NNS	enzyme	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
(	(	(	O	O	NONE
CYP1A2	NN	cyp1a2	B-e3	O	drug
,	,	,	O	O	NONE
CYP2A6	NN	cyp2a6	B-e4	O	drug
,	,	,	O	O	NONE
CYP2C9	NN	cyp2c9	B-e5	O	drug
,	,	,	O	O	NONE
CYP2D6	NN	cyp2d6	B-e6	O	drug
,	,	,	O	O	NONE
CYP2E1	NN	cyp2e1	B-e7	O	drug
,	,	,	O	O	NONE
CYP4A9	NN	cyp4a9	O	O	NONE
and	CC	and	O	O	NONE
CYP4A11	NN	cyp4a11	B-e8	O	drug
)	)	)	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
exception	NN	exception	O	O	NONE
of	IN	of	O	O	NONE
CYP2C19	NN	cyp2c19	B-e9	O	drug
and	CC	and	O	O	NONE
CYP3A4	NN	cyp3a4	B-e10	T	drug
/5	NN	/5	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s3
Results	NNS	result	O	O	NONE
demonstrate	VBP	demonstrate	O	O	NONE
that	IN	that	O	O	NONE
oxcarbazepine	NN	oxcarbazepine	B-e0	O	drug
and	CC	and	O	O	NONE
its	PRP$	its	O	O	NONE
pharmacologically	RB	pharmacologically	O	O	NONE
active	JJ	active	B-e1	T	drug
10-monohydroxy	NN	10-monohydroxy	I-e1	T	drug
metabolite	NN	metabolite	I-e1	T	drug
(	(	(	O	O	NONE
MHD	NN	mhd	O	O	NONE
)	)	)	O	O	NONE
have	VBP	have	O	O	NONE
little	JJ	little	O	O	NONE
or	CC	or	O	O	NONE
no	DT	no	O	O	NONE
capacity	NN	capacity	O	O	NONE
to	TO	to	O	O	NONE
function	VB	function	O	O	NONE
as	IN	as	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
for	IN	for	O	O	NONE
most	JJS	most	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
human	JJ	human	O	O	NONE
cytochrome	NN	cytochrome	B-e2	T	drug
P450	NN	p450	I-e2	T	drug
enzymes	NNS	enzyme	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
(	(	(	O	O	NONE
CYP1A2	NN	cyp1a2	B-e3	O	drug
,	,	,	O	O	NONE
CYP2A6	NN	cyp2a6	B-e4	O	drug
,	,	,	O	O	NONE
CYP2C9	NN	cyp2c9	B-e5	O	drug
,	,	,	O	O	NONE
CYP2D6	NN	cyp2d6	B-e6	O	drug
,	,	,	O	O	NONE
CYP2E1	NN	cyp2e1	B-e7	O	drug
,	,	,	O	O	NONE
CYP4A9	NN	cyp4a9	O	O	NONE
and	CC	and	O	O	NONE
CYP4A11	NN	cyp4a11	B-e8	O	drug
)	)	)	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
exception	NN	exception	O	O	NONE
of	IN	of	O	O	NONE
CYP2C19	NN	cyp2c19	B-e9	O	drug
and	CC	and	O	O	NONE
CYP3A4	NN	cyp3a4	B-e10	O	drug
/5	NN	/5	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s3
Results	NNS	result	O	O	NONE
demonstrate	VBP	demonstrate	O	O	NONE
that	IN	that	O	O	NONE
oxcarbazepine	NN	oxcarbazepine	B-e0	O	drug
and	CC	and	O	O	NONE
its	PRP$	its	O	O	NONE
pharmacologically	RB	pharmacologically	O	O	NONE
active	JJ	active	B-e1	T	drug
10-monohydroxy	NN	10-monohydroxy	I-e1	T	drug
metabolite	NN	metabolite	I-e1	T	drug
(	(	(	O	O	NONE
MHD	NN	mhd	O	O	NONE
)	)	)	O	O	NONE
have	VBP	have	O	O	NONE
little	JJ	little	O	O	NONE
or	CC	or	O	O	NONE
no	DT	no	O	O	NONE
capacity	NN	capacity	O	O	NONE
to	TO	to	O	O	NONE
function	VB	function	O	O	NONE
as	IN	as	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
for	IN	for	O	O	NONE
most	JJS	most	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
human	JJ	human	O	O	NONE
cytochrome	NN	cytochrome	B-e2	O	drug
P450	NN	p450	I-e2	O	drug
enzymes	NNS	enzyme	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
(	(	(	O	O	NONE
CYP1A2	NN	cyp1a2	B-e3	T	drug
,	,	,	O	O	NONE
CYP2A6	NN	cyp2a6	B-e4	O	drug
,	,	,	O	O	NONE
CYP2C9	NN	cyp2c9	B-e5	O	drug
,	,	,	O	O	NONE
CYP2D6	NN	cyp2d6	B-e6	O	drug
,	,	,	O	O	NONE
CYP2E1	NN	cyp2e1	B-e7	O	drug
,	,	,	O	O	NONE
CYP4A9	NN	cyp4a9	O	O	NONE
and	CC	and	O	O	NONE
CYP4A11	NN	cyp4a11	B-e8	O	drug
)	)	)	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
exception	NN	exception	O	O	NONE
of	IN	of	O	O	NONE
CYP2C19	NN	cyp2c19	B-e9	O	drug
and	CC	and	O	O	NONE
CYP3A4	NN	cyp3a4	B-e10	O	drug
/5	NN	/5	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s3
Results	NNS	result	O	O	NONE
demonstrate	VBP	demonstrate	O	O	NONE
that	IN	that	O	O	NONE
oxcarbazepine	NN	oxcarbazepine	B-e0	O	drug
and	CC	and	O	O	NONE
its	PRP$	its	O	O	NONE
pharmacologically	RB	pharmacologically	O	O	NONE
active	JJ	active	B-e1	T	drug
10-monohydroxy	NN	10-monohydroxy	I-e1	T	drug
metabolite	NN	metabolite	I-e1	T	drug
(	(	(	O	O	NONE
MHD	NN	mhd	O	O	NONE
)	)	)	O	O	NONE
have	VBP	have	O	O	NONE
little	JJ	little	O	O	NONE
or	CC	or	O	O	NONE
no	DT	no	O	O	NONE
capacity	NN	capacity	O	O	NONE
to	TO	to	O	O	NONE
function	VB	function	O	O	NONE
as	IN	as	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
for	IN	for	O	O	NONE
most	JJS	most	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
human	JJ	human	O	O	NONE
cytochrome	NN	cytochrome	B-e2	O	drug
P450	NN	p450	I-e2	O	drug
enzymes	NNS	enzyme	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
(	(	(	O	O	NONE
CYP1A2	NN	cyp1a2	B-e3	O	drug
,	,	,	O	O	NONE
CYP2A6	NN	cyp2a6	B-e4	T	drug
,	,	,	O	O	NONE
CYP2C9	NN	cyp2c9	B-e5	O	drug
,	,	,	O	O	NONE
CYP2D6	NN	cyp2d6	B-e6	O	drug
,	,	,	O	O	NONE
CYP2E1	NN	cyp2e1	B-e7	O	drug
,	,	,	O	O	NONE
CYP4A9	NN	cyp4a9	O	O	NONE
and	CC	and	O	O	NONE
CYP4A11	NN	cyp4a11	B-e8	O	drug
)	)	)	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
exception	NN	exception	O	O	NONE
of	IN	of	O	O	NONE
CYP2C19	NN	cyp2c19	B-e9	O	drug
and	CC	and	O	O	NONE
CYP3A4	NN	cyp3a4	B-e10	O	drug
/5	NN	/5	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s3
Results	NNS	result	O	O	NONE
demonstrate	VBP	demonstrate	O	O	NONE
that	IN	that	O	O	NONE
oxcarbazepine	NN	oxcarbazepine	B-e0	O	drug
and	CC	and	O	O	NONE
its	PRP$	its	O	O	NONE
pharmacologically	RB	pharmacologically	O	O	NONE
active	JJ	active	B-e1	T	drug
10-monohydroxy	NN	10-monohydroxy	I-e1	T	drug
metabolite	NN	metabolite	I-e1	T	drug
(	(	(	O	O	NONE
MHD	NN	mhd	O	O	NONE
)	)	)	O	O	NONE
have	VBP	have	O	O	NONE
little	JJ	little	O	O	NONE
or	CC	or	O	O	NONE
no	DT	no	O	O	NONE
capacity	NN	capacity	O	O	NONE
to	TO	to	O	O	NONE
function	VB	function	O	O	NONE
as	IN	as	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
for	IN	for	O	O	NONE
most	JJS	most	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
human	JJ	human	O	O	NONE
cytochrome	NN	cytochrome	B-e2	O	drug
P450	NN	p450	I-e2	O	drug
enzymes	NNS	enzyme	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
(	(	(	O	O	NONE
CYP1A2	NN	cyp1a2	B-e3	O	drug
,	,	,	O	O	NONE
CYP2A6	NN	cyp2a6	B-e4	O	drug
,	,	,	O	O	NONE
CYP2C9	NN	cyp2c9	B-e5	T	drug
,	,	,	O	O	NONE
CYP2D6	NN	cyp2d6	B-e6	O	drug
,	,	,	O	O	NONE
CYP2E1	NN	cyp2e1	B-e7	O	drug
,	,	,	O	O	NONE
CYP4A9	NN	cyp4a9	O	O	NONE
and	CC	and	O	O	NONE
CYP4A11	NN	cyp4a11	B-e8	O	drug
)	)	)	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
exception	NN	exception	O	O	NONE
of	IN	of	O	O	NONE
CYP2C19	NN	cyp2c19	B-e9	O	drug
and	CC	and	O	O	NONE
CYP3A4	NN	cyp3a4	B-e10	O	drug
/5	NN	/5	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s3
Results	NNS	result	O	O	NONE
demonstrate	VBP	demonstrate	O	O	NONE
that	IN	that	O	O	NONE
oxcarbazepine	NN	oxcarbazepine	B-e0	O	drug
and	CC	and	O	O	NONE
its	PRP$	its	O	O	NONE
pharmacologically	RB	pharmacologically	O	O	NONE
active	JJ	active	B-e1	T	drug
10-monohydroxy	NN	10-monohydroxy	I-e1	T	drug
metabolite	NN	metabolite	I-e1	T	drug
(	(	(	O	O	NONE
MHD	NN	mhd	O	O	NONE
)	)	)	O	O	NONE
have	VBP	have	O	O	NONE
little	JJ	little	O	O	NONE
or	CC	or	O	O	NONE
no	DT	no	O	O	NONE
capacity	NN	capacity	O	O	NONE
to	TO	to	O	O	NONE
function	VB	function	O	O	NONE
as	IN	as	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
for	IN	for	O	O	NONE
most	JJS	most	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
human	JJ	human	O	O	NONE
cytochrome	NN	cytochrome	B-e2	O	drug
P450	NN	p450	I-e2	O	drug
enzymes	NNS	enzyme	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
(	(	(	O	O	NONE
CYP1A2	NN	cyp1a2	B-e3	O	drug
,	,	,	O	O	NONE
CYP2A6	NN	cyp2a6	B-e4	O	drug
,	,	,	O	O	NONE
CYP2C9	NN	cyp2c9	B-e5	O	drug
,	,	,	O	O	NONE
CYP2D6	NN	cyp2d6	B-e6	T	drug
,	,	,	O	O	NONE
CYP2E1	NN	cyp2e1	B-e7	O	drug
,	,	,	O	O	NONE
CYP4A9	NN	cyp4a9	O	O	NONE
and	CC	and	O	O	NONE
CYP4A11	NN	cyp4a11	B-e8	O	drug
)	)	)	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
exception	NN	exception	O	O	NONE
of	IN	of	O	O	NONE
CYP2C19	NN	cyp2c19	B-e9	O	drug
and	CC	and	O	O	NONE
CYP3A4	NN	cyp3a4	B-e10	O	drug
/5	NN	/5	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s3
Results	NNS	result	O	O	NONE
demonstrate	VBP	demonstrate	O	O	NONE
that	IN	that	O	O	NONE
oxcarbazepine	NN	oxcarbazepine	B-e0	O	drug
and	CC	and	O	O	NONE
its	PRP$	its	O	O	NONE
pharmacologically	RB	pharmacologically	O	O	NONE
active	JJ	active	B-e1	T	drug
10-monohydroxy	NN	10-monohydroxy	I-e1	T	drug
metabolite	NN	metabolite	I-e1	T	drug
(	(	(	O	O	NONE
MHD	NN	mhd	O	O	NONE
)	)	)	O	O	NONE
have	VBP	have	O	O	NONE
little	JJ	little	O	O	NONE
or	CC	or	O	O	NONE
no	DT	no	O	O	NONE
capacity	NN	capacity	O	O	NONE
to	TO	to	O	O	NONE
function	VB	function	O	O	NONE
as	IN	as	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
for	IN	for	O	O	NONE
most	JJS	most	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
human	JJ	human	O	O	NONE
cytochrome	NN	cytochrome	B-e2	O	drug
P450	NN	p450	I-e2	O	drug
enzymes	NNS	enzyme	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
(	(	(	O	O	NONE
CYP1A2	NN	cyp1a2	B-e3	O	drug
,	,	,	O	O	NONE
CYP2A6	NN	cyp2a6	B-e4	O	drug
,	,	,	O	O	NONE
CYP2C9	NN	cyp2c9	B-e5	O	drug
,	,	,	O	O	NONE
CYP2D6	NN	cyp2d6	B-e6	O	drug
,	,	,	O	O	NONE
CYP2E1	NN	cyp2e1	B-e7	T	drug
,	,	,	O	O	NONE
CYP4A9	NN	cyp4a9	O	O	NONE
and	CC	and	O	O	NONE
CYP4A11	NN	cyp4a11	B-e8	O	drug
)	)	)	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
exception	NN	exception	O	O	NONE
of	IN	of	O	O	NONE
CYP2C19	NN	cyp2c19	B-e9	O	drug
and	CC	and	O	O	NONE
CYP3A4	NN	cyp3a4	B-e10	O	drug
/5	NN	/5	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s3
Results	NNS	result	O	O	NONE
demonstrate	VBP	demonstrate	O	O	NONE
that	IN	that	O	O	NONE
oxcarbazepine	NN	oxcarbazepine	B-e0	O	drug
and	CC	and	O	O	NONE
its	PRP$	its	O	O	NONE
pharmacologically	RB	pharmacologically	O	O	NONE
active	JJ	active	B-e1	T	drug
10-monohydroxy	NN	10-monohydroxy	I-e1	T	drug
metabolite	NN	metabolite	I-e1	T	drug
(	(	(	O	O	NONE
MHD	NN	mhd	O	O	NONE
)	)	)	O	O	NONE
have	VBP	have	O	O	NONE
little	JJ	little	O	O	NONE
or	CC	or	O	O	NONE
no	DT	no	O	O	NONE
capacity	NN	capacity	O	O	NONE
to	TO	to	O	O	NONE
function	VB	function	O	O	NONE
as	IN	as	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
for	IN	for	O	O	NONE
most	JJS	most	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
human	JJ	human	O	O	NONE
cytochrome	NN	cytochrome	B-e2	O	drug
P450	NN	p450	I-e2	O	drug
enzymes	NNS	enzyme	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
(	(	(	O	O	NONE
CYP1A2	NN	cyp1a2	B-e3	O	drug
,	,	,	O	O	NONE
CYP2A6	NN	cyp2a6	B-e4	O	drug
,	,	,	O	O	NONE
CYP2C9	NN	cyp2c9	B-e5	O	drug
,	,	,	O	O	NONE
CYP2D6	NN	cyp2d6	B-e6	O	drug
,	,	,	O	O	NONE
CYP2E1	NN	cyp2e1	B-e7	O	drug
,	,	,	O	O	NONE
CYP4A9	NN	cyp4a9	O	O	NONE
and	CC	and	O	O	NONE
CYP4A11	NN	cyp4a11	B-e8	T	drug
)	)	)	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
exception	NN	exception	O	O	NONE
of	IN	of	O	O	NONE
CYP2C19	NN	cyp2c19	B-e9	O	drug
and	CC	and	O	O	NONE
CYP3A4	NN	cyp3a4	B-e10	O	drug
/5	NN	/5	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s3
Results	NNS	result	O	O	NONE
demonstrate	VBP	demonstrate	O	O	NONE
that	IN	that	O	O	NONE
oxcarbazepine	NN	oxcarbazepine	B-e0	O	drug
and	CC	and	O	O	NONE
its	PRP$	its	O	O	NONE
pharmacologically	RB	pharmacologically	O	O	NONE
active	JJ	active	B-e1	T	drug
10-monohydroxy	NN	10-monohydroxy	I-e1	T	drug
metabolite	NN	metabolite	I-e1	T	drug
(	(	(	O	O	NONE
MHD	NN	mhd	O	O	NONE
)	)	)	O	O	NONE
have	VBP	have	O	O	NONE
little	JJ	little	O	O	NONE
or	CC	or	O	O	NONE
no	DT	no	O	O	NONE
capacity	NN	capacity	O	O	NONE
to	TO	to	O	O	NONE
function	VB	function	O	O	NONE
as	IN	as	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
for	IN	for	O	O	NONE
most	JJS	most	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
human	JJ	human	O	O	NONE
cytochrome	NN	cytochrome	B-e2	O	drug
P450	NN	p450	I-e2	O	drug
enzymes	NNS	enzyme	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
(	(	(	O	O	NONE
CYP1A2	NN	cyp1a2	B-e3	O	drug
,	,	,	O	O	NONE
CYP2A6	NN	cyp2a6	B-e4	O	drug
,	,	,	O	O	NONE
CYP2C9	NN	cyp2c9	B-e5	O	drug
,	,	,	O	O	NONE
CYP2D6	NN	cyp2d6	B-e6	O	drug
,	,	,	O	O	NONE
CYP2E1	NN	cyp2e1	B-e7	O	drug
,	,	,	O	O	NONE
CYP4A9	NN	cyp4a9	O	O	NONE
and	CC	and	O	O	NONE
CYP4A11	NN	cyp4a11	B-e8	O	drug
)	)	)	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
exception	NN	exception	O	O	NONE
of	IN	of	O	O	NONE
CYP2C19	NN	cyp2c19	B-e9	T	drug
and	CC	and	O	O	NONE
CYP3A4	NN	cyp3a4	B-e10	O	drug
/5	NN	/5	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s3
Results	NNS	result	O	O	NONE
demonstrate	VBP	demonstrate	O	O	NONE
that	IN	that	O	O	NONE
oxcarbazepine	NN	oxcarbazepine	B-e0	O	drug
and	CC	and	O	O	NONE
its	PRP$	its	O	O	NONE
pharmacologically	RB	pharmacologically	O	O	NONE
active	JJ	active	B-e1	T	drug
10-monohydroxy	NN	10-monohydroxy	I-e1	T	drug
metabolite	NN	metabolite	I-e1	T	drug
(	(	(	O	O	NONE
MHD	NN	mhd	O	O	NONE
)	)	)	O	O	NONE
have	VBP	have	O	O	NONE
little	JJ	little	O	O	NONE
or	CC	or	O	O	NONE
no	DT	no	O	O	NONE
capacity	NN	capacity	O	O	NONE
to	TO	to	O	O	NONE
function	VB	function	O	O	NONE
as	IN	as	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
for	IN	for	O	O	NONE
most	JJS	most	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
human	JJ	human	O	O	NONE
cytochrome	NN	cytochrome	B-e2	O	drug
P450	NN	p450	I-e2	O	drug
enzymes	NNS	enzyme	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
(	(	(	O	O	NONE
CYP1A2	NN	cyp1a2	B-e3	O	drug
,	,	,	O	O	NONE
CYP2A6	NN	cyp2a6	B-e4	O	drug
,	,	,	O	O	NONE
CYP2C9	NN	cyp2c9	B-e5	O	drug
,	,	,	O	O	NONE
CYP2D6	NN	cyp2d6	B-e6	O	drug
,	,	,	O	O	NONE
CYP2E1	NN	cyp2e1	B-e7	O	drug
,	,	,	O	O	NONE
CYP4A9	NN	cyp4a9	O	O	NONE
and	CC	and	O	O	NONE
CYP4A11	NN	cyp4a11	B-e8	O	drug
)	)	)	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
exception	NN	exception	O	O	NONE
of	IN	of	O	O	NONE
CYP2C19	NN	cyp2c19	B-e9	O	drug
and	CC	and	O	O	NONE
CYP3A4	NN	cyp3a4	B-e10	T	drug
/5	NN	/5	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s3
Results	NNS	result	O	O	NONE
demonstrate	VBP	demonstrate	O	O	NONE
that	IN	that	O	O	NONE
oxcarbazepine	NN	oxcarbazepine	B-e0	O	drug
and	CC	and	O	O	NONE
its	PRP$	its	O	O	NONE
pharmacologically	RB	pharmacologically	O	O	NONE
active	JJ	active	B-e1	O	drug
10-monohydroxy	NN	10-monohydroxy	I-e1	O	drug
metabolite	NN	metabolite	I-e1	O	drug
(	(	(	O	O	NONE
MHD	NN	mhd	O	O	NONE
)	)	)	O	O	NONE
have	VBP	have	O	O	NONE
little	JJ	little	O	O	NONE
or	CC	or	O	O	NONE
no	DT	no	O	O	NONE
capacity	NN	capacity	O	O	NONE
to	TO	to	O	O	NONE
function	VB	function	O	O	NONE
as	IN	as	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
for	IN	for	O	O	NONE
most	JJS	most	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
human	JJ	human	O	O	NONE
cytochrome	NN	cytochrome	B-e2	T	drug
P450	NN	p450	I-e2	T	drug
enzymes	NNS	enzyme	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
(	(	(	O	O	NONE
CYP1A2	NN	cyp1a2	B-e3	T	drug
,	,	,	O	O	NONE
CYP2A6	NN	cyp2a6	B-e4	O	drug
,	,	,	O	O	NONE
CYP2C9	NN	cyp2c9	B-e5	O	drug
,	,	,	O	O	NONE
CYP2D6	NN	cyp2d6	B-e6	O	drug
,	,	,	O	O	NONE
CYP2E1	NN	cyp2e1	B-e7	O	drug
,	,	,	O	O	NONE
CYP4A9	NN	cyp4a9	O	O	NONE
and	CC	and	O	O	NONE
CYP4A11	NN	cyp4a11	B-e8	O	drug
)	)	)	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
exception	NN	exception	O	O	NONE
of	IN	of	O	O	NONE
CYP2C19	NN	cyp2c19	B-e9	O	drug
and	CC	and	O	O	NONE
CYP3A4	NN	cyp3a4	B-e10	O	drug
/5	NN	/5	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s3
Results	NNS	result	O	O	NONE
demonstrate	VBP	demonstrate	O	O	NONE
that	IN	that	O	O	NONE
oxcarbazepine	NN	oxcarbazepine	B-e0	O	drug
and	CC	and	O	O	NONE
its	PRP$	its	O	O	NONE
pharmacologically	RB	pharmacologically	O	O	NONE
active	JJ	active	B-e1	O	drug
10-monohydroxy	NN	10-monohydroxy	I-e1	O	drug
metabolite	NN	metabolite	I-e1	O	drug
(	(	(	O	O	NONE
MHD	NN	mhd	O	O	NONE
)	)	)	O	O	NONE
have	VBP	have	O	O	NONE
little	JJ	little	O	O	NONE
or	CC	or	O	O	NONE
no	DT	no	O	O	NONE
capacity	NN	capacity	O	O	NONE
to	TO	to	O	O	NONE
function	VB	function	O	O	NONE
as	IN	as	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
for	IN	for	O	O	NONE
most	JJS	most	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
human	JJ	human	O	O	NONE
cytochrome	NN	cytochrome	B-e2	T	drug
P450	NN	p450	I-e2	T	drug
enzymes	NNS	enzyme	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
(	(	(	O	O	NONE
CYP1A2	NN	cyp1a2	B-e3	O	drug
,	,	,	O	O	NONE
CYP2A6	NN	cyp2a6	B-e4	T	drug
,	,	,	O	O	NONE
CYP2C9	NN	cyp2c9	B-e5	O	drug
,	,	,	O	O	NONE
CYP2D6	NN	cyp2d6	B-e6	O	drug
,	,	,	O	O	NONE
CYP2E1	NN	cyp2e1	B-e7	O	drug
,	,	,	O	O	NONE
CYP4A9	NN	cyp4a9	O	O	NONE
and	CC	and	O	O	NONE
CYP4A11	NN	cyp4a11	B-e8	O	drug
)	)	)	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
exception	NN	exception	O	O	NONE
of	IN	of	O	O	NONE
CYP2C19	NN	cyp2c19	B-e9	O	drug
and	CC	and	O	O	NONE
CYP3A4	NN	cyp3a4	B-e10	O	drug
/5	NN	/5	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s3
Results	NNS	result	O	O	NONE
demonstrate	VBP	demonstrate	O	O	NONE
that	IN	that	O	O	NONE
oxcarbazepine	NN	oxcarbazepine	B-e0	O	drug
and	CC	and	O	O	NONE
its	PRP$	its	O	O	NONE
pharmacologically	RB	pharmacologically	O	O	NONE
active	JJ	active	B-e1	O	drug
10-monohydroxy	NN	10-monohydroxy	I-e1	O	drug
metabolite	NN	metabolite	I-e1	O	drug
(	(	(	O	O	NONE
MHD	NN	mhd	O	O	NONE
)	)	)	O	O	NONE
have	VBP	have	O	O	NONE
little	JJ	little	O	O	NONE
or	CC	or	O	O	NONE
no	DT	no	O	O	NONE
capacity	NN	capacity	O	O	NONE
to	TO	to	O	O	NONE
function	VB	function	O	O	NONE
as	IN	as	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
for	IN	for	O	O	NONE
most	JJS	most	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
human	JJ	human	O	O	NONE
cytochrome	NN	cytochrome	B-e2	T	drug
P450	NN	p450	I-e2	T	drug
enzymes	NNS	enzyme	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
(	(	(	O	O	NONE
CYP1A2	NN	cyp1a2	B-e3	O	drug
,	,	,	O	O	NONE
CYP2A6	NN	cyp2a6	B-e4	O	drug
,	,	,	O	O	NONE
CYP2C9	NN	cyp2c9	B-e5	T	drug
,	,	,	O	O	NONE
CYP2D6	NN	cyp2d6	B-e6	O	drug
,	,	,	O	O	NONE
CYP2E1	NN	cyp2e1	B-e7	O	drug
,	,	,	O	O	NONE
CYP4A9	NN	cyp4a9	O	O	NONE
and	CC	and	O	O	NONE
CYP4A11	NN	cyp4a11	B-e8	O	drug
)	)	)	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
exception	NN	exception	O	O	NONE
of	IN	of	O	O	NONE
CYP2C19	NN	cyp2c19	B-e9	O	drug
and	CC	and	O	O	NONE
CYP3A4	NN	cyp3a4	B-e10	O	drug
/5	NN	/5	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s3
Results	NNS	result	O	O	NONE
demonstrate	VBP	demonstrate	O	O	NONE
that	IN	that	O	O	NONE
oxcarbazepine	NN	oxcarbazepine	B-e0	O	drug
and	CC	and	O	O	NONE
its	PRP$	its	O	O	NONE
pharmacologically	RB	pharmacologically	O	O	NONE
active	JJ	active	B-e1	O	drug
10-monohydroxy	NN	10-monohydroxy	I-e1	O	drug
metabolite	NN	metabolite	I-e1	O	drug
(	(	(	O	O	NONE
MHD	NN	mhd	O	O	NONE
)	)	)	O	O	NONE
have	VBP	have	O	O	NONE
little	JJ	little	O	O	NONE
or	CC	or	O	O	NONE
no	DT	no	O	O	NONE
capacity	NN	capacity	O	O	NONE
to	TO	to	O	O	NONE
function	VB	function	O	O	NONE
as	IN	as	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
for	IN	for	O	O	NONE
most	JJS	most	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
human	JJ	human	O	O	NONE
cytochrome	NN	cytochrome	B-e2	T	drug
P450	NN	p450	I-e2	T	drug
enzymes	NNS	enzyme	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
(	(	(	O	O	NONE
CYP1A2	NN	cyp1a2	B-e3	O	drug
,	,	,	O	O	NONE
CYP2A6	NN	cyp2a6	B-e4	O	drug
,	,	,	O	O	NONE
CYP2C9	NN	cyp2c9	B-e5	O	drug
,	,	,	O	O	NONE
CYP2D6	NN	cyp2d6	B-e6	T	drug
,	,	,	O	O	NONE
CYP2E1	NN	cyp2e1	B-e7	O	drug
,	,	,	O	O	NONE
CYP4A9	NN	cyp4a9	O	O	NONE
and	CC	and	O	O	NONE
CYP4A11	NN	cyp4a11	B-e8	O	drug
)	)	)	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
exception	NN	exception	O	O	NONE
of	IN	of	O	O	NONE
CYP2C19	NN	cyp2c19	B-e9	O	drug
and	CC	and	O	O	NONE
CYP3A4	NN	cyp3a4	B-e10	O	drug
/5	NN	/5	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s3
Results	NNS	result	O	O	NONE
demonstrate	VBP	demonstrate	O	O	NONE
that	IN	that	O	O	NONE
oxcarbazepine	NN	oxcarbazepine	B-e0	O	drug
and	CC	and	O	O	NONE
its	PRP$	its	O	O	NONE
pharmacologically	RB	pharmacologically	O	O	NONE
active	JJ	active	B-e1	O	drug
10-monohydroxy	NN	10-monohydroxy	I-e1	O	drug
metabolite	NN	metabolite	I-e1	O	drug
(	(	(	O	O	NONE
MHD	NN	mhd	O	O	NONE
)	)	)	O	O	NONE
have	VBP	have	O	O	NONE
little	JJ	little	O	O	NONE
or	CC	or	O	O	NONE
no	DT	no	O	O	NONE
capacity	NN	capacity	O	O	NONE
to	TO	to	O	O	NONE
function	VB	function	O	O	NONE
as	IN	as	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
for	IN	for	O	O	NONE
most	JJS	most	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
human	JJ	human	O	O	NONE
cytochrome	NN	cytochrome	B-e2	T	drug
P450	NN	p450	I-e2	T	drug
enzymes	NNS	enzyme	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
(	(	(	O	O	NONE
CYP1A2	NN	cyp1a2	B-e3	O	drug
,	,	,	O	O	NONE
CYP2A6	NN	cyp2a6	B-e4	O	drug
,	,	,	O	O	NONE
CYP2C9	NN	cyp2c9	B-e5	O	drug
,	,	,	O	O	NONE
CYP2D6	NN	cyp2d6	B-e6	O	drug
,	,	,	O	O	NONE
CYP2E1	NN	cyp2e1	B-e7	T	drug
,	,	,	O	O	NONE
CYP4A9	NN	cyp4a9	O	O	NONE
and	CC	and	O	O	NONE
CYP4A11	NN	cyp4a11	B-e8	O	drug
)	)	)	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
exception	NN	exception	O	O	NONE
of	IN	of	O	O	NONE
CYP2C19	NN	cyp2c19	B-e9	O	drug
and	CC	and	O	O	NONE
CYP3A4	NN	cyp3a4	B-e10	O	drug
/5	NN	/5	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s3
Results	NNS	result	O	O	NONE
demonstrate	VBP	demonstrate	O	O	NONE
that	IN	that	O	O	NONE
oxcarbazepine	NN	oxcarbazepine	B-e0	O	drug
and	CC	and	O	O	NONE
its	PRP$	its	O	O	NONE
pharmacologically	RB	pharmacologically	O	O	NONE
active	JJ	active	B-e1	O	drug
10-monohydroxy	NN	10-monohydroxy	I-e1	O	drug
metabolite	NN	metabolite	I-e1	O	drug
(	(	(	O	O	NONE
MHD	NN	mhd	O	O	NONE
)	)	)	O	O	NONE
have	VBP	have	O	O	NONE
little	JJ	little	O	O	NONE
or	CC	or	O	O	NONE
no	DT	no	O	O	NONE
capacity	NN	capacity	O	O	NONE
to	TO	to	O	O	NONE
function	VB	function	O	O	NONE
as	IN	as	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
for	IN	for	O	O	NONE
most	JJS	most	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
human	JJ	human	O	O	NONE
cytochrome	NN	cytochrome	B-e2	T	drug
P450	NN	p450	I-e2	T	drug
enzymes	NNS	enzyme	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
(	(	(	O	O	NONE
CYP1A2	NN	cyp1a2	B-e3	O	drug
,	,	,	O	O	NONE
CYP2A6	NN	cyp2a6	B-e4	O	drug
,	,	,	O	O	NONE
CYP2C9	NN	cyp2c9	B-e5	O	drug
,	,	,	O	O	NONE
CYP2D6	NN	cyp2d6	B-e6	O	drug
,	,	,	O	O	NONE
CYP2E1	NN	cyp2e1	B-e7	O	drug
,	,	,	O	O	NONE
CYP4A9	NN	cyp4a9	O	O	NONE
and	CC	and	O	O	NONE
CYP4A11	NN	cyp4a11	B-e8	T	drug
)	)	)	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
exception	NN	exception	O	O	NONE
of	IN	of	O	O	NONE
CYP2C19	NN	cyp2c19	B-e9	O	drug
and	CC	and	O	O	NONE
CYP3A4	NN	cyp3a4	B-e10	O	drug
/5	NN	/5	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s3
Results	NNS	result	O	O	NONE
demonstrate	VBP	demonstrate	O	O	NONE
that	IN	that	O	O	NONE
oxcarbazepine	NN	oxcarbazepine	B-e0	O	drug
and	CC	and	O	O	NONE
its	PRP$	its	O	O	NONE
pharmacologically	RB	pharmacologically	O	O	NONE
active	JJ	active	B-e1	O	drug
10-monohydroxy	NN	10-monohydroxy	I-e1	O	drug
metabolite	NN	metabolite	I-e1	O	drug
(	(	(	O	O	NONE
MHD	NN	mhd	O	O	NONE
)	)	)	O	O	NONE
have	VBP	have	O	O	NONE
little	JJ	little	O	O	NONE
or	CC	or	O	O	NONE
no	DT	no	O	O	NONE
capacity	NN	capacity	O	O	NONE
to	TO	to	O	O	NONE
function	VB	function	O	O	NONE
as	IN	as	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
for	IN	for	O	O	NONE
most	JJS	most	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
human	JJ	human	O	O	NONE
cytochrome	NN	cytochrome	B-e2	T	drug
P450	NN	p450	I-e2	T	drug
enzymes	NNS	enzyme	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
(	(	(	O	O	NONE
CYP1A2	NN	cyp1a2	B-e3	O	drug
,	,	,	O	O	NONE
CYP2A6	NN	cyp2a6	B-e4	O	drug
,	,	,	O	O	NONE
CYP2C9	NN	cyp2c9	B-e5	O	drug
,	,	,	O	O	NONE
CYP2D6	NN	cyp2d6	B-e6	O	drug
,	,	,	O	O	NONE
CYP2E1	NN	cyp2e1	B-e7	O	drug
,	,	,	O	O	NONE
CYP4A9	NN	cyp4a9	O	O	NONE
and	CC	and	O	O	NONE
CYP4A11	NN	cyp4a11	B-e8	O	drug
)	)	)	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
exception	NN	exception	O	O	NONE
of	IN	of	O	O	NONE
CYP2C19	NN	cyp2c19	B-e9	T	drug
and	CC	and	O	O	NONE
CYP3A4	NN	cyp3a4	B-e10	O	drug
/5	NN	/5	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s3
Results	NNS	result	O	O	NONE
demonstrate	VBP	demonstrate	O	O	NONE
that	IN	that	O	O	NONE
oxcarbazepine	NN	oxcarbazepine	B-e0	O	drug
and	CC	and	O	O	NONE
its	PRP$	its	O	O	NONE
pharmacologically	RB	pharmacologically	O	O	NONE
active	JJ	active	B-e1	O	drug
10-monohydroxy	NN	10-monohydroxy	I-e1	O	drug
metabolite	NN	metabolite	I-e1	O	drug
(	(	(	O	O	NONE
MHD	NN	mhd	O	O	NONE
)	)	)	O	O	NONE
have	VBP	have	O	O	NONE
little	JJ	little	O	O	NONE
or	CC	or	O	O	NONE
no	DT	no	O	O	NONE
capacity	NN	capacity	O	O	NONE
to	TO	to	O	O	NONE
function	VB	function	O	O	NONE
as	IN	as	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
for	IN	for	O	O	NONE
most	JJS	most	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
human	JJ	human	O	O	NONE
cytochrome	NN	cytochrome	B-e2	T	drug
P450	NN	p450	I-e2	T	drug
enzymes	NNS	enzyme	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
(	(	(	O	O	NONE
CYP1A2	NN	cyp1a2	B-e3	O	drug
,	,	,	O	O	NONE
CYP2A6	NN	cyp2a6	B-e4	O	drug
,	,	,	O	O	NONE
CYP2C9	NN	cyp2c9	B-e5	O	drug
,	,	,	O	O	NONE
CYP2D6	NN	cyp2d6	B-e6	O	drug
,	,	,	O	O	NONE
CYP2E1	NN	cyp2e1	B-e7	O	drug
,	,	,	O	O	NONE
CYP4A9	NN	cyp4a9	O	O	NONE
and	CC	and	O	O	NONE
CYP4A11	NN	cyp4a11	B-e8	O	drug
)	)	)	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
exception	NN	exception	O	O	NONE
of	IN	of	O	O	NONE
CYP2C19	NN	cyp2c19	B-e9	O	drug
and	CC	and	O	O	NONE
CYP3A4	NN	cyp3a4	B-e10	T	drug
/5	NN	/5	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s3
Results	NNS	result	O	O	NONE
demonstrate	VBP	demonstrate	O	O	NONE
that	IN	that	O	O	NONE
oxcarbazepine	NN	oxcarbazepine	B-e0	O	drug
and	CC	and	O	O	NONE
its	PRP$	its	O	O	NONE
pharmacologically	RB	pharmacologically	O	O	NONE
active	JJ	active	B-e1	O	drug
10-monohydroxy	NN	10-monohydroxy	I-e1	O	drug
metabolite	NN	metabolite	I-e1	O	drug
(	(	(	O	O	NONE
MHD	NN	mhd	O	O	NONE
)	)	)	O	O	NONE
have	VBP	have	O	O	NONE
little	JJ	little	O	O	NONE
or	CC	or	O	O	NONE
no	DT	no	O	O	NONE
capacity	NN	capacity	O	O	NONE
to	TO	to	O	O	NONE
function	VB	function	O	O	NONE
as	IN	as	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
for	IN	for	O	O	NONE
most	JJS	most	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
human	JJ	human	O	O	NONE
cytochrome	NN	cytochrome	B-e2	O	drug
P450	NN	p450	I-e2	O	drug
enzymes	NNS	enzyme	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
(	(	(	O	O	NONE
CYP1A2	NN	cyp1a2	B-e3	T	drug
,	,	,	O	O	NONE
CYP2A6	NN	cyp2a6	B-e4	T	drug
,	,	,	O	O	NONE
CYP2C9	NN	cyp2c9	B-e5	O	drug
,	,	,	O	O	NONE
CYP2D6	NN	cyp2d6	B-e6	O	drug
,	,	,	O	O	NONE
CYP2E1	NN	cyp2e1	B-e7	O	drug
,	,	,	O	O	NONE
CYP4A9	NN	cyp4a9	O	O	NONE
and	CC	and	O	O	NONE
CYP4A11	NN	cyp4a11	B-e8	O	drug
)	)	)	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
exception	NN	exception	O	O	NONE
of	IN	of	O	O	NONE
CYP2C19	NN	cyp2c19	B-e9	O	drug
and	CC	and	O	O	NONE
CYP3A4	NN	cyp3a4	B-e10	O	drug
/5	NN	/5	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s3
Results	NNS	result	O	O	NONE
demonstrate	VBP	demonstrate	O	O	NONE
that	IN	that	O	O	NONE
oxcarbazepine	NN	oxcarbazepine	B-e0	O	drug
and	CC	and	O	O	NONE
its	PRP$	its	O	O	NONE
pharmacologically	RB	pharmacologically	O	O	NONE
active	JJ	active	B-e1	O	drug
10-monohydroxy	NN	10-monohydroxy	I-e1	O	drug
metabolite	NN	metabolite	I-e1	O	drug
(	(	(	O	O	NONE
MHD	NN	mhd	O	O	NONE
)	)	)	O	O	NONE
have	VBP	have	O	O	NONE
little	JJ	little	O	O	NONE
or	CC	or	O	O	NONE
no	DT	no	O	O	NONE
capacity	NN	capacity	O	O	NONE
to	TO	to	O	O	NONE
function	VB	function	O	O	NONE
as	IN	as	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
for	IN	for	O	O	NONE
most	JJS	most	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
human	JJ	human	O	O	NONE
cytochrome	NN	cytochrome	B-e2	O	drug
P450	NN	p450	I-e2	O	drug
enzymes	NNS	enzyme	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
(	(	(	O	O	NONE
CYP1A2	NN	cyp1a2	B-e3	T	drug
,	,	,	O	O	NONE
CYP2A6	NN	cyp2a6	B-e4	O	drug
,	,	,	O	O	NONE
CYP2C9	NN	cyp2c9	B-e5	T	drug
,	,	,	O	O	NONE
CYP2D6	NN	cyp2d6	B-e6	O	drug
,	,	,	O	O	NONE
CYP2E1	NN	cyp2e1	B-e7	O	drug
,	,	,	O	O	NONE
CYP4A9	NN	cyp4a9	O	O	NONE
and	CC	and	O	O	NONE
CYP4A11	NN	cyp4a11	B-e8	O	drug
)	)	)	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
exception	NN	exception	O	O	NONE
of	IN	of	O	O	NONE
CYP2C19	NN	cyp2c19	B-e9	O	drug
and	CC	and	O	O	NONE
CYP3A4	NN	cyp3a4	B-e10	O	drug
/5	NN	/5	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s3
Results	NNS	result	O	O	NONE
demonstrate	VBP	demonstrate	O	O	NONE
that	IN	that	O	O	NONE
oxcarbazepine	NN	oxcarbazepine	B-e0	O	drug
and	CC	and	O	O	NONE
its	PRP$	its	O	O	NONE
pharmacologically	RB	pharmacologically	O	O	NONE
active	JJ	active	B-e1	O	drug
10-monohydroxy	NN	10-monohydroxy	I-e1	O	drug
metabolite	NN	metabolite	I-e1	O	drug
(	(	(	O	O	NONE
MHD	NN	mhd	O	O	NONE
)	)	)	O	O	NONE
have	VBP	have	O	O	NONE
little	JJ	little	O	O	NONE
or	CC	or	O	O	NONE
no	DT	no	O	O	NONE
capacity	NN	capacity	O	O	NONE
to	TO	to	O	O	NONE
function	VB	function	O	O	NONE
as	IN	as	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
for	IN	for	O	O	NONE
most	JJS	most	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
human	JJ	human	O	O	NONE
cytochrome	NN	cytochrome	B-e2	O	drug
P450	NN	p450	I-e2	O	drug
enzymes	NNS	enzyme	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
(	(	(	O	O	NONE
CYP1A2	NN	cyp1a2	B-e3	T	drug
,	,	,	O	O	NONE
CYP2A6	NN	cyp2a6	B-e4	O	drug
,	,	,	O	O	NONE
CYP2C9	NN	cyp2c9	B-e5	O	drug
,	,	,	O	O	NONE
CYP2D6	NN	cyp2d6	B-e6	T	drug
,	,	,	O	O	NONE
CYP2E1	NN	cyp2e1	B-e7	O	drug
,	,	,	O	O	NONE
CYP4A9	NN	cyp4a9	O	O	NONE
and	CC	and	O	O	NONE
CYP4A11	NN	cyp4a11	B-e8	O	drug
)	)	)	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
exception	NN	exception	O	O	NONE
of	IN	of	O	O	NONE
CYP2C19	NN	cyp2c19	B-e9	O	drug
and	CC	and	O	O	NONE
CYP3A4	NN	cyp3a4	B-e10	O	drug
/5	NN	/5	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s3
Results	NNS	result	O	O	NONE
demonstrate	VBP	demonstrate	O	O	NONE
that	IN	that	O	O	NONE
oxcarbazepine	NN	oxcarbazepine	B-e0	O	drug
and	CC	and	O	O	NONE
its	PRP$	its	O	O	NONE
pharmacologically	RB	pharmacologically	O	O	NONE
active	JJ	active	B-e1	O	drug
10-monohydroxy	NN	10-monohydroxy	I-e1	O	drug
metabolite	NN	metabolite	I-e1	O	drug
(	(	(	O	O	NONE
MHD	NN	mhd	O	O	NONE
)	)	)	O	O	NONE
have	VBP	have	O	O	NONE
little	JJ	little	O	O	NONE
or	CC	or	O	O	NONE
no	DT	no	O	O	NONE
capacity	NN	capacity	O	O	NONE
to	TO	to	O	O	NONE
function	VB	function	O	O	NONE
as	IN	as	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
for	IN	for	O	O	NONE
most	JJS	most	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
human	JJ	human	O	O	NONE
cytochrome	NN	cytochrome	B-e2	O	drug
P450	NN	p450	I-e2	O	drug
enzymes	NNS	enzyme	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
(	(	(	O	O	NONE
CYP1A2	NN	cyp1a2	B-e3	T	drug
,	,	,	O	O	NONE
CYP2A6	NN	cyp2a6	B-e4	O	drug
,	,	,	O	O	NONE
CYP2C9	NN	cyp2c9	B-e5	O	drug
,	,	,	O	O	NONE
CYP2D6	NN	cyp2d6	B-e6	O	drug
,	,	,	O	O	NONE
CYP2E1	NN	cyp2e1	B-e7	T	drug
,	,	,	O	O	NONE
CYP4A9	NN	cyp4a9	O	O	NONE
and	CC	and	O	O	NONE
CYP4A11	NN	cyp4a11	B-e8	O	drug
)	)	)	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
exception	NN	exception	O	O	NONE
of	IN	of	O	O	NONE
CYP2C19	NN	cyp2c19	B-e9	O	drug
and	CC	and	O	O	NONE
CYP3A4	NN	cyp3a4	B-e10	O	drug
/5	NN	/5	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s3
Results	NNS	result	O	O	NONE
demonstrate	VBP	demonstrate	O	O	NONE
that	IN	that	O	O	NONE
oxcarbazepine	NN	oxcarbazepine	B-e0	O	drug
and	CC	and	O	O	NONE
its	PRP$	its	O	O	NONE
pharmacologically	RB	pharmacologically	O	O	NONE
active	JJ	active	B-e1	O	drug
10-monohydroxy	NN	10-monohydroxy	I-e1	O	drug
metabolite	NN	metabolite	I-e1	O	drug
(	(	(	O	O	NONE
MHD	NN	mhd	O	O	NONE
)	)	)	O	O	NONE
have	VBP	have	O	O	NONE
little	JJ	little	O	O	NONE
or	CC	or	O	O	NONE
no	DT	no	O	O	NONE
capacity	NN	capacity	O	O	NONE
to	TO	to	O	O	NONE
function	VB	function	O	O	NONE
as	IN	as	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
for	IN	for	O	O	NONE
most	JJS	most	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
human	JJ	human	O	O	NONE
cytochrome	NN	cytochrome	B-e2	O	drug
P450	NN	p450	I-e2	O	drug
enzymes	NNS	enzyme	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
(	(	(	O	O	NONE
CYP1A2	NN	cyp1a2	B-e3	T	drug
,	,	,	O	O	NONE
CYP2A6	NN	cyp2a6	B-e4	O	drug
,	,	,	O	O	NONE
CYP2C9	NN	cyp2c9	B-e5	O	drug
,	,	,	O	O	NONE
CYP2D6	NN	cyp2d6	B-e6	O	drug
,	,	,	O	O	NONE
CYP2E1	NN	cyp2e1	B-e7	O	drug
,	,	,	O	O	NONE
CYP4A9	NN	cyp4a9	O	O	NONE
and	CC	and	O	O	NONE
CYP4A11	NN	cyp4a11	B-e8	T	drug
)	)	)	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
exception	NN	exception	O	O	NONE
of	IN	of	O	O	NONE
CYP2C19	NN	cyp2c19	B-e9	O	drug
and	CC	and	O	O	NONE
CYP3A4	NN	cyp3a4	B-e10	O	drug
/5	NN	/5	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s3
Results	NNS	result	O	O	NONE
demonstrate	VBP	demonstrate	O	O	NONE
that	IN	that	O	O	NONE
oxcarbazepine	NN	oxcarbazepine	B-e0	O	drug
and	CC	and	O	O	NONE
its	PRP$	its	O	O	NONE
pharmacologically	RB	pharmacologically	O	O	NONE
active	JJ	active	B-e1	O	drug
10-monohydroxy	NN	10-monohydroxy	I-e1	O	drug
metabolite	NN	metabolite	I-e1	O	drug
(	(	(	O	O	NONE
MHD	NN	mhd	O	O	NONE
)	)	)	O	O	NONE
have	VBP	have	O	O	NONE
little	JJ	little	O	O	NONE
or	CC	or	O	O	NONE
no	DT	no	O	O	NONE
capacity	NN	capacity	O	O	NONE
to	TO	to	O	O	NONE
function	VB	function	O	O	NONE
as	IN	as	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
for	IN	for	O	O	NONE
most	JJS	most	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
human	JJ	human	O	O	NONE
cytochrome	NN	cytochrome	B-e2	O	drug
P450	NN	p450	I-e2	O	drug
enzymes	NNS	enzyme	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
(	(	(	O	O	NONE
CYP1A2	NN	cyp1a2	B-e3	T	drug
,	,	,	O	O	NONE
CYP2A6	NN	cyp2a6	B-e4	O	drug
,	,	,	O	O	NONE
CYP2C9	NN	cyp2c9	B-e5	O	drug
,	,	,	O	O	NONE
CYP2D6	NN	cyp2d6	B-e6	O	drug
,	,	,	O	O	NONE
CYP2E1	NN	cyp2e1	B-e7	O	drug
,	,	,	O	O	NONE
CYP4A9	NN	cyp4a9	O	O	NONE
and	CC	and	O	O	NONE
CYP4A11	NN	cyp4a11	B-e8	O	drug
)	)	)	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
exception	NN	exception	O	O	NONE
of	IN	of	O	O	NONE
CYP2C19	NN	cyp2c19	B-e9	T	drug
and	CC	and	O	O	NONE
CYP3A4	NN	cyp3a4	B-e10	O	drug
/5	NN	/5	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s3
Results	NNS	result	O	O	NONE
demonstrate	VBP	demonstrate	O	O	NONE
that	IN	that	O	O	NONE
oxcarbazepine	NN	oxcarbazepine	B-e0	O	drug
and	CC	and	O	O	NONE
its	PRP$	its	O	O	NONE
pharmacologically	RB	pharmacologically	O	O	NONE
active	JJ	active	B-e1	O	drug
10-monohydroxy	NN	10-monohydroxy	I-e1	O	drug
metabolite	NN	metabolite	I-e1	O	drug
(	(	(	O	O	NONE
MHD	NN	mhd	O	O	NONE
)	)	)	O	O	NONE
have	VBP	have	O	O	NONE
little	JJ	little	O	O	NONE
or	CC	or	O	O	NONE
no	DT	no	O	O	NONE
capacity	NN	capacity	O	O	NONE
to	TO	to	O	O	NONE
function	VB	function	O	O	NONE
as	IN	as	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
for	IN	for	O	O	NONE
most	JJS	most	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
human	JJ	human	O	O	NONE
cytochrome	NN	cytochrome	B-e2	O	drug
P450	NN	p450	I-e2	O	drug
enzymes	NNS	enzyme	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
(	(	(	O	O	NONE
CYP1A2	NN	cyp1a2	B-e3	T	drug
,	,	,	O	O	NONE
CYP2A6	NN	cyp2a6	B-e4	O	drug
,	,	,	O	O	NONE
CYP2C9	NN	cyp2c9	B-e5	O	drug
,	,	,	O	O	NONE
CYP2D6	NN	cyp2d6	B-e6	O	drug
,	,	,	O	O	NONE
CYP2E1	NN	cyp2e1	B-e7	O	drug
,	,	,	O	O	NONE
CYP4A9	NN	cyp4a9	O	O	NONE
and	CC	and	O	O	NONE
CYP4A11	NN	cyp4a11	B-e8	O	drug
)	)	)	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
exception	NN	exception	O	O	NONE
of	IN	of	O	O	NONE
CYP2C19	NN	cyp2c19	B-e9	O	drug
and	CC	and	O	O	NONE
CYP3A4	NN	cyp3a4	B-e10	T	drug
/5	NN	/5	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s3
Results	NNS	result	O	O	NONE
demonstrate	VBP	demonstrate	O	O	NONE
that	IN	that	O	O	NONE
oxcarbazepine	NN	oxcarbazepine	B-e0	O	drug
and	CC	and	O	O	NONE
its	PRP$	its	O	O	NONE
pharmacologically	RB	pharmacologically	O	O	NONE
active	JJ	active	B-e1	O	drug
10-monohydroxy	NN	10-monohydroxy	I-e1	O	drug
metabolite	NN	metabolite	I-e1	O	drug
(	(	(	O	O	NONE
MHD	NN	mhd	O	O	NONE
)	)	)	O	O	NONE
have	VBP	have	O	O	NONE
little	JJ	little	O	O	NONE
or	CC	or	O	O	NONE
no	DT	no	O	O	NONE
capacity	NN	capacity	O	O	NONE
to	TO	to	O	O	NONE
function	VB	function	O	O	NONE
as	IN	as	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
for	IN	for	O	O	NONE
most	JJS	most	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
human	JJ	human	O	O	NONE
cytochrome	NN	cytochrome	B-e2	O	drug
P450	NN	p450	I-e2	O	drug
enzymes	NNS	enzyme	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
(	(	(	O	O	NONE
CYP1A2	NN	cyp1a2	B-e3	O	drug
,	,	,	O	O	NONE
CYP2A6	NN	cyp2a6	B-e4	T	drug
,	,	,	O	O	NONE
CYP2C9	NN	cyp2c9	B-e5	T	drug
,	,	,	O	O	NONE
CYP2D6	NN	cyp2d6	B-e6	O	drug
,	,	,	O	O	NONE
CYP2E1	NN	cyp2e1	B-e7	O	drug
,	,	,	O	O	NONE
CYP4A9	NN	cyp4a9	O	O	NONE
and	CC	and	O	O	NONE
CYP4A11	NN	cyp4a11	B-e8	O	drug
)	)	)	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
exception	NN	exception	O	O	NONE
of	IN	of	O	O	NONE
CYP2C19	NN	cyp2c19	B-e9	O	drug
and	CC	and	O	O	NONE
CYP3A4	NN	cyp3a4	B-e10	O	drug
/5	NN	/5	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s3
Results	NNS	result	O	O	NONE
demonstrate	VBP	demonstrate	O	O	NONE
that	IN	that	O	O	NONE
oxcarbazepine	NN	oxcarbazepine	B-e0	O	drug
and	CC	and	O	O	NONE
its	PRP$	its	O	O	NONE
pharmacologically	RB	pharmacologically	O	O	NONE
active	JJ	active	B-e1	O	drug
10-monohydroxy	NN	10-monohydroxy	I-e1	O	drug
metabolite	NN	metabolite	I-e1	O	drug
(	(	(	O	O	NONE
MHD	NN	mhd	O	O	NONE
)	)	)	O	O	NONE
have	VBP	have	O	O	NONE
little	JJ	little	O	O	NONE
or	CC	or	O	O	NONE
no	DT	no	O	O	NONE
capacity	NN	capacity	O	O	NONE
to	TO	to	O	O	NONE
function	VB	function	O	O	NONE
as	IN	as	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
for	IN	for	O	O	NONE
most	JJS	most	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
human	JJ	human	O	O	NONE
cytochrome	NN	cytochrome	B-e2	O	drug
P450	NN	p450	I-e2	O	drug
enzymes	NNS	enzyme	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
(	(	(	O	O	NONE
CYP1A2	NN	cyp1a2	B-e3	O	drug
,	,	,	O	O	NONE
CYP2A6	NN	cyp2a6	B-e4	T	drug
,	,	,	O	O	NONE
CYP2C9	NN	cyp2c9	B-e5	O	drug
,	,	,	O	O	NONE
CYP2D6	NN	cyp2d6	B-e6	T	drug
,	,	,	O	O	NONE
CYP2E1	NN	cyp2e1	B-e7	O	drug
,	,	,	O	O	NONE
CYP4A9	NN	cyp4a9	O	O	NONE
and	CC	and	O	O	NONE
CYP4A11	NN	cyp4a11	B-e8	O	drug
)	)	)	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
exception	NN	exception	O	O	NONE
of	IN	of	O	O	NONE
CYP2C19	NN	cyp2c19	B-e9	O	drug
and	CC	and	O	O	NONE
CYP3A4	NN	cyp3a4	B-e10	O	drug
/5	NN	/5	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s3
Results	NNS	result	O	O	NONE
demonstrate	VBP	demonstrate	O	O	NONE
that	IN	that	O	O	NONE
oxcarbazepine	NN	oxcarbazepine	B-e0	O	drug
and	CC	and	O	O	NONE
its	PRP$	its	O	O	NONE
pharmacologically	RB	pharmacologically	O	O	NONE
active	JJ	active	B-e1	O	drug
10-monohydroxy	NN	10-monohydroxy	I-e1	O	drug
metabolite	NN	metabolite	I-e1	O	drug
(	(	(	O	O	NONE
MHD	NN	mhd	O	O	NONE
)	)	)	O	O	NONE
have	VBP	have	O	O	NONE
little	JJ	little	O	O	NONE
or	CC	or	O	O	NONE
no	DT	no	O	O	NONE
capacity	NN	capacity	O	O	NONE
to	TO	to	O	O	NONE
function	VB	function	O	O	NONE
as	IN	as	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
for	IN	for	O	O	NONE
most	JJS	most	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
human	JJ	human	O	O	NONE
cytochrome	NN	cytochrome	B-e2	O	drug
P450	NN	p450	I-e2	O	drug
enzymes	NNS	enzyme	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
(	(	(	O	O	NONE
CYP1A2	NN	cyp1a2	B-e3	O	drug
,	,	,	O	O	NONE
CYP2A6	NN	cyp2a6	B-e4	T	drug
,	,	,	O	O	NONE
CYP2C9	NN	cyp2c9	B-e5	O	drug
,	,	,	O	O	NONE
CYP2D6	NN	cyp2d6	B-e6	O	drug
,	,	,	O	O	NONE
CYP2E1	NN	cyp2e1	B-e7	T	drug
,	,	,	O	O	NONE
CYP4A9	NN	cyp4a9	O	O	NONE
and	CC	and	O	O	NONE
CYP4A11	NN	cyp4a11	B-e8	O	drug
)	)	)	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
exception	NN	exception	O	O	NONE
of	IN	of	O	O	NONE
CYP2C19	NN	cyp2c19	B-e9	O	drug
and	CC	and	O	O	NONE
CYP3A4	NN	cyp3a4	B-e10	O	drug
/5	NN	/5	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s3
Results	NNS	result	O	O	NONE
demonstrate	VBP	demonstrate	O	O	NONE
that	IN	that	O	O	NONE
oxcarbazepine	NN	oxcarbazepine	B-e0	O	drug
and	CC	and	O	O	NONE
its	PRP$	its	O	O	NONE
pharmacologically	RB	pharmacologically	O	O	NONE
active	JJ	active	B-e1	O	drug
10-monohydroxy	NN	10-monohydroxy	I-e1	O	drug
metabolite	NN	metabolite	I-e1	O	drug
(	(	(	O	O	NONE
MHD	NN	mhd	O	O	NONE
)	)	)	O	O	NONE
have	VBP	have	O	O	NONE
little	JJ	little	O	O	NONE
or	CC	or	O	O	NONE
no	DT	no	O	O	NONE
capacity	NN	capacity	O	O	NONE
to	TO	to	O	O	NONE
function	VB	function	O	O	NONE
as	IN	as	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
for	IN	for	O	O	NONE
most	JJS	most	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
human	JJ	human	O	O	NONE
cytochrome	NN	cytochrome	B-e2	O	drug
P450	NN	p450	I-e2	O	drug
enzymes	NNS	enzyme	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
(	(	(	O	O	NONE
CYP1A2	NN	cyp1a2	B-e3	O	drug
,	,	,	O	O	NONE
CYP2A6	NN	cyp2a6	B-e4	T	drug
,	,	,	O	O	NONE
CYP2C9	NN	cyp2c9	B-e5	O	drug
,	,	,	O	O	NONE
CYP2D6	NN	cyp2d6	B-e6	O	drug
,	,	,	O	O	NONE
CYP2E1	NN	cyp2e1	B-e7	O	drug
,	,	,	O	O	NONE
CYP4A9	NN	cyp4a9	O	O	NONE
and	CC	and	O	O	NONE
CYP4A11	NN	cyp4a11	B-e8	T	drug
)	)	)	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
exception	NN	exception	O	O	NONE
of	IN	of	O	O	NONE
CYP2C19	NN	cyp2c19	B-e9	O	drug
and	CC	and	O	O	NONE
CYP3A4	NN	cyp3a4	B-e10	O	drug
/5	NN	/5	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s3
Results	NNS	result	O	O	NONE
demonstrate	VBP	demonstrate	O	O	NONE
that	IN	that	O	O	NONE
oxcarbazepine	NN	oxcarbazepine	B-e0	O	drug
and	CC	and	O	O	NONE
its	PRP$	its	O	O	NONE
pharmacologically	RB	pharmacologically	O	O	NONE
active	JJ	active	B-e1	O	drug
10-monohydroxy	NN	10-monohydroxy	I-e1	O	drug
metabolite	NN	metabolite	I-e1	O	drug
(	(	(	O	O	NONE
MHD	NN	mhd	O	O	NONE
)	)	)	O	O	NONE
have	VBP	have	O	O	NONE
little	JJ	little	O	O	NONE
or	CC	or	O	O	NONE
no	DT	no	O	O	NONE
capacity	NN	capacity	O	O	NONE
to	TO	to	O	O	NONE
function	VB	function	O	O	NONE
as	IN	as	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
for	IN	for	O	O	NONE
most	JJS	most	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
human	JJ	human	O	O	NONE
cytochrome	NN	cytochrome	B-e2	O	drug
P450	NN	p450	I-e2	O	drug
enzymes	NNS	enzyme	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
(	(	(	O	O	NONE
CYP1A2	NN	cyp1a2	B-e3	O	drug
,	,	,	O	O	NONE
CYP2A6	NN	cyp2a6	B-e4	T	drug
,	,	,	O	O	NONE
CYP2C9	NN	cyp2c9	B-e5	O	drug
,	,	,	O	O	NONE
CYP2D6	NN	cyp2d6	B-e6	O	drug
,	,	,	O	O	NONE
CYP2E1	NN	cyp2e1	B-e7	O	drug
,	,	,	O	O	NONE
CYP4A9	NN	cyp4a9	O	O	NONE
and	CC	and	O	O	NONE
CYP4A11	NN	cyp4a11	B-e8	O	drug
)	)	)	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
exception	NN	exception	O	O	NONE
of	IN	of	O	O	NONE
CYP2C19	NN	cyp2c19	B-e9	T	drug
and	CC	and	O	O	NONE
CYP3A4	NN	cyp3a4	B-e10	O	drug
/5	NN	/5	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s3
Results	NNS	result	O	O	NONE
demonstrate	VBP	demonstrate	O	O	NONE
that	IN	that	O	O	NONE
oxcarbazepine	NN	oxcarbazepine	B-e0	O	drug
and	CC	and	O	O	NONE
its	PRP$	its	O	O	NONE
pharmacologically	RB	pharmacologically	O	O	NONE
active	JJ	active	B-e1	O	drug
10-monohydroxy	NN	10-monohydroxy	I-e1	O	drug
metabolite	NN	metabolite	I-e1	O	drug
(	(	(	O	O	NONE
MHD	NN	mhd	O	O	NONE
)	)	)	O	O	NONE
have	VBP	have	O	O	NONE
little	JJ	little	O	O	NONE
or	CC	or	O	O	NONE
no	DT	no	O	O	NONE
capacity	NN	capacity	O	O	NONE
to	TO	to	O	O	NONE
function	VB	function	O	O	NONE
as	IN	as	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
for	IN	for	O	O	NONE
most	JJS	most	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
human	JJ	human	O	O	NONE
cytochrome	NN	cytochrome	B-e2	O	drug
P450	NN	p450	I-e2	O	drug
enzymes	NNS	enzyme	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
(	(	(	O	O	NONE
CYP1A2	NN	cyp1a2	B-e3	O	drug
,	,	,	O	O	NONE
CYP2A6	NN	cyp2a6	B-e4	T	drug
,	,	,	O	O	NONE
CYP2C9	NN	cyp2c9	B-e5	O	drug
,	,	,	O	O	NONE
CYP2D6	NN	cyp2d6	B-e6	O	drug
,	,	,	O	O	NONE
CYP2E1	NN	cyp2e1	B-e7	O	drug
,	,	,	O	O	NONE
CYP4A9	NN	cyp4a9	O	O	NONE
and	CC	and	O	O	NONE
CYP4A11	NN	cyp4a11	B-e8	O	drug
)	)	)	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
exception	NN	exception	O	O	NONE
of	IN	of	O	O	NONE
CYP2C19	NN	cyp2c19	B-e9	O	drug
and	CC	and	O	O	NONE
CYP3A4	NN	cyp3a4	B-e10	T	drug
/5	NN	/5	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s3
Results	NNS	result	O	O	NONE
demonstrate	VBP	demonstrate	O	O	NONE
that	IN	that	O	O	NONE
oxcarbazepine	NN	oxcarbazepine	B-e0	O	drug
and	CC	and	O	O	NONE
its	PRP$	its	O	O	NONE
pharmacologically	RB	pharmacologically	O	O	NONE
active	JJ	active	B-e1	O	drug
10-monohydroxy	NN	10-monohydroxy	I-e1	O	drug
metabolite	NN	metabolite	I-e1	O	drug
(	(	(	O	O	NONE
MHD	NN	mhd	O	O	NONE
)	)	)	O	O	NONE
have	VBP	have	O	O	NONE
little	JJ	little	O	O	NONE
or	CC	or	O	O	NONE
no	DT	no	O	O	NONE
capacity	NN	capacity	O	O	NONE
to	TO	to	O	O	NONE
function	VB	function	O	O	NONE
as	IN	as	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
for	IN	for	O	O	NONE
most	JJS	most	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
human	JJ	human	O	O	NONE
cytochrome	NN	cytochrome	B-e2	O	drug
P450	NN	p450	I-e2	O	drug
enzymes	NNS	enzyme	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
(	(	(	O	O	NONE
CYP1A2	NN	cyp1a2	B-e3	O	drug
,	,	,	O	O	NONE
CYP2A6	NN	cyp2a6	B-e4	O	drug
,	,	,	O	O	NONE
CYP2C9	NN	cyp2c9	B-e5	T	drug
,	,	,	O	O	NONE
CYP2D6	NN	cyp2d6	B-e6	T	drug
,	,	,	O	O	NONE
CYP2E1	NN	cyp2e1	B-e7	O	drug
,	,	,	O	O	NONE
CYP4A9	NN	cyp4a9	O	O	NONE
and	CC	and	O	O	NONE
CYP4A11	NN	cyp4a11	B-e8	O	drug
)	)	)	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
exception	NN	exception	O	O	NONE
of	IN	of	O	O	NONE
CYP2C19	NN	cyp2c19	B-e9	O	drug
and	CC	and	O	O	NONE
CYP3A4	NN	cyp3a4	B-e10	O	drug
/5	NN	/5	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s3
Results	NNS	result	O	O	NONE
demonstrate	VBP	demonstrate	O	O	NONE
that	IN	that	O	O	NONE
oxcarbazepine	NN	oxcarbazepine	B-e0	O	drug
and	CC	and	O	O	NONE
its	PRP$	its	O	O	NONE
pharmacologically	RB	pharmacologically	O	O	NONE
active	JJ	active	B-e1	O	drug
10-monohydroxy	NN	10-monohydroxy	I-e1	O	drug
metabolite	NN	metabolite	I-e1	O	drug
(	(	(	O	O	NONE
MHD	NN	mhd	O	O	NONE
)	)	)	O	O	NONE
have	VBP	have	O	O	NONE
little	JJ	little	O	O	NONE
or	CC	or	O	O	NONE
no	DT	no	O	O	NONE
capacity	NN	capacity	O	O	NONE
to	TO	to	O	O	NONE
function	VB	function	O	O	NONE
as	IN	as	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
for	IN	for	O	O	NONE
most	JJS	most	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
human	JJ	human	O	O	NONE
cytochrome	NN	cytochrome	B-e2	O	drug
P450	NN	p450	I-e2	O	drug
enzymes	NNS	enzyme	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
(	(	(	O	O	NONE
CYP1A2	NN	cyp1a2	B-e3	O	drug
,	,	,	O	O	NONE
CYP2A6	NN	cyp2a6	B-e4	O	drug
,	,	,	O	O	NONE
CYP2C9	NN	cyp2c9	B-e5	T	drug
,	,	,	O	O	NONE
CYP2D6	NN	cyp2d6	B-e6	O	drug
,	,	,	O	O	NONE
CYP2E1	NN	cyp2e1	B-e7	T	drug
,	,	,	O	O	NONE
CYP4A9	NN	cyp4a9	O	O	NONE
and	CC	and	O	O	NONE
CYP4A11	NN	cyp4a11	B-e8	O	drug
)	)	)	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
exception	NN	exception	O	O	NONE
of	IN	of	O	O	NONE
CYP2C19	NN	cyp2c19	B-e9	O	drug
and	CC	and	O	O	NONE
CYP3A4	NN	cyp3a4	B-e10	O	drug
/5	NN	/5	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s3
Results	NNS	result	O	O	NONE
demonstrate	VBP	demonstrate	O	O	NONE
that	IN	that	O	O	NONE
oxcarbazepine	NN	oxcarbazepine	B-e0	O	drug
and	CC	and	O	O	NONE
its	PRP$	its	O	O	NONE
pharmacologically	RB	pharmacologically	O	O	NONE
active	JJ	active	B-e1	O	drug
10-monohydroxy	NN	10-monohydroxy	I-e1	O	drug
metabolite	NN	metabolite	I-e1	O	drug
(	(	(	O	O	NONE
MHD	NN	mhd	O	O	NONE
)	)	)	O	O	NONE
have	VBP	have	O	O	NONE
little	JJ	little	O	O	NONE
or	CC	or	O	O	NONE
no	DT	no	O	O	NONE
capacity	NN	capacity	O	O	NONE
to	TO	to	O	O	NONE
function	VB	function	O	O	NONE
as	IN	as	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
for	IN	for	O	O	NONE
most	JJS	most	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
human	JJ	human	O	O	NONE
cytochrome	NN	cytochrome	B-e2	O	drug
P450	NN	p450	I-e2	O	drug
enzymes	NNS	enzyme	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
(	(	(	O	O	NONE
CYP1A2	NN	cyp1a2	B-e3	O	drug
,	,	,	O	O	NONE
CYP2A6	NN	cyp2a6	B-e4	O	drug
,	,	,	O	O	NONE
CYP2C9	NN	cyp2c9	B-e5	T	drug
,	,	,	O	O	NONE
CYP2D6	NN	cyp2d6	B-e6	O	drug
,	,	,	O	O	NONE
CYP2E1	NN	cyp2e1	B-e7	O	drug
,	,	,	O	O	NONE
CYP4A9	NN	cyp4a9	O	O	NONE
and	CC	and	O	O	NONE
CYP4A11	NN	cyp4a11	B-e8	T	drug
)	)	)	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
exception	NN	exception	O	O	NONE
of	IN	of	O	O	NONE
CYP2C19	NN	cyp2c19	B-e9	O	drug
and	CC	and	O	O	NONE
CYP3A4	NN	cyp3a4	B-e10	O	drug
/5	NN	/5	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s3
Results	NNS	result	O	O	NONE
demonstrate	VBP	demonstrate	O	O	NONE
that	IN	that	O	O	NONE
oxcarbazepine	NN	oxcarbazepine	B-e0	O	drug
and	CC	and	O	O	NONE
its	PRP$	its	O	O	NONE
pharmacologically	RB	pharmacologically	O	O	NONE
active	JJ	active	B-e1	O	drug
10-monohydroxy	NN	10-monohydroxy	I-e1	O	drug
metabolite	NN	metabolite	I-e1	O	drug
(	(	(	O	O	NONE
MHD	NN	mhd	O	O	NONE
)	)	)	O	O	NONE
have	VBP	have	O	O	NONE
little	JJ	little	O	O	NONE
or	CC	or	O	O	NONE
no	DT	no	O	O	NONE
capacity	NN	capacity	O	O	NONE
to	TO	to	O	O	NONE
function	VB	function	O	O	NONE
as	IN	as	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
for	IN	for	O	O	NONE
most	JJS	most	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
human	JJ	human	O	O	NONE
cytochrome	NN	cytochrome	B-e2	O	drug
P450	NN	p450	I-e2	O	drug
enzymes	NNS	enzyme	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
(	(	(	O	O	NONE
CYP1A2	NN	cyp1a2	B-e3	O	drug
,	,	,	O	O	NONE
CYP2A6	NN	cyp2a6	B-e4	O	drug
,	,	,	O	O	NONE
CYP2C9	NN	cyp2c9	B-e5	T	drug
,	,	,	O	O	NONE
CYP2D6	NN	cyp2d6	B-e6	O	drug
,	,	,	O	O	NONE
CYP2E1	NN	cyp2e1	B-e7	O	drug
,	,	,	O	O	NONE
CYP4A9	NN	cyp4a9	O	O	NONE
and	CC	and	O	O	NONE
CYP4A11	NN	cyp4a11	B-e8	O	drug
)	)	)	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
exception	NN	exception	O	O	NONE
of	IN	of	O	O	NONE
CYP2C19	NN	cyp2c19	B-e9	T	drug
and	CC	and	O	O	NONE
CYP3A4	NN	cyp3a4	B-e10	O	drug
/5	NN	/5	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s3
Results	NNS	result	O	O	NONE
demonstrate	VBP	demonstrate	O	O	NONE
that	IN	that	O	O	NONE
oxcarbazepine	NN	oxcarbazepine	B-e0	O	drug
and	CC	and	O	O	NONE
its	PRP$	its	O	O	NONE
pharmacologically	RB	pharmacologically	O	O	NONE
active	JJ	active	B-e1	O	drug
10-monohydroxy	NN	10-monohydroxy	I-e1	O	drug
metabolite	NN	metabolite	I-e1	O	drug
(	(	(	O	O	NONE
MHD	NN	mhd	O	O	NONE
)	)	)	O	O	NONE
have	VBP	have	O	O	NONE
little	JJ	little	O	O	NONE
or	CC	or	O	O	NONE
no	DT	no	O	O	NONE
capacity	NN	capacity	O	O	NONE
to	TO	to	O	O	NONE
function	VB	function	O	O	NONE
as	IN	as	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
for	IN	for	O	O	NONE
most	JJS	most	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
human	JJ	human	O	O	NONE
cytochrome	NN	cytochrome	B-e2	O	drug
P450	NN	p450	I-e2	O	drug
enzymes	NNS	enzyme	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
(	(	(	O	O	NONE
CYP1A2	NN	cyp1a2	B-e3	O	drug
,	,	,	O	O	NONE
CYP2A6	NN	cyp2a6	B-e4	O	drug
,	,	,	O	O	NONE
CYP2C9	NN	cyp2c9	B-e5	T	drug
,	,	,	O	O	NONE
CYP2D6	NN	cyp2d6	B-e6	O	drug
,	,	,	O	O	NONE
CYP2E1	NN	cyp2e1	B-e7	O	drug
,	,	,	O	O	NONE
CYP4A9	NN	cyp4a9	O	O	NONE
and	CC	and	O	O	NONE
CYP4A11	NN	cyp4a11	B-e8	O	drug
)	)	)	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
exception	NN	exception	O	O	NONE
of	IN	of	O	O	NONE
CYP2C19	NN	cyp2c19	B-e9	O	drug
and	CC	and	O	O	NONE
CYP3A4	NN	cyp3a4	B-e10	T	drug
/5	NN	/5	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s3
Results	NNS	result	O	O	NONE
demonstrate	VBP	demonstrate	O	O	NONE
that	IN	that	O	O	NONE
oxcarbazepine	NN	oxcarbazepine	B-e0	O	drug
and	CC	and	O	O	NONE
its	PRP$	its	O	O	NONE
pharmacologically	RB	pharmacologically	O	O	NONE
active	JJ	active	B-e1	O	drug
10-monohydroxy	NN	10-monohydroxy	I-e1	O	drug
metabolite	NN	metabolite	I-e1	O	drug
(	(	(	O	O	NONE
MHD	NN	mhd	O	O	NONE
)	)	)	O	O	NONE
have	VBP	have	O	O	NONE
little	JJ	little	O	O	NONE
or	CC	or	O	O	NONE
no	DT	no	O	O	NONE
capacity	NN	capacity	O	O	NONE
to	TO	to	O	O	NONE
function	VB	function	O	O	NONE
as	IN	as	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
for	IN	for	O	O	NONE
most	JJS	most	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
human	JJ	human	O	O	NONE
cytochrome	NN	cytochrome	B-e2	O	drug
P450	NN	p450	I-e2	O	drug
enzymes	NNS	enzyme	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
(	(	(	O	O	NONE
CYP1A2	NN	cyp1a2	B-e3	O	drug
,	,	,	O	O	NONE
CYP2A6	NN	cyp2a6	B-e4	O	drug
,	,	,	O	O	NONE
CYP2C9	NN	cyp2c9	B-e5	O	drug
,	,	,	O	O	NONE
CYP2D6	NN	cyp2d6	B-e6	T	drug
,	,	,	O	O	NONE
CYP2E1	NN	cyp2e1	B-e7	T	drug
,	,	,	O	O	NONE
CYP4A9	NN	cyp4a9	O	O	NONE
and	CC	and	O	O	NONE
CYP4A11	NN	cyp4a11	B-e8	O	drug
)	)	)	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
exception	NN	exception	O	O	NONE
of	IN	of	O	O	NONE
CYP2C19	NN	cyp2c19	B-e9	O	drug
and	CC	and	O	O	NONE
CYP3A4	NN	cyp3a4	B-e10	O	drug
/5	NN	/5	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s3
Results	NNS	result	O	O	NONE
demonstrate	VBP	demonstrate	O	O	NONE
that	IN	that	O	O	NONE
oxcarbazepine	NN	oxcarbazepine	B-e0	O	drug
and	CC	and	O	O	NONE
its	PRP$	its	O	O	NONE
pharmacologically	RB	pharmacologically	O	O	NONE
active	JJ	active	B-e1	O	drug
10-monohydroxy	NN	10-monohydroxy	I-e1	O	drug
metabolite	NN	metabolite	I-e1	O	drug
(	(	(	O	O	NONE
MHD	NN	mhd	O	O	NONE
)	)	)	O	O	NONE
have	VBP	have	O	O	NONE
little	JJ	little	O	O	NONE
or	CC	or	O	O	NONE
no	DT	no	O	O	NONE
capacity	NN	capacity	O	O	NONE
to	TO	to	O	O	NONE
function	VB	function	O	O	NONE
as	IN	as	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
for	IN	for	O	O	NONE
most	JJS	most	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
human	JJ	human	O	O	NONE
cytochrome	NN	cytochrome	B-e2	O	drug
P450	NN	p450	I-e2	O	drug
enzymes	NNS	enzyme	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
(	(	(	O	O	NONE
CYP1A2	NN	cyp1a2	B-e3	O	drug
,	,	,	O	O	NONE
CYP2A6	NN	cyp2a6	B-e4	O	drug
,	,	,	O	O	NONE
CYP2C9	NN	cyp2c9	B-e5	O	drug
,	,	,	O	O	NONE
CYP2D6	NN	cyp2d6	B-e6	T	drug
,	,	,	O	O	NONE
CYP2E1	NN	cyp2e1	B-e7	O	drug
,	,	,	O	O	NONE
CYP4A9	NN	cyp4a9	O	O	NONE
and	CC	and	O	O	NONE
CYP4A11	NN	cyp4a11	B-e8	T	drug
)	)	)	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
exception	NN	exception	O	O	NONE
of	IN	of	O	O	NONE
CYP2C19	NN	cyp2c19	B-e9	O	drug
and	CC	and	O	O	NONE
CYP3A4	NN	cyp3a4	B-e10	O	drug
/5	NN	/5	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s3
Results	NNS	result	O	O	NONE
demonstrate	VBP	demonstrate	O	O	NONE
that	IN	that	O	O	NONE
oxcarbazepine	NN	oxcarbazepine	B-e0	O	drug
and	CC	and	O	O	NONE
its	PRP$	its	O	O	NONE
pharmacologically	RB	pharmacologically	O	O	NONE
active	JJ	active	B-e1	O	drug
10-monohydroxy	NN	10-monohydroxy	I-e1	O	drug
metabolite	NN	metabolite	I-e1	O	drug
(	(	(	O	O	NONE
MHD	NN	mhd	O	O	NONE
)	)	)	O	O	NONE
have	VBP	have	O	O	NONE
little	JJ	little	O	O	NONE
or	CC	or	O	O	NONE
no	DT	no	O	O	NONE
capacity	NN	capacity	O	O	NONE
to	TO	to	O	O	NONE
function	VB	function	O	O	NONE
as	IN	as	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
for	IN	for	O	O	NONE
most	JJS	most	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
human	JJ	human	O	O	NONE
cytochrome	NN	cytochrome	B-e2	O	drug
P450	NN	p450	I-e2	O	drug
enzymes	NNS	enzyme	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
(	(	(	O	O	NONE
CYP1A2	NN	cyp1a2	B-e3	O	drug
,	,	,	O	O	NONE
CYP2A6	NN	cyp2a6	B-e4	O	drug
,	,	,	O	O	NONE
CYP2C9	NN	cyp2c9	B-e5	O	drug
,	,	,	O	O	NONE
CYP2D6	NN	cyp2d6	B-e6	T	drug
,	,	,	O	O	NONE
CYP2E1	NN	cyp2e1	B-e7	O	drug
,	,	,	O	O	NONE
CYP4A9	NN	cyp4a9	O	O	NONE
and	CC	and	O	O	NONE
CYP4A11	NN	cyp4a11	B-e8	O	drug
)	)	)	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
exception	NN	exception	O	O	NONE
of	IN	of	O	O	NONE
CYP2C19	NN	cyp2c19	B-e9	T	drug
and	CC	and	O	O	NONE
CYP3A4	NN	cyp3a4	B-e10	O	drug
/5	NN	/5	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s3
Results	NNS	result	O	O	NONE
demonstrate	VBP	demonstrate	O	O	NONE
that	IN	that	O	O	NONE
oxcarbazepine	NN	oxcarbazepine	B-e0	O	drug
and	CC	and	O	O	NONE
its	PRP$	its	O	O	NONE
pharmacologically	RB	pharmacologically	O	O	NONE
active	JJ	active	B-e1	O	drug
10-monohydroxy	NN	10-monohydroxy	I-e1	O	drug
metabolite	NN	metabolite	I-e1	O	drug
(	(	(	O	O	NONE
MHD	NN	mhd	O	O	NONE
)	)	)	O	O	NONE
have	VBP	have	O	O	NONE
little	JJ	little	O	O	NONE
or	CC	or	O	O	NONE
no	DT	no	O	O	NONE
capacity	NN	capacity	O	O	NONE
to	TO	to	O	O	NONE
function	VB	function	O	O	NONE
as	IN	as	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
for	IN	for	O	O	NONE
most	JJS	most	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
human	JJ	human	O	O	NONE
cytochrome	NN	cytochrome	B-e2	O	drug
P450	NN	p450	I-e2	O	drug
enzymes	NNS	enzyme	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
(	(	(	O	O	NONE
CYP1A2	NN	cyp1a2	B-e3	O	drug
,	,	,	O	O	NONE
CYP2A6	NN	cyp2a6	B-e4	O	drug
,	,	,	O	O	NONE
CYP2C9	NN	cyp2c9	B-e5	O	drug
,	,	,	O	O	NONE
CYP2D6	NN	cyp2d6	B-e6	T	drug
,	,	,	O	O	NONE
CYP2E1	NN	cyp2e1	B-e7	O	drug
,	,	,	O	O	NONE
CYP4A9	NN	cyp4a9	O	O	NONE
and	CC	and	O	O	NONE
CYP4A11	NN	cyp4a11	B-e8	O	drug
)	)	)	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
exception	NN	exception	O	O	NONE
of	IN	of	O	O	NONE
CYP2C19	NN	cyp2c19	B-e9	O	drug
and	CC	and	O	O	NONE
CYP3A4	NN	cyp3a4	B-e10	T	drug
/5	NN	/5	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s3
Results	NNS	result	O	O	NONE
demonstrate	VBP	demonstrate	O	O	NONE
that	IN	that	O	O	NONE
oxcarbazepine	NN	oxcarbazepine	B-e0	O	drug
and	CC	and	O	O	NONE
its	PRP$	its	O	O	NONE
pharmacologically	RB	pharmacologically	O	O	NONE
active	JJ	active	B-e1	O	drug
10-monohydroxy	NN	10-monohydroxy	I-e1	O	drug
metabolite	NN	metabolite	I-e1	O	drug
(	(	(	O	O	NONE
MHD	NN	mhd	O	O	NONE
)	)	)	O	O	NONE
have	VBP	have	O	O	NONE
little	JJ	little	O	O	NONE
or	CC	or	O	O	NONE
no	DT	no	O	O	NONE
capacity	NN	capacity	O	O	NONE
to	TO	to	O	O	NONE
function	VB	function	O	O	NONE
as	IN	as	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
for	IN	for	O	O	NONE
most	JJS	most	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
human	JJ	human	O	O	NONE
cytochrome	NN	cytochrome	B-e2	O	drug
P450	NN	p450	I-e2	O	drug
enzymes	NNS	enzyme	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
(	(	(	O	O	NONE
CYP1A2	NN	cyp1a2	B-e3	O	drug
,	,	,	O	O	NONE
CYP2A6	NN	cyp2a6	B-e4	O	drug
,	,	,	O	O	NONE
CYP2C9	NN	cyp2c9	B-e5	O	drug
,	,	,	O	O	NONE
CYP2D6	NN	cyp2d6	B-e6	O	drug
,	,	,	O	O	NONE
CYP2E1	NN	cyp2e1	B-e7	T	drug
,	,	,	O	O	NONE
CYP4A9	NN	cyp4a9	O	O	NONE
and	CC	and	O	O	NONE
CYP4A11	NN	cyp4a11	B-e8	T	drug
)	)	)	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
exception	NN	exception	O	O	NONE
of	IN	of	O	O	NONE
CYP2C19	NN	cyp2c19	B-e9	O	drug
and	CC	and	O	O	NONE
CYP3A4	NN	cyp3a4	B-e10	O	drug
/5	NN	/5	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s3
Results	NNS	result	O	O	NONE
demonstrate	VBP	demonstrate	O	O	NONE
that	IN	that	O	O	NONE
oxcarbazepine	NN	oxcarbazepine	B-e0	O	drug
and	CC	and	O	O	NONE
its	PRP$	its	O	O	NONE
pharmacologically	RB	pharmacologically	O	O	NONE
active	JJ	active	B-e1	O	drug
10-monohydroxy	NN	10-monohydroxy	I-e1	O	drug
metabolite	NN	metabolite	I-e1	O	drug
(	(	(	O	O	NONE
MHD	NN	mhd	O	O	NONE
)	)	)	O	O	NONE
have	VBP	have	O	O	NONE
little	JJ	little	O	O	NONE
or	CC	or	O	O	NONE
no	DT	no	O	O	NONE
capacity	NN	capacity	O	O	NONE
to	TO	to	O	O	NONE
function	VB	function	O	O	NONE
as	IN	as	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
for	IN	for	O	O	NONE
most	JJS	most	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
human	JJ	human	O	O	NONE
cytochrome	NN	cytochrome	B-e2	O	drug
P450	NN	p450	I-e2	O	drug
enzymes	NNS	enzyme	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
(	(	(	O	O	NONE
CYP1A2	NN	cyp1a2	B-e3	O	drug
,	,	,	O	O	NONE
CYP2A6	NN	cyp2a6	B-e4	O	drug
,	,	,	O	O	NONE
CYP2C9	NN	cyp2c9	B-e5	O	drug
,	,	,	O	O	NONE
CYP2D6	NN	cyp2d6	B-e6	O	drug
,	,	,	O	O	NONE
CYP2E1	NN	cyp2e1	B-e7	T	drug
,	,	,	O	O	NONE
CYP4A9	NN	cyp4a9	O	O	NONE
and	CC	and	O	O	NONE
CYP4A11	NN	cyp4a11	B-e8	O	drug
)	)	)	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
exception	NN	exception	O	O	NONE
of	IN	of	O	O	NONE
CYP2C19	NN	cyp2c19	B-e9	T	drug
and	CC	and	O	O	NONE
CYP3A4	NN	cyp3a4	B-e10	O	drug
/5	NN	/5	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s3
Results	NNS	result	O	O	NONE
demonstrate	VBP	demonstrate	O	O	NONE
that	IN	that	O	O	NONE
oxcarbazepine	NN	oxcarbazepine	B-e0	O	drug
and	CC	and	O	O	NONE
its	PRP$	its	O	O	NONE
pharmacologically	RB	pharmacologically	O	O	NONE
active	JJ	active	B-e1	O	drug
10-monohydroxy	NN	10-monohydroxy	I-e1	O	drug
metabolite	NN	metabolite	I-e1	O	drug
(	(	(	O	O	NONE
MHD	NN	mhd	O	O	NONE
)	)	)	O	O	NONE
have	VBP	have	O	O	NONE
little	JJ	little	O	O	NONE
or	CC	or	O	O	NONE
no	DT	no	O	O	NONE
capacity	NN	capacity	O	O	NONE
to	TO	to	O	O	NONE
function	VB	function	O	O	NONE
as	IN	as	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
for	IN	for	O	O	NONE
most	JJS	most	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
human	JJ	human	O	O	NONE
cytochrome	NN	cytochrome	B-e2	O	drug
P450	NN	p450	I-e2	O	drug
enzymes	NNS	enzyme	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
(	(	(	O	O	NONE
CYP1A2	NN	cyp1a2	B-e3	O	drug
,	,	,	O	O	NONE
CYP2A6	NN	cyp2a6	B-e4	O	drug
,	,	,	O	O	NONE
CYP2C9	NN	cyp2c9	B-e5	O	drug
,	,	,	O	O	NONE
CYP2D6	NN	cyp2d6	B-e6	O	drug
,	,	,	O	O	NONE
CYP2E1	NN	cyp2e1	B-e7	T	drug
,	,	,	O	O	NONE
CYP4A9	NN	cyp4a9	O	O	NONE
and	CC	and	O	O	NONE
CYP4A11	NN	cyp4a11	B-e8	O	drug
)	)	)	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
exception	NN	exception	O	O	NONE
of	IN	of	O	O	NONE
CYP2C19	NN	cyp2c19	B-e9	O	drug
and	CC	and	O	O	NONE
CYP3A4	NN	cyp3a4	B-e10	T	drug
/5	NN	/5	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s3
Results	NNS	result	O	O	NONE
demonstrate	VBP	demonstrate	O	O	NONE
that	IN	that	O	O	NONE
oxcarbazepine	NN	oxcarbazepine	B-e0	O	drug
and	CC	and	O	O	NONE
its	PRP$	its	O	O	NONE
pharmacologically	RB	pharmacologically	O	O	NONE
active	JJ	active	B-e1	O	drug
10-monohydroxy	NN	10-monohydroxy	I-e1	O	drug
metabolite	NN	metabolite	I-e1	O	drug
(	(	(	O	O	NONE
MHD	NN	mhd	O	O	NONE
)	)	)	O	O	NONE
have	VBP	have	O	O	NONE
little	JJ	little	O	O	NONE
or	CC	or	O	O	NONE
no	DT	no	O	O	NONE
capacity	NN	capacity	O	O	NONE
to	TO	to	O	O	NONE
function	VB	function	O	O	NONE
as	IN	as	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
for	IN	for	O	O	NONE
most	JJS	most	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
human	JJ	human	O	O	NONE
cytochrome	NN	cytochrome	B-e2	O	drug
P450	NN	p450	I-e2	O	drug
enzymes	NNS	enzyme	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
(	(	(	O	O	NONE
CYP1A2	NN	cyp1a2	B-e3	O	drug
,	,	,	O	O	NONE
CYP2A6	NN	cyp2a6	B-e4	O	drug
,	,	,	O	O	NONE
CYP2C9	NN	cyp2c9	B-e5	O	drug
,	,	,	O	O	NONE
CYP2D6	NN	cyp2d6	B-e6	O	drug
,	,	,	O	O	NONE
CYP2E1	NN	cyp2e1	B-e7	O	drug
,	,	,	O	O	NONE
CYP4A9	NN	cyp4a9	O	O	NONE
and	CC	and	O	O	NONE
CYP4A11	NN	cyp4a11	B-e8	T	drug
)	)	)	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
exception	NN	exception	O	O	NONE
of	IN	of	O	O	NONE
CYP2C19	NN	cyp2c19	B-e9	T	drug
and	CC	and	O	O	NONE
CYP3A4	NN	cyp3a4	B-e10	O	drug
/5	NN	/5	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s3
Results	NNS	result	O	O	NONE
demonstrate	VBP	demonstrate	O	O	NONE
that	IN	that	O	O	NONE
oxcarbazepine	NN	oxcarbazepine	B-e0	O	drug
and	CC	and	O	O	NONE
its	PRP$	its	O	O	NONE
pharmacologically	RB	pharmacologically	O	O	NONE
active	JJ	active	B-e1	O	drug
10-monohydroxy	NN	10-monohydroxy	I-e1	O	drug
metabolite	NN	metabolite	I-e1	O	drug
(	(	(	O	O	NONE
MHD	NN	mhd	O	O	NONE
)	)	)	O	O	NONE
have	VBP	have	O	O	NONE
little	JJ	little	O	O	NONE
or	CC	or	O	O	NONE
no	DT	no	O	O	NONE
capacity	NN	capacity	O	O	NONE
to	TO	to	O	O	NONE
function	VB	function	O	O	NONE
as	IN	as	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
for	IN	for	O	O	NONE
most	JJS	most	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
human	JJ	human	O	O	NONE
cytochrome	NN	cytochrome	B-e2	O	drug
P450	NN	p450	I-e2	O	drug
enzymes	NNS	enzyme	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
(	(	(	O	O	NONE
CYP1A2	NN	cyp1a2	B-e3	O	drug
,	,	,	O	O	NONE
CYP2A6	NN	cyp2a6	B-e4	O	drug
,	,	,	O	O	NONE
CYP2C9	NN	cyp2c9	B-e5	O	drug
,	,	,	O	O	NONE
CYP2D6	NN	cyp2d6	B-e6	O	drug
,	,	,	O	O	NONE
CYP2E1	NN	cyp2e1	B-e7	O	drug
,	,	,	O	O	NONE
CYP4A9	NN	cyp4a9	O	O	NONE
and	CC	and	O	O	NONE
CYP4A11	NN	cyp4a11	B-e8	T	drug
)	)	)	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
exception	NN	exception	O	O	NONE
of	IN	of	O	O	NONE
CYP2C19	NN	cyp2c19	B-e9	O	drug
and	CC	and	O	O	NONE
CYP3A4	NN	cyp3a4	B-e10	T	drug
/5	NN	/5	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s3
Results	NNS	result	O	O	NONE
demonstrate	VBP	demonstrate	O	O	NONE
that	IN	that	O	O	NONE
oxcarbazepine	NN	oxcarbazepine	B-e0	O	drug
and	CC	and	O	O	NONE
its	PRP$	its	O	O	NONE
pharmacologically	RB	pharmacologically	O	O	NONE
active	JJ	active	B-e1	O	drug
10-monohydroxy	NN	10-monohydroxy	I-e1	O	drug
metabolite	NN	metabolite	I-e1	O	drug
(	(	(	O	O	NONE
MHD	NN	mhd	O	O	NONE
)	)	)	O	O	NONE
have	VBP	have	O	O	NONE
little	JJ	little	O	O	NONE
or	CC	or	O	O	NONE
no	DT	no	O	O	NONE
capacity	NN	capacity	O	O	NONE
to	TO	to	O	O	NONE
function	VB	function	O	O	NONE
as	IN	as	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
for	IN	for	O	O	NONE
most	JJS	most	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
human	JJ	human	O	O	NONE
cytochrome	NN	cytochrome	B-e2	O	drug
P450	NN	p450	I-e2	O	drug
enzymes	NNS	enzyme	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
(	(	(	O	O	NONE
CYP1A2	NN	cyp1a2	B-e3	O	drug
,	,	,	O	O	NONE
CYP2A6	NN	cyp2a6	B-e4	O	drug
,	,	,	O	O	NONE
CYP2C9	NN	cyp2c9	B-e5	O	drug
,	,	,	O	O	NONE
CYP2D6	NN	cyp2d6	B-e6	O	drug
,	,	,	O	O	NONE
CYP2E1	NN	cyp2e1	B-e7	O	drug
,	,	,	O	O	NONE
CYP4A9	NN	cyp4a9	O	O	NONE
and	CC	and	O	O	NONE
CYP4A11	NN	cyp4a11	B-e8	O	drug
)	)	)	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
exception	NN	exception	O	O	NONE
of	IN	of	O	O	NONE
CYP2C19	NN	cyp2c19	B-e9	T	drug
and	CC	and	O	O	NONE
CYP3A4	NN	cyp3a4	B-e10	T	drug
/5	NN	/5	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s8
As	IN	as	O	O	NONE
MHD	NN	mhd	O	O	NONE
,	,	,	O	O	NONE
the	DT	the	O	O	NONE
predominant	JJ	predominant	O	O	NONE
plasma	NN	plasma	O	O	NONE
substrate	NN	substrate	O	O	NONE
,	,	,	O	O	NONE
is	VBZ	be	O	O	NONE
only	RB	only	O	O	NONE
a	DT	a	O	O	NONE
weak	JJ	weak	O	O	NONE
inducer	NN	inducer	O	O	NONE
of	IN	of	O	O	NONE
UDP-glucuronyl	NN	udp-glucuronyl	B-e0	T	drug
transferase	NN	transferase	I-e0	T	drug
,	,	,	O	O	NONE
it	PRP	it	O	O	NONE
is	VBZ	be	O	O	NONE
unlikely	JJ	unlikely	O	O	NONE
to	TO	to	O	O	NONE
have	VB	have	O	O	NONE
an	DT	a	O	O	NONE
effect	NN	effect	O	O	NONE
on	IN	on	O	O	NONE
drugs	NNS	drug	B-e1	T	drug
that	WDT	that	O	O	NONE
are	VBP	be	O	O	NONE
mainly	RB	mainly	O	O	NONE
eliminated	VBN	eliminate	O	O	NONE
by	IN	by	O	O	NONE
conjugation	NN	conjugation	O	O	NONE
through	IN	through	O	O	NONE
UDP-glucuronyl	JJ	udp-glucuronyl	B-e2	O	drug
transferase	NN	transferase	I-e2	O	drug
(	(	(	O	O	NONE
e.g.	FW	e.g.	O	O	NONE
,	,	,	O	O	NONE
valproic	JJ	valproic	B-e3	O	drug
acid	NN	acid	I-e3	O	drug
,	,	,	O	O	NONE
lamotrigine	NN	lamotrigine	B-e4	O	drug
)	)	)	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s8
As	IN	as	O	O	NONE
MHD	NN	mhd	O	O	NONE
,	,	,	O	O	NONE
the	DT	the	O	O	NONE
predominant	JJ	predominant	O	O	NONE
plasma	NN	plasma	O	O	NONE
substrate	NN	substrate	O	O	NONE
,	,	,	O	O	NONE
is	VBZ	be	O	O	NONE
only	RB	only	O	O	NONE
a	DT	a	O	O	NONE
weak	JJ	weak	O	O	NONE
inducer	NN	inducer	O	O	NONE
of	IN	of	O	O	NONE
UDP-glucuronyl	NN	udp-glucuronyl	B-e0	T	drug
transferase	NN	transferase	I-e0	T	drug
,	,	,	O	O	NONE
it	PRP	it	O	O	NONE
is	VBZ	be	O	O	NONE
unlikely	JJ	unlikely	O	O	NONE
to	TO	to	O	O	NONE
have	VB	have	O	O	NONE
an	DT	a	O	O	NONE
effect	NN	effect	O	O	NONE
on	IN	on	O	O	NONE
drugs	NNS	drug	B-e1	O	drug
that	WDT	that	O	O	NONE
are	VBP	be	O	O	NONE
mainly	RB	mainly	O	O	NONE
eliminated	VBN	eliminate	O	O	NONE
by	IN	by	O	O	NONE
conjugation	NN	conjugation	O	O	NONE
through	IN	through	O	O	NONE
UDP-glucuronyl	JJ	udp-glucuronyl	B-e2	T	drug
transferase	NN	transferase	I-e2	T	drug
(	(	(	O	O	NONE
e.g.	FW	e.g.	O	O	NONE
,	,	,	O	O	NONE
valproic	JJ	valproic	B-e3	O	drug
acid	NN	acid	I-e3	O	drug
,	,	,	O	O	NONE
lamotrigine	NN	lamotrigine	B-e4	O	drug
)	)	)	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s8
As	IN	as	O	O	NONE
MHD	NN	mhd	O	O	NONE
,	,	,	O	O	NONE
the	DT	the	O	O	NONE
predominant	JJ	predominant	O	O	NONE
plasma	NN	plasma	O	O	NONE
substrate	NN	substrate	O	O	NONE
,	,	,	O	O	NONE
is	VBZ	be	O	O	NONE
only	RB	only	O	O	NONE
a	DT	a	O	O	NONE
weak	JJ	weak	O	O	NONE
inducer	NN	inducer	O	O	NONE
of	IN	of	O	O	NONE
UDP-glucuronyl	NN	udp-glucuronyl	B-e0	T	drug
transferase	NN	transferase	I-e0	T	drug
,	,	,	O	O	NONE
it	PRP	it	O	O	NONE
is	VBZ	be	O	O	NONE
unlikely	JJ	unlikely	O	O	NONE
to	TO	to	O	O	NONE
have	VB	have	O	O	NONE
an	DT	a	O	O	NONE
effect	NN	effect	O	O	NONE
on	IN	on	O	O	NONE
drugs	NNS	drug	B-e1	O	drug
that	WDT	that	O	O	NONE
are	VBP	be	O	O	NONE
mainly	RB	mainly	O	O	NONE
eliminated	VBN	eliminate	O	O	NONE
by	IN	by	O	O	NONE
conjugation	NN	conjugation	O	O	NONE
through	IN	through	O	O	NONE
UDP-glucuronyl	JJ	udp-glucuronyl	B-e2	O	drug
transferase	NN	transferase	I-e2	O	drug
(	(	(	O	O	NONE
e.g.	FW	e.g.	O	O	NONE
,	,	,	O	O	NONE
valproic	JJ	valproic	B-e3	T	drug
acid	NN	acid	I-e3	T	drug
,	,	,	O	O	NONE
lamotrigine	NN	lamotrigine	B-e4	O	drug
)	)	)	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s8
As	IN	as	O	O	NONE
MHD	NN	mhd	O	O	NONE
,	,	,	O	O	NONE
the	DT	the	O	O	NONE
predominant	JJ	predominant	O	O	NONE
plasma	NN	plasma	O	O	NONE
substrate	NN	substrate	O	O	NONE
,	,	,	O	O	NONE
is	VBZ	be	O	O	NONE
only	RB	only	O	O	NONE
a	DT	a	O	O	NONE
weak	JJ	weak	O	O	NONE
inducer	NN	inducer	O	O	NONE
of	IN	of	O	O	NONE
UDP-glucuronyl	NN	udp-glucuronyl	B-e0	T	drug
transferase	NN	transferase	I-e0	T	drug
,	,	,	O	O	NONE
it	PRP	it	O	O	NONE
is	VBZ	be	O	O	NONE
unlikely	JJ	unlikely	O	O	NONE
to	TO	to	O	O	NONE
have	VB	have	O	O	NONE
an	DT	a	O	O	NONE
effect	NN	effect	O	O	NONE
on	IN	on	O	O	NONE
drugs	NNS	drug	B-e1	O	drug
that	WDT	that	O	O	NONE
are	VBP	be	O	O	NONE
mainly	RB	mainly	O	O	NONE
eliminated	VBN	eliminate	O	O	NONE
by	IN	by	O	O	NONE
conjugation	NN	conjugation	O	O	NONE
through	IN	through	O	O	NONE
UDP-glucuronyl	JJ	udp-glucuronyl	B-e2	O	drug
transferase	NN	transferase	I-e2	O	drug
(	(	(	O	O	NONE
e.g.	FW	e.g.	O	O	NONE
,	,	,	O	O	NONE
valproic	JJ	valproic	B-e3	O	drug
acid	NN	acid	I-e3	O	drug
,	,	,	O	O	NONE
lamotrigine	NN	lamotrigine	B-e4	T	drug
)	)	)	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s8
As	IN	as	O	O	NONE
MHD	NN	mhd	O	O	NONE
,	,	,	O	O	NONE
the	DT	the	O	O	NONE
predominant	JJ	predominant	O	O	NONE
plasma	NN	plasma	O	O	NONE
substrate	NN	substrate	O	O	NONE
,	,	,	O	O	NONE
is	VBZ	be	O	O	NONE
only	RB	only	O	O	NONE
a	DT	a	O	O	NONE
weak	JJ	weak	O	O	NONE
inducer	NN	inducer	O	O	NONE
of	IN	of	O	O	NONE
UDP-glucuronyl	NN	udp-glucuronyl	B-e0	O	drug
transferase	NN	transferase	I-e0	O	drug
,	,	,	O	O	NONE
it	PRP	it	O	O	NONE
is	VBZ	be	O	O	NONE
unlikely	JJ	unlikely	O	O	NONE
to	TO	to	O	O	NONE
have	VB	have	O	O	NONE
an	DT	a	O	O	NONE
effect	NN	effect	O	O	NONE
on	IN	on	O	O	NONE
drugs	NNS	drug	B-e1	T	drug
that	WDT	that	O	O	NONE
are	VBP	be	O	O	NONE
mainly	RB	mainly	O	O	NONE
eliminated	VBN	eliminate	O	O	NONE
by	IN	by	O	O	NONE
conjugation	NN	conjugation	O	O	NONE
through	IN	through	O	O	NONE
UDP-glucuronyl	JJ	udp-glucuronyl	B-e2	T	drug
transferase	NN	transferase	I-e2	T	drug
(	(	(	O	O	NONE
e.g.	FW	e.g.	O	O	NONE
,	,	,	O	O	NONE
valproic	JJ	valproic	B-e3	O	drug
acid	NN	acid	I-e3	O	drug
,	,	,	O	O	NONE
lamotrigine	NN	lamotrigine	B-e4	O	drug
)	)	)	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s8
As	IN	as	O	O	NONE
MHD	NN	mhd	O	O	NONE
,	,	,	O	O	NONE
the	DT	the	O	O	NONE
predominant	JJ	predominant	O	O	NONE
plasma	NN	plasma	O	O	NONE
substrate	NN	substrate	O	O	NONE
,	,	,	O	O	NONE
is	VBZ	be	O	O	NONE
only	RB	only	O	O	NONE
a	DT	a	O	O	NONE
weak	JJ	weak	O	O	NONE
inducer	NN	inducer	O	O	NONE
of	IN	of	O	O	NONE
UDP-glucuronyl	NN	udp-glucuronyl	B-e0	O	drug
transferase	NN	transferase	I-e0	O	drug
,	,	,	O	O	NONE
it	PRP	it	O	O	NONE
is	VBZ	be	O	O	NONE
unlikely	JJ	unlikely	O	O	NONE
to	TO	to	O	O	NONE
have	VB	have	O	O	NONE
an	DT	a	O	O	NONE
effect	NN	effect	O	O	NONE
on	IN	on	O	O	NONE
drugs	NNS	drug	B-e1	T	drug
that	WDT	that	O	O	NONE
are	VBP	be	O	O	NONE
mainly	RB	mainly	O	O	NONE
eliminated	VBN	eliminate	O	O	NONE
by	IN	by	O	O	NONE
conjugation	NN	conjugation	O	O	NONE
through	IN	through	O	O	NONE
UDP-glucuronyl	JJ	udp-glucuronyl	B-e2	O	drug
transferase	NN	transferase	I-e2	O	drug
(	(	(	O	O	NONE
e.g.	FW	e.g.	O	O	NONE
,	,	,	O	O	NONE
valproic	JJ	valproic	B-e3	T	drug
acid	NN	acid	I-e3	T	drug
,	,	,	O	O	NONE
lamotrigine	NN	lamotrigine	B-e4	O	drug
)	)	)	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s8
As	IN	as	O	O	NONE
MHD	NN	mhd	O	O	NONE
,	,	,	O	O	NONE
the	DT	the	O	O	NONE
predominant	JJ	predominant	O	O	NONE
plasma	NN	plasma	O	O	NONE
substrate	NN	substrate	O	O	NONE
,	,	,	O	O	NONE
is	VBZ	be	O	O	NONE
only	RB	only	O	O	NONE
a	DT	a	O	O	NONE
weak	JJ	weak	O	O	NONE
inducer	NN	inducer	O	O	NONE
of	IN	of	O	O	NONE
UDP-glucuronyl	NN	udp-glucuronyl	B-e0	O	drug
transferase	NN	transferase	I-e0	O	drug
,	,	,	O	O	NONE
it	PRP	it	O	O	NONE
is	VBZ	be	O	O	NONE
unlikely	JJ	unlikely	O	O	NONE
to	TO	to	O	O	NONE
have	VB	have	O	O	NONE
an	DT	a	O	O	NONE
effect	NN	effect	O	O	NONE
on	IN	on	O	O	NONE
drugs	NNS	drug	B-e1	T	drug
that	WDT	that	O	O	NONE
are	VBP	be	O	O	NONE
mainly	RB	mainly	O	O	NONE
eliminated	VBN	eliminate	O	O	NONE
by	IN	by	O	O	NONE
conjugation	NN	conjugation	O	O	NONE
through	IN	through	O	O	NONE
UDP-glucuronyl	JJ	udp-glucuronyl	B-e2	O	drug
transferase	NN	transferase	I-e2	O	drug
(	(	(	O	O	NONE
e.g.	FW	e.g.	O	O	NONE
,	,	,	O	O	NONE
valproic	JJ	valproic	B-e3	O	drug
acid	NN	acid	I-e3	O	drug
,	,	,	O	O	NONE
lamotrigine	NN	lamotrigine	B-e4	T	drug
)	)	)	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s8
As	IN	as	O	O	NONE
MHD	NN	mhd	O	O	NONE
,	,	,	O	O	NONE
the	DT	the	O	O	NONE
predominant	JJ	predominant	O	O	NONE
plasma	NN	plasma	O	O	NONE
substrate	NN	substrate	O	O	NONE
,	,	,	O	O	NONE
is	VBZ	be	O	O	NONE
only	RB	only	O	O	NONE
a	DT	a	O	O	NONE
weak	JJ	weak	O	O	NONE
inducer	NN	inducer	O	O	NONE
of	IN	of	O	O	NONE
UDP-glucuronyl	NN	udp-glucuronyl	B-e0	O	drug
transferase	NN	transferase	I-e0	O	drug
,	,	,	O	O	NONE
it	PRP	it	O	O	NONE
is	VBZ	be	O	O	NONE
unlikely	JJ	unlikely	O	O	NONE
to	TO	to	O	O	NONE
have	VB	have	O	O	NONE
an	DT	a	O	O	NONE
effect	NN	effect	O	O	NONE
on	IN	on	O	O	NONE
drugs	NNS	drug	B-e1	O	drug
that	WDT	that	O	O	NONE
are	VBP	be	O	O	NONE
mainly	RB	mainly	O	O	NONE
eliminated	VBN	eliminate	O	O	NONE
by	IN	by	O	O	NONE
conjugation	NN	conjugation	O	O	NONE
through	IN	through	O	O	NONE
UDP-glucuronyl	JJ	udp-glucuronyl	B-e2	T	drug
transferase	NN	transferase	I-e2	T	drug
(	(	(	O	O	NONE
e.g.	FW	e.g.	O	O	NONE
,	,	,	O	O	NONE
valproic	JJ	valproic	B-e3	T	drug
acid	NN	acid	I-e3	T	drug
,	,	,	O	O	NONE
lamotrigine	NN	lamotrigine	B-e4	O	drug
)	)	)	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s8
As	IN	as	O	O	NONE
MHD	NN	mhd	O	O	NONE
,	,	,	O	O	NONE
the	DT	the	O	O	NONE
predominant	JJ	predominant	O	O	NONE
plasma	NN	plasma	O	O	NONE
substrate	NN	substrate	O	O	NONE
,	,	,	O	O	NONE
is	VBZ	be	O	O	NONE
only	RB	only	O	O	NONE
a	DT	a	O	O	NONE
weak	JJ	weak	O	O	NONE
inducer	NN	inducer	O	O	NONE
of	IN	of	O	O	NONE
UDP-glucuronyl	NN	udp-glucuronyl	B-e0	O	drug
transferase	NN	transferase	I-e0	O	drug
,	,	,	O	O	NONE
it	PRP	it	O	O	NONE
is	VBZ	be	O	O	NONE
unlikely	JJ	unlikely	O	O	NONE
to	TO	to	O	O	NONE
have	VB	have	O	O	NONE
an	DT	a	O	O	NONE
effect	NN	effect	O	O	NONE
on	IN	on	O	O	NONE
drugs	NNS	drug	B-e1	O	drug
that	WDT	that	O	O	NONE
are	VBP	be	O	O	NONE
mainly	RB	mainly	O	O	NONE
eliminated	VBN	eliminate	O	O	NONE
by	IN	by	O	O	NONE
conjugation	NN	conjugation	O	O	NONE
through	IN	through	O	O	NONE
UDP-glucuronyl	JJ	udp-glucuronyl	B-e2	T	drug
transferase	NN	transferase	I-e2	T	drug
(	(	(	O	O	NONE
e.g.	FW	e.g.	O	O	NONE
,	,	,	O	O	NONE
valproic	JJ	valproic	B-e3	O	drug
acid	NN	acid	I-e3	O	drug
,	,	,	O	O	NONE
lamotrigine	NN	lamotrigine	B-e4	T	drug
)	)	)	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s8
As	IN	as	O	O	NONE
MHD	NN	mhd	O	O	NONE
,	,	,	O	O	NONE
the	DT	the	O	O	NONE
predominant	JJ	predominant	O	O	NONE
plasma	NN	plasma	O	O	NONE
substrate	NN	substrate	O	O	NONE
,	,	,	O	O	NONE
is	VBZ	be	O	O	NONE
only	RB	only	O	O	NONE
a	DT	a	O	O	NONE
weak	JJ	weak	O	O	NONE
inducer	NN	inducer	O	O	NONE
of	IN	of	O	O	NONE
UDP-glucuronyl	NN	udp-glucuronyl	B-e0	O	drug
transferase	NN	transferase	I-e0	O	drug
,	,	,	O	O	NONE
it	PRP	it	O	O	NONE
is	VBZ	be	O	O	NONE
unlikely	JJ	unlikely	O	O	NONE
to	TO	to	O	O	NONE
have	VB	have	O	O	NONE
an	DT	a	O	O	NONE
effect	NN	effect	O	O	NONE
on	IN	on	O	O	NONE
drugs	NNS	drug	B-e1	O	drug
that	WDT	that	O	O	NONE
are	VBP	be	O	O	NONE
mainly	RB	mainly	O	O	NONE
eliminated	VBN	eliminate	O	O	NONE
by	IN	by	O	O	NONE
conjugation	NN	conjugation	O	O	NONE
through	IN	through	O	O	NONE
UDP-glucuronyl	JJ	udp-glucuronyl	B-e2	O	drug
transferase	NN	transferase	I-e2	O	drug
(	(	(	O	O	NONE
e.g.	FW	e.g.	O	O	NONE
,	,	,	O	O	NONE
valproic	JJ	valproic	B-e3	T	drug
acid	NN	acid	I-e3	T	drug
,	,	,	O	O	NONE
lamotrigine	NN	lamotrigine	B-e4	T	drug
)	)	)	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s9
In	IN	in	O	O	NONE
addition	NN	addition	O	O	NONE
,	,	,	O	O	NONE
oxcarbazepine	NN	oxcarbazepine	B-e0	T	drug
and	CC	and	O	O	NONE
MHD	NN	mhd	O	O	NONE
induce	VBP	induce	O	O	NONE
a	DT	a	O	O	NONE
subgroup	NN	subgroup	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
cytochrome	NN	cytochrome	B-e1	T	drug
P450	NN	p450	I-e1	T	drug
3A	NN	3a	I-e1	T	drug
family	NN	family	O	O	NONE
(	(	(	O	O	NONE
CYP3A4	NN	cyp3a4	B-e2	O	drug
and	CC	and	O	O	NONE
CYP3A5	NN	cyp3a5	B-e3	O	drug
)	)	)	O	O	NONE
responsible	JJ	responsible	O	O	NONE
for	IN	for	O	O	NONE
the	DT	the	O	O	NONE
metabolism	NN	metabolism	O	O	NONE
of	IN	of	O	O	NONE
dihydropyridine	NN	dihydropyridine	O	O	NONE
calcium	NN	calcium	B-e4	O	drug
antagonist	NN	antagonist	I-e4	O	drug
s	NN	s	O	O	NONE
and	CC	and	O	O	NONE
oral	JJ	oral	B-e5	O	drug
contraceptives	NNS	contraceptive	I-e5	O	drug
,	,	,	O	O	NONE
resulting	VBG	result	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
lower	JJR	lower	O	O	NONE
plasma	NN	plasma	O	O	NONE
concentration	NN	concentration	O	O	NONE
of	IN	of	O	O	NONE
these	DT	these	O	O	NONE
drugs	NNS	drug	B-e6	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s9
In	IN	in	O	O	NONE
addition	NN	addition	O	O	NONE
,	,	,	O	O	NONE
oxcarbazepine	NN	oxcarbazepine	B-e0	T	drug
and	CC	and	O	O	NONE
MHD	NN	mhd	O	O	NONE
induce	VBP	induce	O	O	NONE
a	DT	a	O	O	NONE
subgroup	NN	subgroup	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
cytochrome	NN	cytochrome	B-e1	O	drug
P450	NN	p450	I-e1	O	drug
3A	NN	3a	I-e1	O	drug
family	NN	family	O	O	NONE
(	(	(	O	O	NONE
CYP3A4	NN	cyp3a4	B-e2	T	drug
and	CC	and	O	O	NONE
CYP3A5	NN	cyp3a5	B-e3	O	drug
)	)	)	O	O	NONE
responsible	JJ	responsible	O	O	NONE
for	IN	for	O	O	NONE
the	DT	the	O	O	NONE
metabolism	NN	metabolism	O	O	NONE
of	IN	of	O	O	NONE
dihydropyridine	NN	dihydropyridine	O	O	NONE
calcium	NN	calcium	B-e4	O	drug
antagonist	NN	antagonist	I-e4	O	drug
s	NN	s	O	O	NONE
and	CC	and	O	O	NONE
oral	JJ	oral	B-e5	O	drug
contraceptives	NNS	contraceptive	I-e5	O	drug
,	,	,	O	O	NONE
resulting	VBG	result	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
lower	JJR	lower	O	O	NONE
plasma	NN	plasma	O	O	NONE
concentration	NN	concentration	O	O	NONE
of	IN	of	O	O	NONE
these	DT	these	O	O	NONE
drugs	NNS	drug	B-e6	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s9
In	IN	in	O	O	NONE
addition	NN	addition	O	O	NONE
,	,	,	O	O	NONE
oxcarbazepine	NN	oxcarbazepine	B-e0	T	drug
and	CC	and	O	O	NONE
MHD	NN	mhd	O	O	NONE
induce	VBP	induce	O	O	NONE
a	DT	a	O	O	NONE
subgroup	NN	subgroup	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
cytochrome	NN	cytochrome	B-e1	O	drug
P450	NN	p450	I-e1	O	drug
3A	NN	3a	I-e1	O	drug
family	NN	family	O	O	NONE
(	(	(	O	O	NONE
CYP3A4	NN	cyp3a4	B-e2	O	drug
and	CC	and	O	O	NONE
CYP3A5	NN	cyp3a5	B-e3	T	drug
)	)	)	O	O	NONE
responsible	JJ	responsible	O	O	NONE
for	IN	for	O	O	NONE
the	DT	the	O	O	NONE
metabolism	NN	metabolism	O	O	NONE
of	IN	of	O	O	NONE
dihydropyridine	NN	dihydropyridine	O	O	NONE
calcium	NN	calcium	B-e4	O	drug
antagonist	NN	antagonist	I-e4	O	drug
s	NN	s	O	O	NONE
and	CC	and	O	O	NONE
oral	JJ	oral	B-e5	O	drug
contraceptives	NNS	contraceptive	I-e5	O	drug
,	,	,	O	O	NONE
resulting	VBG	result	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
lower	JJR	lower	O	O	NONE
plasma	NN	plasma	O	O	NONE
concentration	NN	concentration	O	O	NONE
of	IN	of	O	O	NONE
these	DT	these	O	O	NONE
drugs	NNS	drug	B-e6	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s9
In	IN	in	O	O	NONE
addition	NN	addition	O	O	NONE
,	,	,	O	O	NONE
oxcarbazepine	NN	oxcarbazepine	B-e0	T	drug
and	CC	and	O	O	NONE
MHD	NN	mhd	O	O	NONE
induce	VBP	induce	O	O	NONE
a	DT	a	O	O	NONE
subgroup	NN	subgroup	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
cytochrome	NN	cytochrome	B-e1	O	drug
P450	NN	p450	I-e1	O	drug
3A	NN	3a	I-e1	O	drug
family	NN	family	O	O	NONE
(	(	(	O	O	NONE
CYP3A4	NN	cyp3a4	B-e2	O	drug
and	CC	and	O	O	NONE
CYP3A5	NN	cyp3a5	B-e3	O	drug
)	)	)	O	O	NONE
responsible	JJ	responsible	O	O	NONE
for	IN	for	O	O	NONE
the	DT	the	O	O	NONE
metabolism	NN	metabolism	O	O	NONE
of	IN	of	O	O	NONE
dihydropyridine	NN	dihydropyridine	O	O	NONE
calcium	NN	calcium	B-e4	T	drug
antagonist	NN	antagonist	I-e4	T	drug
s	NN	s	O	O	NONE
and	CC	and	O	O	NONE
oral	JJ	oral	B-e5	O	drug
contraceptives	NNS	contraceptive	I-e5	O	drug
,	,	,	O	O	NONE
resulting	VBG	result	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
lower	JJR	lower	O	O	NONE
plasma	NN	plasma	O	O	NONE
concentration	NN	concentration	O	O	NONE
of	IN	of	O	O	NONE
these	DT	these	O	O	NONE
drugs	NNS	drug	B-e6	O	drug
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d20.s9
In	IN	in	O	O	NONE
addition	NN	addition	O	O	NONE
,	,	,	O	O	NONE
oxcarbazepine	NN	oxcarbazepine	B-e0	T	drug
and	CC	and	O	O	NONE
MHD	NN	mhd	O	O	NONE
induce	VBP	induce	O	O	NONE
a	DT	a	O	O	NONE
subgroup	NN	subgroup	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
cytochrome	NN	cytochrome	B-e1	O	drug
P450	NN	p450	I-e1	O	drug
3A	NN	3a	I-e1	O	drug
family	NN	family	O	O	NONE
(	(	(	O	O	NONE
CYP3A4	NN	cyp3a4	B-e2	O	drug
and	CC	and	O	O	NONE
CYP3A5	NN	cyp3a5	B-e3	O	drug
)	)	)	O	O	NONE
responsible	JJ	responsible	O	O	NONE
for	IN	for	O	O	NONE
the	DT	the	O	O	NONE
metabolism	NN	metabolism	O	O	NONE
of	IN	of	O	O	NONE
dihydropyridine	NN	dihydropyridine	O	O	NONE
calcium	NN	calcium	B-e4	O	drug
antagonist	NN	antagonist	I-e4	O	drug
s	NN	s	O	O	NONE
and	CC	and	O	O	NONE
oral	JJ	oral	B-e5	T	drug
contraceptives	NNS	contraceptive	I-e5	T	drug
,	,	,	O	O	NONE
resulting	VBG	result	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
lower	JJR	lower	O	O	NONE
plasma	NN	plasma	O	O	NONE
concentration	NN	concentration	O	O	NONE
of	IN	of	O	O	NONE
these	DT	these	O	O	NONE
drugs	NNS	drug	B-e6	O	drug
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d20.s9
In	IN	in	O	O	NONE
addition	NN	addition	O	O	NONE
,	,	,	O	O	NONE
oxcarbazepine	NN	oxcarbazepine	B-e0	T	drug
and	CC	and	O	O	NONE
MHD	NN	mhd	O	O	NONE
induce	VBP	induce	O	O	NONE
a	DT	a	O	O	NONE
subgroup	NN	subgroup	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
cytochrome	NN	cytochrome	B-e1	O	drug
P450	NN	p450	I-e1	O	drug
3A	NN	3a	I-e1	O	drug
family	NN	family	O	O	NONE
(	(	(	O	O	NONE
CYP3A4	NN	cyp3a4	B-e2	O	drug
and	CC	and	O	O	NONE
CYP3A5	NN	cyp3a5	B-e3	O	drug
)	)	)	O	O	NONE
responsible	JJ	responsible	O	O	NONE
for	IN	for	O	O	NONE
the	DT	the	O	O	NONE
metabolism	NN	metabolism	O	O	NONE
of	IN	of	O	O	NONE
dihydropyridine	NN	dihydropyridine	O	O	NONE
calcium	NN	calcium	B-e4	O	drug
antagonist	NN	antagonist	I-e4	O	drug
s	NN	s	O	O	NONE
and	CC	and	O	O	NONE
oral	JJ	oral	B-e5	O	drug
contraceptives	NNS	contraceptive	I-e5	O	drug
,	,	,	O	O	NONE
resulting	VBG	result	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
lower	JJR	lower	O	O	NONE
plasma	NN	plasma	O	O	NONE
concentration	NN	concentration	O	O	NONE
of	IN	of	O	O	NONE
these	DT	these	O	O	NONE
drugs	NNS	drug	B-e6	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s9
In	IN	in	O	O	NONE
addition	NN	addition	O	O	NONE
,	,	,	O	O	NONE
oxcarbazepine	NN	oxcarbazepine	B-e0	O	drug
and	CC	and	O	O	NONE
MHD	NN	mhd	O	O	NONE
induce	VBP	induce	O	O	NONE
a	DT	a	O	O	NONE
subgroup	NN	subgroup	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
cytochrome	NN	cytochrome	B-e1	T	drug
P450	NN	p450	I-e1	T	drug
3A	NN	3a	I-e1	T	drug
family	NN	family	O	O	NONE
(	(	(	O	O	NONE
CYP3A4	NN	cyp3a4	B-e2	T	drug
and	CC	and	O	O	NONE
CYP3A5	NN	cyp3a5	B-e3	O	drug
)	)	)	O	O	NONE
responsible	JJ	responsible	O	O	NONE
for	IN	for	O	O	NONE
the	DT	the	O	O	NONE
metabolism	NN	metabolism	O	O	NONE
of	IN	of	O	O	NONE
dihydropyridine	NN	dihydropyridine	O	O	NONE
calcium	NN	calcium	B-e4	O	drug
antagonist	NN	antagonist	I-e4	O	drug
s	NN	s	O	O	NONE
and	CC	and	O	O	NONE
oral	JJ	oral	B-e5	O	drug
contraceptives	NNS	contraceptive	I-e5	O	drug
,	,	,	O	O	NONE
resulting	VBG	result	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
lower	JJR	lower	O	O	NONE
plasma	NN	plasma	O	O	NONE
concentration	NN	concentration	O	O	NONE
of	IN	of	O	O	NONE
these	DT	these	O	O	NONE
drugs	NNS	drug	B-e6	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s9
In	IN	in	O	O	NONE
addition	NN	addition	O	O	NONE
,	,	,	O	O	NONE
oxcarbazepine	NN	oxcarbazepine	B-e0	O	drug
and	CC	and	O	O	NONE
MHD	NN	mhd	O	O	NONE
induce	VBP	induce	O	O	NONE
a	DT	a	O	O	NONE
subgroup	NN	subgroup	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
cytochrome	NN	cytochrome	B-e1	T	drug
P450	NN	p450	I-e1	T	drug
3A	NN	3a	I-e1	T	drug
family	NN	family	O	O	NONE
(	(	(	O	O	NONE
CYP3A4	NN	cyp3a4	B-e2	O	drug
and	CC	and	O	O	NONE
CYP3A5	NN	cyp3a5	B-e3	T	drug
)	)	)	O	O	NONE
responsible	JJ	responsible	O	O	NONE
for	IN	for	O	O	NONE
the	DT	the	O	O	NONE
metabolism	NN	metabolism	O	O	NONE
of	IN	of	O	O	NONE
dihydropyridine	NN	dihydropyridine	O	O	NONE
calcium	NN	calcium	B-e4	O	drug
antagonist	NN	antagonist	I-e4	O	drug
s	NN	s	O	O	NONE
and	CC	and	O	O	NONE
oral	JJ	oral	B-e5	O	drug
contraceptives	NNS	contraceptive	I-e5	O	drug
,	,	,	O	O	NONE
resulting	VBG	result	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
lower	JJR	lower	O	O	NONE
plasma	NN	plasma	O	O	NONE
concentration	NN	concentration	O	O	NONE
of	IN	of	O	O	NONE
these	DT	these	O	O	NONE
drugs	NNS	drug	B-e6	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s9
In	IN	in	O	O	NONE
addition	NN	addition	O	O	NONE
,	,	,	O	O	NONE
oxcarbazepine	NN	oxcarbazepine	B-e0	O	drug
and	CC	and	O	O	NONE
MHD	NN	mhd	O	O	NONE
induce	VBP	induce	O	O	NONE
a	DT	a	O	O	NONE
subgroup	NN	subgroup	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
cytochrome	NN	cytochrome	B-e1	T	drug
P450	NN	p450	I-e1	T	drug
3A	NN	3a	I-e1	T	drug
family	NN	family	O	O	NONE
(	(	(	O	O	NONE
CYP3A4	NN	cyp3a4	B-e2	O	drug
and	CC	and	O	O	NONE
CYP3A5	NN	cyp3a5	B-e3	O	drug
)	)	)	O	O	NONE
responsible	JJ	responsible	O	O	NONE
for	IN	for	O	O	NONE
the	DT	the	O	O	NONE
metabolism	NN	metabolism	O	O	NONE
of	IN	of	O	O	NONE
dihydropyridine	NN	dihydropyridine	O	O	NONE
calcium	NN	calcium	B-e4	T	drug
antagonist	NN	antagonist	I-e4	T	drug
s	NN	s	O	O	NONE
and	CC	and	O	O	NONE
oral	JJ	oral	B-e5	O	drug
contraceptives	NNS	contraceptive	I-e5	O	drug
,	,	,	O	O	NONE
resulting	VBG	result	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
lower	JJR	lower	O	O	NONE
plasma	NN	plasma	O	O	NONE
concentration	NN	concentration	O	O	NONE
of	IN	of	O	O	NONE
these	DT	these	O	O	NONE
drugs	NNS	drug	B-e6	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s9
In	IN	in	O	O	NONE
addition	NN	addition	O	O	NONE
,	,	,	O	O	NONE
oxcarbazepine	NN	oxcarbazepine	B-e0	O	drug
and	CC	and	O	O	NONE
MHD	NN	mhd	O	O	NONE
induce	VBP	induce	O	O	NONE
a	DT	a	O	O	NONE
subgroup	NN	subgroup	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
cytochrome	NN	cytochrome	B-e1	T	drug
P450	NN	p450	I-e1	T	drug
3A	NN	3a	I-e1	T	drug
family	NN	family	O	O	NONE
(	(	(	O	O	NONE
CYP3A4	NN	cyp3a4	B-e2	O	drug
and	CC	and	O	O	NONE
CYP3A5	NN	cyp3a5	B-e3	O	drug
)	)	)	O	O	NONE
responsible	JJ	responsible	O	O	NONE
for	IN	for	O	O	NONE
the	DT	the	O	O	NONE
metabolism	NN	metabolism	O	O	NONE
of	IN	of	O	O	NONE
dihydropyridine	NN	dihydropyridine	O	O	NONE
calcium	NN	calcium	B-e4	O	drug
antagonist	NN	antagonist	I-e4	O	drug
s	NN	s	O	O	NONE
and	CC	and	O	O	NONE
oral	JJ	oral	B-e5	T	drug
contraceptives	NNS	contraceptive	I-e5	T	drug
,	,	,	O	O	NONE
resulting	VBG	result	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
lower	JJR	lower	O	O	NONE
plasma	NN	plasma	O	O	NONE
concentration	NN	concentration	O	O	NONE
of	IN	of	O	O	NONE
these	DT	these	O	O	NONE
drugs	NNS	drug	B-e6	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s9
In	IN	in	O	O	NONE
addition	NN	addition	O	O	NONE
,	,	,	O	O	NONE
oxcarbazepine	NN	oxcarbazepine	B-e0	O	drug
and	CC	and	O	O	NONE
MHD	NN	mhd	O	O	NONE
induce	VBP	induce	O	O	NONE
a	DT	a	O	O	NONE
subgroup	NN	subgroup	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
cytochrome	NN	cytochrome	B-e1	T	drug
P450	NN	p450	I-e1	T	drug
3A	NN	3a	I-e1	T	drug
family	NN	family	O	O	NONE
(	(	(	O	O	NONE
CYP3A4	NN	cyp3a4	B-e2	O	drug
and	CC	and	O	O	NONE
CYP3A5	NN	cyp3a5	B-e3	O	drug
)	)	)	O	O	NONE
responsible	JJ	responsible	O	O	NONE
for	IN	for	O	O	NONE
the	DT	the	O	O	NONE
metabolism	NN	metabolism	O	O	NONE
of	IN	of	O	O	NONE
dihydropyridine	NN	dihydropyridine	O	O	NONE
calcium	NN	calcium	B-e4	O	drug
antagonist	NN	antagonist	I-e4	O	drug
s	NN	s	O	O	NONE
and	CC	and	O	O	NONE
oral	JJ	oral	B-e5	O	drug
contraceptives	NNS	contraceptive	I-e5	O	drug
,	,	,	O	O	NONE
resulting	VBG	result	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
lower	JJR	lower	O	O	NONE
plasma	NN	plasma	O	O	NONE
concentration	NN	concentration	O	O	NONE
of	IN	of	O	O	NONE
these	DT	these	O	O	NONE
drugs	NNS	drug	B-e6	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s9
In	IN	in	O	O	NONE
addition	NN	addition	O	O	NONE
,	,	,	O	O	NONE
oxcarbazepine	NN	oxcarbazepine	B-e0	O	drug
and	CC	and	O	O	NONE
MHD	NN	mhd	O	O	NONE
induce	VBP	induce	O	O	NONE
a	DT	a	O	O	NONE
subgroup	NN	subgroup	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
cytochrome	NN	cytochrome	B-e1	O	drug
P450	NN	p450	I-e1	O	drug
3A	NN	3a	I-e1	O	drug
family	NN	family	O	O	NONE
(	(	(	O	O	NONE
CYP3A4	NN	cyp3a4	B-e2	T	drug
and	CC	and	O	O	NONE
CYP3A5	NN	cyp3a5	B-e3	T	drug
)	)	)	O	O	NONE
responsible	JJ	responsible	O	O	NONE
for	IN	for	O	O	NONE
the	DT	the	O	O	NONE
metabolism	NN	metabolism	O	O	NONE
of	IN	of	O	O	NONE
dihydropyridine	NN	dihydropyridine	O	O	NONE
calcium	NN	calcium	B-e4	O	drug
antagonist	NN	antagonist	I-e4	O	drug
s	NN	s	O	O	NONE
and	CC	and	O	O	NONE
oral	JJ	oral	B-e5	O	drug
contraceptives	NNS	contraceptive	I-e5	O	drug
,	,	,	O	O	NONE
resulting	VBG	result	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
lower	JJR	lower	O	O	NONE
plasma	NN	plasma	O	O	NONE
concentration	NN	concentration	O	O	NONE
of	IN	of	O	O	NONE
these	DT	these	O	O	NONE
drugs	NNS	drug	B-e6	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s9
In	IN	in	O	O	NONE
addition	NN	addition	O	O	NONE
,	,	,	O	O	NONE
oxcarbazepine	NN	oxcarbazepine	B-e0	O	drug
and	CC	and	O	O	NONE
MHD	NN	mhd	O	O	NONE
induce	VBP	induce	O	O	NONE
a	DT	a	O	O	NONE
subgroup	NN	subgroup	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
cytochrome	NN	cytochrome	B-e1	O	drug
P450	NN	p450	I-e1	O	drug
3A	NN	3a	I-e1	O	drug
family	NN	family	O	O	NONE
(	(	(	O	O	NONE
CYP3A4	NN	cyp3a4	B-e2	T	drug
and	CC	and	O	O	NONE
CYP3A5	NN	cyp3a5	B-e3	O	drug
)	)	)	O	O	NONE
responsible	JJ	responsible	O	O	NONE
for	IN	for	O	O	NONE
the	DT	the	O	O	NONE
metabolism	NN	metabolism	O	O	NONE
of	IN	of	O	O	NONE
dihydropyridine	NN	dihydropyridine	O	O	NONE
calcium	NN	calcium	B-e4	T	drug
antagonist	NN	antagonist	I-e4	T	drug
s	NN	s	O	O	NONE
and	CC	and	O	O	NONE
oral	JJ	oral	B-e5	O	drug
contraceptives	NNS	contraceptive	I-e5	O	drug
,	,	,	O	O	NONE
resulting	VBG	result	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
lower	JJR	lower	O	O	NONE
plasma	NN	plasma	O	O	NONE
concentration	NN	concentration	O	O	NONE
of	IN	of	O	O	NONE
these	DT	these	O	O	NONE
drugs	NNS	drug	B-e6	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s9
In	IN	in	O	O	NONE
addition	NN	addition	O	O	NONE
,	,	,	O	O	NONE
oxcarbazepine	NN	oxcarbazepine	B-e0	O	drug
and	CC	and	O	O	NONE
MHD	NN	mhd	O	O	NONE
induce	VBP	induce	O	O	NONE
a	DT	a	O	O	NONE
subgroup	NN	subgroup	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
cytochrome	NN	cytochrome	B-e1	O	drug
P450	NN	p450	I-e1	O	drug
3A	NN	3a	I-e1	O	drug
family	NN	family	O	O	NONE
(	(	(	O	O	NONE
CYP3A4	NN	cyp3a4	B-e2	T	drug
and	CC	and	O	O	NONE
CYP3A5	NN	cyp3a5	B-e3	O	drug
)	)	)	O	O	NONE
responsible	JJ	responsible	O	O	NONE
for	IN	for	O	O	NONE
the	DT	the	O	O	NONE
metabolism	NN	metabolism	O	O	NONE
of	IN	of	O	O	NONE
dihydropyridine	NN	dihydropyridine	O	O	NONE
calcium	NN	calcium	B-e4	O	drug
antagonist	NN	antagonist	I-e4	O	drug
s	NN	s	O	O	NONE
and	CC	and	O	O	NONE
oral	JJ	oral	B-e5	T	drug
contraceptives	NNS	contraceptive	I-e5	T	drug
,	,	,	O	O	NONE
resulting	VBG	result	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
lower	JJR	lower	O	O	NONE
plasma	NN	plasma	O	O	NONE
concentration	NN	concentration	O	O	NONE
of	IN	of	O	O	NONE
these	DT	these	O	O	NONE
drugs	NNS	drug	B-e6	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s9
In	IN	in	O	O	NONE
addition	NN	addition	O	O	NONE
,	,	,	O	O	NONE
oxcarbazepine	NN	oxcarbazepine	B-e0	O	drug
and	CC	and	O	O	NONE
MHD	NN	mhd	O	O	NONE
induce	VBP	induce	O	O	NONE
a	DT	a	O	O	NONE
subgroup	NN	subgroup	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
cytochrome	NN	cytochrome	B-e1	O	drug
P450	NN	p450	I-e1	O	drug
3A	NN	3a	I-e1	O	drug
family	NN	family	O	O	NONE
(	(	(	O	O	NONE
CYP3A4	NN	cyp3a4	B-e2	T	drug
and	CC	and	O	O	NONE
CYP3A5	NN	cyp3a5	B-e3	O	drug
)	)	)	O	O	NONE
responsible	JJ	responsible	O	O	NONE
for	IN	for	O	O	NONE
the	DT	the	O	O	NONE
metabolism	NN	metabolism	O	O	NONE
of	IN	of	O	O	NONE
dihydropyridine	NN	dihydropyridine	O	O	NONE
calcium	NN	calcium	B-e4	O	drug
antagonist	NN	antagonist	I-e4	O	drug
s	NN	s	O	O	NONE
and	CC	and	O	O	NONE
oral	JJ	oral	B-e5	O	drug
contraceptives	NNS	contraceptive	I-e5	O	drug
,	,	,	O	O	NONE
resulting	VBG	result	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
lower	JJR	lower	O	O	NONE
plasma	NN	plasma	O	O	NONE
concentration	NN	concentration	O	O	NONE
of	IN	of	O	O	NONE
these	DT	these	O	O	NONE
drugs	NNS	drug	B-e6	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s9
In	IN	in	O	O	NONE
addition	NN	addition	O	O	NONE
,	,	,	O	O	NONE
oxcarbazepine	NN	oxcarbazepine	B-e0	O	drug
and	CC	and	O	O	NONE
MHD	NN	mhd	O	O	NONE
induce	VBP	induce	O	O	NONE
a	DT	a	O	O	NONE
subgroup	NN	subgroup	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
cytochrome	NN	cytochrome	B-e1	O	drug
P450	NN	p450	I-e1	O	drug
3A	NN	3a	I-e1	O	drug
family	NN	family	O	O	NONE
(	(	(	O	O	NONE
CYP3A4	NN	cyp3a4	B-e2	O	drug
and	CC	and	O	O	NONE
CYP3A5	NN	cyp3a5	B-e3	T	drug
)	)	)	O	O	NONE
responsible	JJ	responsible	O	O	NONE
for	IN	for	O	O	NONE
the	DT	the	O	O	NONE
metabolism	NN	metabolism	O	O	NONE
of	IN	of	O	O	NONE
dihydropyridine	NN	dihydropyridine	O	O	NONE
calcium	NN	calcium	B-e4	T	drug
antagonist	NN	antagonist	I-e4	T	drug
s	NN	s	O	O	NONE
and	CC	and	O	O	NONE
oral	JJ	oral	B-e5	O	drug
contraceptives	NNS	contraceptive	I-e5	O	drug
,	,	,	O	O	NONE
resulting	VBG	result	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
lower	JJR	lower	O	O	NONE
plasma	NN	plasma	O	O	NONE
concentration	NN	concentration	O	O	NONE
of	IN	of	O	O	NONE
these	DT	these	O	O	NONE
drugs	NNS	drug	B-e6	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s9
In	IN	in	O	O	NONE
addition	NN	addition	O	O	NONE
,	,	,	O	O	NONE
oxcarbazepine	NN	oxcarbazepine	B-e0	O	drug
and	CC	and	O	O	NONE
MHD	NN	mhd	O	O	NONE
induce	VBP	induce	O	O	NONE
a	DT	a	O	O	NONE
subgroup	NN	subgroup	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
cytochrome	NN	cytochrome	B-e1	O	drug
P450	NN	p450	I-e1	O	drug
3A	NN	3a	I-e1	O	drug
family	NN	family	O	O	NONE
(	(	(	O	O	NONE
CYP3A4	NN	cyp3a4	B-e2	O	drug
and	CC	and	O	O	NONE
CYP3A5	NN	cyp3a5	B-e3	T	drug
)	)	)	O	O	NONE
responsible	JJ	responsible	O	O	NONE
for	IN	for	O	O	NONE
the	DT	the	O	O	NONE
metabolism	NN	metabolism	O	O	NONE
of	IN	of	O	O	NONE
dihydropyridine	NN	dihydropyridine	O	O	NONE
calcium	NN	calcium	B-e4	O	drug
antagonist	NN	antagonist	I-e4	O	drug
s	NN	s	O	O	NONE
and	CC	and	O	O	NONE
oral	JJ	oral	B-e5	T	drug
contraceptives	NNS	contraceptive	I-e5	T	drug
,	,	,	O	O	NONE
resulting	VBG	result	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
lower	JJR	lower	O	O	NONE
plasma	NN	plasma	O	O	NONE
concentration	NN	concentration	O	O	NONE
of	IN	of	O	O	NONE
these	DT	these	O	O	NONE
drugs	NNS	drug	B-e6	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s9
In	IN	in	O	O	NONE
addition	NN	addition	O	O	NONE
,	,	,	O	O	NONE
oxcarbazepine	NN	oxcarbazepine	B-e0	O	drug
and	CC	and	O	O	NONE
MHD	NN	mhd	O	O	NONE
induce	VBP	induce	O	O	NONE
a	DT	a	O	O	NONE
subgroup	NN	subgroup	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
cytochrome	NN	cytochrome	B-e1	O	drug
P450	NN	p450	I-e1	O	drug
3A	NN	3a	I-e1	O	drug
family	NN	family	O	O	NONE
(	(	(	O	O	NONE
CYP3A4	NN	cyp3a4	B-e2	O	drug
and	CC	and	O	O	NONE
CYP3A5	NN	cyp3a5	B-e3	T	drug
)	)	)	O	O	NONE
responsible	JJ	responsible	O	O	NONE
for	IN	for	O	O	NONE
the	DT	the	O	O	NONE
metabolism	NN	metabolism	O	O	NONE
of	IN	of	O	O	NONE
dihydropyridine	NN	dihydropyridine	O	O	NONE
calcium	NN	calcium	B-e4	O	drug
antagonist	NN	antagonist	I-e4	O	drug
s	NN	s	O	O	NONE
and	CC	and	O	O	NONE
oral	JJ	oral	B-e5	O	drug
contraceptives	NNS	contraceptive	I-e5	O	drug
,	,	,	O	O	NONE
resulting	VBG	result	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
lower	JJR	lower	O	O	NONE
plasma	NN	plasma	O	O	NONE
concentration	NN	concentration	O	O	NONE
of	IN	of	O	O	NONE
these	DT	these	O	O	NONE
drugs	NNS	drug	B-e6	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s9
In	IN	in	O	O	NONE
addition	NN	addition	O	O	NONE
,	,	,	O	O	NONE
oxcarbazepine	NN	oxcarbazepine	B-e0	O	drug
and	CC	and	O	O	NONE
MHD	NN	mhd	O	O	NONE
induce	VBP	induce	O	O	NONE
a	DT	a	O	O	NONE
subgroup	NN	subgroup	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
cytochrome	NN	cytochrome	B-e1	O	drug
P450	NN	p450	I-e1	O	drug
3A	NN	3a	I-e1	O	drug
family	NN	family	O	O	NONE
(	(	(	O	O	NONE
CYP3A4	NN	cyp3a4	B-e2	O	drug
and	CC	and	O	O	NONE
CYP3A5	NN	cyp3a5	B-e3	O	drug
)	)	)	O	O	NONE
responsible	JJ	responsible	O	O	NONE
for	IN	for	O	O	NONE
the	DT	the	O	O	NONE
metabolism	NN	metabolism	O	O	NONE
of	IN	of	O	O	NONE
dihydropyridine	NN	dihydropyridine	O	O	NONE
calcium	NN	calcium	B-e4	T	drug
antagonist	NN	antagonist	I-e4	T	drug
s	NN	s	O	O	NONE
and	CC	and	O	O	NONE
oral	JJ	oral	B-e5	T	drug
contraceptives	NNS	contraceptive	I-e5	T	drug
,	,	,	O	O	NONE
resulting	VBG	result	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
lower	JJR	lower	O	O	NONE
plasma	NN	plasma	O	O	NONE
concentration	NN	concentration	O	O	NONE
of	IN	of	O	O	NONE
these	DT	these	O	O	NONE
drugs	NNS	drug	B-e6	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s9
In	IN	in	O	O	NONE
addition	NN	addition	O	O	NONE
,	,	,	O	O	NONE
oxcarbazepine	NN	oxcarbazepine	B-e0	O	drug
and	CC	and	O	O	NONE
MHD	NN	mhd	O	O	NONE
induce	VBP	induce	O	O	NONE
a	DT	a	O	O	NONE
subgroup	NN	subgroup	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
cytochrome	NN	cytochrome	B-e1	O	drug
P450	NN	p450	I-e1	O	drug
3A	NN	3a	I-e1	O	drug
family	NN	family	O	O	NONE
(	(	(	O	O	NONE
CYP3A4	NN	cyp3a4	B-e2	O	drug
and	CC	and	O	O	NONE
CYP3A5	NN	cyp3a5	B-e3	O	drug
)	)	)	O	O	NONE
responsible	JJ	responsible	O	O	NONE
for	IN	for	O	O	NONE
the	DT	the	O	O	NONE
metabolism	NN	metabolism	O	O	NONE
of	IN	of	O	O	NONE
dihydropyridine	NN	dihydropyridine	O	O	NONE
calcium	NN	calcium	B-e4	T	drug
antagonist	NN	antagonist	I-e4	T	drug
s	NN	s	O	O	NONE
and	CC	and	O	O	NONE
oral	JJ	oral	B-e5	O	drug
contraceptives	NNS	contraceptive	I-e5	O	drug
,	,	,	O	O	NONE
resulting	VBG	result	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
lower	JJR	lower	O	O	NONE
plasma	NN	plasma	O	O	NONE
concentration	NN	concentration	O	O	NONE
of	IN	of	O	O	NONE
these	DT	these	O	O	NONE
drugs	NNS	drug	B-e6	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s9
In	IN	in	O	O	NONE
addition	NN	addition	O	O	NONE
,	,	,	O	O	NONE
oxcarbazepine	NN	oxcarbazepine	B-e0	O	drug
and	CC	and	O	O	NONE
MHD	NN	mhd	O	O	NONE
induce	VBP	induce	O	O	NONE
a	DT	a	O	O	NONE
subgroup	NN	subgroup	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
cytochrome	NN	cytochrome	B-e1	O	drug
P450	NN	p450	I-e1	O	drug
3A	NN	3a	I-e1	O	drug
family	NN	family	O	O	NONE
(	(	(	O	O	NONE
CYP3A4	NN	cyp3a4	B-e2	O	drug
and	CC	and	O	O	NONE
CYP3A5	NN	cyp3a5	B-e3	O	drug
)	)	)	O	O	NONE
responsible	JJ	responsible	O	O	NONE
for	IN	for	O	O	NONE
the	DT	the	O	O	NONE
metabolism	NN	metabolism	O	O	NONE
of	IN	of	O	O	NONE
dihydropyridine	NN	dihydropyridine	O	O	NONE
calcium	NN	calcium	B-e4	O	drug
antagonist	NN	antagonist	I-e4	O	drug
s	NN	s	O	O	NONE
and	CC	and	O	O	NONE
oral	JJ	oral	B-e5	T	drug
contraceptives	NNS	contraceptive	I-e5	T	drug
,	,	,	O	O	NONE
resulting	VBG	result	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
lower	JJR	lower	O	O	NONE
plasma	NN	plasma	O	O	NONE
concentration	NN	concentration	O	O	NONE
of	IN	of	O	O	NONE
these	DT	these	O	O	NONE
drugs	NNS	drug	B-e6	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s10
As	IN	as	O	O	NONE
binding	NN	binding	O	O	NONE
of	IN	of	O	O	NONE
MHD	NN	mhd	O	O	NONE
to	TO	to	O	O	NONE
plasma	NN	plasma	B-e0	T	drug
proteins	NNS	protein	I-e0	T	drug
is	VBZ	be	O	O	NONE
low	JJ	low	O	O	NONE
(	(	(	O	O	NONE
40	CD	40	O	O	NONE
%	NN	%	O	O	NONE
)	)	)	O	O	NONE
,	,	,	O	O	NONE
clinically	RB	clinically	O	O	NONE
significant	JJ	significant	O	O	NONE
interactions	NNS	interaction	O	O	NONE
with	IN	with	O	O	NONE
other	JJ	other	O	O	NONE
drugs	NNS	drug	B-e1	T	drug
through	IN	through	O	O	NONE
competition	NN	competition	O	O	NONE
for	IN	for	O	O	NONE
protein	NN	protein	B-e2	O	drug
binding	NN	binding	O	O	NONE
sites	NNS	site	O	O	NONE
are	VBP	be	O	O	NONE
unlikely	JJ	unlikely	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s10
As	IN	as	O	O	NONE
binding	NN	binding	O	O	NONE
of	IN	of	O	O	NONE
MHD	NN	mhd	O	O	NONE
to	TO	to	O	O	NONE
plasma	NN	plasma	B-e0	T	drug
proteins	NNS	protein	I-e0	T	drug
is	VBZ	be	O	O	NONE
low	JJ	low	O	O	NONE
(	(	(	O	O	NONE
40	CD	40	O	O	NONE
%	NN	%	O	O	NONE
)	)	)	O	O	NONE
,	,	,	O	O	NONE
clinically	RB	clinically	O	O	NONE
significant	JJ	significant	O	O	NONE
interactions	NNS	interaction	O	O	NONE
with	IN	with	O	O	NONE
other	JJ	other	O	O	NONE
drugs	NNS	drug	B-e1	O	drug
through	IN	through	O	O	NONE
competition	NN	competition	O	O	NONE
for	IN	for	O	O	NONE
protein	NN	protein	B-e2	T	drug
binding	NN	binding	O	O	NONE
sites	NNS	site	O	O	NONE
are	VBP	be	O	O	NONE
unlikely	JJ	unlikely	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s10
As	IN	as	O	O	NONE
binding	NN	binding	O	O	NONE
of	IN	of	O	O	NONE
MHD	NN	mhd	O	O	NONE
to	TO	to	O	O	NONE
plasma	NN	plasma	B-e0	O	drug
proteins	NNS	protein	I-e0	O	drug
is	VBZ	be	O	O	NONE
low	JJ	low	O	O	NONE
(	(	(	O	O	NONE
40	CD	40	O	O	NONE
%	NN	%	O	O	NONE
)	)	)	O	O	NONE
,	,	,	O	O	NONE
clinically	RB	clinically	O	O	NONE
significant	JJ	significant	O	O	NONE
interactions	NNS	interaction	O	O	NONE
with	IN	with	O	O	NONE
other	JJ	other	O	O	NONE
drugs	NNS	drug	B-e1	T	drug
through	IN	through	O	O	NONE
competition	NN	competition	O	O	NONE
for	IN	for	O	O	NONE
protein	NN	protein	B-e2	T	drug
binding	NN	binding	O	O	NONE
sites	NNS	site	O	O	NONE
are	VBP	be	O	O	NONE
unlikely	JJ	unlikely	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s11
Antiepileptic	JJ	antiepileptic	B-e0	T	drug
drugs	NNS	drug	I-e0	T	drug
Potential	JJ	potential	O	O	NONE
interactions	NNS	interaction	O	O	NONE
between	IN	between	O	O	NONE
Trileptal	NNP	Trileptal	B-e1	T	drug
and	CC	and	O	O	NONE
other	JJ	other	O	O	NONE
AEDs	NNS	aed	O	O	NONE
were	VBD	be	O	O	NONE
assessed	VBN	assess	O	O	NONE
in	IN	in	O	O	NONE
clinical	JJ	clinical	O	O	NONE
studies	NNS	study	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s35
1-	CD	1-	O	O	NONE
nc	NN	nc	O	O	NONE
denotes	VBZ	denote	O	O	NONE
a	DT	a	O	O	NONE
mean	JJ	mean	O	O	NONE
change	NN	change	O	O	NONE
of	IN	of	O	O	NONE
less	JJR	less	O	O	NONE
than	IN	than	O	O	NONE
10	CD	10	O	O	NONE
%	NN	%	O	O	NONE
2-	CD	2-	O	O	NONE
Pediatrics	NN	pediatrics	O	O	NONE
3-	CD	3-	O	O	NONE
Mean	NN	mean	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
adults	NNS	adult	O	O	NONE
at	IN	at	O	O	NONE
high	JJ	high	O	O	NONE
Trileptal	NN	trileptal	B-e0	T	drug
doses	NNS	dose	O	O	NONE
In	FW	in	O	O	NONE
vivo	FW	vivo	O	O	NONE
,	,	,	O	O	NONE
the	DT	the	O	O	NONE
plasma	NN	plasma	O	O	NONE
levels	NNS	level	O	O	NONE
of	IN	of	O	O	NONE
phenytoin	NN	phenytoin	B-e1	T	drug
increased	VBD	increase	O	O	NONE
by	IN	by	O	O	NONE
up	RB	up	O	O	NONE
to	TO	to	O	O	NONE
40	CD	40	O	O	NONE
%	NN	%	O	O	NONE
,	,	,	O	O	NONE
when	WRB	when	O	O	NONE
Trileptal	NN	trileptal	B-e2	O	drug
was	VBD	be	O	O	NONE
given	VBN	give	O	O	NONE
at	IN	at	O	O	NONE
doses	NNS	dose	O	O	NONE
above	IN	above	O	O	NONE
1200	CD	1200	O	O	NONE
mg/day	NN	mg/day	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s35
1-	CD	1-	O	O	NONE
nc	NN	nc	O	O	NONE
denotes	VBZ	denote	O	O	NONE
a	DT	a	O	O	NONE
mean	JJ	mean	O	O	NONE
change	NN	change	O	O	NONE
of	IN	of	O	O	NONE
less	JJR	less	O	O	NONE
than	IN	than	O	O	NONE
10	CD	10	O	O	NONE
%	NN	%	O	O	NONE
2-	CD	2-	O	O	NONE
Pediatrics	NN	pediatrics	O	O	NONE
3-	CD	3-	O	O	NONE
Mean	NN	mean	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
adults	NNS	adult	O	O	NONE
at	IN	at	O	O	NONE
high	JJ	high	O	O	NONE
Trileptal	NN	trileptal	B-e0	T	drug
doses	NNS	dose	O	O	NONE
In	FW	in	O	O	NONE
vivo	FW	vivo	O	O	NONE
,	,	,	O	O	NONE
the	DT	the	O	O	NONE
plasma	NN	plasma	O	O	NONE
levels	NNS	level	O	O	NONE
of	IN	of	O	O	NONE
phenytoin	NN	phenytoin	B-e1	O	drug
increased	VBD	increase	O	O	NONE
by	IN	by	O	O	NONE
up	RB	up	O	O	NONE
to	TO	to	O	O	NONE
40	CD	40	O	O	NONE
%	NN	%	O	O	NONE
,	,	,	O	O	NONE
when	WRB	when	O	O	NONE
Trileptal	NN	trileptal	B-e2	T	drug
was	VBD	be	O	O	NONE
given	VBN	give	O	O	NONE
at	IN	at	O	O	NONE
doses	NNS	dose	O	O	NONE
above	IN	above	O	O	NONE
1200	CD	1200	O	O	NONE
mg/day	NN	mg/day	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s35
1-	CD	1-	O	O	NONE
nc	NN	nc	O	O	NONE
denotes	VBZ	denote	O	O	NONE
a	DT	a	O	O	NONE
mean	JJ	mean	O	O	NONE
change	NN	change	O	O	NONE
of	IN	of	O	O	NONE
less	JJR	less	O	O	NONE
than	IN	than	O	O	NONE
10	CD	10	O	O	NONE
%	NN	%	O	O	NONE
2-	CD	2-	O	O	NONE
Pediatrics	NN	pediatrics	O	O	NONE
3-	CD	3-	O	O	NONE
Mean	NN	mean	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
adults	NNS	adult	O	O	NONE
at	IN	at	O	O	NONE
high	JJ	high	O	O	NONE
Trileptal	NN	trileptal	B-e0	O	drug
doses	NNS	dose	O	O	NONE
In	FW	in	O	O	NONE
vivo	FW	vivo	O	O	NONE
,	,	,	O	O	NONE
the	DT	the	O	O	NONE
plasma	NN	plasma	O	O	NONE
levels	NNS	level	O	O	NONE
of	IN	of	O	O	NONE
phenytoin	NN	phenytoin	B-e1	T	drug
increased	VBD	increase	O	O	NONE
by	IN	by	O	O	NONE
up	RB	up	O	O	NONE
to	TO	to	O	O	NONE
40	CD	40	O	O	NONE
%	NN	%	O	O	NONE
,	,	,	O	O	NONE
when	WRB	when	O	O	NONE
Trileptal	NN	trileptal	B-e2	T	drug
was	VBD	be	O	O	NONE
given	VBN	give	O	O	NONE
at	IN	at	O	O	NONE
doses	NNS	dose	O	O	NONE
above	IN	above	O	O	NONE
1200	CD	1200	O	O	NONE
mg/day	NN	mg/day	O	O	NONE
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d20.s36
Therefore	RB	therefore	O	O	NONE
,	,	,	O	O	NONE
when	WRB	when	O	O	NONE
using	VBG	use	O	O	NONE
doses	NNS	dose	O	O	NONE
of	IN	of	O	O	NONE
Trileptal	NN	trileptal	B-e0	T	drug
greater	JJR	greater	O	O	NONE
than	IN	than	O	O	NONE
1200	CD	1200	O	O	NONE
mg/day	NN	mg/day	O	O	NONE
during	IN	during	O	O	NONE
adjunctive	JJ	adjunctive	O	O	NONE
therapy	NN	therapy	O	O	NONE
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
decrease	NN	decrease	O	O	NONE
in	IN	in	O	O	NONE
the	DT	the	O	O	NONE
dose	NN	dose	O	O	NONE
of	IN	of	O	O	NONE
phenytoin	NN	phenytoin	B-e1	T	drug
may	MD	may	O	O	NONE
be	VB	be	O	O	NONE
required	VBN	require	O	O	NONE
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d20.s38
Strong	JJ	strong	O	O	NONE
inducers	NNS	inducer	O	O	NONE
of	IN	of	O	O	NONE
cytochrome	NN	cytochrome	B-e0	T	drug
P450	NN	p450	I-e0	T	drug
enzymes	NNS	enzyme	O	O	NONE
(	(	(	O	O	NONE
i.e.	FW	i.e.	O	O	NONE
carbamazepine	NN	carbamazepine	B-e1	T	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e2	O	drug
and	CC	and	O	O	NONE
phenobarbital	NN	phenobarbital	B-e3	O	drug
)	)	)	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
shown	VBN	show	O	O	NONE
to	TO	to	O	O	NONE
decrease	VB	decrease	O	O	NONE
the	DT	the	O	O	NONE
plasma	NN	plasma	O	O	NONE
levels	NNS	level	O	O	NONE
of	IN	of	O	O	NONE
MHD	NN	mhd	O	O	NONE
(	(	(	O	O	NONE
29-40%).	NN	29-40%).	O	O	NONE

NO

Sentence: DrugDDI.d20.s38
Strong	JJ	strong	O	O	NONE
inducers	NNS	inducer	O	O	NONE
of	IN	of	O	O	NONE
cytochrome	NN	cytochrome	B-e0	T	drug
P450	NN	p450	I-e0	T	drug
enzymes	NNS	enzyme	O	O	NONE
(	(	(	O	O	NONE
i.e.	FW	i.e.	O	O	NONE
carbamazepine	NN	carbamazepine	B-e1	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e2	T	drug
and	CC	and	O	O	NONE
phenobarbital	NN	phenobarbital	B-e3	O	drug
)	)	)	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
shown	VBN	show	O	O	NONE
to	TO	to	O	O	NONE
decrease	VB	decrease	O	O	NONE
the	DT	the	O	O	NONE
plasma	NN	plasma	O	O	NONE
levels	NNS	level	O	O	NONE
of	IN	of	O	O	NONE
MHD	NN	mhd	O	O	NONE
(	(	(	O	O	NONE
29-40%).	NN	29-40%).	O	O	NONE

NO

Sentence: DrugDDI.d20.s38
Strong	JJ	strong	O	O	NONE
inducers	NNS	inducer	O	O	NONE
of	IN	of	O	O	NONE
cytochrome	NN	cytochrome	B-e0	T	drug
P450	NN	p450	I-e0	T	drug
enzymes	NNS	enzyme	O	O	NONE
(	(	(	O	O	NONE
i.e.	FW	i.e.	O	O	NONE
carbamazepine	NN	carbamazepine	B-e1	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e2	O	drug
and	CC	and	O	O	NONE
phenobarbital	NN	phenobarbital	B-e3	T	drug
)	)	)	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
shown	VBN	show	O	O	NONE
to	TO	to	O	O	NONE
decrease	VB	decrease	O	O	NONE
the	DT	the	O	O	NONE
plasma	NN	plasma	O	O	NONE
levels	NNS	level	O	O	NONE
of	IN	of	O	O	NONE
MHD	NN	mhd	O	O	NONE
(	(	(	O	O	NONE
29-40%).	NN	29-40%).	O	O	NONE

NO

Sentence: DrugDDI.d20.s38
Strong	JJ	strong	O	O	NONE
inducers	NNS	inducer	O	O	NONE
of	IN	of	O	O	NONE
cytochrome	NN	cytochrome	B-e0	O	drug
P450	NN	p450	I-e0	O	drug
enzymes	NNS	enzyme	O	O	NONE
(	(	(	O	O	NONE
i.e.	FW	i.e.	O	O	NONE
carbamazepine	NN	carbamazepine	B-e1	T	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e2	T	drug
and	CC	and	O	O	NONE
phenobarbital	NN	phenobarbital	B-e3	O	drug
)	)	)	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
shown	VBN	show	O	O	NONE
to	TO	to	O	O	NONE
decrease	VB	decrease	O	O	NONE
the	DT	the	O	O	NONE
plasma	NN	plasma	O	O	NONE
levels	NNS	level	O	O	NONE
of	IN	of	O	O	NONE
MHD	NN	mhd	O	O	NONE
(	(	(	O	O	NONE
29-40%).	NN	29-40%).	O	O	NONE

NO

Sentence: DrugDDI.d20.s38
Strong	JJ	strong	O	O	NONE
inducers	NNS	inducer	O	O	NONE
of	IN	of	O	O	NONE
cytochrome	NN	cytochrome	B-e0	O	drug
P450	NN	p450	I-e0	O	drug
enzymes	NNS	enzyme	O	O	NONE
(	(	(	O	O	NONE
i.e.	FW	i.e.	O	O	NONE
carbamazepine	NN	carbamazepine	B-e1	T	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e2	O	drug
and	CC	and	O	O	NONE
phenobarbital	NN	phenobarbital	B-e3	T	drug
)	)	)	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
shown	VBN	show	O	O	NONE
to	TO	to	O	O	NONE
decrease	VB	decrease	O	O	NONE
the	DT	the	O	O	NONE
plasma	NN	plasma	O	O	NONE
levels	NNS	level	O	O	NONE
of	IN	of	O	O	NONE
MHD	NN	mhd	O	O	NONE
(	(	(	O	O	NONE
29-40%).	NN	29-40%).	O	O	NONE

NO

Sentence: DrugDDI.d20.s38
Strong	JJ	strong	O	O	NONE
inducers	NNS	inducer	O	O	NONE
of	IN	of	O	O	NONE
cytochrome	NN	cytochrome	B-e0	O	drug
P450	NN	p450	I-e0	O	drug
enzymes	NNS	enzyme	O	O	NONE
(	(	(	O	O	NONE
i.e.	FW	i.e.	O	O	NONE
carbamazepine	NN	carbamazepine	B-e1	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e2	T	drug
and	CC	and	O	O	NONE
phenobarbital	NN	phenobarbital	B-e3	T	drug
)	)	)	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
shown	VBN	show	O	O	NONE
to	TO	to	O	O	NONE
decrease	VB	decrease	O	O	NONE
the	DT	the	O	O	NONE
plasma	NN	plasma	O	O	NONE
levels	NNS	level	O	O	NONE
of	IN	of	O	O	NONE
MHD	NN	mhd	O	O	NONE
(	(	(	O	O	NONE
29-40%).	NN	29-40%).	O	O	NONE

NO

Sentence: DrugDDI.d20.s40
Hormonal	JJ	hormonal	O	O	NONE
contraceptives	NNS	contraceptive	O	O	NONE
Co-administration	NN	co-administration	O	O	NONE
of	IN	of	O	O	NONE
Trileptal	NN	trileptal	B-e0	T	drug
with	IN	with	O	O	NONE
an	DT	a	O	O	NONE
oral	JJ	oral	B-e1	T	drug
contraceptive	NN	contraceptive	I-e1	T	drug
has	VBZ	have	O	O	NONE
been	VBN	be	O	O	NONE
shown	VBN	show	O	O	NONE
to	TO	to	O	O	NONE
influence	VB	influence	O	O	NONE
the	DT	the	O	O	NONE
plasma	NN	plasma	O	O	NONE
concentrations	NNS	concentration	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
two	CD	two	O	O	NONE
hormonal	JJ	hormonal	O	O	NONE
components	NNS	component	O	O	NONE
,	,	,	O	O	NONE
ethinylestradiol	NN	ethinylestradiol	B-e2	O	drug
(	(	(	O	O	NONE
EE	NN	ee	O	O	NONE
)	)	)	O	O	NONE
and	CC	and	O	O	NONE
levonorgestrel	NN	levonorgestrel	B-e3	O	drug
(	(	(	O	O	NONE
LNG).	NN	lng).	O	O	NONE

YES

Sentence: DrugDDI.d20.s40
Hormonal	JJ	hormonal	O	O	NONE
contraceptives	NNS	contraceptive	O	O	NONE
Co-administration	NN	co-administration	O	O	NONE
of	IN	of	O	O	NONE
Trileptal	NN	trileptal	B-e0	T	drug
with	IN	with	O	O	NONE
an	DT	a	O	O	NONE
oral	JJ	oral	B-e1	O	drug
contraceptive	NN	contraceptive	I-e1	O	drug
has	VBZ	have	O	O	NONE
been	VBN	be	O	O	NONE
shown	VBN	show	O	O	NONE
to	TO	to	O	O	NONE
influence	VB	influence	O	O	NONE
the	DT	the	O	O	NONE
plasma	NN	plasma	O	O	NONE
concentrations	NNS	concentration	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
two	CD	two	O	O	NONE
hormonal	JJ	hormonal	O	O	NONE
components	NNS	component	O	O	NONE
,	,	,	O	O	NONE
ethinylestradiol	NN	ethinylestradiol	B-e2	T	drug
(	(	(	O	O	NONE
EE	NN	ee	O	O	NONE
)	)	)	O	O	NONE
and	CC	and	O	O	NONE
levonorgestrel	NN	levonorgestrel	B-e3	O	drug
(	(	(	O	O	NONE
LNG).	NN	lng).	O	O	NONE

NO

Sentence: DrugDDI.d20.s40
Hormonal	JJ	hormonal	O	O	NONE
contraceptives	NNS	contraceptive	O	O	NONE
Co-administration	NN	co-administration	O	O	NONE
of	IN	of	O	O	NONE
Trileptal	NN	trileptal	B-e0	T	drug
with	IN	with	O	O	NONE
an	DT	a	O	O	NONE
oral	JJ	oral	B-e1	O	drug
contraceptive	NN	contraceptive	I-e1	O	drug
has	VBZ	have	O	O	NONE
been	VBN	be	O	O	NONE
shown	VBN	show	O	O	NONE
to	TO	to	O	O	NONE
influence	VB	influence	O	O	NONE
the	DT	the	O	O	NONE
plasma	NN	plasma	O	O	NONE
concentrations	NNS	concentration	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
two	CD	two	O	O	NONE
hormonal	JJ	hormonal	O	O	NONE
components	NNS	component	O	O	NONE
,	,	,	O	O	NONE
ethinylestradiol	NN	ethinylestradiol	B-e2	O	drug
(	(	(	O	O	NONE
EE	NN	ee	O	O	NONE
)	)	)	O	O	NONE
and	CC	and	O	O	NONE
levonorgestrel	NN	levonorgestrel	B-e3	T	drug
(	(	(	O	O	NONE
LNG).	NN	lng).	O	O	NONE

NO

Sentence: DrugDDI.d20.s40
Hormonal	JJ	hormonal	O	O	NONE
contraceptives	NNS	contraceptive	O	O	NONE
Co-administration	NN	co-administration	O	O	NONE
of	IN	of	O	O	NONE
Trileptal	NN	trileptal	B-e0	O	drug
with	IN	with	O	O	NONE
an	DT	a	O	O	NONE
oral	JJ	oral	B-e1	T	drug
contraceptive	NN	contraceptive	I-e1	T	drug
has	VBZ	have	O	O	NONE
been	VBN	be	O	O	NONE
shown	VBN	show	O	O	NONE
to	TO	to	O	O	NONE
influence	VB	influence	O	O	NONE
the	DT	the	O	O	NONE
plasma	NN	plasma	O	O	NONE
concentrations	NNS	concentration	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
two	CD	two	O	O	NONE
hormonal	JJ	hormonal	O	O	NONE
components	NNS	component	O	O	NONE
,	,	,	O	O	NONE
ethinylestradiol	NN	ethinylestradiol	B-e2	T	drug
(	(	(	O	O	NONE
EE	NN	ee	O	O	NONE
)	)	)	O	O	NONE
and	CC	and	O	O	NONE
levonorgestrel	NN	levonorgestrel	B-e3	O	drug
(	(	(	O	O	NONE
LNG).	NN	lng).	O	O	NONE

NO

Sentence: DrugDDI.d20.s40
Hormonal	JJ	hormonal	O	O	NONE
contraceptives	NNS	contraceptive	O	O	NONE
Co-administration	NN	co-administration	O	O	NONE
of	IN	of	O	O	NONE
Trileptal	NN	trileptal	B-e0	O	drug
with	IN	with	O	O	NONE
an	DT	a	O	O	NONE
oral	JJ	oral	B-e1	T	drug
contraceptive	NN	contraceptive	I-e1	T	drug
has	VBZ	have	O	O	NONE
been	VBN	be	O	O	NONE
shown	VBN	show	O	O	NONE
to	TO	to	O	O	NONE
influence	VB	influence	O	O	NONE
the	DT	the	O	O	NONE
plasma	NN	plasma	O	O	NONE
concentrations	NNS	concentration	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
two	CD	two	O	O	NONE
hormonal	JJ	hormonal	O	O	NONE
components	NNS	component	O	O	NONE
,	,	,	O	O	NONE
ethinylestradiol	NN	ethinylestradiol	B-e2	O	drug
(	(	(	O	O	NONE
EE	NN	ee	O	O	NONE
)	)	)	O	O	NONE
and	CC	and	O	O	NONE
levonorgestrel	NN	levonorgestrel	B-e3	T	drug
(	(	(	O	O	NONE
LNG).	NN	lng).	O	O	NONE

NO

Sentence: DrugDDI.d20.s40
Hormonal	JJ	hormonal	O	O	NONE
contraceptives	NNS	contraceptive	O	O	NONE
Co-administration	NN	co-administration	O	O	NONE
of	IN	of	O	O	NONE
Trileptal	NN	trileptal	B-e0	O	drug
with	IN	with	O	O	NONE
an	DT	a	O	O	NONE
oral	JJ	oral	B-e1	O	drug
contraceptive	NN	contraceptive	I-e1	O	drug
has	VBZ	have	O	O	NONE
been	VBN	be	O	O	NONE
shown	VBN	show	O	O	NONE
to	TO	to	O	O	NONE
influence	VB	influence	O	O	NONE
the	DT	the	O	O	NONE
plasma	NN	plasma	O	O	NONE
concentrations	NNS	concentration	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
two	CD	two	O	O	NONE
hormonal	JJ	hormonal	O	O	NONE
components	NNS	component	O	O	NONE
,	,	,	O	O	NONE
ethinylestradiol	NN	ethinylestradiol	B-e2	T	drug
(	(	(	O	O	NONE
EE	NN	ee	O	O	NONE
)	)	)	O	O	NONE
and	CC	and	O	O	NONE
levonorgestrel	NN	levonorgestrel	B-e3	T	drug
(	(	(	O	O	NONE
LNG).	NN	lng).	O	O	NONE

NO

Sentence: DrugDDI.d20.s43
Therefore	RB	therefore	O	O	NONE
,	,	,	O	O	NONE
concurrent	JJ	concurrent	O	O	NONE
use	NN	use	O	O	NONE
of	IN	of	O	O	NONE
Trileptal	NN	trileptal	B-e0	T	drug
with	IN	with	O	O	NONE
hormonal	JJ	hormonal	O	O	NONE
contraceptives	NNS	contraceptive	B-e1	T	drug
may	MD	may	O	O	NONE
render	VB	render	O	O	NONE
these	DT	these	O	O	NONE
contraceptives	NNS	contraceptive	B-e2	O	drug
less	RBR	less	O	O	NONE
effective	JJ	effective	O	O	NONE
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d20.s43
Therefore	RB	therefore	O	O	NONE
,	,	,	O	O	NONE
concurrent	JJ	concurrent	O	O	NONE
use	NN	use	O	O	NONE
of	IN	of	O	O	NONE
Trileptal	NN	trileptal	B-e0	T	drug
with	IN	with	O	O	NONE
hormonal	JJ	hormonal	O	O	NONE
contraceptives	NNS	contraceptive	B-e1	O	drug
may	MD	may	O	O	NONE
render	VB	render	O	O	NONE
these	DT	these	O	O	NONE
contraceptives	NNS	contraceptive	B-e2	T	drug
less	RBR	less	O	O	NONE
effective	JJ	effective	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s43
Therefore	RB	therefore	O	O	NONE
,	,	,	O	O	NONE
concurrent	JJ	concurrent	O	O	NONE
use	NN	use	O	O	NONE
of	IN	of	O	O	NONE
Trileptal	NN	trileptal	B-e0	O	drug
with	IN	with	O	O	NONE
hormonal	JJ	hormonal	O	O	NONE
contraceptives	NNS	contraceptive	B-e1	T	drug
may	MD	may	O	O	NONE
render	VB	render	O	O	NONE
these	DT	these	O	O	NONE
contraceptives	NNS	contraceptive	B-e2	T	drug
less	RBR	less	O	O	NONE
effective	JJ	effective	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s45
Calcium	NN	calcium	B-e0	T	drug
Antagonist	NN	antagonist	I-e0	T	drug
s	NN	s	O	O	NONE
After	IN	after	O	O	NONE
repeated	JJ	repeated	O	O	NONE
co-administration	NN	co-administration	O	O	NONE
of	IN	of	O	O	NONE
Trileptal	NN	trileptal	B-e1	T	drug
,	,	,	O	O	NONE
the	DT	the	O	O	NONE
AUC	NN	auc	O	O	NONE
of	IN	of	O	O	NONE
felodipine	NN	felodipine	B-e2	O	drug
was	VBD	be	O	O	NONE
lowered	VBN	lower	O	O	NONE
by	IN	by	O	O	NONE
28	CD	28	O	O	NONE
%	NN	%	O	O	NONE
[90	CD	[90	O	O	NONE
%	NN	%	O	O	NONE
CI	NN	ci	O	O	NONE
:	:	:	O	O	NONE
20-33	CD	20-33	O	O	NONE
].	NN	].	O	O	NONE

NO

Sentence: DrugDDI.d20.s45
Calcium	NN	calcium	B-e0	T	drug
Antagonist	NN	antagonist	I-e0	T	drug
s	NN	s	O	O	NONE
After	IN	after	O	O	NONE
repeated	JJ	repeated	O	O	NONE
co-administration	NN	co-administration	O	O	NONE
of	IN	of	O	O	NONE
Trileptal	NN	trileptal	B-e1	O	drug
,	,	,	O	O	NONE
the	DT	the	O	O	NONE
AUC	NN	auc	O	O	NONE
of	IN	of	O	O	NONE
felodipine	NN	felodipine	B-e2	T	drug
was	VBD	be	O	O	NONE
lowered	VBN	lower	O	O	NONE
by	IN	by	O	O	NONE
28	CD	28	O	O	NONE
%	NN	%	O	O	NONE
[90	CD	[90	O	O	NONE
%	NN	%	O	O	NONE
CI	NN	ci	O	O	NONE
:	:	:	O	O	NONE
20-33	CD	20-33	O	O	NONE
].	NN	].	O	O	NONE

NO

Sentence: DrugDDI.d20.s45
Calcium	NN	calcium	B-e0	O	drug
Antagonist	NN	antagonist	I-e0	O	drug
s	NN	s	O	O	NONE
After	IN	after	O	O	NONE
repeated	JJ	repeated	O	O	NONE
co-administration	NN	co-administration	O	O	NONE
of	IN	of	O	O	NONE
Trileptal	NN	trileptal	B-e1	T	drug
,	,	,	O	O	NONE
the	DT	the	O	O	NONE
AUC	NN	auc	O	O	NONE
of	IN	of	O	O	NONE
felodipine	NN	felodipine	B-e2	T	drug
was	VBD	be	O	O	NONE
lowered	VBN	lower	O	O	NONE
by	IN	by	O	O	NONE
28	CD	28	O	O	NONE
%	NN	%	O	O	NONE
[90	CD	[90	O	O	NONE
%	NN	%	O	O	NONE
CI	NN	ci	O	O	NONE
:	:	:	O	O	NONE
20-33	CD	20-33	O	O	NONE
].	NN	].	O	O	NONE

YES

Sentence: DrugDDI.d20.s47
Other	JJ	other	O	O	NONE
drug	NN	drug	O	O	NONE
interactions	NNS	interaction	O	O	NONE
Cimetidine	NN	cimetidine	B-e0	T	drug
,	,	,	O	O	NONE
erythromycin	NN	erythromycin	B-e1	T	drug
and	CC	and	O	O	NONE
dextropropoxyphene	NN	dextropropoxyphene	B-e2	O	drug
had	VBD	have	O	O	NONE
no	DT	no	O	O	NONE
effect	NN	effect	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
pharmacokinetics	NNS	pharmacokinetic	O	O	NONE
of	IN	of	O	O	NONE
MHD	NN	mhd	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s47
Other	JJ	other	O	O	NONE
drug	NN	drug	O	O	NONE
interactions	NNS	interaction	O	O	NONE
Cimetidine	NN	cimetidine	B-e0	T	drug
,	,	,	O	O	NONE
erythromycin	NN	erythromycin	B-e1	O	drug
and	CC	and	O	O	NONE
dextropropoxyphene	NN	dextropropoxyphene	B-e2	T	drug
had	VBD	have	O	O	NONE
no	DT	no	O	O	NONE
effect	NN	effect	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
pharmacokinetics	NNS	pharmacokinetic	O	O	NONE
of	IN	of	O	O	NONE
MHD	NN	mhd	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s47
Other	JJ	other	O	O	NONE
drug	NN	drug	O	O	NONE
interactions	NNS	interaction	O	O	NONE
Cimetidine	NN	cimetidine	B-e0	O	drug
,	,	,	O	O	NONE
erythromycin	NN	erythromycin	B-e1	T	drug
and	CC	and	O	O	NONE
dextropropoxyphene	NN	dextropropoxyphene	B-e2	T	drug
had	VBD	have	O	O	NONE
no	DT	no	O	O	NONE
effect	NN	effect	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
pharmacokinetics	NNS	pharmacokinetic	O	O	NONE
of	IN	of	O	O	NONE
MHD	NN	mhd	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d20.s48
Results	NNS	result	O	O	NONE
with	IN	with	O	O	NONE
warfarin	NN	warfarin	B-e0	T	drug
wshow	VBP	wshow	O	O	NONE
no	DT	no	O	O	NONE
evidence	NN	evidence	O	O	NONE
of	IN	of	O	O	NONE
interaction	NN	interaction	O	O	NONE
with	IN	with	O	O	NONE
either	CC	either	O	O	NONE
single	JJ	single	O	O	NONE
or	CC	or	O	O	NONE
repeated	JJ	repeated	O	O	NONE
doses	NNS	dose	O	O	NONE
of	IN	of	O	O	NONE
Trileptal	NN	trileptal	B-e1	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d480.s0
In	IN	in	O	O	NONE
a	DT	a	O	O	NONE
Phase	NN	phase	O	O	NONE
:	:	:	O	O	NONE
I	NN	i	O	O	NONE
trial	NN	trial	O	O	NONE
using	VBG	use	O	O	NONE
escalating	JJ	escalating	O	O	NONE
doses	NNS	dose	O	O	NONE
of	IN	of	O	O	NONE
TAXOL	NN	taxol	B-e0	T	drug
(	(	(	O	O	NONE
110-200	CD	110-200	O	O	NONE
mg/m2	NN	mg/m2	O	O	NONE
)	)	)	O	O	NONE
and	CC	and	O	O	NONE
cisplatin	NN	cisplatin	B-e1	T	drug
(	(	(	O	O	NONE
50	CD	50	O	O	NONE
or	CC	or	O	O	NONE
75	CD	75	O	O	NONE
mg/m2	NN	mg/m2	O	O	NONE
)	)	)	O	O	NONE
given	VBN	give	O	O	NONE
as	IN	as	O	O	NONE
sequential	JJ	sequential	O	O	NONE
infusions	NNS	infusion	O	O	NONE
,	,	,	O	O	NONE
myelosuppression	NN	myelosuppression	O	O	NONE
was	VBD	be	O	O	NONE
more	RBR	more	O	O	NONE
profound	JJ	profound	O	O	NONE
when	WRB	when	O	O	NONE
TAXOL	NN	taxol	B-e2	O	drug
was	VBD	be	O	O	NONE
given	VBN	give	O	O	NONE
after	IN	after	O	O	NONE
cisplatin	NN	cisplatin	B-e3	O	drug
than	IN	than	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
alternate	JJ	alternate	O	O	NONE
sequence	NN	sequence	O	O	NONE
(	(	(	O	O	NONE
ie	FW	ie	O	O	NONE
,	,	,	O	O	NONE
TAXOL	NN	taxol	B-e4	O	drug
before	IN	before	O	O	NONE
cisplatin	NN	cisplatin	B-e5	O	drug
)	)	)	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d480.s0
In	IN	in	O	O	NONE
a	DT	a	O	O	NONE
Phase	NN	phase	O	O	NONE
:	:	:	O	O	NONE
I	NN	i	O	O	NONE
trial	NN	trial	O	O	NONE
using	VBG	use	O	O	NONE
escalating	JJ	escalating	O	O	NONE
doses	NNS	dose	O	O	NONE
of	IN	of	O	O	NONE
TAXOL	NN	taxol	B-e0	T	drug
(	(	(	O	O	NONE
110-200	CD	110-200	O	O	NONE
mg/m2	NN	mg/m2	O	O	NONE
)	)	)	O	O	NONE
and	CC	and	O	O	NONE
cisplatin	NN	cisplatin	B-e1	O	drug
(	(	(	O	O	NONE
50	CD	50	O	O	NONE
or	CC	or	O	O	NONE
75	CD	75	O	O	NONE
mg/m2	NN	mg/m2	O	O	NONE
)	)	)	O	O	NONE
given	VBN	give	O	O	NONE
as	IN	as	O	O	NONE
sequential	JJ	sequential	O	O	NONE
infusions	NNS	infusion	O	O	NONE
,	,	,	O	O	NONE
myelosuppression	NN	myelosuppression	O	O	NONE
was	VBD	be	O	O	NONE
more	RBR	more	O	O	NONE
profound	JJ	profound	O	O	NONE
when	WRB	when	O	O	NONE
TAXOL	NN	taxol	B-e2	T	drug
was	VBD	be	O	O	NONE
given	VBN	give	O	O	NONE
after	IN	after	O	O	NONE
cisplatin	NN	cisplatin	B-e3	O	drug
than	IN	than	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
alternate	JJ	alternate	O	O	NONE
sequence	NN	sequence	O	O	NONE
(	(	(	O	O	NONE
ie	FW	ie	O	O	NONE
,	,	,	O	O	NONE
TAXOL	NN	taxol	B-e4	O	drug
before	IN	before	O	O	NONE
cisplatin	NN	cisplatin	B-e5	O	drug
)	)	)	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d480.s0
In	IN	in	O	O	NONE
a	DT	a	O	O	NONE
Phase	NN	phase	O	O	NONE
:	:	:	O	O	NONE
I	NN	i	O	O	NONE
trial	NN	trial	O	O	NONE
using	VBG	use	O	O	NONE
escalating	JJ	escalating	O	O	NONE
doses	NNS	dose	O	O	NONE
of	IN	of	O	O	NONE
TAXOL	NN	taxol	B-e0	T	drug
(	(	(	O	O	NONE
110-200	CD	110-200	O	O	NONE
mg/m2	NN	mg/m2	O	O	NONE
)	)	)	O	O	NONE
and	CC	and	O	O	NONE
cisplatin	NN	cisplatin	B-e1	O	drug
(	(	(	O	O	NONE
50	CD	50	O	O	NONE
or	CC	or	O	O	NONE
75	CD	75	O	O	NONE
mg/m2	NN	mg/m2	O	O	NONE
)	)	)	O	O	NONE
given	VBN	give	O	O	NONE
as	IN	as	O	O	NONE
sequential	JJ	sequential	O	O	NONE
infusions	NNS	infusion	O	O	NONE
,	,	,	O	O	NONE
myelosuppression	NN	myelosuppression	O	O	NONE
was	VBD	be	O	O	NONE
more	RBR	more	O	O	NONE
profound	JJ	profound	O	O	NONE
when	WRB	when	O	O	NONE
TAXOL	NN	taxol	B-e2	O	drug
was	VBD	be	O	O	NONE
given	VBN	give	O	O	NONE
after	IN	after	O	O	NONE
cisplatin	NN	cisplatin	B-e3	T	drug
than	IN	than	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
alternate	JJ	alternate	O	O	NONE
sequence	NN	sequence	O	O	NONE
(	(	(	O	O	NONE
ie	FW	ie	O	O	NONE
,	,	,	O	O	NONE
TAXOL	NN	taxol	B-e4	O	drug
before	IN	before	O	O	NONE
cisplatin	NN	cisplatin	B-e5	O	drug
)	)	)	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d480.s0
In	IN	in	O	O	NONE
a	DT	a	O	O	NONE
Phase	NN	phase	O	O	NONE
:	:	:	O	O	NONE
I	NN	i	O	O	NONE
trial	NN	trial	O	O	NONE
using	VBG	use	O	O	NONE
escalating	JJ	escalating	O	O	NONE
doses	NNS	dose	O	O	NONE
of	IN	of	O	O	NONE
TAXOL	NN	taxol	B-e0	T	drug
(	(	(	O	O	NONE
110-200	CD	110-200	O	O	NONE
mg/m2	NN	mg/m2	O	O	NONE
)	)	)	O	O	NONE
and	CC	and	O	O	NONE
cisplatin	NN	cisplatin	B-e1	O	drug
(	(	(	O	O	NONE
50	CD	50	O	O	NONE
or	CC	or	O	O	NONE
75	CD	75	O	O	NONE
mg/m2	NN	mg/m2	O	O	NONE
)	)	)	O	O	NONE
given	VBN	give	O	O	NONE
as	IN	as	O	O	NONE
sequential	JJ	sequential	O	O	NONE
infusions	NNS	infusion	O	O	NONE
,	,	,	O	O	NONE
myelosuppression	NN	myelosuppression	O	O	NONE
was	VBD	be	O	O	NONE
more	RBR	more	O	O	NONE
profound	JJ	profound	O	O	NONE
when	WRB	when	O	O	NONE
TAXOL	NN	taxol	B-e2	O	drug
was	VBD	be	O	O	NONE
given	VBN	give	O	O	NONE
after	IN	after	O	O	NONE
cisplatin	NN	cisplatin	B-e3	O	drug
than	IN	than	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
alternate	JJ	alternate	O	O	NONE
sequence	NN	sequence	O	O	NONE
(	(	(	O	O	NONE
ie	FW	ie	O	O	NONE
,	,	,	O	O	NONE
TAXOL	NN	taxol	B-e4	T	drug
before	IN	before	O	O	NONE
cisplatin	NN	cisplatin	B-e5	O	drug
)	)	)	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d480.s0
In	IN	in	O	O	NONE
a	DT	a	O	O	NONE
Phase	NN	phase	O	O	NONE
:	:	:	O	O	NONE
I	NN	i	O	O	NONE
trial	NN	trial	O	O	NONE
using	VBG	use	O	O	NONE
escalating	JJ	escalating	O	O	NONE
doses	NNS	dose	O	O	NONE
of	IN	of	O	O	NONE
TAXOL	NN	taxol	B-e0	T	drug
(	(	(	O	O	NONE
110-200	CD	110-200	O	O	NONE
mg/m2	NN	mg/m2	O	O	NONE
)	)	)	O	O	NONE
and	CC	and	O	O	NONE
cisplatin	NN	cisplatin	B-e1	O	drug
(	(	(	O	O	NONE
50	CD	50	O	O	NONE
or	CC	or	O	O	NONE
75	CD	75	O	O	NONE
mg/m2	NN	mg/m2	O	O	NONE
)	)	)	O	O	NONE
given	VBN	give	O	O	NONE
as	IN	as	O	O	NONE
sequential	JJ	sequential	O	O	NONE
infusions	NNS	infusion	O	O	NONE
,	,	,	O	O	NONE
myelosuppression	NN	myelosuppression	O	O	NONE
was	VBD	be	O	O	NONE
more	RBR	more	O	O	NONE
profound	JJ	profound	O	O	NONE
when	WRB	when	O	O	NONE
TAXOL	NN	taxol	B-e2	O	drug
was	VBD	be	O	O	NONE
given	VBN	give	O	O	NONE
after	IN	after	O	O	NONE
cisplatin	NN	cisplatin	B-e3	O	drug
than	IN	than	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
alternate	JJ	alternate	O	O	NONE
sequence	NN	sequence	O	O	NONE
(	(	(	O	O	NONE
ie	FW	ie	O	O	NONE
,	,	,	O	O	NONE
TAXOL	NN	taxol	B-e4	O	drug
before	IN	before	O	O	NONE
cisplatin	NN	cisplatin	B-e5	T	drug
)	)	)	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d480.s0
In	IN	in	O	O	NONE
a	DT	a	O	O	NONE
Phase	NN	phase	O	O	NONE
:	:	:	O	O	NONE
I	NN	i	O	O	NONE
trial	NN	trial	O	O	NONE
using	VBG	use	O	O	NONE
escalating	JJ	escalating	O	O	NONE
doses	NNS	dose	O	O	NONE
of	IN	of	O	O	NONE
TAXOL	NN	taxol	B-e0	O	drug
(	(	(	O	O	NONE
110-200	CD	110-200	O	O	NONE
mg/m2	NN	mg/m2	O	O	NONE
)	)	)	O	O	NONE
and	CC	and	O	O	NONE
cisplatin	NN	cisplatin	B-e1	T	drug
(	(	(	O	O	NONE
50	CD	50	O	O	NONE
or	CC	or	O	O	NONE
75	CD	75	O	O	NONE
mg/m2	NN	mg/m2	O	O	NONE
)	)	)	O	O	NONE
given	VBN	give	O	O	NONE
as	IN	as	O	O	NONE
sequential	JJ	sequential	O	O	NONE
infusions	NNS	infusion	O	O	NONE
,	,	,	O	O	NONE
myelosuppression	NN	myelosuppression	O	O	NONE
was	VBD	be	O	O	NONE
more	RBR	more	O	O	NONE
profound	JJ	profound	O	O	NONE
when	WRB	when	O	O	NONE
TAXOL	NN	taxol	B-e2	T	drug
was	VBD	be	O	O	NONE
given	VBN	give	O	O	NONE
after	IN	after	O	O	NONE
cisplatin	NN	cisplatin	B-e3	O	drug
than	IN	than	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
alternate	JJ	alternate	O	O	NONE
sequence	NN	sequence	O	O	NONE
(	(	(	O	O	NONE
ie	FW	ie	O	O	NONE
,	,	,	O	O	NONE
TAXOL	NN	taxol	B-e4	O	drug
before	IN	before	O	O	NONE
cisplatin	NN	cisplatin	B-e5	O	drug
)	)	)	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d480.s0
In	IN	in	O	O	NONE
a	DT	a	O	O	NONE
Phase	NN	phase	O	O	NONE
:	:	:	O	O	NONE
I	NN	i	O	O	NONE
trial	NN	trial	O	O	NONE
using	VBG	use	O	O	NONE
escalating	JJ	escalating	O	O	NONE
doses	NNS	dose	O	O	NONE
of	IN	of	O	O	NONE
TAXOL	NN	taxol	B-e0	O	drug
(	(	(	O	O	NONE
110-200	CD	110-200	O	O	NONE
mg/m2	NN	mg/m2	O	O	NONE
)	)	)	O	O	NONE
and	CC	and	O	O	NONE
cisplatin	NN	cisplatin	B-e1	T	drug
(	(	(	O	O	NONE
50	CD	50	O	O	NONE
or	CC	or	O	O	NONE
75	CD	75	O	O	NONE
mg/m2	NN	mg/m2	O	O	NONE
)	)	)	O	O	NONE
given	VBN	give	O	O	NONE
as	IN	as	O	O	NONE
sequential	JJ	sequential	O	O	NONE
infusions	NNS	infusion	O	O	NONE
,	,	,	O	O	NONE
myelosuppression	NN	myelosuppression	O	O	NONE
was	VBD	be	O	O	NONE
more	RBR	more	O	O	NONE
profound	JJ	profound	O	O	NONE
when	WRB	when	O	O	NONE
TAXOL	NN	taxol	B-e2	O	drug
was	VBD	be	O	O	NONE
given	VBN	give	O	O	NONE
after	IN	after	O	O	NONE
cisplatin	NN	cisplatin	B-e3	T	drug
than	IN	than	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
alternate	JJ	alternate	O	O	NONE
sequence	NN	sequence	O	O	NONE
(	(	(	O	O	NONE
ie	FW	ie	O	O	NONE
,	,	,	O	O	NONE
TAXOL	NN	taxol	B-e4	O	drug
before	IN	before	O	O	NONE
cisplatin	NN	cisplatin	B-e5	O	drug
)	)	)	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d480.s0
In	IN	in	O	O	NONE
a	DT	a	O	O	NONE
Phase	NN	phase	O	O	NONE
:	:	:	O	O	NONE
I	NN	i	O	O	NONE
trial	NN	trial	O	O	NONE
using	VBG	use	O	O	NONE
escalating	JJ	escalating	O	O	NONE
doses	NNS	dose	O	O	NONE
of	IN	of	O	O	NONE
TAXOL	NN	taxol	B-e0	O	drug
(	(	(	O	O	NONE
110-200	CD	110-200	O	O	NONE
mg/m2	NN	mg/m2	O	O	NONE
)	)	)	O	O	NONE
and	CC	and	O	O	NONE
cisplatin	NN	cisplatin	B-e1	T	drug
(	(	(	O	O	NONE
50	CD	50	O	O	NONE
or	CC	or	O	O	NONE
75	CD	75	O	O	NONE
mg/m2	NN	mg/m2	O	O	NONE
)	)	)	O	O	NONE
given	VBN	give	O	O	NONE
as	IN	as	O	O	NONE
sequential	JJ	sequential	O	O	NONE
infusions	NNS	infusion	O	O	NONE
,	,	,	O	O	NONE
myelosuppression	NN	myelosuppression	O	O	NONE
was	VBD	be	O	O	NONE
more	RBR	more	O	O	NONE
profound	JJ	profound	O	O	NONE
when	WRB	when	O	O	NONE
TAXOL	NN	taxol	B-e2	O	drug
was	VBD	be	O	O	NONE
given	VBN	give	O	O	NONE
after	IN	after	O	O	NONE
cisplatin	NN	cisplatin	B-e3	O	drug
than	IN	than	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
alternate	JJ	alternate	O	O	NONE
sequence	NN	sequence	O	O	NONE
(	(	(	O	O	NONE
ie	FW	ie	O	O	NONE
,	,	,	O	O	NONE
TAXOL	NN	taxol	B-e4	T	drug
before	IN	before	O	O	NONE
cisplatin	NN	cisplatin	B-e5	O	drug
)	)	)	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d480.s0
In	IN	in	O	O	NONE
a	DT	a	O	O	NONE
Phase	NN	phase	O	O	NONE
:	:	:	O	O	NONE
I	NN	i	O	O	NONE
trial	NN	trial	O	O	NONE
using	VBG	use	O	O	NONE
escalating	JJ	escalating	O	O	NONE
doses	NNS	dose	O	O	NONE
of	IN	of	O	O	NONE
TAXOL	NN	taxol	B-e0	O	drug
(	(	(	O	O	NONE
110-200	CD	110-200	O	O	NONE
mg/m2	NN	mg/m2	O	O	NONE
)	)	)	O	O	NONE
and	CC	and	O	O	NONE
cisplatin	NN	cisplatin	B-e1	T	drug
(	(	(	O	O	NONE
50	CD	50	O	O	NONE
or	CC	or	O	O	NONE
75	CD	75	O	O	NONE
mg/m2	NN	mg/m2	O	O	NONE
)	)	)	O	O	NONE
given	VBN	give	O	O	NONE
as	IN	as	O	O	NONE
sequential	JJ	sequential	O	O	NONE
infusions	NNS	infusion	O	O	NONE
,	,	,	O	O	NONE
myelosuppression	NN	myelosuppression	O	O	NONE
was	VBD	be	O	O	NONE
more	RBR	more	O	O	NONE
profound	JJ	profound	O	O	NONE
when	WRB	when	O	O	NONE
TAXOL	NN	taxol	B-e2	O	drug
was	VBD	be	O	O	NONE
given	VBN	give	O	O	NONE
after	IN	after	O	O	NONE
cisplatin	NN	cisplatin	B-e3	O	drug
than	IN	than	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
alternate	JJ	alternate	O	O	NONE
sequence	NN	sequence	O	O	NONE
(	(	(	O	O	NONE
ie	FW	ie	O	O	NONE
,	,	,	O	O	NONE
TAXOL	NN	taxol	B-e4	O	drug
before	IN	before	O	O	NONE
cisplatin	NN	cisplatin	B-e5	T	drug
)	)	)	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d480.s0
In	IN	in	O	O	NONE
a	DT	a	O	O	NONE
Phase	NN	phase	O	O	NONE
:	:	:	O	O	NONE
I	NN	i	O	O	NONE
trial	NN	trial	O	O	NONE
using	VBG	use	O	O	NONE
escalating	JJ	escalating	O	O	NONE
doses	NNS	dose	O	O	NONE
of	IN	of	O	O	NONE
TAXOL	NN	taxol	B-e0	O	drug
(	(	(	O	O	NONE
110-200	CD	110-200	O	O	NONE
mg/m2	NN	mg/m2	O	O	NONE
)	)	)	O	O	NONE
and	CC	and	O	O	NONE
cisplatin	NN	cisplatin	B-e1	O	drug
(	(	(	O	O	NONE
50	CD	50	O	O	NONE
or	CC	or	O	O	NONE
75	CD	75	O	O	NONE
mg/m2	NN	mg/m2	O	O	NONE
)	)	)	O	O	NONE
given	VBN	give	O	O	NONE
as	IN	as	O	O	NONE
sequential	JJ	sequential	O	O	NONE
infusions	NNS	infusion	O	O	NONE
,	,	,	O	O	NONE
myelosuppression	NN	myelosuppression	O	O	NONE
was	VBD	be	O	O	NONE
more	RBR	more	O	O	NONE
profound	JJ	profound	O	O	NONE
when	WRB	when	O	O	NONE
TAXOL	NN	taxol	B-e2	T	drug
was	VBD	be	O	O	NONE
given	VBN	give	O	O	NONE
after	IN	after	O	O	NONE
cisplatin	NN	cisplatin	B-e3	T	drug
than	IN	than	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
alternate	JJ	alternate	O	O	NONE
sequence	NN	sequence	O	O	NONE
(	(	(	O	O	NONE
ie	FW	ie	O	O	NONE
,	,	,	O	O	NONE
TAXOL	NN	taxol	B-e4	O	drug
before	IN	before	O	O	NONE
cisplatin	NN	cisplatin	B-e5	O	drug
)	)	)	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d480.s0
In	IN	in	O	O	NONE
a	DT	a	O	O	NONE
Phase	NN	phase	O	O	NONE
:	:	:	O	O	NONE
I	NN	i	O	O	NONE
trial	NN	trial	O	O	NONE
using	VBG	use	O	O	NONE
escalating	JJ	escalating	O	O	NONE
doses	NNS	dose	O	O	NONE
of	IN	of	O	O	NONE
TAXOL	NN	taxol	B-e0	O	drug
(	(	(	O	O	NONE
110-200	CD	110-200	O	O	NONE
mg/m2	NN	mg/m2	O	O	NONE
)	)	)	O	O	NONE
and	CC	and	O	O	NONE
cisplatin	NN	cisplatin	B-e1	O	drug
(	(	(	O	O	NONE
50	CD	50	O	O	NONE
or	CC	or	O	O	NONE
75	CD	75	O	O	NONE
mg/m2	NN	mg/m2	O	O	NONE
)	)	)	O	O	NONE
given	VBN	give	O	O	NONE
as	IN	as	O	O	NONE
sequential	JJ	sequential	O	O	NONE
infusions	NNS	infusion	O	O	NONE
,	,	,	O	O	NONE
myelosuppression	NN	myelosuppression	O	O	NONE
was	VBD	be	O	O	NONE
more	RBR	more	O	O	NONE
profound	JJ	profound	O	O	NONE
when	WRB	when	O	O	NONE
TAXOL	NN	taxol	B-e2	T	drug
was	VBD	be	O	O	NONE
given	VBN	give	O	O	NONE
after	IN	after	O	O	NONE
cisplatin	NN	cisplatin	B-e3	O	drug
than	IN	than	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
alternate	JJ	alternate	O	O	NONE
sequence	NN	sequence	O	O	NONE
(	(	(	O	O	NONE
ie	FW	ie	O	O	NONE
,	,	,	O	O	NONE
TAXOL	NN	taxol	B-e4	T	drug
before	IN	before	O	O	NONE
cisplatin	NN	cisplatin	B-e5	O	drug
)	)	)	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d480.s0
In	IN	in	O	O	NONE
a	DT	a	O	O	NONE
Phase	NN	phase	O	O	NONE
:	:	:	O	O	NONE
I	NN	i	O	O	NONE
trial	NN	trial	O	O	NONE
using	VBG	use	O	O	NONE
escalating	JJ	escalating	O	O	NONE
doses	NNS	dose	O	O	NONE
of	IN	of	O	O	NONE
TAXOL	NN	taxol	B-e0	O	drug
(	(	(	O	O	NONE
110-200	CD	110-200	O	O	NONE
mg/m2	NN	mg/m2	O	O	NONE
)	)	)	O	O	NONE
and	CC	and	O	O	NONE
cisplatin	NN	cisplatin	B-e1	O	drug
(	(	(	O	O	NONE
50	CD	50	O	O	NONE
or	CC	or	O	O	NONE
75	CD	75	O	O	NONE
mg/m2	NN	mg/m2	O	O	NONE
)	)	)	O	O	NONE
given	VBN	give	O	O	NONE
as	IN	as	O	O	NONE
sequential	JJ	sequential	O	O	NONE
infusions	NNS	infusion	O	O	NONE
,	,	,	O	O	NONE
myelosuppression	NN	myelosuppression	O	O	NONE
was	VBD	be	O	O	NONE
more	RBR	more	O	O	NONE
profound	JJ	profound	O	O	NONE
when	WRB	when	O	O	NONE
TAXOL	NN	taxol	B-e2	T	drug
was	VBD	be	O	O	NONE
given	VBN	give	O	O	NONE
after	IN	after	O	O	NONE
cisplatin	NN	cisplatin	B-e3	O	drug
than	IN	than	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
alternate	JJ	alternate	O	O	NONE
sequence	NN	sequence	O	O	NONE
(	(	(	O	O	NONE
ie	FW	ie	O	O	NONE
,	,	,	O	O	NONE
TAXOL	NN	taxol	B-e4	O	drug
before	IN	before	O	O	NONE
cisplatin	NN	cisplatin	B-e5	T	drug
)	)	)	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d480.s0
In	IN	in	O	O	NONE
a	DT	a	O	O	NONE
Phase	NN	phase	O	O	NONE
:	:	:	O	O	NONE
I	NN	i	O	O	NONE
trial	NN	trial	O	O	NONE
using	VBG	use	O	O	NONE
escalating	JJ	escalating	O	O	NONE
doses	NNS	dose	O	O	NONE
of	IN	of	O	O	NONE
TAXOL	NN	taxol	B-e0	O	drug
(	(	(	O	O	NONE
110-200	CD	110-200	O	O	NONE
mg/m2	NN	mg/m2	O	O	NONE
)	)	)	O	O	NONE
and	CC	and	O	O	NONE
cisplatin	NN	cisplatin	B-e1	O	drug
(	(	(	O	O	NONE
50	CD	50	O	O	NONE
or	CC	or	O	O	NONE
75	CD	75	O	O	NONE
mg/m2	NN	mg/m2	O	O	NONE
)	)	)	O	O	NONE
given	VBN	give	O	O	NONE
as	IN	as	O	O	NONE
sequential	JJ	sequential	O	O	NONE
infusions	NNS	infusion	O	O	NONE
,	,	,	O	O	NONE
myelosuppression	NN	myelosuppression	O	O	NONE
was	VBD	be	O	O	NONE
more	RBR	more	O	O	NONE
profound	JJ	profound	O	O	NONE
when	WRB	when	O	O	NONE
TAXOL	NN	taxol	B-e2	O	drug
was	VBD	be	O	O	NONE
given	VBN	give	O	O	NONE
after	IN	after	O	O	NONE
cisplatin	NN	cisplatin	B-e3	T	drug
than	IN	than	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
alternate	JJ	alternate	O	O	NONE
sequence	NN	sequence	O	O	NONE
(	(	(	O	O	NONE
ie	FW	ie	O	O	NONE
,	,	,	O	O	NONE
TAXOL	NN	taxol	B-e4	T	drug
before	IN	before	O	O	NONE
cisplatin	NN	cisplatin	B-e5	O	drug
)	)	)	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d480.s0
In	IN	in	O	O	NONE
a	DT	a	O	O	NONE
Phase	NN	phase	O	O	NONE
:	:	:	O	O	NONE
I	NN	i	O	O	NONE
trial	NN	trial	O	O	NONE
using	VBG	use	O	O	NONE
escalating	JJ	escalating	O	O	NONE
doses	NNS	dose	O	O	NONE
of	IN	of	O	O	NONE
TAXOL	NN	taxol	B-e0	O	drug
(	(	(	O	O	NONE
110-200	CD	110-200	O	O	NONE
mg/m2	NN	mg/m2	O	O	NONE
)	)	)	O	O	NONE
and	CC	and	O	O	NONE
cisplatin	NN	cisplatin	B-e1	O	drug
(	(	(	O	O	NONE
50	CD	50	O	O	NONE
or	CC	or	O	O	NONE
75	CD	75	O	O	NONE
mg/m2	NN	mg/m2	O	O	NONE
)	)	)	O	O	NONE
given	VBN	give	O	O	NONE
as	IN	as	O	O	NONE
sequential	JJ	sequential	O	O	NONE
infusions	NNS	infusion	O	O	NONE
,	,	,	O	O	NONE
myelosuppression	NN	myelosuppression	O	O	NONE
was	VBD	be	O	O	NONE
more	RBR	more	O	O	NONE
profound	JJ	profound	O	O	NONE
when	WRB	when	O	O	NONE
TAXOL	NN	taxol	B-e2	O	drug
was	VBD	be	O	O	NONE
given	VBN	give	O	O	NONE
after	IN	after	O	O	NONE
cisplatin	NN	cisplatin	B-e3	T	drug
than	IN	than	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
alternate	JJ	alternate	O	O	NONE
sequence	NN	sequence	O	O	NONE
(	(	(	O	O	NONE
ie	FW	ie	O	O	NONE
,	,	,	O	O	NONE
TAXOL	NN	taxol	B-e4	O	drug
before	IN	before	O	O	NONE
cisplatin	NN	cisplatin	B-e5	T	drug
)	)	)	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d480.s0
In	IN	in	O	O	NONE
a	DT	a	O	O	NONE
Phase	NN	phase	O	O	NONE
:	:	:	O	O	NONE
I	NN	i	O	O	NONE
trial	NN	trial	O	O	NONE
using	VBG	use	O	O	NONE
escalating	JJ	escalating	O	O	NONE
doses	NNS	dose	O	O	NONE
of	IN	of	O	O	NONE
TAXOL	NN	taxol	B-e0	O	drug
(	(	(	O	O	NONE
110-200	CD	110-200	O	O	NONE
mg/m2	NN	mg/m2	O	O	NONE
)	)	)	O	O	NONE
and	CC	and	O	O	NONE
cisplatin	NN	cisplatin	B-e1	O	drug
(	(	(	O	O	NONE
50	CD	50	O	O	NONE
or	CC	or	O	O	NONE
75	CD	75	O	O	NONE
mg/m2	NN	mg/m2	O	O	NONE
)	)	)	O	O	NONE
given	VBN	give	O	O	NONE
as	IN	as	O	O	NONE
sequential	JJ	sequential	O	O	NONE
infusions	NNS	infusion	O	O	NONE
,	,	,	O	O	NONE
myelosuppression	NN	myelosuppression	O	O	NONE
was	VBD	be	O	O	NONE
more	RBR	more	O	O	NONE
profound	JJ	profound	O	O	NONE
when	WRB	when	O	O	NONE
TAXOL	NN	taxol	B-e2	O	drug
was	VBD	be	O	O	NONE
given	VBN	give	O	O	NONE
after	IN	after	O	O	NONE
cisplatin	NN	cisplatin	B-e3	O	drug
than	IN	than	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
alternate	JJ	alternate	O	O	NONE
sequence	NN	sequence	O	O	NONE
(	(	(	O	O	NONE
ie	FW	ie	O	O	NONE
,	,	,	O	O	NONE
TAXOL	NN	taxol	B-e4	T	drug
before	IN	before	O	O	NONE
cisplatin	NN	cisplatin	B-e5	T	drug
)	)	)	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d480.s1
Pharmacokinetic	JJ	pharmacokinetic	O	O	NONE
data	NNS	datum	O	O	NONE
from	IN	from	O	O	NONE
these	DT	these	O	O	NONE
patients	NNS	patient	O	O	NONE
demonstrated	VBD	demonstrate	O	O	NONE
a	DT	a	O	O	NONE
decrease	NN	decrease	O	O	NONE
in	IN	in	O	O	NONE
paclitaxel	NN	paclitaxel	B-e0	T	drug
clearance	NN	clearance	O	O	NONE
of	IN	of	O	O	NONE
approximately	RB	approximately	O	O	NONE
33	CD	33	O	O	NONE
%	NN	%	O	O	NONE
when	WRB	when	O	O	NONE
TAXOL	NN	taxol	B-e1	T	drug
was	VBD	be	O	O	NONE
administered	VBN	administer	O	O	NONE
following	VBG	follow	O	O	NONE
cisplatin	NN	cisplatin	B-e2	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d480.s1
Pharmacokinetic	JJ	pharmacokinetic	O	O	NONE
data	NNS	datum	O	O	NONE
from	IN	from	O	O	NONE
these	DT	these	O	O	NONE
patients	NNS	patient	O	O	NONE
demonstrated	VBD	demonstrate	O	O	NONE
a	DT	a	O	O	NONE
decrease	NN	decrease	O	O	NONE
in	IN	in	O	O	NONE
paclitaxel	NN	paclitaxel	B-e0	T	drug
clearance	NN	clearance	O	O	NONE
of	IN	of	O	O	NONE
approximately	RB	approximately	O	O	NONE
33	CD	33	O	O	NONE
%	NN	%	O	O	NONE
when	WRB	when	O	O	NONE
TAXOL	NN	taxol	B-e1	O	drug
was	VBD	be	O	O	NONE
administered	VBN	administer	O	O	NONE
following	VBG	follow	O	O	NONE
cisplatin	NN	cisplatin	B-e2	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d480.s1
Pharmacokinetic	JJ	pharmacokinetic	O	O	NONE
data	NNS	datum	O	O	NONE
from	IN	from	O	O	NONE
these	DT	these	O	O	NONE
patients	NNS	patient	O	O	NONE
demonstrated	VBD	demonstrate	O	O	NONE
a	DT	a	O	O	NONE
decrease	NN	decrease	O	O	NONE
in	IN	in	O	O	NONE
paclitaxel	NN	paclitaxel	B-e0	O	drug
clearance	NN	clearance	O	O	NONE
of	IN	of	O	O	NONE
approximately	RB	approximately	O	O	NONE
33	CD	33	O	O	NONE
%	NN	%	O	O	NONE
when	WRB	when	O	O	NONE
TAXOL	NN	taxol	B-e1	T	drug
was	VBD	be	O	O	NONE
administered	VBN	administer	O	O	NONE
following	VBG	follow	O	O	NONE
cisplatin	NN	cisplatin	B-e2	T	drug
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d480.s2
The	DT	the	O	O	NONE
metabolism	NN	metabolism	O	O	NONE
of	IN	of	O	O	NONE
TAXOL	NN	taxol	B-e0	T	drug
is	VBZ	be	O	O	NONE
catalyzed	VBN	catalyze	O	O	NONE
by	IN	by	O	O	NONE
cytochrome	NN	cytochrome	B-e1	T	drug
P450	NN	p450	I-e1	T	drug
isoen-zymes	NNS	isoen-zyme	O	O	NONE
CYP2C8	NN	cyp2c8	O	O	NONE
and	CC	and	O	O	NONE
CYP3A4	NN	cyp3a4	B-e2	O	drug
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d480.s2
The	DT	the	O	O	NONE
metabolism	NN	metabolism	O	O	NONE
of	IN	of	O	O	NONE
TAXOL	NN	taxol	B-e0	T	drug
is	VBZ	be	O	O	NONE
catalyzed	VBN	catalyze	O	O	NONE
by	IN	by	O	O	NONE
cytochrome	NN	cytochrome	B-e1	O	drug
P450	NN	p450	I-e1	O	drug
isoen-zymes	NNS	isoen-zyme	O	O	NONE
CYP2C8	NN	cyp2c8	O	O	NONE
and	CC	and	O	O	NONE
CYP3A4	NN	cyp3a4	B-e2	T	drug
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d480.s2
The	DT	the	O	O	NONE
metabolism	NN	metabolism	O	O	NONE
of	IN	of	O	O	NONE
TAXOL	NN	taxol	B-e0	O	drug
is	VBZ	be	O	O	NONE
catalyzed	VBN	catalyze	O	O	NONE
by	IN	by	O	O	NONE
cytochrome	NN	cytochrome	B-e1	T	drug
P450	NN	p450	I-e1	T	drug
isoen-zymes	NNS	isoen-zyme	O	O	NONE
CYP2C8	NN	cyp2c8	O	O	NONE
and	CC	and	O	O	NONE
CYP3A4	NN	cyp3a4	B-e2	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d480.s3
In	IN	in	O	O	NONE
the	DT	the	O	O	NONE
absence	NN	absence	O	O	NONE
of	IN	of	O	O	NONE
formal	JJ	formal	O	O	NONE
clinical	JJ	clinical	O	O	NONE
drug	NN	drug	O	O	NONE
interaction	NN	interaction	O	O	NONE
studies	NNS	study	O	O	NONE
,	,	,	O	O	NONE
caution	NN	caution	O	O	NONE
should	MD	should	O	O	NONE
be	VB	be	O	O	NONE
exercised	VBN	exercise	O	O	NONE
when	WRB	when	O	O	NONE
administering	VBG	administer	O	O	NONE
TAXOL	NN	taxol	B-e0	T	drug
concomitantly	RB	concomitantly	O	O	NONE
with	IN	with	O	O	NONE
known	JJ	known	O	O	NONE
substrates	NNS	substrate	O	O	NONE
or	CC	or	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
cytochrome	NN	cytochrome	B-e1	T	drug
P450	NN	p450	I-e1	T	drug
isoenzymes	NNS	isoenzyme	O	O	NONE
CYP2C8	NN	cyp2c8	O	O	NONE
and	CC	and	O	O	NONE
CYP3A4	NN	cyp3a4	B-e2	O	drug
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d480.s3
In	IN	in	O	O	NONE
the	DT	the	O	O	NONE
absence	NN	absence	O	O	NONE
of	IN	of	O	O	NONE
formal	JJ	formal	O	O	NONE
clinical	JJ	clinical	O	O	NONE
drug	NN	drug	O	O	NONE
interaction	NN	interaction	O	O	NONE
studies	NNS	study	O	O	NONE
,	,	,	O	O	NONE
caution	NN	caution	O	O	NONE
should	MD	should	O	O	NONE
be	VB	be	O	O	NONE
exercised	VBN	exercise	O	O	NONE
when	WRB	when	O	O	NONE
administering	VBG	administer	O	O	NONE
TAXOL	NN	taxol	B-e0	T	drug
concomitantly	RB	concomitantly	O	O	NONE
with	IN	with	O	O	NONE
known	JJ	known	O	O	NONE
substrates	NNS	substrate	O	O	NONE
or	CC	or	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
cytochrome	NN	cytochrome	B-e1	O	drug
P450	NN	p450	I-e1	O	drug
isoenzymes	NNS	isoenzyme	O	O	NONE
CYP2C8	NN	cyp2c8	O	O	NONE
and	CC	and	O	O	NONE
CYP3A4	NN	cyp3a4	B-e2	T	drug
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d480.s3
In	IN	in	O	O	NONE
the	DT	the	O	O	NONE
absence	NN	absence	O	O	NONE
of	IN	of	O	O	NONE
formal	JJ	formal	O	O	NONE
clinical	JJ	clinical	O	O	NONE
drug	NN	drug	O	O	NONE
interaction	NN	interaction	O	O	NONE
studies	NNS	study	O	O	NONE
,	,	,	O	O	NONE
caution	NN	caution	O	O	NONE
should	MD	should	O	O	NONE
be	VB	be	O	O	NONE
exercised	VBN	exercise	O	O	NONE
when	WRB	when	O	O	NONE
administering	VBG	administer	O	O	NONE
TAXOL	NN	taxol	B-e0	O	drug
concomitantly	RB	concomitantly	O	O	NONE
with	IN	with	O	O	NONE
known	JJ	known	O	O	NONE
substrates	NNS	substrate	O	O	NONE
or	CC	or	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
cytochrome	NN	cytochrome	B-e1	T	drug
P450	NN	p450	I-e1	T	drug
isoenzymes	NNS	isoenzyme	O	O	NONE
CYP2C8	NN	cyp2c8	O	O	NONE
and	CC	and	O	O	NONE
CYP3A4	NN	cyp3a4	B-e2	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d480.s4
Potential	JJ	potential	O	O	NONE
interactions	NNS	interaction	O	O	NONE
between	IN	between	O	O	NONE
TAXOL	NN	taxol	B-e0	T	drug
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
substrate	NN	substrate	O	O	NONE
of	IN	of	O	O	NONE
CYP3A4	NN	cyp3a4	B-e1	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
protease	NN	protease	B-e2	O	drug
inhibitors	NNS	inhibitor	I-e2	O	drug
(	(	(	O	O	NONE
ritonavir	NN	ritonavir	B-e3	O	drug
,	,	,	O	O	NONE
saquinavir	NN	saquinavir	B-e4	O	drug
,	,	,	O	O	NONE
indinavir	NN	indinavir	B-e5	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
nelfinavir	NN	nelfinavir	B-e6	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
which	WDT	which	O	O	NONE
are	VBP	be	O	O	NONE
substrates	NNS	substrate	O	O	NONE
and/or	CC	and/or	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
of	IN	of	O	O	NONE
CYP3A4	NN	cyp3a4	B-e7	O	drug
,	,	,	O	O	NONE
have	VBP	have	O	O	NONE
not	RB	not	O	O	NONE
been	VBN	be	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
in	IN	in	O	O	NONE
clinical	JJ	clinical	O	O	NONE
trials	NNS	trial	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d480.s4
Potential	JJ	potential	O	O	NONE
interactions	NNS	interaction	O	O	NONE
between	IN	between	O	O	NONE
TAXOL	NN	taxol	B-e0	T	drug
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
substrate	NN	substrate	O	O	NONE
of	IN	of	O	O	NONE
CYP3A4	NN	cyp3a4	B-e1	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
protease	NN	protease	B-e2	T	drug
inhibitors	NNS	inhibitor	I-e2	T	drug
(	(	(	O	O	NONE
ritonavir	NN	ritonavir	B-e3	O	drug
,	,	,	O	O	NONE
saquinavir	NN	saquinavir	B-e4	O	drug
,	,	,	O	O	NONE
indinavir	NN	indinavir	B-e5	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
nelfinavir	NN	nelfinavir	B-e6	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
which	WDT	which	O	O	NONE
are	VBP	be	O	O	NONE
substrates	NNS	substrate	O	O	NONE
and/or	CC	and/or	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
of	IN	of	O	O	NONE
CYP3A4	NN	cyp3a4	B-e7	O	drug
,	,	,	O	O	NONE
have	VBP	have	O	O	NONE
not	RB	not	O	O	NONE
been	VBN	be	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
in	IN	in	O	O	NONE
clinical	JJ	clinical	O	O	NONE
trials	NNS	trial	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d480.s4
Potential	JJ	potential	O	O	NONE
interactions	NNS	interaction	O	O	NONE
between	IN	between	O	O	NONE
TAXOL	NN	taxol	B-e0	T	drug
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
substrate	NN	substrate	O	O	NONE
of	IN	of	O	O	NONE
CYP3A4	NN	cyp3a4	B-e1	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
protease	NN	protease	B-e2	O	drug
inhibitors	NNS	inhibitor	I-e2	O	drug
(	(	(	O	O	NONE
ritonavir	NN	ritonavir	B-e3	T	drug
,	,	,	O	O	NONE
saquinavir	NN	saquinavir	B-e4	O	drug
,	,	,	O	O	NONE
indinavir	NN	indinavir	B-e5	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
nelfinavir	NN	nelfinavir	B-e6	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
which	WDT	which	O	O	NONE
are	VBP	be	O	O	NONE
substrates	NNS	substrate	O	O	NONE
and/or	CC	and/or	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
of	IN	of	O	O	NONE
CYP3A4	NN	cyp3a4	B-e7	O	drug
,	,	,	O	O	NONE
have	VBP	have	O	O	NONE
not	RB	not	O	O	NONE
been	VBN	be	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
in	IN	in	O	O	NONE
clinical	JJ	clinical	O	O	NONE
trials	NNS	trial	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d480.s4
Potential	JJ	potential	O	O	NONE
interactions	NNS	interaction	O	O	NONE
between	IN	between	O	O	NONE
TAXOL	NN	taxol	B-e0	T	drug
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
substrate	NN	substrate	O	O	NONE
of	IN	of	O	O	NONE
CYP3A4	NN	cyp3a4	B-e1	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
protease	NN	protease	B-e2	O	drug
inhibitors	NNS	inhibitor	I-e2	O	drug
(	(	(	O	O	NONE
ritonavir	NN	ritonavir	B-e3	O	drug
,	,	,	O	O	NONE
saquinavir	NN	saquinavir	B-e4	T	drug
,	,	,	O	O	NONE
indinavir	NN	indinavir	B-e5	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
nelfinavir	NN	nelfinavir	B-e6	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
which	WDT	which	O	O	NONE
are	VBP	be	O	O	NONE
substrates	NNS	substrate	O	O	NONE
and/or	CC	and/or	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
of	IN	of	O	O	NONE
CYP3A4	NN	cyp3a4	B-e7	O	drug
,	,	,	O	O	NONE
have	VBP	have	O	O	NONE
not	RB	not	O	O	NONE
been	VBN	be	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
in	IN	in	O	O	NONE
clinical	JJ	clinical	O	O	NONE
trials	NNS	trial	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d480.s4
Potential	JJ	potential	O	O	NONE
interactions	NNS	interaction	O	O	NONE
between	IN	between	O	O	NONE
TAXOL	NN	taxol	B-e0	T	drug
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
substrate	NN	substrate	O	O	NONE
of	IN	of	O	O	NONE
CYP3A4	NN	cyp3a4	B-e1	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
protease	NN	protease	B-e2	O	drug
inhibitors	NNS	inhibitor	I-e2	O	drug
(	(	(	O	O	NONE
ritonavir	NN	ritonavir	B-e3	O	drug
,	,	,	O	O	NONE
saquinavir	NN	saquinavir	B-e4	O	drug
,	,	,	O	O	NONE
indinavir	NN	indinavir	B-e5	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
nelfinavir	NN	nelfinavir	B-e6	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
which	WDT	which	O	O	NONE
are	VBP	be	O	O	NONE
substrates	NNS	substrate	O	O	NONE
and/or	CC	and/or	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
of	IN	of	O	O	NONE
CYP3A4	NN	cyp3a4	B-e7	O	drug
,	,	,	O	O	NONE
have	VBP	have	O	O	NONE
not	RB	not	O	O	NONE
been	VBN	be	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
in	IN	in	O	O	NONE
clinical	JJ	clinical	O	O	NONE
trials	NNS	trial	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d480.s4
Potential	JJ	potential	O	O	NONE
interactions	NNS	interaction	O	O	NONE
between	IN	between	O	O	NONE
TAXOL	NN	taxol	B-e0	T	drug
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
substrate	NN	substrate	O	O	NONE
of	IN	of	O	O	NONE
CYP3A4	NN	cyp3a4	B-e1	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
protease	NN	protease	B-e2	O	drug
inhibitors	NNS	inhibitor	I-e2	O	drug
(	(	(	O	O	NONE
ritonavir	NN	ritonavir	B-e3	O	drug
,	,	,	O	O	NONE
saquinavir	NN	saquinavir	B-e4	O	drug
,	,	,	O	O	NONE
indinavir	NN	indinavir	B-e5	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
nelfinavir	NN	nelfinavir	B-e6	T	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
which	WDT	which	O	O	NONE
are	VBP	be	O	O	NONE
substrates	NNS	substrate	O	O	NONE
and/or	CC	and/or	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
of	IN	of	O	O	NONE
CYP3A4	NN	cyp3a4	B-e7	O	drug
,	,	,	O	O	NONE
have	VBP	have	O	O	NONE
not	RB	not	O	O	NONE
been	VBN	be	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
in	IN	in	O	O	NONE
clinical	JJ	clinical	O	O	NONE
trials	NNS	trial	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d480.s4
Potential	JJ	potential	O	O	NONE
interactions	NNS	interaction	O	O	NONE
between	IN	between	O	O	NONE
TAXOL	NN	taxol	B-e0	T	drug
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
substrate	NN	substrate	O	O	NONE
of	IN	of	O	O	NONE
CYP3A4	NN	cyp3a4	B-e1	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
protease	NN	protease	B-e2	O	drug
inhibitors	NNS	inhibitor	I-e2	O	drug
(	(	(	O	O	NONE
ritonavir	NN	ritonavir	B-e3	O	drug
,	,	,	O	O	NONE
saquinavir	NN	saquinavir	B-e4	O	drug
,	,	,	O	O	NONE
indinavir	NN	indinavir	B-e5	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
nelfinavir	NN	nelfinavir	B-e6	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
which	WDT	which	O	O	NONE
are	VBP	be	O	O	NONE
substrates	NNS	substrate	O	O	NONE
and/or	CC	and/or	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
of	IN	of	O	O	NONE
CYP3A4	NN	cyp3a4	B-e7	T	drug
,	,	,	O	O	NONE
have	VBP	have	O	O	NONE
not	RB	not	O	O	NONE
been	VBN	be	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
in	IN	in	O	O	NONE
clinical	JJ	clinical	O	O	NONE
trials	NNS	trial	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d480.s4
Potential	JJ	potential	O	O	NONE
interactions	NNS	interaction	O	O	NONE
between	IN	between	O	O	NONE
TAXOL	NN	taxol	B-e0	O	drug
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
substrate	NN	substrate	O	O	NONE
of	IN	of	O	O	NONE
CYP3A4	NN	cyp3a4	B-e1	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
protease	NN	protease	B-e2	T	drug
inhibitors	NNS	inhibitor	I-e2	T	drug
(	(	(	O	O	NONE
ritonavir	NN	ritonavir	B-e3	O	drug
,	,	,	O	O	NONE
saquinavir	NN	saquinavir	B-e4	O	drug
,	,	,	O	O	NONE
indinavir	NN	indinavir	B-e5	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
nelfinavir	NN	nelfinavir	B-e6	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
which	WDT	which	O	O	NONE
are	VBP	be	O	O	NONE
substrates	NNS	substrate	O	O	NONE
and/or	CC	and/or	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
of	IN	of	O	O	NONE
CYP3A4	NN	cyp3a4	B-e7	O	drug
,	,	,	O	O	NONE
have	VBP	have	O	O	NONE
not	RB	not	O	O	NONE
been	VBN	be	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
in	IN	in	O	O	NONE
clinical	JJ	clinical	O	O	NONE
trials	NNS	trial	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d480.s4
Potential	JJ	potential	O	O	NONE
interactions	NNS	interaction	O	O	NONE
between	IN	between	O	O	NONE
TAXOL	NN	taxol	B-e0	O	drug
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
substrate	NN	substrate	O	O	NONE
of	IN	of	O	O	NONE
CYP3A4	NN	cyp3a4	B-e1	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
protease	NN	protease	B-e2	O	drug
inhibitors	NNS	inhibitor	I-e2	O	drug
(	(	(	O	O	NONE
ritonavir	NN	ritonavir	B-e3	T	drug
,	,	,	O	O	NONE
saquinavir	NN	saquinavir	B-e4	O	drug
,	,	,	O	O	NONE
indinavir	NN	indinavir	B-e5	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
nelfinavir	NN	nelfinavir	B-e6	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
which	WDT	which	O	O	NONE
are	VBP	be	O	O	NONE
substrates	NNS	substrate	O	O	NONE
and/or	CC	and/or	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
of	IN	of	O	O	NONE
CYP3A4	NN	cyp3a4	B-e7	O	drug
,	,	,	O	O	NONE
have	VBP	have	O	O	NONE
not	RB	not	O	O	NONE
been	VBN	be	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
in	IN	in	O	O	NONE
clinical	JJ	clinical	O	O	NONE
trials	NNS	trial	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d480.s4
Potential	JJ	potential	O	O	NONE
interactions	NNS	interaction	O	O	NONE
between	IN	between	O	O	NONE
TAXOL	NN	taxol	B-e0	O	drug
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
substrate	NN	substrate	O	O	NONE
of	IN	of	O	O	NONE
CYP3A4	NN	cyp3a4	B-e1	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
protease	NN	protease	B-e2	O	drug
inhibitors	NNS	inhibitor	I-e2	O	drug
(	(	(	O	O	NONE
ritonavir	NN	ritonavir	B-e3	O	drug
,	,	,	O	O	NONE
saquinavir	NN	saquinavir	B-e4	T	drug
,	,	,	O	O	NONE
indinavir	NN	indinavir	B-e5	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
nelfinavir	NN	nelfinavir	B-e6	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
which	WDT	which	O	O	NONE
are	VBP	be	O	O	NONE
substrates	NNS	substrate	O	O	NONE
and/or	CC	and/or	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
of	IN	of	O	O	NONE
CYP3A4	NN	cyp3a4	B-e7	O	drug
,	,	,	O	O	NONE
have	VBP	have	O	O	NONE
not	RB	not	O	O	NONE
been	VBN	be	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
in	IN	in	O	O	NONE
clinical	JJ	clinical	O	O	NONE
trials	NNS	trial	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d480.s4
Potential	JJ	potential	O	O	NONE
interactions	NNS	interaction	O	O	NONE
between	IN	between	O	O	NONE
TAXOL	NN	taxol	B-e0	O	drug
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
substrate	NN	substrate	O	O	NONE
of	IN	of	O	O	NONE
CYP3A4	NN	cyp3a4	B-e1	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
protease	NN	protease	B-e2	O	drug
inhibitors	NNS	inhibitor	I-e2	O	drug
(	(	(	O	O	NONE
ritonavir	NN	ritonavir	B-e3	O	drug
,	,	,	O	O	NONE
saquinavir	NN	saquinavir	B-e4	O	drug
,	,	,	O	O	NONE
indinavir	NN	indinavir	B-e5	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
nelfinavir	NN	nelfinavir	B-e6	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
which	WDT	which	O	O	NONE
are	VBP	be	O	O	NONE
substrates	NNS	substrate	O	O	NONE
and/or	CC	and/or	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
of	IN	of	O	O	NONE
CYP3A4	NN	cyp3a4	B-e7	O	drug
,	,	,	O	O	NONE
have	VBP	have	O	O	NONE
not	RB	not	O	O	NONE
been	VBN	be	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
in	IN	in	O	O	NONE
clinical	JJ	clinical	O	O	NONE
trials	NNS	trial	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d480.s4
Potential	JJ	potential	O	O	NONE
interactions	NNS	interaction	O	O	NONE
between	IN	between	O	O	NONE
TAXOL	NN	taxol	B-e0	O	drug
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
substrate	NN	substrate	O	O	NONE
of	IN	of	O	O	NONE
CYP3A4	NN	cyp3a4	B-e1	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
protease	NN	protease	B-e2	O	drug
inhibitors	NNS	inhibitor	I-e2	O	drug
(	(	(	O	O	NONE
ritonavir	NN	ritonavir	B-e3	O	drug
,	,	,	O	O	NONE
saquinavir	NN	saquinavir	B-e4	O	drug
,	,	,	O	O	NONE
indinavir	NN	indinavir	B-e5	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
nelfinavir	NN	nelfinavir	B-e6	T	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
which	WDT	which	O	O	NONE
are	VBP	be	O	O	NONE
substrates	NNS	substrate	O	O	NONE
and/or	CC	and/or	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
of	IN	of	O	O	NONE
CYP3A4	NN	cyp3a4	B-e7	O	drug
,	,	,	O	O	NONE
have	VBP	have	O	O	NONE
not	RB	not	O	O	NONE
been	VBN	be	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
in	IN	in	O	O	NONE
clinical	JJ	clinical	O	O	NONE
trials	NNS	trial	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d480.s4
Potential	JJ	potential	O	O	NONE
interactions	NNS	interaction	O	O	NONE
between	IN	between	O	O	NONE
TAXOL	NN	taxol	B-e0	O	drug
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
substrate	NN	substrate	O	O	NONE
of	IN	of	O	O	NONE
CYP3A4	NN	cyp3a4	B-e1	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
protease	NN	protease	B-e2	O	drug
inhibitors	NNS	inhibitor	I-e2	O	drug
(	(	(	O	O	NONE
ritonavir	NN	ritonavir	B-e3	O	drug
,	,	,	O	O	NONE
saquinavir	NN	saquinavir	B-e4	O	drug
,	,	,	O	O	NONE
indinavir	NN	indinavir	B-e5	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
nelfinavir	NN	nelfinavir	B-e6	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
which	WDT	which	O	O	NONE
are	VBP	be	O	O	NONE
substrates	NNS	substrate	O	O	NONE
and/or	CC	and/or	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
of	IN	of	O	O	NONE
CYP3A4	NN	cyp3a4	B-e7	T	drug
,	,	,	O	O	NONE
have	VBP	have	O	O	NONE
not	RB	not	O	O	NONE
been	VBN	be	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
in	IN	in	O	O	NONE
clinical	JJ	clinical	O	O	NONE
trials	NNS	trial	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d480.s4
Potential	JJ	potential	O	O	NONE
interactions	NNS	interaction	O	O	NONE
between	IN	between	O	O	NONE
TAXOL	NN	taxol	B-e0	O	drug
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
substrate	NN	substrate	O	O	NONE
of	IN	of	O	O	NONE
CYP3A4	NN	cyp3a4	B-e1	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
protease	NN	protease	B-e2	T	drug
inhibitors	NNS	inhibitor	I-e2	T	drug
(	(	(	O	O	NONE
ritonavir	NN	ritonavir	B-e3	T	drug
,	,	,	O	O	NONE
saquinavir	NN	saquinavir	B-e4	O	drug
,	,	,	O	O	NONE
indinavir	NN	indinavir	B-e5	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
nelfinavir	NN	nelfinavir	B-e6	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
which	WDT	which	O	O	NONE
are	VBP	be	O	O	NONE
substrates	NNS	substrate	O	O	NONE
and/or	CC	and/or	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
of	IN	of	O	O	NONE
CYP3A4	NN	cyp3a4	B-e7	O	drug
,	,	,	O	O	NONE
have	VBP	have	O	O	NONE
not	RB	not	O	O	NONE
been	VBN	be	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
in	IN	in	O	O	NONE
clinical	JJ	clinical	O	O	NONE
trials	NNS	trial	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d480.s4
Potential	JJ	potential	O	O	NONE
interactions	NNS	interaction	O	O	NONE
between	IN	between	O	O	NONE
TAXOL	NN	taxol	B-e0	O	drug
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
substrate	NN	substrate	O	O	NONE
of	IN	of	O	O	NONE
CYP3A4	NN	cyp3a4	B-e1	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
protease	NN	protease	B-e2	T	drug
inhibitors	NNS	inhibitor	I-e2	T	drug
(	(	(	O	O	NONE
ritonavir	NN	ritonavir	B-e3	O	drug
,	,	,	O	O	NONE
saquinavir	NN	saquinavir	B-e4	T	drug
,	,	,	O	O	NONE
indinavir	NN	indinavir	B-e5	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
nelfinavir	NN	nelfinavir	B-e6	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
which	WDT	which	O	O	NONE
are	VBP	be	O	O	NONE
substrates	NNS	substrate	O	O	NONE
and/or	CC	and/or	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
of	IN	of	O	O	NONE
CYP3A4	NN	cyp3a4	B-e7	O	drug
,	,	,	O	O	NONE
have	VBP	have	O	O	NONE
not	RB	not	O	O	NONE
been	VBN	be	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
in	IN	in	O	O	NONE
clinical	JJ	clinical	O	O	NONE
trials	NNS	trial	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d480.s4
Potential	JJ	potential	O	O	NONE
interactions	NNS	interaction	O	O	NONE
between	IN	between	O	O	NONE
TAXOL	NN	taxol	B-e0	O	drug
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
substrate	NN	substrate	O	O	NONE
of	IN	of	O	O	NONE
CYP3A4	NN	cyp3a4	B-e1	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
protease	NN	protease	B-e2	T	drug
inhibitors	NNS	inhibitor	I-e2	T	drug
(	(	(	O	O	NONE
ritonavir	NN	ritonavir	B-e3	O	drug
,	,	,	O	O	NONE
saquinavir	NN	saquinavir	B-e4	O	drug
,	,	,	O	O	NONE
indinavir	NN	indinavir	B-e5	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
nelfinavir	NN	nelfinavir	B-e6	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
which	WDT	which	O	O	NONE
are	VBP	be	O	O	NONE
substrates	NNS	substrate	O	O	NONE
and/or	CC	and/or	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
of	IN	of	O	O	NONE
CYP3A4	NN	cyp3a4	B-e7	O	drug
,	,	,	O	O	NONE
have	VBP	have	O	O	NONE
not	RB	not	O	O	NONE
been	VBN	be	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
in	IN	in	O	O	NONE
clinical	JJ	clinical	O	O	NONE
trials	NNS	trial	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d480.s4
Potential	JJ	potential	O	O	NONE
interactions	NNS	interaction	O	O	NONE
between	IN	between	O	O	NONE
TAXOL	NN	taxol	B-e0	O	drug
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
substrate	NN	substrate	O	O	NONE
of	IN	of	O	O	NONE
CYP3A4	NN	cyp3a4	B-e1	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
protease	NN	protease	B-e2	T	drug
inhibitors	NNS	inhibitor	I-e2	T	drug
(	(	(	O	O	NONE
ritonavir	NN	ritonavir	B-e3	O	drug
,	,	,	O	O	NONE
saquinavir	NN	saquinavir	B-e4	O	drug
,	,	,	O	O	NONE
indinavir	NN	indinavir	B-e5	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
nelfinavir	NN	nelfinavir	B-e6	T	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
which	WDT	which	O	O	NONE
are	VBP	be	O	O	NONE
substrates	NNS	substrate	O	O	NONE
and/or	CC	and/or	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
of	IN	of	O	O	NONE
CYP3A4	NN	cyp3a4	B-e7	O	drug
,	,	,	O	O	NONE
have	VBP	have	O	O	NONE
not	RB	not	O	O	NONE
been	VBN	be	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
in	IN	in	O	O	NONE
clinical	JJ	clinical	O	O	NONE
trials	NNS	trial	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d480.s4
Potential	JJ	potential	O	O	NONE
interactions	NNS	interaction	O	O	NONE
between	IN	between	O	O	NONE
TAXOL	NN	taxol	B-e0	O	drug
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
substrate	NN	substrate	O	O	NONE
of	IN	of	O	O	NONE
CYP3A4	NN	cyp3a4	B-e1	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
protease	NN	protease	B-e2	T	drug
inhibitors	NNS	inhibitor	I-e2	T	drug
(	(	(	O	O	NONE
ritonavir	NN	ritonavir	B-e3	O	drug
,	,	,	O	O	NONE
saquinavir	NN	saquinavir	B-e4	O	drug
,	,	,	O	O	NONE
indinavir	NN	indinavir	B-e5	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
nelfinavir	NN	nelfinavir	B-e6	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
which	WDT	which	O	O	NONE
are	VBP	be	O	O	NONE
substrates	NNS	substrate	O	O	NONE
and/or	CC	and/or	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
of	IN	of	O	O	NONE
CYP3A4	NN	cyp3a4	B-e7	T	drug
,	,	,	O	O	NONE
have	VBP	have	O	O	NONE
not	RB	not	O	O	NONE
been	VBN	be	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
in	IN	in	O	O	NONE
clinical	JJ	clinical	O	O	NONE
trials	NNS	trial	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d480.s4
Potential	JJ	potential	O	O	NONE
interactions	NNS	interaction	O	O	NONE
between	IN	between	O	O	NONE
TAXOL	NN	taxol	B-e0	O	drug
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
substrate	NN	substrate	O	O	NONE
of	IN	of	O	O	NONE
CYP3A4	NN	cyp3a4	B-e1	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
protease	NN	protease	B-e2	O	drug
inhibitors	NNS	inhibitor	I-e2	O	drug
(	(	(	O	O	NONE
ritonavir	NN	ritonavir	B-e3	T	drug
,	,	,	O	O	NONE
saquinavir	NN	saquinavir	B-e4	T	drug
,	,	,	O	O	NONE
indinavir	NN	indinavir	B-e5	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
nelfinavir	NN	nelfinavir	B-e6	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
which	WDT	which	O	O	NONE
are	VBP	be	O	O	NONE
substrates	NNS	substrate	O	O	NONE
and/or	CC	and/or	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
of	IN	of	O	O	NONE
CYP3A4	NN	cyp3a4	B-e7	O	drug
,	,	,	O	O	NONE
have	VBP	have	O	O	NONE
not	RB	not	O	O	NONE
been	VBN	be	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
in	IN	in	O	O	NONE
clinical	JJ	clinical	O	O	NONE
trials	NNS	trial	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d480.s4
Potential	JJ	potential	O	O	NONE
interactions	NNS	interaction	O	O	NONE
between	IN	between	O	O	NONE
TAXOL	NN	taxol	B-e0	O	drug
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
substrate	NN	substrate	O	O	NONE
of	IN	of	O	O	NONE
CYP3A4	NN	cyp3a4	B-e1	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
protease	NN	protease	B-e2	O	drug
inhibitors	NNS	inhibitor	I-e2	O	drug
(	(	(	O	O	NONE
ritonavir	NN	ritonavir	B-e3	T	drug
,	,	,	O	O	NONE
saquinavir	NN	saquinavir	B-e4	O	drug
,	,	,	O	O	NONE
indinavir	NN	indinavir	B-e5	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
nelfinavir	NN	nelfinavir	B-e6	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
which	WDT	which	O	O	NONE
are	VBP	be	O	O	NONE
substrates	NNS	substrate	O	O	NONE
and/or	CC	and/or	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
of	IN	of	O	O	NONE
CYP3A4	NN	cyp3a4	B-e7	O	drug
,	,	,	O	O	NONE
have	VBP	have	O	O	NONE
not	RB	not	O	O	NONE
been	VBN	be	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
in	IN	in	O	O	NONE
clinical	JJ	clinical	O	O	NONE
trials	NNS	trial	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d480.s4
Potential	JJ	potential	O	O	NONE
interactions	NNS	interaction	O	O	NONE
between	IN	between	O	O	NONE
TAXOL	NN	taxol	B-e0	O	drug
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
substrate	NN	substrate	O	O	NONE
of	IN	of	O	O	NONE
CYP3A4	NN	cyp3a4	B-e1	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
protease	NN	protease	B-e2	O	drug
inhibitors	NNS	inhibitor	I-e2	O	drug
(	(	(	O	O	NONE
ritonavir	NN	ritonavir	B-e3	T	drug
,	,	,	O	O	NONE
saquinavir	NN	saquinavir	B-e4	O	drug
,	,	,	O	O	NONE
indinavir	NN	indinavir	B-e5	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
nelfinavir	NN	nelfinavir	B-e6	T	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
which	WDT	which	O	O	NONE
are	VBP	be	O	O	NONE
substrates	NNS	substrate	O	O	NONE
and/or	CC	and/or	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
of	IN	of	O	O	NONE
CYP3A4	NN	cyp3a4	B-e7	O	drug
,	,	,	O	O	NONE
have	VBP	have	O	O	NONE
not	RB	not	O	O	NONE
been	VBN	be	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
in	IN	in	O	O	NONE
clinical	JJ	clinical	O	O	NONE
trials	NNS	trial	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d480.s4
Potential	JJ	potential	O	O	NONE
interactions	NNS	interaction	O	O	NONE
between	IN	between	O	O	NONE
TAXOL	NN	taxol	B-e0	O	drug
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
substrate	NN	substrate	O	O	NONE
of	IN	of	O	O	NONE
CYP3A4	NN	cyp3a4	B-e1	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
protease	NN	protease	B-e2	O	drug
inhibitors	NNS	inhibitor	I-e2	O	drug
(	(	(	O	O	NONE
ritonavir	NN	ritonavir	B-e3	T	drug
,	,	,	O	O	NONE
saquinavir	NN	saquinavir	B-e4	O	drug
,	,	,	O	O	NONE
indinavir	NN	indinavir	B-e5	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
nelfinavir	NN	nelfinavir	B-e6	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
which	WDT	which	O	O	NONE
are	VBP	be	O	O	NONE
substrates	NNS	substrate	O	O	NONE
and/or	CC	and/or	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
of	IN	of	O	O	NONE
CYP3A4	NN	cyp3a4	B-e7	T	drug
,	,	,	O	O	NONE
have	VBP	have	O	O	NONE
not	RB	not	O	O	NONE
been	VBN	be	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
in	IN	in	O	O	NONE
clinical	JJ	clinical	O	O	NONE
trials	NNS	trial	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d480.s4
Potential	JJ	potential	O	O	NONE
interactions	NNS	interaction	O	O	NONE
between	IN	between	O	O	NONE
TAXOL	NN	taxol	B-e0	O	drug
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
substrate	NN	substrate	O	O	NONE
of	IN	of	O	O	NONE
CYP3A4	NN	cyp3a4	B-e1	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
protease	NN	protease	B-e2	O	drug
inhibitors	NNS	inhibitor	I-e2	O	drug
(	(	(	O	O	NONE
ritonavir	NN	ritonavir	B-e3	O	drug
,	,	,	O	O	NONE
saquinavir	NN	saquinavir	B-e4	T	drug
,	,	,	O	O	NONE
indinavir	NN	indinavir	B-e5	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
nelfinavir	NN	nelfinavir	B-e6	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
which	WDT	which	O	O	NONE
are	VBP	be	O	O	NONE
substrates	NNS	substrate	O	O	NONE
and/or	CC	and/or	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
of	IN	of	O	O	NONE
CYP3A4	NN	cyp3a4	B-e7	O	drug
,	,	,	O	O	NONE
have	VBP	have	O	O	NONE
not	RB	not	O	O	NONE
been	VBN	be	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
in	IN	in	O	O	NONE
clinical	JJ	clinical	O	O	NONE
trials	NNS	trial	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d480.s4
Potential	JJ	potential	O	O	NONE
interactions	NNS	interaction	O	O	NONE
between	IN	between	O	O	NONE
TAXOL	NN	taxol	B-e0	O	drug
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
substrate	NN	substrate	O	O	NONE
of	IN	of	O	O	NONE
CYP3A4	NN	cyp3a4	B-e1	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
protease	NN	protease	B-e2	O	drug
inhibitors	NNS	inhibitor	I-e2	O	drug
(	(	(	O	O	NONE
ritonavir	NN	ritonavir	B-e3	O	drug
,	,	,	O	O	NONE
saquinavir	NN	saquinavir	B-e4	T	drug
,	,	,	O	O	NONE
indinavir	NN	indinavir	B-e5	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
nelfinavir	NN	nelfinavir	B-e6	T	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
which	WDT	which	O	O	NONE
are	VBP	be	O	O	NONE
substrates	NNS	substrate	O	O	NONE
and/or	CC	and/or	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
of	IN	of	O	O	NONE
CYP3A4	NN	cyp3a4	B-e7	O	drug
,	,	,	O	O	NONE
have	VBP	have	O	O	NONE
not	RB	not	O	O	NONE
been	VBN	be	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
in	IN	in	O	O	NONE
clinical	JJ	clinical	O	O	NONE
trials	NNS	trial	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d480.s4
Potential	JJ	potential	O	O	NONE
interactions	NNS	interaction	O	O	NONE
between	IN	between	O	O	NONE
TAXOL	NN	taxol	B-e0	O	drug
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
substrate	NN	substrate	O	O	NONE
of	IN	of	O	O	NONE
CYP3A4	NN	cyp3a4	B-e1	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
protease	NN	protease	B-e2	O	drug
inhibitors	NNS	inhibitor	I-e2	O	drug
(	(	(	O	O	NONE
ritonavir	NN	ritonavir	B-e3	O	drug
,	,	,	O	O	NONE
saquinavir	NN	saquinavir	B-e4	T	drug
,	,	,	O	O	NONE
indinavir	NN	indinavir	B-e5	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
nelfinavir	NN	nelfinavir	B-e6	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
which	WDT	which	O	O	NONE
are	VBP	be	O	O	NONE
substrates	NNS	substrate	O	O	NONE
and/or	CC	and/or	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
of	IN	of	O	O	NONE
CYP3A4	NN	cyp3a4	B-e7	T	drug
,	,	,	O	O	NONE
have	VBP	have	O	O	NONE
not	RB	not	O	O	NONE
been	VBN	be	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
in	IN	in	O	O	NONE
clinical	JJ	clinical	O	O	NONE
trials	NNS	trial	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d480.s4
Potential	JJ	potential	O	O	NONE
interactions	NNS	interaction	O	O	NONE
between	IN	between	O	O	NONE
TAXOL	NN	taxol	B-e0	O	drug
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
substrate	NN	substrate	O	O	NONE
of	IN	of	O	O	NONE
CYP3A4	NN	cyp3a4	B-e1	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
protease	NN	protease	B-e2	O	drug
inhibitors	NNS	inhibitor	I-e2	O	drug
(	(	(	O	O	NONE
ritonavir	NN	ritonavir	B-e3	O	drug
,	,	,	O	O	NONE
saquinavir	NN	saquinavir	B-e4	O	drug
,	,	,	O	O	NONE
indinavir	NN	indinavir	B-e5	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
nelfinavir	NN	nelfinavir	B-e6	T	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
which	WDT	which	O	O	NONE
are	VBP	be	O	O	NONE
substrates	NNS	substrate	O	O	NONE
and/or	CC	and/or	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
of	IN	of	O	O	NONE
CYP3A4	NN	cyp3a4	B-e7	O	drug
,	,	,	O	O	NONE
have	VBP	have	O	O	NONE
not	RB	not	O	O	NONE
been	VBN	be	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
in	IN	in	O	O	NONE
clinical	JJ	clinical	O	O	NONE
trials	NNS	trial	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d480.s4
Potential	JJ	potential	O	O	NONE
interactions	NNS	interaction	O	O	NONE
between	IN	between	O	O	NONE
TAXOL	NN	taxol	B-e0	O	drug
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
substrate	NN	substrate	O	O	NONE
of	IN	of	O	O	NONE
CYP3A4	NN	cyp3a4	B-e1	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
protease	NN	protease	B-e2	O	drug
inhibitors	NNS	inhibitor	I-e2	O	drug
(	(	(	O	O	NONE
ritonavir	NN	ritonavir	B-e3	O	drug
,	,	,	O	O	NONE
saquinavir	NN	saquinavir	B-e4	O	drug
,	,	,	O	O	NONE
indinavir	NN	indinavir	B-e5	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
nelfinavir	NN	nelfinavir	B-e6	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
which	WDT	which	O	O	NONE
are	VBP	be	O	O	NONE
substrates	NNS	substrate	O	O	NONE
and/or	CC	and/or	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
of	IN	of	O	O	NONE
CYP3A4	NN	cyp3a4	B-e7	T	drug
,	,	,	O	O	NONE
have	VBP	have	O	O	NONE
not	RB	not	O	O	NONE
been	VBN	be	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
in	IN	in	O	O	NONE
clinical	JJ	clinical	O	O	NONE
trials	NNS	trial	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d480.s4
Potential	JJ	potential	O	O	NONE
interactions	NNS	interaction	O	O	NONE
between	IN	between	O	O	NONE
TAXOL	NN	taxol	B-e0	O	drug
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
substrate	NN	substrate	O	O	NONE
of	IN	of	O	O	NONE
CYP3A4	NN	cyp3a4	B-e1	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
protease	NN	protease	B-e2	O	drug
inhibitors	NNS	inhibitor	I-e2	O	drug
(	(	(	O	O	NONE
ritonavir	NN	ritonavir	B-e3	O	drug
,	,	,	O	O	NONE
saquinavir	NN	saquinavir	B-e4	O	drug
,	,	,	O	O	NONE
indinavir	NN	indinavir	B-e5	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
nelfinavir	NN	nelfinavir	B-e6	T	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
which	WDT	which	O	O	NONE
are	VBP	be	O	O	NONE
substrates	NNS	substrate	O	O	NONE
and/or	CC	and/or	O	O	NONE
inhibitors	NNS	inhibitor	O	O	NONE
of	IN	of	O	O	NONE
CYP3A4	NN	cyp3a4	B-e7	T	drug
,	,	,	O	O	NONE
have	VBP	have	O	O	NONE
not	RB	not	O	O	NONE
been	VBN	be	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
in	IN	in	O	O	NONE
clinical	JJ	clinical	O	O	NONE
trials	NNS	trial	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d480.s5
Reports	NNS	report	O	O	NONE
in	IN	in	O	O	NONE
the	DT	the	O	O	NONE
literature	NN	literature	O	O	NONE
suggest	VBP	suggest	O	O	NONE
that	IN	that	O	O	NONE
plasma	NN	plasma	O	O	NONE
levels	NNS	level	O	O	NONE
of	IN	of	O	O	NONE
doxorubicin	NN	doxorubicin	B-e0	T	drug
(	(	(	O	O	NONE
and	CC	and	O	O	NONE
its	PRP$	its	O	O	NONE
active	JJ	active	B-e1	T	drug
metabolite	NN	metabolite	I-e1	T	drug
doxorubicinol	NN	doxorubicinol	O	O	NONE
)	)	)	O	O	NONE
may	MD	may	O	O	NONE
be	VB	be	O	O	NONE
increased	VBN	increase	O	O	NONE
when	WRB	when	O	O	NONE
paclitaxel	NN	paclitaxel	B-e2	O	drug
and	CC	and	O	O	NONE
doxorubicin	NN	doxorubicin	B-e3	O	drug
are	VBP	be	O	O	NONE
used	VBN	use	O	O	NONE
in	IN	in	O	O	NONE
combination	NN	combination	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d480.s5
Reports	NNS	report	O	O	NONE
in	IN	in	O	O	NONE
the	DT	the	O	O	NONE
literature	NN	literature	O	O	NONE
suggest	VBP	suggest	O	O	NONE
that	IN	that	O	O	NONE
plasma	NN	plasma	O	O	NONE
levels	NNS	level	O	O	NONE
of	IN	of	O	O	NONE
doxorubicin	NN	doxorubicin	B-e0	T	drug
(	(	(	O	O	NONE
and	CC	and	O	O	NONE
its	PRP$	its	O	O	NONE
active	JJ	active	B-e1	O	drug
metabolite	NN	metabolite	I-e1	O	drug
doxorubicinol	NN	doxorubicinol	O	O	NONE
)	)	)	O	O	NONE
may	MD	may	O	O	NONE
be	VB	be	O	O	NONE
increased	VBN	increase	O	O	NONE
when	WRB	when	O	O	NONE
paclitaxel	NN	paclitaxel	B-e2	T	drug
and	CC	and	O	O	NONE
doxorubicin	NN	doxorubicin	B-e3	O	drug
are	VBP	be	O	O	NONE
used	VBN	use	O	O	NONE
in	IN	in	O	O	NONE
combination	NN	combination	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d480.s5
Reports	NNS	report	O	O	NONE
in	IN	in	O	O	NONE
the	DT	the	O	O	NONE
literature	NN	literature	O	O	NONE
suggest	VBP	suggest	O	O	NONE
that	IN	that	O	O	NONE
plasma	NN	plasma	O	O	NONE
levels	NNS	level	O	O	NONE
of	IN	of	O	O	NONE
doxorubicin	NN	doxorubicin	B-e0	T	drug
(	(	(	O	O	NONE
and	CC	and	O	O	NONE
its	PRP$	its	O	O	NONE
active	JJ	active	B-e1	O	drug
metabolite	NN	metabolite	I-e1	O	drug
doxorubicinol	NN	doxorubicinol	O	O	NONE
)	)	)	O	O	NONE
may	MD	may	O	O	NONE
be	VB	be	O	O	NONE
increased	VBN	increase	O	O	NONE
when	WRB	when	O	O	NONE
paclitaxel	NN	paclitaxel	B-e2	O	drug
and	CC	and	O	O	NONE
doxorubicin	NN	doxorubicin	B-e3	T	drug
are	VBP	be	O	O	NONE
used	VBN	use	O	O	NONE
in	IN	in	O	O	NONE
combination	NN	combination	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d480.s5
Reports	NNS	report	O	O	NONE
in	IN	in	O	O	NONE
the	DT	the	O	O	NONE
literature	NN	literature	O	O	NONE
suggest	VBP	suggest	O	O	NONE
that	IN	that	O	O	NONE
plasma	NN	plasma	O	O	NONE
levels	NNS	level	O	O	NONE
of	IN	of	O	O	NONE
doxorubicin	NN	doxorubicin	B-e0	O	drug
(	(	(	O	O	NONE
and	CC	and	O	O	NONE
its	PRP$	its	O	O	NONE
active	JJ	active	B-e1	T	drug
metabolite	NN	metabolite	I-e1	T	drug
doxorubicinol	NN	doxorubicinol	O	O	NONE
)	)	)	O	O	NONE
may	MD	may	O	O	NONE
be	VB	be	O	O	NONE
increased	VBN	increase	O	O	NONE
when	WRB	when	O	O	NONE
paclitaxel	NN	paclitaxel	B-e2	T	drug
and	CC	and	O	O	NONE
doxorubicin	NN	doxorubicin	B-e3	O	drug
are	VBP	be	O	O	NONE
used	VBN	use	O	O	NONE
in	IN	in	O	O	NONE
combination	NN	combination	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d480.s5
Reports	NNS	report	O	O	NONE
in	IN	in	O	O	NONE
the	DT	the	O	O	NONE
literature	NN	literature	O	O	NONE
suggest	VBP	suggest	O	O	NONE
that	IN	that	O	O	NONE
plasma	NN	plasma	O	O	NONE
levels	NNS	level	O	O	NONE
of	IN	of	O	O	NONE
doxorubicin	NN	doxorubicin	B-e0	O	drug
(	(	(	O	O	NONE
and	CC	and	O	O	NONE
its	PRP$	its	O	O	NONE
active	JJ	active	B-e1	T	drug
metabolite	NN	metabolite	I-e1	T	drug
doxorubicinol	NN	doxorubicinol	O	O	NONE
)	)	)	O	O	NONE
may	MD	may	O	O	NONE
be	VB	be	O	O	NONE
increased	VBN	increase	O	O	NONE
when	WRB	when	O	O	NONE
paclitaxel	NN	paclitaxel	B-e2	O	drug
and	CC	and	O	O	NONE
doxorubicin	NN	doxorubicin	B-e3	T	drug
are	VBP	be	O	O	NONE
used	VBN	use	O	O	NONE
in	IN	in	O	O	NONE
combination	NN	combination	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d480.s5
Reports	NNS	report	O	O	NONE
in	IN	in	O	O	NONE
the	DT	the	O	O	NONE
literature	NN	literature	O	O	NONE
suggest	VBP	suggest	O	O	NONE
that	IN	that	O	O	NONE
plasma	NN	plasma	O	O	NONE
levels	NNS	level	O	O	NONE
of	IN	of	O	O	NONE
doxorubicin	NN	doxorubicin	B-e0	O	drug
(	(	(	O	O	NONE
and	CC	and	O	O	NONE
its	PRP$	its	O	O	NONE
active	JJ	active	B-e1	O	drug
metabolite	NN	metabolite	I-e1	O	drug
doxorubicinol	NN	doxorubicinol	O	O	NONE
)	)	)	O	O	NONE
may	MD	may	O	O	NONE
be	VB	be	O	O	NONE
increased	VBN	increase	O	O	NONE
when	WRB	when	O	O	NONE
paclitaxel	NN	paclitaxel	B-e2	T	drug
and	CC	and	O	O	NONE
doxorubicin	NN	doxorubicin	B-e3	T	drug
are	VBP	be	O	O	NONE
used	VBN	use	O	O	NONE
in	IN	in	O	O	NONE
combination	NN	combination	O	O	NONE
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d480.s10
For	IN	for	O	O	NONE
patients	NNS	patient	O	O	NONE
with	IN	with	O	O	NONE
advanced	JJ	advanced	O	O	NONE
HIV	NN	hiv	B-e0	T	drug
disease	NN	disease	O	O	NONE
and	CC	and	O	O	NONE
poor-risk	JJ	poor-risk	O	O	NONE
AIDS-related	JJ	aids-related	O	O	NONE
Kaposi	NN	kaposus	O	O	NONE
@	NN	@	O	O	NONE
s	NN	s	O	O	NONE
sarcoma	NN	sarcoma	B-e1	O	DISO
,	,	,	O	O	NONE
TAXOL	NN	taxol	B-e2	T	drug
,	,	,	O	O	NONE
at	IN	at	O	O	NONE
the	DT	the	O	O	NONE
recommended	VBN	recommend	O	O	NONE
dose	NN	dose	O	O	NONE
for	IN	for	O	O	NONE
this	DT	this	O	O	NONE
disease	NN	disease	O	O	NONE
,	,	,	O	O	NONE
can	MD	can	O	O	NONE
be	VB	be	O	O	NONE
initiated	VBN	initiate	O	O	NONE
and	CC	and	O	O	NONE
repeated	VBN	repeat	O	O	NONE
if	IN	if	O	O	NONE
the	DT	the	O	O	NONE
neutrophil	NN	neutrophil	O	O	NONE
count	NN	count	O	O	NONE
is	VBZ	be	O	O	NONE
at	IN	at	O	O	NONE
least	JJS	least	O	O	NONE
1000	CD	1000	O	O	NONE
cells/mm3	NN	cells/mm3	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d480.s11
Hypersensitivity	NN	hypersensitivity	O	O	NONE
Reactions	NNS	reaction	O	O	NONE
:	:	:	O	O	NONE
Patients	NNS	patient	O	O	NONE
with	IN	with	O	O	NONE
a	DT	a	O	O	NONE
history	NN	history	O	O	NONE
of	IN	of	O	O	NONE
severe	JJ	severe	O	O	NONE
hypersensitivity	NN	hypersensitivity	O	O	NONE
reactions	NNS	reaction	O	O	NONE
to	TO	to	O	O	NONE
products	NNS	product	O	O	NONE
containing	VBG	contain	O	O	NONE
Cremophor	NN	cremophor	O	O	NONE
@	NN	@	O	O	NONE
EL	NN	el	O	O	NONE
(	(	(	O	O	NONE
eg	NN	eg	O	O	NONE
,	,	,	O	O	NONE
cyclosporin	NN	cyclosporin	B-e0	T	drug
for	IN	for	O	O	NONE
injection	NN	injection	O	O	NONE
concentrate	NN	concentrate	O	O	NONE
and	CC	and	O	O	NONE
teniposide	NN	teniposide	B-e1	T	drug
for	IN	for	O	O	NONE
injection	NN	injection	O	O	NONE
concentrate	NN	concentrate	O	O	NONE
)	)	)	O	O	NONE
should	MD	should	O	O	NONE
not	RB	not	O	O	NONE
be	VB	be	O	O	NONE
treated	VBN	treat	O	O	NONE
with	IN	with	O	O	NONE
TAXOL	NN	taxol	B-e2	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d480.s11
Hypersensitivity	NN	hypersensitivity	O	O	NONE
Reactions	NNS	reaction	O	O	NONE
:	:	:	O	O	NONE
Patients	NNS	patient	O	O	NONE
with	IN	with	O	O	NONE
a	DT	a	O	O	NONE
history	NN	history	O	O	NONE
of	IN	of	O	O	NONE
severe	JJ	severe	O	O	NONE
hypersensitivity	NN	hypersensitivity	O	O	NONE
reactions	NNS	reaction	O	O	NONE
to	TO	to	O	O	NONE
products	NNS	product	O	O	NONE
containing	VBG	contain	O	O	NONE
Cremophor	NN	cremophor	O	O	NONE
@	NN	@	O	O	NONE
EL	NN	el	O	O	NONE
(	(	(	O	O	NONE
eg	NN	eg	O	O	NONE
,	,	,	O	O	NONE
cyclosporin	NN	cyclosporin	B-e0	T	drug
for	IN	for	O	O	NONE
injection	NN	injection	O	O	NONE
concentrate	NN	concentrate	O	O	NONE
and	CC	and	O	O	NONE
teniposide	NN	teniposide	B-e1	O	drug
for	IN	for	O	O	NONE
injection	NN	injection	O	O	NONE
concentrate	NN	concentrate	O	O	NONE
)	)	)	O	O	NONE
should	MD	should	O	O	NONE
not	RB	not	O	O	NONE
be	VB	be	O	O	NONE
treated	VBN	treat	O	O	NONE
with	IN	with	O	O	NONE
TAXOL	NN	taxol	B-e2	T	drug
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d480.s11
Hypersensitivity	NN	hypersensitivity	O	O	NONE
Reactions	NNS	reaction	O	O	NONE
:	:	:	O	O	NONE
Patients	NNS	patient	O	O	NONE
with	IN	with	O	O	NONE
a	DT	a	O	O	NONE
history	NN	history	O	O	NONE
of	IN	of	O	O	NONE
severe	JJ	severe	O	O	NONE
hypersensitivity	NN	hypersensitivity	O	O	NONE
reactions	NNS	reaction	O	O	NONE
to	TO	to	O	O	NONE
products	NNS	product	O	O	NONE
containing	VBG	contain	O	O	NONE
Cremophor	NN	cremophor	O	O	NONE
@	NN	@	O	O	NONE
EL	NN	el	O	O	NONE
(	(	(	O	O	NONE
eg	NN	eg	O	O	NONE
,	,	,	O	O	NONE
cyclosporin	NN	cyclosporin	B-e0	O	drug
for	IN	for	O	O	NONE
injection	NN	injection	O	O	NONE
concentrate	NN	concentrate	O	O	NONE
and	CC	and	O	O	NONE
teniposide	NN	teniposide	B-e1	T	drug
for	IN	for	O	O	NONE
injection	NN	injection	O	O	NONE
concentrate	NN	concentrate	O	O	NONE
)	)	)	O	O	NONE
should	MD	should	O	O	NONE
not	RB	not	O	O	NONE
be	VB	be	O	O	NONE
treated	VBN	treat	O	O	NONE
with	IN	with	O	O	NONE
TAXOL	NN	taxol	B-e2	T	drug
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d480.s12
In	IN	in	O	O	NONE
order	NN	order	O	O	NONE
to	TO	to	O	O	NONE
avoid	VB	avoid	O	O	NONE
the	DT	the	O	O	NONE
occurrence	NN	occurrence	O	O	NONE
of	IN	of	O	O	NONE
severe	JJ	severe	O	O	NONE
hypersensitivity	NN	hypersensitivity	O	O	NONE
reactions	NNS	reaction	O	O	NONE
,	,	,	O	O	NONE
all	DT	all	O	O	NONE
patients	NNS	patient	O	O	NONE
treated	VBN	treat	O	O	NONE
with	IN	with	O	O	NONE
TAXOL	NN	taxol	B-e0	T	drug
should	MD	should	O	O	NONE
be	VB	be	O	O	NONE
premedicated	VBN	premedicate	O	O	NONE
with	IN	with	O	O	NONE
corticosteroids	NNS	corticosteroid	B-e1	T	drug
(	(	(	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
dexamethasone	NN	dexamethasone	B-e2	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
diphen	NN	diphen	B-e3	O	drug
-hydramine	NN	-hydramine	O	O	NONE
and	CC	and	O	O	NONE
H2	NN	h2	O	O	NONE
antagonists	NNS	antagonist	O	O	NONE
(	(	(	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
cimetidine	NN	cimetidine	B-e4	O	drug
or	CC	or	O	O	NONE
ranitidine	NN	ranitidine	B-e5	O	drug
)	)	)	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d480.s12
In	IN	in	O	O	NONE
order	NN	order	O	O	NONE
to	TO	to	O	O	NONE
avoid	VB	avoid	O	O	NONE
the	DT	the	O	O	NONE
occurrence	NN	occurrence	O	O	NONE
of	IN	of	O	O	NONE
severe	JJ	severe	O	O	NONE
hypersensitivity	NN	hypersensitivity	O	O	NONE
reactions	NNS	reaction	O	O	NONE
,	,	,	O	O	NONE
all	DT	all	O	O	NONE
patients	NNS	patient	O	O	NONE
treated	VBN	treat	O	O	NONE
with	IN	with	O	O	NONE
TAXOL	NN	taxol	B-e0	T	drug
should	MD	should	O	O	NONE
be	VB	be	O	O	NONE
premedicated	VBN	premedicate	O	O	NONE
with	IN	with	O	O	NONE
corticosteroids	NNS	corticosteroid	B-e1	O	drug
(	(	(	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
dexamethasone	NN	dexamethasone	B-e2	T	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
diphen	NN	diphen	B-e3	O	drug
-hydramine	NN	-hydramine	O	O	NONE
and	CC	and	O	O	NONE
H2	NN	h2	O	O	NONE
antagonists	NNS	antagonist	O	O	NONE
(	(	(	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
cimetidine	NN	cimetidine	B-e4	O	drug
or	CC	or	O	O	NONE
ranitidine	NN	ranitidine	B-e5	O	drug
)	)	)	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d480.s12
In	IN	in	O	O	NONE
order	NN	order	O	O	NONE
to	TO	to	O	O	NONE
avoid	VB	avoid	O	O	NONE
the	DT	the	O	O	NONE
occurrence	NN	occurrence	O	O	NONE
of	IN	of	O	O	NONE
severe	JJ	severe	O	O	NONE
hypersensitivity	NN	hypersensitivity	O	O	NONE
reactions	NNS	reaction	O	O	NONE
,	,	,	O	O	NONE
all	DT	all	O	O	NONE
patients	NNS	patient	O	O	NONE
treated	VBN	treat	O	O	NONE
with	IN	with	O	O	NONE
TAXOL	NN	taxol	B-e0	T	drug
should	MD	should	O	O	NONE
be	VB	be	O	O	NONE
premedicated	VBN	premedicate	O	O	NONE
with	IN	with	O	O	NONE
corticosteroids	NNS	corticosteroid	B-e1	O	drug
(	(	(	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
dexamethasone	NN	dexamethasone	B-e2	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
diphen	NN	diphen	B-e3	T	drug
-hydramine	NN	-hydramine	O	O	NONE
and	CC	and	O	O	NONE
H2	NN	h2	O	O	NONE
antagonists	NNS	antagonist	O	O	NONE
(	(	(	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
cimetidine	NN	cimetidine	B-e4	O	drug
or	CC	or	O	O	NONE
ranitidine	NN	ranitidine	B-e5	O	drug
)	)	)	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d480.s12
In	IN	in	O	O	NONE
order	NN	order	O	O	NONE
to	TO	to	O	O	NONE
avoid	VB	avoid	O	O	NONE
the	DT	the	O	O	NONE
occurrence	NN	occurrence	O	O	NONE
of	IN	of	O	O	NONE
severe	JJ	severe	O	O	NONE
hypersensitivity	NN	hypersensitivity	O	O	NONE
reactions	NNS	reaction	O	O	NONE
,	,	,	O	O	NONE
all	DT	all	O	O	NONE
patients	NNS	patient	O	O	NONE
treated	VBN	treat	O	O	NONE
with	IN	with	O	O	NONE
TAXOL	NN	taxol	B-e0	T	drug
should	MD	should	O	O	NONE
be	VB	be	O	O	NONE
premedicated	VBN	premedicate	O	O	NONE
with	IN	with	O	O	NONE
corticosteroids	NNS	corticosteroid	B-e1	O	drug
(	(	(	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
dexamethasone	NN	dexamethasone	B-e2	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
diphen	NN	diphen	B-e3	O	drug
-hydramine	NN	-hydramine	O	O	NONE
and	CC	and	O	O	NONE
H2	NN	h2	O	O	NONE
antagonists	NNS	antagonist	O	O	NONE
(	(	(	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
cimetidine	NN	cimetidine	B-e4	T	drug
or	CC	or	O	O	NONE
ranitidine	NN	ranitidine	B-e5	O	drug
)	)	)	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d480.s12
In	IN	in	O	O	NONE
order	NN	order	O	O	NONE
to	TO	to	O	O	NONE
avoid	VB	avoid	O	O	NONE
the	DT	the	O	O	NONE
occurrence	NN	occurrence	O	O	NONE
of	IN	of	O	O	NONE
severe	JJ	severe	O	O	NONE
hypersensitivity	NN	hypersensitivity	O	O	NONE
reactions	NNS	reaction	O	O	NONE
,	,	,	O	O	NONE
all	DT	all	O	O	NONE
patients	NNS	patient	O	O	NONE
treated	VBN	treat	O	O	NONE
with	IN	with	O	O	NONE
TAXOL	NN	taxol	B-e0	T	drug
should	MD	should	O	O	NONE
be	VB	be	O	O	NONE
premedicated	VBN	premedicate	O	O	NONE
with	IN	with	O	O	NONE
corticosteroids	NNS	corticosteroid	B-e1	O	drug
(	(	(	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
dexamethasone	NN	dexamethasone	B-e2	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
diphen	NN	diphen	B-e3	O	drug
-hydramine	NN	-hydramine	O	O	NONE
and	CC	and	O	O	NONE
H2	NN	h2	O	O	NONE
antagonists	NNS	antagonist	O	O	NONE
(	(	(	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
cimetidine	NN	cimetidine	B-e4	O	drug
or	CC	or	O	O	NONE
ranitidine	NN	ranitidine	B-e5	T	drug
)	)	)	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d480.s12
In	IN	in	O	O	NONE
order	NN	order	O	O	NONE
to	TO	to	O	O	NONE
avoid	VB	avoid	O	O	NONE
the	DT	the	O	O	NONE
occurrence	NN	occurrence	O	O	NONE
of	IN	of	O	O	NONE
severe	JJ	severe	O	O	NONE
hypersensitivity	NN	hypersensitivity	O	O	NONE
reactions	NNS	reaction	O	O	NONE
,	,	,	O	O	NONE
all	DT	all	O	O	NONE
patients	NNS	patient	O	O	NONE
treated	VBN	treat	O	O	NONE
with	IN	with	O	O	NONE
TAXOL	NN	taxol	B-e0	O	drug
should	MD	should	O	O	NONE
be	VB	be	O	O	NONE
premedicated	VBN	premedicate	O	O	NONE
with	IN	with	O	O	NONE
corticosteroids	NNS	corticosteroid	B-e1	T	drug
(	(	(	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
dexamethasone	NN	dexamethasone	B-e2	T	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
diphen	NN	diphen	B-e3	O	drug
-hydramine	NN	-hydramine	O	O	NONE
and	CC	and	O	O	NONE
H2	NN	h2	O	O	NONE
antagonists	NNS	antagonist	O	O	NONE
(	(	(	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
cimetidine	NN	cimetidine	B-e4	O	drug
or	CC	or	O	O	NONE
ranitidine	NN	ranitidine	B-e5	O	drug
)	)	)	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d480.s12
In	IN	in	O	O	NONE
order	NN	order	O	O	NONE
to	TO	to	O	O	NONE
avoid	VB	avoid	O	O	NONE
the	DT	the	O	O	NONE
occurrence	NN	occurrence	O	O	NONE
of	IN	of	O	O	NONE
severe	JJ	severe	O	O	NONE
hypersensitivity	NN	hypersensitivity	O	O	NONE
reactions	NNS	reaction	O	O	NONE
,	,	,	O	O	NONE
all	DT	all	O	O	NONE
patients	NNS	patient	O	O	NONE
treated	VBN	treat	O	O	NONE
with	IN	with	O	O	NONE
TAXOL	NN	taxol	B-e0	O	drug
should	MD	should	O	O	NONE
be	VB	be	O	O	NONE
premedicated	VBN	premedicate	O	O	NONE
with	IN	with	O	O	NONE
corticosteroids	NNS	corticosteroid	B-e1	T	drug
(	(	(	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
dexamethasone	NN	dexamethasone	B-e2	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
diphen	NN	diphen	B-e3	T	drug
-hydramine	NN	-hydramine	O	O	NONE
and	CC	and	O	O	NONE
H2	NN	h2	O	O	NONE
antagonists	NNS	antagonist	O	O	NONE
(	(	(	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
cimetidine	NN	cimetidine	B-e4	O	drug
or	CC	or	O	O	NONE
ranitidine	NN	ranitidine	B-e5	O	drug
)	)	)	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d480.s12
In	IN	in	O	O	NONE
order	NN	order	O	O	NONE
to	TO	to	O	O	NONE
avoid	VB	avoid	O	O	NONE
the	DT	the	O	O	NONE
occurrence	NN	occurrence	O	O	NONE
of	IN	of	O	O	NONE
severe	JJ	severe	O	O	NONE
hypersensitivity	NN	hypersensitivity	O	O	NONE
reactions	NNS	reaction	O	O	NONE
,	,	,	O	O	NONE
all	DT	all	O	O	NONE
patients	NNS	patient	O	O	NONE
treated	VBN	treat	O	O	NONE
with	IN	with	O	O	NONE
TAXOL	NN	taxol	B-e0	O	drug
should	MD	should	O	O	NONE
be	VB	be	O	O	NONE
premedicated	VBN	premedicate	O	O	NONE
with	IN	with	O	O	NONE
corticosteroids	NNS	corticosteroid	B-e1	T	drug
(	(	(	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
dexamethasone	NN	dexamethasone	B-e2	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
diphen	NN	diphen	B-e3	O	drug
-hydramine	NN	-hydramine	O	O	NONE
and	CC	and	O	O	NONE
H2	NN	h2	O	O	NONE
antagonists	NNS	antagonist	O	O	NONE
(	(	(	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
cimetidine	NN	cimetidine	B-e4	T	drug
or	CC	or	O	O	NONE
ranitidine	NN	ranitidine	B-e5	O	drug
)	)	)	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d480.s12
In	IN	in	O	O	NONE
order	NN	order	O	O	NONE
to	TO	to	O	O	NONE
avoid	VB	avoid	O	O	NONE
the	DT	the	O	O	NONE
occurrence	NN	occurrence	O	O	NONE
of	IN	of	O	O	NONE
severe	JJ	severe	O	O	NONE
hypersensitivity	NN	hypersensitivity	O	O	NONE
reactions	NNS	reaction	O	O	NONE
,	,	,	O	O	NONE
all	DT	all	O	O	NONE
patients	NNS	patient	O	O	NONE
treated	VBN	treat	O	O	NONE
with	IN	with	O	O	NONE
TAXOL	NN	taxol	B-e0	O	drug
should	MD	should	O	O	NONE
be	VB	be	O	O	NONE
premedicated	VBN	premedicate	O	O	NONE
with	IN	with	O	O	NONE
corticosteroids	NNS	corticosteroid	B-e1	T	drug
(	(	(	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
dexamethasone	NN	dexamethasone	B-e2	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
diphen	NN	diphen	B-e3	O	drug
-hydramine	NN	-hydramine	O	O	NONE
and	CC	and	O	O	NONE
H2	NN	h2	O	O	NONE
antagonists	NNS	antagonist	O	O	NONE
(	(	(	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
cimetidine	NN	cimetidine	B-e4	O	drug
or	CC	or	O	O	NONE
ranitidine	NN	ranitidine	B-e5	T	drug
)	)	)	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d480.s12
In	IN	in	O	O	NONE
order	NN	order	O	O	NONE
to	TO	to	O	O	NONE
avoid	VB	avoid	O	O	NONE
the	DT	the	O	O	NONE
occurrence	NN	occurrence	O	O	NONE
of	IN	of	O	O	NONE
severe	JJ	severe	O	O	NONE
hypersensitivity	NN	hypersensitivity	O	O	NONE
reactions	NNS	reaction	O	O	NONE
,	,	,	O	O	NONE
all	DT	all	O	O	NONE
patients	NNS	patient	O	O	NONE
treated	VBN	treat	O	O	NONE
with	IN	with	O	O	NONE
TAXOL	NN	taxol	B-e0	O	drug
should	MD	should	O	O	NONE
be	VB	be	O	O	NONE
premedicated	VBN	premedicate	O	O	NONE
with	IN	with	O	O	NONE
corticosteroids	NNS	corticosteroid	B-e1	O	drug
(	(	(	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
dexamethasone	NN	dexamethasone	B-e2	T	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
diphen	NN	diphen	B-e3	T	drug
-hydramine	NN	-hydramine	O	O	NONE
and	CC	and	O	O	NONE
H2	NN	h2	O	O	NONE
antagonists	NNS	antagonist	O	O	NONE
(	(	(	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
cimetidine	NN	cimetidine	B-e4	O	drug
or	CC	or	O	O	NONE
ranitidine	NN	ranitidine	B-e5	O	drug
)	)	)	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d480.s12
In	IN	in	O	O	NONE
order	NN	order	O	O	NONE
to	TO	to	O	O	NONE
avoid	VB	avoid	O	O	NONE
the	DT	the	O	O	NONE
occurrence	NN	occurrence	O	O	NONE
of	IN	of	O	O	NONE
severe	JJ	severe	O	O	NONE
hypersensitivity	NN	hypersensitivity	O	O	NONE
reactions	NNS	reaction	O	O	NONE
,	,	,	O	O	NONE
all	DT	all	O	O	NONE
patients	NNS	patient	O	O	NONE
treated	VBN	treat	O	O	NONE
with	IN	with	O	O	NONE
TAXOL	NN	taxol	B-e0	O	drug
should	MD	should	O	O	NONE
be	VB	be	O	O	NONE
premedicated	VBN	premedicate	O	O	NONE
with	IN	with	O	O	NONE
corticosteroids	NNS	corticosteroid	B-e1	O	drug
(	(	(	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
dexamethasone	NN	dexamethasone	B-e2	T	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
diphen	NN	diphen	B-e3	O	drug
-hydramine	NN	-hydramine	O	O	NONE
and	CC	and	O	O	NONE
H2	NN	h2	O	O	NONE
antagonists	NNS	antagonist	O	O	NONE
(	(	(	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
cimetidine	NN	cimetidine	B-e4	T	drug
or	CC	or	O	O	NONE
ranitidine	NN	ranitidine	B-e5	O	drug
)	)	)	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d480.s12
In	IN	in	O	O	NONE
order	NN	order	O	O	NONE
to	TO	to	O	O	NONE
avoid	VB	avoid	O	O	NONE
the	DT	the	O	O	NONE
occurrence	NN	occurrence	O	O	NONE
of	IN	of	O	O	NONE
severe	JJ	severe	O	O	NONE
hypersensitivity	NN	hypersensitivity	O	O	NONE
reactions	NNS	reaction	O	O	NONE
,	,	,	O	O	NONE
all	DT	all	O	O	NONE
patients	NNS	patient	O	O	NONE
treated	VBN	treat	O	O	NONE
with	IN	with	O	O	NONE
TAXOL	NN	taxol	B-e0	O	drug
should	MD	should	O	O	NONE
be	VB	be	O	O	NONE
premedicated	VBN	premedicate	O	O	NONE
with	IN	with	O	O	NONE
corticosteroids	NNS	corticosteroid	B-e1	O	drug
(	(	(	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
dexamethasone	NN	dexamethasone	B-e2	T	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
diphen	NN	diphen	B-e3	O	drug
-hydramine	NN	-hydramine	O	O	NONE
and	CC	and	O	O	NONE
H2	NN	h2	O	O	NONE
antagonists	NNS	antagonist	O	O	NONE
(	(	(	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
cimetidine	NN	cimetidine	B-e4	O	drug
or	CC	or	O	O	NONE
ranitidine	NN	ranitidine	B-e5	T	drug
)	)	)	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d480.s12
In	IN	in	O	O	NONE
order	NN	order	O	O	NONE
to	TO	to	O	O	NONE
avoid	VB	avoid	O	O	NONE
the	DT	the	O	O	NONE
occurrence	NN	occurrence	O	O	NONE
of	IN	of	O	O	NONE
severe	JJ	severe	O	O	NONE
hypersensitivity	NN	hypersensitivity	O	O	NONE
reactions	NNS	reaction	O	O	NONE
,	,	,	O	O	NONE
all	DT	all	O	O	NONE
patients	NNS	patient	O	O	NONE
treated	VBN	treat	O	O	NONE
with	IN	with	O	O	NONE
TAXOL	NN	taxol	B-e0	O	drug
should	MD	should	O	O	NONE
be	VB	be	O	O	NONE
premedicated	VBN	premedicate	O	O	NONE
with	IN	with	O	O	NONE
corticosteroids	NNS	corticosteroid	B-e1	O	drug
(	(	(	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
dexamethasone	NN	dexamethasone	B-e2	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
diphen	NN	diphen	B-e3	T	drug
-hydramine	NN	-hydramine	O	O	NONE
and	CC	and	O	O	NONE
H2	NN	h2	O	O	NONE
antagonists	NNS	antagonist	O	O	NONE
(	(	(	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
cimetidine	NN	cimetidine	B-e4	T	drug
or	CC	or	O	O	NONE
ranitidine	NN	ranitidine	B-e5	O	drug
)	)	)	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d480.s12
In	IN	in	O	O	NONE
order	NN	order	O	O	NONE
to	TO	to	O	O	NONE
avoid	VB	avoid	O	O	NONE
the	DT	the	O	O	NONE
occurrence	NN	occurrence	O	O	NONE
of	IN	of	O	O	NONE
severe	JJ	severe	O	O	NONE
hypersensitivity	NN	hypersensitivity	O	O	NONE
reactions	NNS	reaction	O	O	NONE
,	,	,	O	O	NONE
all	DT	all	O	O	NONE
patients	NNS	patient	O	O	NONE
treated	VBN	treat	O	O	NONE
with	IN	with	O	O	NONE
TAXOL	NN	taxol	B-e0	O	drug
should	MD	should	O	O	NONE
be	VB	be	O	O	NONE
premedicated	VBN	premedicate	O	O	NONE
with	IN	with	O	O	NONE
corticosteroids	NNS	corticosteroid	B-e1	O	drug
(	(	(	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
dexamethasone	NN	dexamethasone	B-e2	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
diphen	NN	diphen	B-e3	T	drug
-hydramine	NN	-hydramine	O	O	NONE
and	CC	and	O	O	NONE
H2	NN	h2	O	O	NONE
antagonists	NNS	antagonist	O	O	NONE
(	(	(	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
cimetidine	NN	cimetidine	B-e4	O	drug
or	CC	or	O	O	NONE
ranitidine	NN	ranitidine	B-e5	T	drug
)	)	)	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d480.s12
In	IN	in	O	O	NONE
order	NN	order	O	O	NONE
to	TO	to	O	O	NONE
avoid	VB	avoid	O	O	NONE
the	DT	the	O	O	NONE
occurrence	NN	occurrence	O	O	NONE
of	IN	of	O	O	NONE
severe	JJ	severe	O	O	NONE
hypersensitivity	NN	hypersensitivity	O	O	NONE
reactions	NNS	reaction	O	O	NONE
,	,	,	O	O	NONE
all	DT	all	O	O	NONE
patients	NNS	patient	O	O	NONE
treated	VBN	treat	O	O	NONE
with	IN	with	O	O	NONE
TAXOL	NN	taxol	B-e0	O	drug
should	MD	should	O	O	NONE
be	VB	be	O	O	NONE
premedicated	VBN	premedicate	O	O	NONE
with	IN	with	O	O	NONE
corticosteroids	NNS	corticosteroid	B-e1	O	drug
(	(	(	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
dexamethasone	NN	dexamethasone	B-e2	O	drug
)	)	)	O	O	NONE
,	,	,	O	O	NONE
diphen	NN	diphen	B-e3	O	drug
-hydramine	NN	-hydramine	O	O	NONE
and	CC	and	O	O	NONE
H2	NN	h2	O	O	NONE
antagonists	NNS	antagonist	O	O	NONE
(	(	(	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
cimetidine	NN	cimetidine	B-e4	T	drug
or	CC	or	O	O	NONE
ranitidine	NN	ranitidine	B-e5	T	drug
)	)	)	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d480.s14
However	RB	however	O	O	NONE
,	,	,	O	O	NONE
severe	JJ	severe	O	O	NONE
reactions	NNS	reaction	O	O	NONE
,	,	,	O	O	NONE
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
hypotension	NN	hypotension	O	O	NONE
requiring	VBG	require	O	O	NONE
treatment	NN	treatment	O	O	NONE
,	,	,	O	O	NONE
dyspnea	NN	dyspnea	O	O	NONE
requiring	VBG	require	O	O	NONE
bronchodilators	NNS	bronchodilator	B-e0	T	drug
,	,	,	O	O	NONE
angioedema	NN	angioedema	O	O	NONE
,	,	,	O	O	NONE
or	CC	or	O	O	NONE
generalized	JJ	generalized	O	O	NONE
urticaria	NN	urticarium	O	O	NONE
require	VBP	require	O	O	NONE
immediate	JJ	immediate	O	O	NONE
discontinuation	NN	discontinuation	O	O	NONE
of	IN	of	O	O	NONE
TAXOL	NN	taxol	B-e1	T	drug
and	CC	and	O	O	NONE
aggressive	JJ	aggressive	O	O	NONE
symptomatic	JJ	symptomatic	O	O	NONE
therapy	NN	therapy	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d480.s21
TAXOL	NN	taxol	B-e0	T	drug
contains	VBZ	contain	O	O	NONE
dehydrated	JJ	dehydrated	B-e1	T	drug
alcohol	NN	alcohol	I-e1	T	drug
USP	NN	usp	I-e1	T	drug
,	,	,	O	O	NONE
396	CD	396	O	O	NONE
mg/mL	NN	mg/ml	O	O	NONE
;	:	;	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d235.s0
Aminoglycosides	NNS	aminoglycoside	B-e0	T	drug
:	:	:	O	O	NONE
The	DT	the	O	O	NONE
mixing	NN	mixing	O	O	NONE
of	IN	of	O	O	NONE
piperacillin	NN	piperacillin	B-e1	T	drug
with	IN	with	O	O	NONE
an	DT	a	O	O	NONE
aminoglycoside	NN	aminoglycoside	B-e2	O	drug
in	IN	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
can	MD	can	O	O	NONE
result	VB	result	O	O	NONE
in	IN	in	O	O	NONE
substantial	JJ	substantial	O	O	NONE
inactivation	NN	inactivation	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
aminoglycoside	NN	aminoglycoside	B-e3	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d235.s0
Aminoglycosides	NNS	aminoglycoside	B-e0	T	drug
:	:	:	O	O	NONE
The	DT	the	O	O	NONE
mixing	NN	mixing	O	O	NONE
of	IN	of	O	O	NONE
piperacillin	NN	piperacillin	B-e1	O	drug
with	IN	with	O	O	NONE
an	DT	a	O	O	NONE
aminoglycoside	NN	aminoglycoside	B-e2	T	drug
in	IN	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
can	MD	can	O	O	NONE
result	VB	result	O	O	NONE
in	IN	in	O	O	NONE
substantial	JJ	substantial	O	O	NONE
inactivation	NN	inactivation	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
aminoglycoside	NN	aminoglycoside	B-e3	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d235.s0
Aminoglycosides	NNS	aminoglycoside	B-e0	T	drug
:	:	:	O	O	NONE
The	DT	the	O	O	NONE
mixing	NN	mixing	O	O	NONE
of	IN	of	O	O	NONE
piperacillin	NN	piperacillin	B-e1	O	drug
with	IN	with	O	O	NONE
an	DT	a	O	O	NONE
aminoglycoside	NN	aminoglycoside	B-e2	O	drug
in	IN	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
can	MD	can	O	O	NONE
result	VB	result	O	O	NONE
in	IN	in	O	O	NONE
substantial	JJ	substantial	O	O	NONE
inactivation	NN	inactivation	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
aminoglycoside	NN	aminoglycoside	B-e3	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d235.s0
Aminoglycosides	NNS	aminoglycoside	B-e0	O	drug
:	:	:	O	O	NONE
The	DT	the	O	O	NONE
mixing	NN	mixing	O	O	NONE
of	IN	of	O	O	NONE
piperacillin	NN	piperacillin	B-e1	T	drug
with	IN	with	O	O	NONE
an	DT	a	O	O	NONE
aminoglycoside	NN	aminoglycoside	B-e2	T	drug
in	IN	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
can	MD	can	O	O	NONE
result	VB	result	O	O	NONE
in	IN	in	O	O	NONE
substantial	JJ	substantial	O	O	NONE
inactivation	NN	inactivation	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
aminoglycoside	NN	aminoglycoside	B-e3	O	drug
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d235.s0
Aminoglycosides	NNS	aminoglycoside	B-e0	O	drug
:	:	:	O	O	NONE
The	DT	the	O	O	NONE
mixing	NN	mixing	O	O	NONE
of	IN	of	O	O	NONE
piperacillin	NN	piperacillin	B-e1	T	drug
with	IN	with	O	O	NONE
an	DT	a	O	O	NONE
aminoglycoside	NN	aminoglycoside	B-e2	O	drug
in	IN	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
can	MD	can	O	O	NONE
result	VB	result	O	O	NONE
in	IN	in	O	O	NONE
substantial	JJ	substantial	O	O	NONE
inactivation	NN	inactivation	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
aminoglycoside	NN	aminoglycoside	B-e3	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d235.s0
Aminoglycosides	NNS	aminoglycoside	B-e0	O	drug
:	:	:	O	O	NONE
The	DT	the	O	O	NONE
mixing	NN	mixing	O	O	NONE
of	IN	of	O	O	NONE
piperacillin	NN	piperacillin	B-e1	O	drug
with	IN	with	O	O	NONE
an	DT	a	O	O	NONE
aminoglycoside	NN	aminoglycoside	B-e2	T	drug
in	IN	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
can	MD	can	O	O	NONE
result	VB	result	O	O	NONE
in	IN	in	O	O	NONE
substantial	JJ	substantial	O	O	NONE
inactivation	NN	inactivation	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
aminoglycoside	NN	aminoglycoside	B-e3	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d235.s1
Vecuronium	NN	vecuronium	B-e0	T	drug
:	:	:	O	O	NONE
When	WRB	when	O	O	NONE
used	VBN	use	O	O	NONE
in	IN	in	O	O	NONE
the	DT	the	O	O	NONE
perioperative	JJ	perioperative	O	O	NONE
period	NN	period	O	O	NONE
,	,	,	O	O	NONE
piperacillin	NN	piperacillin	B-e1	T	drug
has	VBZ	have	O	O	NONE
been	VBN	be	O	O	NONE
implicated	VBN	implicate	O	O	NONE
in	IN	in	O	O	NONE
the	DT	the	O	O	NONE
prolongation	NN	prolongation	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
neuromuscular	JJ	neuromuscular	O	O	NONE
blockade	NN	blockade	O	O	NONE
of	IN	of	O	O	NONE
vecuronium	NN	vecuronium	B-e2	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d235.s1
Vecuronium	NN	vecuronium	B-e0	T	drug
:	:	:	O	O	NONE
When	WRB	when	O	O	NONE
used	VBN	use	O	O	NONE
in	IN	in	O	O	NONE
the	DT	the	O	O	NONE
perioperative	JJ	perioperative	O	O	NONE
period	NN	period	O	O	NONE
,	,	,	O	O	NONE
piperacillin	NN	piperacillin	B-e1	O	drug
has	VBZ	have	O	O	NONE
been	VBN	be	O	O	NONE
implicated	VBN	implicate	O	O	NONE
in	IN	in	O	O	NONE
the	DT	the	O	O	NONE
prolongation	NN	prolongation	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
neuromuscular	JJ	neuromuscular	O	O	NONE
blockade	NN	blockade	O	O	NONE
of	IN	of	O	O	NONE
vecuronium	NN	vecuronium	B-e2	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d235.s1
Vecuronium	NN	vecuronium	B-e0	O	drug
:	:	:	O	O	NONE
When	WRB	when	O	O	NONE
used	VBN	use	O	O	NONE
in	IN	in	O	O	NONE
the	DT	the	O	O	NONE
perioperative	JJ	perioperative	O	O	NONE
period	NN	period	O	O	NONE
,	,	,	O	O	NONE
piperacillin	NN	piperacillin	B-e1	T	drug
has	VBZ	have	O	O	NONE
been	VBN	be	O	O	NONE
implicated	VBN	implicate	O	O	NONE
in	IN	in	O	O	NONE
the	DT	the	O	O	NONE
prolongation	NN	prolongation	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
neuromuscular	JJ	neuromuscular	O	O	NONE
blockade	NN	blockade	O	O	NONE
of	IN	of	O	O	NONE
vecuronium	NN	vecuronium	B-e2	T	drug
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d235.s3
In	IN	in	O	O	NONE
one	CD	one	O	O	NONE
controlled	JJ	controlled	O	O	NONE
clinical	JJ	clinical	O	O	NONE
study	NN	study	O	O	NONE
,	,	,	O	O	NONE
the	DT	the	O	O	NONE
ureidopenicillins	NNS	ureidopenicillin	O	O	NONE
,	,	,	O	O	NONE
including	VBG	include	O	O	NONE
piperacillin	NN	piperacillin	B-e0	T	drug
,	,	,	O	O	NONE
were	VBD	be	O	O	NONE
reported	VBN	report	O	O	NONE
to	TO	to	O	O	NONE
prolong	VB	prolong	O	O	NONE
the	DT	the	O	O	NONE
action	NN	action	O	O	NONE
of	IN	of	O	O	NONE
vecuronium	NN	vecuronium	B-e1	T	drug
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d235.s4
Due	JJ	due	O	O	NONE
to	TO	to	O	O	NONE
their	PRP$	they	O	O	NONE
similar	JJ	similar	O	O	NONE
mechanism	NN	mechanism	O	O	NONE
of	IN	of	O	O	NONE
action	NN	action	O	O	NONE
,	,	,	O	O	NONE
it	PRP	it	O	O	NONE
is	VBZ	be	O	O	NONE
expected	VBN	expect	O	O	NONE
that	IN	that	O	O	NONE
the	DT	the	O	O	NONE
neuromuscular	JJ	neuromuscular	O	O	NONE
blockade	NN	blockade	O	O	NONE
produced	VBN	produce	O	O	NONE
by	IN	by	O	O	NONE
any	DT	any	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
non-depolarizing	JJ	non-depolarizing	B-e0	T	drug
muscle	NN	muscle	I-e0	T	drug
relaxants	NNS	relaxant	I-e0	T	drug
could	MD	could	O	O	NONE
be	VB	be	O	O	NONE
prolonged	VBD	prolong	O	O	NONE
in	IN	in	O	O	NONE
the	DT	the	O	O	NONE
presence	NN	presence	O	O	NONE
of	IN	of	O	O	NONE
piperacillin	NN	piperacillin	B-e1	T	drug
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d235.s5
Probenecid	NN	probenecid	B-e0	T	drug
:	:	:	O	O	NONE
The	DT	the	O	O	NONE
oral	JJ	oral	O	O	NONE
combination	NN	combination	O	O	NONE
of	IN	of	O	O	NONE
probenecid	NN	probenecid	B-e1	T	drug
before	IN	before	O	O	NONE
intramuscular	JJ	intramuscular	O	O	NONE
injection	NN	injection	O	O	NONE
of	IN	of	O	O	NONE
PIPRACIL	NN	pipracil	B-e2	O	drug
produces	VBZ	produce	O	O	NONE
an	DT	a	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
piperacillin	JJ	piperacillin	B-e3	O	drug
peak	JJ	peak	O	O	NONE
serum	NN	serum	O	O	NONE
level	NN	level	O	O	NONE
of	IN	of	O	O	NONE
about	RB	about	O	O	NONE
30	CD	30	O	O	NONE
%.	NN	%.	O	O	NONE

NO

Sentence: DrugDDI.d235.s5
Probenecid	NN	probenecid	B-e0	T	drug
:	:	:	O	O	NONE
The	DT	the	O	O	NONE
oral	JJ	oral	O	O	NONE
combination	NN	combination	O	O	NONE
of	IN	of	O	O	NONE
probenecid	NN	probenecid	B-e1	O	drug
before	IN	before	O	O	NONE
intramuscular	JJ	intramuscular	O	O	NONE
injection	NN	injection	O	O	NONE
of	IN	of	O	O	NONE
PIPRACIL	NN	pipracil	B-e2	T	drug
produces	VBZ	produce	O	O	NONE
an	DT	a	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
piperacillin	JJ	piperacillin	B-e3	O	drug
peak	JJ	peak	O	O	NONE
serum	NN	serum	O	O	NONE
level	NN	level	O	O	NONE
of	IN	of	O	O	NONE
about	RB	about	O	O	NONE
30	CD	30	O	O	NONE
%.	NN	%.	O	O	NONE

NO

Sentence: DrugDDI.d235.s5
Probenecid	NN	probenecid	B-e0	T	drug
:	:	:	O	O	NONE
The	DT	the	O	O	NONE
oral	JJ	oral	O	O	NONE
combination	NN	combination	O	O	NONE
of	IN	of	O	O	NONE
probenecid	NN	probenecid	B-e1	O	drug
before	IN	before	O	O	NONE
intramuscular	JJ	intramuscular	O	O	NONE
injection	NN	injection	O	O	NONE
of	IN	of	O	O	NONE
PIPRACIL	NN	pipracil	B-e2	O	drug
produces	VBZ	produce	O	O	NONE
an	DT	a	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
piperacillin	JJ	piperacillin	B-e3	T	drug
peak	JJ	peak	O	O	NONE
serum	NN	serum	O	O	NONE
level	NN	level	O	O	NONE
of	IN	of	O	O	NONE
about	RB	about	O	O	NONE
30	CD	30	O	O	NONE
%.	NN	%.	O	O	NONE

NO

Sentence: DrugDDI.d235.s5
Probenecid	NN	probenecid	B-e0	O	drug
:	:	:	O	O	NONE
The	DT	the	O	O	NONE
oral	JJ	oral	O	O	NONE
combination	NN	combination	O	O	NONE
of	IN	of	O	O	NONE
probenecid	NN	probenecid	B-e1	T	drug
before	IN	before	O	O	NONE
intramuscular	JJ	intramuscular	O	O	NONE
injection	NN	injection	O	O	NONE
of	IN	of	O	O	NONE
PIPRACIL	NN	pipracil	B-e2	T	drug
produces	VBZ	produce	O	O	NONE
an	DT	a	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
piperacillin	JJ	piperacillin	B-e3	O	drug
peak	JJ	peak	O	O	NONE
serum	NN	serum	O	O	NONE
level	NN	level	O	O	NONE
of	IN	of	O	O	NONE
about	RB	about	O	O	NONE
30	CD	30	O	O	NONE
%.	NN	%.	O	O	NONE

YES

Sentence: DrugDDI.d235.s5
Probenecid	NN	probenecid	B-e0	O	drug
:	:	:	O	O	NONE
The	DT	the	O	O	NONE
oral	JJ	oral	O	O	NONE
combination	NN	combination	O	O	NONE
of	IN	of	O	O	NONE
probenecid	NN	probenecid	B-e1	T	drug
before	IN	before	O	O	NONE
intramuscular	JJ	intramuscular	O	O	NONE
injection	NN	injection	O	O	NONE
of	IN	of	O	O	NONE
PIPRACIL	NN	pipracil	B-e2	O	drug
produces	VBZ	produce	O	O	NONE
an	DT	a	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
piperacillin	JJ	piperacillin	B-e3	T	drug
peak	JJ	peak	O	O	NONE
serum	NN	serum	O	O	NONE
level	NN	level	O	O	NONE
of	IN	of	O	O	NONE
about	RB	about	O	O	NONE
30	CD	30	O	O	NONE
%.	NN	%.	O	O	NONE

NO

Sentence: DrugDDI.d235.s5
Probenecid	NN	probenecid	B-e0	O	drug
:	:	:	O	O	NONE
The	DT	the	O	O	NONE
oral	JJ	oral	O	O	NONE
combination	NN	combination	O	O	NONE
of	IN	of	O	O	NONE
probenecid	NN	probenecid	B-e1	O	drug
before	IN	before	O	O	NONE
intramuscular	JJ	intramuscular	O	O	NONE
injection	NN	injection	O	O	NONE
of	IN	of	O	O	NONE
PIPRACIL	NN	pipracil	B-e2	T	drug
produces	VBZ	produce	O	O	NONE
an	DT	a	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
piperacillin	JJ	piperacillin	B-e3	T	drug
peak	JJ	peak	O	O	NONE
serum	NN	serum	O	O	NONE
level	NN	level	O	O	NONE
of	IN	of	O	O	NONE
about	RB	about	O	O	NONE
30	CD	30	O	O	NONE
%.	NN	%.	O	O	NONE

NO

Sentence: DrugDDI.d235.s6
Anticoagulants	NNS	anticoagulant	B-e0	T	drug
Coagulation	NN	coagulation	O	O	NONE
parameters	NNS	parameter	O	O	NONE
should	MD	should	O	O	NONE
be	VB	be	O	O	NONE
tested	VBN	test	O	O	NONE
more	RBR	more	O	O	NONE
frequently	RB	frequently	O	O	NONE
and	CC	and	O	O	NONE
monitored	VBN	monitor	O	O	NONE
regularly	RB	regularly	O	O	NONE
during	IN	during	O	O	NONE
simultaneous	JJ	simultaneous	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
high	JJ	high	O	O	NONE
doses	NNS	dose	O	O	NONE
of	IN	of	O	O	NONE
heparin	NN	heparin	B-e1	T	drug
,	,	,	O	O	NONE
oral	JJ	oral	B-e2	O	drug
anticoagulants	NNS	anticoagulant	I-e2	O	drug
,	,	,	O	O	NONE
or	CC	or	O	O	NONE
other	JJ	other	O	O	NONE
drugs	NNS	drug	B-e3	O	drug
that	WDT	that	O	O	NONE
may	MD	may	O	O	NONE
affect	VB	affect	O	O	NONE
the	DT	the	O	O	NONE
blood	NN	blood	O	O	NONE
coagulation	NN	coagulation	O	O	NONE
system	NN	system	O	O	NONE
or	CC	or	O	O	NONE
the	DT	the	O	O	NONE
thrombocyte	JJ	thrombocyte	O	O	NONE
function	NN	function	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d235.s6
Anticoagulants	NNS	anticoagulant	B-e0	T	drug
Coagulation	NN	coagulation	O	O	NONE
parameters	NNS	parameter	O	O	NONE
should	MD	should	O	O	NONE
be	VB	be	O	O	NONE
tested	VBN	test	O	O	NONE
more	RBR	more	O	O	NONE
frequently	RB	frequently	O	O	NONE
and	CC	and	O	O	NONE
monitored	VBN	monitor	O	O	NONE
regularly	RB	regularly	O	O	NONE
during	IN	during	O	O	NONE
simultaneous	JJ	simultaneous	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
high	JJ	high	O	O	NONE
doses	NNS	dose	O	O	NONE
of	IN	of	O	O	NONE
heparin	NN	heparin	B-e1	O	drug
,	,	,	O	O	NONE
oral	JJ	oral	B-e2	T	drug
anticoagulants	NNS	anticoagulant	I-e2	T	drug
,	,	,	O	O	NONE
or	CC	or	O	O	NONE
other	JJ	other	O	O	NONE
drugs	NNS	drug	B-e3	O	drug
that	WDT	that	O	O	NONE
may	MD	may	O	O	NONE
affect	VB	affect	O	O	NONE
the	DT	the	O	O	NONE
blood	NN	blood	O	O	NONE
coagulation	NN	coagulation	O	O	NONE
system	NN	system	O	O	NONE
or	CC	or	O	O	NONE
the	DT	the	O	O	NONE
thrombocyte	JJ	thrombocyte	O	O	NONE
function	NN	function	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d235.s6
Anticoagulants	NNS	anticoagulant	B-e0	T	drug
Coagulation	NN	coagulation	O	O	NONE
parameters	NNS	parameter	O	O	NONE
should	MD	should	O	O	NONE
be	VB	be	O	O	NONE
tested	VBN	test	O	O	NONE
more	RBR	more	O	O	NONE
frequently	RB	frequently	O	O	NONE
and	CC	and	O	O	NONE
monitored	VBN	monitor	O	O	NONE
regularly	RB	regularly	O	O	NONE
during	IN	during	O	O	NONE
simultaneous	JJ	simultaneous	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
high	JJ	high	O	O	NONE
doses	NNS	dose	O	O	NONE
of	IN	of	O	O	NONE
heparin	NN	heparin	B-e1	O	drug
,	,	,	O	O	NONE
oral	JJ	oral	B-e2	O	drug
anticoagulants	NNS	anticoagulant	I-e2	O	drug
,	,	,	O	O	NONE
or	CC	or	O	O	NONE
other	JJ	other	O	O	NONE
drugs	NNS	drug	B-e3	T	drug
that	WDT	that	O	O	NONE
may	MD	may	O	O	NONE
affect	VB	affect	O	O	NONE
the	DT	the	O	O	NONE
blood	NN	blood	O	O	NONE
coagulation	NN	coagulation	O	O	NONE
system	NN	system	O	O	NONE
or	CC	or	O	O	NONE
the	DT	the	O	O	NONE
thrombocyte	JJ	thrombocyte	O	O	NONE
function	NN	function	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d235.s6
Anticoagulants	NNS	anticoagulant	B-e0	O	drug
Coagulation	NN	coagulation	O	O	NONE
parameters	NNS	parameter	O	O	NONE
should	MD	should	O	O	NONE
be	VB	be	O	O	NONE
tested	VBN	test	O	O	NONE
more	RBR	more	O	O	NONE
frequently	RB	frequently	O	O	NONE
and	CC	and	O	O	NONE
monitored	VBN	monitor	O	O	NONE
regularly	RB	regularly	O	O	NONE
during	IN	during	O	O	NONE
simultaneous	JJ	simultaneous	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
high	JJ	high	O	O	NONE
doses	NNS	dose	O	O	NONE
of	IN	of	O	O	NONE
heparin	NN	heparin	B-e1	T	drug
,	,	,	O	O	NONE
oral	JJ	oral	B-e2	T	drug
anticoagulants	NNS	anticoagulant	I-e2	T	drug
,	,	,	O	O	NONE
or	CC	or	O	O	NONE
other	JJ	other	O	O	NONE
drugs	NNS	drug	B-e3	O	drug
that	WDT	that	O	O	NONE
may	MD	may	O	O	NONE
affect	VB	affect	O	O	NONE
the	DT	the	O	O	NONE
blood	NN	blood	O	O	NONE
coagulation	NN	coagulation	O	O	NONE
system	NN	system	O	O	NONE
or	CC	or	O	O	NONE
the	DT	the	O	O	NONE
thrombocyte	JJ	thrombocyte	O	O	NONE
function	NN	function	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d235.s6
Anticoagulants	NNS	anticoagulant	B-e0	O	drug
Coagulation	NN	coagulation	O	O	NONE
parameters	NNS	parameter	O	O	NONE
should	MD	should	O	O	NONE
be	VB	be	O	O	NONE
tested	VBN	test	O	O	NONE
more	RBR	more	O	O	NONE
frequently	RB	frequently	O	O	NONE
and	CC	and	O	O	NONE
monitored	VBN	monitor	O	O	NONE
regularly	RB	regularly	O	O	NONE
during	IN	during	O	O	NONE
simultaneous	JJ	simultaneous	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
high	JJ	high	O	O	NONE
doses	NNS	dose	O	O	NONE
of	IN	of	O	O	NONE
heparin	NN	heparin	B-e1	T	drug
,	,	,	O	O	NONE
oral	JJ	oral	B-e2	O	drug
anticoagulants	NNS	anticoagulant	I-e2	O	drug
,	,	,	O	O	NONE
or	CC	or	O	O	NONE
other	JJ	other	O	O	NONE
drugs	NNS	drug	B-e3	T	drug
that	WDT	that	O	O	NONE
may	MD	may	O	O	NONE
affect	VB	affect	O	O	NONE
the	DT	the	O	O	NONE
blood	NN	blood	O	O	NONE
coagulation	NN	coagulation	O	O	NONE
system	NN	system	O	O	NONE
or	CC	or	O	O	NONE
the	DT	the	O	O	NONE
thrombocyte	JJ	thrombocyte	O	O	NONE
function	NN	function	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d235.s6
Anticoagulants	NNS	anticoagulant	B-e0	O	drug
Coagulation	NN	coagulation	O	O	NONE
parameters	NNS	parameter	O	O	NONE
should	MD	should	O	O	NONE
be	VB	be	O	O	NONE
tested	VBN	test	O	O	NONE
more	RBR	more	O	O	NONE
frequently	RB	frequently	O	O	NONE
and	CC	and	O	O	NONE
monitored	VBN	monitor	O	O	NONE
regularly	RB	regularly	O	O	NONE
during	IN	during	O	O	NONE
simultaneous	JJ	simultaneous	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
high	JJ	high	O	O	NONE
doses	NNS	dose	O	O	NONE
of	IN	of	O	O	NONE
heparin	NN	heparin	B-e1	O	drug
,	,	,	O	O	NONE
oral	JJ	oral	B-e2	T	drug
anticoagulants	NNS	anticoagulant	I-e2	T	drug
,	,	,	O	O	NONE
or	CC	or	O	O	NONE
other	JJ	other	O	O	NONE
drugs	NNS	drug	B-e3	T	drug
that	WDT	that	O	O	NONE
may	MD	may	O	O	NONE
affect	VB	affect	O	O	NONE
the	DT	the	O	O	NONE
blood	NN	blood	O	O	NONE
coagulation	NN	coagulation	O	O	NONE
system	NN	system	O	O	NONE
or	CC	or	O	O	NONE
the	DT	the	O	O	NONE
thrombocyte	JJ	thrombocyte	O	O	NONE
function	NN	function	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d235.s7
Methotrexate	NN	methotrexate	B-e0	T	drug
Piperacillin	NN	piperacillin	I-e0	T	drug
sodium	NN	sodium	O	O	NONE
may	MD	may	O	O	NONE
reduce	VB	reduce	O	O	NONE
the	DT	the	O	O	NONE
excretion	NN	excretion	O	O	NONE
of	IN	of	O	O	NONE
methotrexate	NN	methotrexate	B-e1	T	drug
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d235.s9
Drug	NN	drug	B-e0	T	drug
/Laboratory	NN	/laboratory	O	O	NONE
Test	NN	test	O	O	NONE
Interactions	NNS	interaction	O	O	NONE
:	:	:	O	O	NONE
As	IN	as	O	O	NONE
with	IN	with	O	O	NONE
other	JJ	other	B-e1	T	drug
penicillins	NNS	penicillin	I-e1	T	drug
,	,	,	O	O	NONE
the	DT	the	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
PIPRACIL	NN	pipracil	B-e2	O	drug
may	MD	may	O	O	NONE
result	VB	result	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
false-positive	JJ	false-positive	O	O	NONE
reaction	NN	reaction	O	O	NONE
for	IN	for	O	O	NONE
glucose	NN	glucose	B-e3	O	drug
in	IN	in	O	O	NONE
the	DT	the	O	O	NONE
urine	NN	urine	O	O	NONE
using	VBG	use	O	O	NONE
a	DT	a	O	O	NONE
copper	NN	copper	B-e4	O	drug
-reduction	NN	-reduction	O	O	NONE
method	NN	method	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d235.s9
Drug	NN	drug	B-e0	T	drug
/Laboratory	NN	/laboratory	O	O	NONE
Test	NN	test	O	O	NONE
Interactions	NNS	interaction	O	O	NONE
:	:	:	O	O	NONE
As	IN	as	O	O	NONE
with	IN	with	O	O	NONE
other	JJ	other	B-e1	O	drug
penicillins	NNS	penicillin	I-e1	O	drug
,	,	,	O	O	NONE
the	DT	the	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
PIPRACIL	NN	pipracil	B-e2	T	drug
may	MD	may	O	O	NONE
result	VB	result	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
false-positive	JJ	false-positive	O	O	NONE
reaction	NN	reaction	O	O	NONE
for	IN	for	O	O	NONE
glucose	NN	glucose	B-e3	O	drug
in	IN	in	O	O	NONE
the	DT	the	O	O	NONE
urine	NN	urine	O	O	NONE
using	VBG	use	O	O	NONE
a	DT	a	O	O	NONE
copper	NN	copper	B-e4	O	drug
-reduction	NN	-reduction	O	O	NONE
method	NN	method	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d235.s9
Drug	NN	drug	B-e0	T	drug
/Laboratory	NN	/laboratory	O	O	NONE
Test	NN	test	O	O	NONE
Interactions	NNS	interaction	O	O	NONE
:	:	:	O	O	NONE
As	IN	as	O	O	NONE
with	IN	with	O	O	NONE
other	JJ	other	B-e1	O	drug
penicillins	NNS	penicillin	I-e1	O	drug
,	,	,	O	O	NONE
the	DT	the	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
PIPRACIL	NN	pipracil	B-e2	O	drug
may	MD	may	O	O	NONE
result	VB	result	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
false-positive	JJ	false-positive	O	O	NONE
reaction	NN	reaction	O	O	NONE
for	IN	for	O	O	NONE
glucose	NN	glucose	B-e3	T	drug
in	IN	in	O	O	NONE
the	DT	the	O	O	NONE
urine	NN	urine	O	O	NONE
using	VBG	use	O	O	NONE
a	DT	a	O	O	NONE
copper	NN	copper	B-e4	O	drug
-reduction	NN	-reduction	O	O	NONE
method	NN	method	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d235.s9
Drug	NN	drug	B-e0	T	drug
/Laboratory	NN	/laboratory	O	O	NONE
Test	NN	test	O	O	NONE
Interactions	NNS	interaction	O	O	NONE
:	:	:	O	O	NONE
As	IN	as	O	O	NONE
with	IN	with	O	O	NONE
other	JJ	other	B-e1	O	drug
penicillins	NNS	penicillin	I-e1	O	drug
,	,	,	O	O	NONE
the	DT	the	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
PIPRACIL	NN	pipracil	B-e2	O	drug
may	MD	may	O	O	NONE
result	VB	result	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
false-positive	JJ	false-positive	O	O	NONE
reaction	NN	reaction	O	O	NONE
for	IN	for	O	O	NONE
glucose	NN	glucose	B-e3	O	drug
in	IN	in	O	O	NONE
the	DT	the	O	O	NONE
urine	NN	urine	O	O	NONE
using	VBG	use	O	O	NONE
a	DT	a	O	O	NONE
copper	NN	copper	B-e4	T	drug
-reduction	NN	-reduction	O	O	NONE
method	NN	method	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d235.s9
Drug	NN	drug	B-e0	O	drug
/Laboratory	NN	/laboratory	O	O	NONE
Test	NN	test	O	O	NONE
Interactions	NNS	interaction	O	O	NONE
:	:	:	O	O	NONE
As	IN	as	O	O	NONE
with	IN	with	O	O	NONE
other	JJ	other	B-e1	T	drug
penicillins	NNS	penicillin	I-e1	T	drug
,	,	,	O	O	NONE
the	DT	the	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
PIPRACIL	NN	pipracil	B-e2	T	drug
may	MD	may	O	O	NONE
result	VB	result	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
false-positive	JJ	false-positive	O	O	NONE
reaction	NN	reaction	O	O	NONE
for	IN	for	O	O	NONE
glucose	NN	glucose	B-e3	O	drug
in	IN	in	O	O	NONE
the	DT	the	O	O	NONE
urine	NN	urine	O	O	NONE
using	VBG	use	O	O	NONE
a	DT	a	O	O	NONE
copper	NN	copper	B-e4	O	drug
-reduction	NN	-reduction	O	O	NONE
method	NN	method	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d235.s9
Drug	NN	drug	B-e0	O	drug
/Laboratory	NN	/laboratory	O	O	NONE
Test	NN	test	O	O	NONE
Interactions	NNS	interaction	O	O	NONE
:	:	:	O	O	NONE
As	IN	as	O	O	NONE
with	IN	with	O	O	NONE
other	JJ	other	B-e1	T	drug
penicillins	NNS	penicillin	I-e1	T	drug
,	,	,	O	O	NONE
the	DT	the	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
PIPRACIL	NN	pipracil	B-e2	O	drug
may	MD	may	O	O	NONE
result	VB	result	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
false-positive	JJ	false-positive	O	O	NONE
reaction	NN	reaction	O	O	NONE
for	IN	for	O	O	NONE
glucose	NN	glucose	B-e3	T	drug
in	IN	in	O	O	NONE
the	DT	the	O	O	NONE
urine	NN	urine	O	O	NONE
using	VBG	use	O	O	NONE
a	DT	a	O	O	NONE
copper	NN	copper	B-e4	O	drug
-reduction	NN	-reduction	O	O	NONE
method	NN	method	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d235.s9
Drug	NN	drug	B-e0	O	drug
/Laboratory	NN	/laboratory	O	O	NONE
Test	NN	test	O	O	NONE
Interactions	NNS	interaction	O	O	NONE
:	:	:	O	O	NONE
As	IN	as	O	O	NONE
with	IN	with	O	O	NONE
other	JJ	other	B-e1	T	drug
penicillins	NNS	penicillin	I-e1	T	drug
,	,	,	O	O	NONE
the	DT	the	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
PIPRACIL	NN	pipracil	B-e2	O	drug
may	MD	may	O	O	NONE
result	VB	result	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
false-positive	JJ	false-positive	O	O	NONE
reaction	NN	reaction	O	O	NONE
for	IN	for	O	O	NONE
glucose	NN	glucose	B-e3	O	drug
in	IN	in	O	O	NONE
the	DT	the	O	O	NONE
urine	NN	urine	O	O	NONE
using	VBG	use	O	O	NONE
a	DT	a	O	O	NONE
copper	NN	copper	B-e4	T	drug
-reduction	NN	-reduction	O	O	NONE
method	NN	method	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d235.s9
Drug	NN	drug	B-e0	O	drug
/Laboratory	NN	/laboratory	O	O	NONE
Test	NN	test	O	O	NONE
Interactions	NNS	interaction	O	O	NONE
:	:	:	O	O	NONE
As	IN	as	O	O	NONE
with	IN	with	O	O	NONE
other	JJ	other	B-e1	O	drug
penicillins	NNS	penicillin	I-e1	O	drug
,	,	,	O	O	NONE
the	DT	the	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
PIPRACIL	NN	pipracil	B-e2	T	drug
may	MD	may	O	O	NONE
result	VB	result	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
false-positive	JJ	false-positive	O	O	NONE
reaction	NN	reaction	O	O	NONE
for	IN	for	O	O	NONE
glucose	NN	glucose	B-e3	T	drug
in	IN	in	O	O	NONE
the	DT	the	O	O	NONE
urine	NN	urine	O	O	NONE
using	VBG	use	O	O	NONE
a	DT	a	O	O	NONE
copper	NN	copper	B-e4	O	drug
-reduction	NN	-reduction	O	O	NONE
method	NN	method	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d235.s9
Drug	NN	drug	B-e0	O	drug
/Laboratory	NN	/laboratory	O	O	NONE
Test	NN	test	O	O	NONE
Interactions	NNS	interaction	O	O	NONE
:	:	:	O	O	NONE
As	IN	as	O	O	NONE
with	IN	with	O	O	NONE
other	JJ	other	B-e1	O	drug
penicillins	NNS	penicillin	I-e1	O	drug
,	,	,	O	O	NONE
the	DT	the	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
PIPRACIL	NN	pipracil	B-e2	T	drug
may	MD	may	O	O	NONE
result	VB	result	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
false-positive	JJ	false-positive	O	O	NONE
reaction	NN	reaction	O	O	NONE
for	IN	for	O	O	NONE
glucose	NN	glucose	B-e3	O	drug
in	IN	in	O	O	NONE
the	DT	the	O	O	NONE
urine	NN	urine	O	O	NONE
using	VBG	use	O	O	NONE
a	DT	a	O	O	NONE
copper	NN	copper	B-e4	T	drug
-reduction	NN	-reduction	O	O	NONE
method	NN	method	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d235.s9
Drug	NN	drug	B-e0	O	drug
/Laboratory	NN	/laboratory	O	O	NONE
Test	NN	test	O	O	NONE
Interactions	NNS	interaction	O	O	NONE
:	:	:	O	O	NONE
As	IN	as	O	O	NONE
with	IN	with	O	O	NONE
other	JJ	other	B-e1	O	drug
penicillins	NNS	penicillin	I-e1	O	drug
,	,	,	O	O	NONE
the	DT	the	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
PIPRACIL	NN	pipracil	B-e2	O	drug
may	MD	may	O	O	NONE
result	VB	result	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
false-positive	JJ	false-positive	O	O	NONE
reaction	NN	reaction	O	O	NONE
for	IN	for	O	O	NONE
glucose	NN	glucose	B-e3	T	drug
in	IN	in	O	O	NONE
the	DT	the	O	O	NONE
urine	NN	urine	O	O	NONE
using	VBG	use	O	O	NONE
a	DT	a	O	O	NONE
copper	NN	copper	B-e4	T	drug
-reduction	NN	-reduction	O	O	NONE
method	NN	method	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d235.s11
There	EX	there	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
reports	NNS	report	O	O	NONE
of	IN	of	O	O	NONE
positive	JJ	positive	O	O	NONE
test	NN	test	O	O	NONE
results	NNS	result	O	O	NONE
using	VBG	use	O	O	NONE
the	DT	the	O	O	NONE
Bio-Rad	JJ	bio-rad	O	O	NONE
Laboratories	NNS	laboratory	O	O	NONE
Platelia	NN	platelium	O	O	NONE
Aspergillus	NN	aspergillus	O	O	NONE
EIA	NN	eium	O	O	NONE
test	NN	test	O	O	NONE
in	IN	in	O	O	NONE
patients	NNS	patient	O	O	NONE
receiving	VBG	receive	O	O	NONE
piperacillin	NN	piperacillin	B-e0	T	drug
/	:	/	O	O	NONE
tazobactam	NN	tazobactam	B-e1	T	drug
injection	NN	injection	O	O	NONE
who	WP	who	O	O	NONE
were	VBD	be	O	O	NONE
subsequently	RB	subsequently	O	O	NONE
found	VBN	find	O	O	NONE
to	TO	to	O	O	NONE
be	VB	be	O	O	NONE
free	JJ	free	O	O	NONE
of	IN	of	O	O	NONE
Aspergillus	JJ	aspergillus	B-e2	O	DISO
infection	NN	infection	I-e2	O	DISO
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s0
Effect	NN	effect	O	O	NONE
of	IN	of	O	O	NONE
other	JJ	other	O	O	NONE
drugs	NNS	drug	B-e0	T	drug
on	IN	on	O	O	NONE
Vardenafil	NN	vardenafil	B-e1	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s1
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
studies	NNS	study	O	O	NONE
:	:	:	O	O	NONE
Studies	NNS	study	O	O	NONE
in	IN	in	O	O	NONE
human	JJ	human	O	O	NONE
liver	NN	liver	O	O	NONE
microsomes	NNS	microsome	O	O	NONE
showed	VBD	show	O	O	NONE
that	IN	that	O	O	NONE
vardenafil	NN	vardenafil	B-e0	T	drug
is	VBZ	be	O	O	NONE
metabolized	VBN	metabolize	O	O	NONE
primarily	RB	primarily	O	O	NONE
by	IN	by	O	O	NONE
cytochrome	NN	cytochrome	B-e1	T	drug
P450	NN	p450	I-e1	T	drug
(	(	(	O	O	NONE
CYP	NN	cyp	B-e2	O	drug
)	)	)	O	O	NONE
isoforms	NNS	isoform	B-e3	O	drug
3A4/5	NN	3a4/5	O	O	NONE
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
to	TO	to	O	O	NONE
a	DT	a	O	O	NONE
lesser	JJR	lesser	O	O	NONE
degree	NN	degree	O	O	NONE
by	IN	by	O	O	NONE
CYP2C9	NN	cyp2c9	B-e4	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s1
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
studies	NNS	study	O	O	NONE
:	:	:	O	O	NONE
Studies	NNS	study	O	O	NONE
in	IN	in	O	O	NONE
human	JJ	human	O	O	NONE
liver	NN	liver	O	O	NONE
microsomes	NNS	microsome	O	O	NONE
showed	VBD	show	O	O	NONE
that	IN	that	O	O	NONE
vardenafil	NN	vardenafil	B-e0	T	drug
is	VBZ	be	O	O	NONE
metabolized	VBN	metabolize	O	O	NONE
primarily	RB	primarily	O	O	NONE
by	IN	by	O	O	NONE
cytochrome	NN	cytochrome	B-e1	O	drug
P450	NN	p450	I-e1	O	drug
(	(	(	O	O	NONE
CYP	NN	cyp	B-e2	T	drug
)	)	)	O	O	NONE
isoforms	NNS	isoform	B-e3	O	drug
3A4/5	NN	3a4/5	O	O	NONE
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
to	TO	to	O	O	NONE
a	DT	a	O	O	NONE
lesser	JJR	lesser	O	O	NONE
degree	NN	degree	O	O	NONE
by	IN	by	O	O	NONE
CYP2C9	NN	cyp2c9	B-e4	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s1
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
studies	NNS	study	O	O	NONE
:	:	:	O	O	NONE
Studies	NNS	study	O	O	NONE
in	IN	in	O	O	NONE
human	JJ	human	O	O	NONE
liver	NN	liver	O	O	NONE
microsomes	NNS	microsome	O	O	NONE
showed	VBD	show	O	O	NONE
that	IN	that	O	O	NONE
vardenafil	NN	vardenafil	B-e0	T	drug
is	VBZ	be	O	O	NONE
metabolized	VBN	metabolize	O	O	NONE
primarily	RB	primarily	O	O	NONE
by	IN	by	O	O	NONE
cytochrome	NN	cytochrome	B-e1	O	drug
P450	NN	p450	I-e1	O	drug
(	(	(	O	O	NONE
CYP	NN	cyp	B-e2	O	drug
)	)	)	O	O	NONE
isoforms	NNS	isoform	B-e3	T	drug
3A4/5	NN	3a4/5	O	O	NONE
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
to	TO	to	O	O	NONE
a	DT	a	O	O	NONE
lesser	JJR	lesser	O	O	NONE
degree	NN	degree	O	O	NONE
by	IN	by	O	O	NONE
CYP2C9	NN	cyp2c9	B-e4	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s1
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
studies	NNS	study	O	O	NONE
:	:	:	O	O	NONE
Studies	NNS	study	O	O	NONE
in	IN	in	O	O	NONE
human	JJ	human	O	O	NONE
liver	NN	liver	O	O	NONE
microsomes	NNS	microsome	O	O	NONE
showed	VBD	show	O	O	NONE
that	IN	that	O	O	NONE
vardenafil	NN	vardenafil	B-e0	T	drug
is	VBZ	be	O	O	NONE
metabolized	VBN	metabolize	O	O	NONE
primarily	RB	primarily	O	O	NONE
by	IN	by	O	O	NONE
cytochrome	NN	cytochrome	B-e1	O	drug
P450	NN	p450	I-e1	O	drug
(	(	(	O	O	NONE
CYP	NN	cyp	B-e2	O	drug
)	)	)	O	O	NONE
isoforms	NNS	isoform	B-e3	O	drug
3A4/5	NN	3a4/5	O	O	NONE
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
to	TO	to	O	O	NONE
a	DT	a	O	O	NONE
lesser	JJR	lesser	O	O	NONE
degree	NN	degree	O	O	NONE
by	IN	by	O	O	NONE
CYP2C9	NN	cyp2c9	B-e4	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s1
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
studies	NNS	study	O	O	NONE
:	:	:	O	O	NONE
Studies	NNS	study	O	O	NONE
in	IN	in	O	O	NONE
human	JJ	human	O	O	NONE
liver	NN	liver	O	O	NONE
microsomes	NNS	microsome	O	O	NONE
showed	VBD	show	O	O	NONE
that	IN	that	O	O	NONE
vardenafil	NN	vardenafil	B-e0	O	drug
is	VBZ	be	O	O	NONE
metabolized	VBN	metabolize	O	O	NONE
primarily	RB	primarily	O	O	NONE
by	IN	by	O	O	NONE
cytochrome	NN	cytochrome	B-e1	T	drug
P450	NN	p450	I-e1	T	drug
(	(	(	O	O	NONE
CYP	NN	cyp	B-e2	T	drug
)	)	)	O	O	NONE
isoforms	NNS	isoform	B-e3	O	drug
3A4/5	NN	3a4/5	O	O	NONE
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
to	TO	to	O	O	NONE
a	DT	a	O	O	NONE
lesser	JJR	lesser	O	O	NONE
degree	NN	degree	O	O	NONE
by	IN	by	O	O	NONE
CYP2C9	NN	cyp2c9	B-e4	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s1
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
studies	NNS	study	O	O	NONE
:	:	:	O	O	NONE
Studies	NNS	study	O	O	NONE
in	IN	in	O	O	NONE
human	JJ	human	O	O	NONE
liver	NN	liver	O	O	NONE
microsomes	NNS	microsome	O	O	NONE
showed	VBD	show	O	O	NONE
that	IN	that	O	O	NONE
vardenafil	NN	vardenafil	B-e0	O	drug
is	VBZ	be	O	O	NONE
metabolized	VBN	metabolize	O	O	NONE
primarily	RB	primarily	O	O	NONE
by	IN	by	O	O	NONE
cytochrome	NN	cytochrome	B-e1	T	drug
P450	NN	p450	I-e1	T	drug
(	(	(	O	O	NONE
CYP	NN	cyp	B-e2	O	drug
)	)	)	O	O	NONE
isoforms	NNS	isoform	B-e3	T	drug
3A4/5	NN	3a4/5	O	O	NONE
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
to	TO	to	O	O	NONE
a	DT	a	O	O	NONE
lesser	JJR	lesser	O	O	NONE
degree	NN	degree	O	O	NONE
by	IN	by	O	O	NONE
CYP2C9	NN	cyp2c9	B-e4	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s1
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
studies	NNS	study	O	O	NONE
:	:	:	O	O	NONE
Studies	NNS	study	O	O	NONE
in	IN	in	O	O	NONE
human	JJ	human	O	O	NONE
liver	NN	liver	O	O	NONE
microsomes	NNS	microsome	O	O	NONE
showed	VBD	show	O	O	NONE
that	IN	that	O	O	NONE
vardenafil	NN	vardenafil	B-e0	O	drug
is	VBZ	be	O	O	NONE
metabolized	VBN	metabolize	O	O	NONE
primarily	RB	primarily	O	O	NONE
by	IN	by	O	O	NONE
cytochrome	NN	cytochrome	B-e1	T	drug
P450	NN	p450	I-e1	T	drug
(	(	(	O	O	NONE
CYP	NN	cyp	B-e2	O	drug
)	)	)	O	O	NONE
isoforms	NNS	isoform	B-e3	O	drug
3A4/5	NN	3a4/5	O	O	NONE
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
to	TO	to	O	O	NONE
a	DT	a	O	O	NONE
lesser	JJR	lesser	O	O	NONE
degree	NN	degree	O	O	NONE
by	IN	by	O	O	NONE
CYP2C9	NN	cyp2c9	B-e4	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s1
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
studies	NNS	study	O	O	NONE
:	:	:	O	O	NONE
Studies	NNS	study	O	O	NONE
in	IN	in	O	O	NONE
human	JJ	human	O	O	NONE
liver	NN	liver	O	O	NONE
microsomes	NNS	microsome	O	O	NONE
showed	VBD	show	O	O	NONE
that	IN	that	O	O	NONE
vardenafil	NN	vardenafil	B-e0	O	drug
is	VBZ	be	O	O	NONE
metabolized	VBN	metabolize	O	O	NONE
primarily	RB	primarily	O	O	NONE
by	IN	by	O	O	NONE
cytochrome	NN	cytochrome	B-e1	O	drug
P450	NN	p450	I-e1	O	drug
(	(	(	O	O	NONE
CYP	NN	cyp	B-e2	T	drug
)	)	)	O	O	NONE
isoforms	NNS	isoform	B-e3	T	drug
3A4/5	NN	3a4/5	O	O	NONE
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
to	TO	to	O	O	NONE
a	DT	a	O	O	NONE
lesser	JJR	lesser	O	O	NONE
degree	NN	degree	O	O	NONE
by	IN	by	O	O	NONE
CYP2C9	NN	cyp2c9	B-e4	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s1
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
studies	NNS	study	O	O	NONE
:	:	:	O	O	NONE
Studies	NNS	study	O	O	NONE
in	IN	in	O	O	NONE
human	JJ	human	O	O	NONE
liver	NN	liver	O	O	NONE
microsomes	NNS	microsome	O	O	NONE
showed	VBD	show	O	O	NONE
that	IN	that	O	O	NONE
vardenafil	NN	vardenafil	B-e0	O	drug
is	VBZ	be	O	O	NONE
metabolized	VBN	metabolize	O	O	NONE
primarily	RB	primarily	O	O	NONE
by	IN	by	O	O	NONE
cytochrome	NN	cytochrome	B-e1	O	drug
P450	NN	p450	I-e1	O	drug
(	(	(	O	O	NONE
CYP	NN	cyp	B-e2	T	drug
)	)	)	O	O	NONE
isoforms	NNS	isoform	B-e3	O	drug
3A4/5	NN	3a4/5	O	O	NONE
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
to	TO	to	O	O	NONE
a	DT	a	O	O	NONE
lesser	JJR	lesser	O	O	NONE
degree	NN	degree	O	O	NONE
by	IN	by	O	O	NONE
CYP2C9	NN	cyp2c9	B-e4	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s1
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
studies	NNS	study	O	O	NONE
:	:	:	O	O	NONE
Studies	NNS	study	O	O	NONE
in	IN	in	O	O	NONE
human	JJ	human	O	O	NONE
liver	NN	liver	O	O	NONE
microsomes	NNS	microsome	O	O	NONE
showed	VBD	show	O	O	NONE
that	IN	that	O	O	NONE
vardenafil	NN	vardenafil	B-e0	O	drug
is	VBZ	be	O	O	NONE
metabolized	VBN	metabolize	O	O	NONE
primarily	RB	primarily	O	O	NONE
by	IN	by	O	O	NONE
cytochrome	NN	cytochrome	B-e1	O	drug
P450	NN	p450	I-e1	O	drug
(	(	(	O	O	NONE
CYP	NN	cyp	B-e2	O	drug
)	)	)	O	O	NONE
isoforms	NNS	isoform	B-e3	T	drug
3A4/5	NN	3a4/5	O	O	NONE
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
to	TO	to	O	O	NONE
a	DT	a	O	O	NONE
lesser	JJR	lesser	O	O	NONE
degree	NN	degree	O	O	NONE
by	IN	by	O	O	NONE
CYP2C9	NN	cyp2c9	B-e4	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s4
Cimetidine	NN	cimetidine	B-e0	T	drug
(	(	(	O	O	NONE
400	CD	400	O	O	NONE
mg	NN	mg	O	O	NONE
b.i.d.	NN	b.i.d.	O	O	NONE
)	)	)	O	O	NONE
had	VBD	have	O	O	NONE
no	DT	no	O	O	NONE
effect	NN	effect	O	O	NONE
on	IN	on	O	O	NONE
vardenafil	NN	vardenafil	B-e1	T	drug
bioavailability	NN	bioavailability	O	O	NONE
(	(	(	O	O	NONE
AUC	NN	auc	O	O	NONE
)	)	)	O	O	NONE
and	CC	and	O	O	NONE
maximum	NN	maximum	O	O	NONE
concentration	NN	concentration	O	O	NONE
(	(	(	O	O	NONE
Cmax	NN	cmax	O	O	NONE
)	)	)	O	O	NONE
of	IN	of	O	O	NONE
vardenafil	NN	vardenafil	B-e2	O	drug
when	WRB	when	O	O	NONE
co-administered	VBN	co-administer	O	O	NONE
with	IN	with	O	O	NONE
20	CD	20	O	O	NONE
mg	NN	mg	O	O	NONE
Vardenafil	NN	vardenafil	B-e3	O	drug
in	IN	in	O	O	NONE
healthy	JJ	healthy	O	O	NONE
volunteers	NNS	volunteer	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s4
Cimetidine	NN	cimetidine	B-e0	T	drug
(	(	(	O	O	NONE
400	CD	400	O	O	NONE
mg	NN	mg	O	O	NONE
b.i.d.	NN	b.i.d.	O	O	NONE
)	)	)	O	O	NONE
had	VBD	have	O	O	NONE
no	DT	no	O	O	NONE
effect	NN	effect	O	O	NONE
on	IN	on	O	O	NONE
vardenafil	NN	vardenafil	B-e1	O	drug
bioavailability	NN	bioavailability	O	O	NONE
(	(	(	O	O	NONE
AUC	NN	auc	O	O	NONE
)	)	)	O	O	NONE
and	CC	and	O	O	NONE
maximum	NN	maximum	O	O	NONE
concentration	NN	concentration	O	O	NONE
(	(	(	O	O	NONE
Cmax	NN	cmax	O	O	NONE
)	)	)	O	O	NONE
of	IN	of	O	O	NONE
vardenafil	NN	vardenafil	B-e2	T	drug
when	WRB	when	O	O	NONE
co-administered	VBN	co-administer	O	O	NONE
with	IN	with	O	O	NONE
20	CD	20	O	O	NONE
mg	NN	mg	O	O	NONE
Vardenafil	NN	vardenafil	B-e3	O	drug
in	IN	in	O	O	NONE
healthy	JJ	healthy	O	O	NONE
volunteers	NNS	volunteer	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s4
Cimetidine	NN	cimetidine	B-e0	T	drug
(	(	(	O	O	NONE
400	CD	400	O	O	NONE
mg	NN	mg	O	O	NONE
b.i.d.	NN	b.i.d.	O	O	NONE
)	)	)	O	O	NONE
had	VBD	have	O	O	NONE
no	DT	no	O	O	NONE
effect	NN	effect	O	O	NONE
on	IN	on	O	O	NONE
vardenafil	NN	vardenafil	B-e1	O	drug
bioavailability	NN	bioavailability	O	O	NONE
(	(	(	O	O	NONE
AUC	NN	auc	O	O	NONE
)	)	)	O	O	NONE
and	CC	and	O	O	NONE
maximum	NN	maximum	O	O	NONE
concentration	NN	concentration	O	O	NONE
(	(	(	O	O	NONE
Cmax	NN	cmax	O	O	NONE
)	)	)	O	O	NONE
of	IN	of	O	O	NONE
vardenafil	NN	vardenafil	B-e2	O	drug
when	WRB	when	O	O	NONE
co-administered	VBN	co-administer	O	O	NONE
with	IN	with	O	O	NONE
20	CD	20	O	O	NONE
mg	NN	mg	O	O	NONE
Vardenafil	NN	vardenafil	B-e3	T	drug
in	IN	in	O	O	NONE
healthy	JJ	healthy	O	O	NONE
volunteers	NNS	volunteer	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s4
Cimetidine	NN	cimetidine	B-e0	O	drug
(	(	(	O	O	NONE
400	CD	400	O	O	NONE
mg	NN	mg	O	O	NONE
b.i.d.	NN	b.i.d.	O	O	NONE
)	)	)	O	O	NONE
had	VBD	have	O	O	NONE
no	DT	no	O	O	NONE
effect	NN	effect	O	O	NONE
on	IN	on	O	O	NONE
vardenafil	NN	vardenafil	B-e1	T	drug
bioavailability	NN	bioavailability	O	O	NONE
(	(	(	O	O	NONE
AUC	NN	auc	O	O	NONE
)	)	)	O	O	NONE
and	CC	and	O	O	NONE
maximum	NN	maximum	O	O	NONE
concentration	NN	concentration	O	O	NONE
(	(	(	O	O	NONE
Cmax	NN	cmax	O	O	NONE
)	)	)	O	O	NONE
of	IN	of	O	O	NONE
vardenafil	NN	vardenafil	B-e2	T	drug
when	WRB	when	O	O	NONE
co-administered	VBN	co-administer	O	O	NONE
with	IN	with	O	O	NONE
20	CD	20	O	O	NONE
mg	NN	mg	O	O	NONE
Vardenafil	NN	vardenafil	B-e3	O	drug
in	IN	in	O	O	NONE
healthy	JJ	healthy	O	O	NONE
volunteers	NNS	volunteer	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s4
Cimetidine	NN	cimetidine	B-e0	O	drug
(	(	(	O	O	NONE
400	CD	400	O	O	NONE
mg	NN	mg	O	O	NONE
b.i.d.	NN	b.i.d.	O	O	NONE
)	)	)	O	O	NONE
had	VBD	have	O	O	NONE
no	DT	no	O	O	NONE
effect	NN	effect	O	O	NONE
on	IN	on	O	O	NONE
vardenafil	NN	vardenafil	B-e1	T	drug
bioavailability	NN	bioavailability	O	O	NONE
(	(	(	O	O	NONE
AUC	NN	auc	O	O	NONE
)	)	)	O	O	NONE
and	CC	and	O	O	NONE
maximum	NN	maximum	O	O	NONE
concentration	NN	concentration	O	O	NONE
(	(	(	O	O	NONE
Cmax	NN	cmax	O	O	NONE
)	)	)	O	O	NONE
of	IN	of	O	O	NONE
vardenafil	NN	vardenafil	B-e2	O	drug
when	WRB	when	O	O	NONE
co-administered	VBN	co-administer	O	O	NONE
with	IN	with	O	O	NONE
20	CD	20	O	O	NONE
mg	NN	mg	O	O	NONE
Vardenafil	NN	vardenafil	B-e3	T	drug
in	IN	in	O	O	NONE
healthy	JJ	healthy	O	O	NONE
volunteers	NNS	volunteer	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s4
Cimetidine	NN	cimetidine	B-e0	O	drug
(	(	(	O	O	NONE
400	CD	400	O	O	NONE
mg	NN	mg	O	O	NONE
b.i.d.	NN	b.i.d.	O	O	NONE
)	)	)	O	O	NONE
had	VBD	have	O	O	NONE
no	DT	no	O	O	NONE
effect	NN	effect	O	O	NONE
on	IN	on	O	O	NONE
vardenafil	NN	vardenafil	B-e1	O	drug
bioavailability	NN	bioavailability	O	O	NONE
(	(	(	O	O	NONE
AUC	NN	auc	O	O	NONE
)	)	)	O	O	NONE
and	CC	and	O	O	NONE
maximum	NN	maximum	O	O	NONE
concentration	NN	concentration	O	O	NONE
(	(	(	O	O	NONE
Cmax	NN	cmax	O	O	NONE
)	)	)	O	O	NONE
of	IN	of	O	O	NONE
vardenafil	NN	vardenafil	B-e2	T	drug
when	WRB	when	O	O	NONE
co-administered	VBN	co-administer	O	O	NONE
with	IN	with	O	O	NONE
20	CD	20	O	O	NONE
mg	NN	mg	O	O	NONE
Vardenafil	NN	vardenafil	B-e3	T	drug
in	IN	in	O	O	NONE
healthy	JJ	healthy	O	O	NONE
volunteers	NNS	volunteer	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s5
Erythromycin	NN	erythromycin	B-e0	T	drug
(	(	(	O	O	NONE
500	CD	500	B-e1	T	drug
mg	NN	mg	O	O	NONE
t.i.d	CD	t.i.d	O	O	NONE
)	)	)	O	O	NONE
produced	VBD	produce	O	O	NONE
a	DT	a	O	O	NONE
4-fold	JJ	4-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e2	O	drug
AUC	NN	auc	O	O	NONE
and	CC	and	O	O	NONE
a	DT	a	O	O	NONE
3-fold	JJ	3-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
Cmax	NN	cmax	O	O	NONE
when	WRB	when	O	O	NONE
co-administered	VBN	co-administer	O	O	NONE
with	IN	with	O	O	NONE
Vardenafil	NN	vardenafil	B-e3	O	drug
5	CD	5	I-e3	O	drug
mg	NN	mg	I-e3	O	drug
in	IN	in	O	O	NONE
healthy	JJ	healthy	O	O	NONE
volunteers	NNS	volunteer	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s5
Erythromycin	NN	erythromycin	B-e0	T	drug
(	(	(	O	O	NONE
500	CD	500	B-e1	O	drug
mg	NN	mg	O	O	NONE
t.i.d	CD	t.i.d	O	O	NONE
)	)	)	O	O	NONE
produced	VBD	produce	O	O	NONE
a	DT	a	O	O	NONE
4-fold	JJ	4-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e2	T	drug
AUC	NN	auc	O	O	NONE
and	CC	and	O	O	NONE
a	DT	a	O	O	NONE
3-fold	JJ	3-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
Cmax	NN	cmax	O	O	NONE
when	WRB	when	O	O	NONE
co-administered	VBN	co-administer	O	O	NONE
with	IN	with	O	O	NONE
Vardenafil	NN	vardenafil	B-e3	O	drug
5	CD	5	I-e3	O	drug
mg	NN	mg	I-e3	O	drug
in	IN	in	O	O	NONE
healthy	JJ	healthy	O	O	NONE
volunteers	NNS	volunteer	O	O	NONE
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d253.s5
Erythromycin	NN	erythromycin	B-e0	T	drug
(	(	(	O	O	NONE
500	CD	500	B-e1	O	drug
mg	NN	mg	O	O	NONE
t.i.d	CD	t.i.d	O	O	NONE
)	)	)	O	O	NONE
produced	VBD	produce	O	O	NONE
a	DT	a	O	O	NONE
4-fold	JJ	4-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e2	O	drug
AUC	NN	auc	O	O	NONE
and	CC	and	O	O	NONE
a	DT	a	O	O	NONE
3-fold	JJ	3-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
Cmax	NN	cmax	O	O	NONE
when	WRB	when	O	O	NONE
co-administered	VBN	co-administer	O	O	NONE
with	IN	with	O	O	NONE
Vardenafil	NN	vardenafil	B-e3	T	drug
5	CD	5	I-e3	T	drug
mg	NN	mg	I-e3	T	drug
in	IN	in	O	O	NONE
healthy	JJ	healthy	O	O	NONE
volunteers	NNS	volunteer	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s5
Erythromycin	NN	erythromycin	B-e0	O	drug
(	(	(	O	O	NONE
500	CD	500	B-e1	T	drug
mg	NN	mg	O	O	NONE
t.i.d	CD	t.i.d	O	O	NONE
)	)	)	O	O	NONE
produced	VBD	produce	O	O	NONE
a	DT	a	O	O	NONE
4-fold	JJ	4-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e2	T	drug
AUC	NN	auc	O	O	NONE
and	CC	and	O	O	NONE
a	DT	a	O	O	NONE
3-fold	JJ	3-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
Cmax	NN	cmax	O	O	NONE
when	WRB	when	O	O	NONE
co-administered	VBN	co-administer	O	O	NONE
with	IN	with	O	O	NONE
Vardenafil	NN	vardenafil	B-e3	O	drug
5	CD	5	I-e3	O	drug
mg	NN	mg	I-e3	O	drug
in	IN	in	O	O	NONE
healthy	JJ	healthy	O	O	NONE
volunteers	NNS	volunteer	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s5
Erythromycin	NN	erythromycin	B-e0	O	drug
(	(	(	O	O	NONE
500	CD	500	B-e1	T	drug
mg	NN	mg	O	O	NONE
t.i.d	CD	t.i.d	O	O	NONE
)	)	)	O	O	NONE
produced	VBD	produce	O	O	NONE
a	DT	a	O	O	NONE
4-fold	JJ	4-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e2	O	drug
AUC	NN	auc	O	O	NONE
and	CC	and	O	O	NONE
a	DT	a	O	O	NONE
3-fold	JJ	3-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
Cmax	NN	cmax	O	O	NONE
when	WRB	when	O	O	NONE
co-administered	VBN	co-administer	O	O	NONE
with	IN	with	O	O	NONE
Vardenafil	NN	vardenafil	B-e3	T	drug
5	CD	5	I-e3	T	drug
mg	NN	mg	I-e3	T	drug
in	IN	in	O	O	NONE
healthy	JJ	healthy	O	O	NONE
volunteers	NNS	volunteer	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s5
Erythromycin	NN	erythromycin	B-e0	O	drug
(	(	(	O	O	NONE
500	CD	500	B-e1	O	drug
mg	NN	mg	O	O	NONE
t.i.d	CD	t.i.d	O	O	NONE
)	)	)	O	O	NONE
produced	VBD	produce	O	O	NONE
a	DT	a	O	O	NONE
4-fold	JJ	4-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e2	T	drug
AUC	NN	auc	O	O	NONE
and	CC	and	O	O	NONE
a	DT	a	O	O	NONE
3-fold	JJ	3-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
Cmax	NN	cmax	O	O	NONE
when	WRB	when	O	O	NONE
co-administered	VBN	co-administer	O	O	NONE
with	IN	with	O	O	NONE
Vardenafil	NN	vardenafil	B-e3	T	drug
5	CD	5	I-e3	T	drug
mg	NN	mg	I-e3	T	drug
in	IN	in	O	O	NONE
healthy	JJ	healthy	O	O	NONE
volunteers	NNS	volunteer	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s6
It	PRP	it	O	O	NONE
is	VBZ	be	O	O	NONE
recommended	VBN	recommend	O	O	NONE
not	RB	not	O	O	NONE
to	TO	to	O	O	NONE
exceed	VB	exceed	O	O	NONE
a	DT	a	O	O	NONE
single	JJ	single	O	O	NONE
5	CD	5	O	O	NONE
mg	NN	mg	O	O	NONE
dose	NN	dose	O	O	NONE
of	IN	of	O	O	NONE
Vardenafil	NN	vardenafil	B-e0	T	drug
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
24-hour	JJ	24-hour	O	O	NONE
period	NN	period	O	O	NONE
when	WRB	when	O	O	NONE
used	VBN	use	O	O	NONE
in	IN	in	O	O	NONE
combination	NN	combination	O	O	NONE
with	IN	with	O	O	NONE
erythromycin	NN	erythromycin	B-e1	T	drug
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d253.s7
Ketoconazole	NN	ketoconazole	B-e0	T	drug
(	(	(	O	O	NONE
200	CD	200	O	O	NONE
mg	NN	mg	O	O	NONE
once	RB	once	O	O	NONE
daily	JJ	daily	O	O	NONE
)	)	)	O	O	NONE
produced	VBD	produce	O	O	NONE
a	DT	a	O	O	NONE
10-fold	JJ	10-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e1	T	drug
AUC	NN	auc	O	O	NONE
and	CC	and	O	O	NONE
a	DT	a	O	O	NONE
4-fold	JJ	4-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
Cmax	NN	cmax	O	O	NONE
when	WRB	when	O	O	NONE
co-administered	VBN	co-administer	O	O	NONE
with	IN	with	O	O	NONE
Vardenafil	NN	vardenafil	B-e2	O	drug
(	(	(	O	O	NONE
5	CD	5	O	O	NONE
mg	NN	mg	O	O	NONE
)	)	)	O	O	NONE
in	IN	in	O	O	NONE
healthy	JJ	healthy	O	O	NONE
volunteers	NNS	volunteer	O	O	NONE
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d253.s7
Ketoconazole	NN	ketoconazole	B-e0	T	drug
(	(	(	O	O	NONE
200	CD	200	O	O	NONE
mg	NN	mg	O	O	NONE
once	RB	once	O	O	NONE
daily	JJ	daily	O	O	NONE
)	)	)	O	O	NONE
produced	VBD	produce	O	O	NONE
a	DT	a	O	O	NONE
10-fold	JJ	10-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e1	O	drug
AUC	NN	auc	O	O	NONE
and	CC	and	O	O	NONE
a	DT	a	O	O	NONE
4-fold	JJ	4-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
Cmax	NN	cmax	O	O	NONE
when	WRB	when	O	O	NONE
co-administered	VBN	co-administer	O	O	NONE
with	IN	with	O	O	NONE
Vardenafil	NN	vardenafil	B-e2	T	drug
(	(	(	O	O	NONE
5	CD	5	O	O	NONE
mg	NN	mg	O	O	NONE
)	)	)	O	O	NONE
in	IN	in	O	O	NONE
healthy	JJ	healthy	O	O	NONE
volunteers	NNS	volunteer	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s7
Ketoconazole	NN	ketoconazole	B-e0	O	drug
(	(	(	O	O	NONE
200	CD	200	O	O	NONE
mg	NN	mg	O	O	NONE
once	RB	once	O	O	NONE
daily	JJ	daily	O	O	NONE
)	)	)	O	O	NONE
produced	VBD	produce	O	O	NONE
a	DT	a	O	O	NONE
10-fold	JJ	10-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e1	T	drug
AUC	NN	auc	O	O	NONE
and	CC	and	O	O	NONE
a	DT	a	O	O	NONE
4-fold	JJ	4-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
Cmax	NN	cmax	O	O	NONE
when	WRB	when	O	O	NONE
co-administered	VBN	co-administer	O	O	NONE
with	IN	with	O	O	NONE
Vardenafil	NN	vardenafil	B-e2	T	drug
(	(	(	O	O	NONE
5	CD	5	O	O	NONE
mg	NN	mg	O	O	NONE
)	)	)	O	O	NONE
in	IN	in	O	O	NONE
healthy	JJ	healthy	O	O	NONE
volunteers	NNS	volunteer	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s8
A	DT	a	O	O	NONE
5-mg	JJ	5-mg	O	O	NONE
Vardenafil	NN	vardenafil	B-e0	T	drug
dose	NN	dose	O	O	NONE
should	MD	should	O	O	NONE
not	RB	not	O	O	NONE
be	VB	be	O	O	NONE
exceeded	VBD	exceed	O	O	NONE
when	WRB	when	O	O	NONE
used	VBN	use	O	O	NONE
in	IN	in	O	O	NONE
combination	NN	combination	O	O	NONE
with	IN	with	O	O	NONE
200	CD	200	O	O	NONE
mg	NN	mg	O	O	NONE
once	IN	once	O	O	NONE
daily	JJ	daily	O	O	NONE
ketoconazole	NN	ketoconazole	B-e1	T	drug
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d253.s9
Since	IN	since	O	O	NONE
higher	JJR	higher	O	O	NONE
doses	NNS	dose	O	O	NONE
of	IN	of	O	O	NONE
ketoconazole	NN	ketoconazole	B-e0	T	drug
(	(	(	O	O	NONE
400	CD	400	O	O	NONE
mg	NN	mg	O	O	NONE
daily	RB	daily	O	O	NONE
)	)	)	O	O	NONE
may	MD	may	O	O	NONE
result	VB	result	O	O	NONE
in	IN	in	O	O	NONE
higher	JJR	higher	O	O	NONE
increases	NNS	increase	O	O	NONE
in	IN	in	O	O	NONE
Cmax	NN	cmax	O	O	NONE
and	CC	and	O	O	NONE
AUC	NN	auc	O	O	NONE
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
single	JJ	single	O	O	NONE
2.5	CD	2.5	O	O	NONE
mg	NN	mg	O	O	NONE
dose	NN	dose	O	O	NONE
of	IN	of	O	O	NONE
Vardenafil	NN	vardenafil	B-e1	T	drug
should	MD	should	O	O	NONE
not	RB	not	O	O	NONE
be	VB	be	O	O	NONE
exceeded	VBD	exceed	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
24-hour	JJ	24-hour	O	O	NONE
period	NN	period	O	O	NONE
when	WRB	when	O	O	NONE
used	VBN	use	O	O	NONE
in	IN	in	O	O	NONE
combination	NN	combination	O	O	NONE
with	IN	with	O	O	NONE
ketoconazole	NN	ketoconazole	B-e2	O	drug
400	CD	400	I-e2	O	drug
mg	NN	mg	I-e2	O	drug
daily	RB	daily	O	O	NONE
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d253.s9
Since	IN	since	O	O	NONE
higher	JJR	higher	O	O	NONE
doses	NNS	dose	O	O	NONE
of	IN	of	O	O	NONE
ketoconazole	NN	ketoconazole	B-e0	T	drug
(	(	(	O	O	NONE
400	CD	400	O	O	NONE
mg	NN	mg	O	O	NONE
daily	RB	daily	O	O	NONE
)	)	)	O	O	NONE
may	MD	may	O	O	NONE
result	VB	result	O	O	NONE
in	IN	in	O	O	NONE
higher	JJR	higher	O	O	NONE
increases	NNS	increase	O	O	NONE
in	IN	in	O	O	NONE
Cmax	NN	cmax	O	O	NONE
and	CC	and	O	O	NONE
AUC	NN	auc	O	O	NONE
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
single	JJ	single	O	O	NONE
2.5	CD	2.5	O	O	NONE
mg	NN	mg	O	O	NONE
dose	NN	dose	O	O	NONE
of	IN	of	O	O	NONE
Vardenafil	NN	vardenafil	B-e1	O	drug
should	MD	should	O	O	NONE
not	RB	not	O	O	NONE
be	VB	be	O	O	NONE
exceeded	VBD	exceed	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
24-hour	JJ	24-hour	O	O	NONE
period	NN	period	O	O	NONE
when	WRB	when	O	O	NONE
used	VBN	use	O	O	NONE
in	IN	in	O	O	NONE
combination	NN	combination	O	O	NONE
with	IN	with	O	O	NONE
ketoconazole	NN	ketoconazole	B-e2	T	drug
400	CD	400	I-e2	T	drug
mg	NN	mg	I-e2	T	drug
daily	RB	daily	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s9
Since	IN	since	O	O	NONE
higher	JJR	higher	O	O	NONE
doses	NNS	dose	O	O	NONE
of	IN	of	O	O	NONE
ketoconazole	NN	ketoconazole	B-e0	O	drug
(	(	(	O	O	NONE
400	CD	400	O	O	NONE
mg	NN	mg	O	O	NONE
daily	RB	daily	O	O	NONE
)	)	)	O	O	NONE
may	MD	may	O	O	NONE
result	VB	result	O	O	NONE
in	IN	in	O	O	NONE
higher	JJR	higher	O	O	NONE
increases	NNS	increase	O	O	NONE
in	IN	in	O	O	NONE
Cmax	NN	cmax	O	O	NONE
and	CC	and	O	O	NONE
AUC	NN	auc	O	O	NONE
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
single	JJ	single	O	O	NONE
2.5	CD	2.5	O	O	NONE
mg	NN	mg	O	O	NONE
dose	NN	dose	O	O	NONE
of	IN	of	O	O	NONE
Vardenafil	NN	vardenafil	B-e1	T	drug
should	MD	should	O	O	NONE
not	RB	not	O	O	NONE
be	VB	be	O	O	NONE
exceeded	VBD	exceed	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
24-hour	JJ	24-hour	O	O	NONE
period	NN	period	O	O	NONE
when	WRB	when	O	O	NONE
used	VBN	use	O	O	NONE
in	IN	in	O	O	NONE
combination	NN	combination	O	O	NONE
with	IN	with	O	O	NONE
ketoconazole	NN	ketoconazole	B-e2	T	drug
400	CD	400	I-e2	T	drug
mg	NN	mg	I-e2	T	drug
daily	RB	daily	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s10
HIV	NN	hiv	B-e0	T	drug
Protease	NN	protease	I-e0	T	drug
Inhibitors	NNS	inhibitor	I-e0	T	drug
:	:	:	O	O	NONE
Indinavir	NN	indinavir	B-e1	T	drug
(	(	(	O	O	NONE
800	CD	800	B-e2	O	drug
mg	NN	mg	O	O	NONE
t.i.d.	NN	t.i.d.	O	O	NONE
)	)	)	O	O	NONE
co-administered	VBN	co-administer	O	O	NONE
with	IN	with	O	O	NONE
Vardenafil	NN	vardenafil	B-e3	O	drug
10	CD	10	I-e3	O	drug
mg	NN	mg	I-e3	O	drug
resulted	VBD	result	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
16-fold	JJ	16-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e4	O	drug
AUC	NN	auc	O	O	NONE
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
7-fold	JJ	7-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e5	O	drug
Cmax	NN	cmax	O	O	NONE
and	CC	and	O	O	NONE
a	DT	a	O	O	NONE
2-fold	JJ	2-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e6	O	drug
half-life	NN	half-life	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s10
HIV	NN	hiv	B-e0	T	drug
Protease	NN	protease	I-e0	T	drug
Inhibitors	NNS	inhibitor	I-e0	T	drug
:	:	:	O	O	NONE
Indinavir	NN	indinavir	B-e1	O	drug
(	(	(	O	O	NONE
800	CD	800	B-e2	T	drug
mg	NN	mg	O	O	NONE
t.i.d.	NN	t.i.d.	O	O	NONE
)	)	)	O	O	NONE
co-administered	VBN	co-administer	O	O	NONE
with	IN	with	O	O	NONE
Vardenafil	NN	vardenafil	B-e3	O	drug
10	CD	10	I-e3	O	drug
mg	NN	mg	I-e3	O	drug
resulted	VBD	result	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
16-fold	JJ	16-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e4	O	drug
AUC	NN	auc	O	O	NONE
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
7-fold	JJ	7-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e5	O	drug
Cmax	NN	cmax	O	O	NONE
and	CC	and	O	O	NONE
a	DT	a	O	O	NONE
2-fold	JJ	2-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e6	O	drug
half-life	NN	half-life	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s10
HIV	NN	hiv	B-e0	T	drug
Protease	NN	protease	I-e0	T	drug
Inhibitors	NNS	inhibitor	I-e0	T	drug
:	:	:	O	O	NONE
Indinavir	NN	indinavir	B-e1	O	drug
(	(	(	O	O	NONE
800	CD	800	B-e2	O	drug
mg	NN	mg	O	O	NONE
t.i.d.	NN	t.i.d.	O	O	NONE
)	)	)	O	O	NONE
co-administered	VBN	co-administer	O	O	NONE
with	IN	with	O	O	NONE
Vardenafil	NN	vardenafil	B-e3	T	drug
10	CD	10	I-e3	T	drug
mg	NN	mg	I-e3	T	drug
resulted	VBD	result	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
16-fold	JJ	16-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e4	O	drug
AUC	NN	auc	O	O	NONE
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
7-fold	JJ	7-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e5	O	drug
Cmax	NN	cmax	O	O	NONE
and	CC	and	O	O	NONE
a	DT	a	O	O	NONE
2-fold	JJ	2-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e6	O	drug
half-life	NN	half-life	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s10
HIV	NN	hiv	B-e0	T	drug
Protease	NN	protease	I-e0	T	drug
Inhibitors	NNS	inhibitor	I-e0	T	drug
:	:	:	O	O	NONE
Indinavir	NN	indinavir	B-e1	O	drug
(	(	(	O	O	NONE
800	CD	800	B-e2	O	drug
mg	NN	mg	O	O	NONE
t.i.d.	NN	t.i.d.	O	O	NONE
)	)	)	O	O	NONE
co-administered	VBN	co-administer	O	O	NONE
with	IN	with	O	O	NONE
Vardenafil	NN	vardenafil	B-e3	O	drug
10	CD	10	I-e3	O	drug
mg	NN	mg	I-e3	O	drug
resulted	VBD	result	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
16-fold	JJ	16-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e4	T	drug
AUC	NN	auc	O	O	NONE
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
7-fold	JJ	7-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e5	O	drug
Cmax	NN	cmax	O	O	NONE
and	CC	and	O	O	NONE
a	DT	a	O	O	NONE
2-fold	JJ	2-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e6	O	drug
half-life	NN	half-life	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s10
HIV	NN	hiv	B-e0	T	drug
Protease	NN	protease	I-e0	T	drug
Inhibitors	NNS	inhibitor	I-e0	T	drug
:	:	:	O	O	NONE
Indinavir	NN	indinavir	B-e1	O	drug
(	(	(	O	O	NONE
800	CD	800	B-e2	O	drug
mg	NN	mg	O	O	NONE
t.i.d.	NN	t.i.d.	O	O	NONE
)	)	)	O	O	NONE
co-administered	VBN	co-administer	O	O	NONE
with	IN	with	O	O	NONE
Vardenafil	NN	vardenafil	B-e3	O	drug
10	CD	10	I-e3	O	drug
mg	NN	mg	I-e3	O	drug
resulted	VBD	result	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
16-fold	JJ	16-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e4	O	drug
AUC	NN	auc	O	O	NONE
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
7-fold	JJ	7-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e5	T	drug
Cmax	NN	cmax	O	O	NONE
and	CC	and	O	O	NONE
a	DT	a	O	O	NONE
2-fold	JJ	2-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e6	O	drug
half-life	NN	half-life	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s10
HIV	NN	hiv	B-e0	T	drug
Protease	NN	protease	I-e0	T	drug
Inhibitors	NNS	inhibitor	I-e0	T	drug
:	:	:	O	O	NONE
Indinavir	NN	indinavir	B-e1	O	drug
(	(	(	O	O	NONE
800	CD	800	B-e2	O	drug
mg	NN	mg	O	O	NONE
t.i.d.	NN	t.i.d.	O	O	NONE
)	)	)	O	O	NONE
co-administered	VBN	co-administer	O	O	NONE
with	IN	with	O	O	NONE
Vardenafil	NN	vardenafil	B-e3	O	drug
10	CD	10	I-e3	O	drug
mg	NN	mg	I-e3	O	drug
resulted	VBD	result	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
16-fold	JJ	16-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e4	O	drug
AUC	NN	auc	O	O	NONE
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
7-fold	JJ	7-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e5	O	drug
Cmax	NN	cmax	O	O	NONE
and	CC	and	O	O	NONE
a	DT	a	O	O	NONE
2-fold	JJ	2-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e6	T	drug
half-life	NN	half-life	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s10
HIV	NN	hiv	B-e0	O	drug
Protease	NN	protease	I-e0	O	drug
Inhibitors	NNS	inhibitor	I-e0	O	drug
:	:	:	O	O	NONE
Indinavir	NN	indinavir	B-e1	T	drug
(	(	(	O	O	NONE
800	CD	800	B-e2	T	drug
mg	NN	mg	O	O	NONE
t.i.d.	NN	t.i.d.	O	O	NONE
)	)	)	O	O	NONE
co-administered	VBN	co-administer	O	O	NONE
with	IN	with	O	O	NONE
Vardenafil	NN	vardenafil	B-e3	O	drug
10	CD	10	I-e3	O	drug
mg	NN	mg	I-e3	O	drug
resulted	VBD	result	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
16-fold	JJ	16-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e4	O	drug
AUC	NN	auc	O	O	NONE
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
7-fold	JJ	7-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e5	O	drug
Cmax	NN	cmax	O	O	NONE
and	CC	and	O	O	NONE
a	DT	a	O	O	NONE
2-fold	JJ	2-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e6	O	drug
half-life	NN	half-life	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s10
HIV	NN	hiv	B-e0	O	drug
Protease	NN	protease	I-e0	O	drug
Inhibitors	NNS	inhibitor	I-e0	O	drug
:	:	:	O	O	NONE
Indinavir	NN	indinavir	B-e1	T	drug
(	(	(	O	O	NONE
800	CD	800	B-e2	O	drug
mg	NN	mg	O	O	NONE
t.i.d.	NN	t.i.d.	O	O	NONE
)	)	)	O	O	NONE
co-administered	VBN	co-administer	O	O	NONE
with	IN	with	O	O	NONE
Vardenafil	NN	vardenafil	B-e3	T	drug
10	CD	10	I-e3	T	drug
mg	NN	mg	I-e3	T	drug
resulted	VBD	result	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
16-fold	JJ	16-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e4	O	drug
AUC	NN	auc	O	O	NONE
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
7-fold	JJ	7-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e5	O	drug
Cmax	NN	cmax	O	O	NONE
and	CC	and	O	O	NONE
a	DT	a	O	O	NONE
2-fold	JJ	2-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e6	O	drug
half-life	NN	half-life	O	O	NONE
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d253.s10
HIV	NN	hiv	B-e0	O	drug
Protease	NN	protease	I-e0	O	drug
Inhibitors	NNS	inhibitor	I-e0	O	drug
:	:	:	O	O	NONE
Indinavir	NN	indinavir	B-e1	T	drug
(	(	(	O	O	NONE
800	CD	800	B-e2	O	drug
mg	NN	mg	O	O	NONE
t.i.d.	NN	t.i.d.	O	O	NONE
)	)	)	O	O	NONE
co-administered	VBN	co-administer	O	O	NONE
with	IN	with	O	O	NONE
Vardenafil	NN	vardenafil	B-e3	O	drug
10	CD	10	I-e3	O	drug
mg	NN	mg	I-e3	O	drug
resulted	VBD	result	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
16-fold	JJ	16-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e4	T	drug
AUC	NN	auc	O	O	NONE
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
7-fold	JJ	7-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e5	O	drug
Cmax	NN	cmax	O	O	NONE
and	CC	and	O	O	NONE
a	DT	a	O	O	NONE
2-fold	JJ	2-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e6	O	drug
half-life	NN	half-life	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s10
HIV	NN	hiv	B-e0	O	drug
Protease	NN	protease	I-e0	O	drug
Inhibitors	NNS	inhibitor	I-e0	O	drug
:	:	:	O	O	NONE
Indinavir	NN	indinavir	B-e1	T	drug
(	(	(	O	O	NONE
800	CD	800	B-e2	O	drug
mg	NN	mg	O	O	NONE
t.i.d.	NN	t.i.d.	O	O	NONE
)	)	)	O	O	NONE
co-administered	VBN	co-administer	O	O	NONE
with	IN	with	O	O	NONE
Vardenafil	NN	vardenafil	B-e3	O	drug
10	CD	10	I-e3	O	drug
mg	NN	mg	I-e3	O	drug
resulted	VBD	result	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
16-fold	JJ	16-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e4	O	drug
AUC	NN	auc	O	O	NONE
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
7-fold	JJ	7-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e5	T	drug
Cmax	NN	cmax	O	O	NONE
and	CC	and	O	O	NONE
a	DT	a	O	O	NONE
2-fold	JJ	2-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e6	O	drug
half-life	NN	half-life	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s10
HIV	NN	hiv	B-e0	O	drug
Protease	NN	protease	I-e0	O	drug
Inhibitors	NNS	inhibitor	I-e0	O	drug
:	:	:	O	O	NONE
Indinavir	NN	indinavir	B-e1	T	drug
(	(	(	O	O	NONE
800	CD	800	B-e2	O	drug
mg	NN	mg	O	O	NONE
t.i.d.	NN	t.i.d.	O	O	NONE
)	)	)	O	O	NONE
co-administered	VBN	co-administer	O	O	NONE
with	IN	with	O	O	NONE
Vardenafil	NN	vardenafil	B-e3	O	drug
10	CD	10	I-e3	O	drug
mg	NN	mg	I-e3	O	drug
resulted	VBD	result	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
16-fold	JJ	16-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e4	O	drug
AUC	NN	auc	O	O	NONE
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
7-fold	JJ	7-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e5	O	drug
Cmax	NN	cmax	O	O	NONE
and	CC	and	O	O	NONE
a	DT	a	O	O	NONE
2-fold	JJ	2-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e6	T	drug
half-life	NN	half-life	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s10
HIV	NN	hiv	B-e0	O	drug
Protease	NN	protease	I-e0	O	drug
Inhibitors	NNS	inhibitor	I-e0	O	drug
:	:	:	O	O	NONE
Indinavir	NN	indinavir	B-e1	O	drug
(	(	(	O	O	NONE
800	CD	800	B-e2	T	drug
mg	NN	mg	O	O	NONE
t.i.d.	NN	t.i.d.	O	O	NONE
)	)	)	O	O	NONE
co-administered	VBN	co-administer	O	O	NONE
with	IN	with	O	O	NONE
Vardenafil	NN	vardenafil	B-e3	T	drug
10	CD	10	I-e3	T	drug
mg	NN	mg	I-e3	T	drug
resulted	VBD	result	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
16-fold	JJ	16-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e4	O	drug
AUC	NN	auc	O	O	NONE
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
7-fold	JJ	7-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e5	O	drug
Cmax	NN	cmax	O	O	NONE
and	CC	and	O	O	NONE
a	DT	a	O	O	NONE
2-fold	JJ	2-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e6	O	drug
half-life	NN	half-life	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s10
HIV	NN	hiv	B-e0	O	drug
Protease	NN	protease	I-e0	O	drug
Inhibitors	NNS	inhibitor	I-e0	O	drug
:	:	:	O	O	NONE
Indinavir	NN	indinavir	B-e1	O	drug
(	(	(	O	O	NONE
800	CD	800	B-e2	T	drug
mg	NN	mg	O	O	NONE
t.i.d.	NN	t.i.d.	O	O	NONE
)	)	)	O	O	NONE
co-administered	VBN	co-administer	O	O	NONE
with	IN	with	O	O	NONE
Vardenafil	NN	vardenafil	B-e3	O	drug
10	CD	10	I-e3	O	drug
mg	NN	mg	I-e3	O	drug
resulted	VBD	result	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
16-fold	JJ	16-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e4	T	drug
AUC	NN	auc	O	O	NONE
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
7-fold	JJ	7-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e5	O	drug
Cmax	NN	cmax	O	O	NONE
and	CC	and	O	O	NONE
a	DT	a	O	O	NONE
2-fold	JJ	2-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e6	O	drug
half-life	NN	half-life	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s10
HIV	NN	hiv	B-e0	O	drug
Protease	NN	protease	I-e0	O	drug
Inhibitors	NNS	inhibitor	I-e0	O	drug
:	:	:	O	O	NONE
Indinavir	NN	indinavir	B-e1	O	drug
(	(	(	O	O	NONE
800	CD	800	B-e2	T	drug
mg	NN	mg	O	O	NONE
t.i.d.	NN	t.i.d.	O	O	NONE
)	)	)	O	O	NONE
co-administered	VBN	co-administer	O	O	NONE
with	IN	with	O	O	NONE
Vardenafil	NN	vardenafil	B-e3	O	drug
10	CD	10	I-e3	O	drug
mg	NN	mg	I-e3	O	drug
resulted	VBD	result	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
16-fold	JJ	16-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e4	O	drug
AUC	NN	auc	O	O	NONE
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
7-fold	JJ	7-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e5	T	drug
Cmax	NN	cmax	O	O	NONE
and	CC	and	O	O	NONE
a	DT	a	O	O	NONE
2-fold	JJ	2-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e6	O	drug
half-life	NN	half-life	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s10
HIV	NN	hiv	B-e0	O	drug
Protease	NN	protease	I-e0	O	drug
Inhibitors	NNS	inhibitor	I-e0	O	drug
:	:	:	O	O	NONE
Indinavir	NN	indinavir	B-e1	O	drug
(	(	(	O	O	NONE
800	CD	800	B-e2	T	drug
mg	NN	mg	O	O	NONE
t.i.d.	NN	t.i.d.	O	O	NONE
)	)	)	O	O	NONE
co-administered	VBN	co-administer	O	O	NONE
with	IN	with	O	O	NONE
Vardenafil	NN	vardenafil	B-e3	O	drug
10	CD	10	I-e3	O	drug
mg	NN	mg	I-e3	O	drug
resulted	VBD	result	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
16-fold	JJ	16-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e4	O	drug
AUC	NN	auc	O	O	NONE
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
7-fold	JJ	7-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e5	O	drug
Cmax	NN	cmax	O	O	NONE
and	CC	and	O	O	NONE
a	DT	a	O	O	NONE
2-fold	JJ	2-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e6	T	drug
half-life	NN	half-life	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s10
HIV	NN	hiv	B-e0	O	drug
Protease	NN	protease	I-e0	O	drug
Inhibitors	NNS	inhibitor	I-e0	O	drug
:	:	:	O	O	NONE
Indinavir	NN	indinavir	B-e1	O	drug
(	(	(	O	O	NONE
800	CD	800	B-e2	O	drug
mg	NN	mg	O	O	NONE
t.i.d.	NN	t.i.d.	O	O	NONE
)	)	)	O	O	NONE
co-administered	VBN	co-administer	O	O	NONE
with	IN	with	O	O	NONE
Vardenafil	NN	vardenafil	B-e3	T	drug
10	CD	10	I-e3	T	drug
mg	NN	mg	I-e3	T	drug
resulted	VBD	result	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
16-fold	JJ	16-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e4	T	drug
AUC	NN	auc	O	O	NONE
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
7-fold	JJ	7-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e5	O	drug
Cmax	NN	cmax	O	O	NONE
and	CC	and	O	O	NONE
a	DT	a	O	O	NONE
2-fold	JJ	2-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e6	O	drug
half-life	NN	half-life	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s10
HIV	NN	hiv	B-e0	O	drug
Protease	NN	protease	I-e0	O	drug
Inhibitors	NNS	inhibitor	I-e0	O	drug
:	:	:	O	O	NONE
Indinavir	NN	indinavir	B-e1	O	drug
(	(	(	O	O	NONE
800	CD	800	B-e2	O	drug
mg	NN	mg	O	O	NONE
t.i.d.	NN	t.i.d.	O	O	NONE
)	)	)	O	O	NONE
co-administered	VBN	co-administer	O	O	NONE
with	IN	with	O	O	NONE
Vardenafil	NN	vardenafil	B-e3	T	drug
10	CD	10	I-e3	T	drug
mg	NN	mg	I-e3	T	drug
resulted	VBD	result	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
16-fold	JJ	16-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e4	O	drug
AUC	NN	auc	O	O	NONE
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
7-fold	JJ	7-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e5	T	drug
Cmax	NN	cmax	O	O	NONE
and	CC	and	O	O	NONE
a	DT	a	O	O	NONE
2-fold	JJ	2-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e6	O	drug
half-life	NN	half-life	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s10
HIV	NN	hiv	B-e0	O	drug
Protease	NN	protease	I-e0	O	drug
Inhibitors	NNS	inhibitor	I-e0	O	drug
:	:	:	O	O	NONE
Indinavir	NN	indinavir	B-e1	O	drug
(	(	(	O	O	NONE
800	CD	800	B-e2	O	drug
mg	NN	mg	O	O	NONE
t.i.d.	NN	t.i.d.	O	O	NONE
)	)	)	O	O	NONE
co-administered	VBN	co-administer	O	O	NONE
with	IN	with	O	O	NONE
Vardenafil	NN	vardenafil	B-e3	T	drug
10	CD	10	I-e3	T	drug
mg	NN	mg	I-e3	T	drug
resulted	VBD	result	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
16-fold	JJ	16-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e4	O	drug
AUC	NN	auc	O	O	NONE
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
7-fold	JJ	7-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e5	O	drug
Cmax	NN	cmax	O	O	NONE
and	CC	and	O	O	NONE
a	DT	a	O	O	NONE
2-fold	JJ	2-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e6	T	drug
half-life	NN	half-life	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s10
HIV	NN	hiv	B-e0	O	drug
Protease	NN	protease	I-e0	O	drug
Inhibitors	NNS	inhibitor	I-e0	O	drug
:	:	:	O	O	NONE
Indinavir	NN	indinavir	B-e1	O	drug
(	(	(	O	O	NONE
800	CD	800	B-e2	O	drug
mg	NN	mg	O	O	NONE
t.i.d.	NN	t.i.d.	O	O	NONE
)	)	)	O	O	NONE
co-administered	VBN	co-administer	O	O	NONE
with	IN	with	O	O	NONE
Vardenafil	NN	vardenafil	B-e3	O	drug
10	CD	10	I-e3	O	drug
mg	NN	mg	I-e3	O	drug
resulted	VBD	result	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
16-fold	JJ	16-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e4	T	drug
AUC	NN	auc	O	O	NONE
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
7-fold	JJ	7-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e5	T	drug
Cmax	NN	cmax	O	O	NONE
and	CC	and	O	O	NONE
a	DT	a	O	O	NONE
2-fold	JJ	2-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e6	O	drug
half-life	NN	half-life	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s10
HIV	NN	hiv	B-e0	O	drug
Protease	NN	protease	I-e0	O	drug
Inhibitors	NNS	inhibitor	I-e0	O	drug
:	:	:	O	O	NONE
Indinavir	NN	indinavir	B-e1	O	drug
(	(	(	O	O	NONE
800	CD	800	B-e2	O	drug
mg	NN	mg	O	O	NONE
t.i.d.	NN	t.i.d.	O	O	NONE
)	)	)	O	O	NONE
co-administered	VBN	co-administer	O	O	NONE
with	IN	with	O	O	NONE
Vardenafil	NN	vardenafil	B-e3	O	drug
10	CD	10	I-e3	O	drug
mg	NN	mg	I-e3	O	drug
resulted	VBD	result	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
16-fold	JJ	16-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e4	T	drug
AUC	NN	auc	O	O	NONE
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
7-fold	JJ	7-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e5	O	drug
Cmax	NN	cmax	O	O	NONE
and	CC	and	O	O	NONE
a	DT	a	O	O	NONE
2-fold	JJ	2-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e6	T	drug
half-life	NN	half-life	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s10
HIV	NN	hiv	B-e0	O	drug
Protease	NN	protease	I-e0	O	drug
Inhibitors	NNS	inhibitor	I-e0	O	drug
:	:	:	O	O	NONE
Indinavir	NN	indinavir	B-e1	O	drug
(	(	(	O	O	NONE
800	CD	800	B-e2	O	drug
mg	NN	mg	O	O	NONE
t.i.d.	NN	t.i.d.	O	O	NONE
)	)	)	O	O	NONE
co-administered	VBN	co-administer	O	O	NONE
with	IN	with	O	O	NONE
Vardenafil	NN	vardenafil	B-e3	O	drug
10	CD	10	I-e3	O	drug
mg	NN	mg	I-e3	O	drug
resulted	VBD	result	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
16-fold	JJ	16-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e4	O	drug
AUC	NN	auc	O	O	NONE
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
7-fold	JJ	7-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e5	T	drug
Cmax	NN	cmax	O	O	NONE
and	CC	and	O	O	NONE
a	DT	a	O	O	NONE
2-fold	JJ	2-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e6	T	drug
half-life	NN	half-life	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s12
Ritonavir	NN	ritonavir	B-e0	T	drug
(	(	(	O	O	NONE
600	CD	600	O	O	NONE
mg	NN	mg	O	O	NONE
b.i.d.	NN	b.i.d.	O	O	NONE
)	)	)	O	O	NONE
co-administered	VBN	co-administer	O	O	NONE
with	IN	with	O	O	NONE
Vardenafil	NN	vardenafil	B-e1	T	drug
5	CD	5	I-e1	T	drug
mg	NN	mg	I-e1	T	drug
resulted	VBD	result	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
49-fold	JJ	49-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e2	O	drug
AUC	NN	auc	O	O	NONE
and	CC	and	O	O	NONE
a	DT	a	O	O	NONE
13-fold	RB	13-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e3	O	drug
Cmax	NN	cmax	O	O	NONE
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d253.s12
Ritonavir	NN	ritonavir	B-e0	T	drug
(	(	(	O	O	NONE
600	CD	600	O	O	NONE
mg	NN	mg	O	O	NONE
b.i.d.	NN	b.i.d.	O	O	NONE
)	)	)	O	O	NONE
co-administered	VBN	co-administer	O	O	NONE
with	IN	with	O	O	NONE
Vardenafil	NN	vardenafil	B-e1	O	drug
5	CD	5	I-e1	O	drug
mg	NN	mg	I-e1	O	drug
resulted	VBD	result	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
49-fold	JJ	49-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e2	T	drug
AUC	NN	auc	O	O	NONE
and	CC	and	O	O	NONE
a	DT	a	O	O	NONE
13-fold	RB	13-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e3	O	drug
Cmax	NN	cmax	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s12
Ritonavir	NN	ritonavir	B-e0	T	drug
(	(	(	O	O	NONE
600	CD	600	O	O	NONE
mg	NN	mg	O	O	NONE
b.i.d.	NN	b.i.d.	O	O	NONE
)	)	)	O	O	NONE
co-administered	VBN	co-administer	O	O	NONE
with	IN	with	O	O	NONE
Vardenafil	NN	vardenafil	B-e1	O	drug
5	CD	5	I-e1	O	drug
mg	NN	mg	I-e1	O	drug
resulted	VBD	result	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
49-fold	JJ	49-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e2	O	drug
AUC	NN	auc	O	O	NONE
and	CC	and	O	O	NONE
a	DT	a	O	O	NONE
13-fold	RB	13-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e3	T	drug
Cmax	NN	cmax	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s12
Ritonavir	NN	ritonavir	B-e0	O	drug
(	(	(	O	O	NONE
600	CD	600	O	O	NONE
mg	NN	mg	O	O	NONE
b.i.d.	NN	b.i.d.	O	O	NONE
)	)	)	O	O	NONE
co-administered	VBN	co-administer	O	O	NONE
with	IN	with	O	O	NONE
Vardenafil	NN	vardenafil	B-e1	T	drug
5	CD	5	I-e1	T	drug
mg	NN	mg	I-e1	T	drug
resulted	VBD	result	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
49-fold	JJ	49-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e2	T	drug
AUC	NN	auc	O	O	NONE
and	CC	and	O	O	NONE
a	DT	a	O	O	NONE
13-fold	RB	13-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e3	O	drug
Cmax	NN	cmax	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s12
Ritonavir	NN	ritonavir	B-e0	O	drug
(	(	(	O	O	NONE
600	CD	600	O	O	NONE
mg	NN	mg	O	O	NONE
b.i.d.	NN	b.i.d.	O	O	NONE
)	)	)	O	O	NONE
co-administered	VBN	co-administer	O	O	NONE
with	IN	with	O	O	NONE
Vardenafil	NN	vardenafil	B-e1	T	drug
5	CD	5	I-e1	T	drug
mg	NN	mg	I-e1	T	drug
resulted	VBD	result	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
49-fold	JJ	49-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e2	O	drug
AUC	NN	auc	O	O	NONE
and	CC	and	O	O	NONE
a	DT	a	O	O	NONE
13-fold	RB	13-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e3	T	drug
Cmax	NN	cmax	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s12
Ritonavir	NN	ritonavir	B-e0	O	drug
(	(	(	O	O	NONE
600	CD	600	O	O	NONE
mg	NN	mg	O	O	NONE
b.i.d.	NN	b.i.d.	O	O	NONE
)	)	)	O	O	NONE
co-administered	VBN	co-administer	O	O	NONE
with	IN	with	O	O	NONE
Vardenafil	NN	vardenafil	B-e1	O	drug
5	CD	5	I-e1	O	drug
mg	NN	mg	I-e1	O	drug
resulted	VBD	result	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
49-fold	JJ	49-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e2	T	drug
AUC	NN	auc	O	O	NONE
and	CC	and	O	O	NONE
a	DT	a	O	O	NONE
13-fold	RB	13-fold	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
vardenafil	NN	vardenafil	B-e3	T	drug
Cmax	NN	cmax	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s13
The	DT	the	O	O	NONE
interaction	NN	interaction	O	O	NONE
is	VBZ	be	O	O	NONE
a	DT	a	O	O	NONE
consequence	NN	consequence	O	O	NONE
of	IN	of	O	O	NONE
blocking	VBG	block	O	O	NONE
hepatic	JJ	hepatic	O	O	NONE
metabolism	NN	metabolism	O	O	NONE
of	IN	of	O	O	NONE
vardenafil	NN	vardenafil	B-e0	T	drug
by	IN	by	O	O	NONE
ritonavir	NN	ritonavir	B-e1	T	drug
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
highly	RB	highly	O	O	NONE
potent	JJ	potent	O	O	NONE
CYP3A4	NN	cyp3a4	B-e2	O	drug
inhibitor	NN	inhibitor	O	O	NONE
,	,	,	O	O	NONE
which	WDT	which	O	O	NONE
also	RB	also	O	O	NONE
inhibits	VBZ	inhibit	O	O	NONE
CYP2C9	NN	cyp2c9	B-e3	O	drug
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d253.s13
The	DT	the	O	O	NONE
interaction	NN	interaction	O	O	NONE
is	VBZ	be	O	O	NONE
a	DT	a	O	O	NONE
consequence	NN	consequence	O	O	NONE
of	IN	of	O	O	NONE
blocking	VBG	block	O	O	NONE
hepatic	JJ	hepatic	O	O	NONE
metabolism	NN	metabolism	O	O	NONE
of	IN	of	O	O	NONE
vardenafil	NN	vardenafil	B-e0	T	drug
by	IN	by	O	O	NONE
ritonavir	NN	ritonavir	B-e1	O	drug
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
highly	RB	highly	O	O	NONE
potent	JJ	potent	O	O	NONE
CYP3A4	NN	cyp3a4	B-e2	T	drug
inhibitor	NN	inhibitor	O	O	NONE
,	,	,	O	O	NONE
which	WDT	which	O	O	NONE
also	RB	also	O	O	NONE
inhibits	VBZ	inhibit	O	O	NONE
CYP2C9	NN	cyp2c9	B-e3	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s13
The	DT	the	O	O	NONE
interaction	NN	interaction	O	O	NONE
is	VBZ	be	O	O	NONE
a	DT	a	O	O	NONE
consequence	NN	consequence	O	O	NONE
of	IN	of	O	O	NONE
blocking	VBG	block	O	O	NONE
hepatic	JJ	hepatic	O	O	NONE
metabolism	NN	metabolism	O	O	NONE
of	IN	of	O	O	NONE
vardenafil	NN	vardenafil	B-e0	T	drug
by	IN	by	O	O	NONE
ritonavir	NN	ritonavir	B-e1	O	drug
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
highly	RB	highly	O	O	NONE
potent	JJ	potent	O	O	NONE
CYP3A4	NN	cyp3a4	B-e2	O	drug
inhibitor	NN	inhibitor	O	O	NONE
,	,	,	O	O	NONE
which	WDT	which	O	O	NONE
also	RB	also	O	O	NONE
inhibits	VBZ	inhibit	O	O	NONE
CYP2C9	NN	cyp2c9	B-e3	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s13
The	DT	the	O	O	NONE
interaction	NN	interaction	O	O	NONE
is	VBZ	be	O	O	NONE
a	DT	a	O	O	NONE
consequence	NN	consequence	O	O	NONE
of	IN	of	O	O	NONE
blocking	VBG	block	O	O	NONE
hepatic	JJ	hepatic	O	O	NONE
metabolism	NN	metabolism	O	O	NONE
of	IN	of	O	O	NONE
vardenafil	NN	vardenafil	B-e0	O	drug
by	IN	by	O	O	NONE
ritonavir	NN	ritonavir	B-e1	T	drug
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
highly	RB	highly	O	O	NONE
potent	JJ	potent	O	O	NONE
CYP3A4	NN	cyp3a4	B-e2	T	drug
inhibitor	NN	inhibitor	O	O	NONE
,	,	,	O	O	NONE
which	WDT	which	O	O	NONE
also	RB	also	O	O	NONE
inhibits	VBZ	inhibit	O	O	NONE
CYP2C9	NN	cyp2c9	B-e3	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s13
The	DT	the	O	O	NONE
interaction	NN	interaction	O	O	NONE
is	VBZ	be	O	O	NONE
a	DT	a	O	O	NONE
consequence	NN	consequence	O	O	NONE
of	IN	of	O	O	NONE
blocking	VBG	block	O	O	NONE
hepatic	JJ	hepatic	O	O	NONE
metabolism	NN	metabolism	O	O	NONE
of	IN	of	O	O	NONE
vardenafil	NN	vardenafil	B-e0	O	drug
by	IN	by	O	O	NONE
ritonavir	NN	ritonavir	B-e1	T	drug
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
highly	RB	highly	O	O	NONE
potent	JJ	potent	O	O	NONE
CYP3A4	NN	cyp3a4	B-e2	O	drug
inhibitor	NN	inhibitor	O	O	NONE
,	,	,	O	O	NONE
which	WDT	which	O	O	NONE
also	RB	also	O	O	NONE
inhibits	VBZ	inhibit	O	O	NONE
CYP2C9	NN	cyp2c9	B-e3	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s13
The	DT	the	O	O	NONE
interaction	NN	interaction	O	O	NONE
is	VBZ	be	O	O	NONE
a	DT	a	O	O	NONE
consequence	NN	consequence	O	O	NONE
of	IN	of	O	O	NONE
blocking	VBG	block	O	O	NONE
hepatic	JJ	hepatic	O	O	NONE
metabolism	NN	metabolism	O	O	NONE
of	IN	of	O	O	NONE
vardenafil	NN	vardenafil	B-e0	O	drug
by	IN	by	O	O	NONE
ritonavir	NN	ritonavir	B-e1	O	drug
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
highly	RB	highly	O	O	NONE
potent	JJ	potent	O	O	NONE
CYP3A4	NN	cyp3a4	B-e2	T	drug
inhibitor	NN	inhibitor	O	O	NONE
,	,	,	O	O	NONE
which	WDT	which	O	O	NONE
also	RB	also	O	O	NONE
inhibits	VBZ	inhibit	O	O	NONE
CYP2C9	NN	cyp2c9	B-e3	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s14
Ritonavir	NN	ritonavir	B-e0	T	drug
significantly	RB	significantly	O	O	NONE
prolonged	VBD	prolong	O	O	NONE
the	DT	the	O	O	NONE
half-life	NN	half-life	O	O	NONE
of	IN	of	O	O	NONE
vardenafil	NN	vardenafil	B-e1	T	drug
to	TO	to	O	O	NONE
26	CD	26	O	O	NONE
hours	NNS	hour	O	O	NONE
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d253.s16
Other	JJ	other	O	O	NONE
Drug	NN	drug	O	O	NONE
Interactions	NNS	interaction	O	O	NONE
:	:	:	O	O	NONE
No	DT	no	O	O	NONE
pharmacokinetic	JJ	pharmacokinetic	O	O	NONE
interactions	NNS	interaction	O	O	NONE
were	VBD	be	O	O	NONE
observed	VBN	observe	O	O	NONE
between	IN	between	O	O	NONE
vardenafil	NN	vardenafil	B-e0	T	drug
and	CC	and	O	O	NONE
the	DT	the	O	O	NONE
following	JJ	following	O	O	NONE
drugs	NNS	drug	B-e1	T	drug
:	:	:	O	O	NONE
glyburide	NN	glyburide	B-e2	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e3	O	drug
,	,	,	O	O	NONE
digoxin	NN	digoxin	B-e4	O	drug
,	,	,	O	O	NONE
Maalox	NN	maalox	B-e5	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
ranitidine	NN	ranitidine	B-e6	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s16
Other	JJ	other	O	O	NONE
Drug	NN	drug	O	O	NONE
Interactions	NNS	interaction	O	O	NONE
:	:	:	O	O	NONE
No	DT	no	O	O	NONE
pharmacokinetic	JJ	pharmacokinetic	O	O	NONE
interactions	NNS	interaction	O	O	NONE
were	VBD	be	O	O	NONE
observed	VBN	observe	O	O	NONE
between	IN	between	O	O	NONE
vardenafil	NN	vardenafil	B-e0	T	drug
and	CC	and	O	O	NONE
the	DT	the	O	O	NONE
following	JJ	following	O	O	NONE
drugs	NNS	drug	B-e1	O	drug
:	:	:	O	O	NONE
glyburide	NN	glyburide	B-e2	T	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e3	O	drug
,	,	,	O	O	NONE
digoxin	NN	digoxin	B-e4	O	drug
,	,	,	O	O	NONE
Maalox	NN	maalox	B-e5	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
ranitidine	NN	ranitidine	B-e6	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s16
Other	JJ	other	O	O	NONE
Drug	NN	drug	O	O	NONE
Interactions	NNS	interaction	O	O	NONE
:	:	:	O	O	NONE
No	DT	no	O	O	NONE
pharmacokinetic	JJ	pharmacokinetic	O	O	NONE
interactions	NNS	interaction	O	O	NONE
were	VBD	be	O	O	NONE
observed	VBN	observe	O	O	NONE
between	IN	between	O	O	NONE
vardenafil	NN	vardenafil	B-e0	T	drug
and	CC	and	O	O	NONE
the	DT	the	O	O	NONE
following	JJ	following	O	O	NONE
drugs	NNS	drug	B-e1	O	drug
:	:	:	O	O	NONE
glyburide	NN	glyburide	B-e2	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e3	T	drug
,	,	,	O	O	NONE
digoxin	NN	digoxin	B-e4	O	drug
,	,	,	O	O	NONE
Maalox	NN	maalox	B-e5	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
ranitidine	NN	ranitidine	B-e6	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s16
Other	JJ	other	O	O	NONE
Drug	NN	drug	O	O	NONE
Interactions	NNS	interaction	O	O	NONE
:	:	:	O	O	NONE
No	DT	no	O	O	NONE
pharmacokinetic	JJ	pharmacokinetic	O	O	NONE
interactions	NNS	interaction	O	O	NONE
were	VBD	be	O	O	NONE
observed	VBN	observe	O	O	NONE
between	IN	between	O	O	NONE
vardenafil	NN	vardenafil	B-e0	T	drug
and	CC	and	O	O	NONE
the	DT	the	O	O	NONE
following	JJ	following	O	O	NONE
drugs	NNS	drug	B-e1	O	drug
:	:	:	O	O	NONE
glyburide	NN	glyburide	B-e2	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e3	O	drug
,	,	,	O	O	NONE
digoxin	NN	digoxin	B-e4	T	drug
,	,	,	O	O	NONE
Maalox	NN	maalox	B-e5	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
ranitidine	NN	ranitidine	B-e6	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s16
Other	JJ	other	O	O	NONE
Drug	NN	drug	O	O	NONE
Interactions	NNS	interaction	O	O	NONE
:	:	:	O	O	NONE
No	DT	no	O	O	NONE
pharmacokinetic	JJ	pharmacokinetic	O	O	NONE
interactions	NNS	interaction	O	O	NONE
were	VBD	be	O	O	NONE
observed	VBN	observe	O	O	NONE
between	IN	between	O	O	NONE
vardenafil	NN	vardenafil	B-e0	T	drug
and	CC	and	O	O	NONE
the	DT	the	O	O	NONE
following	JJ	following	O	O	NONE
drugs	NNS	drug	B-e1	O	drug
:	:	:	O	O	NONE
glyburide	NN	glyburide	B-e2	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e3	O	drug
,	,	,	O	O	NONE
digoxin	NN	digoxin	B-e4	O	drug
,	,	,	O	O	NONE
Maalox	NN	maalox	B-e5	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
ranitidine	NN	ranitidine	B-e6	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s16
Other	JJ	other	O	O	NONE
Drug	NN	drug	O	O	NONE
Interactions	NNS	interaction	O	O	NONE
:	:	:	O	O	NONE
No	DT	no	O	O	NONE
pharmacokinetic	JJ	pharmacokinetic	O	O	NONE
interactions	NNS	interaction	O	O	NONE
were	VBD	be	O	O	NONE
observed	VBN	observe	O	O	NONE
between	IN	between	O	O	NONE
vardenafil	NN	vardenafil	B-e0	T	drug
and	CC	and	O	O	NONE
the	DT	the	O	O	NONE
following	JJ	following	O	O	NONE
drugs	NNS	drug	B-e1	O	drug
:	:	:	O	O	NONE
glyburide	NN	glyburide	B-e2	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e3	O	drug
,	,	,	O	O	NONE
digoxin	NN	digoxin	B-e4	O	drug
,	,	,	O	O	NONE
Maalox	NN	maalox	B-e5	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
ranitidine	NN	ranitidine	B-e6	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s16
Other	JJ	other	O	O	NONE
Drug	NN	drug	O	O	NONE
Interactions	NNS	interaction	O	O	NONE
:	:	:	O	O	NONE
No	DT	no	O	O	NONE
pharmacokinetic	JJ	pharmacokinetic	O	O	NONE
interactions	NNS	interaction	O	O	NONE
were	VBD	be	O	O	NONE
observed	VBN	observe	O	O	NONE
between	IN	between	O	O	NONE
vardenafil	NN	vardenafil	B-e0	O	drug
and	CC	and	O	O	NONE
the	DT	the	O	O	NONE
following	JJ	following	O	O	NONE
drugs	NNS	drug	B-e1	T	drug
:	:	:	O	O	NONE
glyburide	NN	glyburide	B-e2	T	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e3	O	drug
,	,	,	O	O	NONE
digoxin	NN	digoxin	B-e4	O	drug
,	,	,	O	O	NONE
Maalox	NN	maalox	B-e5	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
ranitidine	NN	ranitidine	B-e6	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s16
Other	JJ	other	O	O	NONE
Drug	NN	drug	O	O	NONE
Interactions	NNS	interaction	O	O	NONE
:	:	:	O	O	NONE
No	DT	no	O	O	NONE
pharmacokinetic	JJ	pharmacokinetic	O	O	NONE
interactions	NNS	interaction	O	O	NONE
were	VBD	be	O	O	NONE
observed	VBN	observe	O	O	NONE
between	IN	between	O	O	NONE
vardenafil	NN	vardenafil	B-e0	O	drug
and	CC	and	O	O	NONE
the	DT	the	O	O	NONE
following	JJ	following	O	O	NONE
drugs	NNS	drug	B-e1	T	drug
:	:	:	O	O	NONE
glyburide	NN	glyburide	B-e2	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e3	T	drug
,	,	,	O	O	NONE
digoxin	NN	digoxin	B-e4	O	drug
,	,	,	O	O	NONE
Maalox	NN	maalox	B-e5	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
ranitidine	NN	ranitidine	B-e6	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s16
Other	JJ	other	O	O	NONE
Drug	NN	drug	O	O	NONE
Interactions	NNS	interaction	O	O	NONE
:	:	:	O	O	NONE
No	DT	no	O	O	NONE
pharmacokinetic	JJ	pharmacokinetic	O	O	NONE
interactions	NNS	interaction	O	O	NONE
were	VBD	be	O	O	NONE
observed	VBN	observe	O	O	NONE
between	IN	between	O	O	NONE
vardenafil	NN	vardenafil	B-e0	O	drug
and	CC	and	O	O	NONE
the	DT	the	O	O	NONE
following	JJ	following	O	O	NONE
drugs	NNS	drug	B-e1	T	drug
:	:	:	O	O	NONE
glyburide	NN	glyburide	B-e2	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e3	O	drug
,	,	,	O	O	NONE
digoxin	NN	digoxin	B-e4	T	drug
,	,	,	O	O	NONE
Maalox	NN	maalox	B-e5	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
ranitidine	NN	ranitidine	B-e6	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s16
Other	JJ	other	O	O	NONE
Drug	NN	drug	O	O	NONE
Interactions	NNS	interaction	O	O	NONE
:	:	:	O	O	NONE
No	DT	no	O	O	NONE
pharmacokinetic	JJ	pharmacokinetic	O	O	NONE
interactions	NNS	interaction	O	O	NONE
were	VBD	be	O	O	NONE
observed	VBN	observe	O	O	NONE
between	IN	between	O	O	NONE
vardenafil	NN	vardenafil	B-e0	O	drug
and	CC	and	O	O	NONE
the	DT	the	O	O	NONE
following	JJ	following	O	O	NONE
drugs	NNS	drug	B-e1	T	drug
:	:	:	O	O	NONE
glyburide	NN	glyburide	B-e2	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e3	O	drug
,	,	,	O	O	NONE
digoxin	NN	digoxin	B-e4	O	drug
,	,	,	O	O	NONE
Maalox	NN	maalox	B-e5	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
ranitidine	NN	ranitidine	B-e6	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s16
Other	JJ	other	O	O	NONE
Drug	NN	drug	O	O	NONE
Interactions	NNS	interaction	O	O	NONE
:	:	:	O	O	NONE
No	DT	no	O	O	NONE
pharmacokinetic	JJ	pharmacokinetic	O	O	NONE
interactions	NNS	interaction	O	O	NONE
were	VBD	be	O	O	NONE
observed	VBN	observe	O	O	NONE
between	IN	between	O	O	NONE
vardenafil	NN	vardenafil	B-e0	O	drug
and	CC	and	O	O	NONE
the	DT	the	O	O	NONE
following	JJ	following	O	O	NONE
drugs	NNS	drug	B-e1	T	drug
:	:	:	O	O	NONE
glyburide	NN	glyburide	B-e2	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e3	O	drug
,	,	,	O	O	NONE
digoxin	NN	digoxin	B-e4	O	drug
,	,	,	O	O	NONE
Maalox	NN	maalox	B-e5	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
ranitidine	NN	ranitidine	B-e6	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s16
Other	JJ	other	O	O	NONE
Drug	NN	drug	O	O	NONE
Interactions	NNS	interaction	O	O	NONE
:	:	:	O	O	NONE
No	DT	no	O	O	NONE
pharmacokinetic	JJ	pharmacokinetic	O	O	NONE
interactions	NNS	interaction	O	O	NONE
were	VBD	be	O	O	NONE
observed	VBN	observe	O	O	NONE
between	IN	between	O	O	NONE
vardenafil	NN	vardenafil	B-e0	O	drug
and	CC	and	O	O	NONE
the	DT	the	O	O	NONE
following	JJ	following	O	O	NONE
drugs	NNS	drug	B-e1	O	drug
:	:	:	O	O	NONE
glyburide	NN	glyburide	B-e2	T	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e3	T	drug
,	,	,	O	O	NONE
digoxin	NN	digoxin	B-e4	O	drug
,	,	,	O	O	NONE
Maalox	NN	maalox	B-e5	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
ranitidine	NN	ranitidine	B-e6	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s16
Other	JJ	other	O	O	NONE
Drug	NN	drug	O	O	NONE
Interactions	NNS	interaction	O	O	NONE
:	:	:	O	O	NONE
No	DT	no	O	O	NONE
pharmacokinetic	JJ	pharmacokinetic	O	O	NONE
interactions	NNS	interaction	O	O	NONE
were	VBD	be	O	O	NONE
observed	VBN	observe	O	O	NONE
between	IN	between	O	O	NONE
vardenafil	NN	vardenafil	B-e0	O	drug
and	CC	and	O	O	NONE
the	DT	the	O	O	NONE
following	JJ	following	O	O	NONE
drugs	NNS	drug	B-e1	O	drug
:	:	:	O	O	NONE
glyburide	NN	glyburide	B-e2	T	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e3	O	drug
,	,	,	O	O	NONE
digoxin	NN	digoxin	B-e4	T	drug
,	,	,	O	O	NONE
Maalox	NN	maalox	B-e5	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
ranitidine	NN	ranitidine	B-e6	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s16
Other	JJ	other	O	O	NONE
Drug	NN	drug	O	O	NONE
Interactions	NNS	interaction	O	O	NONE
:	:	:	O	O	NONE
No	DT	no	O	O	NONE
pharmacokinetic	JJ	pharmacokinetic	O	O	NONE
interactions	NNS	interaction	O	O	NONE
were	VBD	be	O	O	NONE
observed	VBN	observe	O	O	NONE
between	IN	between	O	O	NONE
vardenafil	NN	vardenafil	B-e0	O	drug
and	CC	and	O	O	NONE
the	DT	the	O	O	NONE
following	JJ	following	O	O	NONE
drugs	NNS	drug	B-e1	O	drug
:	:	:	O	O	NONE
glyburide	NN	glyburide	B-e2	T	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e3	O	drug
,	,	,	O	O	NONE
digoxin	NN	digoxin	B-e4	O	drug
,	,	,	O	O	NONE
Maalox	NN	maalox	B-e5	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
ranitidine	NN	ranitidine	B-e6	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s16
Other	JJ	other	O	O	NONE
Drug	NN	drug	O	O	NONE
Interactions	NNS	interaction	O	O	NONE
:	:	:	O	O	NONE
No	DT	no	O	O	NONE
pharmacokinetic	JJ	pharmacokinetic	O	O	NONE
interactions	NNS	interaction	O	O	NONE
were	VBD	be	O	O	NONE
observed	VBN	observe	O	O	NONE
between	IN	between	O	O	NONE
vardenafil	NN	vardenafil	B-e0	O	drug
and	CC	and	O	O	NONE
the	DT	the	O	O	NONE
following	JJ	following	O	O	NONE
drugs	NNS	drug	B-e1	O	drug
:	:	:	O	O	NONE
glyburide	NN	glyburide	B-e2	T	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e3	O	drug
,	,	,	O	O	NONE
digoxin	NN	digoxin	B-e4	O	drug
,	,	,	O	O	NONE
Maalox	NN	maalox	B-e5	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
ranitidine	NN	ranitidine	B-e6	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s16
Other	JJ	other	O	O	NONE
Drug	NN	drug	O	O	NONE
Interactions	NNS	interaction	O	O	NONE
:	:	:	O	O	NONE
No	DT	no	O	O	NONE
pharmacokinetic	JJ	pharmacokinetic	O	O	NONE
interactions	NNS	interaction	O	O	NONE
were	VBD	be	O	O	NONE
observed	VBN	observe	O	O	NONE
between	IN	between	O	O	NONE
vardenafil	NN	vardenafil	B-e0	O	drug
and	CC	and	O	O	NONE
the	DT	the	O	O	NONE
following	JJ	following	O	O	NONE
drugs	NNS	drug	B-e1	O	drug
:	:	:	O	O	NONE
glyburide	NN	glyburide	B-e2	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e3	T	drug
,	,	,	O	O	NONE
digoxin	NN	digoxin	B-e4	T	drug
,	,	,	O	O	NONE
Maalox	NN	maalox	B-e5	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
ranitidine	NN	ranitidine	B-e6	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s16
Other	JJ	other	O	O	NONE
Drug	NN	drug	O	O	NONE
Interactions	NNS	interaction	O	O	NONE
:	:	:	O	O	NONE
No	DT	no	O	O	NONE
pharmacokinetic	JJ	pharmacokinetic	O	O	NONE
interactions	NNS	interaction	O	O	NONE
were	VBD	be	O	O	NONE
observed	VBN	observe	O	O	NONE
between	IN	between	O	O	NONE
vardenafil	NN	vardenafil	B-e0	O	drug
and	CC	and	O	O	NONE
the	DT	the	O	O	NONE
following	JJ	following	O	O	NONE
drugs	NNS	drug	B-e1	O	drug
:	:	:	O	O	NONE
glyburide	NN	glyburide	B-e2	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e3	T	drug
,	,	,	O	O	NONE
digoxin	NN	digoxin	B-e4	O	drug
,	,	,	O	O	NONE
Maalox	NN	maalox	B-e5	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
ranitidine	NN	ranitidine	B-e6	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s16
Other	JJ	other	O	O	NONE
Drug	NN	drug	O	O	NONE
Interactions	NNS	interaction	O	O	NONE
:	:	:	O	O	NONE
No	DT	no	O	O	NONE
pharmacokinetic	JJ	pharmacokinetic	O	O	NONE
interactions	NNS	interaction	O	O	NONE
were	VBD	be	O	O	NONE
observed	VBN	observe	O	O	NONE
between	IN	between	O	O	NONE
vardenafil	NN	vardenafil	B-e0	O	drug
and	CC	and	O	O	NONE
the	DT	the	O	O	NONE
following	JJ	following	O	O	NONE
drugs	NNS	drug	B-e1	O	drug
:	:	:	O	O	NONE
glyburide	NN	glyburide	B-e2	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e3	T	drug
,	,	,	O	O	NONE
digoxin	NN	digoxin	B-e4	O	drug
,	,	,	O	O	NONE
Maalox	NN	maalox	B-e5	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
ranitidine	NN	ranitidine	B-e6	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s16
Other	JJ	other	O	O	NONE
Drug	NN	drug	O	O	NONE
Interactions	NNS	interaction	O	O	NONE
:	:	:	O	O	NONE
No	DT	no	O	O	NONE
pharmacokinetic	JJ	pharmacokinetic	O	O	NONE
interactions	NNS	interaction	O	O	NONE
were	VBD	be	O	O	NONE
observed	VBN	observe	O	O	NONE
between	IN	between	O	O	NONE
vardenafil	NN	vardenafil	B-e0	O	drug
and	CC	and	O	O	NONE
the	DT	the	O	O	NONE
following	JJ	following	O	O	NONE
drugs	NNS	drug	B-e1	O	drug
:	:	:	O	O	NONE
glyburide	NN	glyburide	B-e2	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e3	O	drug
,	,	,	O	O	NONE
digoxin	NN	digoxin	B-e4	T	drug
,	,	,	O	O	NONE
Maalox	NN	maalox	B-e5	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
ranitidine	NN	ranitidine	B-e6	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s16
Other	JJ	other	O	O	NONE
Drug	NN	drug	O	O	NONE
Interactions	NNS	interaction	O	O	NONE
:	:	:	O	O	NONE
No	DT	no	O	O	NONE
pharmacokinetic	JJ	pharmacokinetic	O	O	NONE
interactions	NNS	interaction	O	O	NONE
were	VBD	be	O	O	NONE
observed	VBN	observe	O	O	NONE
between	IN	between	O	O	NONE
vardenafil	NN	vardenafil	B-e0	O	drug
and	CC	and	O	O	NONE
the	DT	the	O	O	NONE
following	JJ	following	O	O	NONE
drugs	NNS	drug	B-e1	O	drug
:	:	:	O	O	NONE
glyburide	NN	glyburide	B-e2	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e3	O	drug
,	,	,	O	O	NONE
digoxin	NN	digoxin	B-e4	T	drug
,	,	,	O	O	NONE
Maalox	NN	maalox	B-e5	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
ranitidine	NN	ranitidine	B-e6	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s16
Other	JJ	other	O	O	NONE
Drug	NN	drug	O	O	NONE
Interactions	NNS	interaction	O	O	NONE
:	:	:	O	O	NONE
No	DT	no	O	O	NONE
pharmacokinetic	JJ	pharmacokinetic	O	O	NONE
interactions	NNS	interaction	O	O	NONE
were	VBD	be	O	O	NONE
observed	VBN	observe	O	O	NONE
between	IN	between	O	O	NONE
vardenafil	NN	vardenafil	B-e0	O	drug
and	CC	and	O	O	NONE
the	DT	the	O	O	NONE
following	JJ	following	O	O	NONE
drugs	NNS	drug	B-e1	O	drug
:	:	:	O	O	NONE
glyburide	NN	glyburide	B-e2	O	drug
,	,	,	O	O	NONE
warfarin	NN	warfarin	B-e3	O	drug
,	,	,	O	O	NONE
digoxin	NN	digoxin	B-e4	O	drug
,	,	,	O	O	NONE
Maalox	NN	maalox	B-e5	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
ranitidine	NN	ranitidine	B-e6	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s17
In	IN	in	O	O	NONE
the	DT	the	O	O	NONE
warfarin	JJ	warfarin	B-e0	T	drug
study	NN	study	O	O	NONE
,	,	,	O	O	NONE
vardenafil	NN	vardenafil	B-e1	T	drug
had	VBD	have	O	O	NONE
no	DT	no	O	O	NONE
effect	NN	effect	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
prothrombin	NN	prothrombin	O	O	NONE
time	NN	time	O	O	NONE
or	CC	or	O	O	NONE
other	JJ	other	O	O	NONE
pharmacodynamic	JJ	pharmacodynamic	O	O	NONE
parameters	NNS	parameter	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s18
Effects	NNS	effect	O	O	NONE
of	IN	of	O	O	NONE
Vardenafil	NN	vardenafil	B-e0	T	drug
on	IN	on	O	O	NONE
other	JJ	other	O	O	NONE
drugs	NNS	drug	B-e1	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s19
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
studies	NNS	study	O	O	NONE
:	:	:	O	O	NONE
Vardenafil	NN	vardenafil	B-e0	T	drug
and	CC	and	O	O	NONE
its	PRP$	its	O	O	NONE
metabolites	NNS	metabolite	B-e1	T	drug
had	VBD	have	O	O	NONE
no	DT	no	O	O	NONE
effect	NN	effect	O	O	NONE
on	IN	on	O	O	NONE
CYP1A2	NN	cyp1a2	B-e2	O	drug
,	,	,	O	O	NONE
2A6	NN	2a6	O	O	NONE
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
2E1	NN	2e1	O	O	NONE
(	(	(	O	O	NONE
Ki	NN	kus	B-e3	O	drug
100uM	NN	100um	I-e3	O	drug
)	)	)	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s19
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
studies	NNS	study	O	O	NONE
:	:	:	O	O	NONE
Vardenafil	NN	vardenafil	B-e0	T	drug
and	CC	and	O	O	NONE
its	PRP$	its	O	O	NONE
metabolites	NNS	metabolite	B-e1	O	drug
had	VBD	have	O	O	NONE
no	DT	no	O	O	NONE
effect	NN	effect	O	O	NONE
on	IN	on	O	O	NONE
CYP1A2	NN	cyp1a2	B-e2	T	drug
,	,	,	O	O	NONE
2A6	NN	2a6	O	O	NONE
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
2E1	NN	2e1	O	O	NONE
(	(	(	O	O	NONE
Ki	NN	kus	B-e3	O	drug
100uM	NN	100um	I-e3	O	drug
)	)	)	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s19
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
studies	NNS	study	O	O	NONE
:	:	:	O	O	NONE
Vardenafil	NN	vardenafil	B-e0	T	drug
and	CC	and	O	O	NONE
its	PRP$	its	O	O	NONE
metabolites	NNS	metabolite	B-e1	O	drug
had	VBD	have	O	O	NONE
no	DT	no	O	O	NONE
effect	NN	effect	O	O	NONE
on	IN	on	O	O	NONE
CYP1A2	NN	cyp1a2	B-e2	O	drug
,	,	,	O	O	NONE
2A6	NN	2a6	O	O	NONE
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
2E1	NN	2e1	O	O	NONE
(	(	(	O	O	NONE
Ki	NN	kus	B-e3	T	drug
100uM	NN	100um	I-e3	T	drug
)	)	)	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s19
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
studies	NNS	study	O	O	NONE
:	:	:	O	O	NONE
Vardenafil	NN	vardenafil	B-e0	O	drug
and	CC	and	O	O	NONE
its	PRP$	its	O	O	NONE
metabolites	NNS	metabolite	B-e1	T	drug
had	VBD	have	O	O	NONE
no	DT	no	O	O	NONE
effect	NN	effect	O	O	NONE
on	IN	on	O	O	NONE
CYP1A2	NN	cyp1a2	B-e2	T	drug
,	,	,	O	O	NONE
2A6	NN	2a6	O	O	NONE
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
2E1	NN	2e1	O	O	NONE
(	(	(	O	O	NONE
Ki	NN	kus	B-e3	O	drug
100uM	NN	100um	I-e3	O	drug
)	)	)	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s19
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
studies	NNS	study	O	O	NONE
:	:	:	O	O	NONE
Vardenafil	NN	vardenafil	B-e0	O	drug
and	CC	and	O	O	NONE
its	PRP$	its	O	O	NONE
metabolites	NNS	metabolite	B-e1	T	drug
had	VBD	have	O	O	NONE
no	DT	no	O	O	NONE
effect	NN	effect	O	O	NONE
on	IN	on	O	O	NONE
CYP1A2	NN	cyp1a2	B-e2	O	drug
,	,	,	O	O	NONE
2A6	NN	2a6	O	O	NONE
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
2E1	NN	2e1	O	O	NONE
(	(	(	O	O	NONE
Ki	NN	kus	B-e3	T	drug
100uM	NN	100um	I-e3	T	drug
)	)	)	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s19
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
studies	NNS	study	O	O	NONE
:	:	:	O	O	NONE
Vardenafil	NN	vardenafil	B-e0	O	drug
and	CC	and	O	O	NONE
its	PRP$	its	O	O	NONE
metabolites	NNS	metabolite	B-e1	O	drug
had	VBD	have	O	O	NONE
no	DT	no	O	O	NONE
effect	NN	effect	O	O	NONE
on	IN	on	O	O	NONE
CYP1A2	NN	cyp1a2	B-e2	T	drug
,	,	,	O	O	NONE
2A6	NN	2a6	O	O	NONE
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
2E1	NN	2e1	O	O	NONE
(	(	(	O	O	NONE
Ki	NN	kus	B-e3	T	drug
100uM	NN	100um	I-e3	T	drug
)	)	)	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s20
Weak	JJ	weak	O	O	NONE
inhibitory	JJ	inhibitory	O	O	NONE
effects	NNS	effect	O	O	NONE
toward	IN	toward	O	O	NONE
other	JJ	other	O	O	NONE
isoforms	NNS	isoform	B-e0	T	drug
(	(	(	O	O	NONE
CYP2C8	NN	cyp2c8	B-e1	T	drug
,	,	,	O	O	NONE
2C9	NN	2c9	O	O	NONE
,	,	,	O	O	NONE
2C19	NN	2c19	O	O	NONE
,	,	,	O	O	NONE
2D6	NN	2d6	O	O	NONE
,	,	,	O	O	NONE
3A4	NN	3a4	O	O	NONE
)	)	)	O	O	NONE
were	VBD	be	O	O	NONE
found	VBN	find	O	O	NONE
,	,	,	O	O	NONE
but	CC	but	O	O	NONE
Ki	NN	kus	O	O	NONE
values	NNS	value	O	O	NONE
were	VBD	be	O	O	NONE
in	IN	in	O	O	NONE
excess	NN	excess	O	O	NONE
of	IN	of	O	O	NONE
plasma	NN	plasma	O	O	NONE
concentrations	NNS	concentration	O	O	NONE
achieved	VBN	achieve	O	O	NONE
following	VBG	follow	O	O	NONE
dosing	NN	dosing	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s21
The	DT	the	O	O	NONE
most	RBS	most	O	O	NONE
potent	JJ	potent	O	O	NONE
inhibitory	JJ	inhibitory	O	O	NONE
activity	NN	activity	O	O	NONE
was	VBD	be	O	O	NONE
observed	VBN	observe	O	O	NONE
for	IN	for	O	O	NONE
vardenafil	NN	vardenafil	B-e0	T	drug
metabolite	NN	metabolite	O	O	NONE
M1	NN	m1	O	O	NONE
,	,	,	O	O	NONE
which	WDT	which	O	O	NONE
had	VBD	have	O	O	NONE
a	DT	a	O	O	NONE
Ki	NN	kus	O	O	NONE
of	IN	of	O	O	NONE
1.4	CD	1.4	O	O	NONE
uM	NN	um	O	O	NONE
toward	IN	toward	O	O	NONE
CYP3A4	NN	cyp3a4	B-e1	T	drug
,	,	,	O	O	NONE
which	WDT	which	O	O	NONE
is	VBZ	be	O	O	NONE
about	RB	about	O	O	NONE
20	CD	20	O	O	NONE
times	NNS	time	O	O	NONE
higher	JJR	higher	O	O	NONE
than	IN	than	O	O	NONE
the	DT	the	O	O	NONE
M1	NN	m1	O	O	NONE
Cmax	NN	cmax	O	O	NONE
values	NNS	value	O	O	NONE
after	IN	after	O	O	NONE
an	DT	a	O	O	NONE
80	CD	80	O	O	NONE
mg	NN	mg	O	O	NONE
Vardenafil	NN	vardenafil	B-e2	O	drug
dose	NN	dose	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s21
The	DT	the	O	O	NONE
most	RBS	most	O	O	NONE
potent	JJ	potent	O	O	NONE
inhibitory	JJ	inhibitory	O	O	NONE
activity	NN	activity	O	O	NONE
was	VBD	be	O	O	NONE
observed	VBN	observe	O	O	NONE
for	IN	for	O	O	NONE
vardenafil	NN	vardenafil	B-e0	T	drug
metabolite	NN	metabolite	O	O	NONE
M1	NN	m1	O	O	NONE
,	,	,	O	O	NONE
which	WDT	which	O	O	NONE
had	VBD	have	O	O	NONE
a	DT	a	O	O	NONE
Ki	NN	kus	O	O	NONE
of	IN	of	O	O	NONE
1.4	CD	1.4	O	O	NONE
uM	NN	um	O	O	NONE
toward	IN	toward	O	O	NONE
CYP3A4	NN	cyp3a4	B-e1	O	drug
,	,	,	O	O	NONE
which	WDT	which	O	O	NONE
is	VBZ	be	O	O	NONE
about	RB	about	O	O	NONE
20	CD	20	O	O	NONE
times	NNS	time	O	O	NONE
higher	JJR	higher	O	O	NONE
than	IN	than	O	O	NONE
the	DT	the	O	O	NONE
M1	NN	m1	O	O	NONE
Cmax	NN	cmax	O	O	NONE
values	NNS	value	O	O	NONE
after	IN	after	O	O	NONE
an	DT	a	O	O	NONE
80	CD	80	O	O	NONE
mg	NN	mg	O	O	NONE
Vardenafil	NN	vardenafil	B-e2	T	drug
dose	NN	dose	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s21
The	DT	the	O	O	NONE
most	RBS	most	O	O	NONE
potent	JJ	potent	O	O	NONE
inhibitory	JJ	inhibitory	O	O	NONE
activity	NN	activity	O	O	NONE
was	VBD	be	O	O	NONE
observed	VBN	observe	O	O	NONE
for	IN	for	O	O	NONE
vardenafil	NN	vardenafil	B-e0	O	drug
metabolite	NN	metabolite	O	O	NONE
M1	NN	m1	O	O	NONE
,	,	,	O	O	NONE
which	WDT	which	O	O	NONE
had	VBD	have	O	O	NONE
a	DT	a	O	O	NONE
Ki	NN	kus	O	O	NONE
of	IN	of	O	O	NONE
1.4	CD	1.4	O	O	NONE
uM	NN	um	O	O	NONE
toward	IN	toward	O	O	NONE
CYP3A4	NN	cyp3a4	B-e1	T	drug
,	,	,	O	O	NONE
which	WDT	which	O	O	NONE
is	VBZ	be	O	O	NONE
about	RB	about	O	O	NONE
20	CD	20	O	O	NONE
times	NNS	time	O	O	NONE
higher	JJR	higher	O	O	NONE
than	IN	than	O	O	NONE
the	DT	the	O	O	NONE
M1	NN	m1	O	O	NONE
Cmax	NN	cmax	O	O	NONE
values	NNS	value	O	O	NONE
after	IN	after	O	O	NONE
an	DT	a	O	O	NONE
80	CD	80	O	O	NONE
mg	NN	mg	O	O	NONE
Vardenafil	NN	vardenafil	B-e2	T	drug
dose	NN	dose	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s22
In	FW	in	O	O	NONE
vivo	FW	vivo	O	O	NONE
studies	NNS	study	O	O	NONE
:	:	:	O	O	NONE
Nitrates	NNS	nitrate	B-e0	T	drug
:	:	:	O	O	NONE
The	DT	the	O	O	NONE
blood	NN	blood	O	O	NONE
pressure	NN	pressure	O	O	NONE
lowering	JJ	lowering	O	O	NONE
effects	NNS	effect	O	O	NONE
of	IN	of	O	O	NONE
sublingual	JJ	sublingual	O	O	NONE
nitrates	NNS	nitrate	B-e1	T	drug
(	(	(	O	O	NONE
0.4	CD	0.4	O	O	NONE
mg	NN	mg	O	O	NONE
)	)	)	O	O	NONE
taken	VBN	take	O	O	NONE
1	CD	1	O	O	NONE
and	CC	and	O	O	NONE
4	CD	4	O	O	NONE
hours	NNS	hour	O	O	NONE
after	IN	after	O	O	NONE
vardenafil	NN	vardenafil	B-e2	O	drug
and	CC	and	O	O	NONE
increases	NNS	increase	O	O	NONE
in	IN	in	O	O	NONE
heart	NN	heart	O	O	NONE
rate	NN	rate	O	O	NONE
when	WRB	when	O	O	NONE
taken	VBN	take	O	O	NONE
at	IN	at	O	O	NONE
1	CD	1	O	O	NONE
,	,	,	O	O	NONE
4	CD	4	O	O	NONE
and	CC	and	O	O	NONE
8	CD	8	O	O	NONE
hours	NNS	hour	O	O	NONE
were	VBD	be	O	O	NONE
potentiated	VBN	potentiate	O	O	NONE
by	IN	by	O	O	NONE
a	DT	a	O	O	NONE
20	CD	20	O	O	NONE
mg	NN	mg	O	O	NONE
dose	NN	dose	O	O	NONE
of	IN	of	O	O	NONE
Vardenafil	NN	vardenafil	B-e3	O	drug
in	IN	in	O	O	NONE
healthy	JJ	healthy	O	O	NONE
middle-aged	JJ	middle-aged	O	O	NONE
subjects	NNS	subject	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s22
In	FW	in	O	O	NONE
vivo	FW	vivo	O	O	NONE
studies	NNS	study	O	O	NONE
:	:	:	O	O	NONE
Nitrates	NNS	nitrate	B-e0	T	drug
:	:	:	O	O	NONE
The	DT	the	O	O	NONE
blood	NN	blood	O	O	NONE
pressure	NN	pressure	O	O	NONE
lowering	JJ	lowering	O	O	NONE
effects	NNS	effect	O	O	NONE
of	IN	of	O	O	NONE
sublingual	JJ	sublingual	O	O	NONE
nitrates	NNS	nitrate	B-e1	O	drug
(	(	(	O	O	NONE
0.4	CD	0.4	O	O	NONE
mg	NN	mg	O	O	NONE
)	)	)	O	O	NONE
taken	VBN	take	O	O	NONE
1	CD	1	O	O	NONE
and	CC	and	O	O	NONE
4	CD	4	O	O	NONE
hours	NNS	hour	O	O	NONE
after	IN	after	O	O	NONE
vardenafil	NN	vardenafil	B-e2	T	drug
and	CC	and	O	O	NONE
increases	NNS	increase	O	O	NONE
in	IN	in	O	O	NONE
heart	NN	heart	O	O	NONE
rate	NN	rate	O	O	NONE
when	WRB	when	O	O	NONE
taken	VBN	take	O	O	NONE
at	IN	at	O	O	NONE
1	CD	1	O	O	NONE
,	,	,	O	O	NONE
4	CD	4	O	O	NONE
and	CC	and	O	O	NONE
8	CD	8	O	O	NONE
hours	NNS	hour	O	O	NONE
were	VBD	be	O	O	NONE
potentiated	VBN	potentiate	O	O	NONE
by	IN	by	O	O	NONE
a	DT	a	O	O	NONE
20	CD	20	O	O	NONE
mg	NN	mg	O	O	NONE
dose	NN	dose	O	O	NONE
of	IN	of	O	O	NONE
Vardenafil	NN	vardenafil	B-e3	O	drug
in	IN	in	O	O	NONE
healthy	JJ	healthy	O	O	NONE
middle-aged	JJ	middle-aged	O	O	NONE
subjects	NNS	subject	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s22
In	FW	in	O	O	NONE
vivo	FW	vivo	O	O	NONE
studies	NNS	study	O	O	NONE
:	:	:	O	O	NONE
Nitrates	NNS	nitrate	B-e0	T	drug
:	:	:	O	O	NONE
The	DT	the	O	O	NONE
blood	NN	blood	O	O	NONE
pressure	NN	pressure	O	O	NONE
lowering	JJ	lowering	O	O	NONE
effects	NNS	effect	O	O	NONE
of	IN	of	O	O	NONE
sublingual	JJ	sublingual	O	O	NONE
nitrates	NNS	nitrate	B-e1	O	drug
(	(	(	O	O	NONE
0.4	CD	0.4	O	O	NONE
mg	NN	mg	O	O	NONE
)	)	)	O	O	NONE
taken	VBN	take	O	O	NONE
1	CD	1	O	O	NONE
and	CC	and	O	O	NONE
4	CD	4	O	O	NONE
hours	NNS	hour	O	O	NONE
after	IN	after	O	O	NONE
vardenafil	NN	vardenafil	B-e2	O	drug
and	CC	and	O	O	NONE
increases	NNS	increase	O	O	NONE
in	IN	in	O	O	NONE
heart	NN	heart	O	O	NONE
rate	NN	rate	O	O	NONE
when	WRB	when	O	O	NONE
taken	VBN	take	O	O	NONE
at	IN	at	O	O	NONE
1	CD	1	O	O	NONE
,	,	,	O	O	NONE
4	CD	4	O	O	NONE
and	CC	and	O	O	NONE
8	CD	8	O	O	NONE
hours	NNS	hour	O	O	NONE
were	VBD	be	O	O	NONE
potentiated	VBN	potentiate	O	O	NONE
by	IN	by	O	O	NONE
a	DT	a	O	O	NONE
20	CD	20	O	O	NONE
mg	NN	mg	O	O	NONE
dose	NN	dose	O	O	NONE
of	IN	of	O	O	NONE
Vardenafil	NN	vardenafil	B-e3	T	drug
in	IN	in	O	O	NONE
healthy	JJ	healthy	O	O	NONE
middle-aged	JJ	middle-aged	O	O	NONE
subjects	NNS	subject	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s22
In	FW	in	O	O	NONE
vivo	FW	vivo	O	O	NONE
studies	NNS	study	O	O	NONE
:	:	:	O	O	NONE
Nitrates	NNS	nitrate	B-e0	O	drug
:	:	:	O	O	NONE
The	DT	the	O	O	NONE
blood	NN	blood	O	O	NONE
pressure	NN	pressure	O	O	NONE
lowering	JJ	lowering	O	O	NONE
effects	NNS	effect	O	O	NONE
of	IN	of	O	O	NONE
sublingual	JJ	sublingual	O	O	NONE
nitrates	NNS	nitrate	B-e1	T	drug
(	(	(	O	O	NONE
0.4	CD	0.4	O	O	NONE
mg	NN	mg	O	O	NONE
)	)	)	O	O	NONE
taken	VBN	take	O	O	NONE
1	CD	1	O	O	NONE
and	CC	and	O	O	NONE
4	CD	4	O	O	NONE
hours	NNS	hour	O	O	NONE
after	IN	after	O	O	NONE
vardenafil	NN	vardenafil	B-e2	T	drug
and	CC	and	O	O	NONE
increases	NNS	increase	O	O	NONE
in	IN	in	O	O	NONE
heart	NN	heart	O	O	NONE
rate	NN	rate	O	O	NONE
when	WRB	when	O	O	NONE
taken	VBN	take	O	O	NONE
at	IN	at	O	O	NONE
1	CD	1	O	O	NONE
,	,	,	O	O	NONE
4	CD	4	O	O	NONE
and	CC	and	O	O	NONE
8	CD	8	O	O	NONE
hours	NNS	hour	O	O	NONE
were	VBD	be	O	O	NONE
potentiated	VBN	potentiate	O	O	NONE
by	IN	by	O	O	NONE
a	DT	a	O	O	NONE
20	CD	20	O	O	NONE
mg	NN	mg	O	O	NONE
dose	NN	dose	O	O	NONE
of	IN	of	O	O	NONE
Vardenafil	NN	vardenafil	B-e3	O	drug
in	IN	in	O	O	NONE
healthy	JJ	healthy	O	O	NONE
middle-aged	JJ	middle-aged	O	O	NONE
subjects	NNS	subject	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s22
In	FW	in	O	O	NONE
vivo	FW	vivo	O	O	NONE
studies	NNS	study	O	O	NONE
:	:	:	O	O	NONE
Nitrates	NNS	nitrate	B-e0	O	drug
:	:	:	O	O	NONE
The	DT	the	O	O	NONE
blood	NN	blood	O	O	NONE
pressure	NN	pressure	O	O	NONE
lowering	JJ	lowering	O	O	NONE
effects	NNS	effect	O	O	NONE
of	IN	of	O	O	NONE
sublingual	JJ	sublingual	O	O	NONE
nitrates	NNS	nitrate	B-e1	T	drug
(	(	(	O	O	NONE
0.4	CD	0.4	O	O	NONE
mg	NN	mg	O	O	NONE
)	)	)	O	O	NONE
taken	VBN	take	O	O	NONE
1	CD	1	O	O	NONE
and	CC	and	O	O	NONE
4	CD	4	O	O	NONE
hours	NNS	hour	O	O	NONE
after	IN	after	O	O	NONE
vardenafil	NN	vardenafil	B-e2	O	drug
and	CC	and	O	O	NONE
increases	NNS	increase	O	O	NONE
in	IN	in	O	O	NONE
heart	NN	heart	O	O	NONE
rate	NN	rate	O	O	NONE
when	WRB	when	O	O	NONE
taken	VBN	take	O	O	NONE
at	IN	at	O	O	NONE
1	CD	1	O	O	NONE
,	,	,	O	O	NONE
4	CD	4	O	O	NONE
and	CC	and	O	O	NONE
8	CD	8	O	O	NONE
hours	NNS	hour	O	O	NONE
were	VBD	be	O	O	NONE
potentiated	VBN	potentiate	O	O	NONE
by	IN	by	O	O	NONE
a	DT	a	O	O	NONE
20	CD	20	O	O	NONE
mg	NN	mg	O	O	NONE
dose	NN	dose	O	O	NONE
of	IN	of	O	O	NONE
Vardenafil	NN	vardenafil	B-e3	T	drug
in	IN	in	O	O	NONE
healthy	JJ	healthy	O	O	NONE
middle-aged	JJ	middle-aged	O	O	NONE
subjects	NNS	subject	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s22
In	FW	in	O	O	NONE
vivo	FW	vivo	O	O	NONE
studies	NNS	study	O	O	NONE
:	:	:	O	O	NONE
Nitrates	NNS	nitrate	B-e0	O	drug
:	:	:	O	O	NONE
The	DT	the	O	O	NONE
blood	NN	blood	O	O	NONE
pressure	NN	pressure	O	O	NONE
lowering	JJ	lowering	O	O	NONE
effects	NNS	effect	O	O	NONE
of	IN	of	O	O	NONE
sublingual	JJ	sublingual	O	O	NONE
nitrates	NNS	nitrate	B-e1	O	drug
(	(	(	O	O	NONE
0.4	CD	0.4	O	O	NONE
mg	NN	mg	O	O	NONE
)	)	)	O	O	NONE
taken	VBN	take	O	O	NONE
1	CD	1	O	O	NONE
and	CC	and	O	O	NONE
4	CD	4	O	O	NONE
hours	NNS	hour	O	O	NONE
after	IN	after	O	O	NONE
vardenafil	NN	vardenafil	B-e2	T	drug
and	CC	and	O	O	NONE
increases	NNS	increase	O	O	NONE
in	IN	in	O	O	NONE
heart	NN	heart	O	O	NONE
rate	NN	rate	O	O	NONE
when	WRB	when	O	O	NONE
taken	VBN	take	O	O	NONE
at	IN	at	O	O	NONE
1	CD	1	O	O	NONE
,	,	,	O	O	NONE
4	CD	4	O	O	NONE
and	CC	and	O	O	NONE
8	CD	8	O	O	NONE
hours	NNS	hour	O	O	NONE
were	VBD	be	O	O	NONE
potentiated	VBN	potentiate	O	O	NONE
by	IN	by	O	O	NONE
a	DT	a	O	O	NONE
20	CD	20	O	O	NONE
mg	NN	mg	O	O	NONE
dose	NN	dose	O	O	NONE
of	IN	of	O	O	NONE
Vardenafil	NN	vardenafil	B-e3	T	drug
in	IN	in	O	O	NONE
healthy	JJ	healthy	O	O	NONE
middle-aged	JJ	middle-aged	O	O	NONE
subjects	NNS	subject	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s24
Potentiation	NN	potentiation	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
hypotensive	JJ	hypotensive	O	O	NONE
effects	NNS	effect	O	O	NONE
of	IN	of	O	O	NONE
nitrates	NNS	nitrate	B-e0	T	drug
for	IN	for	O	O	NONE
patients	NNS	patient	O	O	NONE
with	IN	with	O	O	NONE
ischemic	JJ	ischemic	B-e1	O	DISO
heart	NN	heart	I-e1	O	DISO
disease	NN	disease	I-e1	O	DISO
has	VBZ	have	O	O	NONE
not	RB	not	O	O	NONE
been	VBN	be	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
use	NN	use	O	O	NONE
of	IN	of	O	O	NONE
Vardenafil	NN	vardenafil	B-e2	T	drug
and	CC	and	O	O	NONE
nitrates	NNS	nitrate	B-e3	O	drug
is	VBZ	be	O	O	NONE
contraindicated	VBN	contraindicate	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s24
Potentiation	NN	potentiation	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
hypotensive	JJ	hypotensive	O	O	NONE
effects	NNS	effect	O	O	NONE
of	IN	of	O	O	NONE
nitrates	NNS	nitrate	B-e0	T	drug
for	IN	for	O	O	NONE
patients	NNS	patient	O	O	NONE
with	IN	with	O	O	NONE
ischemic	JJ	ischemic	B-e1	O	DISO
heart	NN	heart	I-e1	O	DISO
disease	NN	disease	I-e1	O	DISO
has	VBZ	have	O	O	NONE
not	RB	not	O	O	NONE
been	VBN	be	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
use	NN	use	O	O	NONE
of	IN	of	O	O	NONE
Vardenafil	NN	vardenafil	B-e2	O	drug
and	CC	and	O	O	NONE
nitrates	NNS	nitrate	B-e3	T	drug
is	VBZ	be	O	O	NONE
contraindicated	VBN	contraindicate	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s24
Potentiation	NN	potentiation	O	O	NONE
of	IN	of	O	O	NONE
the	DT	the	O	O	NONE
hypotensive	JJ	hypotensive	O	O	NONE
effects	NNS	effect	O	O	NONE
of	IN	of	O	O	NONE
nitrates	NNS	nitrate	B-e0	O	drug
for	IN	for	O	O	NONE
patients	NNS	patient	O	O	NONE
with	IN	with	O	O	NONE
ischemic	JJ	ischemic	B-e1	O	DISO
heart	NN	heart	I-e1	O	DISO
disease	NN	disease	I-e1	O	DISO
has	VBZ	have	O	O	NONE
not	RB	not	O	O	NONE
been	VBN	be	O	O	NONE
evaluated	VBN	evaluate	O	O	NONE
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
use	NN	use	O	O	NONE
of	IN	of	O	O	NONE
Vardenafil	NN	vardenafil	B-e2	T	drug
and	CC	and	O	O	NONE
nitrates	NNS	nitrate	B-e3	T	drug
is	VBZ	be	O	O	NONE
contraindicated	VBN	contraindicate	O	O	NONE
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d253.s25
Nifedipine	NN	nifedipine	B-e0	T	drug
:	:	:	O	O	NONE
Vardenafil	NN	vardenafil	B-e1	T	drug
20	CD	20	I-e1	T	drug
mg	NN	mg	I-e1	T	drug
,	,	,	O	O	NONE
when	WRB	when	O	O	NONE
co-administered	VBN	co-administer	O	O	NONE
with	IN	with	O	O	NONE
slow-release	JJ	slow-release	O	O	NONE
nifedipine	NN	nifedipine	B-e2	O	drug
30	CD	30	I-e2	O	drug
mg	NN	mg	I-e2	O	drug
or	CC	or	O	O	NONE
60	CD	60	O	O	NONE
mg	NN	mg	O	O	NONE
once	RB	once	O	O	NONE
daily	RB	daily	O	O	NONE
,	,	,	O	O	NONE
did	VBD	do	O	O	NONE
not	RB	not	O	O	NONE
affect	VB	affect	O	O	NONE
the	DT	the	O	O	NONE
relative	JJ	relative	O	O	NONE
bioavailability	NN	bioavailability	O	O	NONE
(	(	(	O	O	NONE
AUC	NN	auc	O	O	NONE
)	)	)	O	O	NONE
or	CC	or	O	O	NONE
maximum	JJ	maximum	O	O	NONE
concentration	NN	concentration	O	O	NONE
(	(	(	O	O	NONE
Cmax	NN	cmax	O	O	NONE
)	)	)	O	O	NONE
of	IN	of	O	O	NONE
nifedipine	NN	nifedipine	B-e3	O	drug
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
drug	NN	drug	B-e4	O	drug
that	WDT	that	O	O	NONE
is	VBZ	be	O	O	NONE
metabolized	VBN	metabolize	O	O	NONE
via	IN	via	O	O	NONE
CYP3A4	NN	cyp3a4	B-e5	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s25
Nifedipine	NN	nifedipine	B-e0	T	drug
:	:	:	O	O	NONE
Vardenafil	NN	vardenafil	B-e1	O	drug
20	CD	20	I-e1	O	drug
mg	NN	mg	I-e1	O	drug
,	,	,	O	O	NONE
when	WRB	when	O	O	NONE
co-administered	VBN	co-administer	O	O	NONE
with	IN	with	O	O	NONE
slow-release	JJ	slow-release	O	O	NONE
nifedipine	NN	nifedipine	B-e2	T	drug
30	CD	30	I-e2	T	drug
mg	NN	mg	I-e2	T	drug
or	CC	or	O	O	NONE
60	CD	60	O	O	NONE
mg	NN	mg	O	O	NONE
once	RB	once	O	O	NONE
daily	RB	daily	O	O	NONE
,	,	,	O	O	NONE
did	VBD	do	O	O	NONE
not	RB	not	O	O	NONE
affect	VB	affect	O	O	NONE
the	DT	the	O	O	NONE
relative	JJ	relative	O	O	NONE
bioavailability	NN	bioavailability	O	O	NONE
(	(	(	O	O	NONE
AUC	NN	auc	O	O	NONE
)	)	)	O	O	NONE
or	CC	or	O	O	NONE
maximum	JJ	maximum	O	O	NONE
concentration	NN	concentration	O	O	NONE
(	(	(	O	O	NONE
Cmax	NN	cmax	O	O	NONE
)	)	)	O	O	NONE
of	IN	of	O	O	NONE
nifedipine	NN	nifedipine	B-e3	O	drug
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
drug	NN	drug	B-e4	O	drug
that	WDT	that	O	O	NONE
is	VBZ	be	O	O	NONE
metabolized	VBN	metabolize	O	O	NONE
via	IN	via	O	O	NONE
CYP3A4	NN	cyp3a4	B-e5	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s25
Nifedipine	NN	nifedipine	B-e0	T	drug
:	:	:	O	O	NONE
Vardenafil	NN	vardenafil	B-e1	O	drug
20	CD	20	I-e1	O	drug
mg	NN	mg	I-e1	O	drug
,	,	,	O	O	NONE
when	WRB	when	O	O	NONE
co-administered	VBN	co-administer	O	O	NONE
with	IN	with	O	O	NONE
slow-release	JJ	slow-release	O	O	NONE
nifedipine	NN	nifedipine	B-e2	O	drug
30	CD	30	I-e2	O	drug
mg	NN	mg	I-e2	O	drug
or	CC	or	O	O	NONE
60	CD	60	O	O	NONE
mg	NN	mg	O	O	NONE
once	RB	once	O	O	NONE
daily	RB	daily	O	O	NONE
,	,	,	O	O	NONE
did	VBD	do	O	O	NONE
not	RB	not	O	O	NONE
affect	VB	affect	O	O	NONE
the	DT	the	O	O	NONE
relative	JJ	relative	O	O	NONE
bioavailability	NN	bioavailability	O	O	NONE
(	(	(	O	O	NONE
AUC	NN	auc	O	O	NONE
)	)	)	O	O	NONE
or	CC	or	O	O	NONE
maximum	JJ	maximum	O	O	NONE
concentration	NN	concentration	O	O	NONE
(	(	(	O	O	NONE
Cmax	NN	cmax	O	O	NONE
)	)	)	O	O	NONE
of	IN	of	O	O	NONE
nifedipine	NN	nifedipine	B-e3	T	drug
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
drug	NN	drug	B-e4	O	drug
that	WDT	that	O	O	NONE
is	VBZ	be	O	O	NONE
metabolized	VBN	metabolize	O	O	NONE
via	IN	via	O	O	NONE
CYP3A4	NN	cyp3a4	B-e5	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s25
Nifedipine	NN	nifedipine	B-e0	T	drug
:	:	:	O	O	NONE
Vardenafil	NN	vardenafil	B-e1	O	drug
20	CD	20	I-e1	O	drug
mg	NN	mg	I-e1	O	drug
,	,	,	O	O	NONE
when	WRB	when	O	O	NONE
co-administered	VBN	co-administer	O	O	NONE
with	IN	with	O	O	NONE
slow-release	JJ	slow-release	O	O	NONE
nifedipine	NN	nifedipine	B-e2	O	drug
30	CD	30	I-e2	O	drug
mg	NN	mg	I-e2	O	drug
or	CC	or	O	O	NONE
60	CD	60	O	O	NONE
mg	NN	mg	O	O	NONE
once	RB	once	O	O	NONE
daily	RB	daily	O	O	NONE
,	,	,	O	O	NONE
did	VBD	do	O	O	NONE
not	RB	not	O	O	NONE
affect	VB	affect	O	O	NONE
the	DT	the	O	O	NONE
relative	JJ	relative	O	O	NONE
bioavailability	NN	bioavailability	O	O	NONE
(	(	(	O	O	NONE
AUC	NN	auc	O	O	NONE
)	)	)	O	O	NONE
or	CC	or	O	O	NONE
maximum	JJ	maximum	O	O	NONE
concentration	NN	concentration	O	O	NONE
(	(	(	O	O	NONE
Cmax	NN	cmax	O	O	NONE
)	)	)	O	O	NONE
of	IN	of	O	O	NONE
nifedipine	NN	nifedipine	B-e3	O	drug
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
drug	NN	drug	B-e4	T	drug
that	WDT	that	O	O	NONE
is	VBZ	be	O	O	NONE
metabolized	VBN	metabolize	O	O	NONE
via	IN	via	O	O	NONE
CYP3A4	NN	cyp3a4	B-e5	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s25
Nifedipine	NN	nifedipine	B-e0	T	drug
:	:	:	O	O	NONE
Vardenafil	NN	vardenafil	B-e1	O	drug
20	CD	20	I-e1	O	drug
mg	NN	mg	I-e1	O	drug
,	,	,	O	O	NONE
when	WRB	when	O	O	NONE
co-administered	VBN	co-administer	O	O	NONE
with	IN	with	O	O	NONE
slow-release	JJ	slow-release	O	O	NONE
nifedipine	NN	nifedipine	B-e2	O	drug
30	CD	30	I-e2	O	drug
mg	NN	mg	I-e2	O	drug
or	CC	or	O	O	NONE
60	CD	60	O	O	NONE
mg	NN	mg	O	O	NONE
once	RB	once	O	O	NONE
daily	RB	daily	O	O	NONE
,	,	,	O	O	NONE
did	VBD	do	O	O	NONE
not	RB	not	O	O	NONE
affect	VB	affect	O	O	NONE
the	DT	the	O	O	NONE
relative	JJ	relative	O	O	NONE
bioavailability	NN	bioavailability	O	O	NONE
(	(	(	O	O	NONE
AUC	NN	auc	O	O	NONE
)	)	)	O	O	NONE
or	CC	or	O	O	NONE
maximum	JJ	maximum	O	O	NONE
concentration	NN	concentration	O	O	NONE
(	(	(	O	O	NONE
Cmax	NN	cmax	O	O	NONE
)	)	)	O	O	NONE
of	IN	of	O	O	NONE
nifedipine	NN	nifedipine	B-e3	O	drug
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
drug	NN	drug	B-e4	O	drug
that	WDT	that	O	O	NONE
is	VBZ	be	O	O	NONE
metabolized	VBN	metabolize	O	O	NONE
via	IN	via	O	O	NONE
CYP3A4	NN	cyp3a4	B-e5	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s25
Nifedipine	NN	nifedipine	B-e0	O	drug
:	:	:	O	O	NONE
Vardenafil	NN	vardenafil	B-e1	T	drug
20	CD	20	I-e1	T	drug
mg	NN	mg	I-e1	T	drug
,	,	,	O	O	NONE
when	WRB	when	O	O	NONE
co-administered	VBN	co-administer	O	O	NONE
with	IN	with	O	O	NONE
slow-release	JJ	slow-release	O	O	NONE
nifedipine	NN	nifedipine	B-e2	T	drug
30	CD	30	I-e2	T	drug
mg	NN	mg	I-e2	T	drug
or	CC	or	O	O	NONE
60	CD	60	O	O	NONE
mg	NN	mg	O	O	NONE
once	RB	once	O	O	NONE
daily	RB	daily	O	O	NONE
,	,	,	O	O	NONE
did	VBD	do	O	O	NONE
not	RB	not	O	O	NONE
affect	VB	affect	O	O	NONE
the	DT	the	O	O	NONE
relative	JJ	relative	O	O	NONE
bioavailability	NN	bioavailability	O	O	NONE
(	(	(	O	O	NONE
AUC	NN	auc	O	O	NONE
)	)	)	O	O	NONE
or	CC	or	O	O	NONE
maximum	JJ	maximum	O	O	NONE
concentration	NN	concentration	O	O	NONE
(	(	(	O	O	NONE
Cmax	NN	cmax	O	O	NONE
)	)	)	O	O	NONE
of	IN	of	O	O	NONE
nifedipine	NN	nifedipine	B-e3	O	drug
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
drug	NN	drug	B-e4	O	drug
that	WDT	that	O	O	NONE
is	VBZ	be	O	O	NONE
metabolized	VBN	metabolize	O	O	NONE
via	IN	via	O	O	NONE
CYP3A4	NN	cyp3a4	B-e5	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s25
Nifedipine	NN	nifedipine	B-e0	O	drug
:	:	:	O	O	NONE
Vardenafil	NN	vardenafil	B-e1	T	drug
20	CD	20	I-e1	T	drug
mg	NN	mg	I-e1	T	drug
,	,	,	O	O	NONE
when	WRB	when	O	O	NONE
co-administered	VBN	co-administer	O	O	NONE
with	IN	with	O	O	NONE
slow-release	JJ	slow-release	O	O	NONE
nifedipine	NN	nifedipine	B-e2	O	drug
30	CD	30	I-e2	O	drug
mg	NN	mg	I-e2	O	drug
or	CC	or	O	O	NONE
60	CD	60	O	O	NONE
mg	NN	mg	O	O	NONE
once	RB	once	O	O	NONE
daily	RB	daily	O	O	NONE
,	,	,	O	O	NONE
did	VBD	do	O	O	NONE
not	RB	not	O	O	NONE
affect	VB	affect	O	O	NONE
the	DT	the	O	O	NONE
relative	JJ	relative	O	O	NONE
bioavailability	NN	bioavailability	O	O	NONE
(	(	(	O	O	NONE
AUC	NN	auc	O	O	NONE
)	)	)	O	O	NONE
or	CC	or	O	O	NONE
maximum	JJ	maximum	O	O	NONE
concentration	NN	concentration	O	O	NONE
(	(	(	O	O	NONE
Cmax	NN	cmax	O	O	NONE
)	)	)	O	O	NONE
of	IN	of	O	O	NONE
nifedipine	NN	nifedipine	B-e3	T	drug
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
drug	NN	drug	B-e4	O	drug
that	WDT	that	O	O	NONE
is	VBZ	be	O	O	NONE
metabolized	VBN	metabolize	O	O	NONE
via	IN	via	O	O	NONE
CYP3A4	NN	cyp3a4	B-e5	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s25
Nifedipine	NN	nifedipine	B-e0	O	drug
:	:	:	O	O	NONE
Vardenafil	NN	vardenafil	B-e1	T	drug
20	CD	20	I-e1	T	drug
mg	NN	mg	I-e1	T	drug
,	,	,	O	O	NONE
when	WRB	when	O	O	NONE
co-administered	VBN	co-administer	O	O	NONE
with	IN	with	O	O	NONE
slow-release	JJ	slow-release	O	O	NONE
nifedipine	NN	nifedipine	B-e2	O	drug
30	CD	30	I-e2	O	drug
mg	NN	mg	I-e2	O	drug
or	CC	or	O	O	NONE
60	CD	60	O	O	NONE
mg	NN	mg	O	O	NONE
once	RB	once	O	O	NONE
daily	RB	daily	O	O	NONE
,	,	,	O	O	NONE
did	VBD	do	O	O	NONE
not	RB	not	O	O	NONE
affect	VB	affect	O	O	NONE
the	DT	the	O	O	NONE
relative	JJ	relative	O	O	NONE
bioavailability	NN	bioavailability	O	O	NONE
(	(	(	O	O	NONE
AUC	NN	auc	O	O	NONE
)	)	)	O	O	NONE
or	CC	or	O	O	NONE
maximum	JJ	maximum	O	O	NONE
concentration	NN	concentration	O	O	NONE
(	(	(	O	O	NONE
Cmax	NN	cmax	O	O	NONE
)	)	)	O	O	NONE
of	IN	of	O	O	NONE
nifedipine	NN	nifedipine	B-e3	O	drug
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
drug	NN	drug	B-e4	T	drug
that	WDT	that	O	O	NONE
is	VBZ	be	O	O	NONE
metabolized	VBN	metabolize	O	O	NONE
via	IN	via	O	O	NONE
CYP3A4	NN	cyp3a4	B-e5	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s25
Nifedipine	NN	nifedipine	B-e0	O	drug
:	:	:	O	O	NONE
Vardenafil	NN	vardenafil	B-e1	T	drug
20	CD	20	I-e1	T	drug
mg	NN	mg	I-e1	T	drug
,	,	,	O	O	NONE
when	WRB	when	O	O	NONE
co-administered	VBN	co-administer	O	O	NONE
with	IN	with	O	O	NONE
slow-release	JJ	slow-release	O	O	NONE
nifedipine	NN	nifedipine	B-e2	O	drug
30	CD	30	I-e2	O	drug
mg	NN	mg	I-e2	O	drug
or	CC	or	O	O	NONE
60	CD	60	O	O	NONE
mg	NN	mg	O	O	NONE
once	RB	once	O	O	NONE
daily	RB	daily	O	O	NONE
,	,	,	O	O	NONE
did	VBD	do	O	O	NONE
not	RB	not	O	O	NONE
affect	VB	affect	O	O	NONE
the	DT	the	O	O	NONE
relative	JJ	relative	O	O	NONE
bioavailability	NN	bioavailability	O	O	NONE
(	(	(	O	O	NONE
AUC	NN	auc	O	O	NONE
)	)	)	O	O	NONE
or	CC	or	O	O	NONE
maximum	JJ	maximum	O	O	NONE
concentration	NN	concentration	O	O	NONE
(	(	(	O	O	NONE
Cmax	NN	cmax	O	O	NONE
)	)	)	O	O	NONE
of	IN	of	O	O	NONE
nifedipine	NN	nifedipine	B-e3	O	drug
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
drug	NN	drug	B-e4	O	drug
that	WDT	that	O	O	NONE
is	VBZ	be	O	O	NONE
metabolized	VBN	metabolize	O	O	NONE
via	IN	via	O	O	NONE
CYP3A4	NN	cyp3a4	B-e5	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s25
Nifedipine	NN	nifedipine	B-e0	O	drug
:	:	:	O	O	NONE
Vardenafil	NN	vardenafil	B-e1	O	drug
20	CD	20	I-e1	O	drug
mg	NN	mg	I-e1	O	drug
,	,	,	O	O	NONE
when	WRB	when	O	O	NONE
co-administered	VBN	co-administer	O	O	NONE
with	IN	with	O	O	NONE
slow-release	JJ	slow-release	O	O	NONE
nifedipine	NN	nifedipine	B-e2	T	drug
30	CD	30	I-e2	T	drug
mg	NN	mg	I-e2	T	drug
or	CC	or	O	O	NONE
60	CD	60	O	O	NONE
mg	NN	mg	O	O	NONE
once	RB	once	O	O	NONE
daily	RB	daily	O	O	NONE
,	,	,	O	O	NONE
did	VBD	do	O	O	NONE
not	RB	not	O	O	NONE
affect	VB	affect	O	O	NONE
the	DT	the	O	O	NONE
relative	JJ	relative	O	O	NONE
bioavailability	NN	bioavailability	O	O	NONE
(	(	(	O	O	NONE
AUC	NN	auc	O	O	NONE
)	)	)	O	O	NONE
or	CC	or	O	O	NONE
maximum	JJ	maximum	O	O	NONE
concentration	NN	concentration	O	O	NONE
(	(	(	O	O	NONE
Cmax	NN	cmax	O	O	NONE
)	)	)	O	O	NONE
of	IN	of	O	O	NONE
nifedipine	NN	nifedipine	B-e3	T	drug
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
drug	NN	drug	B-e4	O	drug
that	WDT	that	O	O	NONE
is	VBZ	be	O	O	NONE
metabolized	VBN	metabolize	O	O	NONE
via	IN	via	O	O	NONE
CYP3A4	NN	cyp3a4	B-e5	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s25
Nifedipine	NN	nifedipine	B-e0	O	drug
:	:	:	O	O	NONE
Vardenafil	NN	vardenafil	B-e1	O	drug
20	CD	20	I-e1	O	drug
mg	NN	mg	I-e1	O	drug
,	,	,	O	O	NONE
when	WRB	when	O	O	NONE
co-administered	VBN	co-administer	O	O	NONE
with	IN	with	O	O	NONE
slow-release	JJ	slow-release	O	O	NONE
nifedipine	NN	nifedipine	B-e2	T	drug
30	CD	30	I-e2	T	drug
mg	NN	mg	I-e2	T	drug
or	CC	or	O	O	NONE
60	CD	60	O	O	NONE
mg	NN	mg	O	O	NONE
once	RB	once	O	O	NONE
daily	RB	daily	O	O	NONE
,	,	,	O	O	NONE
did	VBD	do	O	O	NONE
not	RB	not	O	O	NONE
affect	VB	affect	O	O	NONE
the	DT	the	O	O	NONE
relative	JJ	relative	O	O	NONE
bioavailability	NN	bioavailability	O	O	NONE
(	(	(	O	O	NONE
AUC	NN	auc	O	O	NONE
)	)	)	O	O	NONE
or	CC	or	O	O	NONE
maximum	JJ	maximum	O	O	NONE
concentration	NN	concentration	O	O	NONE
(	(	(	O	O	NONE
Cmax	NN	cmax	O	O	NONE
)	)	)	O	O	NONE
of	IN	of	O	O	NONE
nifedipine	NN	nifedipine	B-e3	O	drug
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
drug	NN	drug	B-e4	T	drug
that	WDT	that	O	O	NONE
is	VBZ	be	O	O	NONE
metabolized	VBN	metabolize	O	O	NONE
via	IN	via	O	O	NONE
CYP3A4	NN	cyp3a4	B-e5	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s25
Nifedipine	NN	nifedipine	B-e0	O	drug
:	:	:	O	O	NONE
Vardenafil	NN	vardenafil	B-e1	O	drug
20	CD	20	I-e1	O	drug
mg	NN	mg	I-e1	O	drug
,	,	,	O	O	NONE
when	WRB	when	O	O	NONE
co-administered	VBN	co-administer	O	O	NONE
with	IN	with	O	O	NONE
slow-release	JJ	slow-release	O	O	NONE
nifedipine	NN	nifedipine	B-e2	T	drug
30	CD	30	I-e2	T	drug
mg	NN	mg	I-e2	T	drug
or	CC	or	O	O	NONE
60	CD	60	O	O	NONE
mg	NN	mg	O	O	NONE
once	RB	once	O	O	NONE
daily	RB	daily	O	O	NONE
,	,	,	O	O	NONE
did	VBD	do	O	O	NONE
not	RB	not	O	O	NONE
affect	VB	affect	O	O	NONE
the	DT	the	O	O	NONE
relative	JJ	relative	O	O	NONE
bioavailability	NN	bioavailability	O	O	NONE
(	(	(	O	O	NONE
AUC	NN	auc	O	O	NONE
)	)	)	O	O	NONE
or	CC	or	O	O	NONE
maximum	JJ	maximum	O	O	NONE
concentration	NN	concentration	O	O	NONE
(	(	(	O	O	NONE
Cmax	NN	cmax	O	O	NONE
)	)	)	O	O	NONE
of	IN	of	O	O	NONE
nifedipine	NN	nifedipine	B-e3	O	drug
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
drug	NN	drug	B-e4	O	drug
that	WDT	that	O	O	NONE
is	VBZ	be	O	O	NONE
metabolized	VBN	metabolize	O	O	NONE
via	IN	via	O	O	NONE
CYP3A4	NN	cyp3a4	B-e5	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s25
Nifedipine	NN	nifedipine	B-e0	O	drug
:	:	:	O	O	NONE
Vardenafil	NN	vardenafil	B-e1	O	drug
20	CD	20	I-e1	O	drug
mg	NN	mg	I-e1	O	drug
,	,	,	O	O	NONE
when	WRB	when	O	O	NONE
co-administered	VBN	co-administer	O	O	NONE
with	IN	with	O	O	NONE
slow-release	JJ	slow-release	O	O	NONE
nifedipine	NN	nifedipine	B-e2	O	drug
30	CD	30	I-e2	O	drug
mg	NN	mg	I-e2	O	drug
or	CC	or	O	O	NONE
60	CD	60	O	O	NONE
mg	NN	mg	O	O	NONE
once	RB	once	O	O	NONE
daily	RB	daily	O	O	NONE
,	,	,	O	O	NONE
did	VBD	do	O	O	NONE
not	RB	not	O	O	NONE
affect	VB	affect	O	O	NONE
the	DT	the	O	O	NONE
relative	JJ	relative	O	O	NONE
bioavailability	NN	bioavailability	O	O	NONE
(	(	(	O	O	NONE
AUC	NN	auc	O	O	NONE
)	)	)	O	O	NONE
or	CC	or	O	O	NONE
maximum	JJ	maximum	O	O	NONE
concentration	NN	concentration	O	O	NONE
(	(	(	O	O	NONE
Cmax	NN	cmax	O	O	NONE
)	)	)	O	O	NONE
of	IN	of	O	O	NONE
nifedipine	NN	nifedipine	B-e3	T	drug
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
drug	NN	drug	B-e4	T	drug
that	WDT	that	O	O	NONE
is	VBZ	be	O	O	NONE
metabolized	VBN	metabolize	O	O	NONE
via	IN	via	O	O	NONE
CYP3A4	NN	cyp3a4	B-e5	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s25
Nifedipine	NN	nifedipine	B-e0	O	drug
:	:	:	O	O	NONE
Vardenafil	NN	vardenafil	B-e1	O	drug
20	CD	20	I-e1	O	drug
mg	NN	mg	I-e1	O	drug
,	,	,	O	O	NONE
when	WRB	when	O	O	NONE
co-administered	VBN	co-administer	O	O	NONE
with	IN	with	O	O	NONE
slow-release	JJ	slow-release	O	O	NONE
nifedipine	NN	nifedipine	B-e2	O	drug
30	CD	30	I-e2	O	drug
mg	NN	mg	I-e2	O	drug
or	CC	or	O	O	NONE
60	CD	60	O	O	NONE
mg	NN	mg	O	O	NONE
once	RB	once	O	O	NONE
daily	RB	daily	O	O	NONE
,	,	,	O	O	NONE
did	VBD	do	O	O	NONE
not	RB	not	O	O	NONE
affect	VB	affect	O	O	NONE
the	DT	the	O	O	NONE
relative	JJ	relative	O	O	NONE
bioavailability	NN	bioavailability	O	O	NONE
(	(	(	O	O	NONE
AUC	NN	auc	O	O	NONE
)	)	)	O	O	NONE
or	CC	or	O	O	NONE
maximum	JJ	maximum	O	O	NONE
concentration	NN	concentration	O	O	NONE
(	(	(	O	O	NONE
Cmax	NN	cmax	O	O	NONE
)	)	)	O	O	NONE
of	IN	of	O	O	NONE
nifedipine	NN	nifedipine	B-e3	T	drug
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
drug	NN	drug	B-e4	O	drug
that	WDT	that	O	O	NONE
is	VBZ	be	O	O	NONE
metabolized	VBN	metabolize	O	O	NONE
via	IN	via	O	O	NONE
CYP3A4	NN	cyp3a4	B-e5	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s25
Nifedipine	NN	nifedipine	B-e0	O	drug
:	:	:	O	O	NONE
Vardenafil	NN	vardenafil	B-e1	O	drug
20	CD	20	I-e1	O	drug
mg	NN	mg	I-e1	O	drug
,	,	,	O	O	NONE
when	WRB	when	O	O	NONE
co-administered	VBN	co-administer	O	O	NONE
with	IN	with	O	O	NONE
slow-release	JJ	slow-release	O	O	NONE
nifedipine	NN	nifedipine	B-e2	O	drug
30	CD	30	I-e2	O	drug
mg	NN	mg	I-e2	O	drug
or	CC	or	O	O	NONE
60	CD	60	O	O	NONE
mg	NN	mg	O	O	NONE
once	RB	once	O	O	NONE
daily	RB	daily	O	O	NONE
,	,	,	O	O	NONE
did	VBD	do	O	O	NONE
not	RB	not	O	O	NONE
affect	VB	affect	O	O	NONE
the	DT	the	O	O	NONE
relative	JJ	relative	O	O	NONE
bioavailability	NN	bioavailability	O	O	NONE
(	(	(	O	O	NONE
AUC	NN	auc	O	O	NONE
)	)	)	O	O	NONE
or	CC	or	O	O	NONE
maximum	JJ	maximum	O	O	NONE
concentration	NN	concentration	O	O	NONE
(	(	(	O	O	NONE
Cmax	NN	cmax	O	O	NONE
)	)	)	O	O	NONE
of	IN	of	O	O	NONE
nifedipine	NN	nifedipine	B-e3	O	drug
,	,	,	O	O	NONE
a	DT	a	O	O	NONE
drug	NN	drug	B-e4	T	drug
that	WDT	that	O	O	NONE
is	VBZ	be	O	O	NONE
metabolized	VBN	metabolize	O	O	NONE
via	IN	via	O	O	NONE
CYP3A4	NN	cyp3a4	B-e5	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s26
Nifedipine	NN	nifedipine	B-e0	T	drug
did	VBD	do	O	O	NONE
not	RB	not	O	O	NONE
alter	VB	alter	O	O	NONE
the	DT	the	O	O	NONE
plasma	NN	plasma	O	O	NONE
levels	NNS	level	O	O	NONE
of	IN	of	O	O	NONE
Vardenafil	NN	vardenafil	B-e1	T	drug
when	WRB	when	O	O	NONE
taken	VBN	take	O	O	NONE
in	IN	in	O	O	NONE
combination	NN	combination	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s27
In	IN	in	O	O	NONE
these	DT	these	O	O	NONE
patients	NNS	patient	O	O	NONE
whose	WP$	whose	O	O	NONE
hypertension	NN	hypertension	O	O	NONE
was	VBD	be	O	O	NONE
controlled	VBN	control	O	O	NONE
with	IN	with	O	O	NONE
nifedipine	NN	nifedipine	B-e0	T	drug
,	,	,	O	O	NONE
Vardenafil	NN	vardenafil	B-e1	T	drug
20	CD	20	I-e1	T	drug
mg	NN	mg	I-e1	T	drug
produced	VBD	produce	O	O	NONE
mean	JJ	mean	O	O	NONE
additional	JJ	additional	O	O	NONE
supine	NN	supine	O	O	NONE
systolic/diastolic	JJ	systolic/diastolic	O	O	NONE
blood	NN	blood	O	O	NONE
pressure	NN	pressure	O	O	NONE
reductions	NNS	reduction	O	O	NONE
of	IN	of	O	O	NONE
6/5	CD	6/5	O	O	NONE
mm	NN	mm	O	O	NONE
Hg	NN	hg	O	O	NONE
compared	VBN	compare	O	O	NONE
to	TO	to	O	O	NONE
placebo	NN	placebo	O	O	NONE
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d253.s28
Alpha-blockers	NNS	alpha-blocker	O	O	NONE
:	:	:	O	O	NONE
When	WRB	when	O	O	NONE
Vardenafil	NN	vardenafil	B-e0	T	drug
10	CD	10	O	O	NONE
or	CC	or	O	O	NONE
20	CD	20	O	O	NONE
mg	NN	mg	O	O	NONE
was	VBD	be	O	O	NONE
given	VBN	give	O	O	NONE
to	TO	to	O	O	NONE
healthy	JJ	healthy	O	O	NONE
volunteers	NNS	volunteer	O	O	NONE
either	CC	either	O	O	NONE
simultaneously	RB	simultaneously	O	O	NONE
or	CC	or	O	O	NONE
6	CD	6	O	O	NONE
hours	NNS	hour	O	O	NONE
after	IN	after	O	O	NONE
a	DT	a	O	O	NONE
10	CD	10	O	O	NONE
mg	NN	mg	O	O	NONE
dose	NN	dose	O	O	NONE
of	IN	of	O	O	NONE
terazosin	NN	terazosin	B-e1	T	drug
,	,	,	O	O	NONE
significant	JJ	significant	O	O	NONE
hypotension	NN	hypotension	O	O	NONE
developed	VBD	develop	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
substantial	JJ	substantial	O	O	NONE
number	NN	number	O	O	NONE
of	IN	of	O	O	NONE
subjects	NNS	subject	O	O	NONE
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d253.s29
With	IN	with	O	O	NONE
simultaneous	JJ	simultaneous	O	O	NONE
dosing	NN	dosing	O	O	NONE
of	IN	of	O	O	NONE
Vardenafil	NN	vardenafil	B-e0	T	drug
10	CD	10	I-e0	T	drug
mg	NN	mg	I-e0	T	drug
and	CC	and	O	O	NONE
terazosin	NN	terazosin	B-e1	T	drug
10	CD	10	I-e1	T	drug
mg	NN	mg	O	O	NONE
,	,	,	O	O	NONE
6	CD	6	O	O	NONE
of	IN	of	O	O	NONE
8	CD	8	O	O	NONE
subjects	NNS	subject	O	O	NONE
experienced	VBN	experience	O	O	NONE
a	DT	a	O	O	NONE
standing	JJ	standing	O	O	NONE
systolic	JJ	systolic	O	O	NONE
blood	NN	blood	O	O	NONE
pressure	NN	pressure	O	O	NONE
of	IN	of	O	O	NONE
less	JJR	less	O	O	NONE
than	IN	than	O	O	NONE
85	CD	85	O	O	NONE
mm	NN	mm	O	O	NONE
Hg	NN	hg	O	O	NONE
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d253.s30
With	IN	with	O	O	NONE
simultaneous	JJ	simultaneous	O	O	NONE
dosing	NN	dosing	O	O	NONE
of	IN	of	O	O	NONE
Vardenafil	NN	vardenafil	B-e0	T	drug
20	CD	20	I-e0	T	drug
mg	NN	mg	I-e0	T	drug
and	CC	and	O	O	NONE
terazosin	NN	terazosin	B-e1	T	drug
10	CD	10	I-e1	T	drug
mg	NN	mg	O	O	NONE
,	,	,	O	O	NONE
2	CD	2	O	O	NONE
of	IN	of	O	O	NONE
9	CD	9	O	O	NONE
subjects	NNS	subject	O	O	NONE
experienced	VBN	experience	O	O	NONE
a	DT	a	O	O	NONE
standing	JJ	standing	O	O	NONE
systolic	JJ	systolic	O	O	NONE
blood	NN	blood	O	O	NONE
pressure	NN	pressure	O	O	NONE
of	IN	of	O	O	NONE
less	JJR	less	O	O	NONE
than	IN	than	O	O	NONE
85	CD	85	O	O	NONE
mm	NN	mm	O	O	NONE
Hg	NN	hg	O	O	NONE
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d253.s31
When	WRB	when	O	O	NONE
Vardenafil	NN	vardenafil	B-e0	T	drug
dosing	NN	dosing	O	O	NONE
was	VBD	be	O	O	NONE
separated	VBN	separate	O	O	NONE
from	IN	from	O	O	NONE
terazosin	NN	terazosin	B-e1	T	drug
10	CD	10	I-e1	T	drug
mg	NN	mg	O	O	NONE
by	IN	by	O	O	NONE
6	CD	6	O	O	NONE
hours	NNS	hour	O	O	NONE
,	,	,	O	O	NONE
7	CD	7	O	O	NONE
of	IN	of	O	O	NONE
28	CD	28	O	O	NONE
subjects	NNS	subject	O	O	NONE
who	WP	who	O	O	NONE
received	VBD	receive	O	O	NONE
20	CD	20	O	O	NONE
mg	NN	mg	O	O	NONE
of	IN	of	O	O	NONE
Vardenafil	NN	vardenafil	B-e2	O	drug
experienced	VBN	experience	O	O	NONE
a	DT	a	O	O	NONE
decrease	NN	decrease	O	O	NONE
in	IN	in	O	O	NONE
standing	JJ	standing	O	O	NONE
systolic	JJ	systolic	O	O	NONE
blood	NN	blood	O	O	NONE
pressure	NN	pressure	O	O	NONE
below	IN	below	O	O	NONE
85	CD	85	O	O	NONE
mm	NN	mm	O	O	NONE
Hg	NN	hg	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s31
When	WRB	when	O	O	NONE
Vardenafil	NN	vardenafil	B-e0	T	drug
dosing	NN	dosing	O	O	NONE
was	VBD	be	O	O	NONE
separated	VBN	separate	O	O	NONE
from	IN	from	O	O	NONE
terazosin	NN	terazosin	B-e1	O	drug
10	CD	10	I-e1	O	drug
mg	NN	mg	O	O	NONE
by	IN	by	O	O	NONE
6	CD	6	O	O	NONE
hours	NNS	hour	O	O	NONE
,	,	,	O	O	NONE
7	CD	7	O	O	NONE
of	IN	of	O	O	NONE
28	CD	28	O	O	NONE
subjects	NNS	subject	O	O	NONE
who	WP	who	O	O	NONE
received	VBD	receive	O	O	NONE
20	CD	20	O	O	NONE
mg	NN	mg	O	O	NONE
of	IN	of	O	O	NONE
Vardenafil	NN	vardenafil	B-e2	T	drug
experienced	VBN	experience	O	O	NONE
a	DT	a	O	O	NONE
decrease	NN	decrease	O	O	NONE
in	IN	in	O	O	NONE
standing	JJ	standing	O	O	NONE
systolic	JJ	systolic	O	O	NONE
blood	NN	blood	O	O	NONE
pressure	NN	pressure	O	O	NONE
below	IN	below	O	O	NONE
85	CD	85	O	O	NONE
mm	NN	mm	O	O	NONE
Hg	NN	hg	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s31
When	WRB	when	O	O	NONE
Vardenafil	NN	vardenafil	B-e0	O	drug
dosing	NN	dosing	O	O	NONE
was	VBD	be	O	O	NONE
separated	VBN	separate	O	O	NONE
from	IN	from	O	O	NONE
terazosin	NN	terazosin	B-e1	T	drug
10	CD	10	I-e1	T	drug
mg	NN	mg	O	O	NONE
by	IN	by	O	O	NONE
6	CD	6	O	O	NONE
hours	NNS	hour	O	O	NONE
,	,	,	O	O	NONE
7	CD	7	O	O	NONE
of	IN	of	O	O	NONE
28	CD	28	O	O	NONE
subjects	NNS	subject	O	O	NONE
who	WP	who	O	O	NONE
received	VBD	receive	O	O	NONE
20	CD	20	O	O	NONE
mg	NN	mg	O	O	NONE
of	IN	of	O	O	NONE
Vardenafil	NN	vardenafil	B-e2	T	drug
experienced	VBN	experience	O	O	NONE
a	DT	a	O	O	NONE
decrease	NN	decrease	O	O	NONE
in	IN	in	O	O	NONE
standing	JJ	standing	O	O	NONE
systolic	JJ	systolic	O	O	NONE
blood	NN	blood	O	O	NONE
pressure	NN	pressure	O	O	NONE
below	IN	below	O	O	NONE
85	CD	85	O	O	NONE
mm	NN	mm	O	O	NONE
Hg	NN	hg	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s32
In	IN	in	O	O	NONE
a	DT	a	O	O	NONE
similar	JJ	similar	O	O	NONE
study	NN	study	O	O	NONE
with	IN	with	O	O	NONE
tamsulosin	NN	tamsulosin	B-e0	T	drug
in	IN	in	O	O	NONE
healthy	JJ	healthy	O	O	NONE
volunteers	NNS	volunteer	O	O	NONE
,	,	,	O	O	NONE
1	CD	1	O	O	NONE
of	IN	of	O	O	NONE
24	CD	24	O	O	NONE
subjects	NNS	subject	O	O	NONE
dosed	VBN	dose	O	O	NONE
with	IN	with	O	O	NONE
Vardenafil	NN	vardenafil	B-e1	T	drug
20	CD	20	I-e1	T	drug
mg	NN	mg	I-e1	T	drug
and	CC	and	O	O	NONE
tamsulosin	NN	tamsulosin	B-e2	O	drug
0.4	CD	0.4	I-e2	O	drug
mg	NN	mg	I-e2	O	drug
separated	VBN	separate	O	O	NONE
by	IN	by	O	O	NONE
6	CD	6	O	O	NONE
hours	NNS	hour	O	O	NONE
experienced	VBN	experience	O	O	NONE
a	DT	a	O	O	NONE
standing	JJ	standing	O	O	NONE
systolic	JJ	systolic	O	O	NONE
blood	NN	blood	O	O	NONE
pressure	NN	pressure	O	O	NONE
below	IN	below	O	O	NONE
85	CD	85	O	O	NONE
mm	NN	mm	O	O	NONE
Hg	NN	hg	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s32
In	IN	in	O	O	NONE
a	DT	a	O	O	NONE
similar	JJ	similar	O	O	NONE
study	NN	study	O	O	NONE
with	IN	with	O	O	NONE
tamsulosin	NN	tamsulosin	B-e0	T	drug
in	IN	in	O	O	NONE
healthy	JJ	healthy	O	O	NONE
volunteers	NNS	volunteer	O	O	NONE
,	,	,	O	O	NONE
1	CD	1	O	O	NONE
of	IN	of	O	O	NONE
24	CD	24	O	O	NONE
subjects	NNS	subject	O	O	NONE
dosed	VBN	dose	O	O	NONE
with	IN	with	O	O	NONE
Vardenafil	NN	vardenafil	B-e1	O	drug
20	CD	20	I-e1	O	drug
mg	NN	mg	I-e1	O	drug
and	CC	and	O	O	NONE
tamsulosin	NN	tamsulosin	B-e2	T	drug
0.4	CD	0.4	I-e2	T	drug
mg	NN	mg	I-e2	T	drug
separated	VBN	separate	O	O	NONE
by	IN	by	O	O	NONE
6	CD	6	O	O	NONE
hours	NNS	hour	O	O	NONE
experienced	VBN	experience	O	O	NONE
a	DT	a	O	O	NONE
standing	JJ	standing	O	O	NONE
systolic	JJ	systolic	O	O	NONE
blood	NN	blood	O	O	NONE
pressure	NN	pressure	O	O	NONE
below	IN	below	O	O	NONE
85	CD	85	O	O	NONE
mm	NN	mm	O	O	NONE
Hg	NN	hg	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s32
In	IN	in	O	O	NONE
a	DT	a	O	O	NONE
similar	JJ	similar	O	O	NONE
study	NN	study	O	O	NONE
with	IN	with	O	O	NONE
tamsulosin	NN	tamsulosin	B-e0	O	drug
in	IN	in	O	O	NONE
healthy	JJ	healthy	O	O	NONE
volunteers	NNS	volunteer	O	O	NONE
,	,	,	O	O	NONE
1	CD	1	O	O	NONE
of	IN	of	O	O	NONE
24	CD	24	O	O	NONE
subjects	NNS	subject	O	O	NONE
dosed	VBN	dose	O	O	NONE
with	IN	with	O	O	NONE
Vardenafil	NN	vardenafil	B-e1	T	drug
20	CD	20	I-e1	T	drug
mg	NN	mg	I-e1	T	drug
and	CC	and	O	O	NONE
tamsulosin	NN	tamsulosin	B-e2	T	drug
0.4	CD	0.4	I-e2	T	drug
mg	NN	mg	I-e2	T	drug
separated	VBN	separate	O	O	NONE
by	IN	by	O	O	NONE
6	CD	6	O	O	NONE
hours	NNS	hour	O	O	NONE
experienced	VBN	experience	O	O	NONE
a	DT	a	O	O	NONE
standing	JJ	standing	O	O	NONE
systolic	JJ	systolic	O	O	NONE
blood	NN	blood	O	O	NONE
pressure	NN	pressure	O	O	NONE
below	IN	below	O	O	NONE
85	CD	85	O	O	NONE
mm	NN	mm	O	O	NONE
Hg	NN	hg	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s33
Two	CD	two	O	O	NONE
of	IN	of	O	O	NONE
16	CD	16	O	O	NONE
subjects	NNS	subject	O	O	NONE
dosed	VBN	dose	O	O	NONE
simultaneously	RB	simultaneously	O	O	NONE
with	IN	with	O	O	NONE
Vardenafil	NN	vardenafil	B-e0	T	drug
10	CD	10	I-e0	T	drug
mg	NN	mg	I-e0	T	drug
and	CC	and	O	O	NONE
tamsulosin	NN	tamsulosin	B-e1	T	drug
0.4	CD	0.4	I-e1	T	drug
mg	NN	mg	I-e1	T	drug
experienced	VBN	experience	O	O	NONE
a	DT	a	O	O	NONE
standing	JJ	standing	O	O	NONE
systolic	JJ	systolic	O	O	NONE
blood	NN	blood	O	O	NONE
pressure	NN	pressure	O	O	NONE
below	IN	below	O	O	NONE
85	CD	85	O	O	NONE
mm	NN	mm	O	O	NONE
Hg	NN	hg	O	O	NONE
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d253.s35
Based	VBN	base	O	O	NONE
on	IN	on	O	O	NONE
these	DT	these	O	O	NONE
data	NNS	datum	O	O	NONE
,	,	,	O	O	NONE
Vardenafil	NN	vardenafil	B-e0	T	drug
should	MD	should	O	O	NONE
not	RB	not	O	O	NONE
be	VB	be	O	O	NONE
used	VBN	use	O	O	NONE
in	IN	in	O	O	NONE
patients	NNS	patient	O	O	NONE
on	IN	on	O	O	NONE
alpha-blocker	NN	alpha-blocker	B-e1	T	drug
therapy	NN	therapy	O	O	NONE
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d253.s36
Ritonavir	NN	ritonavir	B-e0	T	drug
and	CC	and	O	O	NONE
indinavir	NN	indinavir	B-e1	T	drug
:	:	:	O	O	NONE
Upon	IN	upon	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
5	CD	5	O	O	NONE
mg	NN	mg	O	O	NONE
of	IN	of	O	O	NONE
Vardenafil	NN	vardenafil	B-e2	O	drug
with	IN	with	O	O	NONE
600	CD	600	O	O	NONE
mg	NN	mg	O	O	NONE
BID	NN	bid	O	O	NONE
ritonavir	NN	ritonavir	B-e3	O	drug
,	,	,	O	O	NONE
the	DT	the	O	O	NONE
Cmax	NN	cmax	O	O	NONE
and	CC	and	O	O	NONE
AUC	NN	auc	O	O	NONE
of	IN	of	O	O	NONE
ritonavir	NN	ritonavir	B-e4	O	drug
were	VBD	be	O	O	NONE
reduced	VBN	reduce	O	O	NONE
by	IN	by	O	O	NONE
approximately	RB	approximately	O	O	NONE
20	CD	20	O	O	NONE
%.	NN	%.	O	O	NONE

NO

Sentence: DrugDDI.d253.s36
Ritonavir	NN	ritonavir	B-e0	T	drug
and	CC	and	O	O	NONE
indinavir	NN	indinavir	B-e1	O	drug
:	:	:	O	O	NONE
Upon	IN	upon	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
5	CD	5	O	O	NONE
mg	NN	mg	O	O	NONE
of	IN	of	O	O	NONE
Vardenafil	NN	vardenafil	B-e2	T	drug
with	IN	with	O	O	NONE
600	CD	600	O	O	NONE
mg	NN	mg	O	O	NONE
BID	NN	bid	O	O	NONE
ritonavir	NN	ritonavir	B-e3	O	drug
,	,	,	O	O	NONE
the	DT	the	O	O	NONE
Cmax	NN	cmax	O	O	NONE
and	CC	and	O	O	NONE
AUC	NN	auc	O	O	NONE
of	IN	of	O	O	NONE
ritonavir	NN	ritonavir	B-e4	O	drug
were	VBD	be	O	O	NONE
reduced	VBN	reduce	O	O	NONE
by	IN	by	O	O	NONE
approximately	RB	approximately	O	O	NONE
20	CD	20	O	O	NONE
%.	NN	%.	O	O	NONE

NO

Sentence: DrugDDI.d253.s36
Ritonavir	NN	ritonavir	B-e0	T	drug
and	CC	and	O	O	NONE
indinavir	NN	indinavir	B-e1	O	drug
:	:	:	O	O	NONE
Upon	IN	upon	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
5	CD	5	O	O	NONE
mg	NN	mg	O	O	NONE
of	IN	of	O	O	NONE
Vardenafil	NN	vardenafil	B-e2	O	drug
with	IN	with	O	O	NONE
600	CD	600	O	O	NONE
mg	NN	mg	O	O	NONE
BID	NN	bid	O	O	NONE
ritonavir	NN	ritonavir	B-e3	T	drug
,	,	,	O	O	NONE
the	DT	the	O	O	NONE
Cmax	NN	cmax	O	O	NONE
and	CC	and	O	O	NONE
AUC	NN	auc	O	O	NONE
of	IN	of	O	O	NONE
ritonavir	NN	ritonavir	B-e4	O	drug
were	VBD	be	O	O	NONE
reduced	VBN	reduce	O	O	NONE
by	IN	by	O	O	NONE
approximately	RB	approximately	O	O	NONE
20	CD	20	O	O	NONE
%.	NN	%.	O	O	NONE

NO

Sentence: DrugDDI.d253.s36
Ritonavir	NN	ritonavir	B-e0	T	drug
and	CC	and	O	O	NONE
indinavir	NN	indinavir	B-e1	O	drug
:	:	:	O	O	NONE
Upon	IN	upon	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
5	CD	5	O	O	NONE
mg	NN	mg	O	O	NONE
of	IN	of	O	O	NONE
Vardenafil	NN	vardenafil	B-e2	O	drug
with	IN	with	O	O	NONE
600	CD	600	O	O	NONE
mg	NN	mg	O	O	NONE
BID	NN	bid	O	O	NONE
ritonavir	NN	ritonavir	B-e3	O	drug
,	,	,	O	O	NONE
the	DT	the	O	O	NONE
Cmax	NN	cmax	O	O	NONE
and	CC	and	O	O	NONE
AUC	NN	auc	O	O	NONE
of	IN	of	O	O	NONE
ritonavir	NN	ritonavir	B-e4	T	drug
were	VBD	be	O	O	NONE
reduced	VBN	reduce	O	O	NONE
by	IN	by	O	O	NONE
approximately	RB	approximately	O	O	NONE
20	CD	20	O	O	NONE
%.	NN	%.	O	O	NONE

NO

Sentence: DrugDDI.d253.s36
Ritonavir	NN	ritonavir	B-e0	O	drug
and	CC	and	O	O	NONE
indinavir	NN	indinavir	B-e1	T	drug
:	:	:	O	O	NONE
Upon	IN	upon	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
5	CD	5	O	O	NONE
mg	NN	mg	O	O	NONE
of	IN	of	O	O	NONE
Vardenafil	NN	vardenafil	B-e2	T	drug
with	IN	with	O	O	NONE
600	CD	600	O	O	NONE
mg	NN	mg	O	O	NONE
BID	NN	bid	O	O	NONE
ritonavir	NN	ritonavir	B-e3	O	drug
,	,	,	O	O	NONE
the	DT	the	O	O	NONE
Cmax	NN	cmax	O	O	NONE
and	CC	and	O	O	NONE
AUC	NN	auc	O	O	NONE
of	IN	of	O	O	NONE
ritonavir	NN	ritonavir	B-e4	O	drug
were	VBD	be	O	O	NONE
reduced	VBN	reduce	O	O	NONE
by	IN	by	O	O	NONE
approximately	RB	approximately	O	O	NONE
20	CD	20	O	O	NONE
%.	NN	%.	O	O	NONE

NO

Sentence: DrugDDI.d253.s36
Ritonavir	NN	ritonavir	B-e0	O	drug
and	CC	and	O	O	NONE
indinavir	NN	indinavir	B-e1	T	drug
:	:	:	O	O	NONE
Upon	IN	upon	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
5	CD	5	O	O	NONE
mg	NN	mg	O	O	NONE
of	IN	of	O	O	NONE
Vardenafil	NN	vardenafil	B-e2	O	drug
with	IN	with	O	O	NONE
600	CD	600	O	O	NONE
mg	NN	mg	O	O	NONE
BID	NN	bid	O	O	NONE
ritonavir	NN	ritonavir	B-e3	T	drug
,	,	,	O	O	NONE
the	DT	the	O	O	NONE
Cmax	NN	cmax	O	O	NONE
and	CC	and	O	O	NONE
AUC	NN	auc	O	O	NONE
of	IN	of	O	O	NONE
ritonavir	NN	ritonavir	B-e4	O	drug
were	VBD	be	O	O	NONE
reduced	VBN	reduce	O	O	NONE
by	IN	by	O	O	NONE
approximately	RB	approximately	O	O	NONE
20	CD	20	O	O	NONE
%.	NN	%.	O	O	NONE

NO

Sentence: DrugDDI.d253.s36
Ritonavir	NN	ritonavir	B-e0	O	drug
and	CC	and	O	O	NONE
indinavir	NN	indinavir	B-e1	T	drug
:	:	:	O	O	NONE
Upon	IN	upon	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
5	CD	5	O	O	NONE
mg	NN	mg	O	O	NONE
of	IN	of	O	O	NONE
Vardenafil	NN	vardenafil	B-e2	O	drug
with	IN	with	O	O	NONE
600	CD	600	O	O	NONE
mg	NN	mg	O	O	NONE
BID	NN	bid	O	O	NONE
ritonavir	NN	ritonavir	B-e3	O	drug
,	,	,	O	O	NONE
the	DT	the	O	O	NONE
Cmax	NN	cmax	O	O	NONE
and	CC	and	O	O	NONE
AUC	NN	auc	O	O	NONE
of	IN	of	O	O	NONE
ritonavir	NN	ritonavir	B-e4	T	drug
were	VBD	be	O	O	NONE
reduced	VBN	reduce	O	O	NONE
by	IN	by	O	O	NONE
approximately	RB	approximately	O	O	NONE
20	CD	20	O	O	NONE
%.	NN	%.	O	O	NONE

NO

Sentence: DrugDDI.d253.s36
Ritonavir	NN	ritonavir	B-e0	O	drug
and	CC	and	O	O	NONE
indinavir	NN	indinavir	B-e1	O	drug
:	:	:	O	O	NONE
Upon	IN	upon	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
5	CD	5	O	O	NONE
mg	NN	mg	O	O	NONE
of	IN	of	O	O	NONE
Vardenafil	NN	vardenafil	B-e2	T	drug
with	IN	with	O	O	NONE
600	CD	600	O	O	NONE
mg	NN	mg	O	O	NONE
BID	NN	bid	O	O	NONE
ritonavir	NN	ritonavir	B-e3	T	drug
,	,	,	O	O	NONE
the	DT	the	O	O	NONE
Cmax	NN	cmax	O	O	NONE
and	CC	and	O	O	NONE
AUC	NN	auc	O	O	NONE
of	IN	of	O	O	NONE
ritonavir	NN	ritonavir	B-e4	O	drug
were	VBD	be	O	O	NONE
reduced	VBN	reduce	O	O	NONE
by	IN	by	O	O	NONE
approximately	RB	approximately	O	O	NONE
20	CD	20	O	O	NONE
%.	NN	%.	O	O	NONE

YES

Sentence: DrugDDI.d253.s36
Ritonavir	NN	ritonavir	B-e0	O	drug
and	CC	and	O	O	NONE
indinavir	NN	indinavir	B-e1	O	drug
:	:	:	O	O	NONE
Upon	IN	upon	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
5	CD	5	O	O	NONE
mg	NN	mg	O	O	NONE
of	IN	of	O	O	NONE
Vardenafil	NN	vardenafil	B-e2	T	drug
with	IN	with	O	O	NONE
600	CD	600	O	O	NONE
mg	NN	mg	O	O	NONE
BID	NN	bid	O	O	NONE
ritonavir	NN	ritonavir	B-e3	O	drug
,	,	,	O	O	NONE
the	DT	the	O	O	NONE
Cmax	NN	cmax	O	O	NONE
and	CC	and	O	O	NONE
AUC	NN	auc	O	O	NONE
of	IN	of	O	O	NONE
ritonavir	NN	ritonavir	B-e4	T	drug
were	VBD	be	O	O	NONE
reduced	VBN	reduce	O	O	NONE
by	IN	by	O	O	NONE
approximately	RB	approximately	O	O	NONE
20	CD	20	O	O	NONE
%.	NN	%.	O	O	NONE

NO

Sentence: DrugDDI.d253.s36
Ritonavir	NN	ritonavir	B-e0	O	drug
and	CC	and	O	O	NONE
indinavir	NN	indinavir	B-e1	O	drug
:	:	:	O	O	NONE
Upon	IN	upon	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
5	CD	5	O	O	NONE
mg	NN	mg	O	O	NONE
of	IN	of	O	O	NONE
Vardenafil	NN	vardenafil	B-e2	O	drug
with	IN	with	O	O	NONE
600	CD	600	O	O	NONE
mg	NN	mg	O	O	NONE
BID	NN	bid	O	O	NONE
ritonavir	NN	ritonavir	B-e3	T	drug
,	,	,	O	O	NONE
the	DT	the	O	O	NONE
Cmax	NN	cmax	O	O	NONE
and	CC	and	O	O	NONE
AUC	NN	auc	O	O	NONE
of	IN	of	O	O	NONE
ritonavir	NN	ritonavir	B-e4	T	drug
were	VBD	be	O	O	NONE
reduced	VBN	reduce	O	O	NONE
by	IN	by	O	O	NONE
approximately	RB	approximately	O	O	NONE
20	CD	20	O	O	NONE
%.	NN	%.	O	O	NONE

NO

Sentence: DrugDDI.d253.s37
Upon	IN	upon	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
10	CD	10	O	O	NONE
mg	NN	mg	O	O	NONE
of	IN	of	O	O	NONE
Vardenafil	NN	vardenafil	B-e0	T	drug
with	IN	with	O	O	NONE
800	CD	800	O	O	NONE
mg	NN	mg	O	O	NONE
TID	NN	tid	O	O	NONE
indinavir	NN	indinavir	B-e1	T	drug
,	,	,	O	O	NONE
the	DT	the	O	O	NONE
Cmax	NN	cmax	O	O	NONE
and	CC	and	O	O	NONE
AUC	NN	auc	O	O	NONE
of	IN	of	O	O	NONE
indinavir	NN	indinavir	B-e2	O	drug
were	VBD	be	O	O	NONE
reduced	VBN	reduce	O	O	NONE
by	IN	by	O	O	NONE
40	CD	40	O	O	NONE
%	NN	%	O	O	NONE
and	CC	and	O	O	NONE
30	CD	30	O	O	NONE
%	NN	%	O	O	NONE
,	,	,	O	O	NONE
respectively	RB	respectively	O	O	NONE
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d253.s37
Upon	IN	upon	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
10	CD	10	O	O	NONE
mg	NN	mg	O	O	NONE
of	IN	of	O	O	NONE
Vardenafil	NN	vardenafil	B-e0	T	drug
with	IN	with	O	O	NONE
800	CD	800	O	O	NONE
mg	NN	mg	O	O	NONE
TID	NN	tid	O	O	NONE
indinavir	NN	indinavir	B-e1	O	drug
,	,	,	O	O	NONE
the	DT	the	O	O	NONE
Cmax	NN	cmax	O	O	NONE
and	CC	and	O	O	NONE
AUC	NN	auc	O	O	NONE
of	IN	of	O	O	NONE
indinavir	NN	indinavir	B-e2	T	drug
were	VBD	be	O	O	NONE
reduced	VBN	reduce	O	O	NONE
by	IN	by	O	O	NONE
40	CD	40	O	O	NONE
%	NN	%	O	O	NONE
and	CC	and	O	O	NONE
30	CD	30	O	O	NONE
%	NN	%	O	O	NONE
,	,	,	O	O	NONE
respectively	RB	respectively	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s37
Upon	IN	upon	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
10	CD	10	O	O	NONE
mg	NN	mg	O	O	NONE
of	IN	of	O	O	NONE
Vardenafil	NN	vardenafil	B-e0	O	drug
with	IN	with	O	O	NONE
800	CD	800	O	O	NONE
mg	NN	mg	O	O	NONE
TID	NN	tid	O	O	NONE
indinavir	NN	indinavir	B-e1	T	drug
,	,	,	O	O	NONE
the	DT	the	O	O	NONE
Cmax	NN	cmax	O	O	NONE
and	CC	and	O	O	NONE
AUC	NN	auc	O	O	NONE
of	IN	of	O	O	NONE
indinavir	NN	indinavir	B-e2	T	drug
were	VBD	be	O	O	NONE
reduced	VBN	reduce	O	O	NONE
by	IN	by	O	O	NONE
40	CD	40	O	O	NONE
%	NN	%	O	O	NONE
and	CC	and	O	O	NONE
30	CD	30	O	O	NONE
%	NN	%	O	O	NONE
,	,	,	O	O	NONE
respectively	RB	respectively	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s38
Alcohol	NN	alcohol	B-e0	T	drug
:	:	:	O	O	NONE
Alcohol	NN	alcohol	B-e1	T	drug
(	(	(	O	O	NONE
0.5	CD	0.5	O	O	NONE
g/kg	NN	g/kg	O	O	NONE
body	NN	body	O	O	NONE
weight	NN	weight	O	O	NONE
:	:	:	O	O	NONE
approximately	RB	approximately	O	O	NONE
40	CD	40	O	O	NONE
mL	NN	ml	O	O	NONE
of	IN	of	O	O	NONE
absolute	JJ	absolute	O	O	NONE
alcohol	NN	alcohol	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
70	CD	70	O	O	NONE
kg	NN	kg	O	O	NONE
person	NN	person	O	O	NONE
)	)	)	O	O	NONE
and	CC	and	O	O	NONE
vardenafil	NN	vardenafil	B-e2	O	drug
plasma	NN	plasma	O	O	NONE
levels	NNS	level	O	O	NONE
were	VBD	be	O	O	NONE
not	RB	not	O	O	NONE
altered	VBN	alter	O	O	NONE
when	WRB	when	O	O	NONE
dosed	VBN	dose	O	O	NONE
simultaneously	RB	simultaneously	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s38
Alcohol	NN	alcohol	B-e0	T	drug
:	:	:	O	O	NONE
Alcohol	NN	alcohol	B-e1	O	drug
(	(	(	O	O	NONE
0.5	CD	0.5	O	O	NONE
g/kg	NN	g/kg	O	O	NONE
body	NN	body	O	O	NONE
weight	NN	weight	O	O	NONE
:	:	:	O	O	NONE
approximately	RB	approximately	O	O	NONE
40	CD	40	O	O	NONE
mL	NN	ml	O	O	NONE
of	IN	of	O	O	NONE
absolute	JJ	absolute	O	O	NONE
alcohol	NN	alcohol	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
70	CD	70	O	O	NONE
kg	NN	kg	O	O	NONE
person	NN	person	O	O	NONE
)	)	)	O	O	NONE
and	CC	and	O	O	NONE
vardenafil	NN	vardenafil	B-e2	T	drug
plasma	NN	plasma	O	O	NONE
levels	NNS	level	O	O	NONE
were	VBD	be	O	O	NONE
not	RB	not	O	O	NONE
altered	VBN	alter	O	O	NONE
when	WRB	when	O	O	NONE
dosed	VBN	dose	O	O	NONE
simultaneously	RB	simultaneously	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s38
Alcohol	NN	alcohol	B-e0	O	drug
:	:	:	O	O	NONE
Alcohol	NN	alcohol	B-e1	T	drug
(	(	(	O	O	NONE
0.5	CD	0.5	O	O	NONE
g/kg	NN	g/kg	O	O	NONE
body	NN	body	O	O	NONE
weight	NN	weight	O	O	NONE
:	:	:	O	O	NONE
approximately	RB	approximately	O	O	NONE
40	CD	40	O	O	NONE
mL	NN	ml	O	O	NONE
of	IN	of	O	O	NONE
absolute	JJ	absolute	O	O	NONE
alcohol	NN	alcohol	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
70	CD	70	O	O	NONE
kg	NN	kg	O	O	NONE
person	NN	person	O	O	NONE
)	)	)	O	O	NONE
and	CC	and	O	O	NONE
vardenafil	NN	vardenafil	B-e2	T	drug
plasma	NN	plasma	O	O	NONE
levels	NNS	level	O	O	NONE
were	VBD	be	O	O	NONE
not	RB	not	O	O	NONE
altered	VBN	alter	O	O	NONE
when	WRB	when	O	O	NONE
dosed	VBN	dose	O	O	NONE
simultaneously	RB	simultaneously	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d253.s39
Vardenafil	NN	vardenafil	B-e0	T	drug
(	(	(	O	O	NONE
20	CD	20	O	O	NONE
mg	NN	mg	O	O	NONE
)	)	)	O	O	NONE
did	VBD	do	O	O	NONE
not	RB	not	O	O	NONE
potentiate	VB	potentiate	O	O	NONE
the	DT	the	O	O	NONE
hypotensive	JJ	hypotensive	O	O	NONE
effects	NNS	effect	O	O	NONE
of	IN	of	O	O	NONE
alcohol	NN	alcohol	B-e1	T	drug
during	IN	during	O	O	NONE
the	DT	the	O	O	NONE
4-hour	JJ	4-hour	O	O	NONE
observation	NN	observation	O	O	NONE
period	NN	period	O	O	NONE
in	IN	in	O	O	NONE
healthy	JJ	healthy	O	O	NONE
volunteers	NNS	volunteer	O	O	NONE
when	WRB	when	O	O	NONE
administered	VBN	administer	O	O	NONE
with	IN	with	O	O	NONE
alcohol	NN	alcohol	B-e2	O	drug
(	(	(	O	O	NONE
0.5	CD	0.5	O	O	NONE
g/kg	NN	g/kg	O	O	NONE
body	NN	body	O	O	NONE
weight	NN	weight	O	O	NONE
).	CD	).	O	O	NONE

NO

Sentence: DrugDDI.d253.s39
Vardenafil	NN	vardenafil	B-e0	T	drug
(	(	(	O	O	NONE
20	CD	20	O	O	NONE
mg	NN	mg	O	O	NONE
)	)	)	O	O	NONE
did	VBD	do	O	O	NONE
not	RB	not	O	O	NONE
potentiate	VB	potentiate	O	O	NONE
the	DT	the	O	O	NONE
hypotensive	JJ	hypotensive	O	O	NONE
effects	NNS	effect	O	O	NONE
of	IN	of	O	O	NONE
alcohol	NN	alcohol	B-e1	O	drug
during	IN	during	O	O	NONE
the	DT	the	O	O	NONE
4-hour	JJ	4-hour	O	O	NONE
observation	NN	observation	O	O	NONE
period	NN	period	O	O	NONE
in	IN	in	O	O	NONE
healthy	JJ	healthy	O	O	NONE
volunteers	NNS	volunteer	O	O	NONE
when	WRB	when	O	O	NONE
administered	VBN	administer	O	O	NONE
with	IN	with	O	O	NONE
alcohol	NN	alcohol	B-e2	T	drug
(	(	(	O	O	NONE
0.5	CD	0.5	O	O	NONE
g/kg	NN	g/kg	O	O	NONE
body	NN	body	O	O	NONE
weight	NN	weight	O	O	NONE
).	CD	).	O	O	NONE

NO

Sentence: DrugDDI.d253.s39
Vardenafil	NN	vardenafil	B-e0	O	drug
(	(	(	O	O	NONE
20	CD	20	O	O	NONE
mg	NN	mg	O	O	NONE
)	)	)	O	O	NONE
did	VBD	do	O	O	NONE
not	RB	not	O	O	NONE
potentiate	VB	potentiate	O	O	NONE
the	DT	the	O	O	NONE
hypotensive	JJ	hypotensive	O	O	NONE
effects	NNS	effect	O	O	NONE
of	IN	of	O	O	NONE
alcohol	NN	alcohol	B-e1	T	drug
during	IN	during	O	O	NONE
the	DT	the	O	O	NONE
4-hour	JJ	4-hour	O	O	NONE
observation	NN	observation	O	O	NONE
period	NN	period	O	O	NONE
in	IN	in	O	O	NONE
healthy	JJ	healthy	O	O	NONE
volunteers	NNS	volunteer	O	O	NONE
when	WRB	when	O	O	NONE
administered	VBN	administer	O	O	NONE
with	IN	with	O	O	NONE
alcohol	NN	alcohol	B-e2	T	drug
(	(	(	O	O	NONE
0.5	CD	0.5	O	O	NONE
g/kg	NN	g/kg	O	O	NONE
body	NN	body	O	O	NONE
weight	NN	weight	O	O	NONE
).	CD	).	O	O	NONE

NO

Sentence: DrugDDI.d253.s40
Aspirin	NN	aspirin	B-e0	T	drug
:	:	:	O	O	NONE
Vardenafil	NN	vardenafil	B-e1	T	drug
(	(	(	O	O	NONE
10	CD	10	O	O	NONE
mg	NN	mg	O	O	NONE
and	CC	and	O	O	NONE
20	CD	20	O	O	NONE
mg	NN	mg	O	O	NONE
)	)	)	O	O	NONE
did	VBD	do	O	O	NONE
not	RB	not	O	O	NONE
potentiate	VB	potentiate	O	O	NONE
the	DT	the	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
bleeding	JJ	bleeding	O	O	NONE
time	NN	time	O	O	NONE
caused	VBN	cause	O	O	NONE
by	IN	by	O	O	NONE
aspirin	NN	aspirin	B-e2	O	drug
(	(	(	O	O	NONE
two	CD	two	O	O	NONE
81	CD	81	O	O	NONE
mg	NN	mg	O	O	NONE
tablets	NNS	tablet	O	O	NONE
).	CD	).	O	O	NONE

NO

Sentence: DrugDDI.d253.s40
Aspirin	NN	aspirin	B-e0	T	drug
:	:	:	O	O	NONE
Vardenafil	NN	vardenafil	B-e1	O	drug
(	(	(	O	O	NONE
10	CD	10	O	O	NONE
mg	NN	mg	O	O	NONE
and	CC	and	O	O	NONE
20	CD	20	O	O	NONE
mg	NN	mg	O	O	NONE
)	)	)	O	O	NONE
did	VBD	do	O	O	NONE
not	RB	not	O	O	NONE
potentiate	VB	potentiate	O	O	NONE
the	DT	the	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
bleeding	JJ	bleeding	O	O	NONE
time	NN	time	O	O	NONE
caused	VBN	cause	O	O	NONE
by	IN	by	O	O	NONE
aspirin	NN	aspirin	B-e2	T	drug
(	(	(	O	O	NONE
two	CD	two	O	O	NONE
81	CD	81	O	O	NONE
mg	NN	mg	O	O	NONE
tablets	NNS	tablet	O	O	NONE
).	CD	).	O	O	NONE

NO

Sentence: DrugDDI.d253.s40
Aspirin	NN	aspirin	B-e0	O	drug
:	:	:	O	O	NONE
Vardenafil	NN	vardenafil	B-e1	T	drug
(	(	(	O	O	NONE
10	CD	10	O	O	NONE
mg	NN	mg	O	O	NONE
and	CC	and	O	O	NONE
20	CD	20	O	O	NONE
mg	NN	mg	O	O	NONE
)	)	)	O	O	NONE
did	VBD	do	O	O	NONE
not	RB	not	O	O	NONE
potentiate	VB	potentiate	O	O	NONE
the	DT	the	O	O	NONE
increase	NN	increase	O	O	NONE
in	IN	in	O	O	NONE
bleeding	JJ	bleeding	O	O	NONE
time	NN	time	O	O	NONE
caused	VBN	cause	O	O	NONE
by	IN	by	O	O	NONE
aspirin	NN	aspirin	B-e2	T	drug
(	(	(	O	O	NONE
two	CD	two	O	O	NONE
81	CD	81	O	O	NONE
mg	NN	mg	O	O	NONE
tablets	NNS	tablet	O	O	NONE
).	CD	).	O	O	NONE

NO

Sentence: DrugDDI.d253.s41
Other	JJ	other	O	O	NONE
interactions	NNS	interaction	O	O	NONE
:	:	:	O	O	NONE
Vardenafil	NN	vardenafil	B-e0	T	drug
had	VBD	have	O	O	NONE
no	DT	no	O	O	NONE
effect	NN	effect	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
pharmacodynamics	NNS	pharmacodynamic	O	O	NONE
of	IN	of	O	O	NONE
glyburide	NN	glyburide	B-e1	T	drug
(	(	(	O	O	NONE
glucose	NN	glucose	B-e2	O	drug
and	CC	and	O	O	NONE
insulin	NN	insulin	B-e3	O	drug
concentrations	NNS	concentration	O	O	NONE
)	)	)	O	O	NONE
and	CC	and	O	O	NONE
warfarin	NN	warfarin	B-e4	O	drug
(	(	(	O	O	NONE
prothrombin	NN	prothrombin	O	O	NONE
time	NN	time	O	O	NONE
or	CC	or	O	O	NONE
other	JJ	other	O	O	NONE
pharmacodynamic	JJ	pharmacodynamic	O	O	NONE
parameters	NNS	parameter	O	O	NONE
).	NN	).	O	O	NONE

NO

Sentence: DrugDDI.d253.s41
Other	JJ	other	O	O	NONE
interactions	NNS	interaction	O	O	NONE
:	:	:	O	O	NONE
Vardenafil	NN	vardenafil	B-e0	T	drug
had	VBD	have	O	O	NONE
no	DT	no	O	O	NONE
effect	NN	effect	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
pharmacodynamics	NNS	pharmacodynamic	O	O	NONE
of	IN	of	O	O	NONE
glyburide	NN	glyburide	B-e1	O	drug
(	(	(	O	O	NONE
glucose	NN	glucose	B-e2	T	drug
and	CC	and	O	O	NONE
insulin	NN	insulin	B-e3	O	drug
concentrations	NNS	concentration	O	O	NONE
)	)	)	O	O	NONE
and	CC	and	O	O	NONE
warfarin	NN	warfarin	B-e4	O	drug
(	(	(	O	O	NONE
prothrombin	NN	prothrombin	O	O	NONE
time	NN	time	O	O	NONE
or	CC	or	O	O	NONE
other	JJ	other	O	O	NONE
pharmacodynamic	JJ	pharmacodynamic	O	O	NONE
parameters	NNS	parameter	O	O	NONE
).	NN	).	O	O	NONE

NO

Sentence: DrugDDI.d253.s41
Other	JJ	other	O	O	NONE
interactions	NNS	interaction	O	O	NONE
:	:	:	O	O	NONE
Vardenafil	NN	vardenafil	B-e0	T	drug
had	VBD	have	O	O	NONE
no	DT	no	O	O	NONE
effect	NN	effect	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
pharmacodynamics	NNS	pharmacodynamic	O	O	NONE
of	IN	of	O	O	NONE
glyburide	NN	glyburide	B-e1	O	drug
(	(	(	O	O	NONE
glucose	NN	glucose	B-e2	O	drug
and	CC	and	O	O	NONE
insulin	NN	insulin	B-e3	T	drug
concentrations	NNS	concentration	O	O	NONE
)	)	)	O	O	NONE
and	CC	and	O	O	NONE
warfarin	NN	warfarin	B-e4	O	drug
(	(	(	O	O	NONE
prothrombin	NN	prothrombin	O	O	NONE
time	NN	time	O	O	NONE
or	CC	or	O	O	NONE
other	JJ	other	O	O	NONE
pharmacodynamic	JJ	pharmacodynamic	O	O	NONE
parameters	NNS	parameter	O	O	NONE
).	NN	).	O	O	NONE

NO

Sentence: DrugDDI.d253.s41
Other	JJ	other	O	O	NONE
interactions	NNS	interaction	O	O	NONE
:	:	:	O	O	NONE
Vardenafil	NN	vardenafil	B-e0	T	drug
had	VBD	have	O	O	NONE
no	DT	no	O	O	NONE
effect	NN	effect	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
pharmacodynamics	NNS	pharmacodynamic	O	O	NONE
of	IN	of	O	O	NONE
glyburide	NN	glyburide	B-e1	O	drug
(	(	(	O	O	NONE
glucose	NN	glucose	B-e2	O	drug
and	CC	and	O	O	NONE
insulin	NN	insulin	B-e3	O	drug
concentrations	NNS	concentration	O	O	NONE
)	)	)	O	O	NONE
and	CC	and	O	O	NONE
warfarin	NN	warfarin	B-e4	T	drug
(	(	(	O	O	NONE
prothrombin	NN	prothrombin	O	O	NONE
time	NN	time	O	O	NONE
or	CC	or	O	O	NONE
other	JJ	other	O	O	NONE
pharmacodynamic	JJ	pharmacodynamic	O	O	NONE
parameters	NNS	parameter	O	O	NONE
).	NN	).	O	O	NONE

NO

Sentence: DrugDDI.d253.s41
Other	JJ	other	O	O	NONE
interactions	NNS	interaction	O	O	NONE
:	:	:	O	O	NONE
Vardenafil	NN	vardenafil	B-e0	O	drug
had	VBD	have	O	O	NONE
no	DT	no	O	O	NONE
effect	NN	effect	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
pharmacodynamics	NNS	pharmacodynamic	O	O	NONE
of	IN	of	O	O	NONE
glyburide	NN	glyburide	B-e1	T	drug
(	(	(	O	O	NONE
glucose	NN	glucose	B-e2	T	drug
and	CC	and	O	O	NONE
insulin	NN	insulin	B-e3	O	drug
concentrations	NNS	concentration	O	O	NONE
)	)	)	O	O	NONE
and	CC	and	O	O	NONE
warfarin	NN	warfarin	B-e4	O	drug
(	(	(	O	O	NONE
prothrombin	NN	prothrombin	O	O	NONE
time	NN	time	O	O	NONE
or	CC	or	O	O	NONE
other	JJ	other	O	O	NONE
pharmacodynamic	JJ	pharmacodynamic	O	O	NONE
parameters	NNS	parameter	O	O	NONE
).	NN	).	O	O	NONE

NO

Sentence: DrugDDI.d253.s41
Other	JJ	other	O	O	NONE
interactions	NNS	interaction	O	O	NONE
:	:	:	O	O	NONE
Vardenafil	NN	vardenafil	B-e0	O	drug
had	VBD	have	O	O	NONE
no	DT	no	O	O	NONE
effect	NN	effect	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
pharmacodynamics	NNS	pharmacodynamic	O	O	NONE
of	IN	of	O	O	NONE
glyburide	NN	glyburide	B-e1	T	drug
(	(	(	O	O	NONE
glucose	NN	glucose	B-e2	O	drug
and	CC	and	O	O	NONE
insulin	NN	insulin	B-e3	T	drug
concentrations	NNS	concentration	O	O	NONE
)	)	)	O	O	NONE
and	CC	and	O	O	NONE
warfarin	NN	warfarin	B-e4	O	drug
(	(	(	O	O	NONE
prothrombin	NN	prothrombin	O	O	NONE
time	NN	time	O	O	NONE
or	CC	or	O	O	NONE
other	JJ	other	O	O	NONE
pharmacodynamic	JJ	pharmacodynamic	O	O	NONE
parameters	NNS	parameter	O	O	NONE
).	NN	).	O	O	NONE

NO

Sentence: DrugDDI.d253.s41
Other	JJ	other	O	O	NONE
interactions	NNS	interaction	O	O	NONE
:	:	:	O	O	NONE
Vardenafil	NN	vardenafil	B-e0	O	drug
had	VBD	have	O	O	NONE
no	DT	no	O	O	NONE
effect	NN	effect	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
pharmacodynamics	NNS	pharmacodynamic	O	O	NONE
of	IN	of	O	O	NONE
glyburide	NN	glyburide	B-e1	T	drug
(	(	(	O	O	NONE
glucose	NN	glucose	B-e2	O	drug
and	CC	and	O	O	NONE
insulin	NN	insulin	B-e3	O	drug
concentrations	NNS	concentration	O	O	NONE
)	)	)	O	O	NONE
and	CC	and	O	O	NONE
warfarin	NN	warfarin	B-e4	T	drug
(	(	(	O	O	NONE
prothrombin	NN	prothrombin	O	O	NONE
time	NN	time	O	O	NONE
or	CC	or	O	O	NONE
other	JJ	other	O	O	NONE
pharmacodynamic	JJ	pharmacodynamic	O	O	NONE
parameters	NNS	parameter	O	O	NONE
).	NN	).	O	O	NONE

NO

Sentence: DrugDDI.d253.s41
Other	JJ	other	O	O	NONE
interactions	NNS	interaction	O	O	NONE
:	:	:	O	O	NONE
Vardenafil	NN	vardenafil	B-e0	O	drug
had	VBD	have	O	O	NONE
no	DT	no	O	O	NONE
effect	NN	effect	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
pharmacodynamics	NNS	pharmacodynamic	O	O	NONE
of	IN	of	O	O	NONE
glyburide	NN	glyburide	B-e1	O	drug
(	(	(	O	O	NONE
glucose	NN	glucose	B-e2	T	drug
and	CC	and	O	O	NONE
insulin	NN	insulin	B-e3	T	drug
concentrations	NNS	concentration	O	O	NONE
)	)	)	O	O	NONE
and	CC	and	O	O	NONE
warfarin	NN	warfarin	B-e4	O	drug
(	(	(	O	O	NONE
prothrombin	NN	prothrombin	O	O	NONE
time	NN	time	O	O	NONE
or	CC	or	O	O	NONE
other	JJ	other	O	O	NONE
pharmacodynamic	JJ	pharmacodynamic	O	O	NONE
parameters	NNS	parameter	O	O	NONE
).	NN	).	O	O	NONE

NO

Sentence: DrugDDI.d253.s41
Other	JJ	other	O	O	NONE
interactions	NNS	interaction	O	O	NONE
:	:	:	O	O	NONE
Vardenafil	NN	vardenafil	B-e0	O	drug
had	VBD	have	O	O	NONE
no	DT	no	O	O	NONE
effect	NN	effect	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
pharmacodynamics	NNS	pharmacodynamic	O	O	NONE
of	IN	of	O	O	NONE
glyburide	NN	glyburide	B-e1	O	drug
(	(	(	O	O	NONE
glucose	NN	glucose	B-e2	T	drug
and	CC	and	O	O	NONE
insulin	NN	insulin	B-e3	O	drug
concentrations	NNS	concentration	O	O	NONE
)	)	)	O	O	NONE
and	CC	and	O	O	NONE
warfarin	NN	warfarin	B-e4	T	drug
(	(	(	O	O	NONE
prothrombin	NN	prothrombin	O	O	NONE
time	NN	time	O	O	NONE
or	CC	or	O	O	NONE
other	JJ	other	O	O	NONE
pharmacodynamic	JJ	pharmacodynamic	O	O	NONE
parameters	NNS	parameter	O	O	NONE
).	NN	).	O	O	NONE

NO

Sentence: DrugDDI.d253.s41
Other	JJ	other	O	O	NONE
interactions	NNS	interaction	O	O	NONE
:	:	:	O	O	NONE
Vardenafil	NN	vardenafil	B-e0	O	drug
had	VBD	have	O	O	NONE
no	DT	no	O	O	NONE
effect	NN	effect	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
pharmacodynamics	NNS	pharmacodynamic	O	O	NONE
of	IN	of	O	O	NONE
glyburide	NN	glyburide	B-e1	O	drug
(	(	(	O	O	NONE
glucose	NN	glucose	B-e2	O	drug
and	CC	and	O	O	NONE
insulin	NN	insulin	B-e3	T	drug
concentrations	NNS	concentration	O	O	NONE
)	)	)	O	O	NONE
and	CC	and	O	O	NONE
warfarin	NN	warfarin	B-e4	T	drug
(	(	(	O	O	NONE
prothrombin	NN	prothrombin	O	O	NONE
time	NN	time	O	O	NONE
or	CC	or	O	O	NONE
other	JJ	other	O	O	NONE
pharmacodynamic	JJ	pharmacodynamic	O	O	NONE
parameters	NNS	parameter	O	O	NONE
).	NN	).	O	O	NONE

NO

Sentence: DrugDDI.d528.s0
Zidovudine	NN	zidovudine	B-e0	T	drug
:	:	:	O	O	NONE
There	EX	there	O	O	NONE
is	VBZ	be	O	O	NONE
no	DT	no	O	O	NONE
significant	JJ	significant	O	O	NONE
pharmacokinetic	JJ	pharmacokinetic	O	O	NONE
interaction	NN	interaction	O	O	NONE
between	IN	between	O	O	NONE
ZDV	NN	zdv	B-e1	T	drug
and	CC	and	O	O	NONE
zalcitabine	NN	zalcitabine	B-e2	O	drug
which	WDT	which	O	O	NONE
has	VBZ	have	O	O	NONE
been	VBN	be	O	O	NONE
confirmed	VBN	confirm	O	O	NONE
clinically	RB	clinically	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s0
Zidovudine	NN	zidovudine	B-e0	T	drug
:	:	:	O	O	NONE
There	EX	there	O	O	NONE
is	VBZ	be	O	O	NONE
no	DT	no	O	O	NONE
significant	JJ	significant	O	O	NONE
pharmacokinetic	JJ	pharmacokinetic	O	O	NONE
interaction	NN	interaction	O	O	NONE
between	IN	between	O	O	NONE
ZDV	NN	zdv	B-e1	O	drug
and	CC	and	O	O	NONE
zalcitabine	NN	zalcitabine	B-e2	T	drug
which	WDT	which	O	O	NONE
has	VBZ	have	O	O	NONE
been	VBN	be	O	O	NONE
confirmed	VBN	confirm	O	O	NONE
clinically	RB	clinically	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s0
Zidovudine	NN	zidovudine	B-e0	O	drug
:	:	:	O	O	NONE
There	EX	there	O	O	NONE
is	VBZ	be	O	O	NONE
no	DT	no	O	O	NONE
significant	JJ	significant	O	O	NONE
pharmacokinetic	JJ	pharmacokinetic	O	O	NONE
interaction	NN	interaction	O	O	NONE
between	IN	between	O	O	NONE
ZDV	NN	zdv	B-e1	T	drug
and	CC	and	O	O	NONE
zalcitabine	NN	zalcitabine	B-e2	T	drug
which	WDT	which	O	O	NONE
has	VBZ	have	O	O	NONE
been	VBN	be	O	O	NONE
confirmed	VBN	confirm	O	O	NONE
clinically	RB	clinically	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s1
Zalcitabine	NN	zalcitabine	B-e0	T	drug
also	RB	also	O	O	NONE
has	VBZ	have	O	O	NONE
no	DT	no	O	O	NONE
significant	JJ	significant	O	O	NONE
effect	NN	effect	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
intracellular	JJ	intracellular	O	O	NONE
phosphorylation	NN	phosphorylation	O	O	NONE
of	IN	of	O	O	NONE
ZDV	NN	zdv	B-e1	T	drug
,	,	,	O	O	NONE
as	IN	as	O	O	NONE
shown	VBN	show	O	O	NONE
in	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
in	IN	in	O	O	NONE
peripheral	JJ	peripheral	O	O	NONE
blood	NN	blood	O	O	NONE
mononuclear	JJ	mononuclear	O	O	NONE
cells	NNS	cell	O	O	NONE
or	CC	or	O	O	NONE
in	IN	in	O	O	NONE
two	CD	two	O	O	NONE
other	JJ	other	O	O	NONE
cell	NN	cell	O	O	NONE
lines	NNS	line	O	O	NONE
(	(	(	O	O	NONE
U937	NN	u937	O	O	NONE
and	CC	and	O	O	NONE
Molt-4	NN	molt-4	O	O	NONE
).	NN	).	O	O	NONE

NO

Sentence: DrugDDI.d528.s2
In	IN	in	O	O	NONE
the	DT	the	O	O	NONE
same	JJ	same	O	O	NONE
study	NN	study	O	O	NONE
it	PRP	it	O	O	NONE
was	VBD	be	O	O	NONE
shown	VBN	show	O	O	NONE
that	IN	that	O	O	NONE
didanosine	NN	didanosine	B-e0	T	drug
and	CC	and	O	O	NONE
stavudine	NN	stavudine	B-e1	T	drug
had	VBD	have	O	O	NONE
no	DT	no	O	O	NONE
significant	JJ	significant	O	O	NONE
effect	NN	effect	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
intracellular	JJ	intracellular	O	O	NONE
phosphorylation	NN	phosphorylation	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e2	O	drug
in	IN	in	O	O	NONE
peripheral	JJ	peripheral	O	O	NONE
blood	NN	blood	O	O	NONE
mononuclear	JJ	mononuclear	O	O	NONE
cells	NNS	cell	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s2
In	IN	in	O	O	NONE
the	DT	the	O	O	NONE
same	JJ	same	O	O	NONE
study	NN	study	O	O	NONE
it	PRP	it	O	O	NONE
was	VBD	be	O	O	NONE
shown	VBN	show	O	O	NONE
that	IN	that	O	O	NONE
didanosine	NN	didanosine	B-e0	T	drug
and	CC	and	O	O	NONE
stavudine	NN	stavudine	B-e1	O	drug
had	VBD	have	O	O	NONE
no	DT	no	O	O	NONE
significant	JJ	significant	O	O	NONE
effect	NN	effect	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
intracellular	JJ	intracellular	O	O	NONE
phosphorylation	NN	phosphorylation	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e2	T	drug
in	IN	in	O	O	NONE
peripheral	JJ	peripheral	O	O	NONE
blood	NN	blood	O	O	NONE
mononuclear	JJ	mononuclear	O	O	NONE
cells	NNS	cell	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s2
In	IN	in	O	O	NONE
the	DT	the	O	O	NONE
same	JJ	same	O	O	NONE
study	NN	study	O	O	NONE
it	PRP	it	O	O	NONE
was	VBD	be	O	O	NONE
shown	VBN	show	O	O	NONE
that	IN	that	O	O	NONE
didanosine	NN	didanosine	B-e0	O	drug
and	CC	and	O	O	NONE
stavudine	NN	stavudine	B-e1	T	drug
had	VBD	have	O	O	NONE
no	DT	no	O	O	NONE
significant	JJ	significant	O	O	NONE
effect	NN	effect	O	O	NONE
on	IN	on	O	O	NONE
the	DT	the	O	O	NONE
intracellular	JJ	intracellular	O	O	NONE
phosphorylation	NN	phosphorylation	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e2	T	drug
in	IN	in	O	O	NONE
peripheral	JJ	peripheral	O	O	NONE
blood	NN	blood	O	O	NONE
mononuclear	JJ	mononuclear	O	O	NONE
cells	NNS	cell	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s3
Lamivudine	NN	lamivudine	B-e0	T	drug
:	:	:	O	O	NONE
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
studies	NNS	study	O	O	NONE
in	IN	in	O	O	NONE
peripheral	JJ	peripheral	O	O	NONE
blood	NN	blood	O	O	NONE
mononuclear	JJ	mononuclear	O	O	NONE
cells	NNS	cell	O	O	NONE
,	,	,	O	O	NONE
U937	NN	u937	O	O	NONE
and	CC	and	O	O	NONE
Molt-4	NN	molt-4	O	O	NONE
cells	NNS	cell	O	O	NONE
revealed	VBD	reveal	O	O	NONE
that	IN	that	O	O	NONE
lamivudine	NN	lamivudine	B-e1	T	drug
significantly	RB	significantly	O	O	NONE
inhibited	VBD	inhibit	O	O	NONE
zalcitabine	NN	zalcitabine	B-e2	O	drug
phosphorylation	NN	phosphorylation	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
dose	NN	dose	O	O	NONE
dependent	JJ	dependent	O	O	NONE
manner	NN	manner	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s3
Lamivudine	NN	lamivudine	B-e0	T	drug
:	:	:	O	O	NONE
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
studies	NNS	study	O	O	NONE
in	IN	in	O	O	NONE
peripheral	JJ	peripheral	O	O	NONE
blood	NN	blood	O	O	NONE
mononuclear	JJ	mononuclear	O	O	NONE
cells	NNS	cell	O	O	NONE
,	,	,	O	O	NONE
U937	NN	u937	O	O	NONE
and	CC	and	O	O	NONE
Molt-4	NN	molt-4	O	O	NONE
cells	NNS	cell	O	O	NONE
revealed	VBD	reveal	O	O	NONE
that	IN	that	O	O	NONE
lamivudine	NN	lamivudine	B-e1	O	drug
significantly	RB	significantly	O	O	NONE
inhibited	VBD	inhibit	O	O	NONE
zalcitabine	NN	zalcitabine	B-e2	T	drug
phosphorylation	NN	phosphorylation	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
dose	NN	dose	O	O	NONE
dependent	JJ	dependent	O	O	NONE
manner	NN	manner	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s3
Lamivudine	NN	lamivudine	B-e0	O	drug
:	:	:	O	O	NONE
In	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
studies	NNS	study	O	O	NONE
in	IN	in	O	O	NONE
peripheral	JJ	peripheral	O	O	NONE
blood	NN	blood	O	O	NONE
mononuclear	JJ	mononuclear	O	O	NONE
cells	NNS	cell	O	O	NONE
,	,	,	O	O	NONE
U937	NN	u937	O	O	NONE
and	CC	and	O	O	NONE
Molt-4	NN	molt-4	O	O	NONE
cells	NNS	cell	O	O	NONE
revealed	VBD	reveal	O	O	NONE
that	IN	that	O	O	NONE
lamivudine	NN	lamivudine	B-e1	T	drug
significantly	RB	significantly	O	O	NONE
inhibited	VBD	inhibit	O	O	NONE
zalcitabine	NN	zalcitabine	B-e2	T	drug
phosphorylation	NN	phosphorylation	O	O	NONE
in	IN	in	O	O	NONE
a	DT	a	O	O	NONE
dose	NN	dose	O	O	NONE
dependent	JJ	dependent	O	O	NONE
manner	NN	manner	O	O	NONE
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d528.s4
Effects	NNS	effect	O	O	NONE
were	VBD	be	O	O	NONE
already	RB	already	O	O	NONE
seen	VBN	see	O	O	NONE
with	IN	with	O	O	NONE
doses	NNS	dose	O	O	NONE
corresponding	VBG	correspond	O	O	NONE
to	TO	to	O	O	NONE
relevant	JJ	relevant	O	O	NONE
plasma	NN	plasma	O	O	NONE
levels	NNS	level	O	O	NONE
in	IN	in	O	O	NONE
humans	NNS	human	O	O	NONE
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
the	DT	the	O	O	NONE
intracellular	JJ	intracellular	O	O	NONE
phosphorylation	NN	phosphorylation	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e0	T	drug
to	TO	to	O	O	NONE
its	PRP$	its	O	O	NONE
three	CD	three	O	O	NONE
metabolites	NNS	metabolite	B-e1	T	drug
(	(	(	O	O	NONE
including	VBG	include	O	O	NONE
the	DT	the	O	O	NONE
active	JJ	active	O	O	NONE
zalcitabine	NN	zalcitabine	B-e2	O	drug
triphosphate	NN	triphosphate	O	O	NONE
metabolite	NN	metabolite	O	O	NONE
)	)	)	O	O	NONE
was	VBD	be	O	O	NONE
significantly	RB	significantly	O	O	NONE
inhibited	VBN	inhibit	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s4
Effects	NNS	effect	O	O	NONE
were	VBD	be	O	O	NONE
already	RB	already	O	O	NONE
seen	VBN	see	O	O	NONE
with	IN	with	O	O	NONE
doses	NNS	dose	O	O	NONE
corresponding	VBG	correspond	O	O	NONE
to	TO	to	O	O	NONE
relevant	JJ	relevant	O	O	NONE
plasma	NN	plasma	O	O	NONE
levels	NNS	level	O	O	NONE
in	IN	in	O	O	NONE
humans	NNS	human	O	O	NONE
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
the	DT	the	O	O	NONE
intracellular	JJ	intracellular	O	O	NONE
phosphorylation	NN	phosphorylation	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e0	T	drug
to	TO	to	O	O	NONE
its	PRP$	its	O	O	NONE
three	CD	three	O	O	NONE
metabolites	NNS	metabolite	B-e1	O	drug
(	(	(	O	O	NONE
including	VBG	include	O	O	NONE
the	DT	the	O	O	NONE
active	JJ	active	O	O	NONE
zalcitabine	NN	zalcitabine	B-e2	T	drug
triphosphate	NN	triphosphate	O	O	NONE
metabolite	NN	metabolite	O	O	NONE
)	)	)	O	O	NONE
was	VBD	be	O	O	NONE
significantly	RB	significantly	O	O	NONE
inhibited	VBN	inhibit	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s4
Effects	NNS	effect	O	O	NONE
were	VBD	be	O	O	NONE
already	RB	already	O	O	NONE
seen	VBN	see	O	O	NONE
with	IN	with	O	O	NONE
doses	NNS	dose	O	O	NONE
corresponding	VBG	correspond	O	O	NONE
to	TO	to	O	O	NONE
relevant	JJ	relevant	O	O	NONE
plasma	NN	plasma	O	O	NONE
levels	NNS	level	O	O	NONE
in	IN	in	O	O	NONE
humans	NNS	human	O	O	NONE
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
the	DT	the	O	O	NONE
intracellular	JJ	intracellular	O	O	NONE
phosphorylation	NN	phosphorylation	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e0	O	drug
to	TO	to	O	O	NONE
its	PRP$	its	O	O	NONE
three	CD	three	O	O	NONE
metabolites	NNS	metabolite	B-e1	T	drug
(	(	(	O	O	NONE
including	VBG	include	O	O	NONE
the	DT	the	O	O	NONE
active	JJ	active	O	O	NONE
zalcitabine	NN	zalcitabine	B-e2	T	drug
triphosphate	NN	triphosphate	O	O	NONE
metabolite	NN	metabolite	O	O	NONE
)	)	)	O	O	NONE
was	VBD	be	O	O	NONE
significantly	RB	significantly	O	O	NONE
inhibited	VBN	inhibit	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s5
Zalcitabine	NN	zalcitabine	B-e0	T	drug
inhibited	VBD	inhibit	O	O	NONE
lamivudine	NN	lamivudine	B-e1	T	drug
phosphorylation	NN	phosphorylation	O	O	NONE
at	IN	at	O	O	NONE
high	JJ	high	O	O	NONE
concentration	NN	concentration	O	O	NONE
ratios	NNS	ratio	O	O	NONE
(	(	(	O	O	NONE
10	CD	10	O	O	NONE
and	CC	and	O	O	NONE
100	CD	100	O	O	NONE
)	)	)	O	O	NONE
;	:	;	O	O	NONE
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d528.s6
however	RB	however	O	O	NONE
,	,	,	O	O	NONE
it	PRP	it	O	O	NONE
is	VBZ	be	O	O	NONE
considered	VBN	consider	O	O	NONE
to	TO	to	O	O	NONE
be	VB	be	O	O	NONE
unlikely	JJ	unlikely	O	O	NONE
that	IN	that	O	O	NONE
this	DT	this	O	O	NONE
decrease	NN	decrease	O	O	NONE
of	IN	of	O	O	NONE
phosphorylated	VBN	phosphorylate	O	O	NONE
lamivudine	NN	lamivudine	B-e0	T	drug
concentration	NN	concentration	O	O	NONE
is	VBZ	be	O	O	NONE
of	IN	of	O	O	NONE
clinical	JJ	clinical	O	O	NONE
significance	NN	significance	O	O	NONE
,	,	,	O	O	NONE
as	IN	as	O	O	NONE
lamivudine	NN	lamivudine	B-e1	T	drug
is	VBZ	be	O	O	NONE
a	DT	a	O	O	NONE
more	RBR	more	O	O	NONE
efficient	JJ	efficient	O	O	NONE
substrate	NN	substrate	O	O	NONE
for	IN	for	O	O	NONE
deoxycytidine	NN	deoxycytidine	B-e2	O	drug
kinase	NN	kinase	I-e2	O	drug
than	IN	than	O	O	NONE
zalcitabine	NN	zalcitabine	B-e3	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s6
however	RB	however	O	O	NONE
,	,	,	O	O	NONE
it	PRP	it	O	O	NONE
is	VBZ	be	O	O	NONE
considered	VBN	consider	O	O	NONE
to	TO	to	O	O	NONE
be	VB	be	O	O	NONE
unlikely	JJ	unlikely	O	O	NONE
that	IN	that	O	O	NONE
this	DT	this	O	O	NONE
decrease	NN	decrease	O	O	NONE
of	IN	of	O	O	NONE
phosphorylated	VBN	phosphorylate	O	O	NONE
lamivudine	NN	lamivudine	B-e0	T	drug
concentration	NN	concentration	O	O	NONE
is	VBZ	be	O	O	NONE
of	IN	of	O	O	NONE
clinical	JJ	clinical	O	O	NONE
significance	NN	significance	O	O	NONE
,	,	,	O	O	NONE
as	IN	as	O	O	NONE
lamivudine	NN	lamivudine	B-e1	O	drug
is	VBZ	be	O	O	NONE
a	DT	a	O	O	NONE
more	RBR	more	O	O	NONE
efficient	JJ	efficient	O	O	NONE
substrate	NN	substrate	O	O	NONE
for	IN	for	O	O	NONE
deoxycytidine	NN	deoxycytidine	B-e2	T	drug
kinase	NN	kinase	I-e2	T	drug
than	IN	than	O	O	NONE
zalcitabine	NN	zalcitabine	B-e3	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s6
however	RB	however	O	O	NONE
,	,	,	O	O	NONE
it	PRP	it	O	O	NONE
is	VBZ	be	O	O	NONE
considered	VBN	consider	O	O	NONE
to	TO	to	O	O	NONE
be	VB	be	O	O	NONE
unlikely	JJ	unlikely	O	O	NONE
that	IN	that	O	O	NONE
this	DT	this	O	O	NONE
decrease	NN	decrease	O	O	NONE
of	IN	of	O	O	NONE
phosphorylated	VBN	phosphorylate	O	O	NONE
lamivudine	NN	lamivudine	B-e0	T	drug
concentration	NN	concentration	O	O	NONE
is	VBZ	be	O	O	NONE
of	IN	of	O	O	NONE
clinical	JJ	clinical	O	O	NONE
significance	NN	significance	O	O	NONE
,	,	,	O	O	NONE
as	IN	as	O	O	NONE
lamivudine	NN	lamivudine	B-e1	O	drug
is	VBZ	be	O	O	NONE
a	DT	a	O	O	NONE
more	RBR	more	O	O	NONE
efficient	JJ	efficient	O	O	NONE
substrate	NN	substrate	O	O	NONE
for	IN	for	O	O	NONE
deoxycytidine	NN	deoxycytidine	B-e2	O	drug
kinase	NN	kinase	I-e2	O	drug
than	IN	than	O	O	NONE
zalcitabine	NN	zalcitabine	B-e3	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s6
however	RB	however	O	O	NONE
,	,	,	O	O	NONE
it	PRP	it	O	O	NONE
is	VBZ	be	O	O	NONE
considered	VBN	consider	O	O	NONE
to	TO	to	O	O	NONE
be	VB	be	O	O	NONE
unlikely	JJ	unlikely	O	O	NONE
that	IN	that	O	O	NONE
this	DT	this	O	O	NONE
decrease	NN	decrease	O	O	NONE
of	IN	of	O	O	NONE
phosphorylated	VBN	phosphorylate	O	O	NONE
lamivudine	NN	lamivudine	B-e0	O	drug
concentration	NN	concentration	O	O	NONE
is	VBZ	be	O	O	NONE
of	IN	of	O	O	NONE
clinical	JJ	clinical	O	O	NONE
significance	NN	significance	O	O	NONE
,	,	,	O	O	NONE
as	IN	as	O	O	NONE
lamivudine	NN	lamivudine	B-e1	T	drug
is	VBZ	be	O	O	NONE
a	DT	a	O	O	NONE
more	RBR	more	O	O	NONE
efficient	JJ	efficient	O	O	NONE
substrate	NN	substrate	O	O	NONE
for	IN	for	O	O	NONE
deoxycytidine	NN	deoxycytidine	B-e2	T	drug
kinase	NN	kinase	I-e2	T	drug
than	IN	than	O	O	NONE
zalcitabine	NN	zalcitabine	B-e3	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s6
however	RB	however	O	O	NONE
,	,	,	O	O	NONE
it	PRP	it	O	O	NONE
is	VBZ	be	O	O	NONE
considered	VBN	consider	O	O	NONE
to	TO	to	O	O	NONE
be	VB	be	O	O	NONE
unlikely	JJ	unlikely	O	O	NONE
that	IN	that	O	O	NONE
this	DT	this	O	O	NONE
decrease	NN	decrease	O	O	NONE
of	IN	of	O	O	NONE
phosphorylated	VBN	phosphorylate	O	O	NONE
lamivudine	NN	lamivudine	B-e0	O	drug
concentration	NN	concentration	O	O	NONE
is	VBZ	be	O	O	NONE
of	IN	of	O	O	NONE
clinical	JJ	clinical	O	O	NONE
significance	NN	significance	O	O	NONE
,	,	,	O	O	NONE
as	IN	as	O	O	NONE
lamivudine	NN	lamivudine	B-e1	T	drug
is	VBZ	be	O	O	NONE
a	DT	a	O	O	NONE
more	RBR	more	O	O	NONE
efficient	JJ	efficient	O	O	NONE
substrate	NN	substrate	O	O	NONE
for	IN	for	O	O	NONE
deoxycytidine	NN	deoxycytidine	B-e2	O	drug
kinase	NN	kinase	I-e2	O	drug
than	IN	than	O	O	NONE
zalcitabine	NN	zalcitabine	B-e3	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s6
however	RB	however	O	O	NONE
,	,	,	O	O	NONE
it	PRP	it	O	O	NONE
is	VBZ	be	O	O	NONE
considered	VBN	consider	O	O	NONE
to	TO	to	O	O	NONE
be	VB	be	O	O	NONE
unlikely	JJ	unlikely	O	O	NONE
that	IN	that	O	O	NONE
this	DT	this	O	O	NONE
decrease	NN	decrease	O	O	NONE
of	IN	of	O	O	NONE
phosphorylated	VBN	phosphorylate	O	O	NONE
lamivudine	NN	lamivudine	B-e0	O	drug
concentration	NN	concentration	O	O	NONE
is	VBZ	be	O	O	NONE
of	IN	of	O	O	NONE
clinical	JJ	clinical	O	O	NONE
significance	NN	significance	O	O	NONE
,	,	,	O	O	NONE
as	IN	as	O	O	NONE
lamivudine	NN	lamivudine	B-e1	O	drug
is	VBZ	be	O	O	NONE
a	DT	a	O	O	NONE
more	RBR	more	O	O	NONE
efficient	JJ	efficient	O	O	NONE
substrate	NN	substrate	O	O	NONE
for	IN	for	O	O	NONE
deoxycytidine	NN	deoxycytidine	B-e2	T	drug
kinase	NN	kinase	I-e2	T	drug
than	IN	than	O	O	NONE
zalcitabine	NN	zalcitabine	B-e3	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s7
These	DT	these	O	O	NONE
in	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
studies	NNS	study	O	O	NONE
suggest	VBP	suggest	O	O	NONE
that	IN	that	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e0	T	drug
and	CC	and	O	O	NONE
lamivudine	NN	lamivudine	B-e1	T	drug
in	IN	in	O	O	NONE
humans	NNS	human	O	O	NONE
may	MD	may	O	O	NONE
result	VB	result	O	O	NONE
in	IN	in	O	O	NONE
sub-therapeutic	JJ	sub-therapeutic	O	O	NONE
concentrations	NNS	concentration	O	O	NONE
of	IN	of	O	O	NONE
active	JJ	active	O	O	NONE
phosphorylated	JJ	phosphorylated	O	O	NONE
zalcitabine	NN	zalcitabine	B-e2	O	drug
,	,	,	O	O	NONE
which	WDT	which	O	O	NONE
may	MD	may	O	O	NONE
lead	VB	lead	O	O	NONE
to	TO	to	O	O	NONE
a	DT	a	O	O	NONE
decreased	VBN	decrease	O	O	NONE
antiretroviral	JJ	antiretroviral	O	O	NONE
effect	NN	effect	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e3	O	drug
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d528.s7
These	DT	these	O	O	NONE
in	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
studies	NNS	study	O	O	NONE
suggest	VBP	suggest	O	O	NONE
that	IN	that	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e0	T	drug
and	CC	and	O	O	NONE
lamivudine	NN	lamivudine	B-e1	O	drug
in	IN	in	O	O	NONE
humans	NNS	human	O	O	NONE
may	MD	may	O	O	NONE
result	VB	result	O	O	NONE
in	IN	in	O	O	NONE
sub-therapeutic	JJ	sub-therapeutic	O	O	NONE
concentrations	NNS	concentration	O	O	NONE
of	IN	of	O	O	NONE
active	JJ	active	O	O	NONE
phosphorylated	JJ	phosphorylated	O	O	NONE
zalcitabine	NN	zalcitabine	B-e2	T	drug
,	,	,	O	O	NONE
which	WDT	which	O	O	NONE
may	MD	may	O	O	NONE
lead	VB	lead	O	O	NONE
to	TO	to	O	O	NONE
a	DT	a	O	O	NONE
decreased	VBN	decrease	O	O	NONE
antiretroviral	JJ	antiretroviral	O	O	NONE
effect	NN	effect	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e3	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s7
These	DT	these	O	O	NONE
in	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
studies	NNS	study	O	O	NONE
suggest	VBP	suggest	O	O	NONE
that	IN	that	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e0	T	drug
and	CC	and	O	O	NONE
lamivudine	NN	lamivudine	B-e1	O	drug
in	IN	in	O	O	NONE
humans	NNS	human	O	O	NONE
may	MD	may	O	O	NONE
result	VB	result	O	O	NONE
in	IN	in	O	O	NONE
sub-therapeutic	JJ	sub-therapeutic	O	O	NONE
concentrations	NNS	concentration	O	O	NONE
of	IN	of	O	O	NONE
active	JJ	active	O	O	NONE
phosphorylated	JJ	phosphorylated	O	O	NONE
zalcitabine	NN	zalcitabine	B-e2	O	drug
,	,	,	O	O	NONE
which	WDT	which	O	O	NONE
may	MD	may	O	O	NONE
lead	VB	lead	O	O	NONE
to	TO	to	O	O	NONE
a	DT	a	O	O	NONE
decreased	VBN	decrease	O	O	NONE
antiretroviral	JJ	antiretroviral	O	O	NONE
effect	NN	effect	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e3	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s7
These	DT	these	O	O	NONE
in	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
studies	NNS	study	O	O	NONE
suggest	VBP	suggest	O	O	NONE
that	IN	that	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e0	O	drug
and	CC	and	O	O	NONE
lamivudine	NN	lamivudine	B-e1	T	drug
in	IN	in	O	O	NONE
humans	NNS	human	O	O	NONE
may	MD	may	O	O	NONE
result	VB	result	O	O	NONE
in	IN	in	O	O	NONE
sub-therapeutic	JJ	sub-therapeutic	O	O	NONE
concentrations	NNS	concentration	O	O	NONE
of	IN	of	O	O	NONE
active	JJ	active	O	O	NONE
phosphorylated	JJ	phosphorylated	O	O	NONE
zalcitabine	NN	zalcitabine	B-e2	T	drug
,	,	,	O	O	NONE
which	WDT	which	O	O	NONE
may	MD	may	O	O	NONE
lead	VB	lead	O	O	NONE
to	TO	to	O	O	NONE
a	DT	a	O	O	NONE
decreased	VBN	decrease	O	O	NONE
antiretroviral	JJ	antiretroviral	O	O	NONE
effect	NN	effect	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e3	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s7
These	DT	these	O	O	NONE
in	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
studies	NNS	study	O	O	NONE
suggest	VBP	suggest	O	O	NONE
that	IN	that	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e0	O	drug
and	CC	and	O	O	NONE
lamivudine	NN	lamivudine	B-e1	T	drug
in	IN	in	O	O	NONE
humans	NNS	human	O	O	NONE
may	MD	may	O	O	NONE
result	VB	result	O	O	NONE
in	IN	in	O	O	NONE
sub-therapeutic	JJ	sub-therapeutic	O	O	NONE
concentrations	NNS	concentration	O	O	NONE
of	IN	of	O	O	NONE
active	JJ	active	O	O	NONE
phosphorylated	JJ	phosphorylated	O	O	NONE
zalcitabine	NN	zalcitabine	B-e2	O	drug
,	,	,	O	O	NONE
which	WDT	which	O	O	NONE
may	MD	may	O	O	NONE
lead	VB	lead	O	O	NONE
to	TO	to	O	O	NONE
a	DT	a	O	O	NONE
decreased	VBN	decrease	O	O	NONE
antiretroviral	JJ	antiretroviral	O	O	NONE
effect	NN	effect	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e3	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s7
These	DT	these	O	O	NONE
in	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
studies	NNS	study	O	O	NONE
suggest	VBP	suggest	O	O	NONE
that	IN	that	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e0	O	drug
and	CC	and	O	O	NONE
lamivudine	NN	lamivudine	B-e1	O	drug
in	IN	in	O	O	NONE
humans	NNS	human	O	O	NONE
may	MD	may	O	O	NONE
result	VB	result	O	O	NONE
in	IN	in	O	O	NONE
sub-therapeutic	JJ	sub-therapeutic	O	O	NONE
concentrations	NNS	concentration	O	O	NONE
of	IN	of	O	O	NONE
active	JJ	active	O	O	NONE
phosphorylated	JJ	phosphorylated	O	O	NONE
zalcitabine	NN	zalcitabine	B-e2	T	drug
,	,	,	O	O	NONE
which	WDT	which	O	O	NONE
may	MD	may	O	O	NONE
lead	VB	lead	O	O	NONE
to	TO	to	O	O	NONE
a	DT	a	O	O	NONE
decreased	VBN	decrease	O	O	NONE
antiretroviral	JJ	antiretroviral	O	O	NONE
effect	NN	effect	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e3	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s9
Concomitant	JJ	concomitant	O	O	NONE
use	NN	use	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e0	T	drug
and	CC	and	O	O	NONE
lamivudine	NN	lamivudine	B-e1	T	drug
is	VBZ	be	O	O	NONE
not	RB	not	O	O	NONE
recommended	VBN	recommend	O	O	NONE
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d528.s10
Saquinavir	NN	saquinavir	B-e0	T	drug
:	:	:	O	O	NONE
The	DT	the	O	O	NONE
combination	NN	combination	O	O	NONE
of	IN	of	O	O	NONE
HIVID	NN	hivid	B-e1	T	drug
,	,	,	O	O	NONE
saquinavir	NN	saquinavir	B-e2	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
ZDV	NN	zdv	B-e3	O	drug
has	VBZ	have	O	O	NONE
been	VBN	be	O	O	NONE
studied	VBN	study	O	O	NONE
(	(	(	O	O	NONE
as	IN	as	O	O	NONE
triple	JJ	triple	O	O	NONE
combination	NN	combination	O	O	NONE
)	)	)	O	O	NONE
in	IN	in	O	O	NONE
adults	NNS	adult	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s10
Saquinavir	NN	saquinavir	B-e0	T	drug
:	:	:	O	O	NONE
The	DT	the	O	O	NONE
combination	NN	combination	O	O	NONE
of	IN	of	O	O	NONE
HIVID	NN	hivid	B-e1	O	drug
,	,	,	O	O	NONE
saquinavir	NN	saquinavir	B-e2	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
ZDV	NN	zdv	B-e3	O	drug
has	VBZ	have	O	O	NONE
been	VBN	be	O	O	NONE
studied	VBN	study	O	O	NONE
(	(	(	O	O	NONE
as	IN	as	O	O	NONE
triple	JJ	triple	O	O	NONE
combination	NN	combination	O	O	NONE
)	)	)	O	O	NONE
in	IN	in	O	O	NONE
adults	NNS	adult	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s10
Saquinavir	NN	saquinavir	B-e0	T	drug
:	:	:	O	O	NONE
The	DT	the	O	O	NONE
combination	NN	combination	O	O	NONE
of	IN	of	O	O	NONE
HIVID	NN	hivid	B-e1	O	drug
,	,	,	O	O	NONE
saquinavir	NN	saquinavir	B-e2	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
ZDV	NN	zdv	B-e3	T	drug
has	VBZ	have	O	O	NONE
been	VBN	be	O	O	NONE
studied	VBN	study	O	O	NONE
(	(	(	O	O	NONE
as	IN	as	O	O	NONE
triple	JJ	triple	O	O	NONE
combination	NN	combination	O	O	NONE
)	)	)	O	O	NONE
in	IN	in	O	O	NONE
adults	NNS	adult	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s10
Saquinavir	NN	saquinavir	B-e0	O	drug
:	:	:	O	O	NONE
The	DT	the	O	O	NONE
combination	NN	combination	O	O	NONE
of	IN	of	O	O	NONE
HIVID	NN	hivid	B-e1	T	drug
,	,	,	O	O	NONE
saquinavir	NN	saquinavir	B-e2	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
ZDV	NN	zdv	B-e3	O	drug
has	VBZ	have	O	O	NONE
been	VBN	be	O	O	NONE
studied	VBN	study	O	O	NONE
(	(	(	O	O	NONE
as	IN	as	O	O	NONE
triple	JJ	triple	O	O	NONE
combination	NN	combination	O	O	NONE
)	)	)	O	O	NONE
in	IN	in	O	O	NONE
adults	NNS	adult	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s10
Saquinavir	NN	saquinavir	B-e0	O	drug
:	:	:	O	O	NONE
The	DT	the	O	O	NONE
combination	NN	combination	O	O	NONE
of	IN	of	O	O	NONE
HIVID	NN	hivid	B-e1	T	drug
,	,	,	O	O	NONE
saquinavir	NN	saquinavir	B-e2	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
ZDV	NN	zdv	B-e3	T	drug
has	VBZ	have	O	O	NONE
been	VBN	be	O	O	NONE
studied	VBN	study	O	O	NONE
(	(	(	O	O	NONE
as	IN	as	O	O	NONE
triple	JJ	triple	O	O	NONE
combination	NN	combination	O	O	NONE
)	)	)	O	O	NONE
in	IN	in	O	O	NONE
adults	NNS	adult	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s10
Saquinavir	NN	saquinavir	B-e0	O	drug
:	:	:	O	O	NONE
The	DT	the	O	O	NONE
combination	NN	combination	O	O	NONE
of	IN	of	O	O	NONE
HIVID	NN	hivid	B-e1	O	drug
,	,	,	O	O	NONE
saquinavir	NN	saquinavir	B-e2	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
ZDV	NN	zdv	B-e3	T	drug
has	VBZ	have	O	O	NONE
been	VBN	be	O	O	NONE
studied	VBN	study	O	O	NONE
(	(	(	O	O	NONE
as	IN	as	O	O	NONE
triple	JJ	triple	O	O	NONE
combination	NN	combination	O	O	NONE
)	)	)	O	O	NONE
in	IN	in	O	O	NONE
adults	NNS	adult	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s12
Drugs	NNS	drug	B-e0	T	drug
Associated	VBN	associate	O	O	NONE
With	IN	with	O	O	NONE
Peripheral	JJ	peripheral	B-e1	O	DISO
Neuropathy	NN	neuropathy	I-e1	O	DISO
:	:	:	O	O	NONE
The	DT	the	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
use	NN	use	O	O	NONE
of	IN	of	O	O	NONE
HIVID	NN	hivid	B-e2	T	drug
with	IN	with	O	O	NONE
drugs	NNS	drug	B-e3	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
the	DT	the	O	O	NONE
potential	NN	potential	O	O	NONE
to	TO	to	O	O	NONE
cause	VB	cause	O	O	NONE
peripheral	JJ	peripheral	O	O	NONE
neuropathy	NN	neuropathy	B-e4	O	DISO
should	MD	should	O	O	NONE
be	VB	be	O	O	NONE
avoided	VBN	avoid	O	O	NONE
where	WRB	where	O	O	NONE
possible	JJ	possible	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s12
Drugs	NNS	drug	B-e0	T	drug
Associated	VBN	associate	O	O	NONE
With	IN	with	O	O	NONE
Peripheral	JJ	peripheral	B-e1	O	DISO
Neuropathy	NN	neuropathy	I-e1	O	DISO
:	:	:	O	O	NONE
The	DT	the	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
use	NN	use	O	O	NONE
of	IN	of	O	O	NONE
HIVID	NN	hivid	B-e2	O	drug
with	IN	with	O	O	NONE
drugs	NNS	drug	B-e3	T	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
the	DT	the	O	O	NONE
potential	NN	potential	O	O	NONE
to	TO	to	O	O	NONE
cause	VB	cause	O	O	NONE
peripheral	JJ	peripheral	O	O	NONE
neuropathy	NN	neuropathy	B-e4	O	DISO
should	MD	should	O	O	NONE
be	VB	be	O	O	NONE
avoided	VBN	avoid	O	O	NONE
where	WRB	where	O	O	NONE
possible	JJ	possible	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s12
Drugs	NNS	drug	B-e0	O	drug
Associated	VBN	associate	O	O	NONE
With	IN	with	O	O	NONE
Peripheral	JJ	peripheral	B-e1	O	DISO
Neuropathy	NN	neuropathy	I-e1	O	DISO
:	:	:	O	O	NONE
The	DT	the	O	O	NONE
concomitant	JJ	concomitant	O	O	NONE
use	NN	use	O	O	NONE
of	IN	of	O	O	NONE
HIVID	NN	hivid	B-e2	T	drug
with	IN	with	O	O	NONE
drugs	NNS	drug	B-e3	T	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
the	DT	the	O	O	NONE
potential	NN	potential	O	O	NONE
to	TO	to	O	O	NONE
cause	VB	cause	O	O	NONE
peripheral	JJ	peripheral	O	O	NONE
neuropathy	NN	neuropathy	B-e4	O	DISO
should	MD	should	O	O	NONE
be	VB	be	O	O	NONE
avoided	VBN	avoid	O	O	NONE
where	WRB	where	O	O	NONE
possible	JJ	possible	O	O	NONE
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	T	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	T	drug
nucleoside	NN	nucleoside	I-e2	T	drug
analogues	NNS	analogue	I-e2	T	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	T	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	T	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	T	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	T	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	T	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	T	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	T	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	T	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	T	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	T	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	T	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	T	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	T	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	T	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	T	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	T	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	T	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	T	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	T	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	T	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	T	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	T	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	T	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	T	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	T	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	T	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	T	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	T	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	T	drug
nucleoside	NN	nucleoside	I-e2	T	drug
analogues	NNS	analogue	I-e2	T	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	T	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	T	drug
nucleoside	NN	nucleoside	I-e2	T	drug
analogues	NNS	analogue	I-e2	T	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	T	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	T	drug
nucleoside	NN	nucleoside	I-e2	T	drug
analogues	NNS	analogue	I-e2	T	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	T	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	T	drug
nucleoside	NN	nucleoside	I-e2	T	drug
analogues	NNS	analogue	I-e2	T	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	T	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	T	drug
nucleoside	NN	nucleoside	I-e2	T	drug
analogues	NNS	analogue	I-e2	T	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	T	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	T	drug
nucleoside	NN	nucleoside	I-e2	T	drug
analogues	NNS	analogue	I-e2	T	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	T	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	T	drug
nucleoside	NN	nucleoside	I-e2	T	drug
analogues	NNS	analogue	I-e2	T	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	T	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	T	drug
nucleoside	NN	nucleoside	I-e2	T	drug
analogues	NNS	analogue	I-e2	T	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	T	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	T	drug
nucleoside	NN	nucleoside	I-e2	T	drug
analogues	NNS	analogue	I-e2	T	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	T	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	T	drug
nucleoside	NN	nucleoside	I-e2	T	drug
analogues	NNS	analogue	I-e2	T	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	T	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	T	drug
nucleoside	NN	nucleoside	I-e2	T	drug
analogues	NNS	analogue	I-e2	T	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	T	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	T	drug
nucleoside	NN	nucleoside	I-e2	T	drug
analogues	NNS	analogue	I-e2	T	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	T	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	T	drug
nucleoside	NN	nucleoside	I-e2	T	drug
analogues	NNS	analogue	I-e2	T	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	T	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	T	drug
nucleoside	NN	nucleoside	I-e2	T	drug
analogues	NNS	analogue	I-e2	T	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	T	drug
nucleoside	NN	nucleoside	I-e2	T	drug
analogues	NNS	analogue	I-e2	T	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	T	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	T	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	T	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	T	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	T	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	T	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	T	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	T	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	T	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	T	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	T	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	T	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	T	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	T	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	T	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	T	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	T	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	T	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	T	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	T	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	T	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	T	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	T	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	T	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	T	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	T	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	T	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	T	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	T	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	T	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	T	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	T	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	T	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	T	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	T	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	T	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	T	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	T	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	T	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	T	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	T	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	T	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	T	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	T	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	T	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	T	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	T	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	T	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	T	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	T	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	T	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	T	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	T	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	T	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	T	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	T	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	T	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	T	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	T	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	T	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	T	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	T	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	T	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	T	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	T	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	T	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	T	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	T	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	T	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	T	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	T	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	T	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	T	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	T	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	T	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	T	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	T	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	T	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	T	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	T	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	T	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	T	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	T	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	T	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	T	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	T	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	T	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	T	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	T	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	T	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	T	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	T	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	T	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	T	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	T	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	T	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	T	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	T	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	T	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	T	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	T	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	T	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	T	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	T	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	T	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	T	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	T	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	T	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	T	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	T	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	T	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	T	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	T	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	T	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	T	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	T	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	T	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	T	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	T	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	T	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	T	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	T	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	T	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	T	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	T	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	T	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	T	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	T	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	T	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	T	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	T	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	T	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	T	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	T	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	T	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	T	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	T	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	T	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	T	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	T	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	T	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	T	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	T	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	T	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	T	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	T	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	T	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	T	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	T	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	T	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	T	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	T	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	T	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	T	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	T	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	T	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	T	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	T	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	T	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	T	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	T	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	T	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	T	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	T	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	T	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	T	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	T	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	T	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	T	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	T	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	T	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	T	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	T	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	T	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	T	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	T	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	T	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	T	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	T	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	T	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	T	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	T	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s13
Drugs	NNS	drug	B-e0	O	drug
that	WDT	that	O	O	NONE
have	VBP	have	O	O	NONE
been	VBN	be	O	O	NONE
associated	VBN	associate	O	O	NONE
with	IN	with	O	O	NONE
peripheral	JJ	peripheral	B-e1	O	DISO
neuropathy	NN	neuropathy	I-e1	O	DISO
include	VBP	include	O	O	NONE
antiretroviral	JJ	antiretroviral	B-e2	O	drug
nucleoside	NN	nucleoside	I-e2	O	drug
analogues	NNS	analogue	I-e2	O	drug
,	,	,	O	O	NONE
chloramphenicol	NN	chloramphenicol	B-e3	O	drug
,	,	,	O	O	NONE
cisplatin	NN	cisplatin	B-e4	O	drug
,	,	,	O	O	NONE
dapsone	NN	dapsone	B-e5	O	drug
,	,	,	O	O	NONE
disulfiram	NN	disulfiram	B-e6	O	drug
,	,	,	O	O	NONE
ethionamide	NN	ethionamide	B-e7	O	drug
,	,	,	O	O	NONE
glutethimide	NN	glutethimide	B-e8	O	drug
,	,	,	O	O	NONE
gold	NN	gold	B-e9	O	drug
,	,	,	O	O	NONE
hydralazine	NN	hydralazine	B-e10	O	drug
,	,	,	O	O	NONE
iodoquinol	NN	iodoquinol	B-e11	O	drug
,	,	,	O	O	NONE
isoniazid	NN	isoniazid	B-e12	O	drug
,	,	,	O	O	NONE
metronidazole	NN	metronidazole	B-e13	O	drug
,	,	,	O	O	NONE
nitrofurantoin	NN	nitrofurantoin	B-e14	O	drug
,	,	,	O	O	NONE
phenytoin	NN	phenytoin	B-e15	O	drug
,	,	,	O	O	NONE
ribavirin	NN	ribavirin	B-e16	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
vincristine	NN	vincristine	B-e17	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s14
Concomitant	JJ	concomitant	O	O	NONE
use	NN	use	O	O	NONE
of	IN	of	O	O	NONE
HIVID	NN	hivid	B-e0	T	drug
with	IN	with	O	O	NONE
didanosine	NN	didanosine	B-e1	T	drug
is	VBZ	be	O	O	NONE
not	RB	not	O	O	NONE
recommended	VBN	recommend	O	O	NONE
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d528.s15
Intravenous	JJ	intravenous	O	O	NONE
Pentamidin	NN	pentamidin	B-e0	T	drug
e	NN	e	O	O	NONE
:	:	:	O	O	NONE
Treatment	NN	treatment	O	O	NONE
with	IN	with	O	O	NONE
HIVID	NN	hivid	B-e1	T	drug
should	MD	should	O	O	NONE
be	VB	be	O	O	NONE
interrupted	VBN	interrupt	O	O	NONE
when	WRB	when	O	O	NONE
the	DT	the	O	O	NONE
use	NN	use	O	O	NONE
of	IN	of	O	O	NONE
a	DT	a	O	O	NONE
drug	NN	drug	B-e2	O	drug
that	WDT	that	O	O	NONE
has	VBZ	have	O	O	NONE
the	DT	the	O	O	NONE
potential	NN	potential	O	O	NONE
to	TO	to	O	O	NONE
cause	VB	cause	O	O	NONE
pancreatitis	NN	pancreatitis	B-e3	O	DISO
is	VBZ	be	O	O	NONE
required	VBN	require	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s15
Intravenous	JJ	intravenous	O	O	NONE
Pentamidin	NN	pentamidin	B-e0	T	drug
e	NN	e	O	O	NONE
:	:	:	O	O	NONE
Treatment	NN	treatment	O	O	NONE
with	IN	with	O	O	NONE
HIVID	NN	hivid	B-e1	O	drug
should	MD	should	O	O	NONE
be	VB	be	O	O	NONE
interrupted	VBN	interrupt	O	O	NONE
when	WRB	when	O	O	NONE
the	DT	the	O	O	NONE
use	NN	use	O	O	NONE
of	IN	of	O	O	NONE
a	DT	a	O	O	NONE
drug	NN	drug	B-e2	T	drug
that	WDT	that	O	O	NONE
has	VBZ	have	O	O	NONE
the	DT	the	O	O	NONE
potential	NN	potential	O	O	NONE
to	TO	to	O	O	NONE
cause	VB	cause	O	O	NONE
pancreatitis	NN	pancreatitis	B-e3	O	DISO
is	VBZ	be	O	O	NONE
required	VBN	require	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s15
Intravenous	JJ	intravenous	O	O	NONE
Pentamidin	NN	pentamidin	B-e0	O	drug
e	NN	e	O	O	NONE
:	:	:	O	O	NONE
Treatment	NN	treatment	O	O	NONE
with	IN	with	O	O	NONE
HIVID	NN	hivid	B-e1	T	drug
should	MD	should	O	O	NONE
be	VB	be	O	O	NONE
interrupted	VBN	interrupt	O	O	NONE
when	WRB	when	O	O	NONE
the	DT	the	O	O	NONE
use	NN	use	O	O	NONE
of	IN	of	O	O	NONE
a	DT	a	O	O	NONE
drug	NN	drug	B-e2	T	drug
that	WDT	that	O	O	NONE
has	VBZ	have	O	O	NONE
the	DT	the	O	O	NONE
potential	NN	potential	O	O	NONE
to	TO	to	O	O	NONE
cause	VB	cause	O	O	NONE
pancreatitis	NN	pancreatitis	B-e3	O	DISO
is	VBZ	be	O	O	NONE
required	VBN	require	O	O	NONE
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d528.s16
Death	NN	death	O	O	NONE
due	IN	due	O	O	NONE
to	TO	to	O	O	NONE
fulminant	JJ	fulminant	O	O	NONE
pancreatitis	NN	pancreatitis	B-e0	O	DISO
possibly	RB	possibly	O	O	NONE
related	JJ	related	O	O	NONE
to	TO	to	O	O	NONE
intravenous	JJ	intravenous	O	O	NONE
pentamidin	NN	pentamidin	B-e1	T	drug
e	NN	e	O	O	NONE
and	CC	and	O	O	NONE
HIVID	NN	hivid	B-e2	T	drug
has	VBZ	have	O	O	NONE
been	VBN	be	O	O	NONE
reported	VBN	report	O	O	NONE
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d528.s17
If	IN	if	O	O	NONE
intravenous	JJ	intravenous	O	O	NONE
pentamidin	NN	pentamidin	B-e0	T	drug
e	NN	e	O	O	NONE
is	VBZ	be	O	O	NONE
required	VBN	require	O	O	NONE
to	TO	to	O	O	NONE
treat	VB	treat	O	O	NONE
Pneumocystis	NN	pneumocystis	B-e1	O	DISO
carinii	NN	carinius	I-e1	O	DISO
pneumonia	NNS	pneumonia	I-e1	O	DISO
,	,	,	O	O	NONE
treatment	NN	treatment	O	O	NONE
with	IN	with	O	O	NONE
HIVID	NN	hivid	B-e2	T	drug
should	MD	should	O	O	NONE
be	VB	be	O	O	NONE
interrupted	VBN	interrupt	O	O	NONE
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d528.s18
Amphotericin	NN	amphotericin	B-e0	T	drug
,	,	,	O	O	NONE
Foscarnet	NN	foscarnet	B-e1	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
Aminoglycosides	NN	aminoglycoside	B-e2	O	drug
:	:	:	O	O	NONE
Drugs	NNS	drug	B-e3	O	drug
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
amphotericin	NN	amphotericin	B-e4	O	drug
,	,	,	O	O	NONE
foscarnet	NN	foscarnet	B-e5	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
aminoglycosides	NNS	aminoglycoside	B-e6	O	drug
may	MD	may	O	O	NONE
increase	VB	increase	O	O	NONE
the	DT	the	O	O	NONE
risk	NN	risk	O	O	NONE
of	IN	of	O	O	NONE
developing	VBG	develop	O	O	NONE
peripheral	JJ	peripheral	B-e7	O	DISO
neuropathy	NN	neuropathy	I-e7	O	DISO
or	CC	or	O	O	NONE
other	JJ	other	O	O	NONE
HIVID	NN	hivid	B-e8	O	drug
-associated	JJ	-associated	O	O	NONE
adverse	JJ	adverse	O	O	NONE
events	NNS	event	O	O	NONE
by	IN	by	O	O	NONE
interfering	VBG	interfere	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
renal	JJ	renal	O	O	NONE
clearance	NN	clearance	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e9	O	drug
(	(	(	O	O	NONE
thereby	RB	thereby	O	O	NONE
raising	VBG	raise	O	O	NONE
systemic	JJ	systemic	O	O	NONE
exposure	NN	exposure	O	O	NONE
).	NN	).	O	O	NONE

NO

Sentence: DrugDDI.d528.s18
Amphotericin	NN	amphotericin	B-e0	T	drug
,	,	,	O	O	NONE
Foscarnet	NN	foscarnet	B-e1	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
Aminoglycosides	NN	aminoglycoside	B-e2	T	drug
:	:	:	O	O	NONE
Drugs	NNS	drug	B-e3	O	drug
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
amphotericin	NN	amphotericin	B-e4	O	drug
,	,	,	O	O	NONE
foscarnet	NN	foscarnet	B-e5	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
aminoglycosides	NNS	aminoglycoside	B-e6	O	drug
may	MD	may	O	O	NONE
increase	VB	increase	O	O	NONE
the	DT	the	O	O	NONE
risk	NN	risk	O	O	NONE
of	IN	of	O	O	NONE
developing	VBG	develop	O	O	NONE
peripheral	JJ	peripheral	B-e7	O	DISO
neuropathy	NN	neuropathy	I-e7	O	DISO
or	CC	or	O	O	NONE
other	JJ	other	O	O	NONE
HIVID	NN	hivid	B-e8	O	drug
-associated	JJ	-associated	O	O	NONE
adverse	JJ	adverse	O	O	NONE
events	NNS	event	O	O	NONE
by	IN	by	O	O	NONE
interfering	VBG	interfere	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
renal	JJ	renal	O	O	NONE
clearance	NN	clearance	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e9	O	drug
(	(	(	O	O	NONE
thereby	RB	thereby	O	O	NONE
raising	VBG	raise	O	O	NONE
systemic	JJ	systemic	O	O	NONE
exposure	NN	exposure	O	O	NONE
).	NN	).	O	O	NONE

NO

Sentence: DrugDDI.d528.s18
Amphotericin	NN	amphotericin	B-e0	T	drug
,	,	,	O	O	NONE
Foscarnet	NN	foscarnet	B-e1	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
Aminoglycosides	NN	aminoglycoside	B-e2	O	drug
:	:	:	O	O	NONE
Drugs	NNS	drug	B-e3	T	drug
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
amphotericin	NN	amphotericin	B-e4	O	drug
,	,	,	O	O	NONE
foscarnet	NN	foscarnet	B-e5	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
aminoglycosides	NNS	aminoglycoside	B-e6	O	drug
may	MD	may	O	O	NONE
increase	VB	increase	O	O	NONE
the	DT	the	O	O	NONE
risk	NN	risk	O	O	NONE
of	IN	of	O	O	NONE
developing	VBG	develop	O	O	NONE
peripheral	JJ	peripheral	B-e7	O	DISO
neuropathy	NN	neuropathy	I-e7	O	DISO
or	CC	or	O	O	NONE
other	JJ	other	O	O	NONE
HIVID	NN	hivid	B-e8	O	drug
-associated	JJ	-associated	O	O	NONE
adverse	JJ	adverse	O	O	NONE
events	NNS	event	O	O	NONE
by	IN	by	O	O	NONE
interfering	VBG	interfere	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
renal	JJ	renal	O	O	NONE
clearance	NN	clearance	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e9	O	drug
(	(	(	O	O	NONE
thereby	RB	thereby	O	O	NONE
raising	VBG	raise	O	O	NONE
systemic	JJ	systemic	O	O	NONE
exposure	NN	exposure	O	O	NONE
).	NN	).	O	O	NONE

NO

Sentence: DrugDDI.d528.s18
Amphotericin	NN	amphotericin	B-e0	T	drug
,	,	,	O	O	NONE
Foscarnet	NN	foscarnet	B-e1	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
Aminoglycosides	NN	aminoglycoside	B-e2	O	drug
:	:	:	O	O	NONE
Drugs	NNS	drug	B-e3	O	drug
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
amphotericin	NN	amphotericin	B-e4	T	drug
,	,	,	O	O	NONE
foscarnet	NN	foscarnet	B-e5	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
aminoglycosides	NNS	aminoglycoside	B-e6	O	drug
may	MD	may	O	O	NONE
increase	VB	increase	O	O	NONE
the	DT	the	O	O	NONE
risk	NN	risk	O	O	NONE
of	IN	of	O	O	NONE
developing	VBG	develop	O	O	NONE
peripheral	JJ	peripheral	B-e7	O	DISO
neuropathy	NN	neuropathy	I-e7	O	DISO
or	CC	or	O	O	NONE
other	JJ	other	O	O	NONE
HIVID	NN	hivid	B-e8	O	drug
-associated	JJ	-associated	O	O	NONE
adverse	JJ	adverse	O	O	NONE
events	NNS	event	O	O	NONE
by	IN	by	O	O	NONE
interfering	VBG	interfere	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
renal	JJ	renal	O	O	NONE
clearance	NN	clearance	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e9	O	drug
(	(	(	O	O	NONE
thereby	RB	thereby	O	O	NONE
raising	VBG	raise	O	O	NONE
systemic	JJ	systemic	O	O	NONE
exposure	NN	exposure	O	O	NONE
).	NN	).	O	O	NONE

NO

Sentence: DrugDDI.d528.s18
Amphotericin	NN	amphotericin	B-e0	T	drug
,	,	,	O	O	NONE
Foscarnet	NN	foscarnet	B-e1	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
Aminoglycosides	NN	aminoglycoside	B-e2	O	drug
:	:	:	O	O	NONE
Drugs	NNS	drug	B-e3	O	drug
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
amphotericin	NN	amphotericin	B-e4	O	drug
,	,	,	O	O	NONE
foscarnet	NN	foscarnet	B-e5	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
aminoglycosides	NNS	aminoglycoside	B-e6	O	drug
may	MD	may	O	O	NONE
increase	VB	increase	O	O	NONE
the	DT	the	O	O	NONE
risk	NN	risk	O	O	NONE
of	IN	of	O	O	NONE
developing	VBG	develop	O	O	NONE
peripheral	JJ	peripheral	B-e7	O	DISO
neuropathy	NN	neuropathy	I-e7	O	DISO
or	CC	or	O	O	NONE
other	JJ	other	O	O	NONE
HIVID	NN	hivid	B-e8	O	drug
-associated	JJ	-associated	O	O	NONE
adverse	JJ	adverse	O	O	NONE
events	NNS	event	O	O	NONE
by	IN	by	O	O	NONE
interfering	VBG	interfere	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
renal	JJ	renal	O	O	NONE
clearance	NN	clearance	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e9	O	drug
(	(	(	O	O	NONE
thereby	RB	thereby	O	O	NONE
raising	VBG	raise	O	O	NONE
systemic	JJ	systemic	O	O	NONE
exposure	NN	exposure	O	O	NONE
).	NN	).	O	O	NONE

NO

Sentence: DrugDDI.d528.s18
Amphotericin	NN	amphotericin	B-e0	T	drug
,	,	,	O	O	NONE
Foscarnet	NN	foscarnet	B-e1	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
Aminoglycosides	NN	aminoglycoside	B-e2	O	drug
:	:	:	O	O	NONE
Drugs	NNS	drug	B-e3	O	drug
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
amphotericin	NN	amphotericin	B-e4	O	drug
,	,	,	O	O	NONE
foscarnet	NN	foscarnet	B-e5	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
aminoglycosides	NNS	aminoglycoside	B-e6	T	drug
may	MD	may	O	O	NONE
increase	VB	increase	O	O	NONE
the	DT	the	O	O	NONE
risk	NN	risk	O	O	NONE
of	IN	of	O	O	NONE
developing	VBG	develop	O	O	NONE
peripheral	JJ	peripheral	B-e7	O	DISO
neuropathy	NN	neuropathy	I-e7	O	DISO
or	CC	or	O	O	NONE
other	JJ	other	O	O	NONE
HIVID	NN	hivid	B-e8	O	drug
-associated	JJ	-associated	O	O	NONE
adverse	JJ	adverse	O	O	NONE
events	NNS	event	O	O	NONE
by	IN	by	O	O	NONE
interfering	VBG	interfere	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
renal	JJ	renal	O	O	NONE
clearance	NN	clearance	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e9	O	drug
(	(	(	O	O	NONE
thereby	RB	thereby	O	O	NONE
raising	VBG	raise	O	O	NONE
systemic	JJ	systemic	O	O	NONE
exposure	NN	exposure	O	O	NONE
).	NN	).	O	O	NONE

NO

Sentence: DrugDDI.d528.s18
Amphotericin	NN	amphotericin	B-e0	T	drug
,	,	,	O	O	NONE
Foscarnet	NN	foscarnet	B-e1	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
Aminoglycosides	NN	aminoglycoside	B-e2	O	drug
:	:	:	O	O	NONE
Drugs	NNS	drug	B-e3	O	drug
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
amphotericin	NN	amphotericin	B-e4	O	drug
,	,	,	O	O	NONE
foscarnet	NN	foscarnet	B-e5	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
aminoglycosides	NNS	aminoglycoside	B-e6	O	drug
may	MD	may	O	O	NONE
increase	VB	increase	O	O	NONE
the	DT	the	O	O	NONE
risk	NN	risk	O	O	NONE
of	IN	of	O	O	NONE
developing	VBG	develop	O	O	NONE
peripheral	JJ	peripheral	B-e7	O	DISO
neuropathy	NN	neuropathy	I-e7	O	DISO
or	CC	or	O	O	NONE
other	JJ	other	O	O	NONE
HIVID	NN	hivid	B-e8	T	drug
-associated	JJ	-associated	O	O	NONE
adverse	JJ	adverse	O	O	NONE
events	NNS	event	O	O	NONE
by	IN	by	O	O	NONE
interfering	VBG	interfere	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
renal	JJ	renal	O	O	NONE
clearance	NN	clearance	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e9	O	drug
(	(	(	O	O	NONE
thereby	RB	thereby	O	O	NONE
raising	VBG	raise	O	O	NONE
systemic	JJ	systemic	O	O	NONE
exposure	NN	exposure	O	O	NONE
).	NN	).	O	O	NONE

NO

Sentence: DrugDDI.d528.s18
Amphotericin	NN	amphotericin	B-e0	T	drug
,	,	,	O	O	NONE
Foscarnet	NN	foscarnet	B-e1	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
Aminoglycosides	NN	aminoglycoside	B-e2	O	drug
:	:	:	O	O	NONE
Drugs	NNS	drug	B-e3	O	drug
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
amphotericin	NN	amphotericin	B-e4	O	drug
,	,	,	O	O	NONE
foscarnet	NN	foscarnet	B-e5	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
aminoglycosides	NNS	aminoglycoside	B-e6	O	drug
may	MD	may	O	O	NONE
increase	VB	increase	O	O	NONE
the	DT	the	O	O	NONE
risk	NN	risk	O	O	NONE
of	IN	of	O	O	NONE
developing	VBG	develop	O	O	NONE
peripheral	JJ	peripheral	B-e7	O	DISO
neuropathy	NN	neuropathy	I-e7	O	DISO
or	CC	or	O	O	NONE
other	JJ	other	O	O	NONE
HIVID	NN	hivid	B-e8	O	drug
-associated	JJ	-associated	O	O	NONE
adverse	JJ	adverse	O	O	NONE
events	NNS	event	O	O	NONE
by	IN	by	O	O	NONE
interfering	VBG	interfere	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
renal	JJ	renal	O	O	NONE
clearance	NN	clearance	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e9	T	drug
(	(	(	O	O	NONE
thereby	RB	thereby	O	O	NONE
raising	VBG	raise	O	O	NONE
systemic	JJ	systemic	O	O	NONE
exposure	NN	exposure	O	O	NONE
).	NN	).	O	O	NONE

NO

Sentence: DrugDDI.d528.s18
Amphotericin	NN	amphotericin	B-e0	O	drug
,	,	,	O	O	NONE
Foscarnet	NN	foscarnet	B-e1	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
Aminoglycosides	NN	aminoglycoside	B-e2	T	drug
:	:	:	O	O	NONE
Drugs	NNS	drug	B-e3	O	drug
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
amphotericin	NN	amphotericin	B-e4	O	drug
,	,	,	O	O	NONE
foscarnet	NN	foscarnet	B-e5	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
aminoglycosides	NNS	aminoglycoside	B-e6	O	drug
may	MD	may	O	O	NONE
increase	VB	increase	O	O	NONE
the	DT	the	O	O	NONE
risk	NN	risk	O	O	NONE
of	IN	of	O	O	NONE
developing	VBG	develop	O	O	NONE
peripheral	JJ	peripheral	B-e7	O	DISO
neuropathy	NN	neuropathy	I-e7	O	DISO
or	CC	or	O	O	NONE
other	JJ	other	O	O	NONE
HIVID	NN	hivid	B-e8	O	drug
-associated	JJ	-associated	O	O	NONE
adverse	JJ	adverse	O	O	NONE
events	NNS	event	O	O	NONE
by	IN	by	O	O	NONE
interfering	VBG	interfere	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
renal	JJ	renal	O	O	NONE
clearance	NN	clearance	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e9	O	drug
(	(	(	O	O	NONE
thereby	RB	thereby	O	O	NONE
raising	VBG	raise	O	O	NONE
systemic	JJ	systemic	O	O	NONE
exposure	NN	exposure	O	O	NONE
).	NN	).	O	O	NONE

NO

Sentence: DrugDDI.d528.s18
Amphotericin	NN	amphotericin	B-e0	O	drug
,	,	,	O	O	NONE
Foscarnet	NN	foscarnet	B-e1	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
Aminoglycosides	NN	aminoglycoside	B-e2	O	drug
:	:	:	O	O	NONE
Drugs	NNS	drug	B-e3	T	drug
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
amphotericin	NN	amphotericin	B-e4	O	drug
,	,	,	O	O	NONE
foscarnet	NN	foscarnet	B-e5	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
aminoglycosides	NNS	aminoglycoside	B-e6	O	drug
may	MD	may	O	O	NONE
increase	VB	increase	O	O	NONE
the	DT	the	O	O	NONE
risk	NN	risk	O	O	NONE
of	IN	of	O	O	NONE
developing	VBG	develop	O	O	NONE
peripheral	JJ	peripheral	B-e7	O	DISO
neuropathy	NN	neuropathy	I-e7	O	DISO
or	CC	or	O	O	NONE
other	JJ	other	O	O	NONE
HIVID	NN	hivid	B-e8	O	drug
-associated	JJ	-associated	O	O	NONE
adverse	JJ	adverse	O	O	NONE
events	NNS	event	O	O	NONE
by	IN	by	O	O	NONE
interfering	VBG	interfere	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
renal	JJ	renal	O	O	NONE
clearance	NN	clearance	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e9	O	drug
(	(	(	O	O	NONE
thereby	RB	thereby	O	O	NONE
raising	VBG	raise	O	O	NONE
systemic	JJ	systemic	O	O	NONE
exposure	NN	exposure	O	O	NONE
).	NN	).	O	O	NONE

NO

Sentence: DrugDDI.d528.s18
Amphotericin	NN	amphotericin	B-e0	O	drug
,	,	,	O	O	NONE
Foscarnet	NN	foscarnet	B-e1	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
Aminoglycosides	NN	aminoglycoside	B-e2	O	drug
:	:	:	O	O	NONE
Drugs	NNS	drug	B-e3	O	drug
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
amphotericin	NN	amphotericin	B-e4	T	drug
,	,	,	O	O	NONE
foscarnet	NN	foscarnet	B-e5	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
aminoglycosides	NNS	aminoglycoside	B-e6	O	drug
may	MD	may	O	O	NONE
increase	VB	increase	O	O	NONE
the	DT	the	O	O	NONE
risk	NN	risk	O	O	NONE
of	IN	of	O	O	NONE
developing	VBG	develop	O	O	NONE
peripheral	JJ	peripheral	B-e7	O	DISO
neuropathy	NN	neuropathy	I-e7	O	DISO
or	CC	or	O	O	NONE
other	JJ	other	O	O	NONE
HIVID	NN	hivid	B-e8	O	drug
-associated	JJ	-associated	O	O	NONE
adverse	JJ	adverse	O	O	NONE
events	NNS	event	O	O	NONE
by	IN	by	O	O	NONE
interfering	VBG	interfere	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
renal	JJ	renal	O	O	NONE
clearance	NN	clearance	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e9	O	drug
(	(	(	O	O	NONE
thereby	RB	thereby	O	O	NONE
raising	VBG	raise	O	O	NONE
systemic	JJ	systemic	O	O	NONE
exposure	NN	exposure	O	O	NONE
).	NN	).	O	O	NONE

NO

Sentence: DrugDDI.d528.s18
Amphotericin	NN	amphotericin	B-e0	O	drug
,	,	,	O	O	NONE
Foscarnet	NN	foscarnet	B-e1	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
Aminoglycosides	NN	aminoglycoside	B-e2	O	drug
:	:	:	O	O	NONE
Drugs	NNS	drug	B-e3	O	drug
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
amphotericin	NN	amphotericin	B-e4	O	drug
,	,	,	O	O	NONE
foscarnet	NN	foscarnet	B-e5	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
aminoglycosides	NNS	aminoglycoside	B-e6	O	drug
may	MD	may	O	O	NONE
increase	VB	increase	O	O	NONE
the	DT	the	O	O	NONE
risk	NN	risk	O	O	NONE
of	IN	of	O	O	NONE
developing	VBG	develop	O	O	NONE
peripheral	JJ	peripheral	B-e7	O	DISO
neuropathy	NN	neuropathy	I-e7	O	DISO
or	CC	or	O	O	NONE
other	JJ	other	O	O	NONE
HIVID	NN	hivid	B-e8	O	drug
-associated	JJ	-associated	O	O	NONE
adverse	JJ	adverse	O	O	NONE
events	NNS	event	O	O	NONE
by	IN	by	O	O	NONE
interfering	VBG	interfere	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
renal	JJ	renal	O	O	NONE
clearance	NN	clearance	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e9	O	drug
(	(	(	O	O	NONE
thereby	RB	thereby	O	O	NONE
raising	VBG	raise	O	O	NONE
systemic	JJ	systemic	O	O	NONE
exposure	NN	exposure	O	O	NONE
).	NN	).	O	O	NONE

NO

Sentence: DrugDDI.d528.s18
Amphotericin	NN	amphotericin	B-e0	O	drug
,	,	,	O	O	NONE
Foscarnet	NN	foscarnet	B-e1	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
Aminoglycosides	NN	aminoglycoside	B-e2	O	drug
:	:	:	O	O	NONE
Drugs	NNS	drug	B-e3	O	drug
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
amphotericin	NN	amphotericin	B-e4	O	drug
,	,	,	O	O	NONE
foscarnet	NN	foscarnet	B-e5	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
aminoglycosides	NNS	aminoglycoside	B-e6	T	drug
may	MD	may	O	O	NONE
increase	VB	increase	O	O	NONE
the	DT	the	O	O	NONE
risk	NN	risk	O	O	NONE
of	IN	of	O	O	NONE
developing	VBG	develop	O	O	NONE
peripheral	JJ	peripheral	B-e7	O	DISO
neuropathy	NN	neuropathy	I-e7	O	DISO
or	CC	or	O	O	NONE
other	JJ	other	O	O	NONE
HIVID	NN	hivid	B-e8	O	drug
-associated	JJ	-associated	O	O	NONE
adverse	JJ	adverse	O	O	NONE
events	NNS	event	O	O	NONE
by	IN	by	O	O	NONE
interfering	VBG	interfere	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
renal	JJ	renal	O	O	NONE
clearance	NN	clearance	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e9	O	drug
(	(	(	O	O	NONE
thereby	RB	thereby	O	O	NONE
raising	VBG	raise	O	O	NONE
systemic	JJ	systemic	O	O	NONE
exposure	NN	exposure	O	O	NONE
).	NN	).	O	O	NONE

NO

Sentence: DrugDDI.d528.s18
Amphotericin	NN	amphotericin	B-e0	O	drug
,	,	,	O	O	NONE
Foscarnet	NN	foscarnet	B-e1	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
Aminoglycosides	NN	aminoglycoside	B-e2	O	drug
:	:	:	O	O	NONE
Drugs	NNS	drug	B-e3	O	drug
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
amphotericin	NN	amphotericin	B-e4	O	drug
,	,	,	O	O	NONE
foscarnet	NN	foscarnet	B-e5	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
aminoglycosides	NNS	aminoglycoside	B-e6	O	drug
may	MD	may	O	O	NONE
increase	VB	increase	O	O	NONE
the	DT	the	O	O	NONE
risk	NN	risk	O	O	NONE
of	IN	of	O	O	NONE
developing	VBG	develop	O	O	NONE
peripheral	JJ	peripheral	B-e7	O	DISO
neuropathy	NN	neuropathy	I-e7	O	DISO
or	CC	or	O	O	NONE
other	JJ	other	O	O	NONE
HIVID	NN	hivid	B-e8	T	drug
-associated	JJ	-associated	O	O	NONE
adverse	JJ	adverse	O	O	NONE
events	NNS	event	O	O	NONE
by	IN	by	O	O	NONE
interfering	VBG	interfere	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
renal	JJ	renal	O	O	NONE
clearance	NN	clearance	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e9	O	drug
(	(	(	O	O	NONE
thereby	RB	thereby	O	O	NONE
raising	VBG	raise	O	O	NONE
systemic	JJ	systemic	O	O	NONE
exposure	NN	exposure	O	O	NONE
).	NN	).	O	O	NONE

NO

Sentence: DrugDDI.d528.s18
Amphotericin	NN	amphotericin	B-e0	O	drug
,	,	,	O	O	NONE
Foscarnet	NN	foscarnet	B-e1	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
Aminoglycosides	NN	aminoglycoside	B-e2	O	drug
:	:	:	O	O	NONE
Drugs	NNS	drug	B-e3	O	drug
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
amphotericin	NN	amphotericin	B-e4	O	drug
,	,	,	O	O	NONE
foscarnet	NN	foscarnet	B-e5	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
aminoglycosides	NNS	aminoglycoside	B-e6	O	drug
may	MD	may	O	O	NONE
increase	VB	increase	O	O	NONE
the	DT	the	O	O	NONE
risk	NN	risk	O	O	NONE
of	IN	of	O	O	NONE
developing	VBG	develop	O	O	NONE
peripheral	JJ	peripheral	B-e7	O	DISO
neuropathy	NN	neuropathy	I-e7	O	DISO
or	CC	or	O	O	NONE
other	JJ	other	O	O	NONE
HIVID	NN	hivid	B-e8	O	drug
-associated	JJ	-associated	O	O	NONE
adverse	JJ	adverse	O	O	NONE
events	NNS	event	O	O	NONE
by	IN	by	O	O	NONE
interfering	VBG	interfere	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
renal	JJ	renal	O	O	NONE
clearance	NN	clearance	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e9	T	drug
(	(	(	O	O	NONE
thereby	RB	thereby	O	O	NONE
raising	VBG	raise	O	O	NONE
systemic	JJ	systemic	O	O	NONE
exposure	NN	exposure	O	O	NONE
).	NN	).	O	O	NONE

NO

Sentence: DrugDDI.d528.s18
Amphotericin	NN	amphotericin	B-e0	O	drug
,	,	,	O	O	NONE
Foscarnet	NN	foscarnet	B-e1	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
Aminoglycosides	NN	aminoglycoside	B-e2	T	drug
:	:	:	O	O	NONE
Drugs	NNS	drug	B-e3	T	drug
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
amphotericin	NN	amphotericin	B-e4	O	drug
,	,	,	O	O	NONE
foscarnet	NN	foscarnet	B-e5	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
aminoglycosides	NNS	aminoglycoside	B-e6	O	drug
may	MD	may	O	O	NONE
increase	VB	increase	O	O	NONE
the	DT	the	O	O	NONE
risk	NN	risk	O	O	NONE
of	IN	of	O	O	NONE
developing	VBG	develop	O	O	NONE
peripheral	JJ	peripheral	B-e7	O	DISO
neuropathy	NN	neuropathy	I-e7	O	DISO
or	CC	or	O	O	NONE
other	JJ	other	O	O	NONE
HIVID	NN	hivid	B-e8	O	drug
-associated	JJ	-associated	O	O	NONE
adverse	JJ	adverse	O	O	NONE
events	NNS	event	O	O	NONE
by	IN	by	O	O	NONE
interfering	VBG	interfere	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
renal	JJ	renal	O	O	NONE
clearance	NN	clearance	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e9	O	drug
(	(	(	O	O	NONE
thereby	RB	thereby	O	O	NONE
raising	VBG	raise	O	O	NONE
systemic	JJ	systemic	O	O	NONE
exposure	NN	exposure	O	O	NONE
).	NN	).	O	O	NONE

NO

Sentence: DrugDDI.d528.s18
Amphotericin	NN	amphotericin	B-e0	O	drug
,	,	,	O	O	NONE
Foscarnet	NN	foscarnet	B-e1	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
Aminoglycosides	NN	aminoglycoside	B-e2	T	drug
:	:	:	O	O	NONE
Drugs	NNS	drug	B-e3	O	drug
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
amphotericin	NN	amphotericin	B-e4	T	drug
,	,	,	O	O	NONE
foscarnet	NN	foscarnet	B-e5	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
aminoglycosides	NNS	aminoglycoside	B-e6	O	drug
may	MD	may	O	O	NONE
increase	VB	increase	O	O	NONE
the	DT	the	O	O	NONE
risk	NN	risk	O	O	NONE
of	IN	of	O	O	NONE
developing	VBG	develop	O	O	NONE
peripheral	JJ	peripheral	B-e7	O	DISO
neuropathy	NN	neuropathy	I-e7	O	DISO
or	CC	or	O	O	NONE
other	JJ	other	O	O	NONE
HIVID	NN	hivid	B-e8	O	drug
-associated	JJ	-associated	O	O	NONE
adverse	JJ	adverse	O	O	NONE
events	NNS	event	O	O	NONE
by	IN	by	O	O	NONE
interfering	VBG	interfere	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
renal	JJ	renal	O	O	NONE
clearance	NN	clearance	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e9	O	drug
(	(	(	O	O	NONE
thereby	RB	thereby	O	O	NONE
raising	VBG	raise	O	O	NONE
systemic	JJ	systemic	O	O	NONE
exposure	NN	exposure	O	O	NONE
).	NN	).	O	O	NONE

NO

Sentence: DrugDDI.d528.s18
Amphotericin	NN	amphotericin	B-e0	O	drug
,	,	,	O	O	NONE
Foscarnet	NN	foscarnet	B-e1	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
Aminoglycosides	NN	aminoglycoside	B-e2	T	drug
:	:	:	O	O	NONE
Drugs	NNS	drug	B-e3	O	drug
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
amphotericin	NN	amphotericin	B-e4	O	drug
,	,	,	O	O	NONE
foscarnet	NN	foscarnet	B-e5	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
aminoglycosides	NNS	aminoglycoside	B-e6	O	drug
may	MD	may	O	O	NONE
increase	VB	increase	O	O	NONE
the	DT	the	O	O	NONE
risk	NN	risk	O	O	NONE
of	IN	of	O	O	NONE
developing	VBG	develop	O	O	NONE
peripheral	JJ	peripheral	B-e7	O	DISO
neuropathy	NN	neuropathy	I-e7	O	DISO
or	CC	or	O	O	NONE
other	JJ	other	O	O	NONE
HIVID	NN	hivid	B-e8	O	drug
-associated	JJ	-associated	O	O	NONE
adverse	JJ	adverse	O	O	NONE
events	NNS	event	O	O	NONE
by	IN	by	O	O	NONE
interfering	VBG	interfere	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
renal	JJ	renal	O	O	NONE
clearance	NN	clearance	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e9	O	drug
(	(	(	O	O	NONE
thereby	RB	thereby	O	O	NONE
raising	VBG	raise	O	O	NONE
systemic	JJ	systemic	O	O	NONE
exposure	NN	exposure	O	O	NONE
).	NN	).	O	O	NONE

NO

Sentence: DrugDDI.d528.s18
Amphotericin	NN	amphotericin	B-e0	O	drug
,	,	,	O	O	NONE
Foscarnet	NN	foscarnet	B-e1	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
Aminoglycosides	NN	aminoglycoside	B-e2	T	drug
:	:	:	O	O	NONE
Drugs	NNS	drug	B-e3	O	drug
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
amphotericin	NN	amphotericin	B-e4	O	drug
,	,	,	O	O	NONE
foscarnet	NN	foscarnet	B-e5	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
aminoglycosides	NNS	aminoglycoside	B-e6	T	drug
may	MD	may	O	O	NONE
increase	VB	increase	O	O	NONE
the	DT	the	O	O	NONE
risk	NN	risk	O	O	NONE
of	IN	of	O	O	NONE
developing	VBG	develop	O	O	NONE
peripheral	JJ	peripheral	B-e7	O	DISO
neuropathy	NN	neuropathy	I-e7	O	DISO
or	CC	or	O	O	NONE
other	JJ	other	O	O	NONE
HIVID	NN	hivid	B-e8	O	drug
-associated	JJ	-associated	O	O	NONE
adverse	JJ	adverse	O	O	NONE
events	NNS	event	O	O	NONE
by	IN	by	O	O	NONE
interfering	VBG	interfere	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
renal	JJ	renal	O	O	NONE
clearance	NN	clearance	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e9	O	drug
(	(	(	O	O	NONE
thereby	RB	thereby	O	O	NONE
raising	VBG	raise	O	O	NONE
systemic	JJ	systemic	O	O	NONE
exposure	NN	exposure	O	O	NONE
).	NN	).	O	O	NONE

NO

Sentence: DrugDDI.d528.s18
Amphotericin	NN	amphotericin	B-e0	O	drug
,	,	,	O	O	NONE
Foscarnet	NN	foscarnet	B-e1	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
Aminoglycosides	NN	aminoglycoside	B-e2	T	drug
:	:	:	O	O	NONE
Drugs	NNS	drug	B-e3	O	drug
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
amphotericin	NN	amphotericin	B-e4	O	drug
,	,	,	O	O	NONE
foscarnet	NN	foscarnet	B-e5	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
aminoglycosides	NNS	aminoglycoside	B-e6	O	drug
may	MD	may	O	O	NONE
increase	VB	increase	O	O	NONE
the	DT	the	O	O	NONE
risk	NN	risk	O	O	NONE
of	IN	of	O	O	NONE
developing	VBG	develop	O	O	NONE
peripheral	JJ	peripheral	B-e7	O	DISO
neuropathy	NN	neuropathy	I-e7	O	DISO
or	CC	or	O	O	NONE
other	JJ	other	O	O	NONE
HIVID	NN	hivid	B-e8	T	drug
-associated	JJ	-associated	O	O	NONE
adverse	JJ	adverse	O	O	NONE
events	NNS	event	O	O	NONE
by	IN	by	O	O	NONE
interfering	VBG	interfere	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
renal	JJ	renal	O	O	NONE
clearance	NN	clearance	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e9	O	drug
(	(	(	O	O	NONE
thereby	RB	thereby	O	O	NONE
raising	VBG	raise	O	O	NONE
systemic	JJ	systemic	O	O	NONE
exposure	NN	exposure	O	O	NONE
).	NN	).	O	O	NONE

NO

Sentence: DrugDDI.d528.s18
Amphotericin	NN	amphotericin	B-e0	O	drug
,	,	,	O	O	NONE
Foscarnet	NN	foscarnet	B-e1	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
Aminoglycosides	NN	aminoglycoside	B-e2	T	drug
:	:	:	O	O	NONE
Drugs	NNS	drug	B-e3	O	drug
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
amphotericin	NN	amphotericin	B-e4	O	drug
,	,	,	O	O	NONE
foscarnet	NN	foscarnet	B-e5	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
aminoglycosides	NNS	aminoglycoside	B-e6	O	drug
may	MD	may	O	O	NONE
increase	VB	increase	O	O	NONE
the	DT	the	O	O	NONE
risk	NN	risk	O	O	NONE
of	IN	of	O	O	NONE
developing	VBG	develop	O	O	NONE
peripheral	JJ	peripheral	B-e7	O	DISO
neuropathy	NN	neuropathy	I-e7	O	DISO
or	CC	or	O	O	NONE
other	JJ	other	O	O	NONE
HIVID	NN	hivid	B-e8	O	drug
-associated	JJ	-associated	O	O	NONE
adverse	JJ	adverse	O	O	NONE
events	NNS	event	O	O	NONE
by	IN	by	O	O	NONE
interfering	VBG	interfere	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
renal	JJ	renal	O	O	NONE
clearance	NN	clearance	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e9	T	drug
(	(	(	O	O	NONE
thereby	RB	thereby	O	O	NONE
raising	VBG	raise	O	O	NONE
systemic	JJ	systemic	O	O	NONE
exposure	NN	exposure	O	O	NONE
).	NN	).	O	O	NONE

NO

Sentence: DrugDDI.d528.s18
Amphotericin	NN	amphotericin	B-e0	O	drug
,	,	,	O	O	NONE
Foscarnet	NN	foscarnet	B-e1	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
Aminoglycosides	NN	aminoglycoside	B-e2	O	drug
:	:	:	O	O	NONE
Drugs	NNS	drug	B-e3	T	drug
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
amphotericin	NN	amphotericin	B-e4	T	drug
,	,	,	O	O	NONE
foscarnet	NN	foscarnet	B-e5	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
aminoglycosides	NNS	aminoglycoside	B-e6	O	drug
may	MD	may	O	O	NONE
increase	VB	increase	O	O	NONE
the	DT	the	O	O	NONE
risk	NN	risk	O	O	NONE
of	IN	of	O	O	NONE
developing	VBG	develop	O	O	NONE
peripheral	JJ	peripheral	B-e7	O	DISO
neuropathy	NN	neuropathy	I-e7	O	DISO
or	CC	or	O	O	NONE
other	JJ	other	O	O	NONE
HIVID	NN	hivid	B-e8	O	drug
-associated	JJ	-associated	O	O	NONE
adverse	JJ	adverse	O	O	NONE
events	NNS	event	O	O	NONE
by	IN	by	O	O	NONE
interfering	VBG	interfere	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
renal	JJ	renal	O	O	NONE
clearance	NN	clearance	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e9	O	drug
(	(	(	O	O	NONE
thereby	RB	thereby	O	O	NONE
raising	VBG	raise	O	O	NONE
systemic	JJ	systemic	O	O	NONE
exposure	NN	exposure	O	O	NONE
).	NN	).	O	O	NONE

NO

Sentence: DrugDDI.d528.s18
Amphotericin	NN	amphotericin	B-e0	O	drug
,	,	,	O	O	NONE
Foscarnet	NN	foscarnet	B-e1	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
Aminoglycosides	NN	aminoglycoside	B-e2	O	drug
:	:	:	O	O	NONE
Drugs	NNS	drug	B-e3	T	drug
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
amphotericin	NN	amphotericin	B-e4	O	drug
,	,	,	O	O	NONE
foscarnet	NN	foscarnet	B-e5	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
aminoglycosides	NNS	aminoglycoside	B-e6	O	drug
may	MD	may	O	O	NONE
increase	VB	increase	O	O	NONE
the	DT	the	O	O	NONE
risk	NN	risk	O	O	NONE
of	IN	of	O	O	NONE
developing	VBG	develop	O	O	NONE
peripheral	JJ	peripheral	B-e7	O	DISO
neuropathy	NN	neuropathy	I-e7	O	DISO
or	CC	or	O	O	NONE
other	JJ	other	O	O	NONE
HIVID	NN	hivid	B-e8	O	drug
-associated	JJ	-associated	O	O	NONE
adverse	JJ	adverse	O	O	NONE
events	NNS	event	O	O	NONE
by	IN	by	O	O	NONE
interfering	VBG	interfere	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
renal	JJ	renal	O	O	NONE
clearance	NN	clearance	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e9	O	drug
(	(	(	O	O	NONE
thereby	RB	thereby	O	O	NONE
raising	VBG	raise	O	O	NONE
systemic	JJ	systemic	O	O	NONE
exposure	NN	exposure	O	O	NONE
).	NN	).	O	O	NONE

NO

Sentence: DrugDDI.d528.s18
Amphotericin	NN	amphotericin	B-e0	O	drug
,	,	,	O	O	NONE
Foscarnet	NN	foscarnet	B-e1	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
Aminoglycosides	NN	aminoglycoside	B-e2	O	drug
:	:	:	O	O	NONE
Drugs	NNS	drug	B-e3	T	drug
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
amphotericin	NN	amphotericin	B-e4	O	drug
,	,	,	O	O	NONE
foscarnet	NN	foscarnet	B-e5	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
aminoglycosides	NNS	aminoglycoside	B-e6	T	drug
may	MD	may	O	O	NONE
increase	VB	increase	O	O	NONE
the	DT	the	O	O	NONE
risk	NN	risk	O	O	NONE
of	IN	of	O	O	NONE
developing	VBG	develop	O	O	NONE
peripheral	JJ	peripheral	B-e7	O	DISO
neuropathy	NN	neuropathy	I-e7	O	DISO
or	CC	or	O	O	NONE
other	JJ	other	O	O	NONE
HIVID	NN	hivid	B-e8	O	drug
-associated	JJ	-associated	O	O	NONE
adverse	JJ	adverse	O	O	NONE
events	NNS	event	O	O	NONE
by	IN	by	O	O	NONE
interfering	VBG	interfere	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
renal	JJ	renal	O	O	NONE
clearance	NN	clearance	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e9	O	drug
(	(	(	O	O	NONE
thereby	RB	thereby	O	O	NONE
raising	VBG	raise	O	O	NONE
systemic	JJ	systemic	O	O	NONE
exposure	NN	exposure	O	O	NONE
).	NN	).	O	O	NONE

NO

Sentence: DrugDDI.d528.s18
Amphotericin	NN	amphotericin	B-e0	O	drug
,	,	,	O	O	NONE
Foscarnet	NN	foscarnet	B-e1	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
Aminoglycosides	NN	aminoglycoside	B-e2	O	drug
:	:	:	O	O	NONE
Drugs	NNS	drug	B-e3	T	drug
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
amphotericin	NN	amphotericin	B-e4	O	drug
,	,	,	O	O	NONE
foscarnet	NN	foscarnet	B-e5	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
aminoglycosides	NNS	aminoglycoside	B-e6	O	drug
may	MD	may	O	O	NONE
increase	VB	increase	O	O	NONE
the	DT	the	O	O	NONE
risk	NN	risk	O	O	NONE
of	IN	of	O	O	NONE
developing	VBG	develop	O	O	NONE
peripheral	JJ	peripheral	B-e7	O	DISO
neuropathy	NN	neuropathy	I-e7	O	DISO
or	CC	or	O	O	NONE
other	JJ	other	O	O	NONE
HIVID	NN	hivid	B-e8	T	drug
-associated	JJ	-associated	O	O	NONE
adverse	JJ	adverse	O	O	NONE
events	NNS	event	O	O	NONE
by	IN	by	O	O	NONE
interfering	VBG	interfere	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
renal	JJ	renal	O	O	NONE
clearance	NN	clearance	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e9	O	drug
(	(	(	O	O	NONE
thereby	RB	thereby	O	O	NONE
raising	VBG	raise	O	O	NONE
systemic	JJ	systemic	O	O	NONE
exposure	NN	exposure	O	O	NONE
).	NN	).	O	O	NONE

NO

Sentence: DrugDDI.d528.s18
Amphotericin	NN	amphotericin	B-e0	O	drug
,	,	,	O	O	NONE
Foscarnet	NN	foscarnet	B-e1	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
Aminoglycosides	NN	aminoglycoside	B-e2	O	drug
:	:	:	O	O	NONE
Drugs	NNS	drug	B-e3	T	drug
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
amphotericin	NN	amphotericin	B-e4	O	drug
,	,	,	O	O	NONE
foscarnet	NN	foscarnet	B-e5	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
aminoglycosides	NNS	aminoglycoside	B-e6	O	drug
may	MD	may	O	O	NONE
increase	VB	increase	O	O	NONE
the	DT	the	O	O	NONE
risk	NN	risk	O	O	NONE
of	IN	of	O	O	NONE
developing	VBG	develop	O	O	NONE
peripheral	JJ	peripheral	B-e7	O	DISO
neuropathy	NN	neuropathy	I-e7	O	DISO
or	CC	or	O	O	NONE
other	JJ	other	O	O	NONE
HIVID	NN	hivid	B-e8	O	drug
-associated	JJ	-associated	O	O	NONE
adverse	JJ	adverse	O	O	NONE
events	NNS	event	O	O	NONE
by	IN	by	O	O	NONE
interfering	VBG	interfere	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
renal	JJ	renal	O	O	NONE
clearance	NN	clearance	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e9	T	drug
(	(	(	O	O	NONE
thereby	RB	thereby	O	O	NONE
raising	VBG	raise	O	O	NONE
systemic	JJ	systemic	O	O	NONE
exposure	NN	exposure	O	O	NONE
).	NN	).	O	O	NONE

YES

Sentence: DrugDDI.d528.s18
Amphotericin	NN	amphotericin	B-e0	O	drug
,	,	,	O	O	NONE
Foscarnet	NN	foscarnet	B-e1	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
Aminoglycosides	NN	aminoglycoside	B-e2	O	drug
:	:	:	O	O	NONE
Drugs	NNS	drug	B-e3	O	drug
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
amphotericin	NN	amphotericin	B-e4	T	drug
,	,	,	O	O	NONE
foscarnet	NN	foscarnet	B-e5	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
aminoglycosides	NNS	aminoglycoside	B-e6	O	drug
may	MD	may	O	O	NONE
increase	VB	increase	O	O	NONE
the	DT	the	O	O	NONE
risk	NN	risk	O	O	NONE
of	IN	of	O	O	NONE
developing	VBG	develop	O	O	NONE
peripheral	JJ	peripheral	B-e7	O	DISO
neuropathy	NN	neuropathy	I-e7	O	DISO
or	CC	or	O	O	NONE
other	JJ	other	O	O	NONE
HIVID	NN	hivid	B-e8	O	drug
-associated	JJ	-associated	O	O	NONE
adverse	JJ	adverse	O	O	NONE
events	NNS	event	O	O	NONE
by	IN	by	O	O	NONE
interfering	VBG	interfere	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
renal	JJ	renal	O	O	NONE
clearance	NN	clearance	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e9	O	drug
(	(	(	O	O	NONE
thereby	RB	thereby	O	O	NONE
raising	VBG	raise	O	O	NONE
systemic	JJ	systemic	O	O	NONE
exposure	NN	exposure	O	O	NONE
).	NN	).	O	O	NONE

NO

Sentence: DrugDDI.d528.s18
Amphotericin	NN	amphotericin	B-e0	O	drug
,	,	,	O	O	NONE
Foscarnet	NN	foscarnet	B-e1	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
Aminoglycosides	NN	aminoglycoside	B-e2	O	drug
:	:	:	O	O	NONE
Drugs	NNS	drug	B-e3	O	drug
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
amphotericin	NN	amphotericin	B-e4	T	drug
,	,	,	O	O	NONE
foscarnet	NN	foscarnet	B-e5	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
aminoglycosides	NNS	aminoglycoside	B-e6	T	drug
may	MD	may	O	O	NONE
increase	VB	increase	O	O	NONE
the	DT	the	O	O	NONE
risk	NN	risk	O	O	NONE
of	IN	of	O	O	NONE
developing	VBG	develop	O	O	NONE
peripheral	JJ	peripheral	B-e7	O	DISO
neuropathy	NN	neuropathy	I-e7	O	DISO
or	CC	or	O	O	NONE
other	JJ	other	O	O	NONE
HIVID	NN	hivid	B-e8	O	drug
-associated	JJ	-associated	O	O	NONE
adverse	JJ	adverse	O	O	NONE
events	NNS	event	O	O	NONE
by	IN	by	O	O	NONE
interfering	VBG	interfere	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
renal	JJ	renal	O	O	NONE
clearance	NN	clearance	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e9	O	drug
(	(	(	O	O	NONE
thereby	RB	thereby	O	O	NONE
raising	VBG	raise	O	O	NONE
systemic	JJ	systemic	O	O	NONE
exposure	NN	exposure	O	O	NONE
).	NN	).	O	O	NONE

NO

Sentence: DrugDDI.d528.s18
Amphotericin	NN	amphotericin	B-e0	O	drug
,	,	,	O	O	NONE
Foscarnet	NN	foscarnet	B-e1	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
Aminoglycosides	NN	aminoglycoside	B-e2	O	drug
:	:	:	O	O	NONE
Drugs	NNS	drug	B-e3	O	drug
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
amphotericin	NN	amphotericin	B-e4	T	drug
,	,	,	O	O	NONE
foscarnet	NN	foscarnet	B-e5	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
aminoglycosides	NNS	aminoglycoside	B-e6	O	drug
may	MD	may	O	O	NONE
increase	VB	increase	O	O	NONE
the	DT	the	O	O	NONE
risk	NN	risk	O	O	NONE
of	IN	of	O	O	NONE
developing	VBG	develop	O	O	NONE
peripheral	JJ	peripheral	B-e7	O	DISO
neuropathy	NN	neuropathy	I-e7	O	DISO
or	CC	or	O	O	NONE
other	JJ	other	O	O	NONE
HIVID	NN	hivid	B-e8	T	drug
-associated	JJ	-associated	O	O	NONE
adverse	JJ	adverse	O	O	NONE
events	NNS	event	O	O	NONE
by	IN	by	O	O	NONE
interfering	VBG	interfere	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
renal	JJ	renal	O	O	NONE
clearance	NN	clearance	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e9	O	drug
(	(	(	O	O	NONE
thereby	RB	thereby	O	O	NONE
raising	VBG	raise	O	O	NONE
systemic	JJ	systemic	O	O	NONE
exposure	NN	exposure	O	O	NONE
).	NN	).	O	O	NONE

NO

Sentence: DrugDDI.d528.s18
Amphotericin	NN	amphotericin	B-e0	O	drug
,	,	,	O	O	NONE
Foscarnet	NN	foscarnet	B-e1	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
Aminoglycosides	NN	aminoglycoside	B-e2	O	drug
:	:	:	O	O	NONE
Drugs	NNS	drug	B-e3	O	drug
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
amphotericin	NN	amphotericin	B-e4	T	drug
,	,	,	O	O	NONE
foscarnet	NN	foscarnet	B-e5	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
aminoglycosides	NNS	aminoglycoside	B-e6	O	drug
may	MD	may	O	O	NONE
increase	VB	increase	O	O	NONE
the	DT	the	O	O	NONE
risk	NN	risk	O	O	NONE
of	IN	of	O	O	NONE
developing	VBG	develop	O	O	NONE
peripheral	JJ	peripheral	B-e7	O	DISO
neuropathy	NN	neuropathy	I-e7	O	DISO
or	CC	or	O	O	NONE
other	JJ	other	O	O	NONE
HIVID	NN	hivid	B-e8	O	drug
-associated	JJ	-associated	O	O	NONE
adverse	JJ	adverse	O	O	NONE
events	NNS	event	O	O	NONE
by	IN	by	O	O	NONE
interfering	VBG	interfere	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
renal	JJ	renal	O	O	NONE
clearance	NN	clearance	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e9	T	drug
(	(	(	O	O	NONE
thereby	RB	thereby	O	O	NONE
raising	VBG	raise	O	O	NONE
systemic	JJ	systemic	O	O	NONE
exposure	NN	exposure	O	O	NONE
).	NN	).	O	O	NONE

YES

Sentence: DrugDDI.d528.s18
Amphotericin	NN	amphotericin	B-e0	O	drug
,	,	,	O	O	NONE
Foscarnet	NN	foscarnet	B-e1	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
Aminoglycosides	NN	aminoglycoside	B-e2	O	drug
:	:	:	O	O	NONE
Drugs	NNS	drug	B-e3	O	drug
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
amphotericin	NN	amphotericin	B-e4	O	drug
,	,	,	O	O	NONE
foscarnet	NN	foscarnet	B-e5	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
aminoglycosides	NNS	aminoglycoside	B-e6	T	drug
may	MD	may	O	O	NONE
increase	VB	increase	O	O	NONE
the	DT	the	O	O	NONE
risk	NN	risk	O	O	NONE
of	IN	of	O	O	NONE
developing	VBG	develop	O	O	NONE
peripheral	JJ	peripheral	B-e7	O	DISO
neuropathy	NN	neuropathy	I-e7	O	DISO
or	CC	or	O	O	NONE
other	JJ	other	O	O	NONE
HIVID	NN	hivid	B-e8	O	drug
-associated	JJ	-associated	O	O	NONE
adverse	JJ	adverse	O	O	NONE
events	NNS	event	O	O	NONE
by	IN	by	O	O	NONE
interfering	VBG	interfere	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
renal	JJ	renal	O	O	NONE
clearance	NN	clearance	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e9	O	drug
(	(	(	O	O	NONE
thereby	RB	thereby	O	O	NONE
raising	VBG	raise	O	O	NONE
systemic	JJ	systemic	O	O	NONE
exposure	NN	exposure	O	O	NONE
).	NN	).	O	O	NONE

NO

Sentence: DrugDDI.d528.s18
Amphotericin	NN	amphotericin	B-e0	O	drug
,	,	,	O	O	NONE
Foscarnet	NN	foscarnet	B-e1	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
Aminoglycosides	NN	aminoglycoside	B-e2	O	drug
:	:	:	O	O	NONE
Drugs	NNS	drug	B-e3	O	drug
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
amphotericin	NN	amphotericin	B-e4	O	drug
,	,	,	O	O	NONE
foscarnet	NN	foscarnet	B-e5	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
aminoglycosides	NNS	aminoglycoside	B-e6	O	drug
may	MD	may	O	O	NONE
increase	VB	increase	O	O	NONE
the	DT	the	O	O	NONE
risk	NN	risk	O	O	NONE
of	IN	of	O	O	NONE
developing	VBG	develop	O	O	NONE
peripheral	JJ	peripheral	B-e7	O	DISO
neuropathy	NN	neuropathy	I-e7	O	DISO
or	CC	or	O	O	NONE
other	JJ	other	O	O	NONE
HIVID	NN	hivid	B-e8	T	drug
-associated	JJ	-associated	O	O	NONE
adverse	JJ	adverse	O	O	NONE
events	NNS	event	O	O	NONE
by	IN	by	O	O	NONE
interfering	VBG	interfere	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
renal	JJ	renal	O	O	NONE
clearance	NN	clearance	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e9	O	drug
(	(	(	O	O	NONE
thereby	RB	thereby	O	O	NONE
raising	VBG	raise	O	O	NONE
systemic	JJ	systemic	O	O	NONE
exposure	NN	exposure	O	O	NONE
).	NN	).	O	O	NONE

NO

Sentence: DrugDDI.d528.s18
Amphotericin	NN	amphotericin	B-e0	O	drug
,	,	,	O	O	NONE
Foscarnet	NN	foscarnet	B-e1	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
Aminoglycosides	NN	aminoglycoside	B-e2	O	drug
:	:	:	O	O	NONE
Drugs	NNS	drug	B-e3	O	drug
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
amphotericin	NN	amphotericin	B-e4	O	drug
,	,	,	O	O	NONE
foscarnet	NN	foscarnet	B-e5	T	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
aminoglycosides	NNS	aminoglycoside	B-e6	O	drug
may	MD	may	O	O	NONE
increase	VB	increase	O	O	NONE
the	DT	the	O	O	NONE
risk	NN	risk	O	O	NONE
of	IN	of	O	O	NONE
developing	VBG	develop	O	O	NONE
peripheral	JJ	peripheral	B-e7	O	DISO
neuropathy	NN	neuropathy	I-e7	O	DISO
or	CC	or	O	O	NONE
other	JJ	other	O	O	NONE
HIVID	NN	hivid	B-e8	O	drug
-associated	JJ	-associated	O	O	NONE
adverse	JJ	adverse	O	O	NONE
events	NNS	event	O	O	NONE
by	IN	by	O	O	NONE
interfering	VBG	interfere	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
renal	JJ	renal	O	O	NONE
clearance	NN	clearance	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e9	T	drug
(	(	(	O	O	NONE
thereby	RB	thereby	O	O	NONE
raising	VBG	raise	O	O	NONE
systemic	JJ	systemic	O	O	NONE
exposure	NN	exposure	O	O	NONE
).	NN	).	O	O	NONE

YES

Sentence: DrugDDI.d528.s18
Amphotericin	NN	amphotericin	B-e0	O	drug
,	,	,	O	O	NONE
Foscarnet	NN	foscarnet	B-e1	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
Aminoglycosides	NN	aminoglycoside	B-e2	O	drug
:	:	:	O	O	NONE
Drugs	NNS	drug	B-e3	O	drug
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
amphotericin	NN	amphotericin	B-e4	O	drug
,	,	,	O	O	NONE
foscarnet	NN	foscarnet	B-e5	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
aminoglycosides	NNS	aminoglycoside	B-e6	T	drug
may	MD	may	O	O	NONE
increase	VB	increase	O	O	NONE
the	DT	the	O	O	NONE
risk	NN	risk	O	O	NONE
of	IN	of	O	O	NONE
developing	VBG	develop	O	O	NONE
peripheral	JJ	peripheral	B-e7	O	DISO
neuropathy	NN	neuropathy	I-e7	O	DISO
or	CC	or	O	O	NONE
other	JJ	other	O	O	NONE
HIVID	NN	hivid	B-e8	T	drug
-associated	JJ	-associated	O	O	NONE
adverse	JJ	adverse	O	O	NONE
events	NNS	event	O	O	NONE
by	IN	by	O	O	NONE
interfering	VBG	interfere	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
renal	JJ	renal	O	O	NONE
clearance	NN	clearance	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e9	O	drug
(	(	(	O	O	NONE
thereby	RB	thereby	O	O	NONE
raising	VBG	raise	O	O	NONE
systemic	JJ	systemic	O	O	NONE
exposure	NN	exposure	O	O	NONE
).	NN	).	O	O	NONE

NO

Sentence: DrugDDI.d528.s18
Amphotericin	NN	amphotericin	B-e0	O	drug
,	,	,	O	O	NONE
Foscarnet	NN	foscarnet	B-e1	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
Aminoglycosides	NN	aminoglycoside	B-e2	O	drug
:	:	:	O	O	NONE
Drugs	NNS	drug	B-e3	O	drug
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
amphotericin	NN	amphotericin	B-e4	O	drug
,	,	,	O	O	NONE
foscarnet	NN	foscarnet	B-e5	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
aminoglycosides	NNS	aminoglycoside	B-e6	T	drug
may	MD	may	O	O	NONE
increase	VB	increase	O	O	NONE
the	DT	the	O	O	NONE
risk	NN	risk	O	O	NONE
of	IN	of	O	O	NONE
developing	VBG	develop	O	O	NONE
peripheral	JJ	peripheral	B-e7	O	DISO
neuropathy	NN	neuropathy	I-e7	O	DISO
or	CC	or	O	O	NONE
other	JJ	other	O	O	NONE
HIVID	NN	hivid	B-e8	O	drug
-associated	JJ	-associated	O	O	NONE
adverse	JJ	adverse	O	O	NONE
events	NNS	event	O	O	NONE
by	IN	by	O	O	NONE
interfering	VBG	interfere	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
renal	JJ	renal	O	O	NONE
clearance	NN	clearance	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e9	T	drug
(	(	(	O	O	NONE
thereby	RB	thereby	O	O	NONE
raising	VBG	raise	O	O	NONE
systemic	JJ	systemic	O	O	NONE
exposure	NN	exposure	O	O	NONE
).	NN	).	O	O	NONE

YES

Sentence: DrugDDI.d528.s18
Amphotericin	NN	amphotericin	B-e0	O	drug
,	,	,	O	O	NONE
Foscarnet	NN	foscarnet	B-e1	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
Aminoglycosides	NN	aminoglycoside	B-e2	O	drug
:	:	:	O	O	NONE
Drugs	NNS	drug	B-e3	O	drug
such	JJ	such	O	O	NONE
as	IN	as	O	O	NONE
amphotericin	NN	amphotericin	B-e4	O	drug
,	,	,	O	O	NONE
foscarnet	NN	foscarnet	B-e5	O	drug
,	,	,	O	O	NONE
and	CC	and	O	O	NONE
aminoglycosides	NNS	aminoglycoside	B-e6	O	drug
may	MD	may	O	O	NONE
increase	VB	increase	O	O	NONE
the	DT	the	O	O	NONE
risk	NN	risk	O	O	NONE
of	IN	of	O	O	NONE
developing	VBG	develop	O	O	NONE
peripheral	JJ	peripheral	B-e7	O	DISO
neuropathy	NN	neuropathy	I-e7	O	DISO
or	CC	or	O	O	NONE
other	JJ	other	O	O	NONE
HIVID	NN	hivid	B-e8	T	drug
-associated	JJ	-associated	O	O	NONE
adverse	JJ	adverse	O	O	NONE
events	NNS	event	O	O	NONE
by	IN	by	O	O	NONE
interfering	VBG	interfere	O	O	NONE
with	IN	with	O	O	NONE
the	DT	the	O	O	NONE
renal	JJ	renal	O	O	NONE
clearance	NN	clearance	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e9	T	drug
(	(	(	O	O	NONE
thereby	RB	thereby	O	O	NONE
raising	VBG	raise	O	O	NONE
systemic	JJ	systemic	O	O	NONE
exposure	NN	exposure	O	O	NONE
).	NN	).	O	O	NONE

YES

Sentence: DrugDDI.d528.s19
Patients	NNS	patient	O	O	NONE
who	WP	who	O	O	NONE
require	VBP	require	O	O	NONE
the	DT	the	O	O	NONE
use	NN	use	O	O	NONE
of	IN	of	O	O	NONE
one	CD	one	O	O	NONE
of	IN	of	O	O	NONE
these	DT	these	O	O	NONE
drugs	NNS	drug	B-e0	T	drug
with	IN	with	O	O	NONE
HIVID	NN	hivid	B-e1	T	drug
should	MD	should	O	O	NONE
have	VBP	have	O	O	NONE
frequent	JJ	frequent	O	O	NONE
clinical	JJ	clinical	O	O	NONE
and	CC	and	O	O	NONE
laboratory	JJ	laboratory	O	O	NONE
monitoring	NN	monitoring	O	O	NONE
with	IN	with	O	O	NONE
dosage	JJ	dosage	O	O	NONE
adjustment	NN	adjustment	O	O	NONE
for	IN	for	O	O	NONE
any	DT	any	O	O	NONE
significant	JJ	significant	O	O	NONE
change	NN	change	O	O	NONE
in	IN	in	O	O	NONE
renal	JJ	renal	O	O	NONE
function	NN	function	O	O	NONE
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d528.s20
Probenecid	NN	probenecid	B-e0	T	drug
or	CC	or	O	O	NONE
Cimetidine	NN	cimetidine	B-e1	T	drug
:	:	:	O	O	NONE
Concomitant	JJ	concomitant	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
probenecid	NN	probenecid	B-e2	O	drug
or	CC	or	O	O	NONE
cimetidine	NN	cimetidine	B-e3	O	drug
decreases	VBZ	decrease	O	O	NONE
the	DT	the	O	O	NONE
elimination	NN	elimination	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e4	O	drug
,	,	,	O	O	NONE
most	RBS	most	O	O	NONE
likely	RB	likely	O	O	NONE
by	IN	by	O	O	NONE
inhibition	NN	inhibition	O	O	NONE
of	IN	of	O	O	NONE
renal	JJ	renal	O	O	NONE
tubular	JJ	tubular	O	O	NONE
secretion	NN	secretion	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e5	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s20
Probenecid	NN	probenecid	B-e0	T	drug
or	CC	or	O	O	NONE
Cimetidine	NN	cimetidine	B-e1	O	drug
:	:	:	O	O	NONE
Concomitant	JJ	concomitant	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
probenecid	NN	probenecid	B-e2	T	drug
or	CC	or	O	O	NONE
cimetidine	NN	cimetidine	B-e3	O	drug
decreases	VBZ	decrease	O	O	NONE
the	DT	the	O	O	NONE
elimination	NN	elimination	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e4	O	drug
,	,	,	O	O	NONE
most	RBS	most	O	O	NONE
likely	RB	likely	O	O	NONE
by	IN	by	O	O	NONE
inhibition	NN	inhibition	O	O	NONE
of	IN	of	O	O	NONE
renal	JJ	renal	O	O	NONE
tubular	JJ	tubular	O	O	NONE
secretion	NN	secretion	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e5	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s20
Probenecid	NN	probenecid	B-e0	T	drug
or	CC	or	O	O	NONE
Cimetidine	NN	cimetidine	B-e1	O	drug
:	:	:	O	O	NONE
Concomitant	JJ	concomitant	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
probenecid	NN	probenecid	B-e2	O	drug
or	CC	or	O	O	NONE
cimetidine	NN	cimetidine	B-e3	T	drug
decreases	VBZ	decrease	O	O	NONE
the	DT	the	O	O	NONE
elimination	NN	elimination	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e4	O	drug
,	,	,	O	O	NONE
most	RBS	most	O	O	NONE
likely	RB	likely	O	O	NONE
by	IN	by	O	O	NONE
inhibition	NN	inhibition	O	O	NONE
of	IN	of	O	O	NONE
renal	JJ	renal	O	O	NONE
tubular	JJ	tubular	O	O	NONE
secretion	NN	secretion	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e5	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s20
Probenecid	NN	probenecid	B-e0	T	drug
or	CC	or	O	O	NONE
Cimetidine	NN	cimetidine	B-e1	O	drug
:	:	:	O	O	NONE
Concomitant	JJ	concomitant	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
probenecid	NN	probenecid	B-e2	O	drug
or	CC	or	O	O	NONE
cimetidine	NN	cimetidine	B-e3	O	drug
decreases	VBZ	decrease	O	O	NONE
the	DT	the	O	O	NONE
elimination	NN	elimination	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e4	T	drug
,	,	,	O	O	NONE
most	RBS	most	O	O	NONE
likely	RB	likely	O	O	NONE
by	IN	by	O	O	NONE
inhibition	NN	inhibition	O	O	NONE
of	IN	of	O	O	NONE
renal	JJ	renal	O	O	NONE
tubular	JJ	tubular	O	O	NONE
secretion	NN	secretion	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e5	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s20
Probenecid	NN	probenecid	B-e0	T	drug
or	CC	or	O	O	NONE
Cimetidine	NN	cimetidine	B-e1	O	drug
:	:	:	O	O	NONE
Concomitant	JJ	concomitant	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
probenecid	NN	probenecid	B-e2	O	drug
or	CC	or	O	O	NONE
cimetidine	NN	cimetidine	B-e3	O	drug
decreases	VBZ	decrease	O	O	NONE
the	DT	the	O	O	NONE
elimination	NN	elimination	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e4	O	drug
,	,	,	O	O	NONE
most	RBS	most	O	O	NONE
likely	RB	likely	O	O	NONE
by	IN	by	O	O	NONE
inhibition	NN	inhibition	O	O	NONE
of	IN	of	O	O	NONE
renal	JJ	renal	O	O	NONE
tubular	JJ	tubular	O	O	NONE
secretion	NN	secretion	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e5	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s20
Probenecid	NN	probenecid	B-e0	O	drug
or	CC	or	O	O	NONE
Cimetidine	NN	cimetidine	B-e1	T	drug
:	:	:	O	O	NONE
Concomitant	JJ	concomitant	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
probenecid	NN	probenecid	B-e2	T	drug
or	CC	or	O	O	NONE
cimetidine	NN	cimetidine	B-e3	O	drug
decreases	VBZ	decrease	O	O	NONE
the	DT	the	O	O	NONE
elimination	NN	elimination	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e4	O	drug
,	,	,	O	O	NONE
most	RBS	most	O	O	NONE
likely	RB	likely	O	O	NONE
by	IN	by	O	O	NONE
inhibition	NN	inhibition	O	O	NONE
of	IN	of	O	O	NONE
renal	JJ	renal	O	O	NONE
tubular	JJ	tubular	O	O	NONE
secretion	NN	secretion	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e5	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s20
Probenecid	NN	probenecid	B-e0	O	drug
or	CC	or	O	O	NONE
Cimetidine	NN	cimetidine	B-e1	T	drug
:	:	:	O	O	NONE
Concomitant	JJ	concomitant	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
probenecid	NN	probenecid	B-e2	O	drug
or	CC	or	O	O	NONE
cimetidine	NN	cimetidine	B-e3	T	drug
decreases	VBZ	decrease	O	O	NONE
the	DT	the	O	O	NONE
elimination	NN	elimination	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e4	O	drug
,	,	,	O	O	NONE
most	RBS	most	O	O	NONE
likely	RB	likely	O	O	NONE
by	IN	by	O	O	NONE
inhibition	NN	inhibition	O	O	NONE
of	IN	of	O	O	NONE
renal	JJ	renal	O	O	NONE
tubular	JJ	tubular	O	O	NONE
secretion	NN	secretion	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e5	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s20
Probenecid	NN	probenecid	B-e0	O	drug
or	CC	or	O	O	NONE
Cimetidine	NN	cimetidine	B-e1	T	drug
:	:	:	O	O	NONE
Concomitant	JJ	concomitant	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
probenecid	NN	probenecid	B-e2	O	drug
or	CC	or	O	O	NONE
cimetidine	NN	cimetidine	B-e3	O	drug
decreases	VBZ	decrease	O	O	NONE
the	DT	the	O	O	NONE
elimination	NN	elimination	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e4	T	drug
,	,	,	O	O	NONE
most	RBS	most	O	O	NONE
likely	RB	likely	O	O	NONE
by	IN	by	O	O	NONE
inhibition	NN	inhibition	O	O	NONE
of	IN	of	O	O	NONE
renal	JJ	renal	O	O	NONE
tubular	JJ	tubular	O	O	NONE
secretion	NN	secretion	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e5	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s20
Probenecid	NN	probenecid	B-e0	O	drug
or	CC	or	O	O	NONE
Cimetidine	NN	cimetidine	B-e1	T	drug
:	:	:	O	O	NONE
Concomitant	JJ	concomitant	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
probenecid	NN	probenecid	B-e2	O	drug
or	CC	or	O	O	NONE
cimetidine	NN	cimetidine	B-e3	O	drug
decreases	VBZ	decrease	O	O	NONE
the	DT	the	O	O	NONE
elimination	NN	elimination	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e4	O	drug
,	,	,	O	O	NONE
most	RBS	most	O	O	NONE
likely	RB	likely	O	O	NONE
by	IN	by	O	O	NONE
inhibition	NN	inhibition	O	O	NONE
of	IN	of	O	O	NONE
renal	JJ	renal	O	O	NONE
tubular	JJ	tubular	O	O	NONE
secretion	NN	secretion	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e5	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s20
Probenecid	NN	probenecid	B-e0	O	drug
or	CC	or	O	O	NONE
Cimetidine	NN	cimetidine	B-e1	O	drug
:	:	:	O	O	NONE
Concomitant	JJ	concomitant	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
probenecid	NN	probenecid	B-e2	T	drug
or	CC	or	O	O	NONE
cimetidine	NN	cimetidine	B-e3	T	drug
decreases	VBZ	decrease	O	O	NONE
the	DT	the	O	O	NONE
elimination	NN	elimination	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e4	O	drug
,	,	,	O	O	NONE
most	RBS	most	O	O	NONE
likely	RB	likely	O	O	NONE
by	IN	by	O	O	NONE
inhibition	NN	inhibition	O	O	NONE
of	IN	of	O	O	NONE
renal	JJ	renal	O	O	NONE
tubular	JJ	tubular	O	O	NONE
secretion	NN	secretion	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e5	O	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s20
Probenecid	NN	probenecid	B-e0	O	drug
or	CC	or	O	O	NONE
Cimetidine	NN	cimetidine	B-e1	O	drug
:	:	:	O	O	NONE
Concomitant	JJ	concomitant	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
probenecid	NN	probenecid	B-e2	T	drug
or	CC	or	O	O	NONE
cimetidine	NN	cimetidine	B-e3	O	drug
decreases	VBZ	decrease	O	O	NONE
the	DT	the	O	O	NONE
elimination	NN	elimination	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e4	T	drug
,	,	,	O	O	NONE
most	RBS	most	O	O	NONE
likely	RB	likely	O	O	NONE
by	IN	by	O	O	NONE
inhibition	NN	inhibition	O	O	NONE
of	IN	of	O	O	NONE
renal	JJ	renal	O	O	NONE
tubular	JJ	tubular	O	O	NONE
secretion	NN	secretion	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e5	O	drug
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d528.s20
Probenecid	NN	probenecid	B-e0	O	drug
or	CC	or	O	O	NONE
Cimetidine	NN	cimetidine	B-e1	O	drug
:	:	:	O	O	NONE
Concomitant	JJ	concomitant	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
probenecid	NN	probenecid	B-e2	T	drug
or	CC	or	O	O	NONE
cimetidine	NN	cimetidine	B-e3	O	drug
decreases	VBZ	decrease	O	O	NONE
the	DT	the	O	O	NONE
elimination	NN	elimination	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e4	O	drug
,	,	,	O	O	NONE
most	RBS	most	O	O	NONE
likely	RB	likely	O	O	NONE
by	IN	by	O	O	NONE
inhibition	NN	inhibition	O	O	NONE
of	IN	of	O	O	NONE
renal	JJ	renal	O	O	NONE
tubular	JJ	tubular	O	O	NONE
secretion	NN	secretion	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e5	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s20
Probenecid	NN	probenecid	B-e0	O	drug
or	CC	or	O	O	NONE
Cimetidine	NN	cimetidine	B-e1	O	drug
:	:	:	O	O	NONE
Concomitant	JJ	concomitant	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
probenecid	NN	probenecid	B-e2	O	drug
or	CC	or	O	O	NONE
cimetidine	NN	cimetidine	B-e3	T	drug
decreases	VBZ	decrease	O	O	NONE
the	DT	the	O	O	NONE
elimination	NN	elimination	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e4	T	drug
,	,	,	O	O	NONE
most	RBS	most	O	O	NONE
likely	RB	likely	O	O	NONE
by	IN	by	O	O	NONE
inhibition	NN	inhibition	O	O	NONE
of	IN	of	O	O	NONE
renal	JJ	renal	O	O	NONE
tubular	JJ	tubular	O	O	NONE
secretion	NN	secretion	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e5	O	drug
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d528.s20
Probenecid	NN	probenecid	B-e0	O	drug
or	CC	or	O	O	NONE
Cimetidine	NN	cimetidine	B-e1	O	drug
:	:	:	O	O	NONE
Concomitant	JJ	concomitant	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
probenecid	NN	probenecid	B-e2	O	drug
or	CC	or	O	O	NONE
cimetidine	NN	cimetidine	B-e3	T	drug
decreases	VBZ	decrease	O	O	NONE
the	DT	the	O	O	NONE
elimination	NN	elimination	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e4	O	drug
,	,	,	O	O	NONE
most	RBS	most	O	O	NONE
likely	RB	likely	O	O	NONE
by	IN	by	O	O	NONE
inhibition	NN	inhibition	O	O	NONE
of	IN	of	O	O	NONE
renal	JJ	renal	O	O	NONE
tubular	JJ	tubular	O	O	NONE
secretion	NN	secretion	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e5	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s20
Probenecid	NN	probenecid	B-e0	O	drug
or	CC	or	O	O	NONE
Cimetidine	NN	cimetidine	B-e1	O	drug
:	:	:	O	O	NONE
Concomitant	JJ	concomitant	O	O	NONE
administration	NN	administration	O	O	NONE
of	IN	of	O	O	NONE
probenecid	NN	probenecid	B-e2	O	drug
or	CC	or	O	O	NONE
cimetidine	NN	cimetidine	B-e3	O	drug
decreases	VBZ	decrease	O	O	NONE
the	DT	the	O	O	NONE
elimination	NN	elimination	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e4	T	drug
,	,	,	O	O	NONE
most	RBS	most	O	O	NONE
likely	RB	likely	O	O	NONE
by	IN	by	O	O	NONE
inhibition	NN	inhibition	O	O	NONE
of	IN	of	O	O	NONE
renal	JJ	renal	O	O	NONE
tubular	JJ	tubular	O	O	NONE
secretion	NN	secretion	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e5	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s21
Patients	NNS	patient	O	O	NONE
receiving	VBG	receive	O	O	NONE
these	DT	these	O	O	NONE
drugs	NNS	drug	B-e0	T	drug
in	IN	in	O	O	NONE
combination	NN	combination	O	O	NONE
with	IN	with	O	O	NONE
zalcitabine	NN	zalcitabine	B-e1	T	drug
should	MD	should	O	O	NONE
be	VB	be	O	O	NONE
monitored	VBN	monitor	O	O	NONE
for	IN	for	O	O	NONE
signs	NNS	sign	O	O	NONE
of	IN	of	O	O	NONE
toxicity	NN	toxicity	O	O	NONE
and	CC	and	O	O	NONE
the	DT	the	O	O	NONE
dose	NN	dose	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e2	O	drug
reduced	VBD	reduce	O	O	NONE
if	IN	if	O	O	NONE
warranted	VBN	warrant	O	O	NONE
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d528.s21
Patients	NNS	patient	O	O	NONE
receiving	VBG	receive	O	O	NONE
these	DT	these	O	O	NONE
drugs	NNS	drug	B-e0	T	drug
in	IN	in	O	O	NONE
combination	NN	combination	O	O	NONE
with	IN	with	O	O	NONE
zalcitabine	NN	zalcitabine	B-e1	O	drug
should	MD	should	O	O	NONE
be	VB	be	O	O	NONE
monitored	VBN	monitor	O	O	NONE
for	IN	for	O	O	NONE
signs	NNS	sign	O	O	NONE
of	IN	of	O	O	NONE
toxicity	NN	toxicity	O	O	NONE
and	CC	and	O	O	NONE
the	DT	the	O	O	NONE
dose	NN	dose	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e2	T	drug
reduced	VBD	reduce	O	O	NONE
if	IN	if	O	O	NONE
warranted	VBN	warrant	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s21
Patients	NNS	patient	O	O	NONE
receiving	VBG	receive	O	O	NONE
these	DT	these	O	O	NONE
drugs	NNS	drug	B-e0	O	drug
in	IN	in	O	O	NONE
combination	NN	combination	O	O	NONE
with	IN	with	O	O	NONE
zalcitabine	NN	zalcitabine	B-e1	T	drug
should	MD	should	O	O	NONE
be	VB	be	O	O	NONE
monitored	VBN	monitor	O	O	NONE
for	IN	for	O	O	NONE
signs	NNS	sign	O	O	NONE
of	IN	of	O	O	NONE
toxicity	NN	toxicity	O	O	NONE
and	CC	and	O	O	NONE
the	DT	the	O	O	NONE
dose	NN	dose	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e2	T	drug
reduced	VBD	reduce	O	O	NONE
if	IN	if	O	O	NONE
warranted	VBN	warrant	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s22
Magnesium	NN	magnesium	B-e0	T	drug
/Aluminum-containing	JJ	/aluminum-containing	B-e1	T	drug
Antacid	JJ	antacid	I-e1	T	drug
Products	NNS	product	O	O	NONE
:	:	:	O	O	NONE
Absorption	NN	absorption	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e2	O	drug
is	VBZ	be	O	O	NONE
moderately	RB	moderately	O	O	NONE
reduced	VBN	reduce	O	O	NONE
(	(	(	O	O	NONE
approximately	RB	approximately	O	O	NONE
25	CD	25	O	O	NONE
%	NN	%	O	O	NONE
)	)	)	O	O	NONE
when	WRB	when	O	O	NONE
coadministered	VBN	coadminister	O	O	NONE
with	IN	with	O	O	NONE
magnesium	NN	magnesium	B-e3	O	drug
/aluminum-containing	NN	/aluminum-containing	B-e4	O	drug
antacid	JJ	antacid	I-e4	O	drug
products	NNS	product	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s22
Magnesium	NN	magnesium	B-e0	T	drug
/Aluminum-containing	JJ	/aluminum-containing	B-e1	O	drug
Antacid	JJ	antacid	I-e1	O	drug
Products	NNS	product	O	O	NONE
:	:	:	O	O	NONE
Absorption	NN	absorption	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e2	T	drug
is	VBZ	be	O	O	NONE
moderately	RB	moderately	O	O	NONE
reduced	VBN	reduce	O	O	NONE
(	(	(	O	O	NONE
approximately	RB	approximately	O	O	NONE
25	CD	25	O	O	NONE
%	NN	%	O	O	NONE
)	)	)	O	O	NONE
when	WRB	when	O	O	NONE
coadministered	VBN	coadminister	O	O	NONE
with	IN	with	O	O	NONE
magnesium	NN	magnesium	B-e3	O	drug
/aluminum-containing	NN	/aluminum-containing	B-e4	O	drug
antacid	JJ	antacid	I-e4	O	drug
products	NNS	product	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s22
Magnesium	NN	magnesium	B-e0	T	drug
/Aluminum-containing	JJ	/aluminum-containing	B-e1	O	drug
Antacid	JJ	antacid	I-e1	O	drug
Products	NNS	product	O	O	NONE
:	:	:	O	O	NONE
Absorption	NN	absorption	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e2	O	drug
is	VBZ	be	O	O	NONE
moderately	RB	moderately	O	O	NONE
reduced	VBN	reduce	O	O	NONE
(	(	(	O	O	NONE
approximately	RB	approximately	O	O	NONE
25	CD	25	O	O	NONE
%	NN	%	O	O	NONE
)	)	)	O	O	NONE
when	WRB	when	O	O	NONE
coadministered	VBN	coadminister	O	O	NONE
with	IN	with	O	O	NONE
magnesium	NN	magnesium	B-e3	T	drug
/aluminum-containing	NN	/aluminum-containing	B-e4	O	drug
antacid	JJ	antacid	I-e4	O	drug
products	NNS	product	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s22
Magnesium	NN	magnesium	B-e0	T	drug
/Aluminum-containing	JJ	/aluminum-containing	B-e1	O	drug
Antacid	JJ	antacid	I-e1	O	drug
Products	NNS	product	O	O	NONE
:	:	:	O	O	NONE
Absorption	NN	absorption	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e2	O	drug
is	VBZ	be	O	O	NONE
moderately	RB	moderately	O	O	NONE
reduced	VBN	reduce	O	O	NONE
(	(	(	O	O	NONE
approximately	RB	approximately	O	O	NONE
25	CD	25	O	O	NONE
%	NN	%	O	O	NONE
)	)	)	O	O	NONE
when	WRB	when	O	O	NONE
coadministered	VBN	coadminister	O	O	NONE
with	IN	with	O	O	NONE
magnesium	NN	magnesium	B-e3	O	drug
/aluminum-containing	NN	/aluminum-containing	B-e4	T	drug
antacid	JJ	antacid	I-e4	T	drug
products	NNS	product	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s22
Magnesium	NN	magnesium	B-e0	O	drug
/Aluminum-containing	JJ	/aluminum-containing	B-e1	T	drug
Antacid	JJ	antacid	I-e1	T	drug
Products	NNS	product	O	O	NONE
:	:	:	O	O	NONE
Absorption	NN	absorption	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e2	T	drug
is	VBZ	be	O	O	NONE
moderately	RB	moderately	O	O	NONE
reduced	VBN	reduce	O	O	NONE
(	(	(	O	O	NONE
approximately	RB	approximately	O	O	NONE
25	CD	25	O	O	NONE
%	NN	%	O	O	NONE
)	)	)	O	O	NONE
when	WRB	when	O	O	NONE
coadministered	VBN	coadminister	O	O	NONE
with	IN	with	O	O	NONE
magnesium	NN	magnesium	B-e3	O	drug
/aluminum-containing	NN	/aluminum-containing	B-e4	O	drug
antacid	JJ	antacid	I-e4	O	drug
products	NNS	product	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s22
Magnesium	NN	magnesium	B-e0	O	drug
/Aluminum-containing	JJ	/aluminum-containing	B-e1	T	drug
Antacid	JJ	antacid	I-e1	T	drug
Products	NNS	product	O	O	NONE
:	:	:	O	O	NONE
Absorption	NN	absorption	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e2	O	drug
is	VBZ	be	O	O	NONE
moderately	RB	moderately	O	O	NONE
reduced	VBN	reduce	O	O	NONE
(	(	(	O	O	NONE
approximately	RB	approximately	O	O	NONE
25	CD	25	O	O	NONE
%	NN	%	O	O	NONE
)	)	)	O	O	NONE
when	WRB	when	O	O	NONE
coadministered	VBN	coadminister	O	O	NONE
with	IN	with	O	O	NONE
magnesium	NN	magnesium	B-e3	T	drug
/aluminum-containing	NN	/aluminum-containing	B-e4	O	drug
antacid	JJ	antacid	I-e4	O	drug
products	NNS	product	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s22
Magnesium	NN	magnesium	B-e0	O	drug
/Aluminum-containing	JJ	/aluminum-containing	B-e1	T	drug
Antacid	JJ	antacid	I-e1	T	drug
Products	NNS	product	O	O	NONE
:	:	:	O	O	NONE
Absorption	NN	absorption	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e2	O	drug
is	VBZ	be	O	O	NONE
moderately	RB	moderately	O	O	NONE
reduced	VBN	reduce	O	O	NONE
(	(	(	O	O	NONE
approximately	RB	approximately	O	O	NONE
25	CD	25	O	O	NONE
%	NN	%	O	O	NONE
)	)	)	O	O	NONE
when	WRB	when	O	O	NONE
coadministered	VBN	coadminister	O	O	NONE
with	IN	with	O	O	NONE
magnesium	NN	magnesium	B-e3	O	drug
/aluminum-containing	NN	/aluminum-containing	B-e4	T	drug
antacid	JJ	antacid	I-e4	T	drug
products	NNS	product	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s22
Magnesium	NN	magnesium	B-e0	O	drug
/Aluminum-containing	JJ	/aluminum-containing	B-e1	O	drug
Antacid	JJ	antacid	I-e1	O	drug
Products	NNS	product	O	O	NONE
:	:	:	O	O	NONE
Absorption	NN	absorption	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e2	T	drug
is	VBZ	be	O	O	NONE
moderately	RB	moderately	O	O	NONE
reduced	VBN	reduce	O	O	NONE
(	(	(	O	O	NONE
approximately	RB	approximately	O	O	NONE
25	CD	25	O	O	NONE
%	NN	%	O	O	NONE
)	)	)	O	O	NONE
when	WRB	when	O	O	NONE
coadministered	VBN	coadminister	O	O	NONE
with	IN	with	O	O	NONE
magnesium	NN	magnesium	B-e3	T	drug
/aluminum-containing	NN	/aluminum-containing	B-e4	O	drug
antacid	JJ	antacid	I-e4	O	drug
products	NNS	product	O	O	NONE
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d528.s22
Magnesium	NN	magnesium	B-e0	O	drug
/Aluminum-containing	JJ	/aluminum-containing	B-e1	O	drug
Antacid	JJ	antacid	I-e1	O	drug
Products	NNS	product	O	O	NONE
:	:	:	O	O	NONE
Absorption	NN	absorption	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e2	T	drug
is	VBZ	be	O	O	NONE
moderately	RB	moderately	O	O	NONE
reduced	VBN	reduce	O	O	NONE
(	(	(	O	O	NONE
approximately	RB	approximately	O	O	NONE
25	CD	25	O	O	NONE
%	NN	%	O	O	NONE
)	)	)	O	O	NONE
when	WRB	when	O	O	NONE
coadministered	VBN	coadminister	O	O	NONE
with	IN	with	O	O	NONE
magnesium	NN	magnesium	B-e3	O	drug
/aluminum-containing	NN	/aluminum-containing	B-e4	T	drug
antacid	JJ	antacid	I-e4	T	drug
products	NNS	product	O	O	NONE
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d528.s22
Magnesium	NN	magnesium	B-e0	O	drug
/Aluminum-containing	JJ	/aluminum-containing	B-e1	O	drug
Antacid	JJ	antacid	I-e1	O	drug
Products	NNS	product	O	O	NONE
:	:	:	O	O	NONE
Absorption	NN	absorption	O	O	NONE
of	IN	of	O	O	NONE
zalcitabine	NN	zalcitabine	B-e2	O	drug
is	VBZ	be	O	O	NONE
moderately	RB	moderately	O	O	NONE
reduced	VBN	reduce	O	O	NONE
(	(	(	O	O	NONE
approximately	RB	approximately	O	O	NONE
25	CD	25	O	O	NONE
%	NN	%	O	O	NONE
)	)	)	O	O	NONE
when	WRB	when	O	O	NONE
coadministered	VBN	coadminister	O	O	NONE
with	IN	with	O	O	NONE
magnesium	NN	magnesium	B-e3	T	drug
/aluminum-containing	NN	/aluminum-containing	B-e4	T	drug
antacid	JJ	antacid	I-e4	T	drug
products	NNS	product	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s23
The	DT	the	O	O	NONE
clinical	JJ	clinical	O	O	NONE
significance	NN	significance	O	O	NONE
of	IN	of	O	O	NONE
this	DT	this	O	O	NONE
reduction	NN	reduction	O	O	NONE
is	VBZ	be	O	O	NONE
not	RB	not	O	O	NONE
known	VBN	know	O	O	NONE
,	,	,	O	O	NONE
hence	RB	hence	O	O	NONE
zalcitabine	NN	zalcitabine	B-e0	T	drug
is	VBZ	be	O	O	NONE
not	RB	not	O	O	NONE
recommended	VBN	recommend	O	O	NONE
to	TO	to	O	O	NONE
be	VB	be	O	O	NONE
ingested	VBN	ingest	O	O	NONE
simultaneously	RB	simultaneously	O	O	NONE
with	IN	with	O	O	NONE
magnesium	NN	magnesium	B-e1	T	drug
/	:	/	O	O	NONE
aluminum-containing	JJ	aluminum-containing	B-e2	O	drug
antacids	NNS	antacid	I-e2	O	drug
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d528.s23
The	DT	the	O	O	NONE
clinical	JJ	clinical	O	O	NONE
significance	NN	significance	O	O	NONE
of	IN	of	O	O	NONE
this	DT	this	O	O	NONE
reduction	NN	reduction	O	O	NONE
is	VBZ	be	O	O	NONE
not	RB	not	O	O	NONE
known	VBN	know	O	O	NONE
,	,	,	O	O	NONE
hence	RB	hence	O	O	NONE
zalcitabine	NN	zalcitabine	B-e0	T	drug
is	VBZ	be	O	O	NONE
not	RB	not	O	O	NONE
recommended	VBN	recommend	O	O	NONE
to	TO	to	O	O	NONE
be	VB	be	O	O	NONE
ingested	VBN	ingest	O	O	NONE
simultaneously	RB	simultaneously	O	O	NONE
with	IN	with	O	O	NONE
magnesium	NN	magnesium	B-e1	O	drug
/	:	/	O	O	NONE
aluminum-containing	JJ	aluminum-containing	B-e2	T	drug
antacids	NNS	antacid	I-e2	T	drug
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d528.s23
The	DT	the	O	O	NONE
clinical	JJ	clinical	O	O	NONE
significance	NN	significance	O	O	NONE
of	IN	of	O	O	NONE
this	DT	this	O	O	NONE
reduction	NN	reduction	O	O	NONE
is	VBZ	be	O	O	NONE
not	RB	not	O	O	NONE
known	VBN	know	O	O	NONE
,	,	,	O	O	NONE
hence	RB	hence	O	O	NONE
zalcitabine	NN	zalcitabine	B-e0	O	drug
is	VBZ	be	O	O	NONE
not	RB	not	O	O	NONE
recommended	VBN	recommend	O	O	NONE
to	TO	to	O	O	NONE
be	VB	be	O	O	NONE
ingested	VBN	ingest	O	O	NONE
simultaneously	RB	simultaneously	O	O	NONE
with	IN	with	O	O	NONE
magnesium	NN	magnesium	B-e1	T	drug
/	:	/	O	O	NONE
aluminum-containing	JJ	aluminum-containing	B-e2	T	drug
antacids	NNS	antacid	I-e2	T	drug
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s24
Metoclopramide	NN	metoclopramide	B-e0	T	drug
:	:	:	O	O	NONE
Bioavailability	NN	bioavailability	O	O	NONE
is	VBZ	be	O	O	NONE
mildly	RB	mildly	O	O	NONE
reduced	VBN	reduce	O	O	NONE
(	(	(	O	O	NONE
approximately	RB	approximately	O	O	NONE
10	CD	10	O	O	NONE
%	NN	%	O	O	NONE
)	)	)	O	O	NONE
when	WRB	when	O	O	NONE
zalcitabine	NN	zalcitabine	B-e1	T	drug
and	CC	and	O	O	NONE
metoclopramide	NN	metoclopramide	B-e2	O	drug
are	VBP	be	O	O	NONE
coadministered	VBN	coadminister	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s24
Metoclopramide	NN	metoclopramide	B-e0	T	drug
:	:	:	O	O	NONE
Bioavailability	NN	bioavailability	O	O	NONE
is	VBZ	be	O	O	NONE
mildly	RB	mildly	O	O	NONE
reduced	VBN	reduce	O	O	NONE
(	(	(	O	O	NONE
approximately	RB	approximately	O	O	NONE
10	CD	10	O	O	NONE
%	NN	%	O	O	NONE
)	)	)	O	O	NONE
when	WRB	when	O	O	NONE
zalcitabine	NN	zalcitabine	B-e1	O	drug
and	CC	and	O	O	NONE
metoclopramide	NN	metoclopramide	B-e2	T	drug
are	VBP	be	O	O	NONE
coadministered	VBN	coadminister	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s24
Metoclopramide	NN	metoclopramide	B-e0	O	drug
:	:	:	O	O	NONE
Bioavailability	NN	bioavailability	O	O	NONE
is	VBZ	be	O	O	NONE
mildly	RB	mildly	O	O	NONE
reduced	VBN	reduce	O	O	NONE
(	(	(	O	O	NONE
approximately	RB	approximately	O	O	NONE
10	CD	10	O	O	NONE
%	NN	%	O	O	NONE
)	)	)	O	O	NONE
when	WRB	when	O	O	NONE
zalcitabine	NN	zalcitabine	B-e1	T	drug
and	CC	and	O	O	NONE
metoclopramide	NN	metoclopramide	B-e2	T	drug
are	VBP	be	O	O	NONE
coadministered	VBN	coadminister	O	O	NONE
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d528.s25
Doxorubicin	NN	doxorubicin	B-e0	T	drug
:	:	:	O	O	NONE
Doxorubicin	NN	doxorubicin	B-e1	T	drug
caused	VBD	cause	O	O	NONE
a	DT	a	O	O	NONE
decrease	NN	decrease	O	O	NONE
in	IN	in	O	O	NONE
zalcitabine	NN	zalcitabine	B-e2	O	drug
phosphorylation	NN	phosphorylation	O	O	NONE
(	(	(	O	O	NONE
50	CD	50	O	O	NONE
%	NN	%	O	O	NONE
inhibition	NN	inhibition	O	O	NONE
of	IN	of	O	O	NONE
total	JJ	total	O	O	NONE
phosphate	NN	phosphate	O	O	NONE
formation	NN	formation	O	O	NONE
)	)	)	O	O	NONE
in	IN	in	O	O	NONE
U937/Molt	NN	u937/molt	O	O	NONE
4	CD	4	O	O	NONE
cells	NNS	cell	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s25
Doxorubicin	NN	doxorubicin	B-e0	T	drug
:	:	:	O	O	NONE
Doxorubicin	NN	doxorubicin	B-e1	O	drug
caused	VBD	cause	O	O	NONE
a	DT	a	O	O	NONE
decrease	NN	decrease	O	O	NONE
in	IN	in	O	O	NONE
zalcitabine	NN	zalcitabine	B-e2	T	drug
phosphorylation	NN	phosphorylation	O	O	NONE
(	(	(	O	O	NONE
50	CD	50	O	O	NONE
%	NN	%	O	O	NONE
inhibition	NN	inhibition	O	O	NONE
of	IN	of	O	O	NONE
total	JJ	total	O	O	NONE
phosphate	NN	phosphate	O	O	NONE
formation	NN	formation	O	O	NONE
)	)	)	O	O	NONE
in	IN	in	O	O	NONE
U937/Molt	NN	u937/molt	O	O	NONE
4	CD	4	O	O	NONE
cells	NNS	cell	O	O	NONE
.	.	.	O	O	NONE

NO

Sentence: DrugDDI.d528.s25
Doxorubicin	NN	doxorubicin	B-e0	O	drug
:	:	:	O	O	NONE
Doxorubicin	NN	doxorubicin	B-e1	T	drug
caused	VBD	cause	O	O	NONE
a	DT	a	O	O	NONE
decrease	NN	decrease	O	O	NONE
in	IN	in	O	O	NONE
zalcitabine	NN	zalcitabine	B-e2	T	drug
phosphorylation	NN	phosphorylation	O	O	NONE
(	(	(	O	O	NONE
50	CD	50	O	O	NONE
%	NN	%	O	O	NONE
inhibition	NN	inhibition	O	O	NONE
of	IN	of	O	O	NONE
total	JJ	total	O	O	NONE
phosphate	NN	phosphate	O	O	NONE
formation	NN	formation	O	O	NONE
)	)	)	O	O	NONE
in	IN	in	O	O	NONE
U937/Molt	NN	u937/molt	O	O	NONE
4	CD	4	O	O	NONE
cells	NNS	cell	O	O	NONE
.	.	.	O	O	NONE

YES

Sentence: DrugDDI.d528.s26
Although	IN	although	O	O	NONE
there	EX	there	O	O	NONE
may	MD	may	O	O	NONE
be	VB	be	O	O	NONE
decreased	VBN	decrease	O	O	NONE
zalcitabine	NN	zalcitabine	B-e0	T	drug
activity	NN	activity	O	O	NONE
because	IN	because	O	O	NONE
of	IN	of	O	O	NONE
lessened	JJ	lessened	O	O	NONE
active	JJ	active	B-e1	T	drug
metabolite	NN	metabolite	I-e1	T	drug
formation	NN	formation	O	O	NONE
,	,	,	O	O	NONE
the	DT	the	O	O	NONE
clinical	JJ	clinical	O	O	NONE
relevance	NN	relevance	O	O	NONE
of	IN	of	O	O	NONE
these	DT	these	O	O	NONE
in	FW	in	O	O	NONE
vitro	FW	vitro	O	O	NONE
results	NNS	result	O	O	NONE
are	VBP	be	O	O	NONE
not	RB	not	O	O	NONE
known	VBN	know	O	O	NONE
.	.	.	O	O	NONE

NO

